1.67@cancer cancer cancer cancer cancer inhibitor inhibitor available effective tumour currently part nucleotide unknown irreversibly dnmt dnmt replicate affect generally fact nucleoside case demethylation demethylation cell cell cell cell far drug drug drug dependent large epigenetic replication replication cause cause cause toxic do type methyl dna dna dna however dose dose kill bind bind function still trial current effect die quickly due since transface decitabine decitabine decitabine decitabine decitabine decitabine mean come analouge haematological small 
1.0@similarly stable class pharmacologically mode control baylin slow inhibitor inhibitor agent agent agent agent agent specific medicine inhibit since since growth growth md treat grow amount decitabine decitabine decitabine decitabine decitabine expression epigenetic epigenetic precurorsor help discuss impede demethylating dr potentiate operate hopkins cell process tumour tumour tumour leukaemia leukaemia standard identify patient action cannot alteration combination school myeologeneous limit result reverse bring do occur furthermore demethylation syndrome dna dna dna dna hypomethylating deactylase histone chemotherapy act act well gene myelodysplatic john similar evidence belong thus thus methylation methylation allow work form per 
1.33@plastic cancer od invasive overmethylation supression way susceptible really change penetrate penetrate treat decrease grow response epigenetic epigenetic efficient tumoral dramatically tumor tumor difficult treatment first ell tomors patient erase general drug drug drug drug analogue combination citidine progeny cell cell cell cell kill without completely solid solid good syndrome non histone chemotherapy act inherit mi chemical inhibitor deacetylase apparently methylation decitabine decitabine daughter y form combine alter azacitidine 
2.0@one clinical cancer methyltransferases promote within within stability agent decitabine process rescue decrease inhibit prognosis degree dna dna dna profile loose establish expression demethylating gene inactivate tumor hand hand genomic increase hypermethylation usually methylation methylation methylation methylation genome high tumorigenicity cpg cell worse try promoter supressor 
2.0@suppressor cause cause methyltransferase mitotic remove methyl untouched manner agent agent word waste problem leave become inhibit prevent somatic previously previously dna dna dna divide divide non heritability group act target demethylating demethylating furthermore rapidly many tumor tumor tumor tumor tumor mechanism cellular death silence silence resource methylation decitabine gene gene express express passive passive cell cell cell cell cell cell cell may may 
2.0@suppressor also tumor antimetabolite reactivation via via tumour region structure agent decitabine result anti incorporation promoter inhibit disruption action lead dna dna dna dna dna epigenetic transferase act demthylating function drug gene gene might dicetabine epigenetically mechanism death silence may methylation reduce possible incorporate cell methyl level associate 
2.0@inhibitor class dnmt dnmt tumour tumour stem result since upkeeping anti overall decrease inhibit dna dna belong cpg island effect hypermethylation methylation methylation decitabine establishment require 
1.33@cancer cancer cancer cancer cancel restore therefore epigenetic fight ch methyl cause appear add healthy agent process goal hypomethylation hypomethylation type abnormal group class dna dna wherein development body help help responsible function demethylating drug drug induce normal essential hypermethylation hypermethylation hypermethylation entire silence methylation decitabine decitabine gene gene many cell cell may associate 
2.0@one heavy also inactivate demethylates divide methyl inhibitor substantially transpher transpher gene gene copy group dna dna dna island several epigenetic expression act act allow cpg protein protein protein way way reduce tumor pattern block attach methylation methylation decitabine decitabine production cell control supressor 
2.0@cancer cancer dnmt dnmt dnmt dnmt replication mutate become analog dnmti make type nucleotide stop stop dna dna irreversibly bind bind enzyme methyltransferase inhibitor pattern inactive usually methylation methylation decitabine decitabine decitabine nucleoside aberrant incorporate come cell drug associate 
2.0@critical restore formation synthesize methyl methyl concentration newly methylating cytotoxicity hypomethylation hypomethylation exert transferase transferase inhibit inhibit inhibit inhibit adduct achieve believe responsible enzyme inhibitor proliferation conversion normal neoplastic may may thus directly nucleoside mammalian insensitive triphosphate cell cell cell cell control decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine also drug analogue cause apoptosis suppression result proliferate dna dna dna dna dna dna dna dna dna dna dna dna dna divide non synthesis covalent function gene rapidly effect induce relatively cellular cellular antineoplastic belong vitro major methylation ul ul attribute incorporate incorporate incorporate hypomethylates differentiation differentiation methyltransferase methyltransferase methyltransferase follow class 
1.33@cancer cancer critical abnormal restore restore blood blood agent maximum favor since hypomethylation hypomethylation oncogene incorporation marrow inhibit exert lead help treat think demethylating proliferation proliferation tumor tumor tumor tumor affect hypermethylation phosphorylation case many often may myelodysplasic suppressor also certain information cause cause add normal normal normal prescribe anti anti know dna dna dna dna dna cell cell cell cell syndrome function gene gene methyltransferase effect effect cellular control belong undergo decitabine decitabine decitabine decitabine decitabine decitabine production class bone kill differentiation hence dysfunction dysfunction 
0.33@specifically cause cause advance therefore activation excessive imprint use carry system mathylaton whose process process article overactivated leave genetic mention inhibit lead normalize mathylatins histone function function ezh gene gene gene eliminate tumor tumor silence repair possible mathylations enzyme enzyme significant drug majority decitabine decitabine 
2.0@body cancer cause cause cause daughter daughter dnmt dnmt dnmt much analogue analogue inhibitor agent decitabine decitabine decitabine decitabine irreversibly result constantly harm hypermethylated copy prevent synthesise dna dna dna dna dna dna dna dna divide divide strand strand get bind bind nelwy le function demethylating methyltransferase consequently mehylation normal replicate replicate thus thus thus methylation conversely nucleoside nucleoside region incorporate demethylation demethylation cell cell replication onto ul ul 
2.0@cancer cancer cancer cannot inhibition disrupt dnmt dnmt activate use include agent agent hypomethylating myelodysplastic analog also aberration aberration treat call island often irreversibly strand strand tumour precursor hypermethylation hypermethylation demethylating tumor tumor normal normal contribute ing nucleoside affect cell cell cell cell cell methyl methyl leukaemia one suppressor suppressor transfer transfer get replication cause mean pass anti ease ease promoter syndrome dna dna dna dna dna maintenance acute bind epigenetic inhibitor inhibitor cpg gene gene effect copy silence replicate myelogenous methylation methylation methylation decitabine decitabine decitabine decitabine daughter daughter region incorporate ur 
1.67@mean cancer cancer transfer patient therefore therefore therefore get cannot use dependent correct lay target since dosage marker type type occur transferase transferase treat dna dna dna dna divide strand strand strand propagate bind quickly affect copy inhibitor effecively permanently division division new methylation methylation methylation release daughter daughter incorporate come cell cell cell cell cell cell methyl methyl decitabine decitabine decitabine 
1.67@cancer methylating therefore able relate use cacer likely know know agent behind transcribe effect hypermetylation consist amount decrease inhibit inhibit inhibit decitabine decitabine dna dna dna dna pack cell cell methylated methylated example le metylating drug island supressing tumor tumor expresion densly cpg may silence silence genome usually gene instance de antitumoral supressor 
2.0@cancer methyltransferases class dnmt induce induce tumour activity dnmti dnmti hypomethylation inhibit inhibit lead lead epigenetic enzyme demethylating proliferation tumor tumor hypermethylation express cell drug suppressor suppressor decitabine decitabine specifically therefore fight replication work apoptosis target result maintain antitumor promoter treatment dna dna dna dna dna get reverse allow inhibitor gene gene gene gene methyltransferase methyltransferase effect upon place cellular first belong word silence silence silence tool deplete region incorporate action differentiation enable hypometilating 
1.67@cancer receive inhibition class term dnmt others every manner long since since tend call nucleotide unable epigenetic strand strand consequence tumor normal normal eventual release demethylation cell cell cell cell cell cell cell cell drug deplete belong dependent divide divide divide replication subsequent eventually result ultimately depletion know parent amp amp amp think dna dna dna dna dna dna get kill bind point point inhibitor inhibitor inhibitor irreversible rapidly effect effect effect induce cellular cellular cellular cellular death death division division methylation decitabine decitabine decitabine daughter time incorporate upon methyltransferase methyltransferase methyltransferase methyltransferase methyltransferase methyltransferase would 
1.67@cancer cancer impact class last use inhibitor agent process process since silence growth change subsequently suppress regulate regulate epigenetic epigenetic epigenetic tumour tumour methylated kind responsible hyper demethylating inhibit reduce affect enzyme enzyme enzyme cell cell cell cell cell may belong dna dna dna dna dna dna dna therefore therefore seem drug drug drug drug drug overgrowth anti methylation methylation methylation methylation know group treatment several action act act inherit gene methyltransferase effect epigenetically overactive division thus regulator decitabine decitabine decitabine daughter activity activity modify 
2.0@cancer cancer cancer myelodisplasic able may hematological de hypomethylation hypomethylation leukemia nevertheless pre island lead lead cytosine cytosine strand methylated establish inhibitor way dnmt dnmt dnmt feature hypermethylation nucleoside myeloid cell cell cell cell cell tumour tumour tumour suppressor suppressor dna dna dna drug transcription however replication analogue precede novo condition condition cancerous gene gene anti compete occur promoter reason treatment several maintenance acute bind syndrome use function perform irreversible methyltransferase methyltransferase effect induce disregulated repress cpg replicate new methylation decitabine decitabine decitabine decitabine decitabine em incorporate approve proliferation 
1.0@dna anti effect methylation decitabine gene demethylating remove supressing tumor tumor agent 
1.67@substitute cancer inhibitor inhibitor inhibitor inhibitor class dnmt dnmt dnmt dnmt tumour agent process de susceptible drug nucleotide unknown recognize irreversibly kind kind enzyme enzyme demethylating fall mechanism block feature nucleoside substrate substrate case cell cell cell cell cell much machinery one abnormally dependent high epigenetic epigenetic decitabine decitabine replication analogue healthy however natural cytosine exact become bind dna dna dna dna dna dna get get get mark deduce act function still methyltransferase rate copy division division division replicate main methylation methylation initiate incorporate action paragraph previous would 
2.0@cancer cancer inhibitor dnmt dnmt n methyl prove syndrom selective growth decrease dna dna dna irreversibly tumor tumor affect epigenome supressors nucleoside like demethylation cell cell cell cell cell tra suppressor cytidine also greater epigenetic prolipheration drug drug analogue suppose describe ase show protect study divide non bind myelodisplastic expression positive gene effect effect dependant increase increase division thus methylation methylation decitabine decitabine incorporate 
2.0@suppressor inhibitor dnmt dnmt activate use agent add demethylated myelodysplactic anti bind treat group prevent dna epigenetic methylated syndrome expression gene effect tumor tumor new regulator allow methyl enzymatic decitabine decitabine 
2.0@suppressor cancer critical therefore myelodysplastic tumor may may may signature cytidine shore precise event analog regard hypomethylation drug prevent treatment dna epigenetic epigenetic action consider syndrome target cpg cpg inhibit unclear mechanism normal silence methylation methylation decitabine decitabine decitabine although gene gene island approve cell require 
1.67@transfer inhibition dnmt dnmt dnmt tumor methyl cause apoptosis anti result facilitate hypomethylation hypomethylation direct incorporation show group exert island dna dna dna function drug inhibit methyltransferase inhibitor induce induce cellular cellular normal believe cpg silence decitabine gene gene activity differentiation differentiation proliferation would important 
1.33@suppressor cancer inhibitor class therefore enzymatic activate methylates de de oncogene island dna dna epigenetic non methylate example cpg gene effect tumor belong combat decitabine region region region control would 
2.0@inhibition growth agent agent hypomethylating newly analog hypomethylation unmethylated inhibit previously next cytosine representative consequence tumor tumor round theformation lead repress one suppressor cytidine residue decitanine replication restoration subsequent anti treatment dna dna dna dna cell chemotherapy expression gene gene methyltransferase methyltransferase effect induce control belong replicate thus decitabine decitabine decitabine class follow azacitidine 
1.67@cancer cancer deacreased suppresor reactivation use cause inhibit kill treat decrease island division dna inhibitory propeties cpg progressive dnmt dnmt tumor methylations hypermethylation thus decitabine dectiabine gene cell 
1.67@suppressor cancer also antimetabolite agent stop hypomethlating result growth effect effect become inhibit dna dna dna divide cytotoxic gene take reduce tumor fast fast death interfere methylation methylation decitabine active cell methyltransferase 
1.33@suppressor suppressor cancer article magazine use agent april epicentre hypermethylate exact anon bind treat know unable dna irreversibly methylated syndrome dnmts demethylating gene gene continue effect mechanism myelodysplastic decitabine express action tumour tumour 
1.0@mitotically loss article tumour cancer cancer cancer cancer pattern pattern economist economist hypomethylation hypomethylation generation unmethylating heritable affect previously class epigenetic epigenetic promoter responsible give proliferation impact tumor week normal normal resource icrs cell cell may may may dna dna dna dna dna dna dna dna promote imprint answer subsequent reference effect effect anti process bind function gene gene gene gene gene gene gene gene expression expression expression expression expression kennedy kennedy cellular cellular belong methylation methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine come follow characteristic restore restore restore dnmt use use include lecture epicentre epicentre analog methylating deborah growth growth growth restrict restrict explain inhibit treat irreversibly write write courseware assignment epigenome nucleoside retain control control control control one transcription identify area drug drug april result result permit permit several point inhibitor think describe describe describe along silence epigenetics epigenetics daughter region incorporate differentiation protein alter 
0.67@cancer inhibitor translation erase regulation cell cell tumour tumour agent stop anti anti kill untill without change change generation show grow therapy next dna epigenetic epigenetic epigenetic pass form demethylating gene effect effect effect effect accord involvng daughter belong due thus actively decitabine decitabine thet factor class various 
2.0@ce ce cancer along dnmt dnmt dnmt progress use pattern myelodysplastic malignancy dnmti overall nucleotide irreversibly strand onto silence myeloid mechanism dnmtis hypermethylation hypermethylation release demethylation cell cell tumour tumour tumour leukaemia suppressor suppressor dependent dependent transfer transfer therefore therefore relate replication analogue target anti bind methyl methyl counter counter dna dna dna dna dna divide postulate acute upon syndrome inhibitor gene gene aml effect effect unclear copy division division longer methylation decitabine decitabine decitabine daughter incorporate come action rapidly haematological 
1.33@elod plastic class dysfunctional blood appear agent hypomethylating hypomethylates reactivate leukemia inhibit response define clinical epigenetic myeloid tumor drugfor difficult mode induction cell suppressor specifically patient substantial alteration drug certain apoptosis condition show treatment dna dna dna however acute syndrome act gene methyltransferase methyltransferase inhibitor epigenetically silence vitro potency decitabine decitabine decitabine y influence action 
1.67@cancer effect class dnmt much agent myelodysplastic myelodysplastic dnmti dnmti might island nucleotide effective irreversibly strand get demethylating severely outcome mechanism affect neoplastic hypermethylation release high demethylation demethylation cell cell drug decitabine decitabine decitabine dependent lower epigenetic seem replication cause toxic body anti know dna dna dna dna dna dna dna divide dose dose bind bind syndrome syndrome inhibitor inhibitor cpg poor rapidly along upon copy belong longer methylation would would daughter incorporate come action methyltransferase methyltransferase methyltransferase prognostic 
1.33@cancer rate exact dnmt dnmt progress tumour tumour maximum whose whose correct myelodysplastic analog myelogenous dnmti dnmti drug drug drug drug nucleotide class class effective irreversibly inhibitor administer reduce mechanism mechanism hypermethylation hypermethylation tumourous vidaza purpose enzyme cell bind leukaemia suppressor dependent greater origin fight replication replication againts however hypothetically terminate like completely know reason treatment dna dna dna dna dna divide dose acute moment moment syndrome act dnmts still gene methyltransferase effect dependant along belong thus methylation methylation decitabine decitabine work incorporate approve action action 
2.0@cancer cancer inhibitor think think think term reactivation tumour stop long affect affect affect irreversibly strand methylate methylate consequence able rapidly normal may release nucleoside enzyme enzyme enzyme cell cell cell cell cell drug drug catch suppressor also also however however replication analogue prevent prevent dnamethyltransferase dnamethyltransferase dna dna dna dna dna divide divide divide bind act section methyltransferase along silence interfere methylation methylation decitabine decitabine decitabine decitabine decitabine daughter gene incorporate come enable 
1.67@dna histone use demethylating gene gene tumour tumour inactivate remove agent mutation reactivate ezh methylation overactivated become hypermethylated sereval decitabine decitabine supressor supressor 
1.67@cancer cancer class use agent originally excite myelogenous growth treat treat decrease grow lead precursor disease demethylating tumor turn uncontrolled uncontrolled normal may cell cell cell cell cell cell cell control control control belong patient successfully cease seem drug healthy target cancerous reprograms completely occur dna dna acute syndrome myelodysplastic anti affect rather effect dissapear division division division division division longer silence methylation methylation decitabine decitabine decitabine decitabine decitabine gene gene leukaemia 
1.67@mitotically cancer methylating class therefore dnmt tumour certain fda dependent long myelodysplastic find growth growth type heritable affect inhibit inhibit epigenetic epigenetic lead dna dna divide divide pass bind syndrome inhibitor inhibitor division drug drug drug rapidly rate tumor cutaneous effective belong decitabine daughter approve cell cell cell replication enzymatic 
2.0@cancer cancer inhibitor dnmt use dnmts agent myelodysplastic analog transfer meet dnmti growth high tumour tumour copy irreversibly irreversibly strand strand ineffective reduce normal bind bind bind may release nucleoside express demethylation demethylation cell cell cell cell control suppressor expression sensitivity dependent also also promote authorise nucelotide cause cause combination therapy toxic epigentically healthy anti balance parent treatment dna dna dna dna dna dna cytotoxic dose dose ase syndrome act important drug gene gene gene gene rather effect induce methyltransferase methyltransferase range combine increase silence longer methylation decitabine decitabine decitabine decitabine decitabine daughter create incorporate comprise enable replication chemotherapeutic 
1.33@growth growth unregulated cancer cancer category within within produce activity way agent process major similar substance substance direct call decitabinealso restore restore believe belong demethylating twofold tumor mechanism block normal normal expression anticancer thus decitabineis regulate regulate control blockage decitabine one suppressor suppressor suppressor chemotherapy promote antimetabolite antimetabolite drug cause target result number allow become know demethylation demethylation metabolism dna dna dna dna divide cell cell cell cell cell cell cell cell cytotoxic death function gene gene gene gene rapidly effect effect interact cellular increase division division interfere new methylation methylation methylation member work incorporate class 
1.67@cancer proliferate class excess use potential fully agent agent hypomethylating myelodysplastic extra malignancy leukemia treat chemotherapeutics lead lead lead epigenetic malignant malignant inhibitor inhibitor allow demethylating demethylating reduce tumor tumor mechanism epigenome may although demethylation cell cell tumour suppressor suppressor irreversibly drug cause exact effect effect anti consist methyl methyl show group dna dna dna dna understand blood histone bind syndrome function gene gene gene methyltransferase inactivate remove cellular deacetylase belong synergistic decitabine decitabine normally action combine 
2.0@cancer cancer cancer size medication scientist tumour tumour tumour reversion metastatic myelodysplastic quantity hypermethylated dmnt dna dna dna dna epigenetic demethylating demethylating em block normal consequently nucleoside cell cell cell reprogram suppressor state irreversibly drug analogue analogue myeloma incorporate result low especially prevent example reduction dose bind syndrome act gene gene methyltransferase methyltransferase inhibitor epigenetically retrieve thereby replicate methylation decitabine decitabine decitabine work activity 
0.67@standard cancer size able tumor tumor tumor methyl agent epicentre article economist note anti group effect dna dna publish development chemotherapy demethylating rate remove sensitize reduce cell passively decitabine 
0.67@suppressor cancer cancer methylating identify class tumour tumour possibly cause cell cell describe describe methylate de de susceptible make normal dna epigenetic effect histone histone histone methylated chemotherapy least epigenome inhibitor inhibitor gene gene impact deacetylase belong methylation allow express modify anti decitabine decitabine decitabine 
1.67@cancer cancer instead growth dnmt dnmt dnmt tumour slow replace cannot cytotoxicity reactivate methylgroup unmethylated direct hemimethylated locus aza sup sup lead methylated pyrimidine enzyme proliferation proliferation disrupt mechanism gradually program passive cell cell cell cell cell cell demethylation incorporate incorporate one suppressor cytidine replication analogue base suppression course atom maintain except particular dna dna dna dna dna however ring bind le inhibitor differentiation methyltransferase aggressive remain deoxycytidine hemymethylated death thus methylation decitabine decitabine decitabine decitabine gene another th action differentiate attach 
2.0@cancer inhibition restore dnmt dnmt produce nova nova methyl sub sub sub sub mutation mutation mutation mutation stop mark myelodysplastic multipotent multipotent impair de de growth md md md md progressively treat marrow inhibit incorporation granddaughter clinical decitabines dmnt dmnt responsible hypomethylation control normal effectiveness effectiveness count differentiate cell cell cell cell cell cell cell cell cell cell blood blood one red red become em em mutate appropriate white white result result low anti normally occur occur show treatment dna dna divide divide syndrome least differentiation methyltransferase methyltransferase methyltransferase effect compatible evidence bone thus combat decitabine decitabine decitabine daughter production lay worse exist 
2.0@suppressor cancer reduce reduce class excess epigenetically use cause agent hypomethylating result growth effect anti tumour suppress dna dna dna dna epigenetic help inhibitor inhibitor hyper demethylating gene methyltransferase impact tumor tumor tumor human silence methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine em em em mean drug spread belong 
2.0@suppressor methylating agenet dnmt relate may analogue myelodysplastic result inhibit act unknown dna dna bind syndrome le allow prevent methyltransferase inhibitor tumor mechanism antineoplastic hypermethylation methylation ul ul nucleoside region otherwise express action would decitabine 
2.0@blewitt cancer cancer cancer article irreversibly marnie replication replication cause decitabine epicentre analogue ul ul economist hypomethylation gain hypermethylated exert lecture methyltransferase methyltransferase lead dna dna dna dna dna divide acknowledgement get bind epigenetic inhibitor function gene gene rapidly effect tumor dependant question silence consequently bigger nucleoside incorporate demethylation cell cell control suppressor expression 
1.67@cancer cancer cancer inhibitor inhibitor higher term dnmt methyl note fda long medicine myelodysplastic part drug drug inhibit inhibit epigenetic strand severe methylated enzyme enzyme enzyme effective pattern know dilute second demethylation cell cell cell cell cell much machinery lower daughter divide mitotic seem replication answer hemi toxic side maintain maintain fully lecture group methyltransferase methyltransferase methyltransferase family family dna dna dna dna mark mark base kill bind syndrome still rather effect effect effect effect dramatic doze doze division division thus methylation methylation decitabine decitabine mainly strong approve rapidly 
0.67@compound specific cancer cannot therefore able use agent agent stop mutation hypomethylating result reversible without change change therapy hypermethylated unlike grow previously dna dna epigenetic epigenetic kill erase expression demethylating inhibit inhibit effect remove silence methylation decitabine gene mean case return cell 
1.67@oneand cancer importantly predictor methyl appear agent agent hypomethylating hypomethylating hypomethylating demethylate analog analog find azacytidine dnmti hypomethylation hypermethylated drug transferase unlike lead epigenetic see inappropriately common respond respond interest interest enhance tumor tumor tumor please enormous silence biomarker role prim many cell cell cell cell may expression suppressor identify patient patient seem need cause answer healthy apoptosis acytindine andcause depletion arrest limit treatment dna dna dna profile abberent use inhibitor still gene gene methyltransferase effect effect molecular increase decitabinemainly thus decitabine decitabine approach another side 
2.0@cancer cancer research category category dnmt dnmt overregulated occure agent analog growth possibly oncogene inhibit lead lead cytosine position strand methylated silence silence silence demethylating demethylating overmethylation tumor mechanism decitabineis cell cell suppressor cytidine cytidine also methylates drug apoptosis mean problem normally normally show prevent prevent dna dna dna dna dna dna bind bind name expression gene gene gene gene gene gene regulate regulate induce remain increase division interfere methylation methylation methylation decitabine decitabine decitabine work another active whenc 
1.67@cancer therefore epigenetic agent scientist uncontrolled cause dependent stop toxic md low dnmti dnmti dnmti dnmti growth growth anti treat good dna dna irreversibly dose dose tumour bind syndrome dnmts demethylating drug effect neoplastic find myelodysplastic high incorporate replication cell use dicitabine dicitabine 
1.67@cancer cannot cell cell cell use purpose marketplace process myelodysplastic currently currently currently economist de nucleotide achieve amount epigenetic methylate precursor aim aim aim research primary go bond treatment control one specifically variety drug drug drug drug drug either target focus cancerous whose introduce methyl dnamethyltransferase dna acute bind syndrome fe tan time inhibitor myelogenousleukemia division replicate replicate rase methylation decitabine daughter dmnt limit period 
1.33@advance methyled use slow combination agent syndrom myelodysplastic growth demethylate treat desitabine dna stag gene inhibitor tumor deacetylase belong decitabine really demethylation drug drug 
1.67@find pdf epigenetics upload answer question 
2.0@effect effect effect within dnmt chance reactivate unmethylated overall drug dmnt island molecule lead lead dmnts irreversibly strand strand strand know methylated prevent tumor tumor tumor tumor tumor tumor tumor tumor affect hypermethylation nucleoside many many cell cell cell try suppressor suppressor suppressor dependent replication replication analogue hemi mean anti type show home demethylation dna dna dna dna dna dna dna bind inhibitor cpg time methyltransferase newer newer copy copy increase increase increase quickly replicate methylation methylation decitabine decitabine decitabine decitabine daughter daughter daughter gene gene incorporate 
2.0@cancer cancer cancer toxicity target dnmt dnmt progress slow include agent specific remain since malignancy malignancy leukemia make inhibit suppress molecule clinical irreversibly promoter establish demethylating island effective tumor tumor tumor tumor endure clinically unmethylated myeloid demethylation demethylation cell cell far line nuceloside suppressor suppressor dependent transcription therapeutic fda replication replication analogue non property low across anti type solid immune later dna dna dna dna divide dose acute bind bind site important cpg gene gene aml aml employ methyltransferase trial especially undergo methylation methylation decitabine region region incorporate perhaps approve progression rapidly haematological small 
2.0@cancer cancer dnmt analog dnmti quite drug drug drug drug call island lead epigenetic inhibator enzyme enzyme inhibit take tumor mechanism clear nucleoside case cell replication suppressor understand however amongst cause cause therapy promotor exact demethylate know prevent dna dna dna dna divide postulate group still hence hence methyltransferase dependant preferentially cpg silence silence methylation methylation gene gene action rapidly 
2.0@suppressor transcription promote tumour tumour tumour cause agent add add slow growth growth gene gene prevent genomic permament dna dna dna pass form additional demethylating group group group eipgenome reduce remove increase dinucleotides silence methylation contribute daughter daughter instability cpg cpg island cell cell removal removal methyl methyl onto decitabine decitabine 
2.0@inhibitor restore metabolise phosphorylated progress use agent hypomethylating myelodysplastic cytosine hypomethylates reactivate leukemia transferase dmnts sequence contribute myeloid tumor tumor presumably nucleoside induction induction cell methyl methyl expression suppressor dependent transcription residue relate seem replication analogue decitabine decitabine decitabine apoptosis apoptosis inhibitory moreover favor antitumor promoter group damage treatment dna dna dna acute bind bind syndrome act dnmts drug gene gene gene effect remove belong thus methylation inside incorporate silence downstream 
2.0@drug growth dnmt dnmt replication cause agent irreversibly mimic hypomethylation back prevent suppress dna dna dna dna get methylate bind morenormal demethylating gene methyltransferase happen tumor tumor slide consequently methylation decitabine decitabine decitabine decitabine nucleoside aberrant incorporate cell cell try remethylation 
1.67@dacogen critical inhibition restore last tumour susceptible chemically agent direct myelogenous aza cellular cellular hypomethylation hypomethylation leukemia make exert normal incorporation class foracute precursor demethylating control proliferation myeloid standard neoplastic may phosphorylation myelodysplastic treatment way leukaemia cytidineanalog dysfunctional eisai cause epigenetic drug drug certain cell cell cell condition acute company dna dna dna dna antineoplastic blood japanese togenesthat chemotherapy sell function methyltransferase effect deoxycytidine syndrome believe decitabine decitabine decitabine differentiation differentiation aml alter 
1.67@elod unregulated cancer cancer cancer restore restore within within produce activity use agent process become myelogenous similar growth growth direct treat call category consider precursor allow demethylating adna demethylizes tumor nti normal normal metabolite demethylation cell cell cell cell cell cell cell control promote metabolism suppressor suppressor suppressor block regulate drug cause decitabine decitabine decitabine target result number anti syndrome dna divide substance substance acute cytotoxic chemotherapy chemotherapy function gene gene gene rapidly effect y interact cellular death division division interfere thus methylation methylation blockage incorporate plastic 
1.67@therefore therefore overproduction methyl agent hypomethylating target transcribe restrict level prevent prevent synthesise dna dna dna histone methylater allow inhibit resume expression methyltransferase normal keep silence group gene gene removal protein decitabine 
1.33@cancer cancer think class remember tumour tumour mark myelodysplastic capable change potential myelogenous treat call island dna dna dna dna dna epigenetic methylated methylated therefore precursor enhance reduce heritability normal nucleotide proliferative ensue methylation methylation cell cell removal blood leukaemia one suppressor residue physiological mitotic drug drug cause condition demethylated anti demethylases demethylases promoter develop relative kind acute syndrome expression cpg cpg gene gene effect remove remove belong due thus actively decitabine decitabine recently modifier prime 
2.0@cancer cancer article able agent anti growth note hypermethylated call island island island island lead development methylated inhibitor inhibitor allow allow demethylating inhibit dnmt tumor tumor tumor tumor tumor normal express express express cell expression also patient therefore drug function suppression suppression suppression course become prevent dna dna dna act act important important cpg cpg cpg cpg gene gene gene gene gene methyltransferase effect remove remove thus thus thus methylation methylation methylation decitabine decitabine decitabine decitabine work associate associate associate 
2.0@cancer effect usual class reactivation produce tumour tumour note note book book quite treat treat marrow coursera silence deform impact helpful link main recommend wikipedia read use suppressor cause text text stanford myelodysplatic internet anti old dna dna blood syndrome gene methyltransferase inhibitor epigenetically bone onset belong epigenetics epigenetics methylation decitabine decitabine work 
0.67@suppressor cytidine class drug chemically hypermethylation hypomethylation gene gene gene decrease island cpg lead dna dna dna promoter anologue important especially inhibit methyltransferase effect tumor belong repair although region decitabine 
0.67@dnm decapatine inhibitor class belong 
2.0@one cancer cancer suppresor undo induce drug methylyzer bring de change might island dna epigenetic whereby act silence cpg gene reduce tumor tumor hypermethylation thus decitabine control 
1.67@normally extremely run tumor dnmt dnmt favorable progress use fda usage hemi myeloplastic myelodysplastic loss throughout leukemia type cancer particular lead dna dna dna dna dna sustain latter acute methylated syndrome fe time curtain inhibitor methylation methylation methylation block chain division rase suppress decitabine decitabine decitabine substrate case approve cell methyl 
2.0@along demethylates term dnmt n methyl include cycle shore long analog azacytidine dnmti hypomethylation genetic overall grow suppress regulate body methylated particularly particularly division especially island island tumor tumor longer permanently hypermethylation repair nucleoside instability counteract cell cell cell cell cell may may tra specifically also greater however general replication se rea mean methylate number age become occur counter protect basically dna dna dna dna dna divide divide bind le inhibitor cpg cpg gene gene rapidly rapidly effect effect effect globally similar still due silence regulator decitabine decitabine decitabine decitabine create incorporate come indirectly enzymatic 
2.0@dna suppressor suppressor reverse expression expression demethylating activate gene gene effect reversion agent decitabine silence hypermethylation hypermethylation hypermethylation since methylation regression tumor tumor tumor prevent cpg cpg cpg lead 
0.0@heavy cancer cancer class use agent stop already already also chance chance hypomethylation oncogene hypermethylated decrease decrease island island area area area unwanted methylated tumor intergenic hypermethylation genome deactivation allele cell cell drug drug drug supressor ecitabine methylating methylating activation presumably recombination cause cause target precursory gene become become element occur know hypomethylated region unfortunately repetitive dna cpgs cpg cpg ailment belong find methylation methylation decitabine wide expose would would would 
2.0@different inactivate class order induce tumour tumour tumour appear agent agent analog since round hypomethylation hypomethylation note transferase lead even promoter evaluation easy demethylating prose reduce question question essential express cell short methyl methyl suppressor suppressor cytidine transfer antimetabolite general drug write succesive number number number read anti address address meaningful dna dna dna dna block dinucleotide point cpg gene gene hence effect remove belong methylation methylation decitabine incorporate action paragraph replication without 
2.0@loss methyltransferases class able administration prsence agent analog find generation hemimethylated island next strand methylate methylated belong demethylating demethylating inhibit effective tumor tumor consider many unable way cytidine suppresor relate imprint drug drug tumoral type promoter dna dna dna cell cell cell cpg gene contain division new methylation decitabine decitabine decitabine region promise daghter antitumoral 
2.0@inhibitor class dnmt dnmt dnmt tumour tumour tumour state cytidine cytidine specific long process azacytidine dosis normal absence post strand density epigenome locus reduce reduce block affect irreversebly hypermethylation new release enzyme cell cell cell passively belong dependent suppresor therefore drug analogue analogue low bring anti promoter dna dna replicational bind gene demethylated effect similar division division longer longer thus methylation methylation decitabine decitabine possible methyltransferase 
2.0@cancer proliferate lead bee order hypomethylate methyl agent tend analog since since hypomethylation part make drug drug island achieve sequence methylated demethylating tumor tumor tumor replicate replicate bind nucleoside nucleoside nucleoside anymore mass basic cell cell global supressor mechansim large therefore therefore action need analogue analogue decitabine decitabine lay anti dmtase dmtase occur promoter group dna dna dna dna dna region region wich cpg gene rapidly effect effect remain cellular division dependent longer cant much incorporate form attach 
1.67@dacogen cancer along class dnmt use dnmts inhibitor inhibitor inhibitor agent eisai myelogenous dnmti treat inhibit nucleotide molecule epigenetic strand body precursor demethylating severely tumor affect neoplastic myelodysplastic release nucleoside japanese far far much leukaemia specifically irreversibly irreversibly replication analogue acute mean low anti good company dna dna dna dna divide dose cell cell cell bind bind bind bind syndrome sell function drug drug drug rapidly effect upon methyltransferase methyltransferase copy belong belong longer methylation decitabine decitabine daughter incorporate come come kill modifier small 
2.0@suppressor cancer action mitotic tumor methyl occupy remain functional gene gene anti transferase inhibit presence stick know help site enzyme cpg cpg island inhibitor detect upstream contribute contribute methylation decitabine decitabine daughter aberrant come active cell cell downstream drug machinery 
0.67@suppressor cancer higher indeed overmethylation methylates uncontrolled drug evolve agent result result growth occur call inhibit important dna dna show likelihood enzyme demethylating gene gene impact normal ezh may silence silence decitabine work activity cell cell cell tumour tumour belong 
1.0@mean mean mean cancer cannot term dnmt get use analogue mouse dependent embryo process irreversibly result dnmti fda replication replication tumour inhibit lead dna dna death death kill bind particularly act dnmts dnmts inhibitor rapidly mid methyltransferase lack effective replicate methylation decitabine nucleoside much incorporate approve cell cell cell may 
2.0@mean could inhibitor last dnmt dnmt regulation tumour long sit growth direct heritable island nucleotide nucleotide irreversibly strand methylated take usualy replicate opossite produce turn thing nucleoside case cell cell may also replication analogue function incorporate transcribe translate methyl methyl methyl group group group dna dna consideration repressor bind bind act important cpg time effect effect remove stage copy silence modification go work decitabine decitabine decitabine daughter gene gene another protein 
1.67@mean mean cancer cancer cancer cancer cannot cannot dnmt dnmt dnmt progress use along myelodysplastic treat nucleotide irreversibly strand strand methylate way may may release knowledge demethylation cell cell cell cell cell cell tumour nuceloside certain get replication analogue cause cause suppression effect effect become antitumour promoter dna dna divide bind bind syndrome act inhibitor gene aml importantly upon dependant copy division thus methylation methylation decitabine decitabine decitabine decitabine decitabine daughter daughter incorporate come action rapidly 
1.67@cancer newer class dnmt dnmt dnmt dnmt dnmt dna dna dna dna use use activity mark lower call suppress irreversibly strand show enzyme enhance activation tumor tumor high maintain cell cell cell suppressor belong older unmethylation methylating nucleoside depend epigenetic epigenetic drug drug drug analogue toxic context anti halt nonspecific prevent study study dose dose bind inhibitor inhibitor gene methyltransferase effect effect division methylation decitabine decitabine daughter possible incorporate promise tumorigenesis 
2.0@growth restart restart able able tumour near include agent hypomethylating since since de de change change sit regulatory transferase island island suppress granddaughter epigenetic pass methylated methylated inhibit proliferation tumor tumor intergenic normal express cell cell cell cell cell cell cell inheritable methyl machinery methylating regain function ability decitabine decitabine decitabine decitabine apoptosis demethylated cancerous cancerous anti element halt repetitive dna dna dna dnmts cpg cpg affect hence effect effect effect effect preferentially preferentially would would would daughter gene gene mean bring differentiation onto 
1.67@suppressor demethylates dnmt upon replication dnmti gene gene bind promoter hypomethylated dna dna methylated act inhibit methyltransferase inhibitor tumor tumor decitabine decitabine daughter region express action 
1.33@one myc cancer transcription activate drug drug drug slow myeloma cause capable refulated forby anti type inhibit inhibit particular fordna dna therefor shut common involve responsible responsible belong demethylating gene gene gene proliferation effect tumor human methylation decitabine factor mean cell methyltransferase expression 
0.67@dacogen dacogen cancer abnormal class surely mode drug certain agent mark trademark type know group lead dna dna dna dna work sell belong demethylating gene way expression remove remove normal hypermethylation decitabine region action methyl methyl associate associate 
1.67@dacogen cancer cancer methyltransferases dnmt synthesize use use stop newly myelogenous dnmti dnmti hypomethylation direct inhibit molecule unable effective effective epigenetic strand methylate methylated especially reactivation tumor tumor tumor tumor longer generally thrive release cell cell cell cell control leukaemia suppressor methylating residue irreversibly fight spread analogue eventually md approach myelodysplastic constantly cytosine cytosine need lead lead treatment dna dna dna dna bind syndrome dnmts dnmts drug gene methyltransferase inhibitor replicate replicate new actively decitabine decitabine daughter activity action 
0.0@cancer cancer growth lymphoma uncontrolled system mutation whose meet substance part make call call inhibit surround enzyme enzyme ezh ezh group chromosome tumor glaxosmithkline methylates hyperactivity cell methyl pharmaceutical one suppressor include cause cause largest effort describe lot immune prevent develop company package histone histone function gene gene overactive world silence longer thus activity confer form protein 
1.0@cannot dnmt dnmt dnmt methyl methyl fda myelodysplastic high transferase lead lead recognize irreversibly strand effectas involve tumor conversion neoplatic nucleoside maintain many cell cell fast use use cytosine dependent lower adays therefore methyled replication analogue hemi exclusively incorporate relatively dosage do anti occur severly mylegenous dna dna dna dna dna dose acute bind syndrome cpg hence inhibitor whichis first replicate replicate methylation decitabine decitabine daughter lay approve 
0.67@promotion cancer effect achieve cancerour therefore methyltransferase tumour correct dosage dnmti dnmti growth growth anti type severly acceptable dna action expression inhibitor important proliferation reduce reduce dependant affect neoplastic division decitabine cell cell cell drug drug operate 
1.33@cancer restore restore within within produce agent process hypomethylates similar growth direct call decitabinealso category demethylating inhibit tumor normal normal demethylation demethylation cell cell cell cell cell control suppressor antimetabolite antimetabolite cause target number metabolism dna dna dna dna divide substance substance cytotoxic chemotherapy function gene methyltransferase effect interact cellular death belong interfere thus methylation decitabine work incorporate rapidly 
1.0@dna dna epigenetic deciabine specifically demethylating demethylating gene methyltransferase allow tumor tumor agent suppressor suppressor decitabine work strong drug promoter inhibit job would 
2.0@usual dnmt activate tumour tumour tumour agent useful hypomethylates generation test inhibit inhibit next strand precursor disease demethylating way dependend normal hypermethylation hypermethylation aberrant like cell cell use belong suppressor suppressor suppressor dependent also also therefore replication normally solid prevent dna dna dna dna bind dnmts gene gene gene aml division methylation methylation methylation decitabine daughter work work incorporate methyltransferase 
2.0@restrictor restrictor cannot suppressor suppressor myelosplastic use euchromatin agent agent stop island island result uncontrollably transcribe growth growth growth hypermethylated treat prevent dna dna action open divide pack tumour tumour tumour tumour group syndrome heterochromatin expression demethylating demethylating densely remove grow belong silence decitabine decitabine gene gene gene gene cpg cpg express many cell methyl reactivate 
2.0@suppressor class activate activate tumour tumour agent mark growth gene gene gene gene gene decrease inhibit many many many dna dna dna dna dna epigenetic example act prevent prevent methyltransferase inhibitor tumor block block silence thus methylation methylation methylation decitabine decitabine decitabine uncontrolable lay demethylation cell supressor 
1.33@myeloid methyltransferases class presumably regain use work inhibitor add agent hypomethylating leukemia treat group cpg island dna dna dna acute syndrome precursor allow thereby inhibit inhibit methyltransferase reduce tumor tumor tumor myelodisplastic belong turn thus thus methylation decitabine decitabine decitabine gene gene activity suppressive suppressive suppressive methyl 
1.33@cancer effective although irreversibly seem replication analogue dependent dependent malignancy avoid island cpg dna dna dna dna dna divide work action bind inhibitor hypermethylation still affect methyltransferase dnmts unclear mechanism normal give thus actively decitabine decitabine nucleoside severely incorporate incorporate methylation cell cell drug 
1.67@kind cancer effect suppresor therefore activate tumour tumour agent since anti hypermethylated drug group cpg dna dna help silence demethylating island take along start decitabine decitabine gene gene mean cell methyl would 
2.0@cancer inhibitor inhibitor inhibition restore dnmt dnmt dnmt dnmt dnmt dnmt synthesize use mark mark newly analog malignancy dnmti hypomethylation hypermethylated treat lead lead irreversibly strand take essential tumor tumor tumor mechanism normal inactivation hypermethylation hypermethylation clear myelodysplastic nucleoside retain like like drug drug cell cell cell cell may care suppressor suppressor suppressor dependent dependent therefore activation replication replication region imaginable highly maintain althrough treatment dna dna dna bind syndrome target still gene dnmts unclear growth growth control set due methylation methylation decitabine decitabine daughter mitosis incorporate action haematological 
1.67@reason cancer cancer growth therefore drug agent decitabine decitabine hypomethylating anti hypomethylation useful tumour tumour tumour promoter promoter treat treat lead dna expression syndrome act silence gene gene gene last effect week uncontrolled myelodisplastic hypermethylation due allow learn demethylation cell cell use supressor supressor 
2.0@rate inhibition disrupt tumour tumour tumour tumour tumour process disease unmethylated treat affect island cpg often amount irreversibly strand comparasion division inhibit due normal genome genome correlation like cell cell cell use belong dependent potentional replication replication development incorporate anti normally methyl promoter group example dna dna dna dna dna dna dna dna segment consequence inhibitor drug gene methyltransferase methyltransferase effect increase increase increase great longer methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter region lay supressor bound small 
2.0@growthare cancer methyltransferases restore dnmt tumour agent result gene gene gene hypermethylated hypermethylated drug promoter promoter group action treatment dna cell function demethylating inhibit turn normal belong anticancer decitabine decitabine decitabine work regulate lead removal methyl suppressor class 
2.0@cancer inhibitor inhibitor dnmt activate check methyl methyl certain cycle cycle island analog like isalnds type decrease lead potentially dna dna dna dna dna irreversibly transferase transferase bind function cpg cpg gene gene gene reduce result block keep hypermethylation treatment silence silence methylation methylation decitabine decitabine decitabine nucleoside incorporate enzyme cell cell control important 
1.33@cannot inhibition class progress use state appear myelodysplastic analog leukemia treat island molecule molecule position sequence particularly hypermethylation myeloid tumor block myelodisplastic link nucleoside anymore cell cell cell way reach decitabine decitabine dependent via replication highly opportune dna dna dna dna dna divide acute syndrome syndrome act act cpg irreversible methyltransferase methyltransferase methyltransferase inhibitor belong mother methylation methylation identical daughter incorporate incorporate active reproduce 
2.0@one cancer cancer cancer also presumably tumour cause agent way since since effect anti inhibit inhibit dna dna dna expression demethylating locus methyltransferase reduce belong usually silence silence methylation methylation decitabine gene gene gene gene mean enable supressor supressor 
1.67@fail reduce reduce exact dnmt dnmt dnmt produce use use precise effecte also substance md md transferase inhibit irreversibly regulator inhibitor refer take stun mechanism normal besides fact nucleoside case benefcial way enzymatic discover epigenetic regain drug drug function toxic target result without yet anti methyl analogon dna dna dna dna dna dose dose bind bind chemotherapy dnmts dnmts irreversible effect effect place belong longer new new methylation methylation methylation decitabine decitabine work incorporate action neoplastic small 
2.0@suppressor critical restore need cause cause tend apoptosis apoptosis suppression hypomethylation hypomethylation anti hypermethylated methyl transferase dna dna dna dna inhibitor function function gene gene gene effect tumor tumor tumor tumor tumor growth growth normal normal normal silence decitabine decitabine many cell cell cell differentiation may tissue 
2.0@cancer cancer cancer methyltransferases inhibition class lymphoma dnmt dnmt dnmt check manner agent specific specific correct sit sit growth growth potential make progressively island lead irreversibly strand display inhibitor silence demethylating inhibit proliferation tumor tumor tumor tumor tumor hypermethylation thus dilute factor express demethylation thereby control suppressor suppressor suppressor expression reduction cytidine upstream therefore hallmark replication replication analogue could could cycle facilitate facilitate anti especially treatment dna dna dna dna dna maintenance cell cell bind unlikely act dnmts cpg gene gene gene methyltransferase effect keep belong new methylation methylation methylation decitabine decitabine decitabine progressive incorporate active full 
0.67@cancer suprressor inhibition gene within reactivation methyl agent hypomethylating cycle epigenitic target fast since economist leave decrease lead lead tranferase dna dna divide divide delution le wikipedia affect effect tumor coursera coursera normal methylation decitabine possible incorporate prone cell cell cell drug tissue 
1.67@dna suppressor cancer cause therefore activation gene effect tumor agent could decitabine silence turn tumoreginec hypomethelation hypermethylated anti case demethylation lead 
1.33@analogue class depend upon regular cause mostly myelodysplastic target since dosage dnmti anti decibine decibine dna dna dna get bind bind syndrome inhibitor dnmts dnmts methyltransferase effect tumor incorperated neoplastic belong decitabine nucleoside demethylation cell cell replication replication small 
1.67@suppressor lead lower apply drug slow agent succesive histone around growth growth hypermethylation inhibit epigenomic dna even kill inherit demethylating gene gene gene take tumor tumor tumor affect division silence methylation methylation decitabine daughter factor mean cell cell cell cell cell overactivity overactivity control control region 
2.0@inhibitor class able able use state hence deactylases myelodysplastic methylating dnmti penetrate hypermethylated treat decrease island irreversibly irreversibly tumour tumour involve establish belong conjugation proliferation initial mechanism modifier consideration genome nucleoside methylation drug drug drug drug cell cell trial yet level suppressor dependent lower possibility epigenetic replication replication replication analogue answer subsequent result result positive bring show dna dna dna however histone bind bind syndrome dnmts dnmts dnmts cpg gene methyltransferase effect control division actively decitabine decitabine decitabine decitabine mainly work incorporate across observe 
2.0@dacogen inhibitor disrupt dnmt dnmt dnmt use agent eisai myelogenous tumorigenic hypomethylation treat decrease inhibit irreversibly strand precursor demethylating severely reduce block affect hypermethylation nucleoside methylation methylation cell cell tumour tumour tumour leukaemia suppressor dependent excessive imprint replication analogue icr typically activity activity activity result promoter treatment dna dna dna dna divide acute bind syndrome sell myelodysplastic gene methyltransferase effect actively decitabine decitabine decitabine decitabine decitabine incorporate 
2.0@cancer inhibitor within dnmt use mark myelodysplastic dnmti dnmti dnmti treat inactive act effective effective effective strand tumour allow reduce reduce due permanently rase render aberrant case demethylation cell cell cell methyl methyl inhibtor tra high rat cause cause decitabine decitabine decitabine decitabine low cancerous fact type particular syndrome dna dna dna dna dna dna dna dna dna dna dna dna however dose reverse bind integrate integrate fe dnmts aml effect effect must division division replicate replicate new new methylation methylation reach daughter lay kill methyltransferase methyltransferase 
1.67@one reason cancer dnmt drug let become become reducedna easier make decrease inhibit treatment dna dna dna dna dna strand expression gene gene methyltransferase reduce unite belong may methylation methylation methylation decitabine express tumour tumour 
1.0@cancer cancer cancer methyltransferases term effective effective agent agent agent long mark mark cannot change treat effectively inhibit inhibit inhibit suppress previously often pass help enzyme enzyme demethylating island island island reduce tumor hypermethylation hypermethylation hypermethylation hypermethylation rely molecule carcinogenic like like cell cell cell cell cell cell erase pas cancerous basically treatment dna dna dna dna divide divide sodecitabine cpg cpg gene gene methyltransferase expression expression increase increase silence methylation methylation methylation decitabine decitabine daughter daughter return action rapidly onto onto associate 
2.0@adversative cancer cancer cancer cancer cancer methyltransferases determine dnmt tumor state appear agent specific specific myelodysplastic hypomethylation leukemia instability affect inhibit inhibit suppress benefit benefit irreversibly reversible inhibitor demethylating severely myeloid categorize round normal hypermethylation suppressor alteration methylation methylation methylation primarily treatment cell cell recover dna dna dna dna dna dna dependent therefore epigenetic epigenetic epigenetic mostly replication replication certain however result target condition synthesis ultimately depletion type subsequent fact genomic decetabine several get acute syndrome dnmts drug gene aml effect interact enzymatic replicate regulator decitabine decitabine decitabine decitabine drive drive tumorigenesis rapidly follow 
1.67@dna dna dna dna decrease help itis gene proliferation reduce tumor tumor agent hypomethylating hypomethylates decitabine nucleoside incorporate methylation cell inhibit molecule supressor 
1.33@cancer methyltransferases conclusion order uncontrolled remain cannot growth unmethylated hypermethylated hypermethylated molecule methylate consequence consequence provide group activation tumor tumor tumor tumor normal access basic cell cell cell cell methyl decitabine decitabine substitute suppressor cytidine transcription large application find replication analogue revert condition number demethylate prevent damage dna dna dna repressor allow allow act act function drug drug drug gene gene gene gene hence hence supressing induce demethylation silence longer respectively rna incorporate return protein protein 
1.33@cancer cancer dnmt dnmt others use mostly add add add island analog meet dnmti useful avoid avoid inhibit cpg dnmtidecitabine irreversibly strand strand hyper severely replicate replicate affect nucleoside nucleoside hilum like cell cell cell cell tumour tumour belong dependent enzyme get hypomethylated replication cause anti methyl methyl methyl group group group dna dna dna dna dna dna divide bind bind drug rapidly along upon die division ti methylation decitabine decitabine decitabine decitabine daughter daughter incorporate come action methyltransferase methyltransferase 
2.0@cancer cancer cancer cancer inhibitor inhibition class dnmt activate activity tumour tumour hematological mutation aberrantly depletion also malignancy hypomethylation hypermethylated transferase transferase transferase island dna dna dna dna dna lead irreversibly see allow proliferation effective effective tumor normal may nucleoside often methyl methyl methyl level supressor suppressor transcription depend depend however replication analogue cause cause decitabine target reverse anti region hence promoter cpg reduction get dose cell cell cell cell bind drug drug multiply rapidly effect effect induce growth contain belong silence methylation methylation methylation inside gene gene gene incorporate resume 
1.0@cancer inhibitor inhibitor specificity dnmt dnmt subject use use use agent long myelodysplastic remain myelogenous therapeutically change change md md hypermethylated treat transferase inhibit inhibit act achieve open epigenetic epigenetic level term precursor issue demethylating island research tumor mechanism lack chromatin nucleoside gsk cell methyl suppressor drug drug drug drug drug detail patient consequence via need analogue structure toxic irreversibily target result without do know good dna dna excessively dose histone histone bind syndrome accessibility expression cpg gene methyltransferase enzyme enzyme molecular stage deacetylase silence replicate thus methylation decitabine work activity action 
1.33@dacogen cancer cancer cancer cancer characteristic inhibition mode activate uncontrolled agent whose epicentre azacytidine azacytidine growth carlo transferase transferase inhibit job cytosine cytosine epigenetic dna dna dna dna dna dna dna dna common establish hyper hyper demethylating tumor tumor turn bond enzyme cell cell may may suppressor suppressor cause cause analogue information activity result result prescribe reference stop methyl methyl reduction deoxy lyko covalent gene gene frank inhibitor inhibitor int belong silence silence methylation methylation methylation decitabine decitabine decitabine decitabine stresemann incorporate action action methyltransferase 
2.0@cancer cancer faster dnmt dnmt decitabine use analogue dependent agent hypermethylate myelogenous treat better act dna dna dna irreversibly acute bind bind syndrome precursor dnmts demethylating drug inhibitor myelodisplastic normal replicate release nucleoside incorporate cell cell cell replication replication leukaemia 
0.33@suppressor lead therefore use syndrome myelodysplastic hypomethylation inhibit weaken dna dna acute particularly demethylating gene gene methyltransferase myeloid tumor mechanism silence decitabine primarily treatment drug leukaemia 
2.0@cancer cancer methyltransferases dnmt dnmt use agent place article article article economist economist note generation treat call inhibit nucleotide benefit strand lose inhibitor inhibitor wikipedia take undesired week reduce reduce cell cell cell cell strongest identify decitabine decitabine decitabine decitabine trap cause function function function likely likely reference lecture prevent particular dna dna dna dna dna dna dna dna dna divide dnmts progressive rapidly effect dependant copy copy demethylating replicate methylation methylation methylation methylation desire daughter daughter course methyltransferase 
1.67@cancer cancer inhibitor dnmt replicationupon say lock analog similar nucleotide irreversibly strand body severely way able rid affect nucleoside cell cell cell much decitabine one dna dna dna dna dna dependent aredividing replication cause cause actually modification modification mean good kind kind get get bind bind bind act additional methyltransferase methyltransferase methyltransferase along along range copy division replicate replicate methylation methylation longer daughter incorporate come come rapidly 
2.0@mitotically cancer inhibitor able progress methyl methyl fda add dnmtiis contrast dnmti potential potential genetic heritable inhibit often irreversibly strand reversible dnmt tumor tumor tumor tumor activation normal hypermethylation hypermethylation hypermethylation myelodysplastic therapeutic cell cell cell drug fore tra dependent suppresor suppresor epigenetic epigenetic decitabine decitabine decitabine alteration alteration replication analogue mutation incorporate result result result anti promoter group treatment dna dna dna dna dna dna reverse reverse bind bind syndrome fe dnmts dnmts inactived gene gene target effect devide belong suppresorgenes rase nuceloside daughter mean approve approve methyltransferase methyltransferase reversibility 
1.0@cannot dnmt formation formation reach say slow agent event article article economist dnmti dnmti overall transferase inhibit inhibit inhibit lecture atherapeutic especially tumor tumor tumor tumor tumor accord hypermethylation may properly read cell methyl level decitabine decitabine decitabine suppressor suppressor chromatinremodeling answer three limit know unfortunately dna dna decrease decrease function gene inhibitor inhibitor try increase belong methylation methylation expect learn protein progression 
2.0@reduction transfer insert patient able use analogue trap activity result meet silence md drug prevent suppress molecule dna dna dna enzyme demethylating island provoke elderly hypermethylation go decitabine decitabine gene cpg as tumour 
1.67@dna dna dna dna abnormal abnormal syndrome hypomethylate methyl effect tumor agent hypomethylating hypomethylating myelodysplastic decitabine decitabine decitabine anti hypermethylated transferase inhibit 
2.0@reduction cancer cannot inhibition preparation suppressor via via tumour tumour carry cycle stop decitabine decitabine mark mark mark suppression analog growth replication methyl inhibit lead dna dna dna dna dna irreversibly bind bind daughter act gene gene methyltransferase methyltransferase mean uncontrolled uncontrolled control division division division replicate replicate may methylation methylation methylation vital nucleoside incorporate cell cell cell cell cell attach alter genome 
0.33@myc myc different cancer abnormal class approximately agent two cytotoxicity hypomethylation inhibition incorporation marrow inhibit inhibit molecule regulate epigenetic epigenetic strand involve human human bone reduce reduce tumor tumor tumor mechanism mechanism block block block incidence give high factor regulator cell cell belong transcription become via via cause cause cause decitabine decitabine decitabine hematopoietic ultimate encode anti improperly lead common dna dna dna dna dna dna dose act expression gene gene gene gene gene methyltransferase methyltransferase inhibitor jq death aim methylation locate activity hypomethylates brd brd 
2.0@cancer reduce class cite agent potentially hypomethylating apparent number note treat affect degree reduction epigenetic effect tumour inhibitor refer proliferation bullit question normal hypermethylation decitabine decitabine decitabine nearby gsk cell cell cell use associate 
2.0@suppressor cancer restore overmethylation overmethylation excess use certain agent accumulation suppression result group dna dna involve act proper demethylating prevent prevent expression tumor tumor silence thus thus decitabine decitabine gene gene methyl 
1.33@suppressor cancer also category antimetabolite agent activity similar cytotoxic normal metabolism call methylated chemotherapy demethylating adna effect tumor accord cellular inactive restore belong metabolite decitabine gene incorporate cell 
0.67@cancer effect comparison dnmt dnmt dnmt tumour fda analog dnmti replicate affect irreversibly strand methylate inhibitor belong severely longer normal normal vidaza nucleoside nucleoside like cell cell cell drug drug release dependent need theyll mean see come anti dna dna dna divide base bind bind function methyltransferase methyltransferase along copy division mother methylation decitabine decitabine incorporate theyre approve rapidly replication replication 
1.33@cancer cancer inhibitor tumor use drug concretly agent afecting gene hypermethylated treat could reactive dna dna epigenetic conytibutes wich demethylase ezh end enzyme enzyme remove remove demethylating methylation methylation decitabine decitabine possible cell deactive would supressor 
2.0@cancer class dnmt dnmt tumour tumour newly newly change generation generation back transferase inhibit next next status strand pass pass methylated enzyme island island island activation methylate normal hypermethylation hypermethylation usually release nucleoside actively cell cell cell cell cell cell methyl region one suppressor suppressor erase epigenetic decitabine decitabine replication analogue hemi revert incorporate result see gene gene become completely promoter prevent dna dna get action bind bind cpg cpg irreversible inhibitor belong replicate silence methylation longer mitosis mitosis lead come form form onto 
0.67@cancer cancer cancer also higher restore dnmt dnmt may concentration unmethylated demethylate cytotoxic inhibit dna divide divide methylated normally rapidly inhibitor normal generally methylation cytozines incorporate cell cell cell decitabine 
1.67@hasbeen tumor indicate reactivation epigenetically agent hypomethylating myelodysplastic myelogenous hypomethylates lation antitumour inhibit treatment dna acute syndrome precursor link gene effect induce belong silence decitabine decitabine hypo supressor leukaemia 
0.67@specifically cancer class target dnmt dnmt dnmt formation much certain likely healthy decitabine decitabine process newly probably since idea show hinder disrupt dna divide divide establish discuss enzyme inhibit rapidly inhibitor tumor tumor pattern pattern pattern pattern pattern belong thus methylation methylation methylation crucial establishment aberrant cancerous demethylation demethylation cell cell cell cell drug drug associate 
1.33@dna dna cancer kill class demethylating remove tumour effect epigenetically agent turn decitabine anti cell cell group methyl imply 
2.0@cancer reduce abnormal reactivation use agent hypomethylating analog analog alsodirect leukemia incorporation marrow inhibit previously lead ctyadine bone inactive myeloid affect hypermethylation supressors render demethylation cell cell cell tumour myelodysplasic cytadine cause hematopoietic dual treatment dna dna dna dna exacerbate acute syndrome act gene methyltransferase methyltransferase inhibitor death due methylation decitabine decitabine decitabine decitabine mainly cytotoxicity action differentiation 
2.0@suppressor cancer methyltransferases promote therefore use drug agent anti inhibates treat dna dna dna dna reverse consider dnmts demethylating demethylating gene effect tumuor affect hypermethylation due fact methylation decitabine tumour 
2.0@dacogen cancer stronger class effective effective aka methyl currently decrease island desirable irreversibly transferase inhibitor inhibitor demethylating impact affect dnmtis hypermethylation clear thus cell cell tumour certain patient epigenetic seem drug cause cause improve property oftentimes know prognosis prognosis dna dna dna dna divide dose bind dnmts cpg poor rapidly effect effect effect must belong replicate since methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine theory strong severly incorperated 
2.0@unregulated cancer cancer demethylates dnmt dnmt activate drug drug drug mutation correctly growth growth unmethylated occur occur occur normal suppress maintenance dna dna epigenetic reversible allow allow allow gene gene gene methyltransferase tumor tumor tumor mechanism block maintenace hypermethylation silence methylation decitabine work demethylation demethylation cell cell supressor 
1.33@dna dna get get lot bind bind adversely irreversible methyltransferase reduce dependant take affect division replicate thus decitabine decitabine tumour cell replication 
1.33@assignment 
1.67@suppressor cannot demethylates therefore therefore drug agent form useful remain since economist transcribe change make make counter act dna dna dna dna epigenetic see makeup le demethylating demethylating gene gene tumor tumor question normal thereby methylation methylation decitabine motor quiet quiet cell cell zacitidine 
0.0@loss inhibition target reactivation produce use agent agent specific event event analog analog since malignancy differentiation growth suppress search lead epigenetic reversible provide interest phasespecific tumor nucleotide neoplastic induction effectiveness deoxcytidine many cell kinase expression suppressor aza aza aza aza silent patient relapse activation via require aberrant combination phosphorylation therapy cdr cdr cdr remission demethylation dna dna dna dna dna intervention demonstrate inactivation prodrug irreversible aml inhibitor induce deoxycytidine rationale increase silence senescence methylation methylation decitabine gene gene incorporate complete methyltransferase 
2.0@cannot available dnmt dnmt use deme place myelogenous dnmti growth make treat analogous analogous irreversibly strand methylate precursor especially especially way block release nucleoside like cell cell tumour leukaemia dependent transfer high replication replication replication replication malignant novo slow bind bind occur thy treatment dna dna dna acute ase act act act le inhibitor drug methyltransferase rate methylations force try belong methylation methylation decitabine decitabine daughter much original machinery de 
2.0@suppressor suppressor cancer cancer cancer thing render dnmt dnmt fight much inhibitor useless silence silence silence irreversibly analog find dnmti dnmti like useful treat decrease prevent imply dna dna dna dna divide lot bind bind act responsible dnmts cpg island enzyme tumor tumor hypermethylation hypermethylation hypermethylation word since since methylation decitabine decitabine nucleoside gene gene mean area cell cell cell drug drug inhibit 
1.0@suppressor cytidine analogue analogue high dnmt dnmt trap methyl carry development toxic become low cytosine cytosine silence replication transferase prevent prevent dna dose dose bind enzyme drug inhibit inhibit tumor tumor hypermethylation thus thus methylation decitabine nucleoside nucleoside gene incorporate may alter 
1.33@cancer methyltransferases methyltransferases reactivation may cytidine meet hypomethylation inhibit nucleotide irreversibly strand body dnmt tumor senescence rapidly release program cell cell cell cell cell cell much decitabine decitabine suppressor dependent transfer get induction replication analogue deoxynucleotide as result result incorprated methylation promoter dna dna dna dna dna dna divide dose bind bind bind inhibitor inhibitor gene gene methyltransferase along along upon copy death division replicate low methyltransferses longer daughter mean come come action differentiation selectively 
2.0@maybe begin cancer cancer cancer cancer also threatment restore therefore reactivation use stability agent demethylases decitabine silence silence myelodysplastic result myelogenous reactivate bind group previously treatment dna acute help syndrome division demethylating inhibit inhibit inhibit tumor maintnance progression progression belong leukaemia methylation genome genome gene gene gene cell drug supressor 
2.0@suppressor suppressor restore restore use cause agent agent process myelodysplastic hypomethylates hypomethylation treat inhibit dna dna syndrome act function demethylating control methyltransferase tumor growth normal hypermethylation thus decitabine decitabine gene gene activity demethylation cell tumour blockage 
2.0@alt could methyltransferases methyltransferases restore dnmt synthesize methyl induce induce silence silence significantly hypomethylates reactivate hypomethylation hypomethylation potential call inhibit inhibit inhibit inhibit six epigenetic malignant show show inhibitor enzyme thereby proliferation research tumor tumor tumor mechanism mechanism block link underexpressed alteration img cell cell cell catalyze promoter promoter expression expression suppressor suppressor lower promote residue residue nonreversible presumably src decitabine decitabine decitabine decitabine apoptosis suppression result synthesis cytosine cytosine antitumor immune group group reverse dna dna dna dna dna dna dna dna dna dna dose inhibitory carcinoma covalent act newly downstream methyltransferase methyltransferase effect remove growth reversal classic replicate thus methylation methylation sequence gene gene gene gene gene differentiation differentiation stimulation adrenocortical 
1.33@suppressor cytidine myeloid restore restore use cause phase myelodysplastic analog since hypomethylation hypomethylation leukemia treat level inhibit aza expression expression dna dna acute syndrome hypermethylation cgi methyltransferase reduce tumor tumor result deoxycytidine normal increase division may dac dac dac decitabine gene many cell cell control promoter associate 
2.0@cancer cancer cancer along along restore restore within dnmt produce agent process growth direct call nucleotide category irreversibly strand silence tumor normal hypermethylation reversal release attractive demethylation demethylation demethylation cell cell cell cell control decitidine suppressor also antimetabolite antimetabolite divide replication cause cause therapy approach target number anti bind bind bind promoter metabolism dna dna dna dna dna get substance sgi cytotoxic chemotherapy chemotherapy function drug gene gene rapidly effect upon interact cellular copy death belong longer thus methylation decitabine decitabine daughter incorporate incorporate come come methyltransferase methyltransferase associate 
0.0@exaple inactivate deliver class reactivation produce others use agent therapeutic therapeutic hypomethylating hypomethylating find azacytidine reactivate carboplatin md adduct clinical epigenetic decitabineshows display involve variety info potency effective tumor tumor mechanism ing repair high gene gene gene hypo control decitabine decitabine decitabine suppressor patient patient therefore action study drug analogue strategy dose dose dose cycle cell cell cell low cytosine reversal effect methyl know treatment dna dna dna dna substantial deoxy hasdual death covalent function irreversible methyltransferase inhibitor epigenetically epigenetically growth increase silence silence silence solid capable ul ul possible incorporate cytotoxicity form differentiation differentiation combine would 
2.0@cancer cancer methyltransferases methyltransferases inhibition inhibition restore activate could shore potential potential propagate inhibit suppress cytosine cytosine epigenetic strand methylated island island reduce tumor tumor tumor tumor tumor tumor tumor tumor pattern affect hypermethylation hypermethylation hypermethylation usually express many suppressor suppressor suppressor suppressor suppressor transfer promote balance replication create cimps normally promoter promoter promoter parent potentially dna dna dna dna dna shut colorectal expression expression expression cpg cpg gene gene gene gene gene gene methyltransferase inhibitor epigenetically increase silence silence silence methylation methylation methylation methylation decitabine decitabine daughter mitosis imbalance associate 
1.33@different cancer inhibitor restore manifest tumor tumor tumor blood lock whose loop inhibit response walk malignant overcome enzyme stick relief close aza mitotic promotor express insulation cell cell cell cell demethylation demethylation may decitabine decitabine decitabine decitabine decitabine transcription extend activation activation relate induction induction plot cause deoxycitidin therapy cycle cycle apoptosis apoptosis suppression result phase phase type immune many dna dna dna dna synthesis syndrome site expression expression drug gene gene gene gene gene gene methyltransferase methyltransferase effect effect effect effect induce control methylation methylation complex resistance possible desirable differentiation operate 
2.0@cancer cancer cancer classify unmethalyted restore restore activate tumour tumour tumour tumour state mostly agent intergenic analog additional growth useful genetic heritable inhibit select area area methylate methylated therefore thereby island island island island particularly normal normal nucleotide produce usually phosphorylation demethylation cell cell cell cell cell control region suppressor suppressor suppressor faster also suppresor antimetabolite epigenetic hypomethylated hypomethylated via cause mutation contrastingly typically methalyted oppose effect element promoter intrans repetitive dna dna dna dna dna divide decitbine demthylating function cpg cpg cpg cpg gene gene gene gene methyltransferase inactivate epigenetically death silence additionally thus methylation methylation decitabine decitabine work incorporate miotcally interfere 
2.0@cancer cancer characteristic dnmt dnmt dnmt progress methyl fda specific dnaand myelodysplastic myelodysplastic cannot cannot treat transferase island island island lead lead lead irreversibly inhibit hypermethylation release nucleoside demethylation demethylation demethylation cell cell analogue get cause incorporate incorporate treatment dna dna dna divide acute bind bind bind syndrome syndrome act cpg cpg hence aml inhibitor methyltransferase bygetting belong methylation decitabine decitabine decitabine decitabine decitabine activity approve rapidly 
2.0@effective within dnmt tumour tumour tumour exsposure process upregulation result result currently hypomethylation hypomethylation anti lead approve treatment dna dna dna dna expression md syndrome division gene methyltransferase inhibitor lack hypermethylation myelodysplastic decitabine decitabine drive passive cell replication supressor 
1.67@suppressor dependent inhibitor class dnmt dnmt tumour tumour analogue manner irreversibly silence anti drug call prevent prevent angent prevention dna dna dna dna epigenetic bind bear enzyme demethylating gene effect ill belong thus thus methylation methylation decitabine decitabine nucleoside incorporate may replication 
2.0@proliferate restore incorporation formation drug cause agent apoptosis incorporate relatively also cytotoxicity hypomethylation hypomethylation effect exert antineoplastic inhibit inhibit adduct important dna dna dna dna dna dna dna dna divide non rapidly covalent function demethylating gene proliferation enzyme methyltransferase methyltransferase methyltransferase cellular cellular normal neoplastic may may phosphorylation decitabine decitabine decitabine decitabine decitabine attribute insensitive hypomethylates cell cell cell differentiation differentiation control class 
1.67@suppressor transcription run therefore methylates methyl reference anti hypermethylated lecture inhibit inhibit suppress dna dna dna dna dna dna dna irreversibly bind fe inhibitor gene methyltransferase methyltransferase methyltransferase effect tumor tumor slide rase methylation decitabine decitabine role tumorigenesis replication play 
2.0@vivo cancer methyltransferases restore restore within within produce way include agent process intensively reactivate growth potential direct change call decitabinealso category death malignant inhibitor silence blast inhibit twofold myeloid tumor normal normal early anticancer incorporate demethylation demethylation cell cell cell cell cell cell control one suppressor patient antimetabolite study cause apoptosis target acute number deacetylases show metabolism dna dna dna dna divide substance substance histone cytotoxic chemotherapy function gene gene rapidly effect effect induce induce interact cellular believe belong interfere thus methylation methylation class similar differentiation methyltransferase 
1.67@cancer inhibitor class activate methyl methyl methyl fda inhibibor shore analog transfer dnmti hypomethylation inhibit inhibit methytranferase phenotype irreversibly irreversibly strand enzyme island island island island proliferation tumor tumor tumor nucleoside interruption genespromoting drug drug helix tra suppressor also cimp epigenetic decitabine decitabine decitabine replication cause novo anti normally group tranferase dna dna dna dna dna dna dna dna cell bind bind guard fe cpg cpg cpg cpg methylator effect cellular belong rase methylation methylation double double incorporate incorporate safe approve de 
1.67@suppressor methylating drug cause cause include effect anti level prevent lead dna dna dna act enzyme demethylating gene gene gene nearby reduce tumor tumor tumor increase thereby silence methylation decitabine decitabine activity activity active tumorigenesis supressor 
1.33@cancer cancer inhibitor class effective progress use attempt myelodysplastic find de leukemia tumour tumour decrease inhibit suppress irreversibly irreversibly development transferase belong demethylating island chromosome myeloid methylate normal normal proliferative nucleoside general cell cell cell cell way decitabine dependent greater epigenetic necessary seem replication analogue prevalent novo highly result low course normally methyl treatment dna dna divide dose acute bind syndrome act dnmts dnmts cpg drug aml effect effect effect relatively cellular integration concern methylation methylation desire hence action survival side tissue 
2.0@inhibitor inhibition dnmt dnmt methyl methyl myelodysplastic analog find hypomethylation hypomethylation cytosine cytosine irreversibly strand consider tumor turn genome nucleoside five suppressor specifically patient epigenetic epigenetic replication incorporate result result result without bind promoter group group dna dna dna dna dna dna dna dna position base base reverse demonstrate syndrome act gene gene methyltransferase effect remove silence modification methylation methylation decitabine decitabine decitabine region activity modify 
1.33@myc myc myc myc myc dacogen cancer inhibitor activate wrong use slow jq jq jq already eisai myelogenous substance inshutting treat call call market job unable epigenetic epigenetic involve whichinhibits proliferation pattern block block block test precursor go myelodysplastic directly factor name cell way methyltraferase leukaemia one one surprisingly transcription researcher mouse drug cause myeloma result encode do common company dna however acute syndrome sell function function gene gene gene expression describe similar human find regulator decitabine decitabine em em em em em activity activity brd brd collaborator indirectly protein 
2.0@suppressor cancer also restore antimetabolite produce tumour cause agent ability hypomethylates growth direct class dna dna divide cytotoxic demethylates belong demethylating gene rapidly effect death division decitabine decitabine decitabine regulate cell cell 
2.0@cancer cancer rate higher suppressor behave progress tumour agent heathy anti myelogenous meet hypomethylation vulnerable catalyse treat inhibit addition irreversibly involve normally allow demethylating wherethe theenzyme bind nucleoside hypermethylated counteract cell cell cell may leukaemia compare transfer ofconditions replication analogue cause become type methyl group group dna dna dna dna dna dna blood acute ase syndrome myelodysplastic gene methyltransferase effect effect upon silence replicate currently decitabine decitabine dectiabine work incorporate approve 
2.0@mitotically cancer cannot dnmt use state attempt place anti analog analog resolve heritable transferase island treat time decrease methylated inhibitor enzyme enzyme enzyme enzyme stick stick tumor tumor tumor affect hypermethylation degrade nucleoside cell methyl suppressor drive one dna dna dna become therefore fewer drug drug promotors loss methylate cytosine depletion several transition bind dnmts dnmts cpg gene effect result result force epigenetics methylation methylation decitabine decitabine decitabine decitabine decitabine region incorporate covalently 
2.0@cancer cancer never dnmt dnmt dnmt may chemically agent hypomethylating affect inhibit nucleotide addition body involve well well severely mechanism normal lack release cytidine demethylation demethylation cell cell cell cell cell cell cell compare faster divide replication cause permanently add demethylated do particular dna dna understand understand duplicate bind bind time rapidly effect upon similar methylation decitabine decitabine decitabine daughter incorporate come 
1.67@cancer characteristic metastatis tumor tumor tumor tumour tumour slow agent agent stop inactivation myelogenous growth growth penetrate sit treat treat island island dna dna dna epigenetic know help common precursor demethylating demethylating control proliferation serve uncontrolled resistant feature hypermethylation fact myelodysplastic aberrant cell cell use use leukaemia one suppressor activation decitabine hallmark drug drug drug drug drug combination cycle apoptosis target target acute chemotherapeutic solid promoter etc lung harder histone syndrome function cpg cpg gene gene gene inhibitor notable deacetylase methylation locate resistance region machinery 
1.0@cancer cancer inhibitor class dnmt dnmt dnmt dnmt dnmt dnmt dnmt progress use guarnine since de catalyse incorporation hemimethylated cytosine irreversibly strand methylated responsible enzyme cellsthey normal mammal nucleoside maintain human tumour tumour dnais leukaemia one suppressor dependent transfer therefore divide isapproved fda replication analogue mylodysplastic acute mythyl aremore anti greatly novo group becomeincorporated dna dna dna dna dna maintenance cell cell bind syndrome act dnmts affect aml effect methyltransferase myloid belong methylation methylation methylation decitabine decitabine much lay rapidly follow anddna 
1.67@cancer cancer article magazine manner agent epicentre event hypomethylates reactivate change leukemia pharmacokinetic inhibit aza aza aza epigenetic strand reversible myeloid tumor good richard myelodysplastic although aberrant economist decitabine decitabine decitabine suppressor drug frequent therapy karahoca target th april type chain treatment dna dna dna dna dna hypomethylating similar acute syndrome cdr cdr gene aml function deoxycytidine silence methylation rna incorporate incorporate reference methyltransferase momparler azacitidine azacitidine 
2.0@cancer inhibitor higher restore regulation methyl concentration concentration agent whose derivative analog since azacytidine silence hypomethylation hypermethylated transferase inhibit inhibit class epigenetic call administer demethylating island nearby reduce tumor tumor tumor tumor turn block anticancer evident cell firstly drug belong suppressor suppressor cytidine lower extend divide epimutations require cause cause function methlyation activity histone anti reverse dna dna dna dna dna dna dna get deoxy synthesis synthesis dnmts dnmts cpg gene gene gene rapidly effect interact protein thereby thus thus decitabine decitabine decitabine decitabine decitabine work incorporate incorporate cytotoxicity secondly 
1.33@ecitabine methyltransferases inhibition incorporation use cause agent agent apoptosis myelodysplastic myelogenous hypomethylates hypomethylation direct exert inhibit treat dna dna dna dna dna dna dna strand acute syndrome precursor demethylating hypomethylated methyltransferase effect antineoplastic phosphorylation decitabine decitabine incorporate cell differentiation leukaemia 
1.67@dna dna dna dna dna strand impact activity syndrome demethylating cml methyltransferase reduce agent cause myelodysplastic incorporate methylation decitabine encourage anti treat mehtylation inhibit use 
1.67@inhibitor class class suppress agent anti histone overmethylation call call particular lead lead lead dna dna epigenetic reverse methylated name enzyme demethylating gene effect tumor tumor overactive suggest ezh ezh silence methylation methylation decitabine decitabine decitabine decitabine counteract action demethylation 
1.67@dacogen cancer inhibitor inhibitor activity restore hypomethylate use agent aberrantly silence myelodysplastic myelogenous malignancy reactivate growth treat call inhibit expression epigenetic precursor belong demethylating way impact uncontrolled affect like cell tumour supressor one commercialize consequently drug drug drug decitabine decitabine hematopoietic result result stop type show group good treatment dna dna dna acute syndrome usefull function som methyltransferase along induce hope great great main normal metyhilation gene gene another similar leukaemia azacitidine 
1.33@cancer cancer cancer cancer inhibitor inhibitor class dnmt use employ agent alteration hypomethylating myelodysplastic analog dnmti growth tsg tsg tsg tumour tumour inhibit treat nzymatic epigenetic epigenetic whereby reversible effectsinactive unlike reduce persist give directly render aberrant aberrant express passive cell cell cell cell way suppressor machinery transcriptionally ofepigenetic nucleoside irreversibly decitabine decitabine via replication mitosis mutation target target result chemotherapeutic methylationmaintenance anti andbinds occur promoter promoter dnmts dna dna dna dna reverse syndrome syndromeshypermethylation isincorporated gene gene gene methyltransferase effect effect upon loss division thus regulator inappropriate daughter methylation methylation methylation methylation silence silence yelodysplastic associate 
2.0@suppressor inhibitor class methyl methyl include include methy suppessor anti transferase inhibit inhibit demethylates dna dna dna dna dna epigenetic bind function demethylating proceed methyltransferase along normal belong silence group group gene gene gene gene tumour tumour tumour decitabine decitabine 
2.0@one inhibitor inhibitor class use agent already myelodysplastic currently occur know inhibit inhibit treat syndrome dna dna epigenetic development action action often involve involve sell enzyme enzyme demethylating effect effect tumor turn belong due methylation methylation methylation methylation decitabine work mean mean case interruption drug drug 
1.67@mitotically cancer dnmt dnmt dnmt dnmt dnmt uncontrolled place silence silence silence myelodysplastic de growth growth sit island island suppress epigenetic methylated precursor enzyme take tumor tumor tumor tumor tumor block hypermethylation nucleoside maintain possible drug drug suppressor suppressor suppressor angiogenesis un promotors metastasis depend irreversibly replication analogue incorporate result result retard allow allow type production production treatment dna dna dna dna divide cell cell cell bind syndrome act expression expression cpg cpg gene gene gene gene aml inhibitor inhibitor inhibitor condition division modification thus methylation methylation methylation methylation decitabine dmnt activity approve action protein protein 
2.0@cancer eliminate pome activate way agent could could probably th growth restrict inhibit treatment dna dna dna dna strand function function function ah methyltransferase methyltransferase supressing tumor tumor pro block apoptotic thus decitabine lat gene gene incorporate hypomethylates cell cell repress 
1.67@different cancer cancer inhibitor inhibitor inhibitor term progress use use use use agent long long long myelodysplastic find change ago azasytocine overall back effectively inhibit treat firstly firstly status usage therefore enzyme severely take myeloid affect nucleotide early style release high like counteract cell cell cell cell cell however yet leukaemia risk risk also incorporation consideration study need cause strategy toxic expectancy low azacitidine replication methylation methyl methyl whenever demethylation demethylation dna dna dna dna dna dna divide dose dose acute bind syndrome recent still time rapidly effect transferee transferee dependant life increase division division undergo normal normal decitabine decitabine dmnt mean action totally 
2.0@inhibitor class dnmt use agent stop decitabin become hypomethylates dnmti growth growth methyle decitabene decitabene decitabene decitabene affect inhibit suppress suppress epigenetic strand methylated belong demethylating demethylating severely normal nucleoside demethylation demethylation cell cell cell cell tumour tumour tumour tumour tumour tumour decitabine decitabine suppressor suppressor dependent transfer transfer therefore therefore understand replication replication mean result result gene gene anti bind bind methyl methyl know group dna dna dna dna dna dna divide irreversibaly ase ase act le le dnmts dependency analouge effect copy division decitaben new regulator ul ul ul ul ul ul daughter much much incorporate active action action rapidly enzymatic 
0.0@dacogen dacogen dacogen cancer cancer cancer medication medication effective baby baby use use use use use purpose myelodysplastic easily lower bodyfight growth type ache harm treat marrow unborn body doctor doctor tell bone pregnant pregnant list blood blood blood may may may unusual cell cell control also call bruise spread certain man could father become child treatment get fever syndrome chill defect interfere birth birth decitabine decitabine bleed bleed sign clot infection infection infection help help 
1.67@relate state agent pathway dnaopening bind apoptosis specially prevent dna maintenance help dnmts demethylating gene chromatin silence methylation decitabine express cell differentiation 
2.0@mitotically methyltransferases higher use state agent agent long mark analog since since reactivate change useful find heritable normal island dna dna dna dna dna cytosine epigenetic strand reversible particularly demethylating inhibit affect affect hypermethylation hypermethylation may thus express cell cell cell cell tumour tumour tumour tumour one suppressor suppressor therefore drug promoter prevent several cpg gene gene gene rate remain silence replicate replicate replicate new methylation methylation methylation decitabine decitabine incorporate 
1.0@dna dna cancer regard class wild inhibit replication inhibitor methyltransferase stop belong go methylation dnmti work cell prevent drug decitabine 
2.0@begin cancer cannot class class slowly dnmt dnmt dnmt dnmt use dnmti normal irreversibly depend fall subject affect neoplastic hypermethylation release methylation cell cell cell far lower patient therefore drug result low anti merge prevent particularly dna divide divide dose bind bind act inhibitor inhibitor rapidly effect effect copy replicate thus terrible decitabine decitabine decitabine mitosis mean side 
0.0@dna duplicate site therefore progress inhibitor tumor stop belong decitabine demethylation prevent class 
0.33@analogue specificity dnmt dnmt dnmt drug hematological toxic md low malignancy mechanism anti effective long suppress action dna neoplastic dose dose irreversibaly bind depend inhibitor inhibitor gene inherent effect effect tumor neuclerside desitabine normal lack hypermethylation high incorporate term cell 
1.0@observable cancer cancer inhibitor class mode regulation decreasedmethylation subset agent stem since since growth growth regulatory renew oncogene change change inhibit suppress lead lead epigenetic epigenetic belong dna dna dna therefore division characteristic block affect hypermethylation turn vital role demethylation demethylation regulate control control crucial one suppressor suppressor suppressor tumor tumor tumor tumor patient antimetabolite activation necessary drug drug function know decitabine decitabine decitabine pathway population low dosage restoration come anti anti promoter several cell cell cell cell expression expression expression expression important gene gene gene gene gene gene gene effect memory resemble deregulate interfere epigenetics methylation methylation genome wide give machinery self play 
1.33@cancer cancer inhibitingdna term use use system agent agent alreadysuccessful cutaneous hypomethylating myelodysplastic analog myelogenous hypomethylates fda treat treat call call illness epigenetic epigenetic development mention mention precursor strategy demethylating demethylating adna alteration treatment treatment treatment way reversible one compare also also also also manner acytidine combination even acute mutation mutation cell sequence isused know develop company dna dna dna dna already already already already histone histone histone syndrome act act act drug inhibitor advantage rare deacetylase solid modification new methylation decitabine another approve acetylation 
2.0@suppressor cancer reduce dnmt dnmt dnmt dnmt agent methyl hematological chemically cytidine stop stop novo hypomethylating analog analog malignancy de transferase inhibit important dna dna maintenance bind bind responsible hypermethylation hypermethylation gene methyltransferase enzyme tumor tumor dependant suprressor human methylation decitabine decitabine nucleoside incorporate cell methylations 
2.0@dna suppressor suppressor methylating bind dnmt dnmt dnmt gene gene gene tumour tumour tumour tumour inhibitor cause suppress hypermethylation due decitabine decitabine methylated express prevent prevent use would 
1.67@cancer cancer cancer instead think class sugar dnmt use use fda faster nucleic mark mark myelodysplastic dnmti treat transferase island suppress effective irreversibly strand allow severely happen mechanism affect affect effectiveness vidaza nucleoside nucleoside acl drug drug cell methyl region acid dependent replication analogue analogue mean u uncertain express know dna dna dna get dose kill bind syndrome inhibitor cpg time along along remove copy contain belong replicate work methylation methylation decitabine decitabine daughter gene incorporate come approve action alter small 
1.67@cytidine critical become restore tumor use analogue agent acute hypomethylating cellulardifferentiation myelogenous hypomethylation hypomethylation replication treat affect inhibit dna dna dna dna body syndrome precursor function control proliferation stronger induce methyltransferase normal normal normal neoplastic replicate may myelodysplastic decitabine decitabine gene incorporate cell cell cell cell much 
2.0@myc myc dacogen cancer activate use slow slow agent agent agent john medicine eisai growth growth growth treat deacetylase island suppress lead enzyme demethylating demethylating demethylating reduce tumor tumor tumor block hypermethylation hopkins cell cell uncontrolled lung promote compactor cause mutation suppression become show bet dna dna dna school histone histone syndrome sell myelodysplastic cpg gene gene methylator inhibitor remove overactive chromatin ezh silence methylation decitabine decitabine advance brd brd protein 
2.0@cancer along gene gene dnmt dnmt dnmt dnmt activate upon use island myelodysplastic analog hypomethylation hypomethylation might transferase inhibit inhibit nucleotide irreversibly strand rapidly responsible enzyme severely reduce reduce tumor tumor tumor longer question question affect hypermethylation hypermethylation hypermethylation release nucleoside tumorigenicity cell cell cell cell cell methyl suppressor suppressor suppressor dependent dependent lower replication cause restoration mean mean body progressive promoter dna dna dna dna dna divide dose bind bind syndrome cpg bite methyltransferase methyltransferase inhibitor induce little copy division replicate replicate thus methylation methylation decitabine daughter daughter much much incorporate come action selectively 
1.0@dacogen abnormal dnmt dnmt drug cause irreversibly low commercially de hypomethylation metylating know group epigenetic lead dna dna dna divide dose bind integrate well belong inhibitor death azacitadine decitabine decitabine hematopoietic cell cell 
2.0@unregulated cancer cancer category within within produce activity way agent process similar growth growth direct call decitabinealso restore restore death belong demethylating twofold tumor block normal normal anticancer decitabineis regulate control blockage decitabine one suppressor suppressor suppressor promote antimetabolite antimetabolite drug cause information target result number chemocare gene gene gene become demethylation metabolism dna dna dna divide substance substance cell cell cell cell cell cell cell cytotoxic chemotherapy function believe rapidly effect effect interact cellular increase division division interfere thus methylation methylation allow work incorporate 
1.67@suppressor cancer lower much agent become anti level inhibit dna dna action demethylating prevent prevent prevent methyltransferase effect uncontrolled normal hypermethylation methylation methylation genome gene gene hypomethylated cell tumour tumour replication decitabine 
0.0@inhibitor class beongs reactivation tumor tumor induce md hypomethylation hypomethylation useful treat dna dna leaukemia acute syndrome precursor link anti aml effect epigenetically contribute silence myelodysplastic decitabine decitabine decitabine gen case myelogenic methyltransferase supressor 
2.0@cancer cancer myeloid dnmt dnmt progress fda myelodysplastic leukemia island island cpg cpg irreversibly strand common severely reactivation tumor tumor affect hypermethylation growh nucleoside demethylation demethylation cell cell global release suppressor suppressor dependent get replication analogue result result result halt treatment dna dna dna divide acute bind bind syndrome end gene gene rapidly inhibitor upon copy death division longer methylation decitabine decitabine daughter incorporate come approve action methyltransferase associate 
2.0@suppressor cancer cancer methyltransferases methyltransferases selectively therefore consequently much dependent decitabine decitabine decitabine decitabine decitabine incorporate result commonly number hypomethylation effect anti inhibit dna irreversibly action bind inhibitor consequence cpg cpg gene chromosome chromosome impact tumor tumor methyltransferase methyltransferase normal division division mother silence methylation methylation ensure daughter mitosis role cell cell cell cell rapid replication expression 
0.67@dacogen cancer suppressor uncontrolled include agent whose eisai find silence growth make treat call job lead immune precursor enzyme ezh proliferation reduce thus japanese tumour tumour systemare leukaemia kind therefore use methylates cause cause acute mutation cell cell lot surround stop lymphomascancers company dna dna histone syndrome sell myelodysplastic gene gene effect overactive demethylating demethylating myelogenous decitabine decitabine decitabine overactivity 
0.33@attachment see 
2.0@activate progress use agent agent agent hypomethylating myelodysplastic myelogenous hypomethylates dnmti growth hypermethylated back inhibit treat previously previously epigenetic decitabines antimetabolite well demethylating demethylating tumor tumor tumor normal neoplastic cell cell cell say leukaemia suppressor suppressor also also therefore relate drug drug drug bring anti know particular metabolism dna dna dna acute syndrome name gene gene gene gene aml effect induce suggest death silence silence interfere epigenetics decitabine decitabine another active methyltransferase follow azacitidine 
1.67@suppressor suppressor cancer cancer therefore able use dependent agent target replication replication hypermethylated occur inhibit undergo die dna dna irreversibly bind hypermethylation demethylating gene gene rapidly dnmt dnmt tumor tumor tumor longer normal generally replicate silence decitabine decitabine daughter daughter mitosis incorporate maintain influence cell cell cell cell cell cell much 
2.0@whichbelongs inhibitor cgis cgis class tern remove use beused agent myelodysplastic thedecitabine reactivate hypomethylation oncogene treat treat inhibit suppress lead precursor demethylating island affect hypermethylation turn express tumour tumour tumour leukaemia hypermethyltion suppressor suppressor suppressor therefore activation drug region could suppression promoter dna dna expression expression acute syndrome ofdna cpg gene gene gene gene methyltransferase inactivate epigenetically silence myelogenous methylation decitabine adna activity dnmti 
2.0@suppressor cancer activate use aid stop hypomethylating inhibit myelogenous hypomethylates treat grow dna dna divide acute syndrome precursor myelodysplastic demethylating adna methyltransferase tumor decitabine gene cell protein leukaemia 
1.67@document cancer methyltransferases higher class dnmt use concentration pattern process myelodysplastic cytostasis hypomethylation treat copy partially nucleotide irreversibly strand get methylated involve responsible modulate demethylating severely tumor mechanism affect establish release cell cell much angiogenesis agentens divide appear replication decitabine decitabine apoptosis mean body bind bind bind syndrome dna dna dna dna dna dna dna maintenance cytotoxic mediate act act inhibitor gene methyltransferase methyltransferase effect upon cellular along along belong replicate methylation longer daughter incorporate come come differentiation rapidly 
1.33@cancer state inhibition erase n methyl cause specific lower growth occur often dna dna dna reverse promotors expression inhibitor tumor tumor tumor hypermethylation decitabine tra supressors supressors 
2.0@elod plastic introduction proliferate dnmt tumour tumour tumour tumour tumour chemically agent hypomethylating hypomethylating inhibitingdna hypomethylates growth leukemia hypermethylated avoid avoid aza epigenetic strand acytidineanalog inhibitor inhibitor impact cpgislands hypermethylation hypermethylation therfore reduce adrugfor express many control expression suppressor suppressor dependent foracute relication y antitumor adequate myeloid treatment dna dna dna dna dna dna dose bind syndrome dnmts gene gene aml effect effect deoxycytidine antineoplastic methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine region incorporate incorporate methyltransferase 
2.0@cancer cancer size greater therefore dnmt activate tumour tumour tumour tumour dependent cancerous dnmti surpressor surpressor surpressor effect incorperated bind treat prevent often dna dna irreversibly even help inhibitor dnmts dnmts cpg island reduce reduce reduce gene gene gene normal hypermethylation hypermethylation replicate methylation methylation allow work lay cell cell cell replication decitabine decitabine decitabine 
1.67@promoterregion effective supression tumour tumour tumour agent agent transfer transfer hypomethylating ytosine silent malignancy hypomethylation methyl inhibit inhibit inhibit methylcytosine addition transcriptionally ucleotides methylated involve demethylating island pattern normal inactivation hypermethylation hypermethylation high aberrant like like may level supressor compare also large large intheir iochemical meet meet body transcriptionand number anti demonstrate occur promoter group cpg dna dna dna dna dna dna dna dna dna process ase ase act le important drug gene gene gene gene gene effect evidence human word denine methylation methylation methylation methylation decitabine decitabine regulator region typically hypomethylates active tissue associate associate 
2.0@elod plastic cancer methyltransferases methyltransferases inhibition class produce use leukemia agent specific island myelogenous growth possibly treat treat effectively subsequently suppress suppress suppress stop call discuss discuss enzyme enzyme demethylating inhibit impact tumor tumor tumor mechanism uncontrolled precursor hypermethylation hypermethylation factor cell catalyze residue could y result result reaction cancerous transcribe occur know condition condition reverse dna dna histone syndrome act cpg gene gene gene overactive chromatin silence silence remodel thus methylation decitabine decitabine decitabine region activity 
1.67@cancer cancer cancer cancer certain growth dnmt dnmt healthy use use carry manner specific specific process methyltransferase adversely change associate type occur inhibit inhibit cpg dna dna dna dna epigenetic inhibitor enzyme drug drug island proliferation reduce reduce gene pattern affect hypermethylation hypermethylation thus methylation methylation methylation decitabine silence region lay slow slow cell cell cell tissue supressor 
1.33@cancer cancer article class germline sugar note require agent epicentre since almost potential incorporation call heritable epigenetic strand methylate differ demethylating enhance order mechanism nucleoside nucleoside nucleoside demethylation cell cell tumour tumour decitabine decitabine one dna dna dna dna dna dna dna drug divide divide replication analogue analogue combination postulate result cancerous four anti type know reduction process base bind bind act inhibitor inhibitor still irreversible rapidly effect effect unclear methyltransferase methyltransferase explain contain allow daughter possible incorporate action absolute chemotherapeutic 
0.67@enzymatic cancer class progress replication replication analogue fda dependent epigenitic myelodysplastic since growth transferase inhibit tumor dna dna dmnti bind syndrome function thereby affect affect aml inhibitor upon normal dnmtis dnmtis replicate methylation decitabine decitabine nucleoside incorporate approve cell cell modifier 
1.0@suppressor suppressor dependent specificity effective tumor tumor may uncertain analog malignancy malignancy overall decrease inhibit dna dna irreversibly bind dnamethylation allow drug time methyltransferase effect effect remove mechanism lack hypermethylation hypermethylation hematologic decitabine nucleoside gene gene gene incorporate express action replication would 
2.0@suppressor suppressor cancer cancer dnmt cgg tumour tumour cause agent could reactivation reactivate hypomethylation normally island dna act silence silence demethylating gene gene gene inhibitor remove hypermethylation methylation decitabine decitabine associate 
1.67@cancer cancer article tumour agent transcription economist de sit island island island decitabine decitabine regulate cytosine work step mitosis contribute inhibit reduce reduce tumor accord normal hypermethylation turn cell cell cell cell cell methyl path one suppressor suppressor methylating tp production cycle promoter prevent protect dna dna dna dna base group inherit cpg cpg cpg cpg gene gene gene gene methyltransferase inactivate remove death dinucleotides methylation methylation inappropriate daughter em protein 
1.33@vivo inhibitor higher administration use agent phase globely myelodysplastic myelogenous hypomethylates island leukemia decrease inhibit response clinical see decipher demethylating interest em tumor tumor tumor tumor mechanism mechanism sensitize high cell trial promoter region one suppressor suppressor suppressor ongoing via syndrome therapy chronic result effort anti ii considerable dna dna dna dna substantial histone chemotherapy expression expression cpg gene gene gene methyltransferase effect decreaseddna biologic belong finally methylation methylation decitabine decitabine decitabine decitabine deacetylase activity combine report 
2.0@elod plastic cancer cancer myeloid dnmt dnmt dnmt progress tumour tumour tumour part part include process formy dnmti dnmti change leukemia might affect methyltransferaseinhibitor suppress effective epigenetic epigenetic epigenetic epigenetic methylate allow inhibit inhibit way reduce reduce mean normal hypermethylation hypermethylation hypermethylation genome genome although blood suppressor irreversibly relate fda drug drug cause typically incorporate condition number anti show develop dna dna dna dna dna acute bind syndrome act target still gene gene gene methyltransferase effect unclear suggest silence silence thus thus methylation methylation methylation decitabine decitabine decitabine y approve action action enzymatic 
2.0@cancer rate induce tumour agent since cytotoxicity similar hypomethylation methyl methyl incorporation transferase inhibit suppress cytosine decitabines mechanism block aza turn high cell cell cell use tra suppressor activation via replication replication structure structure result low occur prevent several action covalent dna dna dna dna dose kill bind bind integrate fe function drug gene gene effect synthesis synthesis deoxycytidine report division division division rase methylation decitabine decitabine form propose 
1.33@cancer cancer inhibitor produce methyl prove hypomethylating myelodysplastic hypomethylation parameter epigentic island epigenetic epigenetic epigenetic strand belong mechanism mechanism block normal rase nucleoside knowledge cell cell cell cell way tra one one faster researcher divide drug drug drug drug enzimatic target focus bind group develop dna dna understand base action action dependent syndrome fe dnmts cpg irreversible current effect division main regulator decitabine possible incorporate machinery alter alter 
2.0@suppressor cancer analogue class dnmt activate via use cause apoptosis probably since silence growth anti treat island demethylation demethylation lead lead dna dna irreversibly tumour bind inhibitor dnmts cpg gene effect tumor control belong epigenetics decitabine incorporate influence cell way nuceloside 
1.0@cut dna cancer group therefore allow demethylating remove methyl tumor agent cpg methylation decitabine gene express treat island suppressor 
2.0@suppressor suppressor cancer methyltransferases daughter depend dnmt dnmt decitabine decitabine decitabine tumour tumour tumour analogue novo generation ul ul ul ul ul ul malignancy de like anti bind inhibit inhibit suppress next dna dna dna dna dna dna irreversibly help help maintain maintain inhibitor dnmts dnmts gene reduce activation hypermethylation hypermethylation thus methylation methylation methylation methylation haematological gen incorporate replication lead may nuceloside belong 
0.0@cancer cancer cancer instead abnormal excess use state agent myelodysplastic currently growth leukemia hypermethylated treat treat inhibit benefit epigenetic epigenetic precursor silence demethylating demethylating myeloid tumor normal usually terrible cell cell reprogram machinery market suppressor patient drug drug target kill cancerous case type treatment dna non acute syndrome function gene gene gene gene resume effect remove aim new methylation decitabine decitabine method work side 
2.0@cancer cancer methyltransferases available available effective uncontrolled unmethylated fda stop become transcription growth leukemia leukemia affect affect lead decitabines tumor tumor block normal epigenome although express cell cell cell cell cell suppressor also therefore package drug ability test result methylate anti solid loosely treatment dna dna dna dna dna divide bind syndrome inhibitor gene gene rapidly effect dependant must division decitabine decitabine work incorporate approve action methyltransferase 
1.67@cancer myeloid dnmt seem tumour tumour analogue inhibitor inhibitor induce specific mitosis myelodysplastic fast since dnmti leukemia anti island action dna dna divide non acute cytidine syndrome act target still methyltransferase effect unclear mechanism force preferentially cpg methylation methylation decitabine decitabine progress cell cell require drive 
0.67@successfully drug slow agent myelodysplastic myelogenous growth solid treat lymphoma deploy acute syndrome use ofdna demethylating rather people precursor decitabine decitabine form tumour tumour leukaemia leukaemia 
2.0@cancer cancer cancer cancer cancer formation hypomethylate slow agent tend hypomethylating transfer economist methylization methylization methylization growth growth leukemia inhibit inhibit suppress lead help enzyme enzyme island island myaloid tumor tumor dmt dmt dmt lack turn genome retain cell cell cell cell cell decitabine suppressor deme deactivate april mitosis mitosis th thy demethylizing reduction epicentre acute ase unconstrained cpg cpg gene gene function remove allow daughter daughter daughter work reference form add reactivate 
2.0@decline also class lymphoma overmethylation tumour inhibitor agent crucially animal currently dhanak effect treat treat amount develop dna refer proliferation culture laboratory name newly demethylating histone dramatically reduce normal belong nearby find find decitabine dr gsk gsk cell cell cell cell colleague unmemorable apparent 
2.0@cancer methylating class epigenetic use use unmethylated agent hypomethylating myelodysplastic result result surpressor leukemia treat effectively inhibit inhibit back dna dna divide mark acute syndrome division drug gene gene gene methyltransferase methyltransferase myeloid tumor tumor tumor describe suppress belong turn turn decitabine decitabine decitabine decitabine daughter cell cell cell cell tumour alter 
2.0@unknown cancer cancer inhibitor restore specificity dnmt use state agent hypomethylating myelodysplastic transcription dnmti dnmti change unmethylating hypermethylated predominant chemotherapeutics achieve irreversibly tumour tumour enzyme susceptibility happen mechanism normal lack epigenome thus directly nucleoside demethylation cell cell cell however global suppressor also high epigenetic epigenetic seem seem seem drug analogue could toxic low present anti occur nonspecific prevent dna dna dna dna mark dose dose bind syndrome still gene methyltransferase effect effect effect molecular hand silence currently methylation decitabine decitabine decitabine action action indirectly alter 
1.0@cancer cancer inhibitor inhibitor able produce continously tumour tumour prove quantity ocurring dnmti dnmti note useful block island solid imply irreversibly nonetheless ut better neoplastic dnmtis clear nucleoside small cell cell cell use one standard also final c fight replication work work functional dose know toxic target result analogus anti anti conjunction exactly show whereas develop dna dna get non histone bind name suitable dnmts drug drug drug moter ape effect dependant dependant must deacetylase replicate subsequent methylation methylation decitabine che much activity hdaci cpgs methyltransferase recently 
1.0@kind kind cancer cancer effect suppresor lymphoma relate tumour agent decitabine overmethylated substance immune dna dna level demethylating gene gene proliferation reduce reduce tumor normal belong methylation sytem region cell cell nearby apparent 
1.33@methyltransferases restore able others tumour tumour include likely hypomethylates reactivate aza aza cytosine epigenetic strand sequence observation demonstrataed mechanism link signal nucleoside nucleoside like metabolism removal cell cell locate transcription action either decitabine decitabine apoptosis apoptosis target target energy fa fa methyl promoter group integrate dna dna dna dna pathway inhibitory death mediate expression gene hence inhibitor inhibitor suggest increase epigenetics receptor rna incorporate malignancy azacitidine downstream associate 
2.0@begin begin cancer cancer cancer classify restore dnmt methyl unmethylated unmethylated chemically stop probably proliferate dpg inhibit open epigenetic silence grow tumor tumor tumor tumor tumor block block normal neoplastic hypermethylation create create gene gene gene gene gene express cell cell cell cell control control region suppressor suppressor suppressor suppressor hypomethylated drug promotors promotors healthy target version cytosine effect become become euchromatin group dna dna act heterochromatin function positive time methyltransferase methyltransferase inhibitor epigenetically similar chromatin dinucleotides decitabine decitabine daughter daughter daughter mitosis incorporate incorporate action 
1.0@cancer cancer cancer cancer methyltransferases reactivation progress methyl methyl state concentration agent epicentre demethylating transfer economist reactivate growth inhibit suppress often epigenetic allow aim as tumor tumor tumor tumor tumor tumor tumor tumor tumor block directly demethylation demethylation cell cell cell may may may decitabine decitabine decitabine suppressor suppressor suppressor deme limit drug revert lay introduce anti anti anti anti occur thy group group potentially dna dna dna dna domain bind act function function gene gene gene gene gene gene gene hence effect effect effect remove remove increase provide silence silence silence silence methylation methylation methylation methylation drastic region article propose propose alter associate 
0.67@myc transcription transcription act expression gene slow tumor block block decitabine decitabine growth factor factor show indirectly regulate 
1.67@critical dacogen dependent proliferate restore dnmt formation induce independent specific incorporate relatively also cytotoxicity hypomethylation hypomethylation anti normal inhibit adduct dna dna dna divide non proliferation covalent well function gene gene methyltransferase rapidly tumor mechanism cellular control increase may may decitabine decitabine decitabine decitabine decitabine attribute insensitive cell cell cell differentiation global promoter expression 
1.0@cancer inhibitor dnmt dnmt progress use agent know however irreversibly since yet leukemia treat normal normal dna dna divide divide acute bind syndrome act myelodysplastic demethylating rapidly myeloid methyltransferase affect affect dir decitabine ltr cell cell cell cell dont extent 
2.0@begin also article indicate dnmt check use use classify tumour online myelogenous economist reactivate leukemia md md treat treat lecture myelodyplastic myelodyplastic dna dna acute syndrome syndrome inhibitor source demethylating affect take decitibine gene accord accord progress progress death silence may decitabine place seem program demethylation cell aml aml suppressor 
1.67@myc lat transcription tumour deme lower encode hypermethylated antitumor thy lead gage gene gene effect block usually since methylation decitabine decitabine decitabine factor brd may andna 
2.0@cancer cancer methylating promote dnmt dnmt tumour tumour mean effect counter prevent suppress suppress lead dna hypermethylation gene inhibitor particular belong longer silence decitabine decitabine otherwise way would class 
1.67@different lung cancer cancer consequence use manner agent decitabine decitabine decitabine myelodysplastic hypomethylates silence gene anti treat treat inhibit previously syndrome dna dna dna dna non action covalent dnmts demethylating irreversible methyltransferase effect upon mechanism aaron line believe hypermethylation nguyen contribute small express cell cell cell tumour azacitidine 
1.67@guidebook cancer restore restore person produce use loss epicentre stem economist growth growth treat marrow june june june regulate epigenetic demethylating myelodisplastic myelodisplastic normal hypermethylation anticancer access access access cell cell cell cell cell blood one one one suppressor suppressor red cause seem drug drug function ability agent white therapy chemocare group dna dna divide kill cytotoxic syndrome syndrome syndrome syndrome platelet gene gene rapidly effect effect effect control division interfere methylation decitabine decitabine decitabine disorder bone medifocus medifocus 
2.0@cancer cancer methyltransferases methyltransferases methyltransferases activity may agent specific dnmti decitabine decitabine susceptible quite avoid inhibit inhibit molecule sequence methylated responsible enzyme enzyme enzyme demethylating tumor tumor tumor block block normal speculate cell cell cell cell catalyze promoter expression expression expression expression suppressor suppressor nucleoside relate study drug possible structure could cycle highly gene gene gene gene anti show treatment dna dna dna dna dna dna divide bind function function irreversible chemical effect similar division silence silence silence methylation allow time incorporate replication progression 
1.67@cancer dnmt dnmt progress use use fda specific myelodysplastic hypomethylation decrease inhibit epigenetic usage level enzyme enzyme myeloid tumor mechanism mechanism feature hypermethylation special nucleoside case supressor one analogue indicate due drug drug drug cause anti anti medical hiv treatment acute syndrome gene inhibitor leucaemia similar herpes methylation decitabine decitabine importance work approve modify haematological haematological malignacies 
1.67@loss patient use region mostly agent stop irreversible hypomethylating inhibit result result hypermethylation gene gene gene md md treat decrease group properly syndrome dna dna dna dna bind covalent function ineffective myleodysplastic methyltransferase belong silence methylation methylation decitabine decitabine production express cell differentiate blood blood 
0.67@cancer cancer effect class depend produce cell cell cell cell much agent normal since antitumor antitumor decrease response dna issa know antimetabolite demethylating demethylating dr impact explain belong methylation methylation methylation decitabine decitabine memory survival drug drug 
1.67@dna dna dna cancer transfer suppressor suppressor excessive tumour tumour island result bring hypomethylation hypomethylation transferase inhibit hallmark epigenetic involve act expression drug prevent inhibitor normal believe cpg silence methylation decitabine daughter gene gene lay cell methyl 
1.67@cause class therefore therefore dnmt dnmt dnmt tumour tumour analogue cure target irreversibly depend preform transferase dna dna dna divide divide strand bind daughter inhibitor belong drug rapidly effective easily copy division division longer methylation methylation decitabine decitabine decitabine nucleoside incorporate cell cell cell cell cell cell methyl dnmti 
2.0@cancer cancer methyltransferases patient able tumour tumour tumour tumour slow agent cause decitabine decitabine decitabine island property loss cannot reactivate growth azacitidine generation valuable decrease inhibit though next dna dna dna promoter shore well give demethylating demethylating cgi could gene time cpg belong new methylation methylation supressors aberrant destroy cell cell drug supressor 
2.0@dna suppressor tumorigenesis inhibition inhibitor expression thereby gene dnmt tumor methylation decitabine decitabine decrease prevent prevent 
2.0@dacogen cancer cancer methyltransferases class enzymatic administration use state fda manufacturer eisai malignancy malignancy de japan md incorporation call inhibit unknown irreversibly lay regulator inhibitor pattern unspecific impact tumor mechanism feature hypermethylation may haemtological nucleoside name drug drug cell cell cell tumour food one one one suppressor dependent cause epigenetic myelodysplastic via replication analogue novo highly describe trade exact effect anti hallmark group demethylation dna dna dna however bind syndrome promotors function still gene hence dnmts dnmts unite especially replicate methylation methylation decitabine decitabine work work incorporate imagine approve due due haematological 
1.67@cancer cancer todna able n use use reversion manner agent decitabine decitabine decitabine myelodysplastic myelogenous hypomethylates azt treat treat normal inhibit inhibit back dna dna dna dna dna dna dna dna strand acute syndrome precursor function demethylating inhibitor fare similar chain increase increase belong due fact methylation methylation methylation methylation rna although level incorporate incorporate like like tra methyl initiate azacitidine azacitidine 
1.67@cancer cancer cancer cancer apparition class class class class class western western western western say include agent agent xml xml myelodysplastic change useful hypermethylated avoid island origin promoter promoter en en en en demethylating tumor tumor tumor affect hypermethylation usually fight align align align align methylation use level suppressor suppressor justify justify justify justify transcription relate epimutations drug drug cause cause suppression demethylated maintain type lecture particular properly dna dna u u u u syndrome function cpg gene gene gene inhibitor inhibitor lang lang lang lang kind epigenetics tool decitabine decitabine work mean safe would 
2.0@cancer cancer cancer methyltransferases may may system agent become aberration unmethylated many catalyse inhibit euchromatin previuosly lead lead hyperactive strand among enzyme enzyme ezh tumor tumor tumor tumor tumor convert supressors supressors attachment cell cell cell cell use supressor supressor methylating activation activation methylates apoptosis lot anti methyl immune group tail treatment dna dna dna dna dna dna blood histone heterochromatin expression gene gene gene gene methyltransferase effect demethylation demethylation demethylation death death silence silence due due thus decitabine decitabine decitabine daughter daughter mitosis mitosis mitosis active active leukaemia myelodysplasia passive 
2.0@loss abnormal dnmt dnmt dnmt agent stop stop mark mark probably growth inhibition island demethylation demethylation lead lead lead dna dna dna act responsible expression demethylating gene methyltransferase inhibitor tumor keep cpg methylation methylation decitabine daughter mitosis mitosis passive cell 
2.0@knownas think class medication dnmt dnmt inhibitor inhibitor use state fda add syndrom myelodysplastic currently irreversibly hypomethylation make hypermethylated tumour tumour call island nucleotide previously lead cytosine epigenetic mention involve resultson consequence bone group group happen worldwide question normal hypermethylation apoptotic express treatment treatment treatment far methyl expression earlier commonly however drug marrow md cycle pathway spectacular ultimately success anti solid prevent considerable dna dna dna dna maintenance cell bind le dnmts dnmts cpg gene gene methyltransferase effect upon similar control belong silence methylation decitabine decitabine decitabine decitabine disorder incorporate approve differentiation 
2.0@cancer commonly dnmt dnmt dnmt tumour add island mean break find anti group dna dna dna bind inhibitor cpg prevent methyltransferase effect permanently hypermethylation reduce incorporate cell methyl decitabine decitabine 
2.0@suppressor cancer replication context reactivate hypomethylation inhibit molecule lead dna dna dna pass enzyme gene methyltransferase methyltransferase tumor division silence decitabine decitabine daughter region incorporate demethylation cell cell andinhibits nearby dnmti 
1.67@cancer growth progress way agent hypomethylating since trigger anti inhibit inhibit molecule molecule regulate dna dna dna expression allow demethylating gene methyltransferase effect tumor tumor tumor block contribute methylation decitabine decitabine hypomethylate activity survival supressor 
0.33@standard standard possible aid responsive use slow drug agent syndrome myelodysplastic somewhat somehow growth possibly demethylate treat response significant dna epigenetic even reaction help chemotherapy chemotherapy allow allow demethylating change previous tumor tumor tumor suggest apparently apparently silence solid decitabine successful class good cell trial may expression 
2.0@suppressor effect class produce tumour inhibitor agent acute decitabine decitabine decitabine precursor myelodysplastic myelogenous hypomethylates anti hypermethylated treat inhibit rase dna dna dna epigenetic methyl syndrome fe epigenome demethylating gene reduce tumor suggest expression belong thus allow name tra use leukaemia 
1.67@dna dna dna dna dna dna dna dna dna cancer cause restore therefore dnmt dnmt dnmt dnmt dnmt dnmt dnmt get much analogue agent hemi three sequence hypomethylates mammal maintain incorporation normal inhibit inhibit recognize divide strand effectively dependent dependent kind demethylating rapidly inhibitor methyltransferase methyltransferase methyltransferase affect belong thereby decitabine decitabine decitabine nucleoside incorporate methylation methylation methylation demethylation cell cell cell replication replication replication 
0.33@cancer cannot dna dna dna dna methyl agent chromosomal correct correct growth response irreversibly strand strand methylate allow demethylating reduce stimulate affect hypermethylation hypermethylation release nucleoside nucleoside instability cell cell tumour tumour tumour tumour tumour promoter drive suppressor suppressor also insert bond therefore divide drug analogue analogue effect anti halt immune reduction get dose surround bind covalent expression gene gene rapidly along remove remove stage thereby due new methylation decitabine decitabine decitabine decitabine daughter region incorporate come methyltransferase replication 
2.0@methyltransferases methyltransferases class reactivation use agent myelodysplastic find azacytidine hypomethylation theri treat call incorporation recognize decrease inhibitor enzyme tumor tumor guanine block chain hypermethylation particular metabolic like cell methyl suppressor turn therefore replication subsequent result reaction cytosine trigger group consecutively syndrome dna dna dna dna dna dna azacytosine azacytosine azacytosine instance bind degradation function drug drug gene azanucleoside allow dinucleotides similar impede methylation decitabine decitabine decitabine incorporate cpgs methyltransferase onto 
2.0@cancer dnmt activate unclear may appear dependent stop stop inhibibitor irriversibly overall tumour tumour tumour transferase solid effective strand disease thereby reduce mechanism hypermethylation say suppressor supressor dna dna dna dna cytidine replication replication analogue dose promotor pathway low free success methyl reduction therefor action bind ii act act dnmts dnmts still gene gene think upon upon cellular copy dependence due new methylation methylation methylation decitabine region incorporate non would would progression 
0.33@ezh ezh cancer cancer cancer growth overmethylation activate cell use include agent whose make make overmethylated find change leukemia myelogenous back dna dna dna lead open epigenetic epigenetic involve responsible responsible enzyme enzyme demethylating interest research tumor tumor anticancer uncontrolled normal regulation turn role demethylation demethylation often way suppressor suppressor myelodysplasic myelodysplasic specifically effective drug drug evolve acute mutation support result histone histone histone histone histone stop normally methyl methyl group group treatment treatment treatment acethyl surround surround syndrome syndrome gene gene gene gene gene gene field overactive attach attach silence new decitabine decitabine decitabine protein protein 
2.0@cancer cancer methyltransferases think restore target produce tumour tumour tumour state state agent agent agent agent pattern myelodysplastic myelogenous growth unmethylated restrict inhibit treat lead lead firstly demethylating demethylating demethylating proliferation reduce mechanism normal normal expression expression hypermethylation hypermethylation case cell cell cell use leukaemia suppressor suppressor hypomethylation also antimetabolite therapeutic via cause could limit reverse chemotherapeutic chemotherapeutic anti anti normally promoter develop dna dna dna dna dna divide acute cytotoxic syndrome act act function function function gene gene gene rapidly effect effect epigenetically control death due thus methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine two secondly would 
1.0@mode cancer cancer also become disrupt dnmt methyl methyl drug drug dependent mark essencial analog nitrogenated th functional make exactly transferase transferase strand strand action dna dna dna dna dna dna divide non copy bind epigenetic inhibitor inhibitor base rapidly impact mechanism dir dir irreversibly hypermethylation new methylation decitabine decitabine ltr ltr incorporate come cell cell protein replication 
0.67@dacogen cancer promote administration study tumour slow improve agent stop reaction chemotherapeutic growth growth drug drug drug drug call reduction lead dna epigenetic epigenetic epigenetic kill help allow demethylating interest hypermethylation show routine decitabine decitabine decitabine could mean demethylation use without 
2.0@dna dna dna dna dna methylating prevent methyltransferase effect tumor agent agent cause hypomethylating thus decitabine hypomethylation anti synthesis inhibit 
1.67@cancer instead dnmt dnmt synthesize synthesize tumour tumour tumour every agent agent newly newly meet inhibit inhibit aza often irreversibly strand strand methylated hyper demethylating demethylating reduce key bind divide cell cell suppressor suppressor cytidine cytidine transfer maintenance cause loss anlaogue consider promoter promoter dna dna dna dna dna however ase expression expression gene gene methyltransferase inhibitor inhibitor deoxycytidine division methylation methylation methylation methylation decitabine decitabine decitabine incorporate active enable would 
2.0@suppressor cancer effect class tumour agent hypomethylates reactivate anti know inhibit dna dna dna epigenetic silence gene methyltransferase inhibitor tumor belong methylation decitabine decitabine demythylating 
2.0@cancer cancer cancer abnormal produce thatdecitabine agent agent analog also hypomethylates growth growth might inhibit lead dmnts irreversibly enhance as tumor interfere block block hypermethylation nucleoside ofcell cell cell cell cell cell cell blockage supressor transfer antimetabolite bydemethylation describe cytotoxic ademethylating metabolism dna dna dna dna dna divide bind chemotherapy dnmts gene rapidly effect result cellular death death division due methylation decitabine decitabine decitabine decitabine decitabine work work work incorporate incorporate meet 
0.33@cancer cancer proliferate progressively dnmt progress methyl methyl fda mark myelodysplastic myelodysplastic analog leukemia inhibit nucleotide molecule molecule epigenetic epigenetic strand methylate methylated particularly enzyme island effective effective hypermethylation order dilute nucleoside myeloid demethylation cell cell cell tumour dicitabine dicitabine dicitabine machinery enzymatic transfer transfer use seem replication hemi target type occur particular dna dna dna already acute bind syndrome syndrome principle hall cpg aml inhibitor inhibitor upon division longer methylation daughter incorporate approve rapidly small 
0.33@cancer cancer effect class lymphoma dnmt use slow stop example growth penetrate make make illness cutaneous grow granddaughter epigenetic pass ei way impact mechanism suceptible permanently tratments successful like cell cell cell cell cell tumour tumour ul ul ul ul ul ul destroy erase fight alteration cause tumorous therapy result histone without solid treatment standard supposition chemotherapy act change eliminate epigenetically rare deacetylase division actively agains daughter affect eg alter elimination 
2.0@cancer cancer inhibitor remember dnmt dnmt progress use place myelodysplastic leukamia easier characterize treat island nucleotide unable irreversibly strand body disease take longer affect hypermethylation release cell cell cell cell way specifically replication drug drug drug target methylate become hypomethylated severly example dna dna dna dna dna dna divide divide acute bind bind syndrome cpg rapidly along methylations copy replicate myelogenous actively decitabine daughter incorporate come action methyltransferase methyltransferase 
2.0@cancer cancer methyltransferases disrupt specificity others specific myelodysplastic easily nevertheless hypermethylated inhibit characteristically see consider consider inhibs responsible enzyme island island tumor mechanism reflect hypermethylation turn ensure gene cell cell drug drug drug decitabine decitabine decitabine suppressor methylating downside patient therefore replication target intake number effect effect know know prognosis dna dna dna dna dna bind syndrome act positive dependency methyltransferase inhibitor cpg cpg replicate silence methylation methylation methylation allow poor incorporate cancerous action rapidly progression 
1.67@suppressor suppressor cancer restore undo methyl agent target bring growth hypomethylation group presence dna dna act act expression demethylating gene gene proliferation reduce remove silence decitabine decitabine mean demethylation tumour tumour 
1.67@cancer cancer reduce class suppressor use use slow appear appear stop hypomethylating hypomethylating myelodysplastic analog analog lower growth treat effectively effectively island aza achieve pass pass effective pattern pattern difficult nucleoside methylation significant process tumour tumour tumour promoter penetrance specifically cytidine also drug drug drug drug certain cell cell cell cell dexoycytidine best solid solid show syndrome divide dose dose histone point risk switch cpg gene gene inhibitor deacetylase increase actively decitabine daughter daughter work work sensitive methylating 
1.67@suppressor suppressor cancer cancer analogue nucleoside irreversibly activate tumour tumour unmethlyted agent cause build target hypermethylation growth possibly bind drug island cpg class dna dna area development methylated dnmts demethylating gene gene gene expression usually give replicate silence decitabine cant interrupt cell cell cell need belong 
1.0@mitotically could certain restore hypomethylate island cause subsequent copy prevent cpg tumor tumor dna dna dna divide strand inhibitor function function drug gene methyltransferase supressing serve normal normal hypermethylation thus methylation methylation decitabine daughter second cell resume 
2.0@cancer cancer inhibitor growth dnmt use include since hypomethylates dnmti dnmti dnmti dnmti dnmti dnmti hypomethylation hypomethylation exert island restrict class irreversibly silence inhibit way tumor tumor tumor tumor affect t nucleoside many cell may expression suppressor suppressor dependent decitabinecan therefore get get get replication replication analogue target bring bring bring hdaci anti anti type dna dna divide bind bind epigenetic dnmts drug gene gene rapidly effect effect effect place antineoplastic cpg cpg thus regulator decitabine decitabine incorporate incorporate come enzymatic 
1.67@elod cancer cancer cancer article growth lymphoma reactivation induce uncontrolled include mutation stop epicentre useful break myelogenous economist magazine hypomethylation leukemia make treat call class particularly link impact tumor tumor damage dacitabine contribute turn thus thus repair silence silence methylates cell supressor suppressor system cause cause cause acute april decitabine decitabine y lot surround whose effect antitumour immune hypothemylation deal dna dna dna dna histone syndrome inhibitor gene gene gene gene methyltransferase platic epigenetically belong find procursors wzh activity th active 
2.0@suppressor cancer certain tumor tumor restore induce dnmts trap apoptosis target result reverse number growth regulatory arrest change show inhibit treatment dna dna dna epigenetic development histone covalent inhibitor inhibitor function function nucleosidethat deacetylation epigenetically normal expression complex silence methylation methylation decitabine progression gene gene gene gene role cell reactivate 
0.67@inhibitor class dnmt dnmt dnmt methyl add protrude depend irreversibly rat firstly facilitate effective tumor hypermethylation nucleoside demethylation cell replication dependent analogue therefore epigenetic drug drug drug cause target cancerous arginine group tail dna dna dna dna lysine dose histone bind nucleosome methyltransferase effect similar antineoplastic belong replicate methylation decitabine decitabine incorporate action accelerate small 
0.67@cancer cancer produce use agent guanine guanine hypomethylating inhibating hypomethylation oncogene oncogene decrease island island recognize recognize methylated methylated methylated well consequence tumoral impact mechanism possibility way boost potencial transfer nucleoside activation activation drug analogue result describe cysteine cytosine cytosine anti methyl methyl methyl know group dna dna base bind act cpg cpg gene gene chemical methyltransferase methyltransferase methyltransferase similar remarkable decitabine decitabine protein exist azacitidine 
1.67@distinguish mean cancer cancer inhibitor inhibitor erase erase dnmt dnmt dnmt dnmt replication reinstablished specific specific specific mark irreversibly analog susceptible make methyltransfer locus nucleotide order lead dna dna dna process bind bind act act enzyme inhibit happen longer must normal replicate methylation methylation decitabine nucleoside lay like cell cell cell cell cell 
2.0@et cancer methylgroup dnmt dnmt dnmt dnmt use use every sam anti transfer hypomethylation hypomethylation md unmethylable transferase inhibit treat hemimethylated lead strand opposite enzyme enzyme demethylating tumor tumor pattern dilute genome methylation methylation cell methyl methyl suppressor methylating become daugther acytidine analogue cause trick repaire april maintain dnmtinhibitor thedna division dna dna dna dna dna dna promotors expression drug gene inhibitor upon kantarjin catalyze thereby longer since al decitabine incorporate donor replication 
1.33@mitotically cancer cancer toxicity higher restore also also dnmt much concentration concentration concentration agent specific dysregulated analog lower meet dnaduring hypomethylation hypomethylation hypomethylation inhibition inhibition inhibition heritable island adduct epigenetic methylated well demethylating proliferation dilution nucleoside like cell cell drug drug dependent transfer daughter thatgets replication cause result result result result without inhibitor cytotoxic toformation dna dna dna dna dna dna however non synthesis synthesis ase covalent function function cpg gene effect effect effect cellular increase sythesis due methylation decitabine decitabine decitabine decitabine mainly incorporate incorporate deoxycytodine differentiation betweendna inthe anddna 
1.67@suppressor cancer classify suppresor hypomethylation tumor tumor tumor use use agent epicentre mark myelodysplastic result article economist growth growth effect anti inhibition treat inhibit promote promote dna dna dna dna epigenetic methylated syndrome expression expression cpg island provoke induce demethylating word silence methylation methylation decitabine gene gene gene gene mean icrs drug drug would would 
2.0@different different different cancer cancer inhibitor inhibition suppressor use agent pattern hypomethylating myelodysplastic find hypermethylation hypermethylation hypermethylation hypermethylation hypomethylation genetic treat call precisely dna regulate epigenetic epigenetic sequence sequence particularly silence thereby island island derive reduce mechanism activation hypo genome genome genome genome role case cell blood one dysfunctional poorly area drug drug cause result become normally normally promoter group group tumour tumour hallmark acute often syndrome act important cpg cpg gene gene gene methyltransferase expression relevant belong methylation decitabine disorder wide degree active form 
1.33@cancer inhibitor high high action need reader acute toxic process cromatine leukimia find sindrome replication bind might avoid lead dna dna understand dose see myelodysblastic act act use important drug drug rate division usually completly decitabine nucleoside work cell way metiltranferase 
0.33@cytidine use hypomethylating analog capable reference inhibit treatment dna dna dna strand acute cytotoxic enzyme wikipedia methyltransferase myeloid aml decitabine render incorporate drug leukaemia 
0.67@cytosine inhibition polymerase dnmt dnmt dnmt dnmt drug drug drug cause activity structural suppression suppression synthesis part genetic act inhibit damage epigenetic dna dna dna dna dna dna irreversibly base get bind catalytic least function way reduce induce mechanism death anticancer phosphorylation methylation decitabine decitabine decitabine methyltransferase instability incorporate incorporate enzyme enzyme cell obstruct catalyze 
2.0@cancer cancer along class medication progress use use every agent myelodysplastic find hypomethylation hypomethylation leukemia treat call island nucleotide epigenetic strand rapidly silence silence severely myeloid tumor longer affect neoplastic release nucleoside express cell cell tumour suppressor suppressor dependent promote get study replication analogue mean low anti type good dna dna dna dna dna dna divide dose acute bind bind syndrome act inhibitor cpg gene gene rather effect upon methyltransferase methyltransferase methyltransferase must copy consequent division replicate methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter incorporate come action aml 
1.0@cancer critical restore lymphoma unlike regulation may concentration could stop cutaneous major rare hypomethylation change change call grow might achieve epigenetic epigenetic pass involve inhibitor belong suppression inhibit proliferation caueses normal neoplastic genethat illess factor methylation granddaughter control kill transcription therefore actively cause therapy cell cell cell cell cell synthesis erase erase without antitumor though dna dna histone example function gene effect effect induce cellular deacetylase reversal division vitro silence hdacis decitabine decitabine decitabine daughter em class return form differentiation 
1.67@one dacogen cancer cancer article magazine decitabine decitabine decitabine use cause agent acute tend epicentre myelodysplastic acknowledge th april underlie become hypermethylated treat promoter inhibit inhibit men company dna dna dna dna japanese leukaemia syndrome sell silence demethylating island precursor cpg myelogenous methylation genome gene hypomethylates cell t recently 
1.67@please find attachment epigenetics assignment 
1.67@cancer patient use agent whose process normally tumour tumour island island cpg cpg lead dna methylated expression act hypermethylation drug gene gene restitution detect block block repress belong methylation methylation decitabine case demethylation cell may supressor 
1.0@mitotically cancer cancer inhibitor dnmt dnmt progress progress tumour tumour tumour tumour tumour every claas funtion dnmti methyl catalyse heritable transferase inhibit inhibit inhibit suppress suppress molecule epigenetic strand island reduce hypermethylation supressors replication suppressor suppressor doen one enzymatic drug dmnt dectabine disturb anti occur dna dna dna dna dna dna dna dna dna reaction cpg effect belong undergo methylation methylation methylation methylation methylation methylation methylation methylation drive action would reactivate 
1.67@cancer proliferate restore formation tumour tumour tumour slow agent notable two critical cytotoxicity dnmti growth penetrate demethylation treat transferase response class epigenetic control proliferation harder people normal neoplastic may may unexpectedly participant insensitive second good cell cell cell trial much lung hypomethylation also researcher deploy drug drug combination aducts subsequent another result reaction gene chemotherapeutics solid solid show show show reason dna dna dna divide non histone covalent function time rapidly inhibitor inhibitor induce relatively cellular deacetylase belong methylation decitabine decitabine decitabine decitabine advance attribute incorporate first azacitidine differentiation methyltransferase succesfully 
2.0@cancer cancer effective agent opposite part treat concomitant island cpg molecule treatment dna dna bottom segment careful act human demethylating chromosome effect intergenic must demethylation repeat hypermethylation minimize margin methylation methylation genome area decrease decrease decrease decitabine 
2.0@reduce effective synthesize methyl possibly newly malignancy lation susceptible characterize treat transferase island island irreversibly strand common inhibitor hyper reactivation tumor tumor mechanism nucleoside like cell replication replication supressor individual divide seem seem drug analogue hematopoietic constantly exact prevent dna dna dna dna however bind dnmts cpg cpg gene aml allow unclear elderly methylation methylation decitabine decitabine decitabine decitabine establishment time incorporate action 
1.33@preferably preferably renewal renewal cytotocic dnmt haematopoietic agent agent uncertain hypomethylating hypomethylating turnover malignancy hypomethylation progressively might locus lead igf irreversibly work methylated allow demethylating inhibit mechanism affect contribute genome nucleoside seem seem program demethylation cell cell cell cell cell cell tumour tumour tumour region suppressor dependent dependent also therefore decitabine decitabine imprint replication replication replication analogue dose prolong cycle fast demethylated without anti know treatment dna dna dna however non bind example expression gene aml effect induce leukaemic thus ul ul wide incorporate strongly self haematological 
1.33@one suppressor suppressor effective effective cause cause agent lukemia imagine de hypomethylation might show dna lead open prelukemia know heterochromatin disease demethylating gene gene expression tumor tumor chromatin silence improperly improperly methylation decitabine repress would would 
1.0@member unregulated cancer myeloid restore restore suppressor suppressor suppressor drug drug activity acute decitabine process process myelodysplastic result major growth growth become affect treatment treatment dna dna expression marrow allow syndrome function bone gene gene gene gene disease tumor tumor mechanism block normal increase division division thus methylation methylation blockage regulate regulate demethylation demethylation cell cell cell cell control promote class 
2.0@methyltransferases methyltransferases class encounter may may agent analog since reactivate hypomethylation normal island cytosine cytosine anit instead inhibit tumor tumor tumor block affect hypermethylation uptaken demethylation demethylation cell decitabine decitabine suppressor suppressor also via incorporate inactivate occur promoter prevent dna dna dna dna dna dna bind act act function cpg gene gene effect belong thus desire region activity covalently methylating 
2.0@suppressor dnmt use analogue agent hypomethylating myelodysplastic dnmti md decrease treatment dna dna irreversibly bind syndrome act gene methyltransferase inhibitor tumor methylation decitabine nucleoside 
1.0@cancer cancer inhibitor growth hypomethylate use slow agent stop without myelodysplastic hypomethylation change grow granddaughter epigenetic epigenetic pass demethylating provoke people may routine like like treatment tumour kill lung also erase drug combination therapy later cell cell cell cell cell finally chemotherapeutic reaction solid good syndrome dna dna blood histone point employ deacetylase division decitabine decitabine decitabine decitabine daughter activity return tumoral totally 
0.0@abeerant hipomethylation drug drug drug cause agent agent target myelodysplastic hypomethylation potential occur promoter inhibit methylcytosine lead dna dna dna dna strand syndrome act hipomethylates gene methyltransferase mechanism methylation decitabine decitabine aberrant incorporate indirectly deplete 
1.67@unregulated cancer restore restore able way way agent agent intodna hypomethylating hypomethylating hypomethylates growth regulatory incorporation affect inhibit inhibit inhibit regulate believe sequence allow thereby twofold tumor block normal anticancer substrate demethylation demethylation demethylation cell cell cell cell control blockage decitabine decitabine decitabine decitabine one suppressor suppressor suppressor transcription promote replication cause adversely activity result become presence dna dna dna dna dna dna dna process bind function drug gene gene gene methyltransferase effect increase division division interfere thus methylation methylation rna rna rna work incorporate protein 
2.0@suppressor cancer inhibitor inhibition therefore irreversibly myelodysplastic use certain suppression analog analog hypomethylation leukemia treat decrease inhibit nucleotide often dna dna dna dna dna get blood action bind expression disease gene gene aml allow tumor tumor tumor methyltransferase methyltransferase progression hypermethylation silence cytodine decitabine decitabine incorporate methylation methylation lead may associate 
2.0@dna akin dnmti class methyltransferase decitabine 
2.0@dacogen cancer cancer article article article dnmt use appear purpose economist economist hypomethylation hypomethylation leukemia characterize marrow lead lead mention tumoral reactivation tumor deform may often often myelodysplatic one suppresor promote drug drug certain april cell condition th anti magazine treatment dna dna blood blood form syndrome sell gene methyltransferase inhibitor creation silence decitabine decitabine bone reference action 
1.67@successfully epigenetic baylin slow slow combination combination therapy reaction invasion growth participant show show prevent good dna deploy histone histone chemotherapeutic time time drug drug dr becitabine impact deacetylase deacetylase methylaton belong solid unexpectedly routine routine decitabine decitabine trail first responese tumour tumour tumour go stephen 
2.0@elod effect class reactivation produce induce blood inhibitor link condition myelogenous silence hypomethylation leukemia useful treat marrow hypothemylation antitumour particularly dna dna case acute syndrome precursor contribute deform gene methyltransferase platic tumor belong turn thus decitabine decitabine bone y epigenetically cell supressor 
1.0@cancer cancer classify cero tumour tumour tumour tumour agent stop stop growth penetrate decrease suppress tosilencing igf level level level lose functionality demethylating theca pair block block gradually lack genome high high maintain maintain cell cell cell cell cell methyl cellthat one suppressor methylationstarts promote therefore cdkn drug stability throughout overgrowth cytosine promoter group dna dna dna dna dna dna dna dna dna base u dnmts dnmts hence target enzyme remove die contain due methylation methylation methylation methylation methylation methylation decitabine gen gene gene eventually instance indirectly chemical reestablish 
1.33@cancer cancer inhibitor abnormal term excessive use fda agent natural dnmti growth growth island suppress example dna epigenetic ene expression demethylating gene supressing remove remove block simple cpg methylation methylation methylation allow approve cell cell drug would decitabine 
2.0@aspect suppressor lead transcription inhibition restore residue presumably tumor tumor tumor tumor tumor methyl include cycle aberrantly aberrantly aberrantly apoptosis inhibitory cytosine reactivate growth growth become antitumor promoter group involve involve dna epigenetic development sequence methylated methylated methylated therefore act silence gene gene gene gene gene methyltransferase inhibitor remove regulation decitabine decitabine activity cell cell cell downstream reverse 
1.67@one suppressor cancer activate check tumour tumour system agent agent myelodysplastic precede balance hypermethylated treat promoter island suppress etc dna development reverse help syndrome establish hypermethylation demethylating demethylating gene gene reduce remove normal death cpg silence decitabine possibility license cell 
1.33@dna epigenetic reverse silence demethylating gene hence tumor agent suppression clear methylation methylation inappropriate cancerous decitabine decitabine 
2.0@cancer cancer cancer improper growth growth bindingto uncontrolled uncontrolled slow agent hypomethylating sit aza cellular change generation overall ofcancer decrease inhibit suppress lead lead cytosine epigenetic epigenetic development establish island proliferation tumor tumor tumor modifier normal lack genome otherwise affect often way suppressor suppressor transfer name subsequent product product suppression relatively demethylated become halt promoter dna dna dna cell cell cell ase mediate le expression cpg gene gene gene gene chemical inhibitor deoxycytidine sore configuration methylation methylation methylation methylation methylation decitabine decitabine decitabine work meet methyltransferase tissue tissue 
2.0@igf igf like class produce tumour tumour cluster agent could could could icr suppression wilm demethylated reactivate case become hypermethylated amount know island ctcf dna dna epigenetic bind allow demethylating gene reduce remove remove belong thus methylation methylation decitabine decitabine cpg allele maternal drug 
1.0@cancer cancer cancer cancer cancer inhibitor inhibitor inhibitor inhibition methyltransferase methyltransferase methyl methyl methyl include hand pattern pattern decitabin decitabin decitabin cure probably wrong potential approve lead status methylated repression enzyme enzyme enzyme facilitate close mechanism area demethylation cell cell cell explore dna dna dna dna therefore epigenetic certain certain could add add course course group tail tail tail tail treatment several position histone histone histone histone syndrome le myelodysplastic gene chemical effect remove acetyl set go methylation methylation work influence acetylation would associate 
2.0@dacogen cancer cancer impact higher dnmt dnmt methyl fda mark mark analog profoundly reactivate growth treat call island cpg clinical irreversibly range well reduce tumor mechanism amendment hypermethylation understand nucleoside regulator many cell cell cell removal may suppressor dependent transfer although get seem replication healthy toxic dosage dosage present type type prevent particular dna dna divide bind epigenetic use drug trial aml inhibitor inhibitor must effective effective methylation methylation decitabine decitabine daughter much incorporate approve rapidly enzymatic 
1.0@cancer effect stable homeostasis throughbinding activate analogue inhibitor agent agent toxic hypomethylating necessaryfor selective moreover deoxycytidine negative among dnamethyltransferase status methylated well le dnmts demethylating affect impact classicdna normal belong thus lower decitabine gene methylation influence cell cell cell protein azacitidine 
2.0@critical inhibition restore proliferate may concentration myelodysplastic major cytotoxicity hypomethylation hypomethylation hypomethylation part direct incorporation normal inhibit exert achieve proliferation adduct neoplastic formation phosphorylation nucleoside insensitive treatment control aza also indicate drug analogue cause cause apoptosis suppression relatively synthesis group syndrome dna dna dna dna dna dna dna divide non cell cell cell cell cell covalent function gene rapidly effect induce natural deoxycytidine deoxycytidine antineoplastic vitro methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine attribute incorporate differentiation differentiation methyltransferase methyltransferase 
2.0@suppressor cancer transfer class antimetabolite action activate remove remove methyl methyl deme cause dnmti growth anti cytotoxic inhibit call prevent prevent lead lead dna dna dna epigenetic thy ase bind inhibitor inhibitor enzyme enzyme group group methyltransferase effect effect tumor tumor accord death belong additionally thus decitabine decitabine decitabine gene gene cell cell cell uncontrolled 
1.67@cancer higher class use dependent hypomethylating hypomethylating myelodysplastic analog selective susceptible make treat irreversibly strand except belong demethylating tumor normal conventional cell cell cell cytidine also epigenetic drug incorporate result low bind show show chemotherapy dna dna dna dna divide dose dose cytotoxic syndrome act methyltransferase inhibitor death division currently decitabine decitabine activity action rapidly 
1.67@cancer cancer inhibitor class within dnmt dnmt tumour permanent mark mark dnmti epigenetic epigenetic epigenetic epigenetic pass available belong severely order order mechanism affect neoplastic give rely genome nucleoside cell cell cell cell replication ensure enzymatic drug strongly anti know dna dna divide divide kill bind bind methyltransferase methyltransferase effect proxy division longer thus regulator decitabine decitabine work work work strong modify modify rapidly rapidly 
0.0@time im prepare read sorry paper thesis 
1.33@suppressor methyltransferases class dnmt dnmt dnmt mitotic tumour tumour decitabine decitabine decitabine cancerous maintain anti lead lead treatment dna dna dna dna availability methylated inhibitor belong thereby inhibit inhibit effect heritability necessary replicate methylation reduce gene impair demethylation demethylation cell machinery drug tissue 
2.0@cancer cancer critical class able able able methyl methyl state agent whose epicentre myelodysplastic chance reactivate growth unmethylated treat decrease suppress imply cytosine epigenetic error error methylated demethylating group group tumor tumor mechanism genome genome cell cell use reach expression one suppressor also suppresor drug stability could slow cancerous cancerous demethylate normally occur promoter prevent potentially dna base reverse syndrome name function cpg gene gene gene gene gene organism remove become dinucleotides due thus methylation decitabine decitabine approve would would associate 
1.67@suppressor suppressor cancer transcription class residue residue activation tumor tumor tumor tumor drug cause cause agent could promotor probably meet meet meet gene gene anti island island cpg cpg treatment dna dna epigenetic efficient hyper hyper hyper demethylating drive effect remove remove belong ti ti ti main decitabine hilum hilum hilum often methyl methyl would region 
1.33@cancer dnmt dnmt use use fda agent myelodysplastic myelodysplastic myelodysplastic analog myelogenous high nucleotide treat affect affect island might epigenetic strand kind precursor demethylating order normal neoplastic hypermethylation clear nucleoside regulator cell cell much much leukaemia specifically dependent dependent also although get get replication drug drug could toxic target anti completely dna dna divide dose dose acute bind bind syndrome syndrome syndrome cpg irreversible aml inhibitor upon copy division well methylation decitabine daughter work work incorporate approve rapidly enzymatic small 
1.67@also real lymphoma tumor tumor tumor tumor use drug drug solve agent mutation myelodysplastic result result transcribe change leukemia treat promotor promotor myelogenia dna dna dna dna epigenetic repress syndrome precursor demethylating gene gene rather remove remove try silence due methylation methylation methylation decitabine much region region mean demethylation repressor way supressor 
2.0@cancer myeloid dnmt dnmt dnmt tumour tumour hematological include oftumor predominantly major malignancy change leukemia md might decrease inhibit inhibit correlate clinical irreversibly responsible enzyme severely effective tumor affect hypermethylation hypermethylation dilute dilute nucleoside good cell cell replication suppressor example example preferable dependent analogue therefore maintenance total cause autonomy mean result acute course course gene type show prognosis repetitive dna dna dna divide profile bind syndrome use function function drug drug drug myelodysplastic aml effect effect demethylation methylation decitabine decitabine region incorporate rapidly 
2.0@happen erasable class dnmt dnmt methyl methyl mark mark mark analog generation transferase transferase inhibit epigenetic epigenetic epigenetic enzyme distribution tumor tumor tumor due normal normal abnormality genome genome genome nucleoside affect many cell cell cell cell cell cell cell cell require belong preferable dependent divide replication replication replication cause target result contact rectify become hypomethylated develop treatment dna dna dna get action action bind bind maintain site function drug irreversible unequal inhibitor fast time division division replicate methylation methylation decitabine decitabine decitabine decitabine daughter daughter possible incorporate come machinery 
0.67@atconcentrations critical inhibition restore incorporationinto formation may md analog proliferate cytotoxicity hypomethylation potential direct exert inhibit adduct achieve clinical believe decitabineincorporated proliferation tumor normal neoplastic phosphorylation dac gene insensitive cell cell cell cytidine mayalso cause cause controlof apoptosis suppression relatively effect solid syndrome dna dna dna dna dna dna dna divide non synthesis covalent cellulardifferentiation myelodysplastic rapidly function methyltransferase methyltransferase cellular antineoplastic vitro major methylation decitabine decitabine decitabine decitabine decitabine decitabine attribute activity activity differentiation azanucleoside inducedhypomethylation 
1.67@reason cancer inhibitor regular regular class depend however metyl need dependent adversely myelodysplastic low possibly drug drug drug drug transferase transferase transferase inhibit nucleotide molecule syndrome dna dna dna dna divide dose action action bind bind particularly division cpg island rapidly effective effective affect belong replicate may methylation decitabine incorporate give give cell cell cell cell methyl methyl 
1.0@thisinhibitorby cancer cancer retain silence growth treat decrease decrease dna dna dna pressor demethylating gene gene inhibitor tumor hypermethylation thus methylation methylation ul ul adna activity cell control expression 
1.67@cancer change change erase erase healthy use use agent stop anti myelogenous without growth make treat demethylation therapy granddaughter dna dna epigenetic epigenetic base pass acute syndrome precursor myelodysplastic demethylating effect kill division division well actively decitabine daughter return cell cell cell cell welcome tumour neighbour leukaemia 
2.0@cancer inhibitor inhibitor dnmt tumour analog irreversibly strand body severely longer question affect release nucleoside demethylation cell cell cell much dependent also divide replication cause mean result effect anti dna dna dna dna dna dna get bind bind bind act methyltransferase methyltransferase methyltransferase methyltransferase along along upon must copy division replicate replicate thus methylation decitabine decitabine decitabine decitabine decitabine daughter incorporate come come action rapidly 
1.67@elod plastic methylating use cause agent adversely rnasubstrate y myelogenous de replication regulatory treat affect inhibit thedna dna dna dna get transcriptionthereby sequence acute syndrome precursor function methyltransferase hypo protein intodna bind ing decitabine decitabine na incorporate demethylation cell methyl 
1.33@
2.0@cancer cancer methyltransferases lymphoma transcriptional uncontrolled agent agent whose hypomethylating myelodysplastic accumulation reactivate growth leukemia make make might might inhibit lead correlate epigenetic epigenetic help precursor enzyme enzyme enzyme demethylating tumor tumor conversion affect neoplastic methylgroups silence silence like thereby thereby thereby blood example one suppressor suppressor histone histone excessive cause myolegenous acute could mutation white cell cell result reverse euchromation become medical treatment dna dna dna dna mark lot syndrome heterochromatin target anti gene gene gene effect overactive overactive modifier ezh ezh thus methylation methylation decitabine decitabine possible mean hypomethylates attach 
2.0@cancer inactivate apart dnmt get get methyl methyl dnmts fda loss mark two detail reactivate growth md hypermethylated change transferase transferase response degradation cytosine epigenetic epigenetic promoter inhibitor enzyme especially myeloid myeloid tumor tumor tumor mechanism block normal complex go vidaza deactivation regulator cell cell cell control suppressor suppressor machinery compare faster near metastasis irreversibly study drug analogue analogue target result prescribe reversal trigger demethylate among lead damage treatment dna dna dna dna dna divide divide four action bind bind syndrome aredna event cpg affect hence rate cellular awry thus thus thus methylation methylation methylation decitabine decitabine methylate gene gene incorporate dysplastic approve tumorigenesis enzymatic 
1.67@cancer cancer rate higher class dnmt dnmt tumor tumor uncontrolled mutation specific overactive silence myelodysplastic lower malignancy malignancy dnmti dnmti growth note sit treat molecule epigenetic epigenetic acknowledge inhibitor inhibitor inhibitor give demethylating effective effective hassler affect hypermethylation hypermethylation particular nucleoside aberrant methylation demethylation cell cell t machinery suppressor suppressor dependent certain agent methylates replication analogue non toxic incorporate course stop become men show amp dna dna egger dose dose bind syndrome act important drug drug drug gene gene target effect dependant belong replicate epigenetics regulator decitabine em em em em em activity faster haemotogical 
1.67@cancer methyltransferases higher higher standard specificity activate activate use mostly cycle mark analog since dnmti growth susceptible permanently epigenetic epigenetic body erase give reduce reduce tumor tumor tumor tumor tumor normal lack hypermethylation nucleoside methylation cell cell cell cell cell cell cell cell may expression suppressor dependent therefore however mitotic concentration replication throughout dmntis pass effect effect anti amount promoter prevent dna dna dna dna divide bind chemotherapy chemotherapy act inhibitor drug drug drug gene gene gene methyltransferase rate remain division thus regulator decitabine decitabine decitabine daughter daughter incorporate alter 
1.67@suppressor suppressor cancer size become uncontrollable therefore tumour tumour tumour deactivate appear likely agent uncontrollabe extra reactivate sit hypermethylated occur dna dna dna tumorigenesis le le allow demethylating gene gene reduce remove increase increase division division division methylation methylation decitabine decitabine mean cell cell cell control 
1.0@also dnmt dnmt dnmt dnmt dnmt way analogue analogue add add add cause detach detach dnmti dnmti hypomethylation make make bind bind group dna dna dna dna dna strand methylate wide prevent prevent prevent methyltransferase inhibitor try new methylation methylation genome nucleoside irreversible irreversible replication form methyl mantain decitabine decitabine 
2.0@cancer standard dnmt dnmt activate kinase state fda cycle rib newly class azacytidine reactivate hypomethylation vulnerable make drug drug drug drug molecule molecule next cytosine cytosine irreversibly methylate chemotherapeutic refer thereby way tumor tumor drop normal genome genome substrate cell may level machinery substitute suppressor lower patient replication analogue structure base result body around gene become type obtain group oxy treatment dna dna get deoxy bind name function prodrug time eoside deoxycytidine nitrogen administer silence methylation methylation decitabine decitabine decitabine wide wide incorporate incorporate come approve form form de 
1.67@cancer cancer inhibitor inhibitor dnmt dnmt yet inherit prove specific island myelodysplastic myelodysplastic myelogenous malignancy leukemia elsewhere hdacis irreversibly strand strand well well tolerate enhance effective tumor tumor mechanism affect neoplastic hypermethylation release nucleoside high cell cell replication replication dependent dependent become patient progesses seem drug analogue improve dose could low anti anti methylation traditional dnmtis prevent prognosis treatment dna dna non acute bind chemotherapy dnmts cpg greatly aml effect effect effect syndrome syndrome quickly replicate disallow decitabine decitabine decitabine daughter daughter work incorporate perhaps approve methyltransferase haematological 
1.33@cancer hopefully regulation tumor spread slow agent stop mean growth methylated might could grow previously dna help demethylating gene remove remove division methylation methylation decitabine role active cell suppresors play 
1.67@transcription transcription translation produce tumour tumour tumour tumour tumour include agent decitabine decitabine decitabine property property say effect anti anti inhibit inhibit dna dna dna dna dna supressing supressing supressing help demethylating demethylating methyltransferase inhibitor silence silence methylation methylation methylation ul ul gen gen gen gen protein ordna 
2.0@translocation effect effect substantially tumour tumour every agent pattern hypomethylating impair insertion hypomethylation hypomethylation hypomethylation possibly sit hypermethylated might inhibit inhibit lead death strand sequence sequence responsible firstly dnmt tumor mechanism insure methylation methylation methylation methylation work genome instability express passive dont cycle recombination suppressor decitabine decitabine decitabine decitabine dna dna dna dna dna dna many divide replication cause prove anti type occur genomic repetitive repetitive several maintenance cell cell frequency act function gene gene methyltransferase nature induce carcinogenesis cellular cellular copy increase silence interfere reciprocal actively deletion daughter wide degree normally secondly exist beneficial 
2.0@cancer methyltransferases restore may chemically agent hypomethylating myelodysplastic degradation similarly azacytidine md incorporation marrow partially aza benefit lead clinical lose inhibitor silence silence trap island tumor significant hypermethylation hypermethylation signal demethylation cell decitabine decitabine decitabine one suppressor cytidine cause cause replication analogue therapy revert behind result moreover ability trigger become show prevent damage syndrome dna dna dna dna dna dna dna dna dna dna mark bind bind covalent least expression cpg gene gene methyltransferase methyltransferase effect induce deoxycytidine protein belong treatment methylation methylation methylation rna disorder bone incorporate incorporate preleukemic rationale 
1.67@dacogen cancer cancer inhibitor use eisai myelogenous dnmti hypomethylation treat transferase island irreversibly promoter precursor myelodysplastic nucleoside demethylation demethylation japanese tumour tumour leukaemia suppressor dependent replication analogue cell cell result result present anti methyl show company dna dna dna dna get acute bind syndrome sell dnmts cpg gene rapidly effect effect replicate thus decitabine incorporate hence 
1.33@cancer methyltransferases inhibition dnmt dnmt dnmt activate tumour manner agent pattern cannot cannot dnmti dnmti sit hypermethylated inhibit unspecific strand methylated methylated methylated demethylating island mechanism genome genome nucleoside maintain cell cell cycle suppressor dna dna dna dna dna dna analogue wrongfully replication replication certain throughout novo course hemi without toxic hypomethylated potentially several get get dose bind synthetic act inhibitor cpg gene gene effect effect increase division replicate work methylation methylation decitabine could original de 
1.33@chemical chemical cancer insert determine epigenetic much decitabine decitabine decitabine analog dnmti replication copy inhibit inhibit nucleotide molecule molecule dna dna dna dna dna dna get strand strand severe bind bind regulator act important drug drug irreversible rapidly effect word normal feature division replicate new methylation methylation longer daughter dependency incorporate come cell cell cell complete methyltransferase methyltransferase enzymatic release 
1.0@one suppressor suppressor suppressor inhibitor promote order decitabine decitabine decitabine tumour tumour tumour tumour agent cycle apoptosis event since sit normally occur decrease prevent recapitulate important dna dna dna dna dna epigenetic avoid demethylates act hypermethylation demethylating gene gene gene effect belong silence silence methylation methylation repair activity cell anti drug class class 
0.67@dacogen cancer cancer larger effective use agent stop switch switch canceours treat alone even even specially grow myeloid tumor regular least name cell cell methyl tra lat also pome patient get seem drug drug drug target result thy dna divide acute chemotherapy sell thereafter positive gene effect fe suggest brand rase decitabine work mean leukaemia ovarian protein 
2.0@cancer instead sugar dnmt dnmt disease medicinal slow chemically likely stand inactivation replace detail part chemist tumour island aza cytosine irreversibly strand see well differ wikipedia portion reduce reduce block draw hypermethylation carbon enzyme ref may suppressor patient retire untreated drug page structure structure deoxyribose mimic ribose like become bind level description dna dna dna dna position base base gpg le le inhibitor still gene methyltransferase inactivate unclear globally deoxycytidine progression nitrogen modification thus methylation methylation decitabine decitabine decitabine em incorporate triazinone active enough azacitidine azacitidine azacitidine 
2.0@dacogen myeloid class series formation tumour tumour agent specific andinduces switch plan cellular hypomethylation traditional expression epigenetic allow allow demethylating proliferation reduce reduce normal normal normal nucleotide hypermethylation act access genome side japanese discontinue leukaemia market suppressor cytidine transcription pathological undo replication analogue restoration restoration decitabine decitabine incorporate gene gene calledeisaiand protein company dna dna dna dna dna acute chemotherapy sell function drug drug hence target effect effect prevention methyltransferase range myelodysplasia myelodysplasia belong new unsilenced rna rna wide unravel differentiation enable 
1.0@cancer cancer cancer cancer cancer effect effect effect disrupt dnmt dnmt much use use hematological inhibitor characteristic myelodysplastic find leukemia treat primary intolerable normally allow allow ineffective myeloid tumor normal nucleoside cell cell cell cell disruptive suppressor large utilize utilize depend replication analogue result course formerly excellent element treatment treatment treatment dna dna however dose dose dose acute bind syndrome smaller smaller sufficient numerous side function thus methylation decitabine gene inclusion recently 
1.33@suppressor cancer substance methylates tumour cause include agent whose chromosomal silence surround stop growth part methyl call call group job dna package histone histone enzyme enzyme demethylating inhibit uncontrolled protein ezh thus decitabine gene gene activity cell overactivity attach 
2.0@suppressor suppressor cancer cancer cancer suppresor therefore therefore tumor tumor overexpressed agent methylate demethylate avoid develop develop lead dna dna get histone enzyme demethylating gene gene inhibitor advantage silence silence silence methylation decitabine would 
1.67@strain mean mean cancer dnmt methyl agent syndtome already myelodysplastic myelogenous dnmti dnmti dnmti treat nucleotide tho irreversibly precursor demethylating severely leykaemia longer affect cell cell use tra market depend get inhibitour cames cames relested dacoger dna dna dna divide acute bind bind bind epigenetic epigenetic sell target drug rapidly along fe copy replicate rase methylation decitabine daughter incorporate machinery replication replication 
1.33@pronounce cancer cancer methyltransferases class dnmt dnmt likely process myelodysplastic myelodysplastic since malignancy generation inhibit irreversibly hyper thereby island effective effective normal reduce reduce maintain cell cell cell cell cell cell cell impact belong future drug like like know treatment dna dna dna divide divide mark bind syndrome syndrome act dnmts cpg rapidly inhibitor inhibitor division methylation methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter region lay methyltransferase haematological associate 
1.67@cancer cancer cancer inhibitor introduce available anucleotide goal state state myelodysplastic analog analog since since overall transferase transferase nucleotide lead irreversibly enzyme demethylating reduce reduce tumor affect hypermethylation hypermethylation genome potent case primarily primarily cell cell cell cell cell cell cell cell cell methyl methyl replication result problem anti level parent presence nucleus dna bind syndrome act drug drug drug drug rapidly effect upon diminution copy copy copy thus methylation methylation methylation decitabine decitabine daughter incorporate 
1.0@reduction reduction reduction transcription transcription live standard need cause cause cause agent mark change gene drug drug dna epigenetic work pass chemotherapy least demethylating multiply susceptibility block increase canerous methylation daughter mitosis cell cell protein 
1.0@mthylation generalise devision demethyating dnmt produce use state agent throughout mark myelodysplastic result result hypomethylation treat dilution prevent genomic lead dna dna dna dna bind syndrome act irreverasbly tumor widespread maintenace lack thus methylation genome instability incorporate cell cell cell tumour decitabine decitabine 
1.67@suppressor lead tumor tumor tumor formation remove methyl agent inhibit myelogenous growth leukemia anti treat group myelodyrplastic dna dna dna pack acute syndrome use demethylating prevent effect loosely precursor keep keep silence turn since decitabine decitabine decitabine gene gene cell uncontrolled would would would 
1.33@cytidine methyltransferases cause cause analog low hypomethylation incorporation inhibit dna dna dna dna dna dna divide dose dose synthesis bind covalent prevent methyltransferase inhibitor die methylation decitabine high cell 
2.0@earlier cancer inhibitor inhibitor insert nucleoside dnmt dnmt use analogue concentration concentration interact process irreversibly result find dnmti methylation methylation occur show show assignment day class dna dna divide strand strand get le rapidly effect effect dependant people good good antineoplastic belong readily decitabine decitabine decitabine decitabine high daughter daughter come cell replication replication recently 
1.67@different different cancer inhibitor class term use state state agent stop long correct newly myelogenous chance dnmti leukemia hypermethylated treat island island suppress unknown epigenetic strand see precursor consequence demethylating reduce reduce methylases hypermethylation thus let express many often tumour tumour tumour tumour belong specifically dependent also identify action drug mechanismof know decitabine decitabine decitabine decitabine acute exact type type type promoter synthesise dna dna dna cell syndrome myelodysplastic cpg cpg gene gene supressing division likelyto methylation allow dependency form machinery althoughthe 
1.0@cancer methyltransferases dnmt synthesize use state manner cycle aberrantly newly analog hypomethylation md treat treat previously lead methylated involve inhibitor contribute apoptotic normal hypermethylation anticancer myelodysplastic nucleoside express cell cell line expression cytidine consequence drug drug pathway sequestration become prevent covalent dna dna dna dna dna maintenance bind syndrome dnmts dnmts irreversible effect upon control believe silence methylation decitabine decitabine gene gene incorporate differentiation 
1.0@mean cancer anucleoside dnmt much dependent irreversibly analog copy nucleotide molecule dna dna dna divide strand body bind bind drug adna rapidly inhibitor inhibitor upon methyltransferase methyltransferase methyltransferase affect division replicate methylation decitabine daughter severely incorporate cell cell cell replication 
2.0@plastic cancer myeloid class dnmt progress methyl appear prove myelodysplastic myelodysplastic transfer dnmti dnmti dnmti dnmti dnmti fda leukemia ace drug effectively demythelate aza lead stage island take effective tumor normal hypermethylation effectiveness nucleoside good cell cell cell cell much dysfunctional dependent analogue seem replication certain dose cause cause target condition fact hence could prognosis treatment treatment dna dna dna dna divide blood acute bind syndrome syndrome cpg irreversible aml inhibitor place deoxycytidine demethylation due methylation decitabine decitabine compare neo incorporate approve action rapidly small 
1.67@suppressor cancer also antimetabolite fight cause fda agent likely hypomethylating myelodysplastic gene gene md inhibit treatment dna divide syndrome allow hence rapidly tumor tumor normal death silence interfere methylation decitabine decitabine decitabine work express approve cell cell methyltransferase 
2.0@mitotically cancer cancer inhibitor dnmt dnmt dnmt dnmt dnmt may agent transfer dnmti dnmti dnmti mother mother heritable island nucleotide irreversibly strand strand lose functionality proliferation able tumor pattern pattern hypermethylation hypermethylation release nucleoside enzyme many cell cell cell suppressor methylating therefore replication replication analogue exhibit loss cancerous halt prevent dna dna dna dna dna dna get bind bind inherit cpg gene methyltransferase methyltransferase function longer since since methylation methylation decitabine daughter daughter incorporate 
1.33@cancer methyltransferases dnmt dnmt use analogue agent irreversibly treat inhibit dna dna dna divide bind syndrome inhibitor inhibitor dnmts demethylating severely effect affect myelodysplastic decitabine decitabine nucleoside dependency incorporate like drug cell replication replication agains 
2.0@dna dna dna mean promotors able cpg gene gene gene tumour tumour tumour tumour effect remove remove agent cause demethylating methylation methylation methylation decitabine decitabine silincing anti course activate repressor repressor island 
1.67@several erase outcome tumour tumour therefore agent agent myelodysplastic reactivate growth methyl decrease group suppress weaken dna status syndrome treat hypermethylation demethylating gene might division thus decitabine use 
1.67@cancer cancer cancer activate may agent agent agent disease since growth normally affect inhibit inhibit suppress regulate development see well administer demethylating take positively normal normal generally generally anticancer although case cell cell cell removal tolerate decitabine dependent lower lower therefore replication target suppressive demonstrate traditional level dna dna dose action allow chemotherapy act act act drug drug multiply rapidly enzyme division methylation methylation methylation methylation would would gene gene gene activity instance methyltransferase haematological associate associate 
2.0@elod plastic growth suppressor use slow stop hypomethylating ofdna malignancy typically hypomethylation gene treat island dna reversal work see bind syndrome cpg adna methyltransferase methyltransferase inhibitor tumor tumor block believe hypermethylation decitabine daughter mitosis y cell 
2.0@suppressor could inhibitor restore within dnmt induction methyl slow apoptosis result result hypomethylation susceptible make treat treat transferase prevent dna promoter division cpg cpg island island rate tumor tumor tumor tumor growth hypermethylation thus decitabine decitabine gene activity cell cell cell cell cell cell 
0.67@compound compound dacogen cytidine also restore erase suppressor n tumour mechanism hypomethylating analog hypomethyled number drug call inhibit class dna dna dna dna divide strand action antimetabolite function demethylating gene interact rapid death belong result decitabine decitabine incorporate cell methyl tra 
2.0@cancer cancer cancer cancer methyltransferases class reactivation reactivation use use use agent agent specific specific situation anti hypomethylation inhibit inhibit island silecing lead epigenetic epigenetic belong demethylating locus locus reduce hypermethylation hypermethylation turn may may nucleoside case case demethylation demethylation demethylation cell cell cell tumour tumour tumour supressor supressor analogue promote promote promote depend consequently replication cause throughout mean result demethylate dna dna dna dna dna dna dna dna example example dnmts cpg gene gene gene inhibitor division division methylation decitabine decitabine decitabine decitabine decitabine decitabine context tumorigenesis associate 
1.33@translocation mitotically cancer cancer think use alternative agent agent originally myelodysplastic myelogenous genetic treat island heritable methylated methylated precursor silence demethylating demethylating insertion genome maintain passive cell tumour leukaemia suppressor stabilize decitabine failure mutation result reverse intergernic except demetylation repetitive dna dna dna however acute syndrome cpg gene irremovable effect thereby reciprocal methylation methylation methylation deletion region active 
2.0@cancer cancer cancer dnmt dnmt tumour fda trap process analog since avoid avoid island nucleotide nucleotide often development lose kind functionality happen affect hypermethylation clear cell cell cell cell drug drug one suppressor also insert replication replication replication normal course methyl promoter dna dna dna get bind bind bind act cpg methyltransferase inhibitor upon upon longer find methylation decitabine decitabine possible mean mean mean approve 
1.33@cancer cancer cancer methyltransferases inhibition inhibition thattreatment malignancy suppressor activate use use hematological fda agent aberrantly cr myelodysplastic analog azacytidine growth potential realization grow aza aza aza lead lead lead culture inhibit reduce tumor tumor hypermethylation nucleoside cell cell cell cell zacitidine tumour supressor dna dna dna dna dna dna also decitabine replication cause cause therapy trap cdr result ohter depletion discovery promoter decitabibe treatment treatment reduction get cytotoxic syndrome act expression drug drug gene gene gene rapidly induce induce deoxycytidine remarkable emerge silence word methylation methylation methylation inside incorporate promise approve differentiation onto 
2.0@suppressor cancer cancer cancer daughter therefore dnmt dnmt activate replication analogue fda dependent irreversibly myelodysplastic strand hypermethylated inhibit inhibit prevent dna dna dna dna divide dose bind syndrome hypermethylation severely rapidly methyltransferase affect belong replicate silence methylation methylation decitabine decitabine decitabine decitabine nucleoside gene gene gene approve cell cell cell cell drug 
2.0@cancer cancer cause cause cause inhibition change dnmt dnmt relate methyl state state revert suppression since across hypomethylation hypermethylated decrease inhibit decitabine decitabine treatment dna death expression expression fe epigenetics epigenetics cpg island take reduce tumor normal normal increase hypermethylation rase genome gene gene return cell cell cell cell tra 
1.33@dacogen cancer cause suppressor cell uncontrolled certain agent whose eisai stop growth call inhibit job company dna japanese sell allow demethylating gene gene gene expression methylation decitabine form tumour 
2.0@myeloid methyltransferases higher dnmt dnmt methyl add alteration leukemia inhibition myelodisplastic inhibit nucleotide epigenetic responsible disease disease grow reduce reduce reduce tumor tumor demethilation di implicate enzyme cell control control relate seem drug mutation tet result anti level level group dna dna dna acute gpg syndrome act important effect effect accumulate protein protein protein defect methylation methylation methylation decitabine action generate generate progression 
2.0@cancer cancer methyltransferases methyltransferases suppressor suppressor suppressor activate methyl methyl could could could hypermethylate objective hypomethylation oncogene oncogene oncogene treat inhibit inhibit often revolutionary involve hyper rid hypermethylation turn ing directly utilize program considred cell tumour tumour tumour tumour tra kind decitabine decitabine need biological overexpressed therapy accomplish switch result cod bring anti lead lead rase dna dna get kill overexpression fe inhibitor drug drug drug gene gene gene gene label enzyme try thus desire methyltransferase methyltransferase would would 
1.33@suppressor methyltransferases class tumor agent tumorogenesis also age become decrease inhibit suppress lead dna dna level demethylating gene induce block belong methylation decitabine decitabine decitabine mitosis activity active cell differentiation rapid 
0.67@several cancer cancer also higher cant therefore epigenetic use analogue agent mark mark target myelodysplastic find leukemia make type treat treat dna dna dna dna irreversibly reversible frequency syndrome name function demethylating severely methyltransferase enzyme enzyme tumor usually affect bind dependent methylation decitabine nucleoside possible cell replication replication 
1.67@inhibitor inhibitor dnmt formation tumor agent agent agent hypomethylating analog basis azacytidine md anderson inc inc inc nucleotide lead irreversibly intracellular intracellular consider therefore enzyme demethylating hematology therapeutic persist gt aza goodman nucleoside nucleoside mcgraw mcgraw mcgraw many cell global deplete cytidine also williams position manual replication analogue pharmacological apoptosis reference become bind bind medical amp company company company dna dna dna dna deoxy cytotoxic dnmts dnmts methyltransferase effect effect demethylation due hour decitabine decitabine decitabine decitabine decitabine oncology incorporate incorporate hill hill hill covalently differentiation gilman 
1.0@dacogen cancer cancer cancer cancer proliferate class overmethylation overmethylation may leave agent agent agent agent mark make silence change susceptible generation epigenetic epigenetic epigenetic pass therefore belong demethylating demethylating proliferation able tumor andthat reduce reduce reduce like like cell cell cell cell cell drug decitabine decitabine decitabine decitabine decitabine decitabine suppressor also also patient forward future regular chemotherapeutic effect treatment treatment treatment treatment dna case histone histone name gene gene continue along hold division brand new allow work promise alter beneficial 
2.0@cancer methyltransferases dnmt dnmt interphase order exhibit dnmti growth growth inhibit inhibit inhibit next strand strand strand strand methylate particularly well allow allow inhibitor parent parent reduce tumor tumor tumor tumor tumor pattern pattern pattern hypermethylation hypermethylation hypermethylation parental express cell cell cell cell cell one suppressor suppressor suppressor enzyme replication ability irreversably dna dna dna dna dna replicate base bind bind dnmts gene gene gene gene methyltransferase prepare copy copy copy division division undergo silence methylation methylation methylation decitabine decitabine daughter daughter daughter work 
2.0@kind cancer transfer demethylates formation tumour agent island ame since thuspermitting overall treat thy prevent dna dna ase act inhibitor demethylating gene gene reduce undergo normal cpg may methylation decitabine mitosis cell use would expression expression 
2.0@suppressor suppressor cancer cancer rate tumor tumor tumor tumor tumor tumor promote depend action include replication replication manner dependent throughout since growth methylation could lead lead demethylation treatment dna dna dna dna divide divide dose promoter promoter allow least inhibitor gene methyltransferase reduce reduce optimal death hypermethylation silence induce genome protective express sensitive cell cell cell cell rapidly rapidly decitabine decitabine decitabine decitabine 
0.33@cancer yet fda agent specific myelodysplastic probably since exert island irreversibly prognosticoutcome severely hypermethylationof tumor mechanism affect affect neoplastic nucleoside case cell cell drug drug andis dependent get seem seem seem replication cause forexample low anti know know good dna dna dna dna divide dose bind least demethylating cpg poor methyltransferase effect effect upon analog division replicate methylation decitabine decitabine incorporate approve action action 
2.0@cancer article class dnmt tumor tumor tumor tumor use agent mark myelodysplastic economist growth growth treat inhibit job open epigenetic keep inhibitor enzyme demethylating control control control serve accord may release cell cell methyl methyl methyl belong suppressor suppressor drug drug cause decitabine decitabine normally normally know group group group dna dna dna dna dna dna syndrome dnmts gene gene gene methyltransferase expression remove remove place chromatin increase division division silence silence methylation allow 
1.33@elod plastic host unbind n use agent agent hypomethylating structurally island treat inhibit lead cytosine cytosine nitrogen tumour decitibane well enzyme demethylating unlike take mean mean carbon unable methyl tra substitute suppressor also erase tot decitabine y trigger gene prevent damage degradation dna dna dna dna dna however bind syndrome act function cpg progressive place similar increase silence due signal locate adna incorporate covalently would 
1.67@cancer cancer article quick tumour every agent stop note treat affect inhibit benefit often see lose hyper hyper demethylating conserve mechanism mechanism gradually potent behaviour cell cell cell cell cell however machinery also hopefully drug healthy add describe cancerous cancerous dna dna dna dna divide act principle important effect molecular division division new methylation methylation methylation methylation methylation methylation methylation decitabine work mean influence action would would would would associate 
1.67@dna dna dna cancer inhibitor tumour ability decitabine best normal unlike lead irrivesibly divide methylate bind enzyme gene proliferation reduce reduce methyltransferase control methylation methylation deplete work cell cell cell rapidly would inside 
2.0@inject growth cancer cancer methyltransferases restore phosphorylated produce use mostly agent hypomethylating myelodysplastic since since cellular hypomethylation rate tumour inactive lead irreversibly body establish think replicate normal normal render decitabineis treatment control suppressor faster also antimetabolite antimetabolite seem replication replication cause apoptosis target number bind metabolism dna dna dna dna divide cell cell cell cell cell cell cell cytotoxic syndrome function gene effect remove interact must interfere methylation methylation decitabine decitabine decitabine incorporate incorporate incorporate incorporate 
2.0@suppressor cancer methylating dnmt class activation tumour analogue include base transfer otherwise cytosine generalise meet silence hypomethylation part bind usual promoter island often dna dna dna dna irreversibly development ase inhibitor dnmts drug inhibit function cpg thus decitabine decitabine gene gene incorporate lead lead replication associate 
0.67@dna dna umor cancer anti demethylating gene drug drug drug reduce agent suppress belong turn genome hypermethlyated number work sit inhibit methyltransferase decitabine 
2.0@suppressor suppressor methyltransferases methyltransferases tumor able helpful use analogue result characterize occur decrease decrease prevent cpg regulate dna dna dna dna irreversibly bind expression expression drug island proliferation inhibitor induce affect hypermethylation hypermethylation silence methylation methylation decitabine nucleoside incorporate migration cell survival tumour tumour replication 
2.0@dnmt rapid rid process incorporate reactivate clearly disruption show lose well ineffective proliferation tumor tumor mechanism apoptotic although cell cell drug suppressor dependent render divide replication replication eventually dosage become know hypomethylated dna dna get synthesis bind dnmts still right inhibitor control thus thus methylation decitabine decitabine decitabine gene activity action 
2.0@elod dacogen inhibitor growth dnmt induce induce use agent analog reactivate hypomethylation onsilencing cytosine reversible involve inductor demethylating tumor tumor tumor mechanism block link clear incorporaton high demethylation treatment supressor supressor also nucleoside successfully decitabine decitabine completely thedna promoter covalent dna dna dna non synthesis syndrome act dependence gene gene plastic supressing epigenetically probably probably silence thus apotency y asapoptosis action differentiation methyltransferase 
0.67@cancer devision use use fda prove without process myelodysplastic myelodysplastic currently dnmti leukemia myelogenous treat promote epigenetic strand precursor impact normal directly small side many cell cell cell one one dependent large patient deleterious drug drug four toxic target well slower become demethylation dna dna dna divide dose dose acute bind syndrome syndrome initially function methyltransferase effect copy find methylation decitabine decitabine daughter work work incorporate approve azacitidine le recently 
0.67@et et cancer cancer cancer inhibitor class tumour agent agent aberrantly epicentre dinucleotides myelogenous economist hypomethylation hypermethylated treat treat island methylcytosine cytosine epigenetic strand promoter promoter promoter responsible belong demethylating normal precursor act aberrant al al cell deplete supressor silent cause cause decitabine decitabine decitabine target free counter dna dna dna egger acute syndrome methylcitosine myelodysplastic cpg cpg gene gene methyltransferase enzyme keep wikipedia kantarjian methylation methylation methylation pathologically em incorporate indirectly 
2.0@om cancer critical od inflammation dnmt may may include agent specific myeloplastic myelodysplastic myelodysplastic dnmti dnmti hypomethylation possibly abnormal treat unknown irreversibly work work help disease demethylating reduce mechanism hypermethylation hypermethylation proliferative nucleoside factor like demethylation cell tumour suppressor ula lung analogue mun study replication cause combination baylins exact pdl know think dna dna reverse bind inhibitor poor methyltransferase effect effect unclear suggest silence due thus methylation decitabine decitabine disorder disorder disorder gene gene gene incorporate ti prognostic stephen 
1.33@cancer inhibitor inhibitor class dnmt progress use fda myelodysplastic myelodysplastic myelogenous dnmti dnmti leukemia treat decrease island amount tumor tumor tumor irreversibly well hyper severely impact impact helpful test suspect high huge cell dna dna dna dependent dependent lower replication cause toxic mean solid reason dose dose acute bind syndrome syndrome dnmts cpg aml disease still replicate methylation methylation methylation decitabine decitabine work work work incorporate approve action methyltransferase would de 
1.67@cancer cancer inhibitor dnmt dnmt dnmt may stop process process growth lead irreversibly body responsible enzyme tumor block normal difficult right maintain cell cell cell blood faster insert mitotic replication mitosis bulk incorporate inheritance cancerous cancerous cancerous normally prevent potentially dna bind act gene multiply upon preferentially silence prescribe methylation methylation decitabine decitabine decitabine decitabine work activity shrink protein 
2.0@standard cancer effect tumor tumor class dnmt dnmt progress tumour drug agent aml anti degradation susceptible chemeotherapy treat myelodisplastic inhibit suppress become achieve dna dna dna dna epigenetic epigenetic syndrome act act act inhibitor inhibitor inhibitor demethylating gene methyltransferase methyltransferase impact upon block particular particular belong replicate induce decitabine decitabine decitabine decitabine methylation methylation approve cell cell enable alter expression 
2.0@could effect class stimulate tumor tumor tumor tumor drug drug cause agent decitabine decitabine considerably make hypomythelating demythelating hypomethylation come anti island island suppress unable dna dna dna dna dna epigenetic act act injection suppression thereby gene gene hence hence inhibitor remove contact result expression hypermethylation due methylation neuclotide di case cpg cpg express enhance would associate 
1.33@cancer cancer cancer cancer methyltransferases methyltransferases class progress use fda mutation myelodysplastic analog change leukemia useful might affect act often epigenetic epigenetic reversible well belong take take myeloid mechanism normal hypermethylation fact fact release although cell cell cell methyl tra dna dna dna dependent dowstream nucleoside therefore irreversibly relate drug drug drug mutate decitabine decitabine target prosnostic type prevent reason divide acute bind syndrome syndrome fe dense cpg poor rapidly inhibitor place place division due due rase methylation longer daughter approve modifier mistake 
1.67@dacogen inhibition multiple may myelodysplastic since deoxycytidine hypomethylation direct exert incorporation indicate death tumor tumor apoptotic nucleoside demethylation cell cell control suppressor specifically analogue promote cause restoration trade mute anti type treatment dna dna dna dna divide syndrome name function gene gene gene rapidly effect cellular believe methylation decitabine decitabine make em active active differentiation methyltransferase associate 
1.67@cancer proliferate dnmt dnmt dnmt use mark myelodysplastic myelogenous treat inhibit act act irreversibly precursor neoplastic hypermethylation hypermethylation may thus thus nucleoside many cell tumour tumour leukaemia compound suppressor dependent promote replication replication analogue anti show prevent demethylation dna dna get dose acute bind syndrome smaller inhibitor gene effect effect set due since methylation decitabine decitabine decitabine arise incorporate action 
2.0@cancer restore restore regulation tumour tumour unmethylated agent process growth hypermethylated catalyse call inhibit previously regulate regulate regulate regulate methylated kind enzyme demethylating mechanism block like demethylation cell cell cell cell use belong one suppressor suppressor suppressor also suppresor promote antimetabolite unregulation result anti bind know hypomethylated dna dna dna however reaction cathegory expression expression function function drug gene gene gene gene gene gene gene gene methyltransferase effect division division division due silence methylation methylation decitabine decitabine decitabine decitabine important 
2.0@methyltransferases methyltransferases formation tumor drug certain agent generation generation generation generation remain transfer new number possibly make suppress thier division dna malignant help function demethylating gene inhibitting inhibitting eliminate carcenogenesis methylations copy methlyated give due thus methylation methylation reduce work case cell cell abberant decitabine 
1.67@standard standard cancer also class magazine tumor tumor use agent agent april hypomethylating article economist chemotherapeutic change susceptible anti conjunction drug drug know inhibit treatment dna dna epicentre chemotherapy demethylating effect effect epigenetically turn belong word methylation follow th cell cell may alter decitabine decitabine decitabine 
2.0@suppressor cancer analogue change therefore dnmt dnmt upon replication replication certain dependent dnmti growth generation hypermethylated decrease inhibit suppress example dna dna status strand pass methylated epigenetic epigenetic act act act inhibitor gene gene methyltransferase activation tumor tumor pattern copy usually methylation methylation follow nucleoside level daughter drug drug alter decitabine decitabine 
1.33@cancer cancer stable class dnmt use irreversably agent stand hypomethylating inhibit since dnmti dnmti leukemia higher treat perfect lead strand body body lose become become grow myeloid tumor methylate neoplastic order high case cell cell cell cell much decitabine decitabine decitabine one lower always rapid therefore therefore divide spread region region build toxic result see dosage anti methylated methylated methylated amount better prevent dna dna dna however acute bind example le multiply whereas effect effect try contain great due thus desire daughter mitosis mitosis methyltransferase frequently frequently 
2.0@cancer cancer methyltransferases could could hypomethylating change make precarious regulate area disease tumor hypermethylation usually want case accessible replication supressor also antimetabolite irreversibly drug incorporate describe somewhat present effect effect effect bind occur dna dna dna divide cell cell cell powerful example act gene rapidly inhibitor remove antineoplastic division methylation methylation decitabine decitabine work another arrive methyltransferase 
1.67@dacogen inhibition restore use agent process myelodysplastic member hypomethylation leukemia direct japanese treat incorporation regulate regulate epigenetic silence demethylating myeloid tumor tumor tumor mechanism normal normal demethylation cell cell cell cell way expression suppressor suppressor drug drug cause cause result gain know know company dna dna dna dna dna dna acute syndrome sell eisai gene gene gene aml function growth growth control increase increase division new methylation methylation methylation decitabine work class methyltransferase 
2.0@cancer dnmt use myelodysplastic analog myelogenous azacytidine similar potential treat affect affect inhibit nucleotide irreversibly strand body precursor demethylating severely tumor mechanism normal divide release nucleoside regulator cell cell cell cell cell much doseto leukaemia enzymatic dependent epigenetic replication usedat acute decitabine decitabine target low know action action dna dna dna dna dna get kill bind bind bind syndrome drug methyltransferase methyltransferase methyltransferase along along upon must copy division replicate replicate well methylation longer daughter incorporate come come thesedrug rapidly 
2.0@cancer cancer cancer isnt restore lower able produce use use every inhibitor agent agent agent myelodysplastic analog myelogenous leukemia direct incorporation nucleotide consider consider consider consider therefore precursor allow demethylating demethylating dnmt dnmt tumor antineoplasic separate normal bind usually genome nucleoside metabolism drug drug drug drug drug suppressor also antimetabolite antimetabolite get replication replication work work cause apoptosis anti consist group syndrome dna dna dna dna dna divide dose cell cell cell cytotoxic chemotherapy act function gene rapidly effect upon methyltransferase keep belong interfere methylation decitabine decitabine decitabine region incorporate incorporate constant aml methylating 
1.67@dacogen drug methyltransferases commonly suppressor suppressor methylates use use cause cause cause include agent whose tumour tumour myelodysplastic myelogenous stop growth leukemia treat know inhibit inhibit job dna dna dna acute syndrome precursor allow demethylating overactivity expression normal hypo word silence silence methylation decitabine decitabine gene gene gene cell cancer uncontrolled 
0.67@dna cythosines demethylates silence demethylating gene effect tumor tumor agent cpg hypermethylation metil thus decitabine consecuence island antitumoral supressor 
1.33@cancer cancer methyltransferases lymphoma progress methyl every mutation mutation mutation mutation since change leukemia leukemia genetic treat treat test solid myelodisplastic epigenetic epigenetic epigenetic epigenetic epigenetic strand reversible inhibitor enzyme myeloid tumor normal readily high regulator passive cell cell cell cell use use tra one enzymatic cytidine cause cause irreversibly replication analogue toxic proper low without occur somatic somatic treatment treatment dna dna dna dna dna dna dna dose dose acute bind syndrome fe target target drug drug drug affect rapidly effect demethylation division replicate rase methylation decitabine decitabine decitabine decitabine irreversible incorporate tissue side recently 
2.0@cancer effect class dnmt tumour tumour tumour tumour cause cause inhibitor function mark target strand hypermethylation hypermethylation hypermethylation anti methylated drug inhibit inhibit island island dna dna dna dna dna dna dna epigenetic epigenetic non help consequence responsible enzyme cpg cpg gene gene gene methyltransferase happen pattern affect keep belong consequently thus methylation methylation methylation decitabine decitabine decitabine arise lay mantainance silence silence replication supressor supressor 
2.0@article class effective transcriptional use slow appear appear agent agent stop two member change call locus locus benefit epigenetic enhancer generally demethylating demethylating enhance tumor tumor tumor accord affect give although far may may may one suppressor suppressor also also drug drug cause therapy likely activity activity cod solid promoter approve dna dna get likelihood syndrome site myelodysplastic gene gene effect increase increase demethylated decitabine decitabine decitabine another tumorogenesis exist azacitidine 
2.0@dacogen cancer cancer tumour tumour tumour fda add example mark meet dnmti epigentic inhibit molecule clinical take mechanism block hypermethylation hypermethalted assume push repress pharmaceutical decitabine decitabine decitabine one measurable suppresor methylayion divide drug drug success anti develop company dna dna however cell sell recent gene methyltransferase effect unclear place thus ul ul activity approve protein small 
2.0@suppressor cancer methylating class therefore dnmt dnmt dnmt tumour tumour cause could decitabine decitabine island anti result hypomethylation like sit show inhibit dna reverse help well responsible inhibitor cpg cpg gene methyltransferase effect tumor block hypermethylation hypermethylation hypermethylation silence genome genome deregulation region region typically icrs cell protein promoter progression 
2.0@become promote dnmt sustaine may may cause cause agent md demethylate probably dnmti growth anti anti methylated island island island cpg cpg lineage disease dna dna therefor pass help bind le hypermethylation demethylating effect effect tumor irriversibly try believe belong methylation decitabine decitabine decitabine daughter daughter demethylation cell cell cell cell complete drug 
2.0@cancer cancer mode use use use use trialled analog find malignancy island decrease decrease decrease decrease inhibit inhibit cytosine irreversibly ineffective interest hypermethylation hypermethylation hypermethylation hypermethylation hypermethylation thus thus high many tumour tumour tumour tumour tumour suppressor suppressor suppressor decitibine replication toxic suppression result dosage dosage promoter particular action nucleus dna dna dna dna dna dna correct various bind expression cpg gene gene gene methyltransferase methyltransferase methyltransferase inhibitor unclear range increase thereby currently currently decitabine decitabine decitabine decitabine decitabine incorporate availability haematological associate 
1.33@cancer cancer methyltransferases stable growth dnmt activity use agent agent agent hypomethylating hypomethylating cytotoxicity change change generation tsg incorporation decrease inhibit nucleotide addition lead strand sequence prevent successive disrupt pattern pattern block affect contribute cell methyl methyl cytidine excessive ability subsequent ofdna without underlie amount group group dna dna dna dna dna dna dna dna dna dna dna dna dna dna synthesis bind covalent correspond function methyltransferase methyltransferase inhibitor inhibitor cellular cellular cellular division modification methylation methylation methylation methylation methylation rna incorporate hypomethylates survival associate 
1.67@cancer reduce stable restore available dnmt dnmt induce methyl agent agent specific mechanism hypomethylating hypomethylating transcription hypomethylation hypomethylation theoretically change suggest suggest inhibit inhibit amount addition lead cytosine reversal sequence well silence proliferation able tumor tumor pattern pattern may analyse reexpression signal decrease cell secondary deplete progrowth suppressor dependent also proteosomal residue presumably disrupt could apoptosis data solid promoter promoter group dna dna dna dna dna pathway inhibitory exploratory degradation act expression gene gene gene methyltransferase inhibitor remove cellular cellular global increase increase division methylation methylation methylation decitabine decitabine decitabine decitabine decitabine regulate downstream enhance independent progression 
0.0@effect reactivation reactivation produce induce blood myelogenous dnmti hypomethylation leukemia useful treat marrow island lead particularly precursor contribute deform inhibit tumor tumor tumor link turn demethylation demethylation cell myelodysplatic supressor suppressor condition trigger antitumour desitabine hypothemylation dna dna dna dna acute syndrome cpg gene gene gene methyltransferase methyltransferase inhibitor inhibitor epigenetically result silence decitabine bone 
1.67@cancer cancer restore dnmt dnmt dnmt dnmt dnmt dnmt dnmt likely analog generation hypermethylated exert call inhibit class recognize import hypermethylation tumor normal link convert proteasomal bond cell cell cell cell drug suppressor suppressor cytidine cytidine need ability trap trigger antitumor tri covalent covalent dna dna dna however kill degradation le le expression expression irreversible methyltransferase inhibitor inhibitor first increase belong replicate thus thus decitabine decitabine decitabine decitabine decitabine decitabine decitabine gene gene incorporate incorporate active active form form hence phosphorylated 
2.0@suppressor cytidine cytidine activation agent result bring hypomethylation anti might inhibit lead dna dna dna dna dna methylate bind kind act function demethylating gene methyltransferase methyltransferase effect tumor tumor analog decitabine decitabine incorporate incorporate come covalently nearby 
1.33@inhibitor class class class within dnmt dnmt methyl methyl maintain maintain newly dnmti dnmti dnmti hypomethylation make transferase transferase transferase inhibit work lose remember well belong island tumor tumor hypermethylation thing myelodysplastic genome nucleoside case cell cell cell cell cell drug drug drug one analogue divide divide need need cause cause cause fast like prevent though action action dna dna dna dna dna dna maintenance lot bind syndrome methy cpg hence hence rate unavailable due thus methylation methylation methylation methylation methylation decitabine decitabine decitabine daughter wide incorporate tumorogenesis form 
2.0@inhibitor class reactivation produce induce tumour link useful condition myelogenous silence hypomethylation leukemia anti treat marrow hypothemylation syndrome dna dna case blood acute particularly precursor contribute deform gene methyltransferase effect tumor belong turn thus decitabine decitabine bone epigenetically cell myelodysplatic supressor 
2.0@mitotically inhibitor dnmt dnmt dnmt dnmt dnmt dnmt use use agent specific correct anti de hypomethylation unmethylated md md treat island enzimes intervent cytosine strand strand strand methylated group way occours occours block block mammal neoplastic hypermethylation heritable respect cell cell far methyl lower enzime enzime drug drug hemi novo lay symmetrical fashion present maintain contrast occur toxic parent parent cpg cpg cpg dna dna dna dna dna dna dose dinucleotide dinucleotide syndrome myelodysplastic dinucleotides methyltransferase methyltransferase effect must division replicate methylation methylation methylation methylation methylation decitabine decitabine daughter another 
1.0@different different different maybe cancer cancer cgis lower activate tumour tumour tumour tumour tumour tumour agent mark find impair dnmti treat inhibit cautious belong demethylating stadium supressors anymore cell recombination supressor supressor dependent dependent dependent also therefore drug drug could could supressive lay become level dna dna stag dnmts dnmts gene methyltransferase inhibitor great silence methylation decitabine decitabine illegemate active tumorigenesis enhance 
0.67@dacogen cancer effect class hopefully tumour tumour fully agent likely imply surpressed discover present growth potential type amount decrease suppress company dna dna expression expression name name sell eisai demethylating gene gene side reduce eradicate increase increase turn thus methylation methylation genome wide many japanese decitabine decitabine 
1.33@cancer cause high therefore dnmt dnmt dnmt replication analogue dependent irreversibly call inhibit good class dna divide bind epigenetic act target inhibitor inhibitor rate serve belong actively ul ul nucleoside incorporate demethylation cell decitabine decitabine 
1.67@cancer critical use use state state state agent agent also dnmti md hypermethylated treat treat island back lead open epigenetic demethylating demethylating inhibit tumor tumor tumor hypermethylation supressors express heterochromatic machinery mode transcription wherein fight drug drug therapy target bring healthy like demethylate demethylate occur could could could dna dna action maintain function cpg gene gene gene important silence decitabine decitabine region region cancerous supressor protein 
1.33@cancer cancer cancer cancer restore produce uncontrolled agent growth growth island island class help silence demethylating demethylating demethylating proliferation tumor tumor due due normal normal normal hypermethylation cell cell cell cell cell cell cell cell control control suppressor suppressor also also promote drug cause cause toxic escape gene gene know metabolism dna dna divide function cpg cpg hop rapidly effect remove cellular death belong interfere thus thus methylation decitabine decitabine decitabine work incorporate 
2.0@cancer tumour tumour way dnmti hypomethylation hypomethylation leukemia demithylation occur occur unknown epigenetic strand copy acronim disease take myeloid genome although privilege hypo may also patient depend divide apoptosis acute present type pharmac demethylation treatment non cell cell bind gene methyltransferase suggest belong methylation methylation decitabine decitabine decitabine decitabine mainly mean different class dnmt agent agent analog associate differencial island island island nucleotide irreversibly get involve division role like reproducible recover supressor one methylating fight replication chromossomic target become random know prevent dna dna dna dna profile region region expression cpg cpg cpg rapidly inhibitor inhibitor induce place allow daughter wide activity action action play 
2.0@cancer cancer cancer cancer inhibitor suppressor theundoing tumour agent process analog since itbounds preferentially island irreversibly tooncogenesis help hpermethylation demethylating proliferation tumor affect hypermethylation thannormal nucleoside decitabineis cell cell control canhelp dependent therefore therefore get relate replication replication mutation anti promoter demethylation dna dna dna dna divide epigenetic cpg gene gene gene gene rapidly effect induce methyltransferase methyltransferase revert silence silence incorporate upon cellscontribute asa 
2.0@dna dna suppressor cancer state excessive decetabine expression thereby gene slow tumor tumor agent could demethylating incpg methylation disrupt growth demethylation island lead 
1.67@dacogen cancer cancer myeloid class dnmt dnmt activate use slow agent impose myelodysplastic leukemia treat treat treat effectively inhibit inhibit inhibit epigenetic repression precursor demethylating island impact tumor tumor tumor tumor mechanism mitigate otherwise regulator cell way suppressor suppressor suppressor expression enzymatic irreversibly function ideally result shut cancerous gene gene gene anti promoter prevent syndrome dna dna dna dna dna acute bind chemotherapy name additional cpg sell methyltransferase effect thereby methylation methylation methylation decitabine decitabine decitabine decitabine region typically perhaps would would would 
1.33@cytidine class manner use chemically agent decitabine decitabine decitabine myelodysplastic analog myelogenous hypomethylates leukemia treat inhibit chain dna dna dna dna dna epigenetic strand acute syndrome precursor function demethylating methyltransferase inhibitor similar belong rna although incorporate incorporate drug azacitidine azacitidine 
1.67@cancer also also daughter cannot replication analogue agent low dosage dnmti dnmti hypomethylation come anti methylation know good dna dna dna dna divide strand copy bind bind inhibitor give demethylating methyltransferase methyltransferase effect tumor along neoplastic belong since irrevesebly release nucleoside incorporate prone cell cell cell kill decitabine decitabine 
1.67@dna dna suppressor cancer methyltransferases therefore allow demethylating gene gene proliferation expression induce induce agent cell silence silence decitabine decitabine hypomethylation decrease previously tumor 
2.0@mean inhibitor dnmt activate use use fda agent process myelodysplastic currently growth hypermethylated treat inhibit inhibit irreversibly tumour tumour tumour tumour precursor demethylating nucleoside area drug drug leukaemia suppressor dependent patient therefore epigenetic amongst analogue target target express anti know dna dna dna dna acute bind syndrome dnmts gene methyltransferase effect myelogenous methylation decitabine decitabine incorporate approve associate machinery replication progression 
1.33@cancer tumour near stop stop easily hypomethylation hypomethylation island island often inhibit nearby block affect affect hypermethylation divide spot cell cell cell cell cell cell express suppressor greater therefore package drug drug cause healthy result cancerous transcribe tightly anti obtain dna dna dna dna dna get get beside le act expression expression cpg cpg gene gene gene rapidly inhibitor upon upon division methylation methylation methylation decitabine decitabine daughter incorporate incorporate return associate 
1.67@one unknown cancer fordecitabine irreversibly use use although today stop appropriate myelodysplastic fourfda dosage dnmti growth md type treat decrease amount analoge promote dna divide action dependent syndrome dnmts hypomethylation research tumor tumor mechanism epigeneticinhibitor bind hypermethylation methylation decitabine nucleoside region specific cell cell expend replication 
2.0@dacogen cancer cannot dnmt dnmt activate use agent specific myelodysplastic myelogenous sit treat transferase island might strand see precursor enzyme demethylating matter tumor block permanently contribute fact demethylation demethylation thereby tumour supressor supressor reason cytidine drug analogue structure cell describe methylate commercially anti methyl show dna dna dna divide acute bind syndrome sell inhibitor cpg gene gene chemical effect induce silence produce thus methylation decitabine daughter progressive article 
1.67@cancer cancer cannot effective behave tumour nett agent agent pattern probably also hypomethylation defence inhibit cytosine irreversibly strand body particularly hypermethylation hypermethylation demethylating demethylating mechanism mitotic susceptible nucleoside cell cell cell cell cell cell may may substitute chemical cytidine cytidine reuse render relate analogue apoptosis natural reaction effect normally reverse dna dna dna dna dna dna divide divide kill bind example act act rapidly enzyme enzyme division division replicate strip methylation decitabine daughter daughter incorporate complete methyltransferase methyltransferase associate 
1.33@one suppressor suppressor cancer cancer tumour tumour tumour class class therefore able able methyl cause agent epigenome hypermethylation hypermethylation anti type treat promoter group exert exert previously dna dna dna un un mention act use use function demethylating gene gene gene gene effect effect remove demethylation belong silence silence silence decitabine decitabine work many drug drug drug recover region 
2.0@suppressor cancer seppressor fully growth therefore transposon activate tumour tumour tumour slow include promotor whole new hypomethylation reaction might severe hypomethylated presence dna dna dna divide strand get get get methylated methylated methylated least silence ofdecitabine island island disapear inhibitor repeat cpg cpg thus decitabine daughter gene gene case cell cell cell methyltransferase adverse 
1.67@cancer cancer characteristic dnmt dnmt methyl methyl add stop stop process find unmethylated useful epigenetic strand lose attack way reduce difficult much methylation methylation methylation cell cell cell cell control machinery let transfer researcher therefore themethylation drug drug drug drug drug drug target cancerous without ease group good dna divide divide bind bind inhibitor performance enzyme go combat decitabine decitabine daughter work come 
2.0@cancer cancer class effective use use use myelodysplastic currently currently since since dnmti treat island suppress suppresser irreversibly common precursor allow demethylating research tumor tumor tumor tumor tumor affect hypermethylation release nucleoside express many cell cell cell cell cell leukaemia leukaemia drug drug drug drug offer myelogenouses type type demethylation potentially dna divide divide divide acute bind syndrome dnmts cpg gene gene rapidly inhibitor longer myelogenous methylation decitabine work mean 
1.67@suppressor cancer also restore imprint region region shore revert revert hypomethylation potential anti exert promoter promoter lead lead lead lead might treatment dna dna malignant kill inhibitor cpg cpg island island methyltransferase effect tumor tumor pattern pattern normal hypermethylation hypermethylation hypermethylation silence methylation decitabine decitabine aberrant gene gene gene cell expression expression expression 
2.0@fuel suppressor suppressor proliferate restore methyltransferase island agent agent apoptosis hypermethylation oncogene inhibit call grow damage class dna dna dna epigenetic cell act function function demethylating demethylating prevent rather inhibitor tumor tumor tumor die dir normal belong undergo decitabine decitabine decitabine ltr gene gene cpg thereby enable 
2.0@document blewitt cancer cancer inhibitor abnormal class tumor tumor tumor tumor agent probably growth back island island propagate lead body source dr hassler turn hypermethylation hypermethylation defense effectiveness fight cell cell cell variously drug drug decitabine compound suppressor dependent stresemann presumably replication egger suppression natural anti best lecture parent amp think dna dna dna divide grand lyco integrate act cpg cpg gene methyltransferase effect remove describe describe blewitts silence thus actively allow allow daughter daughter drive learn epigenetically approve enable haematological 
1.67@maybe maybe cancer dnmt dnmt progress relieve slow fda mark newly newly dnmti md md tsg tumour tumour transferase island unknown targetting irreversibly strand methylated repression provide mechanism affect hypermethylation may nucleoside cell cell cell cell cell methyl methyl suppresssor transfer high therefore analogue dectabine exact become type level prevent methyltransferase synthesise synthesise dna dna dna dna divide divide divide bind cpg poor aml inhibitor dependant dependant copy division division cels methylation methylation decitabine decitabine decitabine daughter gene gene incorporate incorporate approve action action indicator heavily prognostic 
0.0@faster cause daughter therefore order uppon may analogue healthy methyltransferases irrevesibly demethyliation copy nucleotide dna dna dna dna dna get strand methyliation bind bind incoporated methyltransferase methyltransferase inhibitor tumor tumor tumor replicate affect longer release nucleoside replecated come cell cell cell cell replication decitabine decitabine decitabine decitabine 
2.0@alt cytidine decitabineinto agent specific hypomethylating result hypomethylates incorporation src inhibit dna dna dna dna gene gene activation tumor analog block methylation ul ul img suppressor decitabine 
0.67@cancer cancer class specificity use state mutation example hypomethylating myelodysplastic analog leukemia genetic exert inhibit molecule molecule important irreversibly strand reversible well enzyme enzyme enzyme enzyme unlike myeloid tumor block nucleoside role cell cell cell cell catalyze belong one standard lower lower daughter daughter epigenetic epigenetic general drug drug drug cause incorporate level action action treatment treatment treatment dna dna dna dna divide acute bind chemotherapy inherit positive treatable rapidly effect effect effect syndrome division due thus methylation methylation decitabine decitabine decitabine decitabine mainly counteraction availability methyltransferase methyltransferase 
1.67@suppressor cancer abnormal class reactivation tumour analogue analogue run run run loss island result result since mode arrest reverse prevent cpg action potentially dna dna dna dna dna irreversibly see bind fe fe fe allow drug drug inhibit proliferation inhibitor belong turn rase rase rase methylation methylation methylation decitabine nucleoside gene incorporate active cell apopotosis methyl methyl methyl 
0.33@cancer histone inhibitor cpg reduce reduce remodel chromatin hypermethylation usually thus methylation methylation decitabine decitabine change island 
2.0@cancer inhibitor higher dnmt dnmt use agent myelodysplastic myelogenous leukemia treat island lead irreversibly strand precursor demethylating demethylating tumor pattern normal supressors nucleoside cell cell tumour tumour suppressor specifically dependent promotors epigenetic drug analogue anti prevent dna dna dna dna divide acute bind syndrome cpg gene rapidly effect effect copy increase thereby methylation decitabine decitabine decitabine decitabine daughter incorporate methyltransferase replication 
2.0@aptoposis fail restore restore restore use state agent hypomethylating myelodysplastic regulatory treat grow epigenetic assignemnt discuss silence island tumor tumor question hypermethylation impaced cell cell cell cell inhibit suppressor possibily erase cause pas proper erasure normally level dna divide syndrome function function function cpg gene continue inhibitor cellular cellular previous shrink methylation methylation methylation decitabine decitabine decitabine daughter methyltransferase would 
2.0@reason cancer inactivate therefore tumour tumour slow agent could analog classify growth bind drug mention inhibit cpg say dna dna dna dna irreversibly consider expression demethylating island methyltransferase reduce increase thereby methylation methylation decitabine nucleoside gene gene incorporate repressor replication would 
1.33@effect class lower reactivation upon methyl agent silence myelodysplastic myelogenous dnmti dnmti hypomethylation hypomethylation treat nucleotide epigenetic strand andthen precursor contribute demethylating adna neoplastic link release cell cell use leukaemia dependent cause run seem replication analogue acute anti anti tumour tumour tumour good dna dna dna dna dna get dose kill bind bind bind syndrome fe inhibitor inhibitor drug irreversible aml along along epigenetically supressor copy division longer rase methylation decitabine decitabine daughter incorporate come come action methyltransferase methyltransferase methyltransferase effector 
1.67@suppressor cancer cancer cancer also dnmt tumour cause however larger targt growth part inhibit divide effect inhibitor prevent rapidly reduce normal normal normal dnmtis dnmtis hypermethylation silence methylation decitabine cell cell cell cell cell 
2.0@inhibitor inhibitor inhibitor inhibitor inhibition class dnmt withdrawal trap hypomethylating portray fundamental call inhibit inhibit molecule lead lead epigenetic epigenetic epigenetic work decitabines regulator catalytic administer reactivation tumor mechanism block block dnmtis thus effectively nucleoside small enzyme enzyme cell cell cell cell cell belong enzymatic enzymatic dependent analogue either target target low free reversal pocket reaction anti arrest damage damage reverse dna dna dna dna mark dose synthesis synthesis death site gene gene chemical chemical effect effect induce induce protein protein inturn division replicate silence silence methylation decitabine decitabine decitabine establishment attribute confer active action methyltransferase methyltransferase dnmti 
1.67@cancer cancer cancer nucleoslide class unclear tumour likely cannot dnmti drug drug island cpg molecule epigenetic epigenetic epigenetic epigenetic strand show inhibitor inhibitor inhibitor belong reduce mechanism dmt normal abnormality treatment incorporarted pharmaceutical machinery dependent rapid therefore irreversibly alteration replication analogue target target low present exact anti know develop company dna dna dose cell cell cell cell dmnti still bindsdna effect effect upon methyltransferase methyltransferase copy division division undergo methylation methylation decitabine decitabine decitabine daughter possible action action reverse reverse small 
1.33@methyltransferases abnormal methyl methyl agent stop mark become become analog since hypomethylates aza transport lead lead cytosine strand lose hypomethylated happen tumor block thus citotoxicity cell cell replication tra substitute cytidine therefore drug cause ultimately anti group presence dna dna dna dna dna dna dna dna hypomethylating bind bind bind fe function effect remain deoxycytidine death rase methylation decitabine decitabine incorporate covalently 
2.0@suppressor lat methyltransferases pome class activation tumour tumour tumour fda cancer agent loss growth md type inhibit inhibit thy lead treatment dna dna dna ah rapidly inhibitor grow belong methylation methylation decitabine decitabine decitabine gene incorporate approve cell replication replication recently 
1.67@hipermethylated cancer cancer restore therefore use use agent specific gene gene gain treat group dna caracteristic disease demethylating locus expression tumor invert methylation decitabine decitabine region may may supressor 
1.67@slide resource lecture 
2.0@suppressor methyltransferases methyltransferases dnmt administration inhibit inhibit prevent dna dna dna dna irreversibly dose bind bind mediate gene inhibitor tumor silence thus methylation methylation reduce daughter small cell decitabine decitabine decitabine 
2.0@inhibitor dnmt dnmt tumour tumour tumour tumour tumour cycle chromosomal mark analog methyl transferase inhibit lead epigenetic decrease lose involve however enhance intergenic somatic instability instability like demethylation cell cell may may may region region region suppressor cytadine depend activation transposable drive accomplish result result anti element occur promotor genomic example dna dna maintenance maintenance contribution function gene methyltransferase effect upon satellite repeat methylation methylation methylation decitabine create 
1.67@inhibitor inhibition class intra use drug agent phase myelodysplastic result myelogenous hypomethylation anti treat incorporation company dna dna dna dna dna epigenetic acute syndrome sell demethylating methyltransferase effect precursor belong decitabine decitabine come japanese tumour replication leukaemia 
2.0@sensible effective noxious cause mark need dnmti hypomethylation hypomethylation replication methyl normal group dna dna dna dna divide epigenetic drug drug methyltransferase inhibitor tumor attach replicate new decitabine cell cell cell cell much 
1.0@cancer cancer cancer toxicity think order activate use use fda agent maximum leukemiaas meet de de hypomethylation ya normal inhibitor hyper become dnmt dnmt tumor tumor due affect neoplastic give mode repair myeloid cell cell cell cell cell checkpoint suppressor suppressor belong market specifically methylating limit therefore action drug cause cause cause dose cycle apoptosis target without anti region promoter damage treatment dna dna dna dna dna divide non acute bind integrate act myelodysplastic still irreversible rapidly effect unclear cellular syndrome division ti decitabine decitabine mainly mainly gene gene incorporate approve progression small 
2.0@suppressor cancer inhibitor promote tumour tumour island dysregulated cytosine occur inhibit lead dna dna reverse group silence cpg gene proliferation reduce reduce methyltransferase hypermethylation new methylation decitabine attachment cell methyl onto 
1.67@dacogen inhibitor restore suppressor administration tumour agent hypomethylating md md myelodysplastic myelogenous hypomethylates leukemia anti inhibit treatment dna dna dna syndrome sell function demethylating gene methyltransferase effect tumor precursor silence brand methylation metabolic nucleoside name approve drug food decitabine decitabine decitabine decitabine 
2.0@et et cancer cancer classify randomize outcome use kantarjian kantarjian phase myelodysplastic myelogenous hypomethylates leukemia treat reactive jp issa help precursor amp repressor demethylation demethylation cell cell tumour decitabine decitabine decitabine dna dna dna dna meet transfer iii patient c improve april ly result rosenfeld reagent study acute ase syndrome syndrome gene inhibitor silence al al ul ul myelodyplatic widely 
1.67@cancer inhibitor dnmt use order dependent neoplasic dnmti doesnt obtain allow able severity affect high cell cell much faster lower therefore drug strand toxic mean wont body anti know good dna dna dna dna divide dose dose bind important methyltransferase methyltransferase effect effect upon copy belong word methylation decitabine decitabine decitabine decitabine daughter incorporate replication replication 
2.0@cancer inhibitor class dnmt dnmt use fda myelodysplastic analog myelogenous reactivate reactivate growth growth leukemia treat call nucleotide molecule lead epigenetic epigenetic well belong demethylating tolerate tumor tumor tumor tumor mechanism suppress suppress hypermethylation high demethylation cell cell cell cell cell blood machinery suppressor suppressor dependent lower patient irreversibly drug drug drug drug vulnerable toxic target target cancerous exact demethylate type occur especially dna dna dose dose acute bind syndrome gene gene gene methyltransferase methyltransferase enzyme enzyme unclear rapid division division undergo methylation decitabine incorporate approve nonspecifically small 
1.33@mitotically mitotically cancer cancer effect effect class suppressor suppressor healthy use use slow include agent methylating de marker note md decitibine treat inhibit inhibit heritable granddaughter granddaughter epigenetic epigenetic tumoragenesis see see erase inhibitor activation activation tumor tumor tumor tumor develop precurser show thus routine demethylation cell cell cell cell cell cell far tolerate neighbor lung also also hyperplasia wherein carry carry combination cause bring without anti solid better parent damage dna histone chemotherapy synergistic aml employ deacetylase belong currently actively decitabine daughter daughter influence follow 
0.33@document suberoylanilide cancer methyltransferases lymphoma effective effective administration way undoubtedly already two detail azacytidine de cutaneous clinical epigenetic development enzyme dysregulation myelodysplastic vorinostat cell trial food acid patient drug drug drug microsoft office target deacetylases translate oxy treatment treatment treatment dna dna understand histone histone pdf syndrome zac inhibitor inhibitor chromatin hydroxamic word new new methylation tid approve approve modify 
2.0@suppressor suppressor cancer cancer effect effect dnmt growth reactivation reactivation methyl cause agent stop decitabine decitabina result major hypomethylation anti treat genomic dna dna tumour tumour help fe inhibitor demethylating gene gene proliferation reduce uncontrolled job tomour tomour due rase allow cell cell use tra 
1.33@dacogen cancer cancer cancer cancer class use use agent agent tend already myelodysplastic way easier part treat treat inhibit inhibit inhibit precursor island proliferation tumor tumor affect epigenetics concentrate everywhere demethylation demethylation cell accessibility leukaemia leukaemia suppressor drug drug else trade anti ease solid treatment dna dna non syndrome name cpg gene due demethylated methylation methylation decitabine mean 
2.0@suppressor able model seem use manner aim animal animal treat tumor dna non histone consequence act hypermethylation drug drug gene reduce reduce subject similar test human silence methylation decitabine decitabine gsk gsk case approve commercial control study 
2.0@suppressor suppressor cancer article mean dnmt dnmt dnmt tumour tumour cause agent specific unlimited island target probably lot growth effect inhibit transferase locus cpg dna dna sequence loose expression inhibitor allow demethylating group reduce put accord control hypermethylation thus thus methylation genome genome gene gene hypomethylated malfunction cell methyl methyl decitabine decitabine 
2.0@suppressor suppressor cancer cancer methyltransferases suppresor dnmt excessive use slow agent stop silence target target remain hypermethylation hypermethylation shore shore tumour tumour tumour inhibit presence dna dna dnmts demethylating island island chromosome reduce reduce division thus methylation methylation decitabine decitabine gene gene gene cpg cpg active cell cell spread spread 
1.33@cancer inhibitor inhibition class entinostat entinostat activate tumour include stop repressive dicsion trimethylation presence achieve m well eto eto reduce mocetinostat hdac mgcd induction express hdacs cell cell way specifically lat lat lat lat lat consequently additive replication mrna combination pharmacological derepression result fashion specific anti conclusion several several mark mark histone histone histone histone least expression expression gene gene gene aml aml effect induce increase modification decitabine decitabine chance acetylation 
2.0@dna cancer cancer proliferate dnmt tumour promotors likely likely ie process mean dnmti hypomethylation bind normal irreversably methyltransferase lead compare non action dependent act inhibitor still gene rapidly reduce mechanism affect clear thus thus methylation decitabine incorporate like like cell cell replication suppressor expression 
2.0@one suppressor suppressor cancer transcription gene gene gene gene gene begin replication include suppression overgrowth result hypomethylation unmethylated make incorporation inhibit active division dna dna dna dna assosiated help responsible belong cpg island proliferation inhibitor tumor tumor tumor methyltransferase methyltransferase inactive feature hypermethylation silence rna possible incorporate transcriptionally transcriptionally tumorogenesis cell cell cell cell control control decitabine decitabine decitabine 
1.0@mitotically cancer cancer cancer cancer cancer cancer deoxycytidine growth tumour tumour slow likely specific specific major exhibit frequently hypomethylation hypomethylation heritable transferase grow dna dna dna dna dna dna status decitabines lose well epigenome demethylating impact fresh affect hypermethylation hypermethylation genome genome cell cell cell cell cell methyl decitabine decitabine decitabine decitabine suppressor dependent cause analogue ability agent result become prevent somatic reduction reverse cytidine act act change inhibitor aza must global division division silence methylation methylation methylation methylation methylation permanent gene gene impair active would would would would would would 
2.0@derepress inhibitor inhibitor inhibitor stable restore transcriptional transcriptional dnmts use state inevitable induce recur find malignancy malignancy malignancy hypermethylated alone benefit important clinical irreversibly help nonexpressed cessation tumor normal hypermethylation hypermethylation hematologic genome maintain many drug nuceloside ensure suppressor dependent cause large patient patient necessary alteration replication analogue combination therapy deoxyribose hematopoietic number bind group demethylation demethylation treatment dna dna dna dna dna maintenance powerful expression function gene gene gene gene gene continue effect upon contain silence silence silence undergo noncoding methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine region incorporate incorporate active various methyltransferase 
2.0@dna section mark syndrome myelodysplastic demethylating induce tumour remove agent growth neoplastic limit methylation decitabine decitabine hypomethylation gene treat cell cell use 
2.0@elod plastic cancer inhibitor suppressor produce use near cycle toacute product myelodysplastic easily myelogenous reactivate growth hypermethylated treat marrow marrow island act previously lead methylated precursor bone bone hypomethylated tumor tumor hypermethylation fact count genome cell cell cell cell cell cell blood blood blood blood blood formation leukaemia specifically red red become become cytopenia immature cause myeloblast y low encourage anti help promoter prevent develop etc dna dna dna white white white syndrome syndrome le cpg gene irregular effect methyltransferase protein due thus thus decitabine decitabine decitabine disorder production regulate perhaps form indirectly heavily would enough 
2.0@cancer cancer article restore restore use use include epicentre eisai economist hypomethylation treat treat normal dna dna dna dna dna imply epigenetic epigenetic call methylated inhibitor inhibitor silence impact tumor tumor affect epigenome myelodysplastic company may suppressor identify promote drug drug answer mean describe describe describe reference anti anti tumour several point reduction process japanese syndrome sell function function gene gene methyltransferase effect effect effect explain belong due methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine class follow 
1.0@cancer cancer cancer cancer cancer change behave inherit manner manner agent agent mark make also dnmti growth susceptible generation stably dna epigenetic epigenetic enzyme demethylating demethylating group proliferation furthur normal conventional like like cell cell cell cell cell cell cell cell belong one wofold destroy methylating study drug unwanted unaltered target subsequent cancerous without show prevent prevent treatment standard profile profile profile chemotherapy chemotherapy recent two succesful hence along remove remove division thus combat decitabine decitabine method sensitive alter alter alter azacitidine 
0.0@cancer inhibitor restore restore within within produce use agent process similar growth direct call decitabinealso class epigenetic demethylating tumor normal normal demethylation demethylation metabolism way myelodysplasic one suppressor antimetabolite antimetabolite cause treatement target number syndrome dna dna divide substance substance cell cell cell cell cell cytotoxic chemotherapy function gene rapidly effect interact cellular control death belong belong interfere thus methylation decitabine decitabine work incorporate category 
1.33@enzymatic inhibitor dnmt dnmt methyl cause cause since dnmti transferase inhibit often dna dna dna epigenetic lecture effective tumor affect source divide divide methylation decitabine decitabine regulator demethylation cell cell 
0.33@vivo higher hyperacetylation order formation control cycle mechanism acetyl major coil inhibit lead transcriptionally epigenetic around culture silence thereby remodel proliferation tumor interfere block affect acetylase constitute cell cell chromatin chromatin uncoil expression expression expression core residue require structure apoptosis result reversible arrest condense group tail dna lysine deactylase histone histone histone histone histone histone histone histone function gene gene gene inhibitor inhibitor induce deacetylase deacetylase deacetylase hdi modification terminal decitabine decitabine action action differentiation remove 
1.33@cancer analogue run either requirement deme cause process stop growth make incorporation incorporation decrease decrease inhibit deal unfortunately lead lead dna dna dna irreversibly work lot bind fe use dnmts dnmts drug gene gene side effect effect global hypermethylation thy rase methylation methylation decitabine decitabine decitabine nucleoside region mean express specific tumour tumour replication supressor 
2.0@could methyltransferases methyltransferases methylgroup use drug process transcribe surpressor surpressor become inhibit job dna dna dna dna dna methylated methylated methylated le le site gene gene gene methyltransferase inhibitor inhibitor tumor place decitabine case tumour present 
2.0@cancer cancer cancer disrupt available dnmt synthesize trap newly dnmti dnmti overall permanently inhibit molecule molecule decrease consequence island gradually hypermethylation hypermethylation special nucleoside nucleoside cell drug deplete decitabine correlation depend replication analogue mean result type show prognosis dna dna dna dna dna dna get bind dnmts perform poor methyltransferase inhibitor upon dampen cpg thus methylation methylation methylation would would possible incorporate approve haematological 
1.33@cancer cancer suppressor suppressor use slow chemically agent mark mark mark disease disease probably find enzymmes growth myelogenous overall treat treat treat decrease inhibit inhibit epigenetic epigenetic involve precursor enzyme demethylating pseudo tumor tumor myelodisplastic generally may may fact genome possibility factor cell tumour leukaemia removable accidental also abbherrent relate combination drug promotors overexpressed offer throughout mutation suppression result citation overexpression level dna acute syndrome name gene gene knack epigenetically hope hope suggest silence since methylation methylation decitabine lay lay various 
1.67@one dna dna dna could class height excessive tumor tumor tumor drug drug cause structure msonormal since shore change gene gene hypermethylated methyl methyl demethlating demethlating group group hallmark epigenetic allow cpg cpg island island chromosome reduce remove remove increase hypermethylation style decitabine decitabine region mean like line suppressor suppressor expression expression 
1.67@mitotically cancer size field dna others may include agent agent stop stop mark mark objective growth growth potential potential heritable island suppress epigenetic epigenetic demethylating demethylating reduce reduce tumor tumor tumor tumor hypermethylation hypermethylation turn turn epigenetics factor behaviour treatment treatment cell suppressor suppressor oreven transcription application drug drug certain behind kill cancerous without concept group develop either potentially several correct histone expression expression cpg gene gene gene toreduce inhibitor deacetylase thus methylation methylation decitabine activity return modify modify acetylation exist 
2.0@cancer cancer larger class lower lower dnmt tumour tumour tumour stop tend hypomethylating proliferate dnmti hypomethylation sit molecule whereas strand see well give inhibitor myeloid myeloid permanently hypermethylation hypermethylation hypermethylation genome nucleoside express cell way leukaemia suppressor suppressor cause efficiency serious safety replication analogue decitabine decitabine decitabine decitabine throughout dyplastic side target optimise reverse present aggressively anti dna dna dna however dose dose dose acute bind syndrome function drug drug gene gene rapidly effect effect effect effect effect remove methyltransferase widespread attach attach allow work work come enable 
1.33@cancer cancer myeloid class specificity progress use although attempt specific irreversibly probably lower dnmti dnmti note drug drug unto island important epigenetic strand call inhibitor inhibitor however reduce mechanism lack give fact myelodysplastic nucleoside potent high cell cell cell cell require require belong study dependent analogue patient patient divide replication replication cause dose dose toxic mean demethylated become become methylation methylation though dna dna get non acute bind bind syndrome dnmts cpg suffer rapidly effect effect unclear remain copy antineoplastic division due regional decitabine decitabine decitabine daughter daughter irreversible incorporate upon upon action methyltransferase 
2.0@unregulated cancer effect effect substancesinto restore restore within dnmt bodyand much canno hypomethylating anf funtion alongto direct increase nucleotide regulate irreversibly inhibitor inhibitor allow severely tumor tumor block normal methyltransferasecomes produce cell cell cell cell cell cell cell cell cell control blockage suppressor suppressor dependent promote replication cause ofdna result anti bind bind bind metabolism dna dna dna dna divide divide cytotoxic target gene gene gene rapidly rapidly along upon interact copy death division division division longer methylation methylation decitabine daughter work incorporate incorporate come action methyltransferase methyltransferase methyltransferase 
2.0@one cancer daughter way analogue agent suppression island cell cell since cpg cpg bind bind drug decrease prevent prevent nucleotide dna dna dna dna dna irreversibly dinucleotide dependent expression act hypermethylation demethylating gene copy inhibitor tumor methyltransferase methyltransferase methyltransferase affect increase division replicate thus thus methylation decitabine nucleoside incorporate restriction replication without 
2.0@cancer inhibition hypomethylate use meanwhile agent aberrantly epicentre myelodysplastic analog economist treat avoid inhibit stop silence demethylating myeloid tumor tumor tumor thethe vidaza express supressor andazacitidine cytidine drug drug drug april april th number anti thedna dna dna dna dna dna dna acute syndrome volume gene methyltransferase methyltransferase effect belong due methylation decitabine decitabine work work incorporate intake azacitidine 
2.0@epigenetic tumor tumor tumor tumor tumor tumor suppresing exhibit agent hypomethylating suppression result surround surround cancerous number hypomethylation hypomethylation anti amount amount decrease decrease decrease decrease prevent suppress lead lead lead dna dna dna dna dna dna dna dna probability strand strand histone methylated methylated methylated methylated involve enzyme inhibit proliferation proliferation effect epigenetically methyltransferase methyltransferase silence silence silence turn turn turn cod methylation methylation decitabine high gene gene gene gene activity active cell cell may may associate 
2.0@compound suppressor cancer methyltransferases inhibition restore result growth hypermethylated inhibit previously regulate dna dna function demethylating gene gene effect tumor demethylationwith normal normal silence silence methylation decitabine decitabine tent cell cell expression 
2.0@suppressor cancer cause suppresor restore epigenetic methyl analogue malignancy silence effect abnormal decibitabine rase dna dna dna irreversibly see bind act fe function inhibitor inhibitor gene gene methyltransferase enzyme mechanism neoplastic hypermethylation hypermethylation due thus thus thus decitabine decitabine nucleoside class demethylation tra tumour tumour haematological belong 
2.0@unregulated cancer inhibitor become dnmt activate tumour analogue agent stop otherwise otherwise suppression hypomethylates part replication normal suppress expression dna dna dna dna rapidly bind would hypermethylation demethylating gene proliferation allow allow remove methyltransferase block permanently belong replicate methylation genome nucleoside work incorporate case cell cell cell uncontrolled suppressor decitabine decitabine decitabine decitabine 
2.0@igf igf effect effect effect growth suppressor suppressor decitabine decitabine tumour tumour tumour tumour tumour cluster agent cause icr hypomethylation anti occur counter resultant class dna dna dna epigenetic overexpression discuss inhibitor demethylating gene gene reduce reduce reduce mechanism expression increase hypermethylation hypermethylation hypermethylation example methylation methylation wilms factor another may drive beneficial 
2.0@cancer inhibitor class dnmt dnmt yet order agent methlylated newly currently since unmethylated generation overall treat call island nucleotide strand lecture allow demethylating parent reduce reduce tumor hypermethylation clear thus myelodysplastic possibility level level express cell may suppressor one one reduction drug drug cause toxic limit stop match prevent dna dna dose duplicate bind syndrome use important cpg gene gene resume effect force progression slide new methylation methylation methylation methylation decitabine drive totally beneficial 
2.0@cancer cancer cancer cancer inhibitor effective tumour tumour could specific specific process charge reactivate treat normal inhibit want see enzyme island happen mechanism affect affect hypermethylation hypermethylation cell cell cell myelodysplasic drug drug dose actually low shore effect effect anti prevent prevent prognosis dna dna non syndrome cpg cpg gene gene methyltransferase supressing silence poor methylation decitabine decitabine decitabine region mean action 
2.0@suppressor suppressor suppressor cancer methylating class therefore mean tumour tumour tumour tumour analogue agent ability mechanism become chromatine effect anti bind inhibit inhibit prevent prevent nucleotide dna dna dna package reaction consider dnmts still densely happen unclear dependant hand protect demethylating silence silence methylation methylation methylation methylation decitabine decitabine decitabine gene gene incorporate come drug drug cell replication would would would expression expression 
2.0@suppressor could hypomethylation activation methylates pharmacological apoptosis exact age become normally hypomethylated lead lead dna dna dna dna enzyme inhibit inhibit methyltransferase function tumor clear decitabine decitabine induction gene cell differentiation 
2.0@dacogen cancer inhibitor mean lymphoma dnmt dnmt unclear use use cluster agent cutaneous process myelodysplastic analog myelogenous growth susceptible genetic treat treat call inhibit suppress epigenetic epigenetic precursor demethylating chromosome mechanism vidaza nucleoside cell way leukaemia market atom already either rapid therefore action replication replication drug drug mutation switch support target acute reaction bind methyl group dna dna dna dna intervention histone dependent syndrome sell sell function still gene chemical nature upon acetyl deacetylase sort decitabine decitabine plaster incorporate form protein azacitidine 
0.33@celgene dacogen impact class lymphoma decline firm use use inhibitor inhibitor agent acute cutaneous precursor toeisai myelogenous make treat treat call illness company dna dna epigenetic base histone histone syndrome sell myelodysplastic demethylating dramatically overmethylation rare deacetylase belong jersey new methylation decitabine decitabine decitabine merck another japanese cell amount leukaemia 
1.67@suppressor fix class certain certain inhibitor decitabine decitabine decitabine myelodysplastic myelodysplastic myelogenous hypomethylates example leukemia useful useful treat strongly inhibit demethylates dna dna dna epigenetic acute syndrome syndrome precursor demethylating cpg island methyltransferase allow tumor expression belong methylation genome region case associate 
1.67@cancer cannot dnmt dnmt dnmt dnmt dnmt may may hematological fda agent hypomethylating hypomethylating myelodysplastic malignancy dnmti island irreversibly irreversibly strand think inhibit tumor tumor mechanism affect hypermethylation hypermethylation release nucleoside cell replication suppressor dependent dependent dependent understand drug drug drug analogue anti fully dna dna dna divide bind bind bind inhibitor inhibitor cpg gene rapidly effect methyltransferase copy methylation decitabine decitabine decitabine decitabine daughter work work incorporate incorporate come approve action action full 
2.0@dna dna dna cancer cancer reduce reduce reduce change term dnmt dnmt yet inhibitor inhibitor specific long stag result exact anti anti overall prevent island compare development act hypomethilation cpg gene methyltransferase effect effect effect effect tumor tumor mechanism normal hypermethylation clear silence methylation methylation methylation decitabine decitabine like cell drug suppressor 
2.0@mitotically cancer inhibitor available dnmt dnmt dnmt methyl attempt two two analog analog member dnmti hypomethylation heritable effectively nucleotide effective irreversibly strand strand strand transferase help enzyme stick way reduce tumor longer hypermethylation rely nucleoside nucleoside substrate second cell cell tumour suppressor dna dna dna dna dna dna dna become become divide divide due hemi hemi incorporate result anti methylated methylated methylated methylated amount group split get get bind bind bind gene effect first set word find methylation methylation methylation methylation decitabine decitabine decitabine facilitate lay faciliate onto 
1.0@cannot suppressor suppressor suppressor let methyltransferases therefore therefore histone proliferate formation tumour tumour tumour tumour tumour tumour slow agent could could already anti transfer hypomethylates growth hypermethylated make methylated inhibit inhibit promoter prevent prevent prevent damage dna dna dna dna dna demethylate methastasis help silence demethylating group effect gene gene gene kill hypermethylation methylation decitabine decitabine wither active active cell methyl would would would region 
1.67@dna dna dna divide strand methylated methylated thus suppression gene tumour thin keep keep silence version decitabine daughter dememythylating methyltransferase exist 
1.67@pronounce cancer reduce faster disrupt shinks seem need agent could apoptosis condition ultimately growth effect effect effect drug affect lead potentially dna dna dna dna dna dna counter frequency well responsible enzyme demethylating inhibit proliferation rate tumor tumor methyltransferase normal hypermethylation hypermethylation hypermethylation methylation methylation methylation methylation decitabine high cell cell cell use 
0.0@cancer cancer effec tumor tumor tumor use susceptible mutation stop process myelodysplastic myelogenous reactivate change potential genetic treat grow incorporation open epigenetic epigenetic pass precursor silence thereby inhibit detect due dac dac dac dac demethylation cell cell cell cell cell cell way leukaemia suppressor transcription erase substantial decitabine replication cause cause cycle activity sequence without reaction anti solid show presence treatment dna dna dna dna intervention acute syndrome inhibitor drug drug gene chemical effect effect epigenetically methyltransferase methyltransferase increase division vitro potency demethylated rna rna mainly incorporate return kill analysis 
2.0@loss rate higher daughter methyl methyl analogue targetscancer strand therapy activity dnmti nature anti incorporation transferase transferase dna dna dna dna dna dna irreversibly base methylate bind inhibitor demethylating drug proliferation effect tumor mechanism normal belong due decitabine decitabine decitabine decitabine nucleoside incorporate incorporate cell cell cell replication replication 
2.0@suppressor cancer cancer methyltransferases inhibition imprint imprint tumour certain inbalances hypomethylation leukemia inhibit island island lead lead dna dna acute prevent prevent prevent inhibitor cpg cpg observe myeloid methylases hypermethylation hypermethylation decitabine region like action control 
2.0@suppressor dependent reduce demehtylation dnmt may analogue order limit growth promoter lead dna bind dnmts gene inhibitor tumor mean thus methylation allow nucleoside incorporate express cell replication decitabine decitabine decitabine 
2.0@dacogen lock size dnmt dnmt dnmt use myelodysplastic myelogenous unmethylated hypermethylated treat amount amount previously unable epigenetic strand strand inhibitor inhibitor inhibitor inhibitor inhibitor allow able tumor tumor mechanism clear dilute reduce reduce nucleoside like many replication replication drug carry irreversibly total analogue precoursers lukemia commercially exact occur methyltransferase methyltransferase methyltransferase dna dna dna dna dna dna dna dna dna acute bind bind syndrome sell dnmts still gene continue effect unclear status previous impact mother methylation methylation methylation decitabine decitabine daughter daughter time incorporate incorporate return action remethylate aml tissue tissue tissue 
0.67@cancer cancer inhibitor change lymphoma able way susceptible agent growth leukemia make make treat decrease epigenetic epigenetic pass particularly difficulty demethylating demethylating tumor tumor mechanism test unless cell cell cell compare drug drug combination result experiment type solid show dna dna histone chemotherapy rate remove notable deacetylase actively decitabine decitabine daughter work another modify azacitidine 
0.33@net market cancer reduce restore unregulated activate say agent process eisai overmethylated since dnmti growth penetrate direct japanese mylogenous call precisely solid epigenetic epigenetic decrease help precursor impact hypermethylation overmethylation overmethylation overmethylation cell cell tumour tumour tumour tumour tumour supressor one suppressor suppressor methyl epigeneti demetylation thats drug drug drug mylodysplastic result result histone histone histone histone histone address company reverse treatment treatment dna intervention surround syndrome use gene gene gene gene inhibitor silence silence silence leukamia regulator decitabine decitabine decitabine becuase possible downregulating protein 
2.0@market abnormally lower inhibition regulation fda use instability aggravate amount myelodysplastic hypermethylated treat affect inhibit suppress dna epigenetic syndrome act epigenome gene methyltransferase tumor clear normal apparently undo overly thus methylation decitabine speculate work approve genomic 
2.0@mitotically cancer cancer growth dnmt way state mark fix hypomethylation leave leave make normal inhibit deeper patient phenotype epigenetic epigenetic pass step enzyme island island tumor tumor intergenic intergenic test hdac fact unmethylated unmethylated unmethylated unmethylated unmethylated instability instability maintain lead promoter promoter one lung also closer cimp activation repeat drug cause combination next limit result mitigate bring present case better genomic genomic dna dna dna dna dna dna dna however cell cell cell cell chemotherapy expression cpg cpg gene gene gene gene rather inhibitor inhibitor inhibitor explain increase increase increase division division replicate thus methylation methylation methylation decitabine decitabine decitabine region region lay alter 
1.33@cancer cancer cancer inhibitor inhibitor growth dnmt dnmt dnmt use use susceptible percursors example process hypomethylation hypomethylation leukemia decatabine overall treat chromatin chromatin chromatin cpg open open epigenetic strand get establish enzyme tumor normal repressor nucleoside nucleoside demethylation cell cell cell uncontrolled release suppressor analogue promote irreversibly myolegenous replication cause cause cause structure bond show prevent myelodyplastic family treatment dna dna dna intervention acute bind bind syndrome site drug drug gene chemical along upon copy configuration silence longer methylation decitabine decitabine daughter incorporate come approve modify selectively 
1.67@mean newcells dnmt dnmt dnmt dnmt dnmt dnmt much agent stop sufficient grow nucleotide irreversibly strand strand body demethylating severely cancercells tumor replicate affect lack genome nucleoside regulator many cell cell cell spread release enzymatic get replication wide target normally dna dna dna divide bind bind epigenetic inhibitor drug methyltransferase along upon copy belong longer methylation methylation decitabine decitabine decitabine decitabine daughter daughter daughter work incorporate come rapidly azacitidine 
1.67@different different different cancer cancer cancer cancer outcome administration tumour tumour likely shore chromosomal exacerbate cure probably depend part make infer distinciton cpg cpg latter sequence involve establish demethylating interest impact tumor pattern hypermethylation hypermethylation access genome instability symtoms demethylation counterbalance suppressor suppressor region compare intergenic cimp imprint drug drug cause strand could could could loss methyl group protect repetitive dna dna histone histone example heterochromatin expression positive gene effect remove increase thereby decitabine decitabine decitabine drive hypomethylated action would would 
1.67@mitotically cancer stable class use cluster agent since epicene hypomethylation potential md treat decrease heritable development call methylated methylated precursor hyper demethylating thereby tumor tumor cause cause demethylation hypo tic suppressor suppressor state mainly promotors restoration activity concept occur prevent dna dna dna cell cell cpg gene aml inhibitor belong methylation methylation decitabine daughter region abide perhaps azacitidine near progression 
1.33@cancer cancer cannot dnmt dnmt dnmt dnmt dnmt dnmt dnmt alteration direct analog de make propensity nucleotide molecule often irreversibly copy consider responsible enzyme inhibitor inhibitor effective tumor inefficient divide metabolic nucleoside nucleoside ntimetabolite passive cell cell cell release suppressor dependent basis bond therefore therefore therefore therefore therefore epigenetic decitabine decitabine decitabine decitabine decitabine induction replication replication novo apoptosis highly somewhat specific gene gene gene bind bind bind promoter demethylation demethylation dna dna maintenance cytotoxic covalent covalent function affect effect upon v replicate methylation methylation genome daughter wide incorporate come form form small 
2.0@suppressor could inhibitingdna effective excessive need drug drug agent revert process ofdna myelodysplastic myelogenous hypomethylates hypermethylation hypermethylation problem gene treat biggest isused expression dna dna acute syndrome precursor issue demethylating adna methyltransferase methyltransferase methyltransferase reduce reduce relate turn especially methylation methylation genome silence instability like many tumour decitabine 
1.67@dna dna mean cancer acute syndrome precursor demethylating tumour effect agent epicentre myelodysplastic myelogenous economist decitabine anti treat demethylates 
2.0@drug happen use aberrant mutation agent result growth leukemia anti treat permit suppress suppress expression dna dna dna epigenetic effect reverse syndrome precursor enzyme thereby gene gene gene reduce tumor tumor tumor tumor hypermethylation methylation methylation deceitabine typically stochastically would demythylating demythylating 
2.0@higher dnmt dnmt dnmt dnmt dnmt progress much much fda agent two analog myelogenous affect inhibit nucleotide lead cytosine epigenetic component belong demethylating tumor tumor tumor normal essential nucleoside cell cell cell cell drug drug drug myelodysplasic one one suppressor rat irreversibly replication replication target target sobstitute dna dna dna get acute bind syndrome act expression cpg gene aml inhibitor inhibitor inhibitor division replicate since since methylation decitabine decitabine work incorporate approve approve approve leukaemia machinery 
2.0@cancer cancer along dnmt dnmt dnmt upon methyl methyl near stop mark analog analog hypomethylation transferase island cytosine cytosine cytosine irreversibly lose reduce tumor tumor high unexpressed express cell cell replication replication replication replication suppressor suppressor dependent epigenetic drug drug low promoter group treatment treatment dna dna dna dose lot bind inhibitor cpg gene gene rate remove replicate methylation methylation decitabine incorporate come attract 
1.67@igf could reduce growth growth suppressor produce tumour tumour tumour state icr hypomethylating two hypomethylation antitumour call suppress lead dna dna epigenetic region inhibitor target demethylating gene hence effect mechanism cpg belong methylation decitabine possible class andhypomethylation enhance enhance promote promote expression expression expression expression 
1.67@file find answer attach 
1.33@elod tendency cancer change term formation use agent agent hypomethylating two currently hypomethylation leukemia make decrease market lead epigenetic sequence help precursor aggressive demethylating demethylates tumor pattern block block lack much retain express may one suppressor cause suppresor therefore excessive disrupt drug certain stability become type methyl methyl group genomic treatment dna dna dna bind syndrome expression gene gene plastic inhibitor methylation methylation decitabine y active methyltransferase methyltransferase 
1.67@dna suppressor acute syndrome precursor myelodysplastic demethylating gene use use class agent belong myelogenous decitabine potential demethylate treat leukaemia tumour example 
1.33@cancer characteristic class last dnmt use agent process analog myelogenous restablished leukemia treat affect nucleotide irreversibly strand copy involve precursor demethylating normal release nucleoside cell cell much dependent also get replication replication severly myelodisplatic dna dna dna dna dna divide mark acute bind bind bind syndrome inhibitor rapidly along along upon suggest longer methylation methylation decitabine decitabine daughter incorporate come come mention methyltransferase methyltransferase methyltransferase 
2.0@critical inhibition restore able cytoplasm use agent hypomethylating systemic hypomethylation hypomethylation leukemia tumour myelodisplastic aza lead sequence proliferation myeloid normal neoplastic intravenous anticancer cell cell may level decitabine decitabine decitabine decitabine transcription antimetabolite replication significant apoptosis result acute anti type show treatment dna dna affinity permeate syndrome act function drug gene methyltransferase effect effect induce cellular cellular control administer thus thus rna incorporate nuclear differentiation differentiation twofold deoxycytidine membrane 
2.0@cancer cancer selectively dnmt dnmt dnmt dnmt dnmt revesible trap process analog silence hypomethylation make affect inhibit lead recognize strand methylated enzyme enzyme tumor tumor pattern normal hypermethylation degrade nucleoside aberrant maintain treatment closely suppressor suppressor dependent divide replication replication activity cytosine course promoter promoter parent potentially dna dna dna dna dna get cell cell cell function gene gene gene rapidly inhibitor copy division thus methylation methylation decitabine decitabine daughter incorporate impossible methyltransferase associate 
2.0@elod interaction cancer cancer cancer cancer thefuture reactivation activate use include include rea stop indiscriminately growth mention aza benefit epigenetic show aslung research tumor hypomethylationof dac repair high cell cell cell cell cell cell cell azad may kill resent immediate andprovidesto also patient drug agentreversed cause toxic fort low low therapy colleague contrast pathway men immune damage therapywiththis dna dna dna divide dose dose dose dose thatlow syndrome re inhibitor gene gene gene methyltransferase platic epigenetically suggest amy silence decitabine work y death differentiation rapidly without 
1.67@dna dna get methylation decitabine decitabine decitabine activatetumor demethylating gene agent represive rid 
1.67@cancer cancer methyltransferases irreversibly tumour exhibit agent hypermethylation effect effect anti dna dna dna dna dna divide bind inhibitor dnmts demethylating reduce reduce reduce preferentially quickly methylation methylation decitabine decitabine many cell replication 
2.0@term tumour tumour tumour tumour tumour long hypomethylating myelodysplastic malignancy dnmti sit increase previously level enzyme impact mechanism normal life life start clear cell cell use suppressor suppressor faster quality patient depend consequently analogue procedure present effect effect anti anti genomic decitabin bind function perform suffer methyltransferase upon afterwards belong methylation methylation decitabine decitabine decitabine gene come haematological along higher higher class dnmt dnmt dnmt activate still drop agent mark inactivation since since unmethylated treat decrease inhibit irreversibly span consequence dnmtis divide nucleoside replication replication associate drug drug know however cancerous better furthermore dna dna dna dna get dose period syndrome inhibitor administer silence incorporate action number 
2.0@also daugther methyl stay dnmti growth anti occur transferase prevent prevent repetitive dna dna divide strand help help help cpg island inhibitor tumor block keep keep methylation decitabine gene express active active cell control 
1.67@cancer restore way way way cluster agent mark mark find find silence growth growth growth growth grow dna dna dna lead lead igf igf malignant uncontrollably methylated methylated allow demethylating tumor tumor tumor tumor tumor tumor normal hypermethylation allele maternal often methyl decitabine decitabine decitabine one suppressor suppressor suppressor promote imprint icr icr mean result cytosine bring express anti anti methylation methylation methylation methylation methylation halt promoter group several case cell cell cell overexpression expression gene gene gene rapidly effect effect effect remove remove remove remove remove remove control division thus actively icrs another 
2.0@tail suppressor could could also class drug currently de normally hypermethylated methyl transferase hypomethylated treat dna histone syndrome act belong gene inhibitor tumor tumor affect myelodysplatic decitabine use methylating 
1.67@nhibition growth therefore reactivation tumour tumour cause agent supperssor hypomethylation hypomethylation hypermethylated promoter inhibit class dna dna epigenetic help act prevent methyltransferase inhibitor turn decitabine decitabine gene cell 
2.0@erase effective decitabine tumor tumor tumor tumor tumor tumor use slow slow likely agent assign since course hypermethylation growth tumore make make overall drug show though acumulated dna dna even kill chemotherapy well inherit demethylating chemo remove suceptible suppress source reverse methylation video daughter drive read demethylation cell cell cell may progression 
0.67@methyltransferases restore lymphoma dnmt activate independent leukemia manner agent stop cytochrome cytosine cellular hypomethylating unmethylated inhibit aza decitabine decitabine decitabine decitabine oncogenic proto bcl proliferation triphosphates convert activation normal hypermethylation apoptotic apoptotic release nucleoside nucleoside caspase thatinduces cell control rna epimutations phosphorylated byactivateing promote consequently bax alpha analogue deoxynucleotide mitochondrial mitochondrial monocytic overexpresses apoptosis target result downregulating cancerous phase phase anti promoter lead tnf dna dna dna decitabinereverses bind act function gene methyltransferase pathway place deoxycytidine deoxycytidine intrinsic replicate transactivation cancovalently ink ink andincorporated differentiation differentiation protein dysfunction 
2.0@maybe blewitt cancer cancer cancer cancer inhibitor inhibitor dnmt dnmt regulation others use agent stop silence dnmti growth leukemia sit hypermethylated hypermethylated hypermethylated illness island treat tumour methylated involve well respond respond demethylating guardian mechanism block myelodyspastic epigenetics high en cell cell cell cell methyl one one dependent patient rare replication drug drug toxic yet fast low specific like like methylation solid group good treatment dna dna divide dose dose histone syndrome act act act whit gene gene gene effect unclear interact hope cpg becaouse sort decitabine decitabine decitabine decitabine decitabine action protein 
2.0@unregulated cancer cancer cancer rate higher restore dnmt dnmt dnmt much agent mark growth growth high majorly increase might affect affect regulate irreversibly strand demethylating demethylating tumor block normal normal nucleoside maintain cell cell cell cell cell blockage supressor supressor suppressor suppressor analogue promote replication cause activity result gene gene gene become prevent prevent prevent dna dna dna dna get get synthesis bind bind ratio function multiply rapidly inhibitor copy death division division thus thus thus thus methylation methylation methylation methylation decitabine decitabine decitabine decitabine work incorporate deth 
2.0@cancer cancer cancer cancer cancer inhibitor inhibitor class target regulation tumour fda mutation irreversibly easily dnmti dnmti dnmti transferase unlike cpg molecule epigenetic development reversible involve enzyme mechanism mechanism normal hypermethylation clear nucleoside nucleoside small cell cell cell much enzymatic dependent transfer speculate therefore therefore get epimutations replication analogue analogue strand however suppression focus methyl methyl group dna dna dna divide bind act dnmts dnmts drug drug affect severally function upon upon belong main decitabine daughter incorporate approve action rapidly associate 
1.67@methyltransferases class dnmt progress use myelodysplastic growth growth growth leukemia treat hemimethylated island island nucleotide lead methylate belong inhibit reduce tumor tumor uncontrolled uncontrolled uncontrolled hypermethylation dilute genome di myeloid counteract cell cell cell cell cell blood suppressor suppressor thisdisease drug mitosis white result occur promoter promoter dna dna dna acute syndrome inhibitor cpg cpg cpg gene aml effect remove characterise division silence methylation methylation methylation decitabine decitabine wide tumorigenesis 
0.67@cancer abnormal change change signalsand activate others tumour newchemical chemically long event analog reactivate substance leukemia lation incorporation locus aza indicate epigenetic epigenetic md md reversible epigenome thereby inhibit myeloid persist presence hypermethylation constitutinga investigation aberrant dac dac dac demethylation cell drug suppressor example dna dna dna dna cytidine exposure patient alteration replication cause cause frequent therapy phos myelodysplastic responsive type good treatment treatment treatment trace acute often syndrome knownthat prodrug prodrug gene target deoxycytidine deoxycytidine environmental silence thus methylation methylation decitabine photo especific incorporate alterated differentiation methyltransferase 
0.0@oncogene prevent decitabine transcribe 
1.33@mean cancer cancer methyltransferases category within dnmt use use chemically md cannot treatment direct treat treat call inhibit class irreversibly strand copy erase inhibitor belong belong tumor affect neoplastic hypermethylation new directly methylation cell cell cell trial methyl release one suppressor dependent cause antimetabolite epigenetic include replication analogue target do anti anti bind solid tumour tumour tumour syndrome dna dna dna dna dna action action cytotoxic chemotherapy fe myelodysplastic drug drug drug drug gene methyltransferase effect effect upon rapid death division replicate replicate rase actively decitabine decitabine daughter daughter em incorporate incorporate tra 
2.0@cancer cancer methyltransferases dnmt agent correct inactivation analog inhibit suppress imply irreversibly irreversibly strand depend impede demethylating island tumor affect hypermethylation release nucleoside cell drug drug dependent bond therefore therefore replication activity activity activity type develop efficient dna dna dna get bind bind dnmts dnmts cpg gene gene inhibitor upon copy division methylation decitabine decitabine daughter severely incorporate form 
1.33@cancer cancer dnmt dnmt activate synthesize could phase azacytidine reactivate hypomethylation inhibit suppress previously strand help responsible enzyme enzyme enzyme tumor inactive formation dac dac dac bond bond retain case case cell cell cell suppressor aza also also patient therefore therefore fight regain demethylater ability result result express express best know prevent dna dna dna dna dna profile ring covalent time time upon deoxycytidine mother new new methylation methylation decitabine daughter daughter work work gene gene gene malignancy form would would 
0.0@cancer inhibitor inhibitor higher daughter dnmt much analogue dependent agent since normal dna dna irreversibly strand copy bind act dnmts demethylating severely rate methylations affect replicate decitabine decitabine nucleoside incorporate come cell cell replication 
1.33@cancer dnmt dnmt dnmt process stand appropriate apoptosis irreversibly result hypomethylation replication occur division dna dna dna divide dose methylate bind act respond methyltransferase inhibitor upon cellular quickly decitabine decitabine daughter incorporate cell cell cell differentiation attach 
0.33@one market cancer effect therefore overmethylation activate use slow slow considerably otherwise result histone histone cancerous without growth growth effectively neighbor properly epigenetic epigenetic dramatic example inhibitor perform affect proliferation reduce reduce tumor tumor tumor deacetylase health new methylation decitabine decitabine gene mean mean cell cell duty drug drug suppressor 
2.0@dna hypomethylating cancer help incorrectly inhibit methyltransferase cause cause gene agent grow process hypermethylation methylation decitabine decitabine adna hypermethylated cell prevent control 
2.0@cancer toxicity areincorporated overdose tumour fda agent change hypermethylated decrease inhibit inhibit lead irreversibly epigentic demethylating happen normal turn turn replication ul ul specifically dependent suppresor therefore sustain drug therapy overgrowth result result result dosage type dna dna dna dna however reverse bind act dnmts gene effect formerely methylation methylation methylation methylation decitabine decitabine approve reinstatement tissue tissue tissue tissue 
2.0@dna block inhibitor dnmt gene methyl reduce tumor suppression silence thus methylation decitabine transferase prevent 
2.0@dacogen cancer abnormal abnormal restore dnmt dnmt methyl methyl agent hypomethylating newly analog design oncogene inhibit inhibit aza lead proliferation proliferation inhibtior normal athing athing phosphorylation cell cell cell cell cytydine drug loss trade developped act act dna dna dna process transcriptiom hypo hypo bind mediate name function cpg suffer command deoxycytidine protein silence thus thus methylation decitabine mainly mainly gene incorporate reference differentiation enable 
1.67@suppressor suppressor suppressor cancer methyltransferases dnmt produce use process mean present anti anti bind promoter inhibit active dna dna dna methylated inhibitor drug island island proliferation effect effect methyltransferase consequent generally silence methylation methylation decitabine decitabine gene gene cpg cpg interrupt tumour tumour tumour tumour tumour tumour expression 
2.0@cancer cancer methyltransferases abnormal abnormal restore formation activity uncontrolled agent agent hypomethylating characteristic growth growth growth useful call inhibit lead epigenetic body methylated demethylating hypomethylated convert express ingest unable tumour tumour tumour expression suppressor suppressor therefore actively require cause incorporate problem triphosphate triphosphate become become prevent treatment dna dna dna dna dna dna cell cell function function gene gene inhibitor remove belong due main methylation methylation decitabine decitabine decitabine decitabine decitabine regulate strong class 
1.33@cancer cancer cancer reestablishment dnmt dnmt dnmt state trait agent pattern since change sit myelodisplastic inhibit represent achieve status sequence catalytic demethylating reduce tumor tumor transimtted originate normal normal normal normal hypermethylation hypermethylation like lead lead supressor also also epigenetic therapy without anti promoter promoter promoter promoter good dna dna dna dna cell cell syndrome act expression gene gene gene effect explain reversal silence thus methylation methylation methylation methylation decitabine decitabine decitabine daughter mitosis mean reestablish associate 
2.0@blewitt progressively formation specific mark lose make locus response dr inappropriately hypermethylation hypermethylation absence tumor tumor tumor tumor tumor key affect epigenome genome express cell cell decitabine decitabine decitabine decitabine one suppressor suppressor suppressor maintenance necessary spread wide information appropriate limit result methylated methylated methylated lecture particular action treatment dna dna dna dna dna dna dna dna harder reverse le important unlikely gene gene methyltransferase methyltransferase methyltransferase methyltransferase inhibitor inhibitor division division methylation methylation inappropriate region come form 
1.0@arent hypomethylate use slow hypomethylating analog dnmti growth hypermethylated treat island island can irreversibly strand strand methylated inhibit undergo normal expression decetiabine decetiabine release nucleoside express cell cell cell cell tumour tumour tumour tumour tumour myelodysplasic suppressor daughter sensible replication replication drug drug drug drug permit dna dna repress bind syndrome act dnmts dnmts cpg cpg gene gene methyltransferase effect copy replicate new methylation methylation cant cant incorporate frequently 
0.67@dnmt dnmt tumour tumour tumour region suressor myelogenous unmethylated leukemia spuressor myeloplastic acute syndrome precursor gene gene gene aml inhibitor inhibitor inactiveted normal methylation decitabine decitabine daughter mitosis active cell cell use use 
1.67@inhibition class dnmt dnmt tumour fda already myelodysplastic reactivate leukemia md transferase inhibit epigenetic depend silence island proliferation myeloid tumor mechanism hypermethylation may effectiveness although methylation enxyme methyl suppressor patient therefore action replication target exact gene know dna dna acute bind syndrome cpg irreversible inhibitor unclear heavily belong prognosticator decitabine poor approve aprecursorto lab invivo 
1.67@dna dna cancer methylate enzyme demethylating reduce agent epigenoma epigenoma normal make find methylation intergenic element activity like region cell cell inhibit decitabine repetitive 
2.0@suppressor suppressor myeloid inhibitor reactivation epigenetically use slow include hypomethylating myelodysplastic condition reactivate leukemia treat decrease inhibit lead dna dna dna malignant acute help syndrome methylates enzyme gene gene gene gene proliferation able tumor tumor tumor methyltransferase silence silence turn hematologic decitabine decitabine aberrant methylation may promoter promoter associate 
1.67@cancer cancer inhibitor class dnmt use try myelodysplastic myelodysplastic myelodysplastic analog malignancy dnmti high might transferase island nucleotide neoplastic strand methylate well severely tumor rid affect dnmtis dnmtis dnmtis hypermethylation hypermethylation release nucleoside many cell cell cell demethylation methyl decitabine decitabine dna dna dna drug lower patient get get get replication cause msonormal useless behind anti best prognosis extremely reason divide dose dose kill bind syndrome syndrome syndrome cpg rapidly effect upon tolerate replicate test longer daughter work work work incorporate approve 
2.0@cancer classify dnmt dnmt dnmt use fda agent specific malignancy de treat decrease island transcriptionally enzyme inhibit effective tumor epigenome reduce maintain cell decitabine decitabine one suppressor methylating therefore therefore require production suppression result result become drawback promoter promoter promoter haemetological approve dna dna dna dna dna non site site inhibitor cpg gene gene side effect effect concern entire methylation methylation methylation allow region mean mean active action methyltransferase adverse 
2.0@mean cancer cancer cancer inhibitor class dnmt dnmt much tumour tumour every agent myelodysplastic since dnmti overall transferase island suppress irreversibly strand methylate methylated particularly silence demethylating fall blood hypermethylation act thus ensure nucleoside actively thereby removal methyl promoter one therefore divide divide divide replication analogue could target cancerous gene gene level prevent dna dna dna dna dna dna dna however non cell cell cell cell cell cell bind syndrome use cpg time rapidly effect preferentially belong new new methylation methylation methylation decitabine decitabine decitabine decitabine decitabine mitosis incorporate come 
2.0@suppressor cancer cancer lower restore restore therefore endogenous decitabine decitabine decitabine decitabine tumour cause cause cause cause likely specific agent chronic suppression silence silence hypomethylation leukemia amount tend island island cpg cpg potentially dna dna dna dna methylated expression important demethylating inhibit methyltransferase reexpression heavily hypermethylation example methylation allow gene gene gene gene gene gene gene activity activity myeloid demethylation global would progression 
0.67@suppressor suppressor abnormal apply risk epigenetically use agent heighten become result hypomethylation anti hypermethylated dna dna dna development sequence greatly variety silence demethylating demethylating gene gene effect tumor tumor tumor tumor tumor epigenome decitabine decitabine 
1.33@hey proliferate tumour tumour tumour methylationis sit deoxynucleoside methyltransferases methyltransferases meet leave generation grow next pass methylated methylated inhibitor inhibit chromosome epimutations whilst silencetumour maintain cell cell line suppressor cytidine transfer imprint imprint imprint need analogue hemi oppose replication prevent dna dna ase mechinism gene gene important celluar remain suprressor division since decitabine decitabine decitabine daughter action 
1.67@cancer therefore methylates uncontrolled cause agent stop ly suppression find meet de de de growth back ion suppress dna methylated hyper gene gene gene tumor tumor methlylating normal solution silence turn methylation release many cell may decitabine decitabine decitabine 
1.67@mitotically cancer progress fda agent stop since dnmti dnmti dnmti leukemia heritable decrease island island island island island lead increasesat demethylating locus reduce tumor tumor tumor tumor tumor tumor dilute like em cell global global american suppressor suppressor suppressor suppressor drug drug certain specific type treatment dna dna dna divide cpg cpg cpg cpg cpg time time methyltransferase inhibitor increase silence silence silence silence interfere thus methylation methylation methylation methylation methylation decitabine decitabine gene gene gene gene gene incorporate approve spell associate 
2.0@suppressor inhibitor inhibitor standard tumour tumour tumour slow agent dnmti combine drug drug transferase dna dna epigenetic histone histone chemotherapy responsible hyper demethylating reduce deacetylase belong silence methylation decitabine decitabine respond cell methyl alter 
2.0@suppressor suppressor cancer inhibitor disrupt dmti imprint relieve analogue loss specific specific island island since shore icrs anti bind exert could locus locus correlate restore dna dna dna irreversibly prevent example function cpg cpg gene gene methyltransferase effect tumor tumor dmt todmti hypermethylation hypermethylation hypermethylation thus methylation decitabine decitabine em incorporate replication tumour nuceloside belong 
1.67@cancer cancer cancer cancer cancer methylating restore retrieval tumour drug drug drug agent agent actually anti member ability growth effect hypermethylation hypermethylation inhibit inhibit affect prevent prevent lead dna dna dna dna divide kill help act function function demethylating rarely hence reduce loose normal normal normal thereby thereby thereby new methylation decitabine decitabine class case cell cell cell cell cell cell cell indefinitely require 
1.67@antineoplastic cancer cancer classify cytotoxic chemotherapy antimetabolite suppressor gene drug improve agent oft silence reverse methylation decitabine decitabine anti demethylation tumor treatment 
0.67@myc myc myc cancer inhibitor regulation tumour system stop substance part call call inhibit inhibit epigenetic decrease involve nearby proliferation reduce block block normal factor factor regulator cell cell transcription transcription crucially another finally encode know particular dna dna histone name expression gene gene effect jq deacetylase human methylation decitabine decitabine work activity brd protein apparent 
2.0@cancer eliminate class lower dnmt dnmt activate cell cell cell tumour activity activity medicine disease myelogenous reactivate hypomethylation leukemia next recognize malignant finally cytotoxict inhibitor reduce tumor tumor block expression neoplastic hypermethylation apoptotic genome decibatine decibatine decibatine decibatine like demethylation demethylation human belong suppressor also also daughter activation subunitpromotor replication cause strand acute chronic eventually result result low well anti anti dna dna dna pathway dose antigen antigen bind catalytic function positive gene effect effect effect effect cellular cancercells cancercells cancercells telomerase telomerase telomerase produce silence decitabine transcription dmnt incorporate follow associate 
2.0@dna cancer cancer patient dnmt drug drug decitabine decitabine process target decrease island prognosis family promote hallmark physiological expression name belong cpg poor inhibitor deoxycytidine aza hypermethylation silence silence methylation vidaza gene gene gene demethylation commercial azacitidine 
0.33@dna cancer methylate endless therefore overexpression demethylating gene gene may mitosis agent stop stop decitabine example de cause case element cell grow repetitive 
2.0@cancer cancer effect effect class therefore tumour tumour tumour agent result positive anti treat promoter island island island suppress dna epigenetic methylated methylated successfully expression demethylating demethylating demethylating gene gene gene hence inhibitor belong silence methylation decitabine decitabine work cpg cpg cpg express cell suppresing 
1.0@cancer able able able methyl state state fda die decitabin decitabin decitabin analog unmethylated transferase inhibit cytosine repression allow provide dnmt dnmt dnmt dnmt tumor tumor contribute nucleoside heritance like cell cell cell cell cell cell cell cell one seem drug highly result allele anti arrest dna divide divide bind bind act irreversible effect preference copy division division division methylation methylation mitosis activity approve complete complete 
2.0@specifically methyl analogue decitabine myelodysplastic toarrest growth md treat level inhibit dna dna dna usedto irreversibly strand syndrome fe function bydecreasing gene tumor tumor silence act rase methylation chief nucleoside incorporate supressor tra 
2.0@ce dacogen cancer cancer proliferate elimiated dnmt dnmt use chemically agent demthylation two cannot reactivate exert transferase inhibit proteasomal believe counter enzyme enzyme ineffective bios research tumor hypomehtylation degrade degrade ensure cause line insensitive carbon cell cell cell cell cell antineoplastic rapid decitabine decitabine suppressor also indicate land however appear drug drug drug drug replced ie subsequent pathway result finally azacitydine trigger methyl protein group dna dna apoptosis non cytotoxic principle recent inhibitor gene methyltransferase effect effect effect position copy nitrogen division division thus thus methylation methylation inside mitosis similar action attach report report 
2.0@cancer critical inhibition restore tumour tumour agent apoptosis selective dnmti hypomethylation inhibit prevent good dna dna dna hypomethylating development act function inhibitor control methyltransferase effect non cellular cellular normal antineoplastic belong methylation ensure gene cell cell differentiation differentiation may may decitabine 
0.67@dependet dependent inhibitor even cytidine toxic myelodysplastic fast low dosage dosage dnmti dnmti md nonspecific lead treatment dna dna divide dose action action syndrome act inhibit methyltransferase effect tumor analog stage increase belong methylation decitabine mainly approve cell cell cell 
2.0@unregulated cancer inhibitingdna restore restore suppressor suppressor suppressor process result hypomethylates growth growth become isdna promote dna dna dna cell cell cell decitabineworks function demethylating gene gene gene allow tumor block normal increase division division interfere thus methylation methylation decitabine activity demethylation demethylation regulate control blockage 
1.0@cancer cancer inhibitor inhibitor inhibitor higher class dnmt dnmt tumour process dnmti dnmti rate replicate locus often irreversibly strand inhibit pattern pattern nucleoside maintain cell cell cell cell cell methyl tra dependent therefore epigenetic replication replication analogue healthy ability anti know dna dna dna dna get bind fe methyltransferase methyltransferase effect effect negatively copy copy death belong word rase methylation methylation decitabine daughter incorporate arrive 
2.0@cancer cancer inhibitor say hypomethylating complementary sit hypermethylated transferase island dna dna malignant enzyme inhibit reduce reduce tumor normal normal normal normal speed like cell cell cell cell cell cell methyl suppressor dependent also greater greater therefore action action drug drug drug drug carry viability strand strand limit condition facilitate gene favor ease level reason process process inhibitory expression cpg irreversible effect effect effect advantage division replicate methylation methylation methylation decitabine decitabine daughter possible form would would 
1.33@cancer cancer methyltransferases methyltransferases lymphoma regulation use slow agent myelodysplastic currently growth growth regulatory decrease inhibit regulate demethylating demethylating proliferation proliferation happen life generally usually genome treatment individual drug likely amount show later dna dna dna dna dna cell cell cell cell bind bind syndrome act gene gene methyltransferase cutaneous increase modification since methylation methylation decitabine decitabine decitabine wide activity would 
2.0@cancer class dnmt use agent process myelodysplastic myelogenous dnmti treat decrease inhibit futher irreversibly precursor epigenetc demethylating proliferation block normal neoplastic directly cell cell cell cell control belong specifically dependent leukaemia anddifferentiation therefore return dna dna dna dna dna divide acute bind bind syndrome function gene methyltransferase inhibitor cellular believe believe division methylation decitabine decitabine decitabine decitabine decitabine incorporate incorporate active action 
2.0@interaction cancer cancer cancer cancer methyltransferases methyltransferases unpackaging agent center direct back avoid island analogous irreversibly malignant allow allow demethylating inhibit inhibit pattern round hypermethylation hypermethylation heterochromatine nucleoside aberrant cell cell cell cell drug machinery specifically also replication replication could decitabine decitabine version hypomethylated dna dna dna histone bind le act cpg gene effect copy modification expect expect active supressor azacitidine 
0.0@abnormal effective may advancecd agent carcinogenesis dysregulated invasion growth leukemia treat suggest inhibit epigenetic epigenetic epigenetic prevent disease ardenocortical achievable myeloid adjuvant pattern clinically turn silence silence role methylation cell cell cell recover expression expression expression unique also also patient patient synergestic dlbcl therapy exhibit property group group charaacterised modyfying dna profile dose acute carcinoma act highly gene gene gene gene inhibitor inhibitor deacetylase belong thus utilise decitabine decitabine decitabine another antitumoral adrenocortical 
1.67@dacogen dacogen inhibition dnmt transcriptional transcriptional include agent agent specific specific event event myelogenous silence hypomethylation leukemia md inhibit dna dna dna dna dna dna dna dna dna lead precursor hypermethylation hypermethylation demethylating myeloid tumor tumor expression expression regulation leukemogenesis dac induction significant global suppressor leukaemia multiple turnback indicate decitibine via via require frequent treatement activity trade decrement treatment reduction apoptosis base acute acute syndrome syndrome name myelodysplastic myelodysplastic drug drug myeloblast aml aml effect effect induce methyltransferase methyltransferase human well methylation methylation methylation methylation methylation decitabine gene gene gene gene gene gene gene regulate regulate transcriptome single associate 
2.0@one suppressor suppressor dependent analogue dnmt dnmt inhibitor methyl hematological fda agent myelodysplastic since malignancy effect anti prevent act dna dna dna irreversibly bind syndrome responsible dnmts demethylating inhibit enzyme tumor tumor tumor fe hypermethylation rase methylation decitabine decitabine nucleoside gene gene approve drug tra 
0.0@dacogen class lymphoma firm use use chemically agent eisai analog myelogenous hypomethylates make treat treat call inhibit illness precursor blood jersey japanese cell cell leukaemia celgene dysfunctional cytidine pome merck certain another condition histone thy company dna dna base acute syndrome sell myelodysplastic ah methyltransferase inhibitor rare cutaneous new decitabine decitabine deacetylase lat 
2.0@suppressor suppressor suppressor suppressor cancer effect class able decitabine decitabine drug drug agent agent demythlating tend ly suppression new meet neutralize anti effectively prevent suppress expression dna dna get bind tra fe enzyme enzyme demethylating demethylating gene gene gene gene gene gene gene dnmt tumor tumor tumor tumor tumor tumor act rase methylation methylation methylation allow allow work destroy destroy express express cell cell enable would associate 
2.0@cancer succeed agent result result cpg hypomethylation hypomethylation generation oncogene decrease decrease inhibit suppress lead dna dna dna dna dna perm ethylation le hypermethylation demethylating island methyltransferase methyltransferase expression expression tumor analog affect increase wikipedia dilute decitabine decitabine nucleoside gene incorporate cell would would 
2.0@totreat suppressor cancer methyltransferases mean start use cause cause agent island myelodysplastic myelogenous unmethylated silence problem leukemia type inhibit syndrome dna dna acute thwart le thus cpg adna allow tumor mechanism must precursor demethylating main methylation decitabine gene hypomethylated express cell cell pre kill leukaemia 
1.33@compound cancer cancer classify stable dnmt dnmt dnmt deoxycytosine synthesize may may state hypomethylated agent specific hypomethylating newly analog mock locus benefit weaken cytosine irreversibly even methylated immunological inhibitor inhibitor attack parent nucleophilic compromise tumor tumor block primary assault genome render maintain cell cell rapid deplete decitabine decitabine transient suppressor endeavor residue epigenetic cg general replication replication strand pair chemotherapeutic bond effect vulnerable lessen lead resilience covalent dna dna exacerbate mark synthesis integrate inactivate gene enzyme intermediate silence undergo continually position dmnt incorporate phosphorylated 
1.0@cancer cancer tumour tumour compact attempt mostly blocker since treat treat suppress epigenetic level disease disease reduce normal hypermethylation show thus genome cell far use neighbour leukaemia dna dna dna run anticarcinogen seem drug link mutation result specific methyl better prevent hurt fe gene gene enzyme location catalyze rase methylation methylation decitabine work form tissue 
2.0@demethylated cancer inhibitor dosage disrupt slowly divide divide necessary use cause hemi subsequent mark proper low bring demethylate specially prevent class dna dna dna epigenetic usage methylated methylated act inhibit inhibit rapidly dnmt tumor tumor methyltransferase death belong usually since methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine retain activity activity case cell cell cell cell cell cell require 
1.33@inhibitor suppresor tumour tumour tumour cause cause larger dnmti fade act suppress dna dna dose name methylase still gene gene effect unclear suggest decitabine decitabine although active demethylation demethylation may agains 
1.67@inhibitor epigenetically may demethylate myelogenous azacytidine reactivate surpressor cgs treat treat island island response response lead lead lead transcient even repression precursor silence ctl tumor tumor tumor tumor pattern bond reproducible treatment treatment demethylation deoxy leukaemia epimutations also also patient sustain cg cg induction replication analogue dose dose decitabine decitabine decitabine decitabine decitabine cell result low low anti anti random immune passive covalent dna dna dna dna dna dna non non acute cytotoxic mediate myelodysplastic gene methyltransferase methyltransferase effect effect induce lymphocyte syndrome division replicate methylation methylation discontinue incorporate active form reverse efficiently 
1.67@inhibitor real dnmt dnmt dnmt dnmt dnmt dnmt methyl every concentration agent pattern pattern pattern absolutely total hypomethylation hypermethylated abnormal avoid inhibit molecule reactive irreversibly strand despite enzyme enzyme enzyme demethylating group group tumor tumor mechanism block block block block may descend nucleoside maintain way way suppressor erase epigenetic necessary replication replication replication analogue structure revert yet result half fashion anti successive successive dna dna dna dna dna dna dna dna bind drug drug gene chemical effect molecular belong hemymethyleds methylation methylation methylation methylation decitabine decitabine decitabine decitabine daughter mean original clear reestablish 
2.0@elod unregulated platic restore restore produce tumour inhibitor process become myelogenous silence growth growth leukemia useful marrow contributesto precursor belong deform inducedbythe tumor tumor mechanism block normal expression link ing major demethylation demethylation regulate regulate blood promote decitabine decitabine one suppressor suppressor suppressor tear activation tot result activity intreat acute y anti hypothemylation incase dna dna dna theb cell cell cell cell cell allow syndrome re function gene gene gene gene gene methyltransferase effect epigenetically condition control increase division division interfere thus methylation methylation methylation blockage work class 
1.0@elod unregulated cancer cancer effect restore within activity use use agent direct substance substance md treat andcell class epigenetic antimetabolite antimetabolite belong especially andregulates mean essential like many lead tumour expression suppressor suppressor suppressor demethylating cause target number become metabolism dna divide cell cell cell cell cell cytotoxic syndrome function function gene gene gene gene plastic inhibitor y interact death division waytumor decitabine incorporate rapidly associate 
2.0@dna cancer reaction suppresor titrate demthylating enzyme prevent tumour tumour gene agent silence methylation decitabine growth growth work bind inhibit facilitate 
2.0@ce cancer proliferate think restore dnmt activate activate activate disease use system agent intention also dnmti defence treat marrow inhibit adduct irreversibly body inhibitor orhypomethylation demethylating twofold tumor tumor tumor replicate block normal additionthe source myelodysplastic nucleoside st demethylation cell cell methyl methyl refer additional suppressor suppressor dependent transfer greater therefore replication replication analogue toxic mean trade ea dependency anti syndrome dna dna dna dna dna bind covalent name thereafter drug gene gene rapidly effect effect bone thereby ti funtion decitabine decitabine decitabine decitabine atinga incorporate incorporate action methyltransferase methyltransferase 
2.0@et cancer cancer cancer kind patient suppressor suppressor fight answer tumour improve kantarjian agent epicentre myelodysplastic analog cytosine reference hypermethylation againt methylation methylation especially inhibit island dna dna dna dna around bind syndrome belong demethylating gene gene gene expression relate thus al decitabine decitabine decitabine nucleoside em express silence silence progession outcome promoter hagop 
1.33@dacogen cancer dnmt use hypomethylating myelodysplastic malignancy type md inhibit aza uknown effective irreversibly allow especially reduce tumor tumor mechanism hypermethylation hematologic although drug drug nuceloside suppressor dependent dependent transfer replication analogue exact ease methyl treatment dna dna dna action bind bind syndrome function function gene gene dnmts deoxycytidine supprerssor thus methylation decitabine decitabine decitabine incorporate foudn 
1.33@cancer cancer hypomethylation lymphoma overmethylation activate slow include growth leukemia iscausing inhibit lead epigenetic belong resultis proliferation reduce tumor tumor tumor tumor many cell control suppressor suppressor lung also promote activation combination apoptosis natural surround become dna dna dna histone histone histone histone important gene gene gene gene methyltransferase inhibitor inhibitor inhibitor cellular deacetylase death demethylating silence methylation methylation decitabine decitabine activity differentiation class 
1.33@dacogen disrupt say phosphate fully add add process process analog major hypomethylation hypomethylation hypomethylation exert call inhibit inhibit nucleotide restore epigenetic epigenetic know know help well contribute proliferation reduce tumor abnormality hypermethylation phosphorylation although constitute regulator cell cell way way marker cytidine transcription level level indeed therefore fair link synthesis synthesis exact consist methyl adenien group group dna dna dna dna dna dna dna dna dna dna divide kill act act right right rapidly effect probably human thus methylation methylation decitabine decitabine decitabine gene gene incorporate differentiation protein class 
2.0@incorporatedinto effect effect dnmt dnmt class get othersites methyl methyl certain able tothe know process methylate methylate present come anti overall transferase transferase island cpg cpg willbind dna dna dna dna dna dna divide disable dnmts belong islandhypermethylation reduce reduce tumor tumor along hypermethylation longer thus linkedto decitabine decitabine decitabine decitabine methylation strongly cell attach replication 
2.0@mitotically mitotically cancer cancer inhibitor stable stable restore suppressor suppressor tumor tumor demethylated change change note hypermethylated island island cpg cpg promote dna dna dna dna dna area demethylating gene gene methyltransferase effect deciatbine question demethylation demethylation hypermethylation thus thus thus decitabine many capability associate 
1.0@standard cancercells use slow agent progenie mark result growth susceptible make tumour tumour dna epigenetic thegenome chemotherapy demethylating adna remove methylation genome removal drug decitabine 
1.67@loss restore use agent hypomethylating stem myelogenous hypomethylates growth leukemia orderly treat inhibit lead tumour precursor demethylating take mechanism uncontrolled normal retard count like cell cell way leukaemia hematopoietic know nucleus dna dna dna dna dna dna profile blood acute acute syndrome myelodysplastic methyltransferase methyltransferase inhibitor advantage control methylation methylation decitabine decitabine decitabine create towards progression 
1.67@dacogen cancer critical category unregulated thus agent process methyltransferases hypomethylates reactivate growth growth potential call inhibit inhibit aza restore restore malignant malignant know know ethylation belong demethylating demethylating tumor mechanism block normal contribute new silence silence demethylation cell cell cell cell cell cell control suppressor suppressor suppressor decitabine decitabine member transformation also promote antimetabolite drug drug apoptosis activity result trade become show dna dna dna dna dna dna dna dna expression allow chemotherapy name function gene gene gene gene gene gene methyltransferase regulate regulate induce deoxycytidine increase division division major methylation methylation blockage class differentiation 
1.67@aspect cancer list stop originally analog member reactivate change change change clearly md exert affect grow grow might granddaughter epigenetic epigenetic epigenetic epigenetic epigenetic reversible erase erase damage silence inhibit tumor mechanism reflect nucleoside aberrant methylation methylation good cell cell cell cell drug drug drug expression suppressor dependent high therefore therefore irreversibly replication cause function therapy therapy target pass without without success though dna dna dna dna dna however dose dose kill bind develop dnmts gene gene aml effect effect division low actively decitabine decitabine decitabine daughter incorporate return alter 
1.0@cancer happen dnmt dnmt dnmt tumour tumour agent semi dnmti susceptible make hypermethylated dna dna dna dna previously expression irreversibly development inhibitor demethylating group able affect usually nucleoside substrate cell cell may helix decitabine decitabine suppressor dependent also also epigenetic replication replication analogue strand result methyl prevent standard however bind chemotherapy dnmts drug drug gene gene methyltransferase conservative silence new methylation double severely lay alter 
1.67@dacogen cancer cancer cancer company restore lead use agent stop silence myelodysplastic member de de growth hypermethylated treat call island often cytosine level deisai precursor allow tumor feature hypermethylation thus many cell cell tumour leukaemia suppressor suppressor methylating dicatabine drug drug cause decitabine decitabine target loss methyl promoter promoter promoter promoter group common japanese dna dna acute syndrome sell expression expression expression cpg cpg gene gene gene remove protein increase dinucleotides dinucleotides myelogenous methylation methylation methylation inappropriate class attach associate 
2.0@cancer cannot faster enzymatic tumour agent depletion hypomethylation effectively often irreversibly strand transferase demethylating severely pattern normal neoplastic epigenome release high regulator cell cell cell cell cell cell cell replication specifically dependent lower become epigenetic hypomethylated need analogue neucleoside neucleoside result low anti best methyl toxic parent compare dna dna dna dna dna dna dna dna divide dose dose dose kill bind bind inhibitor inhibitor drug drug affect methyltransferase methyltransferase methyltransferase methyltransferase effect copy contain division replicate replicate thus methylation decitabine decitabine daughter daughter work work incorporate action 
0.0@cancer research classical aid agent agent agent sit replace also direct direct direct mutagenic response addition addition explore methylated provide nucleophilic initial question question defense repair repair utilize counteract excision methylating methylating mutagenesis toxic pathway number ber ber ber methyl methyl group damage damage damage dna dna dna dna dna dna uncover base base base use effect remove reversal reversal reversal modification thus decitabine work protein protein protein recently 
2.0@dacogen cancer cancer cancer characteristic restore able agent eisai find effectively inhibit cpg cpg cpg cpg regulate strand strand methylate allow demethylating island island island island tumor tumor pattern pattern hypermethylation dilute manufacture name japanese drug pharmaceutical mean suppressor spread promotors suppression result trade gene gene company dna dna dna dna cell cell downregulate act function function end time methyltransferase expression remove division replicate replicate methylation methylation methylation decitabine decitabine em typically original associate 
0.67@suppressor loss antimetabolite activate tumor way cycle medicine two efect substance call group dna decitabin cytotoxic silence gene remove normal belong methylation decitabine decitabine decitabine work strong cell enable 
2.0@nucleoside dnmt methyl analogue dnmti transferase parent lead dna dna dna dna irreversibly strand strand bind inhibitor copy replicate methylation decitabine daughter work incorporate come demethylation cell drug 
2.0@plastic cancer cancer inhibition inhibition dnmt use use mark anti quantity incorporate dnmti transferase nucleotide molecule epigenetic epigenetic epigenetic reversible involve involve affect regulator cell cell tumour tumour one specifically irreversibly alteration drug drug drug drug appropriate target concept methyl prevent treatment treatment dna dna dna dna get kill bind bind act act chemical effect remove thus thus thus methylation methylation decitabine decitabine neo lay come enzymatic small 
1.67@aspect aspect cancer cancer cancer cancer research use agent agent vigorous process process process region nice reactivate elegant island island expression expression epigenetic epigenetic epigenetic inappropriately disease disease demethylating impact impact pattern pattern generally genome genome carcinogenic terribly cell line machingery dna dna dna intergenic decitabine cause mutation suppression free do demethylate methylated occur promoter hypomethylated tnf treatment several however reverse example important cpg cpg gene gene disregulation investigate repeat silence silence longer methylation methylation allow mitosis whatever various various various exist 
2.0@cancer transfer hopefully methylates tumour tumour hypomethylates island myelodysplastic cancerous cancerous dnmti come type treat group suppress suppress dna dna dna future surround syndrome use inherit cpg hop methyltransferase methyltransferase inhibitor gene gene everything normal silence replicate allow daughter work express many cell cell cell cell methyl inhibit inhibit decitabine decitabine 
1.33@cancer critical inhibition restore may manner agent hypomethylating myelodysplastic major hypomethylates similar hypomethylation hypomethylation direct incorporation inhibit inhibit exert achieve believe strand proliferation normal neoplastic give phosphorylation although cell control decitabine decitabine decitabine decitabine decitabine decitabine indicate concentration cause cause apoptosis suppression anti chain treatment dna dna dna dna dna dna dna dna dna synthesis syndrome function function gene methyltransferase methyltransferase effect effect induce cellular cellular antineoplastic vitro methylation rna incorporate incorporate differentiation differentiation azacitidine azacitidine 
2.0@cancer methyltransferases hypomethylation dnmt progress tumour tumour state likely myelodysplastic analog proliferate economist dnmti growth leukemia md change decrease inhibit chemotherapeutics lead epigenetic epigenetic belong especially myeloid tumor tumor standard act nucleoside thats like counteract cell cell cell cell methyl suppressor cytidine slow become become therefore activation cannot combination replication ch add highly result acute chemotherapeutic maintain anti solid derivate group impossibility treatment dna dna dna dna dna dna non histone bind syndrome use inhibitor inhibitor drug drug irreversible aml effect methyltransferase deacetylase death division selective methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine gene incorporate incorporate hdaci azacytidine azacytidine 
1.33@cancer cancer class dnmt dnmt dnmt dnmt progress use state state fda myelodysplastic meet frequently leukemia useful treat island nucleotide irreversibly strand strand strand lose prevail hilt parent myeloid mammal hypermethylation like cell cell goal run patient depend get drug drug drug drug cause without type prevent prevent dna dna dna dna divide acute bind bind syndrome fe cpg inhibitor copy copy belong replicate replicate rase methylation methylation methylation methylation decitabine decitabine daughter daughter mitosis approve 
1.33@hypermethylates suppressor cancer class uncontrolled cause agent stop surround dnmti growth especially dna histone name silence demethylating gene gene inhibitor suggest belong thus decitabine decitabine decitabine cell tumour 
2.0@cancer cancer cgis dnmt dnmt dnmt dnmt synthesize tumour tumour replace make treat decrease decrease grow suppress level silence tumor affect actively demethylation cell cell cell global global cytidine methylating methylates methilation cause property result intake express normally promoter prevent dna dna dna dna dna dna divide gene gene methyltransferase inhibitor overactive division methylation methylation decitabine decitabine decitabine decitabine work work work work mean decitbine cpgs chemical 
1.33@till class dnmt dnmt prove specific specific high quite quite quite inhibit often irreversibly irreversibly efficient inhibitor belong effective tumor tumor tumor mechanism neoplastic clear nucleoside demethylation demethylation demethylation cell cell cell drug drug drug drug drug drug an enzymatic dependent dependent analogue patient therefore epigenetic decitabine decitabine replication replication cause cause toxic toxic low dosage dosage without anti considerable dna dna dna dna divide bind act act dnmts dnmts rapidly effect administer due regulator ul ul incorporate action protein would 
2.0@dacogen cancer cancer cancer cancer mean restore unregulated national use fda agent inhibit cell cell cell cell cell cell nih treatment growth part restrict avoid interaction act lead lead death keep demethylating grow mechanism expression institute approval methylation methylation metabolism tumour blockage myelodysplasic suppressor also become promote antimetabolite divide spread cause cause cause apoptosis overgrowth july cancerous anti multiple syndrome dna dna dna dna get substance surround cytotoxic chemotherapy site function drug drug gene gene rapidly effect web control increase division interfere receptor decitabine decitabine action august incorporate tissue methyltransferase decatibine 
2.0@dacogen cancer cancer cancer article dnmt dnmt dnmt dnmt tumour tumour mean epicentre eisai economist hypermethylated nucleotide irreversibly strand know know kind belong severely longer affect neoplastic source release slide demethylation cell cell cell much suppressor dependent also get seem replication cause compony highly effect anti lecture lecture group develop video dna dna dna dna divide japanese bind bind inhibitor inhibitor inhibitor drug drug gene rapidly along upon copy division replicate replicate methylation decitabine daughter incorporate come action methyltransferase methyltransferase tissue 
2.0@unregulated cancer cancer cancer cancer methyltransferases growth growth growth dnmt produce network critical change treat decrease response regulate recognize death effectively chemical responsible reset inhibitor reactivation tumor block block affect affect give phosphorylated enzyme cell cell cell cell cell cell cell cell reprogram blockage belong suppressor suppressor inside promote drug metabolize decitabine decitabine decitabine decitabine activity activity result low become antitumor antitumor show dna dna dna dna dna dna dna dna dose function gene gene gene gene methyltransferase effect memory memory increase division division new methylation methylation methylation methylation methylation allow drive incorporate survival reprogramming alter 
2.0@cytosine cause suppressor suppressor decibatine tumour tumour tumour analogue agent reduction effect anti island dna dna dna dna allow demethylating inhibit methyltransferase reduce reduce cpg methylation methylation methylation gene gene typically express expression 
2.0@enzymatic cancer cannot dnmt dnmt dnmt via replication cause solve halation meet problem come occur inhibit dna dna dna epigenetic bind hyper inhibitor copy belong decitabine daughter incorporate case demethylation cell drug drug 
1.67@decline cancer importantly overmethylation use stop ina myelodysplastic myelogenous growth treat job precursor demethylating demethylating adna dramatically reduce tumor uncontrolled normal proliferationof cell cell cell removal tumour tumour leukaemia suppressor suppressor drug drug cause dectabine product result result histone whose treatment treatment mark acute syndrome gene gene gene effect silence methylation methylation decitabine decitabine nearby apparent 
2.0@cancer cancer article dnmt say concentration agent analog economist hyper hypomethylation tumour lead irreversibly despite functionality inhibitor reduce reduce tumor tumor replicate hypermethylation ing nucleoside cell cell methyl suppressor destroy drug heamatological actually result anti could dna dna dna dna bind mediate dnmts dnmts gene methyltransferase effect silence dependent methylation decitabine decitabine incorporate would 
2.0@myeloid lymphoma dnmt dnmt dnmt formation progress use manner specific long myelodysplastic meet dnmti tumour tumour tumour island lead irreversibly know term inhibitor inhibitor inhibitor inhibitor thereby subsequently reduce normal neoplastic hypermethylation nucleoside like many cell cell yet suppressor dependent transfer high include replication analogue dose dose toxic low cancerous anti anti bind promoter promoter treatment dna dna dna however non acute ase syndrome act act dnmts cpg gene gene gene gene aml effect effect effect silence methylation decitabine decitabine region incorporate action hence reactivate 
0.0@et subtypes indicate myelomonocytic excess excess use sideroblast include include novo chronic myelodysplastic myelodysplastic myelogenous hypomethylates de example leukemia md md inhibition treat treat ravandi dna dna previously anemia anemia anemia anemia usedto hypomethylating ring acute syndrome syndrome precursor blast blast aml untreated transformation refractory refractory refractory refractory british al decitabine decitabine french treatment secondary american leukaemia 
2.0@cancer inhibitor decitabinebelongs thatare myelodysplastic replication cause activity withcpg decitabine decitabine inhibit result dnmti hypomethylation type incorporation show island good treatment dna dna dna strand bind syndrome itshypomethylation dnmts dnmts irreversible methyltransferase effect copy hypermethylation methylation ul ul daughter class dnamethyltransferase cell try associate 
2.0@reduce within dnmt dnmt ex remove methyl include add cite cite inactivation analog hypomethylation hypermethylated overall island irreversibly methylate respond reactivation tumor tumor tumor tumor tumor inactive hypermethylation may genome favorably cell replication level suppressor suppressor suppressor cytidine render drug cause ie attempt activity result result result across normally promoter promoter group rb treatment treatment dna dna dna dna bind generally act inhibitor cpg cpg gene gene gene gene gene methyltransferase enzyme upon cellular global silence thus methylation decitabine decitabine decitabine decitabine region incorporate active 
1.0@cancer cancer cancer cancer class use specific really transfer dnmti dnmti dnmti dnmti growth md treat inhibit inhibit molecule epigenetic epigenetic epigenetic strand precursor severely impact impact tumor release methylation cell cell cell much machinery enzymatic dependent also aml certain mutate dyplastic target cancerous theme bind bind limit thy myelo dna dna dna dna divide ase syndrome inherit rapidly inhibitor inhibitor methyltransferase methyltransferase methyltransferase copy division longer regulator regulator decitabine decitabine decitabine decitabine daughter modifier small 
1.67@cancer cancer cancer inhibitor restore dnmt dnmt synthesize tumour hematological concentration agent process newly analog malignancy alternatively hypomethylation hypomethylation hypermethylated treat decrease island lead lead strand transferase transferase demethylating inhibit effective effective affect affect hypermethylation myelodysplastic nucleoside regulate cell cell cell cell cell suppressor abnormally also patient depend get replication replication drug cause cause cycle apoptosis approach result methylate free methyl methyl dna dna dna dna dna dna dna divide divide synthesis bind syndrome function cpg gene gene rapidly rate probably increase replicate decitabine decitabine decitabine mainly incorporate 
2.0@suppressor cancer also restore within dnmt dnmt use cause wont process growth demethylate completely treat inhibit inhibit methyltransferase promote dna dna dna dna cytotoxic strand action action help available drug drug control control take effect interact block gradually death death metabolite methylation decitabine decitabine gene cell cell cell cell cell replication 
0.67@un cancer use slow agent growth make treat seseptible chemotherapy dna area methylate syndrome act demethylating aml tumor precurser thus decitabine decitabine myleodysplastic 
2.0@cancer happen dnmt dnmt tumour tumour tumour stop oncogene hypermethylated treat decrease back irreversibly enzyme enzyme reduce reduce dname normal hypermethylation cystidine dilute disable reach expression expression suppressor suppressor therefore divide replication promotors structure incorporate result anti level level dna dna maintenance cell bind act inhibitor gene effect increase thus methylation methylation decitabine decitabine decitabine drive activity activity simililar 
1.33@dna suppressor demethylating gene methyltransferase inhibitor epigenetically silence vitro reactivate bydna tumor decitabine 
1.67@unregulated cancer cancer cancer cancer restore restore use agent tgss process demethylating myelogenous silence growth leukemia md treat inhibit promote promote clinical believe allow ezh ezh way tumor anticancer block normal may thus myelodysplastic like demethylation demethylation cell cell trial cite expression expression one suppressor tsgs due drug drug target acute reference electronic become know dna dna lysine histone histone syndrome function gene aml effect methyltransferase control increase division interfere new methylation methylation decitabine decitabine decitabine work class twofold progression 
2.0@cancer cancer inhibitor available use use bigger agent agent eisai analog myelogenous de de de treat treat transferase island amount dmnts irreversibly strand methylate hyper reduce tumor tumor develop nucleoside cell cell cell cell may leukaemia dmnt methylating methylating drug drug drug cause normal japonese type methyl particular company dna dna dna dna dna dna divide divide acute bind cpg effect quickly since methylation methylation decitabine decitabine work incorporate associate 
1.0@cancer cancer cancer cancer field use use susceptible chemically agent medicine analog change change potential breakthrough treat treat inhibit aza epigenetic epigenetic epigenetic methylate consider tumor tumor mechanism affect genome maintain cell cell inheritable may suppressor cytidine deoxycytidineis drug drug drug drug drug cause without know furthermore dna hypomethylating act perform gene methyltransferase eliminate truly epigenetics methylation decitabine decitabine decitabine 
2.0@suppressor suppressor cancer cancer effect higher class general agent demethylate underlie anti hypermethylated call lead cpg cpg regulate dna epigenetic level expression demethylating island island inhibitor tumor tumor tumor belong usually usually thus decitabine decitabine decitabine gene gene gene cell cell promoter promoter 
2.0@suppressor cancer use agent myelodysplastic gene gene demethylate promoter island dna syndrome act limit demethylating inhibit proliferation expression tumor cpg thus decitabine region cell enable 
2.0@cancer cancer critical residuesin reactivation transcriptional induce methyl dnmts agent hypomethylating major silence silence growth unmethylated lation change antitumour addition class cytosine epigenetic epigenetic epigenetic inhibitor inhibitor inhibitor enzyme dnmt tumor tumor hypermethylation dilute role regulator cell catalyze supressor suppressor also residue work link mitosis apoptosis loss occur know group methylationof push dna dna dna dna however mark hypo act function isan gene gene effect epigenetically division thus al decitabine stab dmnt cytosineand hypomethylator increasein adenosine play 
1.67@cancer restore suppressor suppressor suppressor suppressor tumour tumour tumour tumour tumour azacytidine azacytidine exert inhibit inhibit june class cytosine silence thereby proliferation amp hypermethylation role control mode promote stresemann drug revert apoptosis property pro reference anti genomic dna dna dna dna deoxy tumorigenesis lyko important gene gene gene gene gene methyltransferase methyltransferase inhibitor inhibitor induce retrieve int belong methylation methylation methylation decitabine decitabine decitabine sensitivity em action play 
2.0@allow inactivate inhibition activation activate activate induction need drug drug system apoptosis result phosphorilation hypomethylation anti enzime transport transport block previously dna dna dna bind inhibitor enzyme prodrug gene methyltransferase methyltransferase effect cellular due fact repair incorporate cell cell differentiation tumour tumour decitabine decitabine decitabine 
2.0@cancer cancer inhibitor effective activate progress use fda stop analog dnmti hypomethylation treat transferase island nucleotide irreversibly tumour tumour tumour enzyme wikipedia question hypermethylation myeloleukemia many cell cell cell methyl decitabine decitabine decitabine decitabine decitabine one suppressor suppressor study replication answer result reference specific bind occur promoter usa treatment dna dna dna dna dna dna divide blood acute allow syndrome site end gene gene rapidly disease induce reversal cpg produce thus methylation rna production incorporate incorporate incorporate approve myelodysplasia 
1.33@cancer cancer inhibition effective formation thatdecitabine break mark probably reactivate reactivate treat inhibit suppress strand lose kind silence dnmt dnmt tumor tumor tumor mechanism mechanism block normal fact cell cell cell cell cell far drug decitabine decitabine suppressor replication cause cause suppose suppose result do show dna dna divide lot gene gene methyltransferase effect effect epigenetically die human methylation methylation double action protein 
2.0@dependent critical restore may analogue agent cause apoptosis thylation transfer hypomethylates hypomethylation bind inhibit dna dna dna dna dna irreversibly ase function demethylating control proliferation reduce induce cellular cellular normal neoplastic division hypome release nucleoside gene methylation cell differentiation differentiation methyl decitabine decitabine 
0.67@cancer instead slowly encounter use agent sit analog analog classify reactivate hypomethylation hypomethylation md md treat block island aza previously cytosine irreversibly dna dna dna dna dna involve demethylating tumor tumor round affect hypermethylation nucleoside cell cell cell substitute suppressor suppressor cause replication replication deactivate deactivate could result result myelodisplastic several divide divide bind syndrome cpg gene gene methyltransferase think die deoxycytidine methylation decitabine decitabine decitabine decitabine incorporate rapidly 
2.0@inhibitor inhibitor inhibitor inhibitor higher class available dna dna dna dna dna dna dna yet cycle cycle precise sufficient since reactivate hypermethylated overall tumour tumour tumour tumour tumour call incorporation previously irreversibly strand methylate demethylating mechanism affect suspect nucleoside like demethylation cell cell cell cell cell cell cell methyl methyl tra tra suppressor cause epigenetic replication replication replication replication analogue subsequent apoptosis normal normal result arrest know reduction bind le fe fe drug drug gene methyltransferase rate induce global belong rase rase methylation decitabine decitabine decitabine daughter incorporate action action dnmti 
1.33@justify toxicity nucleoside specificity produce progress yet analogue concentration although acute depend depend inhibitor avoid group methyltransferase methyltransferase syndrome dna dna dna myologenous dose decrease bind point well enzyme drug inhibit aml effect mechanism demethylation increase belong clear myelodysplastic decitabine high align approve action replication leukaemia 
2.0@elod plastic cancer cancer cancer cancer cancer article dnmt use use agent stop find sit hypermethylated mention island island island island suppress suppress lead epigenetic know help inhibitor inhibitor silence inhibit contribute contribute case many cell cell tumour tumour tumour specifically dependent irreversibly replication dectabine dectabine normally promoter hypomethylated demethylation treatment treatment treatment dna dna dna dna dna bind syndrome act expression drug gene gene gene hence supressing remove cpg cpg cpg cpg thus methylation methylation methylation methylation decitabine decitabine decitabine y action methyltransferase alter 
2.0@cancer impact dnmt dnmt progress use hematological myelodysplastic malignancy dnmti exert transferase inhibit irreversibly think demethylating effective tumor tumor tumor mechanism neoplastic hypermethylation nucleoside like demethylation demethylation methyl suppressor suppressor high therefore drug analogue toxic low low anti anti dna dna dna dose dose dose bind syndrome act inhibitor still gene gene aml effect effect unclear dependant ineffective decitabine decitabine incorporate action would 
1.67@dacogen cancer cancer cancer growth growth dnmt dnmt dnmt include could shore myelodysplastic hypomethylation note hypermethylated avoid inhibit inhibit nucleotide benefit correlate irreversibly thereby island island island island therapeutic tumor block hypermethylation genome genome methylation methylation cell cell cell cell blockage inside older risk certain patient epigenetic necessary drug drug analogue limit relatively age type promoter presence unfortunately dna dna divide divide bind cpg cpg cpg effect effect negatively silence safer actively decitabine decitabine incorporate sensitive period downstream associate 
1.67@cancer cancer cancer cancer cancer inhibition specificity sometimes uncontrolled agent mechanism incorporate growth susceptible inhibit nucleotide lead irreversibly know demethylating island pattern affect besides hypermethylation hypermethylation usually much express cell cell cell cell tumour tumour patient imprint drug drug analogue could apoptosis suppression suppression loss lack become promoter dna dna dna bind example use dnmts still gene gene demethylated effect effect control cpg disappear methylation decitabine mean action 
1.67@suppressor proliferate proliferate mammalian tumour tumour tumour analogue specific apoptosis newly relatively transcription reactivate hypomethylation insensitive anti phase inhibit methyltransferase methyltransferase dna dna dna dna dna non expose act responsible enzyme inhibitor gene rapidly effect epigenetically result result deoxycytidine silence readily rna nucleoside synthesize incorporate incorporate cell cell cell cell cell replication methylating decitabine decitabine decitabine decitabine decitabine 
2.0@decline cancer proliferate abnormal abnormal restore restore tumour tumour tumour tumour tumour every agent stop myelodysplastic also growth growth treat inhibit regulate enzyme demethylating absence reduce hypermethylation hypermethylation cell cell cell cell cell cell use suppressor suppressor suppressor methylating replication cause toxic result dna dna dna dna reverse syndrome accessibility expression gene rapidly inhibitor inhibitor death division due thus thus methylation methylation methylation decitabine decitabine transcription activity action tuomour 
1.0@dna dna dna dacogen sell eisai demethylating gene methyltransferase cause agent indirectly target hypomethylates ul ul hypomethylation promoter inhibit methylcytosine deplete decitabine decitabine decitabine 
1.0@dna dna dna dna lower enzime erase tarjet use agent pas hiper island myelodysplastic myelogenous make drug drug drug drug avoid inhibit overexpress treatment kind acute syndrome name division demethylating group methyltransferase effect tumor tumor tumor methylations precursor belong act thus methylation methylation decitabine daughter cpg cell cell cell way leukaemia 
2.0@suppressor suppressor cancer methyltransferases become hypomethylation dnmt dnmt dnmt replication cause dependent specific silence demethylate analog tumorgenisis dnmti methylgroup effect anti suppress dna dna dna dna dna dna irreversibly bind inhibitor inhibitor inhibitor inhibitor dnmts dnmts demethylating gene gene gene methyltransferase enzyme tumor tumor tumor tumor transfer demethylation hypermethylation thus thus demethylated decitabine decitabine decitabine decitabine decitabine nucleoside incorporate suppressive active tissue 
1.67@mitotically cancer cannot class class last check methyl drus since dnmti growth unmethylated treat absence suppress cytosine strand methylated methylated inhibitor enzyme group tumor tumor tumor tumor tumor normal hypermethylation dilute directly heritable cell cell cell cell beyond drug drug supressor suppressor suppressor dependent also undo undo replication subsequent incorporate result cancerous anti normally occur prevent treatment dna dna dna dna dna dna function gene gene gene methyltransferase methyltransferase effect time keep replicate thus methylation methylation methylation decitabine daughter work lay active action reactivate 
2.0@suppressor suppressor cancer gobal tumour hence suppression result hypomethylation hypomethylation effect anti show inhibit dna dna dna cell prevent prevent methyltransferase methyltransferase inhibitor tumuor tumuor silence methylation methylation decitabine decitabine decitabine gene gene activity action may 
2.0@risk cancer cancer methyltransferases able use itis order island azacytidines demethylate occur especially prevent might dna epigenetic get methylated developmental inhibitor demethylating gene gene reduce tumor feature belong suppressor turnoff decitabine cpg drug hit 
1.67@one study cancer cancer cancer also patient produce diverse need agent stop decitabine decitabine decitabine island replicative capable replication methylation tumour show knudson leukemognesis dna dna dna dna epigenetic body important demethylating group aml effect remove know know cpg leukomogenesis hypothesis hypermethilated failure role aderrant cell cell cell methyl play 
1.67@tumorsuppressor tumorsuppressor especially inhibitor inhibitor restore get way agent analog hypomethylates fact hypomethylation anti hypermethylated inhibit normal normal group dna dna dna dna dna dna irreversibly base bind function demethylating control methyltransferase methyltransferase methyltransferase effect tumor growth inactive belong thus decitabine decitabine nucleoside gene gene incorporate replication 
1.33@neoplastic anti effect dna decitabine hypermethylation demethylating icrs reduce agent 
1.67@inhibitor class term reactivation epigenetically tumour tumour tumour hematological include aberrantly long sequester probably selective malignancy dnmti hypermethylated incorporation affect lead body silence silence tumor mechanism normal hypermethylation degrade many cell cell cell demethylation replication suppressor suppressor suppressor dependent depend drug dose low promoter severly dna dna dna dna divide non dnmts still gene gene gene gene aml effect effect unclear methyltransferase global consequent belong replicate since since since decitabine decitabine action action rapidly reactivate 
2.0@dna dna suppressor acute syndrome precursor demethylating use turmour agent hypomethylating myelodysplastic myelogenous methylation decitabine treat decrease enable leukaemia 
1.33@suppressor cancer inhibitor restore begin regulation imprint imprint certain agent agent likely likely demethylate demethylated growth normally anti hypermethylated know island cpg class dna dna dna area decitabines epigenetic act function function demethylating demethylating gene gene gene effect tumor tumor normal belong genome arise express decitabine decitabine 
2.0@cancer cancer cancer cancer cancer effective tumour agent mark mark cure way reactivate change unmethylated treat back epigenetic pass methylated demethylating group take replicate inactive like cell cell cell cell cell replication suppressor faster erase irreversibly fight actively drug cycle prone prevent dna dna dna dna dna dna bind bind gene methyltransferase methyltransferase methyltransferase inhibitor remove place belong dependent methylation methylation decitabine decitabine daughter come duplication beat dnmti dnmti dnmti 
2.0@dacogen cancer cancer cancer proliferate dnmt use agent mark myelodysplastic myelogenous dnmti treat transferase lead irreversibly precursor hyper demethylating severely proliferation mechanism affect divide maintain cell cell cell tumour tumour leukaemia one suppressor suppressor epigenetic replication methyl prevent prevent dna dna dna dna get acute bind syndrome sell drug drug rapidly inhibitor upon methylation methylation decitabine decitabine daughter incorporate active hence hence enough 
2.0@mitotically mitotically cancer along think change change dnmt dnmt progress tumour agent marker part heritable heritable epigentic epigentic inhibit previously strand sequence wide allow demethylating reduce normal normal genome genome genome genome nucleoside read apparatus far may host supressor dna relate study replication analogue throughout mean fashion trigger antitumour abarrent reduction cell cell cell bind expression act act inhibitor gene hence effect dependant cellular copy increase enter silence methylation methylation methylation methylation decitabine decitabine decitabine decitabine daughter daughter mitosis incorporate 
1.67@suppressor dependent dependent dependent inhibitor class use analogue md result since malignancy exact anti bind know molecule treatment dna dna dna dna irreversibly dose often hypermethylation gene methyltransferase methyltransferase effect unclear mechanism neoplastic belong fact decitabine nucleoside incorporate replication demethylation action tumour haematological small 
2.0@suppressor azacytidina azacytosina epigenetically use analogue agent myelogenous cytosine reactivate treat show act dna dna substantial deoxy acute syndrome precursor demethylating gene methyltransferase inhibitor tumor silence vitro potency decitabine decitabine myelodysplasic 
0.0@dna epigenetic impact identify point inhibitor include tumour effect effect answer belong describe describe class reference ul ul anti methylation epigenome follow cer decitabine decitabine decitabine 
1.67@cancer cancer inhibition unmethlyated dnmt dnmt dnmt dnmt dnmt yet manner agent pattern de growth restrict inhibit inhibit incorporation recognize irreversibly strand strand methylated hyper island chromosome reduce reduce reduce tumor tumor mechanism essential nucleoside like methylizing cell cell cell cell cell decitabine decitabine decitabine suppressor dependent also methylates drug analogue viability viability hemi become fully parent dna dna understand bind act cpg gene methyltransferase allow division methylation methylation inappropriate daughter mitosis activity active proliferation 
2.0@cancer methyltransferases class term dnmt dnmt synthesize methyl state add specific newly analog since dnmti change note tsg inhibit cpg lead lead irreversibly strand inhibitor inhibitor belong island order tumor tumor content recommend express demethylation demethylation cell require expression suppressor dependent tsgs epigenetic replication tumorous extensionreading prior activity course course anti lecture group treatment dna dna dna dna dna get get disable bind bind nucleoside function perform gene methyltransferase methyltransferase effect division replicate silence decitabine decitabine decitabine decitabine daughter incorporate active cpgs cpgs 
0.67@unregulated cancer cause class suppressor suppressor methyl certain mutation april epicentre hypermethylate objective member economist whose growth express become drug decrease group develop regulate dna dna histone histone histone expression hypermethylation demethylating grow highly reduce reduce tumor tumor tumor tumor overactive protein ezh ezh turn silence silence methylation allow gene gene gene enzyme enzyme attach decitabine 
1.67@suppressor cancer inhibitor daughter specifically tumour analogue order strand toxic target administrate consequently dnmti trigger anti type nucleotide lead dna dna dna dna irreversibly dose dose bind bind act smaller dnmts dnmts gene methyltransferase effect upon copy neoplastic longer methylation nonspecifically high incorporate replication demethylation cell cell much nuceloside decitabine decitabine decitabine 
2.0@cancer cancer cancer inhibitor inhibitor inhibition class class able start use fda process currently active hypomethylation unmethylated hypermethylated hypermethylated treat treat treat call locus locus benefit lead recognize epigenetic epigenetic mention association inhibit inhibit dnmt dnmt therapeutic symptom rely genome serious case far tumour decitabine decitabine decitabine one compare also certain decitibine decitibine decitibine include drug drug drug drug cause today product approach worth without azacitidine solid show day treatment dna dna pathway pathway bind chemotherapy demethylase perform function function induce dependant combine approve belong new alter another unbind form protein haematological associate 
0.67@cancer state therefore able methyl cause cause system could immune decitabine decitabine drug hypermethylation hypermethylation anti inhibit know prevent dna dna histone methylated expression expression responsible enzyme enzyme ezh ezh group effect tumor tumor tumor demethylating silence silence methylation allow gene gene many thereby attach supressor supressor 
2.0@dna dna cancer methylating suppressor suppressor excessive excessive tumor tumor tumor tumor drug cause mark result reactivate growth growth unchecked regulatory regulatory suppress often hallmark help common allow gene gene gene proliferation remove hypermethylation hypermethylation hypermethylation silence silence methylation methylation methylation decitabine decitabine region region mean mean activate removal enable de 
1.0@standard standard drug drug drug effect possibly lymphoma decitabine regime use use slow agent acute cutaneous myelodysplastic myelogenous treatment growth susceptible make treat treat better might chemotherapy chemotherapy dna epigenetic histone histone syndrome precursor inhibitor demethylating reduce tumor tumor mechanism secondary deacetylase amount due methylation directly cell cell much alter leukaemia 
1.33@suppressor cancer transcriptional tumor tumor may cause agent aberrantly derepression process since necessary functional growth therapy arrest apoptosis dna dna dna maintenance reversible powerful expression demethylating gene continue inhibitor induce belong silence methylation methylation ensure cell decitabine decitabine decitabine 
1.67@cannot dnmt dnmt tumour slow cycle de accomplish decrease halt previously previously strand level methylated methylated methylated involve tumourigenesis block clear maintain maintain cell cell cell yet expression one suppressor therefore even hemi novo exactly subsequent though dna dna bind example dnmts dnmts dnmts gene methyltransferase inhibitor inhibitor increase division new methylation methylation methylation methylation decitabine mitosis lay complete 
1.67@dna dna dna dnmt dnmt dnmt dnmt dnmt produce tumour tumour agent novo process two inheritance hypomethylates de gene gene anti type prevent island sense maintenance maintenance involve suppression demethylating inhibit inhibit proliferation effect methyltransferase control cpg focus methylation decitabine em case cell differentiation replication recover expression 
1.67@cancer cancer critical restore dnmt dnmt dnmt tumour agent specific classify de growth leukemia methyl normal locus irreversibly oncrporated inhibitor consequence demethylating island island myeloid affect affect abnormality hypermethylation counteract cell replication tra suppressor dependent drug therapy novo highly shore occur dna dna dna base bind example fe function cpg cpg gene gene effect control silence replicate rase decitabine decitabine em 
2.0@cancer cannot dnmt encounter progress use unmethylated add mark myelodysplastic myelogenous dnmti dnmti dnmti dnmti susceptible overall treat hemimethylated hemimethylated inhibit incorporation previously expression leaukaemia irreversibly strand strand tumour tumour inhibitor enzyme enzyme group mechanism hypermethylation nucleoside like demethylation cell cell cell methyl decitabine decitabine decitabine one suppressor become divide divide analogue subsequent target present exact maintain maintain anti prevent dna dna dna dna dna dna dna dna maintenance acute bind syndrome dnmts still gene rapidly effect effect unclear methyltransferase replicate methylation methylation methylation allow incorporate continue 
2.0@cancer lower specificity irreversibly use analogue dependent however mean mean kill dna dna dna dna divide divide dose see see bind dnmts dnmts severely rapidly inhibitor tumor methyltransferase affect lack methylation methylation decitabine decitabine nucleoside incorporate cell cell cell replication hit 
2.0@mean cancer inhibition dnmt dnmt dnmt dnmt dnmt produce may may state agent usually hypomethylating detail aza reactivate incorporation hypermethylated predecessor island cpg epigenetic development obtain methylated therefore enzyme anticancer anticancer tumor mechanism inactive hypermethylation particular genome nucleoside level like cell cell cell cell drug reach closely approve suppressor cytidine slow residue irreversibly replication analogue malignant subsequent incorporate commercially become become become moment promoter prevent hypomehylated act act dna dna dna dna dna however bind le site expression still gene methyltransferase inhibitor inhibitor inhibitor unclear deoxycytidine resemble division new methylation decitabine decitabine decitabine region reproduce though action 
1.67@one cytidine methyltransferases class presumably use agent suppression analog myelogenous anti treat inhibit reverse dna dna expression acute syndrome precursor myelodysplastic demethylating exercise effect effect silence decitabine gene tumour tumour leukaemia 
1.67@one dna dna dna dna dna cancer cause class therefore dnmt dnmt dnmt dnmt methylates replication replication analogue analogue able dependent hemi mean maintain maintain bind call action hallmark irreversibly get methylated inhibitor function perform suffer recognise impact mechanism know belong replicate replicate actively actively longer nucleoside nucleoside incorporate incorporate methylation methylation cell cell cell drug drug decitabine decitabine decitabine 
1.67@cancer inhibition inhibition reactivation formation use loss phase irreversible inactivation analog malignancy growth leukemia leukemia md incorporation inhibit suppress lead clinical silence dnmt tumor tumor preliminary produce produce neoplastic model thus myelodysplastic bond aberrant potent demethylation cell cell cycle expression suppressor silent patient therapeutic mitotic induction drug strategy agent incorporate gene gene show many covalent dna dna dna dna dna dna dna dna dna non demonstrate syndrome act animal nsclc specifically inhibitor deoxycytidine trial antineoplastic antineoplastic lung senescence clonogenicity methylation methylation methylation methylation decitabine decitabine decitabine decitabine possible activity differentiation methyltransferase methyltransferase small 
1.33@heavy cancer effect effect term dnmt progress use use long myelodysplastic myelodysplastic analog since dnmti dnmti dnmti leukemia affect island nucleotide patient clinical irreversibly strand well consequence thereby tolerate reduce normal neoplastic hypermethylation poorer high like cell cell cell trial much release unknown toxicity nucleoside dependent lower indicate get cannot replication cause cause improve life side expectancy anti solid older prognosis myeloid extremely dna dna dna dna dna divide dose dose acute bind bind syndrome syndrome act inhibitor inhibitor cpg hence aml respond methyltransferase methyltransferase methyltransferase copy division replicate methylation methylation decitabine daughter incorporate approve rapidly 
1.33@mitotically cancer cancer methyltransferases dnmt dnmt dnmt tumour agent mark mark de growth possibly hypermethylated inhibit hemimethylated island often cytosine irreversibly strand strand strand transferase transferase demethylating prevent pattern rapidly mammal neoplastic thus nucleoside maintain maintain cell cell cell cell cell cell methyl decitabine methylating divide analogue novo lay methylate cpgsin anti vulnerable match parent dna dna dna dna dna dna dna dna get bind act act dnmts cpg hence single inhibitor thismethylation division division replicate replicate new new methylation methylation methylation methylation double daughter incorporate original protein 
2.0@suppressor cancer cancer effective daughter therefore dnmt dnmt dnmt progress way analogue inhibitor decitabine decitabine decitabine myelodysplastic amr frequently affect affect affect inhibit lead dna epigenetic bind syndrome responsible replcation drug gene remain impact tumor fe normal death replicate rase methylation methylation allow allow nucleoside regulator active cell cell cell cell cell methyl release tra 
2.0@supresor cancer cancer inhibitor demethylates dnmt start tumor use fda dependent myelodysplastic analog hypomethylates dnmti hypomethylation hypermethylated drug island island decitabines methylated allow way myeloid gene gene dilution nucleoside many methyl leukaemia cytidine activation decitabine decitabine decitabine decitabine replication analogue subsequent context sequence oppose therapeutic lie demethylate promoter treatment dna dna dna dna acute bind bind syndrome fe dnmts cpg cpg irreversible effect passively belong rase locate mitosis incorporate approve tra progression 
1.67@rase ongoing therefore tumour tumour agent methylationand result growth hypermethylated itcan inactive inhibit suppress previously lead dna dna reaction bind expression fe enzyme demethylating gene gene reduce catalyze silence thus methylation decitabine render express methyl tra 
1.0@cancer cannot dnmt tumour agent process since dnmti normal normal inhibit irreversibly methylated onto inhibitor inhibitor inhibitor inhibitor inhibitor demethylating affect affect neoplastic specificallydecitabine release nucleoside demethylation cell cell cell cell cell cell need dna dna dna dna dna dna dependent tunour epigenetic drug cause ie ie ie analogue low anti help presence dnamethyltransferase several divide divide dose kill bind bind site function gene rapidly effect remove copy methylation methylation decitabine decitabine daughter work incorporate active action methyltransferase methyltransferase replication replication 
0.0@cancer cancer cancer cancer cancer cancer cancer oncosuppressor class patient seventy fda rich silence switch find meet epygenetic epygenetic growth treat treat myelodisplastic island lead development development involve hyper demethylating change change mechanism affect hypermethylation hypermethylation hilum cell cell cell italy mechansm also live researcher year drug region genoma stop type promoter particular dna divide divide act act expression cpg gene gene inhibitor elderly belong ti new work decitabine decitabine mainly mainly mainly possible approve grug 
2.0@suppressor cancer reduce activate tumour tumour ul ul effect anti amount island dna dna dna see silence bydecitabine gene gene methyltransferase inhibitor cpg methylation methylation inappropriate demethylation cell decitabine decitabine 
2.0@cancer cannot cannot cannot dnmt dnmt dnmt dnmt tumour tumour tumour tumour tumour slow dnmti susceptible make strand strand strand methylated methylated amino proliferation pattern block normal apoptotic nucleoside nucleoside like many cell cell cell cell express suppressor drug fast effect anti group reason dna dna dna divide divide preserve site gene gene inhibitor die similar silence replicate new new methylation methylation decitabine decitabine incorporate incorporate modify protein replication 
1.33@body cancer cancer cancer cancer along higher patient remember dnmt dnmt decitabine decitabine decitabine decitabine decitabine concentration replication replication replication drive chemically unviable hopefully nonspecific process proper result since irreversibly hypomethylation generation component affect hypomethylated somatic analogous dna dna dna dna dna dna already move environment inhibitor methyltransferase rate upon whole normal bind typically could incorporate cell cell cell cell cell disadvantage 
2.0@loss gradual gradual hypermethylationin transcriptional progress may system dnaand md transcription transcription transcription burden tumour tumour tumour tumour tumour island island treat lead lead lead irreversibly strand promoter promoter promoter promoter repression repression silence dnmt dnmt block hypermethylation hypermethylation hypermethylation nucleoside factor factor factor start decreaseof use suppressor suppressor suppressor ofthese also also via analogue byrecruiting cause product fromaccessing condense lecture prevent prevent prevent treatment dna get domain bind bind bind expression cpg cpg cpg gene gene gene gene gene aml aml inhibitor remove chromatin slide methylation decitabine decitabine daughter region region region incorporate mecp mecp relieve regioncauses 
1.33@body cancer inhibitor class medication dnmt dnmt dnmt use use agent hypomethylating myelodysplastic analog analog analog much leukemia call recognize irreversibly strand strand effectively methylated enzyme demethylating severely myeloid tumor methylate affect neoplastic consequently accordingly nucleoside nucleoside nucleoside cell cell cell cell way kill release dependent patient divide acytidine dnathen acute hemi attempt low anti asacytidine prevent good treatment dna dna dna dna dna get dose tumorigenesis bind syndrome act drug time aml effect upon methyltransferase longer replicationmaking methylation decitabine decitabine decitabine decitabine daughter daughter right incorporate action rapidly replication replication 
1.67@use agent agent demethyaltion suppression myelogenouse express anti treat permit inhibit previously define dna expression acute syndrome precursor myelodysplastic demethylating gene gene gene gene effect tumor tumor paper silence silence due thus methylation methylation decitabine decitabine decitabine like leukaemia 
1.67@dependent analogue therefore dnmt replication replication cause specific novo result dnmti anti dna dna irreversibly bind name inhibitor methyltransferase effect tumor suggest nucleoside incorporate demethylation demethylation cell drug de 
2.0@dna suppressor mean syndrome suppression thereby suffer tumor tumor agent demethylating myelodysplastis decitabine decitabine gene demethylate activate patient 
2.0@cancer cancer cancer demethlyization dnmt dnmt tumour tumour tumour attempt methylization unmethylated normal island attack pressor block affect give maintain cellreplication cell cell cell cell control suppressor suppressor faster therefore unblock ofdna describe low hypermethylizes aremore dna dna dna get dose bind cpg gene methyltransferase effect copy contain silence replicate replicate new methylation decitabine decitabine decitabine decitabine incorporate allcells generate 
1.33@cancer use use cluster cluster agent agent currently growth growth growth japan back treat lead see allow group group adhere tumor tumor tumor drop normal hypermethylation may genome like maternal cell methyl methyl manufacture promotion restrict drug icr could somatic wilm allele lgf lgf icrs amount level insulator ctcf dna example continue remove remove demethylation demethylation silence silence decitabine decitabine decitabine possible mean would 
2.0@cancer article refer lymphoma dnmt progress tumour tumour fda agent epicentre myelodysplastic remain dnmti mention inhibit inhibit achieve irreversibly methylate methylated inhibitor enzyme demethylating tumourigenesis tumourigenesis myeloid accute nucleoside express cell decitabine decitabine suppressor suppressor therefore analogue structure anti normally approve approve treatment dna dna dna dna dna dna bind syndrome act inactivate gene gene gene methyltransferase effect effect division replicate thus methylation allow allow incorporate active 
1.67@cancer cancer cancer isnt restore able produce use use appear agent instating myelodysplastic proliferate inhibitor de change change decitabene decitabene decitabene decitabene genetic treat affect affect unlike might class alternatively epigenetic epigenetic body establish demethylating demethylating take innate normal normal normal normal normal hypermethylation apoptotic thus repair protection program cell cell cell cell cell cell cell cell cell may leukaemia destroy lower necessary weak require require either acute pro kill cancerous cancerous fact effect effect demethylate tumour oxy dna dna dna divide dose reverse syndrome function interestingly methyltransferase zac advantage relatively protein modification myelogenous methylation tid create sensitive anti dramatically frequently 
2.0@decitabinecan growth activate way way cause dnmtinhibitor dnmti hypomethylation gene gene make occur block island dna dna reverse expression cpg inhibit tumor tumor tumor tumor surpressor surpressor surpressor hypermethylation decitabine decitabine tumorgrowth possible surpress demethylation 
2.0@gene unregulated cancer cancer also restore dnmt formation upon replication dependent analog dnmti dnmti growth effect become antitumor copy inhibit inhibit promote dna dna dna divide strand action methylated daughter inhibitor division division cant methyltransferase regulate tumor mechanism affect belong go methylation methylation release nucleoside irreversible incorporate cell cell cell cell suppressor decitabine decitabine decitabine 
2.0@dacogen effect effect restore epigenetically include myelodysplastic dnmti hypomethylation hypomethylation md md might exert exert believe estrogen calcitonin thereby tumor tumor tumor accord normal neoplastic hypermethylation hypermethylation metabolic nucleoside many etc supressor supressor study cause cause apoptosis anti treatment dna dna cell syndrome function gene gene gene methyltransferase inhibitor inhibitor induce cellular antineoplastic silence receptor decitabine decitabine decitabine differentiation 
1.33@et kantarjian class class lymphoma suppressor transcriptional use cluster agent hypomethylating find malignancy reactivate kip leukemia treat treat call inhibit job disrupt igf methylated allow tumor tumor tumor formation hypo cip sense hic drug cause hematopoietic transcribe prevent amp dna epigenitic environment example expression likewise aml inhibitor similar silence thus al decitabine decitabine decitabine plimack gene ink form part methyltransferase 
0.33@suppressor suppressor cancer cancer cancer also growth acheived antimetobolity regain use agent toxic reenables fast distrubts hypomethylation element make type type treat suppress regulate dna dna divide substance kill allow drug gene gene produce rely silence methylation methylation decitabine decitabine incorprating cell cell cell cell cell control 
2.0@specifically methyltransferases inhibition dnmt purport induce drug leave mutate event condition lie decatabine el prevent several open expression ezh numerous tumor methylation methylation proliferative gene disruptsdna suppressor 
2.0@ecitabine loss restore suppressor suppressor use agent stop myelodysplastic myelogenous reduction leukemia hypermethylated treat reverse suppress suppress lead dna acute syndrome precursor function function demethylating demethylating hence methyltransferase expression oneinhibits hypermethylation act gene gene gene gene tumour tumour tumour tumour 
2.0@inactivate suppressor cancer methylating patient drug shut mean methylate design lukemia inhibit tail histone histone important thereby prevent prevent go tumor growth thus thus methylation allow gene gene unexpressed cell cell decitabine 
2.0@cancer impeed therefore tumour since useful type transferase island treatment dna avoid bind cpg cpg group inhibitor hypermethylation decitabine repressor methyl methyl would associate 
2.0@cancer methyltransferases class dnmt dnmt progress tumour tumour tumour tumour leukemia fda myelodysplastic dnmti dnmti susceptible inhibit decrease grow irreversibly strand strand pass inhibitor inhibitor inhibitor disease thereby proceed myeloid release nucleoside express cell cell cell cell incorporate decitabine decitabine suppressor suppressor epigenetic epigenetic replication replication analogue toxic suppression result low effect effect effect methyl transferase dna dna dna dna dna dna dna divide dose dose acute bind syndrome target drug drug drug gene gene gene rapidly along place remarkable increase increase belong methylation methylation methylation allow daughter copy approve 
1.33@compound suppressor suppressor could methylating inhibition class therefore specifically island decitabine decitabine switch remain growth type call prevent prevent molecule dna dna epigenetic epigenetic promoter expression inhibitor function cpg gene gene target dnmt tumor tumor tumor methyltransferase belong turn regulator allow allow region hypomethylated methylation drug enzymatic small 
0.67@cancer think become class epigenetic epigenetic use myeloyiplastic agent target target dnmti leukemia hypermethylation hypermethylation treat call dna cpgis acute syndrome act act enzyme demethylating inhibitor lymphocytic affect belong decitabine cell possibly 
2.0@drugcauses inhibitor able control blood work myelodysplastic remain hypomethylation leukemia make type grow treatacute dna dna harder methylate syndrome le disease drug drug gene gene gene methyltransferase myeloid tumor tumor tumor tumor suppress suppress suppress thus decitabine decitabine region express cell use 
1.67@reduction cancer patient erase reactivation regulation tumor tumor tumor drug drug slow combination agent agent potentially mark find cancerous chemotherapeutic growth growth growth gene gene become halt show hypomethylated response lead lead dna dna dna epigenetic epigenetic better responsible function demethylating interest inhibitor inhibitor histone deacetylase administer thus methylation decitabine decitabine could could administration cell demethylation suppressor 
2.0@interaction cancer cancer restore restore within produce uncontrolled agent island two analog transfer growth direct hypermethylated incorporation decitabinealso demethylates sequence belong demethylating demethylating inhibit inhibit mean mean normal cytidine demethylation cell cell cell cell cell methyl suppressor suppressor also silent become antimetabolite antimetabolite replication cause target result result number anti anti tumour tumour tumour tumour dna dna dna dna dna dna divide cytotoxic function cpg gene gene gene gene rapidly effect effect effect control death division decitabine decitabine decitabine decitabine decitabine decitabine incorporate methyltransferase 
1.67@dna epigenetic inhibitor inhibitor dnmt class methyltransferase demethylating demethylating adna tumour effect agent cpg belong decitabine anti hypermethylated call island may 
1.67@suppressor suppressor methylating excessive excessive agent decrease inhibit inhibit degree dna histone histone histone involve act act act enzyme enzyme ezh prevent allow allow tumor tumor demethylating methylation methylation decitabine decitabine decitabine gene gene activity mutilation mutilation expression 
2.0@pronounce cancer dnmt dnmt dnmt produce tumour tumour tumour tumour slow agent specific mark phenomenon since since since growth inhibit inhibit inhibit inhibit epigenetic erase enzyme demethylating observe block hypermethylation actively cell cell cell cell cell replication supressor one dependent therefore irreversibly drug drug drug drug could problem case occur occur group island dna dna dna however bind cpg time methyltransferase effect belong replicate silence methylation methylation methylation decitabine gene 
1.33@cancer methyltransferases promote irreversibly use answer specific incorporate cannot course de methylation treat act dna dna dna dna divide methylate bind syndrome understand myelodysplastic rapidly affect source replicate material decitabine profoundly article economist cell cell drug drug drug 
1.67@cancer cancer effect restore activate agent since growth growth unmethylating island island suppress class around involve belong especially tumor tumor tumor tumor normal normal normal hypermethylation simply thereby thereby thereby control suppressor suppressor cause restoration restoration suppression result demethylate promoter dna dna know act expression expression expression expression cpg cpg gene gene gene gene gene gene gene gene gene function function function remove demrthylating demethylating demethylating silence silence silence methylation methylation decitabine decitabine decitabine region region region activity associate associate associate 
1.33@dna replicate cancer cancer inhibitor bind dnmt others replication effect upon faster affect fast dnmti cell cell cell grow tumour methilase decitabine 
1.67@cancer cancer classify dnmt use use agent agent myelodysplastic proliferate treat treat transferase cytosine help enzyme demethylating reduce tumor normal metabolite metabolite like cell cell methyl methyl deplete suppressor also year decitibine drug cause add mean cancerous number anti group develop dna dna dna dna base cytotoxic syndrome recent gene rapidly effect silence methylation decitabine incorporate dectitbine chemotherapeutic 
1.0@demethyl around methylation decitabine inhibitor histone histone reduce level tranferase 
2.0@cancer cancer cancer cancer inhibitor inhibitor inhibition dnmt dnmt dnmt produce produce tumour tumour agent agent decrease nucleotide irreversibly irreversibly strand body involve belong demethylating demethylating enhance block affect affect hypermethylation nucleoside factor hereditable like cell cell cell drug suppressor dependent dependent transcription transcription expession therapeutic replication replication analogue promotor antitumour dna dna dna dna dna dna dna dna divide bind bind bind bind act dnmts gene gene rapidly effect methyltransferase copy division modification epigenetics methylation methylation methylation decitabine decitabine decitabine decitabine daughter incorporate incorporate come modify generate progression progression 
0.67@one one cancer methyltransferases also dnmt use inhibitor break hypomethylating event transcription hypomethylation md md overall might nucleotide lead cytosine cytosine latter consider damage instead activation tumor block normal hypermethylation apoptotic nucleoside prognosis cell cell cell cell cycle stress decitabine decitabine decitabine decitabine genotoxic dependent cause high agent application relate drug drug analogue strand therapy toxic pro low depletion arrest severe pool treatment dna dna dna dna dna demethylation dose dose covalently bind syndrome act myelodysplastic poor side effect effect induce illegitimate increase increase division double incorporate sensitive action action complete progression 
1.67@blewitt cancer cancer transfer faster disrupt disrupt able decitabine decitabine decitabine much much state dose attempt relatively since dnmti growth normally lecture parent disruption dna dna dna divide latter bind le inhibitor affect affect methyltransferase methyltransferase inactivate tumor accord permanently believe division division replicate thus methylation methylation methylation prof daughter disproportionately cell cell cell cell cell cell cell cell small 
1.67@inhibitor restore dnmt dnmt dnmt use add stop mark myelodysplastic growth treat nucleotide irreversibly strand lose consequence control tumor interfere normal release nucleoside enzyme demethylation cell methyl suppressor therefore replication replication analogue become know group dna dna dna dna dna dna process process bind bind function gene methyltransferase methyltransferase eliminate upon copy longer methylation methylation methylation methylation decitabine decitabine daughter incorporate come protein 
2.0@cancer methyltransferases inhibition use cycle phase de hypomethylation athought lead activityvia enzyme island tumor complex genome nucleoside treatment supressor mantained cytidine tobe patient hypemethylated decitabine decitabine decitabine decitabine analogue improve trap ofdna loss loss dntms present gene prognosis covalent dna dna dna cell degradation dnmts cpg progressive chemical reexpression induce induce induce result must antineoplastic methylation methylation rna ca incorporate active survival 
1.33@cancer inhibitor inhibitor specificity progress use afected long myelodysplastic machanism dnmti leukemia unknown irreversibly body term severely inherent myeloid mechanism normal lack release nucleoside cell cell cell cell much decitabine decitabine cute dependent therefore replication analogue could mean mean dna dna divide bind bind syndrome dnmts still still irreversible methyltransferase methyltransferase effect unclear division replicate replicate longer incorporate approve action action action rapidly 
1.0@deacetylization also become standard suppressor hypomethylate use appear agent subsequent make result demethylization susceptible generation conjunction drug promoter promoter prevent chemotherapy dna dna dna decitibane act inhibitor anti gene proliferation effect tumor tumor interfere line hypermethylation may silence class cell cell methyltransferase 
1.0@dna dna cancer cancer also demethylates suppressor suppressor way agent cell cell cell growth anti anti anti action normalize kill cytotoxic allow allow demethylating demethylating gene gene effect effect tumor tumor tumor division metabolite metabolite decitabine decitabine destroy express form drug drug expression 
1.33@dna suppressor article restore function demethylating demethylating gene tumour agent agent normal source silence economist decitabine hypomethylation methylation 
1.67@unregulated cancer cancer cancer restore restore tumour tumour agent stop receive process silence growth growth make unlike regulate respond demethylating inhibit happen tumor due genesto normal normal hypermethylation signal signal many cell cell cell cell cell control suppressor suppressor suppressor suppressor silent cause cause become type demethylation demethylation dna dna dna dna dna replicate function gene gene gene methyltransferase copy increase division division interfere thus methylation methylation decitabine absence work continue 
1.67@cancer cancer field dnmt dnmt dnmt dnmt dnmt may slow agent significantly value dnmti dnmti growth leukemia md mylogenous decrease inhibit inhibit treat clinical epigenetic help precursor demethylating proliferation proliferation overmethylation tumor tumor tumor tumor tumor uncontrolled myelodysplastic reduce reduce reduce cell cell use suppressor suppressor also identify therefore area study utility combination result acute promise anti amount amount diagnostic dna dna overmethylated histone histone syndrome act act inhibitor inhibitor inhibitor inhibitor drug gene gene methyltransferase effect overactive increase undergo thus decitabine decitabine decitabine decitabine region activity activity hdaci overactivity prognostic 
1.67@dacogen inhibitor activity lower dnmt progress use use although fda agent island analog currently leukemia japanese might superior onwards unknown irreversibly theirquality ananti well hypermethylation demethylating inhibit myeloid tumor mechanism myelodisplastic neoplastic life life nucleoside cell high point far far tolerate one dependent give patient replication name improve toxic expectancy acute extremely nonspecific older company dna dna dna dose dose kill syndrome methylase drug sell methyltransferase effect effect advantage cpg decitabine incorporate upon approve action bound 
0.67@toxicity dacogen drug analogue lower dnmt dnmt progress use use use hematological agent actual mechanism demthylation myelodysplastic find possibly replication molecular previousely better treatment irreversibly dose tumour tumour bind sell le inhibitor demethylating gene side effect unclear dependant syndrome hypermethylation decitabine nucleoside work work much suppressor small 
1.67@dacogen dnmt dnmt cell use analogue agent agent acute actsas hypomethylating eisai myelogenous cytosine leukemia covalently treat action company dna dna japanese bind syndrome sell myelodysplastic demethylating methyltransferase inhibitor tumor block precursor hypermethylation anticancer since decitabine incorporate form drug 
2.0@could could methyltransferases class dnmt tumour tumour tumour tumour tumour tumour agent hypomethylating anti dnmti growth decrease inhibit inhibit inhibit lead irreversibly enzyme demethylating prevent impact nucleoside aberrant express cell cell methyl decitabine decitabine decitabine suppressor suppressor suppressor suppressor transfer therefore drug analogue become hypomethylated island island island dna dna dna dna dna dna divide bind inhibitor inhibitor cpg cpg cpg methyltransferase methyltransferase effect copy death catalyze thus methylation methylation methylation methylation group work incorporate active action 
1.33@suppressor also inhibition standard dnmt seem way region agent agent article hypomethylation susceptible make solid call action basically dna dna strand promoter chemotherapy enzyme gene methyltransferase reduce tumor tumor tumor accord methylation decitabine decitabine decitabine via incorporate demethylation cell alter 
2.0@myeloid dnmt progress use attempt hypomethylating myelodysplastic growth leukemia permanently suppress effective latter particularly control able normal nucleotide nucleoside cell cell cell tumour tumour tumour dependent accept regain replication analogue hypomethylated dna dna dna dna divide acute bind bind syndrome function gene hence hence hence hence inhibitor methyltransferase copy division undergo methylation decitabine daughter rapidly 
1.0@cancer cancer cancer article epicenter class class methyl methyl include add example switch lower meet oncogene oncogene island dna dna dna expression epigenetic promoter survive hilt mechanism block normal nucleoside enzyme cell cell cell way way recover decitabine decitabine suppressor suppressor suppressor analogue run bond cannot drug promotors ferment whole describe level group group covalent several base degradation fe function cpg gene methyltransferase methyltransferase inhibitor remove belong undergo rase methylation hypermethilated activity activity action 
1.33@cancer methyltransferases therefore dnmt dnmt dnmt tumour normal normal result result anti overall decrease inhibit dna dna dna dna dna divide strand copy bind bind inhibitor drug severely rapidly effect pattern pattern affect replicate methylation methylation methylation decitabine decitabine daughter cell cell cell spread level 
1.33@effect become therefore dnmt dnmt synthesize methyl cause agent novo island island newly transfer de generation hypermethylated importantly group dna dna dna dna dna dna dna dna pass dnmts dnmts dnmts demethylating inhibit target reduce reduce tumor tumor function cpg cpg new methylation methylation methylation methylation anti maintain cell cell methyltransferase methyltransferase decytitabine decytitabine decytitabine 
2.0@undesirable haemopoetic class specificity may may agent mark selective malignancy hypermethylation change attatching pleiotropic exert inhibit inhibit cpg threrapy status rapidly responsible responsible enzyme enzyme demethylating group tumor tumor tumor affect dis give high express indiscriminately cell cell cell methyl supressor multiple base therefore divide decitabine decitabine require cause dose dose toxic ly low cytosine like anti anti prop promoter furthermore demethylation island dna dna dna dna however non maintain important te gene ona effect effect effect effect remove methyltransferase belong ti find methylation methylation methylation methylation methylation allow daughter work mean myelodysplasia myelodysplasia 
2.0@dacogen cancer cancer dnmt regulation use system agent stop eisai myelogenous growth growth leukemia make treat inhibit inhibit suppress epigenetic precursor hyper hyper ezh tumor tumor tumor normal hypo include myelodysplastic many japanese uncontrolled pharmaceutical decitabine decitabine decitabine suppressor therefore methylates drug cause cause function acute mutation methlyation cell cell result surround whose anti immune company dna dna dna activitiy histone syndrome sell dnmts dnmts gene gene gene gene methyltransferase effect overactive demethylating due silence methylation allow activity overactivity protein 
2.0@cancer cancer methyltransferases lower progress tumour tumour tumour likely specific myelodysplastic myelogenous high decrease island often irreversibly inhibitor allow therapeutic mechanism normal normal neoplastic nucleoside methylation demethylation cell cell cell cell cell drug leukaemia suppressor analogue although however replication cause dose dose toxic target result result result exact anti anti promoter treatment treatment treatment dna dna dna dna divide non acute bind syndrome expression still gene methyltransferase effect effect effect unclear preferentially death cpg replicate since actively decitabine decitabine decitabine decitabine incorporate upon approve action 
2.0@suppressor suppressor cancer resumption dnmt activity use use agent ie hypomethylating suppression myelodysplastic silence contain prevent chain treatment dna dna epigenetic action action syndrome act dnmts inhibit inhibit hence enzyme enzyme tumor tumor tumor manifestation hypermethylation due thus methylation decitabine decitabine decitabine gene gene incorporate case lead drug example 
2.0@inhibitor inhibitor class able use silence since dnmti dnmti hypomethylation make hypermethylated call island island suppress unable epigenetic strand strand pass belong dnmt methylate particular bond demethylator myloplastic cell de de tumour tumour nuceloside decitabine decitabine decitabine decitabine decitabine decitabine decitabine irreversibly methylates replication analogue reactivate incorporate incorporate result result low impossible occur hypomethylated good unfortunately dna dna dna dna dna dose syndrome dnmts cpg cpg gene methyltransferase effect epigenetically copy death division due thus methylation methylation ul ul daughter daughter work pretty enough 
2.0@dacogen cancer inhibitor inhibitor inhibitor dnmt dnmt dnmt dnmt use hematological hematological agent specific myelodysplastic since malignancy malignancy nucleotide illness affect incorporation lead lead irreversibly irreversibly strand precursor cgi tumor tumor normal life life hypermethylation hypermethylation release high daughter cell cell suppressor demythylating nucleoside dependent cause quality patient depend however fewer replication analogue improve acute toxic expectancy result low anti company good treatment dna dna divide dose dose japanese bind bind bind syndrome sell dnmts gene rapidly effect effect effect myelogenousleukemia copy increase belong methylation decitabine decitabine decitabine decitabine mainly severely side 
2.0@dacogen class activate use chemically add hypomethylating eisai silence silence hypermethylation hypermethylated inhibit inhibit suppress suppress suppress involve responsible enzyme demethylating group myeloid tumor tumor tumor tumor tumor aza produce cell cell cycle methyl formation promotion regulation agent apoptosis condition normally act prevent prevent treatment dna dna dna repressive blood syndrome sell myelodysplastic drug gene gene gene gene methyltransferase effect deoxycytidine ineffective due well methylation decitabine decitabine decitabine production form protein 
2.0@unregulated cancer cancer inhibitor restore restore within produce activity process decitabineisan member dnmti growth growth direct regulate regulate believe allow twofold tumor mechanism block normal anticancer thus major decitabineis cell cell cell cell cell cell cell firstly control blockage expression suppressor suppressor suppressor become promote antimetabolite drug cause target result number demethylate know demethylation demethylation metabolism dna dna dna dna dna divide substance cytotoxic death function gene gene gene gene rapidly effect effect interact cellular increase division division interfere new methylation methylation methylation decitabine work incorporate methyltransferase class 
2.0@dependent analogue restore may cause agent transfer apoptosis thylation critical hypomethylates hypomethylation bind inhibit dna dna dna dna dna irreversibly ase function demethylating control proliferation reduce induce methyltransferase cellular cellular normal neoplastic division hypome release nucleoside gene methylation cell differentiation differentiation methyl decitabine decitabine 
1.33@dacogen cytidine category dysfunctional produce fda use certain chemically eisai analog myelogenous japanese treat inhibit company dna dna dna epigenetic acute cytotoxic syndrome name pregnant drug myelodysplastic methyltransferase impact condition precursor antineoplastic hypo methylation methylation decitabine decitabine class class approve cell commercial blood leukaemia 
2.0@cancer cancer cannot cannot dnmt dnmt dnmt formation progress may fda myelodysplastic remain growth leukemia genesand inhibit treat greatest effective pass subsequentcell particularly inhibitor hyper impact block ion suppress nucleoside incoporated becausesuch drive suppressor therefore myelomonocytic relate spread analogue ly acute replication type tumour tumour tumour prevent prevent action dna dna dna dna blood cell cell cell bind bind syndrome inherit drug rapidly dnmts dnmts remove continue division replicate thus thus methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter daughter mitosis approve tumorigenesis comprise neth 
2.0@cancer cancer glioma class dnmt dnmt others tumour tumour tumour cycle haematopoietic also malignancy growth possibly oncogene epigentic island prevention phenotype irreversibly particularly inhibitor inhibitor enzyme expression expression expression hypermethylation hypermethylation may may repair nucleoside aberrant role program neuroblastoma cell cell cell control region suppressor analogue promote cimp imprint imprint amongst certain disinhibit apoptosis loss decitarabine anti prevent prevent prevent dna dna maintenance bind overexpression colorectal function regulatory gene gene gene methylator effect death cpg silence methylation possible protein 
2.0@erode cannot progressively geneome dnmt dnmt dnmt dnmt use irreversiblyto epigenomic treat island island island molecule disrupt area strand strand pass enzyme reduce heritability hypermethylation hypermethylation hypermethylation hypermethylation hypermethylation may genome regulator maternal cell cell cell cell tumour tumour tumour tumour tumour tumour suppressor suppressor transcription transcription epigenetic epigenetic mitotic replication replication cause reprogramming target without occur show dna dna dna dna dna dna dna bind bind inhibitor inhibitor inhibitor inhibitor cpg cpg cpg gene gene continue effect effect methyltransferase similar pre silence replicate replicate replicate methylation methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter daughter daughter eg repeatedly implantation resume small 
2.0@member suppressor inhibitor tumor tumor class reactivation produce epigenetically blood link acute condition condition find find know hypomethylation hypomethylation leukemia anti marrow treatment dna dna cell syndrome helpful contribute deform gene methyltransferase effect effect induce precursor silence turn myelogenous decitabine decitabine decitabine bone towards myelodysplatic 
2.0@dacogen cancer effect category within within produce use agent eisai myelogenous similar similar hypomethylation direct treat call decitabinealso restore irreversibly body precursor demethylating inhibit proliferation mechanism metabolism normal normal essential hypo myelodysplastic japanese may nuceloside leukaemia cause antimetabolite antimetabolite class methyl analogue acute target methylate number bind company transferase syndrome dna dna dna dna divide substance substance cell cell cell cell cytotoxic chemotherapy sell function gene rapidly dnmts induce interact cellular cellular control death belong decitabine decitabine decitabine incorporate incorporate differentiation azacitidine 
1.33@pose loss dnmt dnmt cell cell cell cell cell cell stop already make make heritable mitoticly inhibit treat epigenetic lose effective tumor tumor tumor mean normal demethylation possible remark risk faster also drug drug cause therapy unreversibly repicating dna dna dna dna dna dna mark therefor kill bind additional nescecarily effect devide contain deviding deviding mother methylation methylation methylation decitabine daughter work incorporate come return 
2.0@cancer inhibitor able methyl state manner cycle tend unmethylated catalyse inhibit suppress whereas cytosine cytosine cytosine belong unspecific island island island island island dnmt dnmt dnmt tumor tumor mechanism normal nucleotide nucleotide hypermethylation repair bond transference hypermethylated maintain cell cell cell cell control enzime enzime therefore action drug analogue revert apoptosis result result free anti group group presence covalent dna however mind degradation act cpg cpg cpg cpg cpg gene gene effect compete must keep division due silence methylation methylation methylation decitabine decitabine decitabine decitabine original form pattern tissue 
2.0@cancer cancer inhibitor enzymatic use fda agent medicine myelodysplastic myelogenous aberration genetic treat transferase inhibit effective irreversibly latter reversible help precursor especially island reduce tumor mechanism hypermethylation hypermethylation rely rely nucleoside methylated regulator methyl methyl leukaemia one dna dna dna dna dependent also fortunately residue epigenetic epigenetic replication cause cause strand ie mutation ocurring target analogue anti type tumour group several get acute bind syndrome demethylating cpg drug aml effect neoplasia result result dnmt dnmt division replicate since methylation decitabine decitabine decitabine daughter incorporate approve hence 
2.0@cancer cannot cannot restore regulation use slow break mark analog find growth sit island act act epigenetic strand help enzyme thereby tumor tumor normal nucleoside substrate cell cycle replication suppressor bond therefore drug hypermehtylated result alleviate dna dna dna dna dna dna covalent le le cpg gene gene methyltransferase methyltransferase methyltransferase methyltransferase inhibitor remove copy silence silence methylation methylation decitabine decitabine decitabine daughter irreversible incorporate form 
2.0@tumorsuppressor compound methyltransferases class available dnmt dnmt dnmt dnmt activity methyl methyl proteasome agent specific hypomethylating analog generation call absence lead cytosine epigenetic malignant transferase inhibitor inhibitor inhibitor inhibitor enzyme enzyme trap inhibit inhibit tumor isa cell catalyze promoter expression market transfer hypomethylated hypomethylated drug drug drug structure ability prove target result synthesis therapy anti limit among group particular dna dna dna dna dna dna dna dna ring histone degradation important cpg gene gene effect deacetylase belong modification silence methylation decitabine daughter region incorporate hdaci efficacious modifier 
2.0@fix dnmt dnmt dnmt administration tumour tumour novo since de growth effect anti decitabine dna dna dna involve le le inhibitor inhibitor drug drug gene methyltransferase reduce uncontrolled belong authority silence methylation methylation methylation ul ul approve cell protein food supressor 
2.0@methyltransferases dnmt faster hypomethylates dnmti inhibit nucleotide irreversibly strand inhibitor severely take take tumor affect neoplastic nucleoside cell cell replication replication specifically duplication also need analogue even healthy dosage anti good dna dna dna dna duplicate duplicate bind act dnmts irreversible methyltransferase effect effect effect upon stage thus methylation decitabine decitabine decitabine decitabine decitabine decitabine incorporate incorporate similar enough rapidly small 
2.0@inhibitor usual wide tumour tumour tumour tumour agent specific specific correct analog transcription dnmti hypomethylation transferase locus locus suppress irreversibly carry carry hypermethylation hypermethylation island island epigenome genome nucleoside demethylation may may region suppressor suppressor methylating commence whole cause decitabine decitabine decitabine target target bring shore anti methyl promoter prevent repetitive dna dna dna dna dna bind function function cpg cpg cpg gene gene gene gene rather effect remove thus allow poor incorporate methyltransferase 
1.0@also silece agent surround without amount normal neighbor dna histone decrease demethylating gene proliferation reduce tumor tumor affect hypermethylation thus decitabine cell cell supressor 
2.0@cancer cancer cause suppresor restore ocurance tumour tumour certain inhibitor agent agent promotor anti island cpg class dna dna divide common cell cell epigenetic act function demethylating gene rapidly eliminate normal hypermethylation methylation decitabine mean thereby removal belong 
2.0@cancer progressively progress use agent myelodysplastic myelodysplastic since higher treat inhibit irreversibly allow demethylating impact tumor normal normal hypermethylation cell cell cell cell much much one suppressor lower lower therefore incorporate cancerous become nucleus dna dna divide bind syndrome syndrome act dnmts time aml dependant quickly replicate go methylation methylation decitabine gene gene eventually active action would 
1.33@cancer cannot cannot class gradual dnmt dnmt dnmt dnmt dnmt dnmt dnmt use use stop growth overall restrict restrict partially restrain demethylates epigenetic strand strand strand strand strand summarize methylated device belong portion tumor tumor divide divide ont demethylation demethylation cell cell cell one faster fix however replication cause even limit fast around normally amount dna dna dna dna dna get act inhibitor inhibitor time continue rate rate copy division replicate replicate thus methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine daughter stick move move onto enough 
2.0@mitotically methyltransferases correspond restore use manner agent hypomethylating myelodysplastic analog analog currently dnmti island leukemia md incorporation normal normal precisely heritable achieve thereby inhibit reduce reduce tumor tumor tumor affect hypermethylation nucleoside myeloid demethylation lead expression suppressor suppressor cytidine cytidine cause bond mitotic certain ability cell syndrome dna dna dna dna dna dna acute covalent function function cpg gene aml inhibitor place increase treatment methylation methylation decitabine decitabine region incorporate form methyltransferase associate 
2.0@suppressor inhibitor inhibitor reactivation epigenetically tumour tumour anti myelogenous silence hypomethylation hypomethylation useful treat dna dna acute syndrome responsible myelodysplastic gene methyltransferase effect induce precursor link member decitabine decitabine case leukaemia 
2.0@suppressor suppressor cancer also class effective activate replication agent ability since dnmti anti copy island dna dna dna strand body methylated inhibitor refer cpg methyltransferase effect tumor tumor tumor assure affect repeat belong replicate silence methylation decitabine decitabine decitabine daughter cell cell disable demythylating 
1.33@hypomethylating dna dna rase run decitabine fe order hypomethylate methyl inhibit 
1.0@could certain mgmt dnmt dnmt tumour state agent cause revert since de overall help level parent rb lead dna dna dna irreversibly non consider act tumoural dnmts cpg cpg island island inhibitor inhibitor brca bind hypermethylation lower decitabine decitabine daughter gene incorporate incorporate methylation demethylation cell cell mlh replication replication methylating 
1.67@dna suppressor suppressor cancer reverse cpg gene gene hence drive tumor tumor agent deoxycytidine process silence analog decitabine decitabine region activate promoter island demethylation demethylation 
1.0@decline inhibitor inhibitor abnormal class lymphoma overmethylation healthy tumour state state state agent agent mark might experimental oversilencing inhibit response regulate epigenetic kind silence silence demethylating protein proliferation reduce reduce reduce reduce tumor tumor tumor tumor tumor tumor normal epigenome epigenome may directly like often way expression expression expression one one suppressor suppressor also also hypermethylates therefore drug drug drug mutate target result therapy anti anti anti anti confirm methyl permit group dna dna dna histone histone histone act function gene gene gene gene effect remove overactive evidence believe ezh ezh ezh thus actively decitabine decitabine em methylation methylation methylation attach alter 
2.0@suppressor cancer cancer inhibitor therefore dnmt dnmt replication become since reactivate anti hypermethylated inhibit often dna divide divide act le gene methyltransferase effect effect tumor dilution timour silence replicate methylation methylation decitabine daughter progressive lead maintain demethylation cell cell cell cell 
1.0@cancer erase agent therapy decitabine hypomethylating cell cell cell since hypomethylates stream change change generation grow stop dna dna dna epigenetic epigenetic strand pass inhibit methyltransferase effect division actively rna incorporate kill without 
2.0@cancer cancer cancer cancer methyltransferases think synthesize use include include island newly de growth leukemia md decrease inhibit often correlate promoter promoter common inhibitor allow producean causative myeloid tumor tumor block hypermethylation hypermethylation cml reexpression role cell cell cell blood supressor suppressor promote promote novo chronic activity result low differentiation differentiation differentiation anti type byslowing treatment dna dna dna dna dna maintenance dose acute syndrome myelodysplastic cpg gene gene gene gene gene gene gene aml effect believe silence silence silence methylation methylation decitabine decitabine dmnt dmnt dmnt incorporate associate premalignacies methyltransferase tumorigenic 
1.67@class able cell cell cell cell use concentration agent agent hypomethylating significantly myelogenous hypomethylates hypomethylation hypomethylation regulatory incorporation affect inhibit inhibit inhibit treat achieve sequence disruptive precursor demethylating adna proliferation dnmt disrupt apoptotic chain may myelodysplastic substrate demethylation thereby way leukaemia transcription promote promote replication cause adversely decitabine decitabine decitabine decitabine decitabine decitabine incorporate incorporate acute restoration bind presence dna dna dna dna dna dna dna dna dna dna divide synthesis synthesis cytotoxic syndrome act function gene rapidly inhibitor methyltransferase methyltransferase cellular control death belong rna rna rna activity associate differentiation protein require 
2.0@mitotically cancer inhibitor class progress tumour tumour tumour fda build myelodysplastic dnmti leukemia inhibit affect island molecule lead irreversibly enzyme thereby thereby severely myeloid mechanism normal hypermethylation usually may nucleoside drug drug cell cell way one suppressor dependent although replication replication analogue reverse exact anti anti approve treatment dna dna dna dna dna acute bind syndrome switch cpg gene gene methyltransferase methyltransferase effect effect unclear demethylation belong demethylated decitabine decitabine work active action action decatibine 
1.33@cancer cancer cause suppresor therefore drug state decitabine decitabine decitabine epicentre normal result th effect anti hypermethylated hypermethylated promoter island island treatment dna dna decrease expression expression function cpg cpg gene gene reduce tumor tumor tumor apr increase silence methylation locate toward economist demethylation level level level supressor 
1.33@suppressor suppressor commonly patient apoptosis induction process process process hypomethylating concept condition find skew reactivate reactivate exact age md reflect inhibit tumor tumor dna epigenetic epigenetic think gene gene gene methyltransferase inhibitor epigenetically mechanism elderly methylation decitabine decitabine alteration requilibrate use 
2.0@cancer cancer effect use agent whose myelodysplastic myelogenous growth treat decrease island island job stop precursor allow demethylating tumor tumor tumor uncontrolled hypermethylation cell methyl leukaemia suppressor suppressor therefore drug cause shore describe number anti group dna dna dna acute syndrome expression cpg cpg gene gene gene methyltransferase inhibitor control silence decitabine region would 
1.67@strain strain loss loss myeloid neoplasm neoplasm progress much much concentration build build specific myelodysplastic analog dnmti dnmti malignacy leukemia call island lead somatic observe observe dnmt dnmt mechanism mechanism block permanently high high shall cell cell cell cell remark may cytidine lower patient therapeutic drug identity toxic fast chemotherapeutic exposition type good treatment dna dna divide divide divide dose acute bind syndrome site inhibitor cpg methyltransferase effect effect effect probably explain due methylation decitabine decitabine tenderer work activity active protein 
1.33@cytidine become whole hypomethylated tumour manner agent specific decitabine decitabine proper analog hypomethylation susceptible make promoter prevent treatment dna dna dna non expression demethylating inhibit methyltransferase tumor result belong word genome gene incorporate tumorigenesis anti protein supressor 
1.33@suppressor act epigenome demethylating demethylating adna effect effect gene agent agent activate decitabine hypomethylation production anti tumor tumor global anddna 
1.0@different different cancer tumour tumour leukemia agent myelodysplastic myelogenous possibly depletion treat suppress dna acute syndrome precursor demethylating drug dependency hypermethylation methylation decitabine drive tumorigenesis use use supressor 
2.0@methyltransferases dnmt dnmt may activity depletion analog hypomethylation part md overall normal island irreversibly strand methylated tumor tumor affect nucleoside like like demethylation cell cell cell tumour tumour suppressor epigenetic drug carry lay anti normally promoter prevent dna dna dna divide bind inhibitor cpg gene rapidly effect effect explain replicate replicate methylation methylation decitabine decitabine decitabine heavily incorporate methyltransferase methyltransferase methyltransferase replication associate 
2.0@cancer cancer cancer effect class use use use fda agent event since dnmti hypomethylation hypomethylation decrease lead lead epigenetic even promoter inhibitor inhibitor contribute reduce key normal hypermethylation hypermethylation myelodysplastic myelodysplastic nucleoside like demethylation tumour tumour tumour expression suppressor suppressor therefore therefore irreversibly drug drug analogue anti type type occur among treatment dna dna dna bind syndrome syndrome dnmts gene gene methyltransferase rate belong silence methylation methylation decitabine decitabine decitabine work incorporate approve would would would 
2.0@cancer cancer cancer inhibitor higher available effective effective use hematological mostly find malignancy fda treat affect suppress epigenetic strand help demethylating demethylating dnmt dnmt tumor tumor normal normal hypermethylation hypermethylation rely assume many cell blood decitabine suppressor seem replication replication production permanently mean become fully deal dna bind le le still gene rate unclear try replicate methylation methylation reliant daughter work incorporate approve 
1.33@cytidine transcription restore may analogue agent hypomethylating md critical hypomethylates present hypomethylation replication incorporation normal inhibit inhibit presence treatment dna dna dna dna dna syndrome function methyltransferaseand gene chemical cellular control neoplastic myelodysplastic rna rna rna nucleoside incorporate cell cell differentiation proliferation indicate decitabine decitabine decitabine 
2.0@cancer cancer cancer dnmt dnmt dnmt progress may agent continue make replicate normal normal suppress irreversibly strand methylated methylated demethylating severely due affect affect nucleoside like passive passive cell cell cell demethylation demethylation tumour suppressor faster methylating therefore therefore replication replication replication replication demethylated become halt halt prevent somatic werereactivated dna dna dna dna dna dna dna maintenance action action bind example dnmts dnmts drug gene gene rapidly inhibitor inhibitor passively dependent new methylation decitabine decitabine incorporate root form methyltransferase would progression 
1.0@myc cancer cancer inactivate hipomethylation incorporaded produce progress use agent agent myelodysplastic silent dnmti bromodomain avoid inhibit epigenetic call involve enzyme enzyme ezh tumor nucleoside factor second methyl supressor transcription drug analogue againts target encode gene gene acetylate group treatment dna dna histone histone bind bind bind syndrome act dnmts irreversible aml consequence induce regulator decitabine decitabine time activity brd methyltransferase elevate 
1.33@suppressor suppressor suppressor therefore agent stop demethylated demethylated unchecked anti inhibit properly dna dna however methylated methylated function demethylating gene gene gene gene gene gene methyltransferase effect tumor tumor tumor tumor tumor tumor grow grow silence silence decitabine decitabine active active 
1.67@hypermethylations suppressor suppressor cancer methyltransferases restore available mode use analogue include dependent decitabine decitabine myelodysplastic myelodysplastic methylating dnmti make therefore mention island act action action treatment dna dna dna dna get tumour tumour bind syndrome syndrome le cpg gene rapidly inhibitor methyltransferase normal dnmtis dnmtis dnmtis replicate efficiently nucleoside incorporate cell cell protein replication replication associate 
2.0@suppressor suppressor dependent cannot therefore therefore dnmt methyl analogue require suppression suppression methylating dnmti hypomethylation part overall incorporation better dna dna dna dna dna irreversibly transferase bind bind inhibitor function irreversible continue dnmts tumor tumor tumor tumor tumor tumor tumor mean mean hypermethylation rely silence release nucleoside gene gene incorporate cell cell cell replication would would decitabine decitabine 
2.0@could effect effect class risk much agent hypomethylating since hypomethylation orderly inhibit achieve strand decitabines enzyme island reduce reduce tumor tumor tumor pattern affect affect hypermethylation divide divide serious lead belong suppressor faster transcription patient however drug drug drug cause throughout cell cell cell cell cell gene anti level prevent potentially dna dna dna dna dna profile promotion surround act act cpg source methyltransferase methyltransferase rate copy administer methylation methylation methylation methylation decitabine daughter time come exist side would would associate 
1.67@methyalate available use state stop drugcontains meet leukemia ya effectively molecule irreversibly methylate thishappens myeloid tumor replicate replicate nucleoside cell cell cell cell try suppressor transfer advance excessive analogue analogue cause slow cancerous become bind thedna prevent prevent prevent dna dna acute ase act gene gene methyltransferase inhibitor thesite contain silence longer methylation decitabine create incorporate 
2.0@cancer cancer instead higher class dnmt dnmt dnmt tumour spar transfer carcinogenesis degradation since dnmti dnmti dnmti hypomethylation rate hypermethylated affect unlike nucleotide weaken irreversibly get shrink thereby tumor mechanism mechanism inhibition normal normal release nucleoside daughter cell cell cell cell cell cell tolerate suppressor dependent cause high therefore activation cannot via replication analogue analogue toxic result low bond bind bind bind hence know chemotherapy dna dna dna dna divide dose dose cytidine cytidine covalent act inhibitor drug drug gene gene gene methyltransferase effect upon division division replicate silence methylation decitabine methylate em incorporate come action eg hypomethylator hypomethylator 
2.0@dna dna suppresor demethylating inhibit inhibit methyl effect tumor tumor agent unmethylted keep keep cpg methylation decitabine decitabine decitabine gene anti active transferase island 
1.33@gene gene gene cancer could class therapeutic excessive tumor tumor methyl work ch agent ability decitabine decitabine potential become hypermethylated promoter group suppress dna dna dna epigenetic inappropriately normally division demethylating island island inhibitor remove progression death belong silence methylation methylation repair region cpg cpg activate cell cell removal control would associate 
1.33@cancer cannot category dnmt dnmt get get system mark myelodysplastic analog md inhibit pull unknown epigenetic epigenetic even sequence methylated well inhibitor stick tumor tumor reason particular nucleoside aberrant like cell cell cell incorporate supressor something patient patient divide divide seem drug drug drug drug strand throughout highly become though dna dna away reverse bind syndrome act act target target gene rapidly supressing upon methyltransferase enzymatic along silence replicate regulator decitabine decitabine work activity come selectively would would class 
2.0@cancer methyltransferases growth growth dnmt dnmt cell cell cell cell cell tumour tumour tumour tumour agent stop hypomethylating inactivation alternatively hypomethylation sit island island class epigenetic inhibitor allow thereby thereby parent decabitine pattern hypermethylation hypermethylation thus role role lead lead way expression suppressor suppressor metastasis replication subsequent subsequent suppression inactivate limit prevent dna dna dna synthesis bind bind two cpg cpg gene gene gene continue continue dnmts dnmts induce copy belong main methylation decitabine daughter work incorporate 
1.0@reduction cancer inhibitor usual oncogenic deleterious effective necessary imprint imprint use cause loss specific nonspecific find malignancy dnmti dnmti hypomethylation locus locus decitabine lead dna dna however step discuss hypermethylation drug methyltransferase effect cellular progression generally methylation inappropriate case case cell may desire 
1.0@dna dna acute syndrome precursor myelodysplastic demethylating tumor tumor use effect remove agent methylaton belong myelogenous decitabine decitabine anti hypermethylated treat cell leukaemia 
0.67@cancer class dnmt dnmt progress use use use agent syndrom myelodysplastic lower treat effectively previously irreversibly transferase demethylating tumor affect nucleoside demethylation cell cell methyl dnamti dnamti analogue high seem drug drug drug cause toxic target target lately dosage dosage replication know dna dna dna dna dna kill bind bind bind point aml inhibitor must belong replicate replicate go methylation decitabine work work incorporate rapidly much much 
1.67@suppressor restore tumour myelodysplastic myelogenous agentused growth treat inhibit dna dna dna acute syndrome precursor function demethylating gene methyltransferase turn decitabine decitabine hypomethylates cell control leukaemia 
1.0@cancer cancer cancer cancer cancer inhibitor higher class dnmt dnmt synthesize process newly dnmti incorporation inhibit inhibit inhibit nucleotide lead irreversibly strand strand strand methylate methylated primary genome genome nucleoside passive cell cell cell cell drug machinery utilize epigenetic replication analogue hemi subsequent highly number number prevent prevent demethylation dna dna dna dna dna dna divide base bind bind function irreversible target dnmts methyltransferase increase belong thus methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine daughter work active protein would would would would 
0.67@dacogen cancer inhibitor company effact lymphoma celgene firm use use use cluster cutaneous process process eisai cell cell myelogenous growth susceptible methyl treat treat call call call illness lead epigenetic epigenetic epigenetic precursor cemicals chromosome research mean suppress jersey myelodysplastic many japanese trial control leukaemia one atom discover merck drug drug drug cause base base switch support acute reaction antitumour group either treatment treatment dna dna intervention mark histone syndrome sell marksabnormalities gene chemical nature acetyl rare deacetylase interfere new decitabine make plaster another protein 
1.33@suppressor cytidine methyltransferases effective therapy repressive gene inhibit prevent dna dna divide malignacies bind bind thus thus irreversible tumor pattern hypermethylation homolog methylation methylation decitabine establishment aberrant cell 
1.67@cancer analogue inhibition dnmt tumour cause tend mean probably sindrome exact anti hypermethylated especially island cpg myeloid dna dna dna dna dna irreversibly bind act inhibitor inhibitor still methyltransferase methyltransferase methyltransferase effect unclear mechanism demethylation demethylation belong due decitabine decitabine nucleoside incorporate dysplastic passive 
1.67@maybe dnmt decitabine decitabine tumor promotors novo mecanism new markts islan occur ide dna dna cpg drecreased inhibitor unclear clear strans methylation replicatin gen cell taht supressor 
0.67@growth cancer cancer category within within produce activity way agent process major similar substance substance direct call restore restore death demethylating twofold tumor mechanism block normal normal expression anticancer demethylation demethylation regulate control blockage decitabine decitabine decitabine one suppressor suppressor suppressor also promote antimetabolite antimetabolite drug cause target result number gene gene gene gene know metabolism dna dna dna divide cell cell cell cell cell cell cell cytotoxic chemotherapy function believe effect effect interact cellular increase belong interfere thus methylation methylation methylation member work incorporate class 
2.0@unregulated cancer cancer category within within produce activity use agent agent process myelodysplastic major similar growth growth part direct treat call decitabinealso restore restore death regulate regulate belong demethylating demethylating tumor mechanism metabolism normal normal expression decitabineis cell cell cell cell cell cell cell cell control blockage decitabine decitabine suppressor suppressor suppressor block promote antimetabolite antimetabolite cause target result number become demethylation demethylation chemotherapy dna dna dna dna divide substance substance cytotoxic syndrome function gene gene gene gene rapidly effect interact cellular increase division division interfere thus methylation methylation methylation allow work incorporate class 
2.0@cancer cancer proliferate therefore dnmt dnmt dnmt tumor much certain dependent cause analog anti type affect dna dna dna irreversibly action bind bind act inhibitor drug severely rapidly effect remove methyltransferase normal hypermethylation decitabine decitabine nucleoside region incorporate cell cell replication replication replication 
2.0@cancer cancer inhibitor oncogenic dnmt administration tumour tumour slow appear could already already remain selective reactivate growth oncogene decrease island island suppress suppress lead lead effective irreversibly write effectively time demethylating demethylating observe impact intergenic intergenic affect demethylated demethylated hypermethylation hypermethylation nucleoside start demethylation cell cell first region region also state drug drug analogue answer healthy suppression low become element element group repetitive repetitive dna dna dna dose danger bind least capacity dnmts cpg cpg gene gene hence effect belong epigenetics methylation decitabine decitabine work hypomethylated silence 
1.33@cancer class methyl methyl fda agent hypomethilating analog dnmti treat recognize irreversibly belong especially nucleoside cell cell cell cell fast manage one incorporeted transfer run therefore drug drug drug analogue cycle apoptosis result result th citosin arrest syndrome dna dna dna divide bind degradation act dependence inhibitor fe protein division division rase decitabine approve myelodysplasia 
1.33@suppressor cancer inhibitor class therefore overmethylation uncontrolled cause stop growth effect anti amount decrease previously dna epigenetic histone histone allow demethylating gene reduce belong silence methylation decitabine decitabine decitabine cell tumour tumour expression 
1.67@cancer cancer cancer cancer cancer article article article restore target nova use use appear epicentre myelodysplastic economist treat class epigenetic get methylated allow biochimie tumor tumor tumor normal methylaton source unusual case many cell cell example one suppressor suppressor also therefore divide fda drug drug drug drug drug drug work therapy epigenomics anti approve syndrome reason demthylation dose chemotherapy smaller function function gene gene rapidly effect effect effect remove demethylation demethylation belong decitabine decitabine decitabine em le form side side beneficial 
1.33@present activate demethylator methyl methyl methyl cause ability without associate anti group group group often dna dna expression allow gene gene gene gene effect effect remove remove unable methylation decitabine decitabine decitabine work express tumor tumor supressor 
1.67@different cancer along class issynergistic dnmt dnmt inhibitor dominate myelodysplastic analog analog instead demethylations inhibit nucleotide molecule epigenetic strand well enzyme enzyme especially island able tumor tumor tumor normal hypermethylation dilute release nucleoside nucleoside cell cell standard decitabine decitabine decitabine suppressor promote irreversibly replication replication work work work work target target multiple dna dna dna bind bind syndrome demethylating cpg multiply chemo true methyltransferase methyltransferase copy belong replicate methylation methylation allow daughter gene gene incorporate come small rapidly would would would would associate 
2.0@cancer cancer inhibitor inhibitor inhibitor standard able able dna dna hypomethylate use use include purpose hypermethylate myelogenous hypomethylates leukemia treat inhibit suppress precursor dnmt dnmt dnmt dnmt tumor tumor tumor normal hdac produce myelodysplastic ongoing cell cell cell cell may suppressor suppressor drug combination mutate subsequent apoptosis acute level syndrome kind profile non histone chemotherapy synergistic gene gene methyltransferase effect induce deacetylase division selective methylation decitabine decitabine decitabine decitabine decitabine activity return 
2.0@pronounce mean cancer instead lead term dnmt encounter yet chemically loss specific long silence analog dnmti dnmti aza unknown cytosine cytosine cytosine irreversibly development methylate methylate inhibitor enzyme deoxycytosine normal normal hypermethylation hypermethylation much role cell cell cell cell cell cell cell tumour tumour tumour tumour decitabine decitabine decitabine suppressor suppressor dependent residue residue however eventually ability incorporate typically occur could prevent dna dna dna dna divide divide bind act use target target perform gene gene rapidly effect effect effect remove unable division division thus methylation methylation allow protective regulate methyltransferase methyltransferase reactivate 
1.67@cancer cancer cancer reduce reduce therefore dnmt dnmt use analogue agent significantly result myelogenous effect effect bind treat affect affect inhibit particular act dna dna dna dna dna dna dna irreversibly myelodysplatics acute dependent syndrome syndrome precursor myelodysplastic demethylating hence hence methyltransferase rate synthesis normal normal hypermethylation rely methylation methylation decitabine decitabine decitabine decitabine decitabine nucleoside nucleoside incorporate like cell cell cell cell mild replication leukaemia 
1.33@cancer cancer cancer inhibitor class dnmt tumour tumour tumour slow likely tend tend tend mark mark dnmti possibly call island epigenetic strand transferase hyper inhibit inhibit way hypermethylation ing nucleoside many cell methyl methyl suppressor suppressor transcription patient irreversibly relate replication replication analogue improve anti anti old promoter prognosis dna dna dna dna divide rapid bind downregulate act act hall drug effect copy increase cpg new methylation decitabine decitabine decitabine work incorporate action eg would would 
0.67@abnormal abnormal restore medication produce use agent agent growth growth restrict marrow marrow inhibit treat class call help mtelodysplastic bone bone way normal normal normal hypermethylation optimum cell cell tumour level tra hypomethylation patient promote anti methyl show hypomethylated dna dna dna dna blood kill syndrome fe expression gene gene gene effect minimize rase methylation decitabine decitabine decitabine work 
2.0@demethylates regulation hypomethylate agent cycle hypomethylating promoter island damage decitabine regulate dna dna dna apoptosis cpg gene inhibitor tumor supressor belong ul ul express cell methyltransferaseepigenetic 
1.0@om cancer cancer article tod use epicentre clinically theta md treat genep epigenetic lation thy methylated difficult r affect epigenome although process may toe tab tobe drug drug clarity describe reference effect show several get name lish te inhibitor deoxycytidine explain belong decitabine decitabine decitabine economist efficacious action 
1.67@dacogen cancer cancer cancer dnmt progress tumour fda myelodysplastic since dnmti leukemia make marrow lead call disease bone myeloid normal cause affect cell cell cell cell cell replication suppressor also targetted nucleoside drug drug drug drug analogue healthy fast type type know dna dna dna get blood blood acute bind syndrome act gene aml inhibitor remove methylations death silence replicate decitabine decitabine decitabine incorporate approve methyltransferase enough 
1.33@suppressor also abnormal abnormal therefore epigenetic remove remove uncontrolled agent agent stop mark align align analog demythelating cancerous growth inhibit call prevent prevent prevent action dna dna dna dna dna hypomethylating histone bind bind act enzyme enzyme cpg island methyltransferase methyltransferase tumor silence replicate methylation methylation methylation methylation methylation decitabine decitabine nucleoside gene gene lay express express cell protein center center 
2.0@different cancer cancer cancer cancer characteristic characteristic dnmt dnmt dnmt dnmt behave activity activity methyl slow chemically agent variably hypomethylating newly find hypomethylation breakthrough treat treat transferase hinder halt effective vary consider responsible enzyme inhibit inhibit addendum research tumor source act act thus myelodysplastic nucleoside exploit treatment treatment treatment treatment occur use path methylating patient distinction analogue target target see strive fact problem lie type look severe synthesize chemotherapy dna dna dna divide divide cell cell cell cell bind syndrome recent epigenetics progress rapidly effect suggest go decitabine decitabine decitabine decitabine incorporate promise side free 
1.33@one cancer cancer inhibitor class cause decitabine decitabine next next approach find cancerous silence underlie express generation generation change promoter island cpg like provide dna dna dna get pass pass hypermethylation hypermethylation demethylating gene gene research remove demethlater belong hypermethylaton methylation methylation allow promise cell removal would tissue 
1.33@mitotically cancer cancer class epigenetic use fda agent stop stop stop since change change change anti heritable grow usa dna dna divide divide pass regulator act demethylating inhibitor tumor belong turn turn actively onto daughter methylation approve cell cell cell drug drug enzymatic decitabine 
1.33@dacogen cancer fix fix demethylates therefore dnmt activate say drug drug agent stop kill erase erase without change change hypermethylated therapy japanese occur could grow might eisay company dna dna epigenetic epigenetic pass name sell enzyme demethylating gene granddaughter affect division actively decitabine daughter cell cell cell cell tumour suppressor 
1.33@et cancer article tar class outcome produce kan tumour tumour kantarjian phase myelodysplastic myelodysplastic myelogenous economist hypomethylation hypomethylation randomize treat marrow inhibit jp issa strand precursor contribute deform link doi cell blood leukaemia suppressor iii patient c activation study drug improve april result anti pmid dna dna dna dna acute rosenfeld syndrome syndrome syndrome name inhibitor gene methyltransferase methyltransferase effect induce condition condition belong silence al decitabine decitabine decitabine bone incorporate beneficial 
1.67@dna dna dna cancer help capacity demethylating gene methyltransferase tumor agent stop decitabine hypomethylating uncontroled reactivate growth cell inhibit supressor 
1.0@cytosine cancer ctr produce independent cause cause cause agent stop hypomethylating result reaction augment hypomethylation decrease grow damage damage dna dna dna synthesis expression inhibit chemical effect cellular protein death belong anticancer thus methylation methylation decitabine decitabine cell global 
1.33@inhibitor class reactivation produce aprecursor blood link induce tohypomethylation decitabine decitabine lation condition myelogenous leukemia useful treat marrow antitumour syndrome dna dna case acute particularly silence deform gene methyltransferase effect tumor belong turn thus contribute bone epigenetically hypo cell myelodysplatic supressor 
1.0@lower may cluster cohesion low make demethlation enhancer island glycosylases promoter dna dna dose decrease bind act mc methyltransferase inactive belong chromatin methylation decitabine ctcf cpg passive protein level level 
2.0@unregulated cancer cancer inhibitor restore restore within within suppressor suppressor produce agent process major growth growth direct call category epigenetic interfere rapidly consider modulate demethylating bodily tumor tumor mechanism normal normal expression govern cell cell cell cell cell cell cell cell control belong dna dna dna dna dna promote antimetabolite profile drug cause decitabine decitabine target result number anti contain know stoppage divide substance substance cytotoxic chemotherapy function function gene gene gene methyltransferase effect effect interact similar increase division division modification thus methylation methylation methylation allow work death modifier follow 
2.0@cancer inhibitor inhibitor inhibitor inhibitor disrupt dnmt dnmt use process analog incorporate growth part call call molecule class class class class class class epigenetic help hyper tumor tumor tumor permanently may nucleoside cell cell cell cell drug machinery one suppressor suppressor hypomethylation subset excessive via replication cause limit prevent dna dna dna dna dna dna dna dna non reverse bind function gene gene gene gene target enzyme enzyme line belong belong silence silence silence methylation methylation methylation methylation methylation decitabine decitabine decitabine decitabine lay methyltransferase methyltransferase small 
1.67@dna dna suppressor suppressor could could demethylating cpg parent tumour tumour tumour effect remove agent silence turn methylation decitabine daughter gene gene anti exert cell island demethylation 
1.67@suppressor cancer transfer promote use cause agent result unmethylated anti treat group class dna dna dna dna epigenetic methyl inhibitor epigenome demethylating gene gene methyltransferase reduce reduce tumor tumor nhibiting belong may methylation methylation decitabine decitabine decitabine decitabine production protein expression 
1.33@several several cancer cancer activation tumour mark express lose lose back mention island lead dna epigenetic decrease wich example act silence drug gene gene paper cpg cpg go methylation methylation decitabine overgrow demethylation cell may supressor 
1.33@cancer cancer hypomethylation effective supression supression methyl slow agent stop hypomethylating become become since since adenyne part island island act decitabine decitabine cytosine hypomethylated methylated methylated attack inhibit inhibit reduce tumor tumor tumor tumor tumor methylation methylation cell cell cell supressor one one also fight cause add side express demethylate vulnerable prevent prevent treatment dna dna dna dna dna dna process nucleotoides group chemotherapy le cpg cpg hence methyltransferase methyltransferase allow allow grouth inside gene gene activity return previous would would would would 
1.0@cancer cancer inhibitor inhibitor hasadditional essentially dnmt use concentration myelodysplastic analog myelogenous azacytidine dnmti higher treat inhibit nucleotide irreversibly strand strand around precursor replicate normal release nucleoside cell drug drug drug leukaemia one compare faster irreversely replication hypomethylates decitabine decitabine decitabine mean anti traditional good dna dna dna dna dna dna dna get acute bind bind bind syndrome methyltransferase methyltransferase methyltransferase methyltransferase methyltransferase along along upon copy belong modification since methylation longer daughter work incorporate incorporate come come action tissue 
2.0@cancer cancer inhibitor think class dnmt dnmt progress use whose myelodysplastic analog since dnmti methyl hypermethylated treat transferase inhibit inhibit inhibit back molecule cytosine irreversibly methylate enzyme island island happen tumor tumor tumor rapidly normal hypermethylation turn inhibitsenzymes nucleoside regulator cell cell cell drug suppressor suppressor suppressor specifically dependent also become therefore epigenetic need target target target demethylated therapeutic replication antitumor promoter dna dna reverse bind syndrome act function cpg cpg cpg cpg gene gene gene aml effect first belong replicate silence methylation decitabine decitabine decitabine decitabine region region incorporate tumorigenesis selectively follow small 
0.67@strain cancer cancer inhibitor higher term dnmt dnmt administration progress methyl fda could could long become analog lower leukemia transferase copy disruptive consequence mechanism normal neoplastic nucleoside affect affect good cell cell cell cell use food myelodysplasic also understand high get replication replication cause cause toxic yet low anti fully know though dna dna dna divide dose dose acute bind bind syndrome act important drug drug drug drug drug irreversible side effect effect effect effect upon ratio selective methylation decitabine daughter incorporate come approve myelod 
2.0@blewitt mitotically cancer cancer inhibitor restore dnmt dnmt dnmt tumour tumour tumour agent myelodysplastic myelogenous economist reactivate leukemia inhibit cytosine irreversibly strand variety hyper demethylating observe take impact heritability normal normal feature precursor thus directly nucleoside express human rapid suppressor suppressor specifically dependent become therefore therefore replication analogue analogue frominside acute target reverse anti normally parent parent amp potentially dna dna dna dna dna cell cell cell cell cell cell bind bind syndrome act cpg gene gene methyltransferase effect upon upon upon copy division division additionally continually methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter daughter would 
2.0@inhibitor commonly dnmt dnmt use hematological appear appear agent elucidate myelodysplastic myelogenous malignancy dnmti find treat consistent inhibit fully irreversibly pass decitibane precursor demethylating cgi reduce reduce reduce tumor tumor tumor mechanism normal neoplastic hypermethylation nucleoside role primarily cell cell blood suppressor suppressor suppressor leukaemia compound specifically dependent dependent dependent lower large disorder therefore replication replication analogue toxic timor anti anti consist amount nonspecific dna dna dna dose dose dose acute bind syndrome gene gene methyltransferase effect effect effect effect effect upon minimize thus methylation methylation decitabine decitabine decitabine decitabine daughter incorporate action side 
1.33@dna histone group demethylates inhibitor enzyme enzyme gene drug effect suppress silence anti surround decitabine methyl tumour tumour inhibit attach 
2.0@cancer cancer classify dnmt dnmt dnmt dnmt methyl agent epigenitic normall inhibiter hypermethylated transferase inhibit molecule nce strand hemimethylated well demethylating take reduce tumor tumor tumor block high substrate like cell cell cell cell cell drug machinery machinery one suppressor suppressor methylating irrevesably divide methylates replication work toxic target result low dosage glimoas normally supress level epigenic dna dna dna dna dna dna maintenance kill bind act site expression gene gene gene methyltransferase inhibitor replicate thus methylation methylation decitabine decitabine decitabine daughter dmnt dmnt active tumorigenesis incorperated small 
2.0@instead specifically methyl methyl methyl hematological malignancy hypomethylation note make transferase transferase inhibit dmnts dmnts irreversibly decrease decrease well source inhibitor group tumor tumor tumor tumor hypermethylation like onto expression suppressor suppressor dependent dependent replication cause cause decitabine decitabine decitabine product dosage express become amount lecture prevent develop dna dna dna dna dna bind bind trasfer dmnti dmnti gene gene aml think time increase longer methylation methylation allow work incorporate would 
2.0@myc dacogen lymphoma regulation methyl agent agent jq hypomethylating inactivation myelogenous hypomethylates treat call call inhibit inhibit inhibit usedto jam dash accordin responsible responsible enzyme enzyme demethylating prevent prevent reduce tumor tumor block precursor dhanak myelodysplastic deactivation second attachment human compound compound suppressor suppressor adna acute approach lot methylation bradner show group syndrome dna dna dna histone histone cure act sell function gene gene gene methyltransferase inhibitor overactive ezh thereby dr dr activity brd protein gsk 
2.0@inhibitor inhibitor lower dnmt dnmt dnmt dnmt agent agent stand hypomethylating myelodysplastic myelogenous de substance dosis call treat epigenetic promoter precursor demethylating demethylating tumor give high role level also dosage therefore drug novo suppression low leukeamia antitumor toxic prevent dna dna maintenance maintenance acute syndrome important gene methyltransferase effect methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine come play 
2.0@dacogen cancer cancer tumour intravenously chemically myelodysplastic analog dnmti hypomethylation leukemia md treat marrow inhibit aza epigenetic bone myeloid act use market enzymatic cytidine also consequently drug cause cause reverse encourage anti know dna dna blood acute syndrome name dnademethylation aml deoxycytidine administer thus methylation decitabine methyltransferase 
1.33@cancer myeloid never dnmt dnmt dnmt progress use use myelodysplastic since dnmti leukemia transferase island nucleotide effective irreversibly strand belong outcome tumor affect hypermethylation release nucleoside demethylation cell one dna dna dna analogue depend depend replication replication cause mean condition low come become group treatment reason dose acute bind bind syndrome cpg poor aml aml aml inhibitor methyltransferase methyltransferase copy administer replicate methylation decitabine daughter incorporate widely action rapidly 
2.0@fail cancer cancer methyltransferases dnmt get may may may viable exhibit maximum analog since insult inhibit achieve irreversibly pass survive thereby island able tumor tumor normal hypermethylation nucleoside cell cell cell cell cell cell cell drug dna dna dna dna dependent therefore therefore epigenetic epigenetic replication certain result tightly anti prevent prevent family treatment several divide four bind example inhibitor inhibitor cpg rapidly effect effect remove belong undergo methylation decitabine decitabine daughter daughter mitosis incorporate original action methyltransferase 
1.0@mode dependent class therefore epigenetic synthesize tumour tumour activity mark irreversibly result anti bind drug show action dna dna dna dna dna dna divide transferase transferase transferase step available act act newly get severely rapidly effect upon normal division division copy methylation methylation decitabine decitabine decitabine nucleoside incorporate incorporate cell cell cell cell methyl methyl methyl replication belong 
1.67@cannot dnmt dnmt activate activate tumour tumour tumour inespecific myelodysplastic analog myelogenous dnmti hypomethylation treat avoid irreversibly strand precursor proliferation pattern affect altready nucleoside cell cell cell cell use leukaemia market suppressor dependent therefore replication cause normal methyl group dna dna dna dna divide acute bind bind syndrome expression expression drug gene gene methyltransferase inhibitor upon copy division thus methylation decitabine decitabine decitabine decitabine daughter incorporate incorporate 
2.0@cancer rate class dnmt dnmt methyl methyl order dnmti dnmti dnmti hypomethylation hypomethylation tsg incorporation transferase transferase island island nucleotide lead lead irreversibly strand strand thereby thereby severely activation tumor affect neoplastic nucleoside cell cell cell rapid suppressor dependent silent get replication analogue normal bring bring ultimately anti prevent cpg cpg dna dna dna dna dna divide bind bind act expression drug gene gene inhibitor copy belong replicate replicate replicate methylation methylation decitabine decitabine decitabine decitabine daughter daughter much incorporate come action would 
1.33@vivo cancer remove way chemically tend transfer azacytosiine unmethylated unmethylated inhibit inhibit aza often cytosine cytosine irreversibly strand methylated methylated enzyme island dmt dmt normal phosphorated mititically create triphosphate cell methyl methyl methyl tra transcription run cause hemi property location demethylated cancerous gene gene normally region promoter group dna dna dna dna dna dna azacytosine loose bind bind least fe inherit short multiply inhibitor deoxhcytidine condition cpg cpg cpg rase decitabine em incorporate free 
1.0@dacogen cancer cancer cannot lymphoma use use agent stop stop stop myelodysplastic myelogenous silence silence silence growth growth growth make treat call inhibit inhibit inhibit inhibit epigenetic epigenetic precursor enzyme enzyme enzyme demethylating uncontrolled uncontrolled uncontrolled anymore cell cell cell tumour tumour tumour tumour tumour leukaemia one suppressor suppressor suppressor suppressor also methylates methylates drug cause cause acute mutation result lot anti prevent dna histone histone histone syndrome sell inhibitor gene gene gene gene gene effect overactive ezh ezh ezh ezh thus thus thus methylation decitabine decitabine decitabine decitabine possible activity active overactivity protein 
2.0@alt effect say agent agent hypomethylating img reverse reactivate anti exert src inhibit supress previously dna dna dna dna dna epigenetic cell inhibitor inactivate demethylating gene gene methyltransferase reduce tumor active generate increase silence thus methylation methylation methylation decitabine decitabine aberrant incorporate triphosphate tumorogenesis form tumour level supressor 
1.33@suppressor transfer abnormal therefore apoptosis tumour tumour cause cause agent restoration ly hypermethlated meet gene gene anti methyl group dna dna hypomethlating ase act function inhibit proliferation effect remove cellular normal allow possible cell differentiation control decitabine decitabine 
2.0@cancer available dnmt dnmt dnmt dnmt dnmt use use could could mark overall hemimethylated island irreversibly strand strand strand pass methylated methylated within silence reduce reduce reduce reduce hypermethylation nascent nucleoside nucleoside nucleoside cell cell tumour tumour suppressor suppressor methylates analogue analogue analogue subsequent mean result reactivation amount amount amount promoter dna dna dna get bind bind example cpg gene gene inhibitor template division longer new methylation methylation methylation methylation decitabine decitabine decitabine region incorporate 
2.0@loss inhibitor inhibitor inhibition inhibition class dnmt dnmt transcriptional use mark mark mark myelodysplastic de treat island suppress lead lead epigenetic strand methylate enzyme perpetuate tumor tumor tumor tumor tumor tumor hypermethylation apoptotic proliferative proliferative aberrant signal passive cell cell cell cell removal expression suppressor result result reactivation ultimately maintain anti anti promoter example dna dna dna dna dna dna syndrome function cpg gene methyltransferase effect effect advantage copy reversal belong replicate silence silence methylation methylation methylation methylation methylation decitabine decitabine daughter region active protein would would 
1.33@ligand cancer cancer able relate tumor drug andhas agent pathway hypomethylation show tnf lead dna apoptosis expression demethylating adna activation induce induce induce induce silence apoptotic decitabine gene cell cell selectively suppressor 
0.67@cancer cancer cancer certain certain demthylates sometimes demethylator tumour cluster agent cause cause part anti unmethylating know prevent prevent class dna dna dna epigenetic form form inhibitor gene effect belong show new new methylation methylation decitabine decitabine decitabine demethylation cell cell 
1.33@cancer promote dnmt drug drug certain fda tend irreversibly analog dnmti encourage anti type prevent demethylation action action treatment dna dna divide divide body bind particularly efcient rapidly effect tumor tumor mechanism normal division actively decitabine nucleoside incorporate methylation approve cell cell cell cell continue class 
1.0@cancer cancer methyltransferases class dnmt dnmt preserve fda mechanism mark mark since de susceptible exert chemotherapeutics irreversibly strand body inhibitor belong thereby methylome block normal neoplastic give render aberrant cell cell cell cell cell cell drug drug dependent greater nucleoside replication analogue progeny pas novo fashion subsequent dna dna divide bind act le rest rapidly effect effect must copy antineoplastic division replicate capable methylation methylation decitabine decitabine daughter incorporate approve action tissue 
1.33@cancer cancer cancer target model use use exposure concentration attempt event currently malignancy reactivate change leukemia md treat treat inhibit response clinical epigenetic epigenetic obtain correlate myeloid tumor aza aza aza aza aza aza aza investigation schedule aberrant potent cell trial drug suppressor patient frequent require preclinical preclinical therapy cdr cdr cdr cdr cdr cdr data data reversible gene type show analyze analyze good dna dna dose acute syndrome eradicate stem animal myelodysplastic aml deoxycytidine antineoplastic silence methylation methylation decitabine time activity review 
2.0@methyltransferases abnormal methyl state appear agent stop mark analog find reactivate growth growth hypermethylated incorporation transcriptionally irreversibly sequence methylated demethylating tumor tumor pattern demethylation demethylation cell cell cell cell cell may supressor cytidine cease cause decitabine decitabine result pass without return dna dna dna replicate kill bind bind gene methyltransferase remove division mother methylation rna daughter incorporate active 
1.67@mean cancer cancer inhibitor dnmt dnmt methyl analogue frequent irreversibly action alleviate strongly become transferase transferase prevent prevent molecule molecule dna dna dna divide get bind bind quickly drug inhibit target effect hypermethylation release nucleoside incorporate case cell cell replication replication decitabine 
2.0@cancer cancer rate term progress use use fda could tend myelodysplastic since dnmti leukemia resist oncogene tumour tumour affect decitabine decitabine epigenetic inhibitor belong severely myeloid put permanently neoplastic give give fact vital nucleoside maintain demethylation demethylation cell cell cell cell methyl supressor risk dependent analogue high fight drug drug cause stability appropriate appropriate cancerous anti anti dnmtis prevent protect family treatment dna dna dna dose acute bind syndrome fe dnmts gene aml effect effect stage division division due rase methylation methylation genome genome tumourigenesis incorporate approve tra methyltransferase 
1.0@correlate myeloid drug inhibitor agent agent myelodysplastic acute acute leukemia myelogenous treat epigentic dna dna histone syndrome precursor enzyme enzyme demethylating demethylating aml hmts chromatin thus decitabine work modify methyltransferase leukaemia 
1.33@cancer methyltransferases irrevocably dnmt dnmt dnmt dnmt use utilize myelogenous de unmethylated useful decay recognize strand methylated methylated establish inhibitor impact tumor pattern myelodisplastic neoplastic early outmost nucleoside case demethylation cell methyl leukaemia suppressor analogue indeed consequently drug cause cause cause development development hemi novo lay low anti bind group later dna dna dna dna dna dose acute wich syndrome important hence dnmts methylation decitabine decitabine daughter work incorporate embryonic haematological 
1.33@cancer think class dnmt use mostly myelodysplastic since generation generation clinical epigenetic strand strand lose well especially parent way effective mechanism dnmtis hypermethylation although case demethylation cell trial tumour machinery study duplication irreversibly seem drug therapy decitabine decitabine decitabine target type prevent dna dna dna dna dna dna dna transmit bind syndrome act still methyltransferase inhibitor belong methylation methylation reliant daughter incorporate heavily 
1.33@dna dna dna transferase restore function differentiation methyl demethylater gene cellular normal methylation decitabine cause proliferation hypo inhibit control 
1.67@cancer improper higher dnmt dnmt dnmt dnmt likely specific malignancy progressively decrease inhibit inhibit nucleotide lead irreversibly hemimethylated methylated enzyme demethylating island enhance outcome tumor tumor nucleotid normal hypermethylation high affect thereby cycle drug drug suppressor suppressor decitabine hallmark transcription methylates replication region region ability agent result analogons gene gene become display level prevent dna dna dna dna dna expression promotor cell cell cell cell cell bind bind le site function cpg irreversible methyltransferase inhibitor belong replicate replicate methylation longer could active hit 
1.33@elod plastic erase erase future agent specific mark mark anti myelogenous hypomethylates without useful treat eradicate dna epigenetic acute syndrome precursor demethylating generation effect tumor tumor tumor tumor mean thus decitabine decitabine y return cell cell cell kill leukaemia 
2.0@elod plastic cancer cancer restore suppressor suppressor start tumour agent specific intervene myelogenous growth growth treat inhibit inhibit inhibit lead lead precursor enzyme demethylating tumor tumor mechanism mechanism normal expression generally style crucial nucleoside align regulate use leukaemia specifically justify also drug analogue text switch y result acute anti type show dna dna dna dna dna dna divide cell cell cell cell syndrome function gene gene gene gene gene rapidly effect describe control control increase division silence methylation methylation methylation methylation decitabine decitabine decitabine work mean various methyltransferase 
1.0@suppressor suppressor tumor tumor tumor tumor interaction myelosplastic use agent agent stop island island cell result demethylated fashion reactivate growth growth growth hypermethylated treat group dna dna dna action lead open divide histone syndrome strength expression demethylating demethylating grow reduce reduce remove chromatin cpg cpg silence exaggerate gene gene gene gene gene express many restriction restriction methyl decitabine decitabine 
1.33@aspect dacogen cancer cancer restore last use agent agent pattern already two japanese island island act act correlate epigenetic epigenetic epigenetic promoter display silence demethylating demethylating research tumor accord instability aberrant treatment market suppressor fight alteration drug syndrome level genomic company dna dna dna correct cell cell example sell myelodysplastic cpg cpg gene hypermetilation hypermetilation hypermetilation belong due main methylation decitabine decitabine decitabine deregulation numerous tissue 
1.67@suppressor cancer tumour agent epicentre myelodysplastic result myelogenous reference note incorporation lecture inhibit reverse dna dna irreversibly acute bind syndrome dnmts demethylating prevent hypermethylation silence decitabine gene limit progression leukaemia 
1.67@elod plastic cancer cancer inhibitingdna class suppressor use drug otherwise hypomethylation tumour call prevent suppress treatment dna dna kill syndrome hypermethylation demethylating gene might reduce methyltransferase belong methylation allow y express cell cell control would decitabine decitabine 
2.0@cancer cancer proliferate higher class reactivation aka tumour tumour appear appear appear spar process toxicity dnmti hypomethylation hypomethylation inhibition effectively previously lead lead lead targetting epigenetic cellular bear responsible enzyme demethylating observe proliferation effective blood hypermethylation may mode although insensitive demethylation demethylation whereas control pharmaceutical belong suppressor ideal range non relatively relatively low level division dna dna dna dose dose cell cell cell expression inhibitor gene gene gene methyltransferase effect systemic rapid silence silence decitabine think action differentiation 
1.0@suppressor cancer add agent epicentre bring hypomethylation back lecture chemotherapy dna dna histone methylated video gene effect tumor deacetylase turn decitabine work demethylation 
2.0@cancer cancer cancer incident dnmt dnmt use include likely tend dnmti dnmti hypermethylated treat inhibit lead irreversibly methylate happen tumor question affect affect affect demethylation cell cell cell replication replication dna dna certain depend seem drug drug cause mean decade become definition several bind least expression gene gene gene gene gene gene methyltransferase supressing quickly replicate decitabine work incorporate form 
2.0@dependent cause daughter irreversibly tumor methyl methyl methyl methyl analogue inhibitor along dnmti possibly replication transferase transferase transferase transferase nucleotide action dna dna dna dna dna dna divide strand get bind bind act act well division drug drug rapidly effect upon normal belong longer copy methylation release nucleoside incorporate come demethylation cell cell much decitabine decitabine 
1.67@cancer cannot class dnmt dnmt dnmt dnmt dnmt dnmt failure replication replication analogue agent appropriate irreversibly result result demethylated anti bind hemimethylated action dna dna dna dna divide dose methylate methylate daughter daughter lay inhibitor inhibitor function demethylating demethylating rapidly effect affect neoplastic replicate methylation decitabine decitabine decitabine nucleoside incorporate cell cell cell first 
2.0@critical inhibition restore formation use agent myelodysplastic proliferate cytotoxicity hypomethylation hypomethylation treat adduct lead precursor demethylating proliferation normal neoplastic may may phosphorylation directly insensitive cell cell cell tumour leukaemia also cause apoptosis relatively gene anti syndrome dna dna dna dna dna dna divide non acute covalent function hence rapidly effect induce cellular cellular control myelogenous decitabine decitabine decitabine decitabine decitabine attribute incorporate incorporate differentiation differentiation methyltransferase methyltransferase 
1.67@cancer inhibitor dnmt dnmt activate progress use use could myelodysplastic analog myelogenous malignancy leukemia treat affect inhibit nucleotide irreversibly strand get concern matter normal demethylation cell cell cell cell cell cell blood divide divide replication cause suppression low hence tumour tumour dna dna however dose acute bind syndrome act act act drug drug drug drug drug gene aml effect upon methyltransferase methyltransferase copy division thus methylation decitabine daughter em incorporate rapidly 
1.67@dependent inhibitor class dnmt dnmt use drug drug decitabine decitabine decitabine island target result low hypomethylates dnmti dependend might inhibit methyltransferase longer treatment dna dna dna dna dna irreversibly dose action bind syndrome dnmts dnmts cpg myelodysplastic demethylates effective probably hypermethylation replicate methylation release incorporate demethylation cell replication belong 
2.0@cancer cancer methyltransferases restore restore progress use leave agent process myelodysplastic analog currently irrevesibly leukemia treat marrow inhibit might lead lead cytosine cytosine see silence demethylating island normal normal hypermethylation hypermethylation act like cell cell cell cell cell cell dive tumour tumour suppressor cytidine also suppresor antimetabolite untreated drug cause incoprorated become become promoter counter dna dna dna dna dna dna dna base toxicto bind syndrome syndrome resemblance function cpg gene gene rapidly effect bone control control death death especially especially interfere methylation methylation decitabine decitabine decitabine decitabine deregulation region incorporate hence hence 
1.0@standard cancer article tumour work hypomethylating make result hypomethylates yet susceptible anti completely decrease inhibit treatment dna dna dna however author sure chemotherapy target drug drug methyltransferase effect contribute methylation decitabine decitabine speculate successful mean cell may 
1.0@cancer proliferate within dnmt dnmt use specific thank myelodysplastic ipso de negative rate rate transferase facto irreversibly see inhibitor think way mechanism block neoplastic hypermethylation may thing nucleoside level maintain cell cell methyl sufferer lower lower high high however drug analogue dose dose toxic mean condition pass anti occur occur novo good dna dna dna dna substantial non action bind syndrome historically function cpg effect effect unclear thus methylation methylation methylation decitabine decitabine decitabine daughter much much incorporate form onto operate 
1.67@cancer cancer cause dnmt methyl analogue analogue target since dnmti problem transferase dna dna divide bind act function perform inhibitor permanently keep hypermethylation decitabine nucleoside nucleoside work demethylation cell cell 
2.0@dacogen cancer cancer article class use use include agent epicentre eisai myelogenous economist hypomethylation leukemia treat treat inhibit lead epigenetic epigenetic tumour precursor enzyme demethylating impact affect epigenome myelodysplastic name may dna dna dna dna identify drug drug drug drug drug accomplish describe describe describe reference inhibitor anti know group genomic declitabine syndrome several process acute point sell function methyltransferase effect effect explain anwer belong belong methylation methylation decitabine decitabine decitabine decitabine follow 
1.33@fail cancer cancer cancer inhibitor inhibitor inhibitor inhibitor able model use use agent specific specific myelodysplastic myelogenous dnmti marker acessibility hypermethylated treat grow grow molecule epigenetic epigenetic epigenetic disable reversible demethylating island severe reduce key develop develop factor side cell cell blood sufferer leukaemia older transcription live patient patient format drug drug improve therapy therapy therapy target acute become vulnerable solid tumour tumour damage dna dna histone bind bind syndrome le function cpg methyltransferase effect must chromatin replicate new actively decitabine decitabine decitabine work modifier small 
2.0@suppressor code code class class determine tumour tumour tumour cause agent result hg hg reactivate effect anti inhibit dna dna example eliminate demethylating gene gene gene methyltransferase inhibitor tinymce tinymce methylation decitabine decitabine drug expression expression 
1.67@myc myc different cancer cancer suppressor dna dna dna institute methyl agent aim jq jq two epimutations myelogenous hypomethylates hypermethylation hypermethylation substance substance substance treat call inhibit inhibit inhibit might ready epigenetic reversible precursor enzyme demethylating prevent dana research tumor block generally glaxosmithkline factor gsk gsk cell trial control leukaemia market interest transcription epigenome consequently disease drug drug drug neither therapy cycle target describe acute encode could could group group group develop develop farber several however histone syndrome use myelodysplastic gene methyltransferase effect upon result protein loss human modification since decitabine decitabine em em activity activity brd attach alter alter azacitidine 
2.0@especially cancer cancer cancer player breast dnmt dnmt regulation use dnmts dnmts dnmts include mutation aberrantly carcinogenesis dense major hypomethylates de hypomethylation genetic grow cpg cpg achieve alteration alteration epigenetic strand reversible island particularly establish silence silence demethylating unlike tumor tumor key normal hypermethylation anticancer aberrant attractive many lead may promoter suppressor suppressor transcription fortunately therefore seem drug instability therapy agent target restoration inhibitor inhibitor become type show colon genomic potentially dna dna decitabin cell bind overexpression function dinucleotides gene gene gene reexpression stomac hand lung since methylation decitabine region incorporate promise covalently associate 
2.0@different cancer classify activate induce use include exhibit hamper acta since reactivate leukemia leukemia myelogenous treat decrease decrease inhibit expression expression cytosine level source demethylating demethylating demethylating island proliferation myeloid tumor tumor tumor tumor biochim hypermethylation directly trail gsk doi cell cell may jan suppressor suppressor rise therefore drug drug agent agent pathway acute acute biophys anti methyl know group external dna dna dna dna dna apoptosis base histone syndrome act myelodysplastic cpg gene gene gene effect remove oct new methylation methylation decitabine decitabine decitabine decitabine give epub 
1.67@myeloid class irreversibly progress tumour analogue acute therapy subsequent anti myelodysplastic currently without tra generation treat prevent action dna dna dna epigenetic sequence bind syndrome use enzyme drug inhibit effect fe affect affect belong rase methylation decitabine nucleoside cell methyl replication leukaemia 
2.0@cancer cancer cannot progressively dnmt dnmt tumour tumour agent shore mark inactivation remain find dnmti growth possibly stably heritable affect island island island cpg cpg cpg surround effective irreversibly strand strand rapidly methylated hypermethylation hypermethylation demethylating able tumor normal link consequently nucleoside nucleoside many cell cell cell cell cell supressor also analogue epigenetic replication cause decitabine decitabine decitabine decitabine decitabine demethylated without anti normally supress dna dna dna dna divide kill bind act act wash poor aml inhibitor upon methyltransferase preferentially copy division division replicate methylation methylation methylation outcome daughter daughter daughter gene gene incorporate attach 
0.67@dna irreversibly dependent brinds therefore inhibitor dnmt dnmt replication analogue decitabine nucleoside incorporate 
2.0@cancer methyltransferases inhibition slowly suppressor use trap aberrantly depletion analog regard growth potential inhibit aza lead lead inhibitor silence activation raise normal normal genome genome nucleoside case minimal cell cell cell cell cell cell cell cell tumour tumour tumour decitabine decitabine decitabine dna dna dna dna dna dna dna dna divide divide divide divide replication cause ability toxic cdr relatively anti treatment reduction reduction however act target drug gene rapidly effect effect effect induce result global concern methylation methylation methylation methylation inside mainly wide incorporate incorporate onto 
1.67@cancer cancer effect effect effect higher class dnmt tumour tumour tumour tumour dnmts agent become currently inherit make hypermethylated treat decrease decrease groth lead epigenetic epigenetic speed inhibitor demethylating many inactive count although affect affect demethylation cell cell cell cell cell much machinery machinery one suppressor therefore replication cause ability cycle unmethylated express anti develop dna dna dna dna get bind death important drug drug gene hence rate increase due methylation methylation decitabine mitosis mean 
1.67@tumorsuppressor dacogen cancer cancer cancer cancer inhibitor divinding progress use appear agent dnmti unmethylated treat dmnt inhibit pleiotrop epigenetic strand rapidly rapidly hypometilaging remethylation normal cytidine allele nucleosid dive replication replication dependent irreversibly fda drug drug analogue side anti dna dna dna dna cell cell cell cell cell bind syndrome le acitvated aml effect effect effect effect division myeloidpalstic new decitabine gene incorporate approve methyltransferase methyltransferase totally 
2.0@dna dna suppressor expression demethylating gene tumour reduce agent cpg methylation reactivate case active island demethylation decitabine 
1.67@suppressor cancer transfer uncontrolled specific meet stop growth gene inhibit dna dna dna ase silence ezh observe inhibitor tumor hypermethylation methylation methylation reduce reduce region cell decitabine decitabine 
1.67@mitotically effect effect effect effect effect class class effective tumour tumour tumour include agent generation generation make heritable call inhibit lead epigenetic epigenetic pass inhibitor inhibitor hyper demethylating impact dns normal normal nhibiting hypermethylation apoptotic demethylation cell cell cell cell may may turn turn identify erase system subsequent subsequent describe describe surround surround demethylate treatment dna dna dna segment function function anti anti gene gene methyltransferase supressing increase belong belong methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine daughter region region 
1.67@dacogen cancer critical restore suppressor decibatine methyl fda hypomethylation epicentre eisai result genessuch trade growth inhibitor company transferase inhibit action lead dna dna japanese name sell function acton gene reduce tumor normal source methylation decitabine decitabine economist cell control 
2.0@strain kind cancer effect daughter use analogue inhibitor dnmti anti treat prevent rase dna dna dna dna irreversibly bind fe dnmts drug reduce tumor tumor thus methylation methylation decitabine nucleoside incorporate methyl replication tra 
2.0@cancer cannot class essentially dnmt dnmt dnmt much fda since since lead epigenetic strand methylated inhibitor belong affect affect ensure nucleoside nucleoside demethylation degree replication replication machinery one one greater release therefore therefore divide divide divide drug drug analogue analogue hemi target occur dna dna dna dna dna dna maintenance cell cell cell cell cell bind bind function rapidly thebody copy division methylation methylation decitabine daughter mitosis incorporate approve action methyltransferase require 
2.0@dna dna dna dna critical restore tumour tumour hypomthylates island since hypomethylation hypermethylated treat call inhibit class compare epigenetic demthylating function cpg gene proliferation inhibitor inhibitor induce methyltransferase methyltransferase cellular normal belong may decitabine decitabine cell differentiation control 
1.33@cancer reduce get replication slow agent growth completely inhibit dna dna dna dna irreversibly bind function demethylating asociated dnmt tumor copy hypermethylation replicate thus methylation decitabine daughter incorporate cell 
1.67@suppressor restore use cause agent myelodysplastic result myelogenous gene gene gene treat grow suppress suppress regulate dna dna dna dna development acute help syndrome precursor belong demethylating inhibit inhibit reduce tumor tumor tumor tumor normal keep division due methylation methylation methylation methylation decitabine decitabine aberrant activity activity express hypo cell cell cell leukaemia 
2.0@one market methyltransferases hypomethlyation able hypomethylated use drug drug drug drug agent stop island island myelodysplastic find cancerous cancerous growth gene hypermethylated treat promoter grow predecessor epigenetic often dna dna divide rapidly syndrome two demethylating affect proliferation demethylizes induce induce particular cpg cpg decitabine decitabine work inhibit cell cell cell differentiation pre would leukaemia 
1.0@dacogen use state appear agent processis de hypomethylation treat methyltransferaseattempts island aza speed copy demethylating block block normal may release successful express cell cell cell cell cell methyl suppressor dependent anucleoside replication replication analogue bedependent unblock genessilencing become completely tumour tumour hypomethylated id oxy dna dna however hypo bind bind zac absorb atinga rapidly place gent replicationtakes cpg cpg replicate methylation methylation methylation decitabine decitabine daughter possible return aml aml whendnmt 
1.67@cancer neoplastic specificity dnmt dnmts agent find dnmti epigenetic well respond inhibitor severely inherent lack life life regulator hypo tolerate enzymatic dependent quality patient irreversibly replication improve expectancy low anti anti better prevent though dna dna dose cell bind target methyltransferase effect effect thus thus methylation methylation decitabine decitabine decitabine decitabine incorporate action 
0.67@cancer cancer article higher outcome agent epicentre new economist reactivate hypomethylation hypermethylated island disruption unspecific epigenetic silence silence demethylating reduce tumor style style style potency directly serious forget many suppressor decitabine one one risk cover bottom bottom bottom constitutionally epimutations drug drug drug cause cause cause could apoptosis low trigger prevent primarily dna dna dna however dose dose cytotoxic act margin margin margin cpg gene gene methyltransferase effect since disturb methylation desire desire region another action side inhibitating 
2.0@cancer cancer inhibitor insert class therefore dnmt methyl permanently tend highly since since anti transferase suppress dna dna dna bind drug drug drug drug gene rapidly effect tumor tumor affect increase belong replicate normal decitabine express demethylation cell cell replication acutely 
2.0@cancer reduce reduce become use agent actually myelodysplastic result hypomethylates anti methyl show inhibit treatment dna dna dna dna epigenetic strand promoter syndrome tumoural inhibitor gene hence effect effect fe belong rase methylation decitabine decitabine decitabine incorporate express demethylation tra tumour supressor 
1.0@cancer cancer cancer rate class use leave tumout agent healthy healthy revert myelodysplastic unmethylated part anti back back alone treat dna reverse syndrome syndrome allow allow allow demethylating multiply effect tumor die normal normal normal longer decitabine decitabine demethylisation theory allele cell cell cell cell cell cell would 
1.67@suppressor dependent inhibitor inhibitor mitotically summary island island analogue dectabine subsequent apoptosis replace cytosine cytosine cancerous covalently covalently become compete avoid inhibit inhibit decitabine decitabine decitabine division dna dna dna dna dna promoter promoter allow allow degradation contribute cpg cpg gene methyltransferase methyltransferase methyltransferase methyltransferase methyltransferase reduce tumor hypermethylation thus methylation inside phosphorylated phosphorylated region enzyme cell cell cell cell differentiation bind bind leukemic 
2.0@characteristic class may dnmts design become meet reactivate growth generation treat island irreversibly inhibitor inhibitor allow allow thereby successive reduce reduce tumor tumor tumor tumor tumor tumor tumor pattern hypermethylation hypermethylation hypermethylation cell cell cell cell cell inhibit suppressor dependent transfer therefore epigenetic drug drug anti amount prevent dna dna dna dna dna divide bind inherit cpg gene methyltransferase effect remove remove division methylation methylation decitabine decitabine decitabine daughter incorporate as dnmti 
2.0@elod plastic cancer higher tranferases o use agent myelodysplastic since treat decrease act degree degree degree irreversibly tumour tumour operation disease demethylating normal hypermethylation usually thus thus genome methylation methylation cell cell replication tra suppressor suppressor dependent methylating drug drug afected like methyl methyl prevent dna dna dna dna divide bind bind syndrome syndrome fe dnmts suffer rase actively decitabine gene gene y haematological 
2.0@cancer cancer inhibitor dnmt dnmt dnmt produce may may shore shore analog growth inhibit nucleotide greatest irreversibly strand help island island island island island reduce reduce tumor tumor tumor replicate myelodyplastic hypermethylation hypermethylation release nucleoside methylation demethylation goal suppressor suppressor dna dna efficiency hallmark replication improve improve mean particular later lung bind bind syndrome expression expression cpg cpg cpg cpg cpg poor methyltransferase effect effect copy longer thus prognosticator decitabine decitabine daughter gene incorporate modify associate 
2.0@cancer methyltransferases methyltransferases suppresor activation activate replication inhibitor agent loss mark approach result result methylating regulatory anti overall damage dna dna dna dna dna dna dna disable bind degradation establish functionality trap trap gene methyltransferase compromise tumor tumor mechanism normal silence methylation decitabine therapeutic incorporate signal cell enable malignantly 
1.0@standard drug drug drug successfully deploy baylin leukemia likely agent myelodysplastic durable myelogenous change penetrate make treat show chemotherapy dna epigenetic acute syndrome precursor demethylating dr employ tumor tumor tumor must full difficult inside speculate cell way decitabine 
2.0@cancer cancer cancer inhibitor inhibitor demethylates dnmt dnmt methyl dnmti overall overall tumour tumour call class irreversibly work work avoid methylated silence reduce mechanism maintain cell cell cell cell cell cell replication suppressor specifically also divide drug cause see exact anti know transferase dna dna however non bind epigenetic act time rapidly effect effect belong methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine gene heavily de 
2.0@cancer methyltransferases class dnmt dnmt regulation may inherit fda reorganize inactivation find hypomethylation inhibit lead lead lead cytosine cytosine interference development know common enzyme tumoral remodel heterogeneous tumor tumor mechanism rexpression hypermethylation include phenotypical gametogenesis thats cell suppressor decitabine decitabine decitabine decitabine one one dna dna dna dna dna irreversibly somatically drug drug analogue analogue mutate apoptosis eventually study study among lineage dnmts several histone bind epigenetic epigenetic epigenetic epigenetic epigenetic inhibitor gene gene gene effect effect induce antitumoral modification modification thus methylation methylation rna arise incorporate approve covalently pattern alter 
2.0@different dacogen progress use hematological fda agent process myelodysplastic analog meet meet hypermethylation tumour market previously clinical epigenetic get respond demethylating inhibit undergo bind nucleoside others myeloleukemia like japanese trial blood expression one suppressor transfer transfer irreversibly decitabine decitabine replication acute dnml condition reversible present companyas treatment treatment dna dna dna already cell ase ase syndrome sell inherit drug drug gene aml inhibitor copy silence longer methylation allow daughter incorporate approve itworks inthe 
2.0@one allow effect growth dnmt dnmt tumour tumour tumour tumour inhibitor strand strand significantly fundamental find change become bind occur decrease island suppress division dna dna dna epigenetic even reverse reverse methylated methylated le function cpg gene methyltransferase reduce remove copy hypermethylation hypermethylation turn new new methylation expect capture come active cell cell cell decitabine 
0.33@cancer lymphoma progress way way include agent whose repressive potential make subtle call suppress epigenetic enzyme ezh proliferation tumor tumor tumor via cell repress suppressor suppressor suppressor methylating greater fewer mutate promotor target histone specific seek dna mark surround gene side effect overactive copy awry silence silence modification go methylation methylation decitabine whatever overactivity attach 
2.0@dacogen inhibitingdna abnormal class dnmt dnmt tumour chemically cytidine analog greater frequently growth identify thereforetheir aza degree irreversibly metabolitehaving methylate ananti impact mechanism affect affect beenincorporated suppressor isstill specifctoxic nucleoside dnareplication like cell cell control nuceloside ul ul ul ul ul ul inhibitingdnmts dependent isalsothought oncells epigenetic appear anon analogue analogue decitabine decitabine decitabine decitabine decitabine decitabine describe describe trade exact effect effect anti genesthat dnamethyltransferase dna dna dna dna divide hypo bind name act inhibitor inhibitor gene inactivate afterit deoxycytidine belong methylation activatingtumour incorporate action action 
1.0@dna suppressor cancer methylated therefore function activate regain tumour inactivate remove remove demethiylating agent word methylation methylation decitabine decitabine apply gene gene mean histons cell 
2.0@suppressor suppressor cancer inhibitor irreversibly blood preservation mark dnmti allow allow allow preserve anti hypermethylated tend inhibit dna dna dna divide strand bind expression dnmts dnmts methyltransferase effect tumor tumor tumor thus methylation methylation genome daughter mean cell decitabine decitabine 
2.0@ezh cancer etiology lymphoma dysfunctional thus agent example find silence silence silence suppress previously lead epigenetic development essentially enzyme prohibitive effective tumor tumor tumor hypermethylation new light counteract cell cell suppressor suppressor decitabine specifically shed cause mutation result result cancerous type occur common dna dna dna expression histone name circumstance function gene gene methyltransferase inhibitor investigate demethylating oncogenesis allow allow promise protein tissue 
1.67@lock methyltransferases inhibition synthesize tumour tumour tumour agent agent mec process newly hypomethylates hypomethylation inhibit nucleotide epigenetic epigenetic hipomethylating methylated involve enzyme enzyme island proliferation block block block contribute dnamt dnamt maintain maintain cell cell cell drug ecitabine also also consequently methylates replication cause ch strand strand strand mutation apoptosis impossible phase phase gene gene anti promoter group dna dna dna dna dna dna dna dna dna mark mark mark dacogene point expression cpg reparation reparation reparation methyltransferase methyltransferase inhibitor induce death enzymesdecitabine methylation methylation methylation methylation methylation decitabine decitabine decitabine daughter daughter mitosis mitosis restriction recruit 
1.67@similarly class methyl agent agent agent two design growth growth note tumour tumour tumour tumour transferase inhibit nucleotide lead epigenetic epigenetic inhibitor demethylating demethylating impact impact tumor mechanism block normal hypermethylation hypermethylation may sooner demethylation reestabilshed way machinery suppressor suppressor promote antimetabolite analogue target natural anti anti offset offset dna dna dna dna divide cell cell cell cell cell function gene gene rapidly effect cellular control control death belong thus decitabine decitabine decitabine decitabine first would 
2.0@dna dna dna loss loss loss loss promotors suppressor tumour tumour tumour analogue analogue ability result reaction malignancy hypermethylation hypermethylation hypomethylation effect anti inhibit grow particular lead lead hallmark strand methylate bind bind act enzyme inhibitor irreversible methyltransferase methyltransferase function function remove hypermethlation epigenome work dnmti decitabine decitabine decitabine decitabine nucleoside gene gene incorporate incorporate suppressive replication haematological ultimately 
1.33@dacogen dacogen anitumor class erase divide drug cause incorporate probably inhibit chemotherapeutics dna dna dna epigenetic epigenetic strand see inhibitor demethylating susceptibility effect effect pattern block increase new methylation decitabine decitabine lay demethylation cell cell fast methyltransferase 
2.0@cancer inhibitor within within dnmt depedent may myelogeous malignancy dnmti island island effective irreversibly strand strand see tra precursor concordance proliferation reduce normal neoplastic hypermethylation accute parental nucleoside cell cell cell cell cell tumour tumour tumour promoter promoter leukaemia suppressor dependent via replication replication analogue result anti myetplastic methyl level prevent severly treatment dna dna dna dna bind bind syndrome fe cpg cpg gene gene methyltransferase effect effect effect upon upon copy increase silence due due due rase methylation methylation decitabine decitabine decitabine decitabine daughter daughter incorporate approve supressor haematological 
2.0@dacogen cancer cancer reduce dnmt dnmt dnmt dnmt use deme hat mistake along myeloplastic eisai acetyl myelogenous one design hypomethylation treat affect lead lead lead epigenetic strand strand strand methylate precursor silence inhibitor recent analoguewhich normal hdac bind turn divide nucleoside aberrant cell much pharmaceutical decitabine andis hallmark transfer transfer year irreversibly methylating replication analogue acute activity suppressor come ase ase tumour prevent family dna dna get histone histone histone histone every syndrome sell target drug drug hmt rapidly includeinhibitors dependant deacetylase increase division thy find member daughter daughter daughter hdm incorporate strongly leukaemia machinery methyltransferase methyltransferase follow 
2.0@maybe cancer cancer cancer inhibitor term dnmt dnmt administration use fda agent long precise cure malignancy de conjunction incorporation affect island island previously irreversibly methylated involve consequence alone as normal nucleoside indicative cell cell cell yet pharmaceutical region mode dependent transfer therefore epigenetic drug drug drug drug analogue therapy approach result low completely traditional know cause prognosis dna dna dna divide dose kill bind syndrome act myelodysplastic cpg cpg poor target rate upon rapid division new methylation methylation methylation decitabine decitabine severely lay meet approve approve action machinery heavily recently 
1.33@article use use use slow load agent agent myelodysplastic find economist growth myelogenous treat mention solid epigenetic global precursor demethylating first reduce demethylation experimentally tumour tumour tumour tumour tumour leukaemia advance relate seem drug drug combination histone leukeamia amount show lung acute syndrome inhibitor time time effect deacetylase increase since methylation methylation decitabine decitabine unexpected oppose azacitidine 
1.33@one could uncontrollable tumour tumour agent suppression suppression suppression cancerous growth growth anti unmethylating unmethylating unmethylating previously lead dna dna dna dna reverse methylated methylated demethylating gene gene effect tumor tumor tumor methylations control control decitabine decitabine region region region mean express active cell way 
2.0@cancer myeloid class able may fda agent agent hypomethylating hypomethylating two analog member malignancy dnmti leukemia treat irreversibly tumour tumour tumour help involve inhibitor hypermethylation dnmt mechanism mechanism life efficacy mode mode thus myelodysplastic repair utilize side demethylation maximize decitabine decitabine decitabine decitabine suppressor suppressor suppressor dependent also pateints action action action induction precise prolong apoptosis expectancy reactivation therapeutic bind prevent treatment dna dna dna pathway acute cytidine syndrome act additional drug gene gene gene azanucleosides effect effect unclear investiation evidence minimize since methylation would possible incorporate approve intuitively methyltransferase haematological reactivate 
2.0@suppressor suppressor cancer cancer methyltransferases identify class dnmt excessive disrupt tumour cause agent ie hypomethylating describe describe hypomethylates hypomethylates reactivate growth effect anti decrease decrease methyltransferaseinhibitor island dna dna dna dna dna dna dna epigenetic inhibitor inhibitor contribute cpg inhibit impact tumor tumor pattern belong replicate silence methylation methylation methylation methylation ul ul ul ul ul ul gene gene like cell survival may decitabine decitabine decitabine decitabine decitabine 
2.0@et cancer cancer effect effect hypomethylation begin produce disease use slow slow agent sit sit currently dnmti growth leukemia useful useful treat inhibit aza lead epigenetic work know leukaemia precursor division inhibitor inhibitor reduce express neoplastic nucleoside like cell cell cell cell tumour tumour supressor cause bond issa drug drug analogue decitabine decitabine decitabine apoptosis target low cancerous gene anti methylation promoter either dna dna divide dose acute syndrome myelodysplastic irreversible rapidly enzyme deoxycytidine progression increase belong myelogenous al allow em class active form differentiate methyltransferase methyltransferase would associate 
2.0@suppressor lower hypomethylation stimulation induce analogue suppression cytosine reverse hypomethylates expressionof growth immune inhibit inhibit protein promote dna dna dna dna dna nonreversible dose dose show covalent link thereby gene proliferation allow tumor tumor mechanism block normal hypermethylation decitabine decitabine decitabine high ink ink cell cell differentiation methyltransferase methyltransferase methyltransferase establishment expression 
1.0@growth cancer class class medication dnmt dnmt produce activity way agent agent specific two two member similar hypomethylation hypomethylation direct inhibit regulate death know within within well belong demethylating demethylating mechanism normal decitabineis cell cell cell cell cell global blockage decitabine decitabine suppressor dependent proteosomal antimetabolite antimetabolite seem drug cause target result number promoter methyltransferase metabolism dna dna dna dna divide substance substance cytotoxic degradation expression gene gene rapidly effect induce interact cellular first increase increase division new methylation deplete work incorporate secondly independent 
1.67@different different older cancer cancer cancer cannot higher class term dnmt dnmt use state chemically enzymatically long island analog md tumour copy subsequently epigenetic epigenetic strand facet particularly well consequence ineffective inhibit outcome life hypermethylation hypermethylation nucleoside primarily cell control suppressor machinery one dna dna dependent commonly quality patient patient irreversibly decitabine decitabine decitabine drug drug drug improve healthy prove target target low toxic replication element nonspecific parent good several dose dose bind act rest still gene gene hence inhibitor tolerate cpg due methylation prognostic daughter drive incorporate assess survival alter 
1.67@body cancer cannot become become therefore therefore dnmt dnmt tumour tumour cause decitabine decitabine decitabine irreversibly analog lack sit decrease dna dna dna dna divide divide methylate methylate bind concentrate inhibitor anti methyltransferase effect effect upon try death division since methylation methylation genome nucleoside incorporate cell cell cell cell cell cell rapidly tissue 
2.0@mitotically cancer cancer cancer methyltransferases specificity suppressor suppressor uncontrolled chemically agent stop tend hypomethylating dnmti heritable subsequently unable irreversibly strand strand methylate allow demethylating inhibit proliferation reduce reduce tumor tumor tumor tumor longer lack hypermethylation hypermethylation nucleoside otherwise often often specifically cytidine greater cease replication replication cause exhibit present anti completely lead island dna dna dna dna dna dna however cell cell cell cell bind inhibitor cpg gene gene methyltransferase methyltransferase methyltransferase effect dependant anolog thereby replicate replicate new methylation decitabine decitabine decitabine decitabine incorporate silence silence action action would 
1.67@methyltransferases dnmt dnmt deoxynucleoside hypomethylation incorporation inhibit inhibit aza lead epigenetic hypermethylation demethylating dctp reactivation tumor tumor vitro complex cell cell supressor dna dna dna dna dna cytidine association activation induction analogue apoptosis apoptosis result result solid several demonstrate demonstrate covalent overexpression irreversible enzyme induce cellular silence senescence senescence methylation decitabine decitabine decitabine gene gene action differentiation differentiation selectively study study leukemic 
1.33@cancer inhibitor inhibitor dnmt dnmt thats use drug agent toxic process myelodysplastic low hypomethylates anti anti treat affect affect inhibit exert epigenetic dna dna dna dna divide dose dose action dependent syndrome demethylating severely rapidly effect effect tumor tumor methyltransferase normal division decitabine decitabine high incorporate cell cell therefor replication 
2.0@one dacogen cancer also inducer dnmt way unnecessary inhibitor therapy target without hypomethylation effect anti inhibit inhibit know prevent damage potentially dna dna epigenetic sell co eisai provide differentiation methyltransferase methyltransferase impact tumor tumor grow expression epigenome vitro methylation methylation genome gene removal may ltd decitabine decitabine decitabine 
1.0@one effect inhibition beongs dnmt dnmt get get replication analogue thing ucleoside targetingdna fact dnmti dnmti like notice inhibit worth later dna dna divide divide kill bind inhibitor dnmts drug suffer methyltransferase function tumor replicate famous give due thus decitabine decitabine decitabine work incorporate strongly primarily cell cell cell rapid would would dysfunction 
1.33@dna dna dna strand level myelodysplastic methyltransferase able belong demethylators incorporate treat decrease inhibit 
2.0@cancer methyltransferases dna dna dna use could could process myelodysplastic myelodysplastic analog much might inhibit treat strand belong severely way affect nucleotide hypermethylation hypermethylation release nucleoside cell cell cell tumour suppressor dependent dependent therefore replication extent prevent island reason divide divide bind syndrome syndrome syndrome inhibitor cpg gene rapidly along upon probably copy division longer silence methylation decitabine decitabine daughter irreversible incorporate come methyltransferase methyltransferase hit 
2.0@growth growth manipulate cancer cancer methyltransferases methyltransferases restore restore suppressor suppressor methyl mutation aberrantly sequester malignancy dnmti hypomethylation genetic restrict call locus molecule irreversibly effectively depend hyper effective mechanism mechanism normal hypermethylation understand ing genome genome although level attractive cell cell cell dive way promoter expression specifically analogue nucleoside therefore therefore therefore epigenetic replication cause likely suppression decitabines impossible fully tumour tumour tumour prevent dna dna dna dna dna away bind mean act target target target drug drug gene rapidly inhibitor upon cellular cellular division decitabine decitabine decitabine decitabine incorporate incorporate give action indirectly methyltransferase haematological 
1.33@repliction daughter divinding effective methyl methyl methyl dependent result dnmti dnmti dnmti analouges leave become best cancer transferase transferase transferase basically dna dna dna dna get strand strand strand unavailable bind function drug drug irreversible rapidly inhibitor tumor incoorperate contain belong longer thus methylation decitabine decitabine nucleoside come cell cell cell cell dive replication 
1.67@cancer cancer cancer inhibitingdna hdac dnmt dnmt produce cell use agent hypomethylating myelodysplastic currently malignancy reactivate change leukemia md genetic treat inhibit aza aza benefit clinical clinical epigenetic epigenetic epigenetic epigenetic epigenetic work reversible reversible consider disease demethylating efficacy tumor tumor abnormality epigenome nucleoside aberrant myeloid increasingly trial explore suppressor dependent irreversibly replication analogue therapy prove cdr result result reverse therapeutic solid unfortunately dna dna dna dna dna blood acute bind syndrome dnmts drug gene aml inhibitor inhibitor inhibitor deoxycytidine silence modification modification novel methylation methylation decitabine decitabine decitabine decitabine em em em incorporate hypomethylates methyltransferase methyltransferase dnmti dnmti 
2.0@mean cancer methyltransferases activity blood manner agent agent silencinghas deoxynucleoside find aza effectively dna dna dna dna dna generally demethylating demethylating reduce tumor mechanism mechanism block affect hypermethylation although cell cell much suppressor faster depend replication replication analogue healthy normal cancerous specific exact areplication could could several divide reverse dependent syndrome act dnmts still gene unclear deoxycytidine pre cpg methylation decitabine decitabine disorder work incorporate ytidine propose 
2.0@cancer methyltransferases inhibition able tumour tumour tumour add instead growth make might grow lead cytosine cytosine cytosine methylated particularly inhibitor group effective negligible feature otherwise regulate methyl one suppressor suppressor activation replication analogue four healthy target cancerous cancerous normally prevent dna dna dna base cell cell cell cell chemotherapy function gene gene gene rapidly effect epigenetically place silence methylation decitabine decitabine decitabine decitabine decitabine incorporate methyltransferase 
1.67@cancer inhibitor lymphoma dnmt activate blood specific growth generation hypermethylated treat bedemethylated suppress lead irreversibly strand strand see think myeloid tumor tumor tumor tumor mechanism although like demethylation unknown suppressor suppressor methylating replication cause subsequent cell cancerous behavior behavior anti dna dna acute bind bind act dnmts gene continue effect copy longer methylation decitabine decitabine daughter daughter come geneswill action methyltransferase 
2.0@unregulated cancer inhibition restore suppressor suppressor suppressor suppressor way agent agent decitabine decitabine result hypomethylates growth eactivation become hypometylating inhibit lead dna dna dna dna fe function demethylating gene gene gene gene tumor tumor tumor tumor block increase division interfere rase methylation methylation blockage activity cell cell methyl promote tra 
1.67@cancer inhibition dnmt dnmt use leukemia manner cytidine specific myelodysplastic analog currently malignancy hypermethylated overall treat demethylation island molecule work methylate inhibit happen tumor thencovalently high level many removal methyl suppressor tra specifically dependent also patient patient patient favorable outcome drug drug cause attempt cellreplication low demethylate know know haemetological prognosis dna dna dna dna get dose bind syndrome fe cpg poor aml aml effect unclear systemicallynon administer replicate rase methylation methylation decitabine decitabine decitabine gene incorporate perhaps small 
2.0@cancer cancer dnmt dnmt methyl agent agent analog de irreversibly enzyme enzyme group reduce tumor tumor normal normal nucleoside nucleoside cell cell cell cell removal nullify suppressor suppressor dependent methylating replication certain cause add target target become could prevent dna dna dna dna dna divide bind le expression expression gene gene rapidly allow division thus methylation methylation decitabine decitabine decitabine work incorporate action attach would would 
1.0@elod plastic thee thee titrate methyl pression rea tot ly y result myelogenous reaction catalyse io ae leuk rev dna oft acute methylated precursor fe fe hyper mi take hep u yn silence rase methylation methylation class class enzyme enzyme drome tra 
2.0@translocation methyltransferases class within able tumour tumour tumour instability mutation stop useful also number hypomethylation hypomethylation hypomethylation effect anti replicate inhibit develop lead lead dna dna dna dna divide therefore inhibitor hypermethylation hypermethylation suppression gene methyltransferase reduce insertion genomic increase belong due suppress decitabine decitabine work express cell may etc frequently 
1.33@mitotically cancer cancer effect therefore dnmt tumour tumour inherit agent mark mark dnmti anti call prevent dna dna lineage inhereted kind irreversibly irreversibly action bind bind epigenetic epigenetic reset demethylating inhibit dnmts dnmts abnormality epigenome methylation decitabine decitabine decitabine decitabine em incorporate cell present 
1.67@cancer methyltransferases inhibition class dnmt dnmt others tumour tumour inhibitor proliferate dnmti dnmti inhibit lead recognize prevail belong thednmts severely proliferation reactivation affect hypermethylation reduce nucleoside dependentnucleoside like demethylation demethylation cell cell cell cell possible expression compound suppressor therefore replication analogue therapy result areplication dna dna dna dna dna however bind example example function gene rapidly along induce division decitabine decitabine decitabine irreversible incorporate constitute 
2.0@gene gene suppressor suppressor cancer cancer class use use cause mutation acute agent silence upregulation myelogenous hypomethylates whose leukemia treat decrease decrease prevent groth example dna dna dna dna dna dna histone syndrome precursor enzyme demethylating methyltransferaseinhibitor proliferation inhibitor tumor tumor tumor methyltransferase methyltransferase methyltransferase hypermethylation hypermethylation thus thus thus myelodysplastic decitabine decitabine decitabine decitabine possible role like cell cell control inhibit belong 
2.0@totreat dacogen cancer cancer article magazine use agent april epicentre myelodysplastic myelogenous th reactivate anti inhibit dna dna dna acute methylated syndrome sell demethylating hence methyltransferase effect tumor nowadays precursor thus decitabine decitabine gene gene reference demethylation leukaemia tumour economist supressor 
1.33@cancer methyltransferases restore order upon use myelodysplastic silence silence tumour decrease inhibit treat lead lead irreversibly methylate importatn kind enzyme proliferation proliferation tumor tumor tumor key hypermethylation hypermethylation may release role cell uncontrolled nuceloside tra suppressor suppressor suppressor therefore replication analogue revert revert anti methyl level prevent protect dna dna dna dna dna dna get hypo bind syndrome fe inhibitor drug gene gene gene methyltransferase effect induce control human word rase methylation decitabine decitabine decitabine incorporate tumorigenesis 
2.0@cancer effect dnmt use mark mark anti analog analog dnmti growth md hypermethylated hypermethylated transferase cytosine lose tumor tumor tumor myelodysplastic repair render signal cell methyl methyl suppressor suppressor patient patient drug apoptosis incorporate demethylate inappropriately group dna dna dna dna bind syndrome function perform gene gene inhibitor remove control silence silence replicate thus methylation methylation decitabine decitabine lay active 
2.0@methyltransferases higher dnmt dnmt use use agent hypomethylating myelodysplastic cytotoxicity design hypomethylation md inhibition inhibition lead lead lead epigenetic methylated responsible inhabit destructive tumor tumorsupressor inefficient hypermethylation nucleoside retain methylation methylation cell cell cell cell global analogue high mitotic promotors activity result low reversal promoter damage treatment dna dna dna divide dose dose dose syndrome initially gene cellular death division actively decitabine decitabine decitabine daughter lay reprogramming mark 
0.67@toxicity along incoperated produce use agent specific hypomethylating irreversibly malignancy characterize inhibit transferase panel well epigenetic strand call help includingtumor responsible belong inhibitor inhibitor histone activation normal anticancer hematologic release nucleoside cell cell cell cell methyl decitabine decitabine decitabine suppressor dependent biological large large application via replication analogue cause cause cycle apoptosis mean result low number reaction arrest group damage damage treatment dna dna dna dna synthesis bind bind bind syndrome act dnmts drug drug drug myelodysplastic chemical effect effect cellular cellular deacetylase death division nolonger dnmt dnmt dnmt dnmt methylation come daughter gene gene copy promise active differentiation protein 
1.67@suppressor suppressor suppressor dependent dependent effect therefore dnmt dnmt produce use analogue inhibitor inhibitor decitabine decitabine myelodysplastic myelogenous malignancy dnmti sit treat island dna dna dna irreversibly acute bind syndrome precursor hypermethylation cpg gene gene methyltransferase reactivation epigenetically generate generate division longer silence silence consequently release nucleoside incorporate replication demethylation demethylation tumour tumour tumour haematological leukaemia 
2.0@cancer cancer cannot cannot dnmt dnmt dnmt way dependent agent since predominantly dna dna dna irreversibly strand methylate bind bind bind act demethylating irreversible rapidly effect affect replicate release daughter cell cell replication replication decitabine decitabine 
1.67@suppressor reduce suppresor therefore reactivation tumour tumour tumour tumour drive agent thank present hypomethylation anti amount group dna dna dna demethylating effect affect affect hypermethylation expect wide mean methyl would decitabine 
2.0@sb cancer cancer cancer effect growth efficacy tumour slow agent long juergens apply susceptible make incorporation discov advance epigenetic epigenetic demethylating inhibit tumor dec routine cell cell baylin dna dna dna dna patient refractory combination therapy therapy loss result anti ra lung non histone chemotherapy inhibitor methyltransferase immediately upon deacetylase methylation decitabine decitabine decitabine activity period combine small 
1.67@inhibition suppessor formation tumour myelodysplastic sit aza molecule consider enzyme demethylating tumor mechanism normal complex proliferative many cell trial trial compound standard cytidine also probabily c divide uptake apoptosis histone deacetylases correspondent covalent function moter ape deoxycytidine belong methylation methylation decitabine decitabine decitabine gene reestablish could higher restore dnmt activate use agent process inactivation analog analog cellular treat nucleotide metabolically irreversibly conduct ut conversion phosphorylation nucleoside like demethylation control synergic specifically lower via need toxic result exact solid better dna dna understand dose doseswhile ideed syndrome cpg effect effect induce due che action hit azacitidine 
1.67@different progenitor stemcells bonemarrow correspond restore patient use work work agent pathway reverse reversal growth lifespan type tumour decrease lead myelodisplastic syndrome dna hypomethylating development cell involve functionality inhibit expression remove normal increase increase silence silence thus thus blood decitabine decitabine aberrant gene methylation primarily tranferase methyl 
2.0@cancer neoplastic think class tumor methyl agent specific process find dnmti dnmti negative negative oncogene island adequately epigenetic concern group impact serve pattern normal dnmtis hypermethylation genome express cell cell cell cell may decitabine suppressor however dose healthy revert relatively low cancerous without anti occur know prevent dna dna divide non act inhibitor inhibitor cpg gene gene methyltransferase effect effect remove globally global belong silence methylation methylation allow oppose 
1.67@suppressor dependent class dnmt dnmt imprint use certain certain trait cancer cancer cancer agent scale target acute work growth leukemia tumour decrease inhibit particular dna dna dna hypothesize know demethylating drug methyltransferase myeloid tumor control hypermethylation hypermethylation may thus methylation decitabine decitabine region gene many cell part global haematological drive 
1.67@cancer cancer inhibitor growth dnmt use state could could analog dnmti hypomethylation part tumour tumour mandate island suppress irreversibly strand strand mechanism hypermethylation fact try leukaemia suppressor cytidine lower lower patient replication cause anti thedna level treatment dna base base bind cpg gene methyltransferase effect replace copy methylation methylation methylation decitabine decitabine decitabine daughter dependency action 
1.0@cancer change unmethylation produce tumour tumour tumour slow slow agent chemeotherapy find growth growth unmethylated island island show methylated belong provide bad normal cicle like cell cell cell cell cell cell tranform one dna patient patient healthy healthy result anti help help help help help help better treatment study divide histone moment recent cpg cpg continue effect remove deacetylase demethylating new methylation methylation decitabine decitabine reproduce combine 
1.67@inhibitor demethylates use include mutation stop myelodysplastic capable reactivate growth growth unmethylated treat grow job lead epigenetic uncontrollably hypermethylation hypermethylation inhibit inhibit tumor tumor tumor tumor tumor tumor tumor tumor tumor normal give unusual repressor suppressive suppressive suppressive suppressive regulate boost silent become cause cause methlyation methlyation cell result surround anti anti dna dna reverse bind syndrome site site gene gene gene gene gene resume effect effect effect previous silence word word methylation methylation decitabine decitabine decitabine decitabine another methyltransferase 
1.0@cancer cancer effect effect effect class class dnmt tumour tumour impact analog azacytidine dnmti dnmti tumorcells direct nucleotide nucleotide irreversibly irreversibly body help belong reduce longer longer normal neoplastic release release nucleoside potent like cell cell cell much decitabine decitabine decitabine decitabine destroy therefore therefore get replication describe describe anti anti anti dna dna dna dna dna dna dna divide bind bind bind bind bind inhibitor drug rapidly along along along copy copy division undergo thus methylation ul ul incorporate come come come methyltransferase methyltransferase methyltransferase methyltransferase 
2.0@cancer methyltransferases higher dnmt dnmt agaisnt use use cytoxic classify hypomethylation direct inhibit expression epigenetic work pyrimidine othe tumor mechanism myelodisplastic although diferentiation cell may supressor promotion activaty lower nucleoside nucleoside therefore position drug analogue analogue dose dose result bring odified type immune treatment dna dna ring syndrome inhibitor inhibitor gene effect practice investigate similiar currently decitabine decitabine decitabine possible stimulation 
1.67@dna epigenetic inhibitor help class target tumour effect decitabine decitabine hypermethylation thus combat dnmti anti enzyme inhibit methyltransferase belong 
2.0@cancer cancer stable dnmt activate tumour tumour slow succeed likely mark myelodysplastic remain growth treat sustain particularly allow future heritability much successful demethylation demethylation cell cell cell use use suppressor lung epigenetic mitotic replication combination histone dna dna dna dna divide reverse syndrome name expression gene rapidly inhibitor inhibitor inhibitor induce deacetylase division due thus methylation methylation decitabine decitabine decitabine mainly mean mean commercial methyltransferase azacitidine 
1.33@cancer analogue lower dnmt replication cause dependent since anti normal dna dna divide dose bind inhibitor inhibitor dnmts rapidly effect affect neoplastic al decitabine nucleoside incorporate demethylation cell cell 
2.0@cancer reduce lead dnmt produce may may may hematological stop methylating malignancy growth md hypermethylated decrease decrease often irreversibly methylate inhibitor enzyme able tumor tumor tumor mechanism inhitits nucleoside cell cell drug ot genome genome genome suppressor suppressor dependent silent silent therefore replication replication analogue prior mean result exact anti level level level prevent dnmts dna dna dna dna bind le function still gene methyltransferase effect unclear perform treatment new new methylation methylation methylation methylation decitabine think work incorporate action exist 
1.67@cancer effect methyl methyl methyl dnmts process make malignancy dnmti dnmti leave md call call call inhibit suppress often epigenetic development backbone silence thedrugs group group turn hypermethylation style align attachment attachment tumour tumour suppressor dependent transfer patient irreversibly text gene gene gene gene anti bind prevent treatment dna dna dna dna dna dna mdswill syndrome myelodysplastic hence chemical inhibitor believe belong modification methylation decitabine decitabine decitabine work incorporate hypomethelates methyltransferase haematological 
1.67@suppressor transfer tumor tumor methyl cause reactivaties hypomethylation anti decrease inhibit dna dna dna dna inhibitor gene methyltransferase effect epigenetically silence replicate actively decitabine incorporate methylation eat 
1.67@cancer cancer inhibitor inhibitor suppressor suppressor yet fda myelodysplastic myelogenous meet leukemia treat transferase transferase island fully achieve effective irreversibly strand pass methylated precursor enhance as mechanism affect divide much drug drug drug cell cell methyl expression dna dna dna dna dependent transfer therefore however replication replication cause dectabine decitabine highly body occur know tumour tumour tumour syndrome reduction get acute bind integrate thus cpg gene gene rapidly along upon copy silence silence since methylation would would daughter incorporate come approve action herewith haematological 
1.33@silence could could methyltransferases cgis class specificity dnmt tumour tumour purpose mark myelodysplastic analog since dnmti approve drug drug avoid avoid island cpg patient clinical epigenetic help kind despite enzyme inhibitor tolerate reduce mechanism permanently life life hypermethylation remarkable nucleoside instability improvement cell trial way suppressor decitabine decitabine decitabine decitabine specifically also also quality final stablished seem replication drive syndormes expectancy low low instauration gene step region promoter genomic potentially dna dna dna carcinogenesis dose bind well well target still irreversible methyltransferase inactivate report belong treatment treatment main methylation inappropriate mainly tumourigenesis mean active action follow 
2.0@dacogen cancer cancer effect effect growth check use use agent agent phase eisai probably myelogenous must hypomethylation manageable renew hypermethylated treat probable island lead targetting increase help involve precursor precursor early demethylating reduce dysregulation intergenic contribute may may myelodysplastic genome demethylation cell cell cycle tumour tumour tumour tumour leukaemia suppressor suppressor suppressor turn turn therefore disease drug drug drug region region add complication result moreover optimal anti specify suitably dna dna however acute greatly syndrome act function cpg gene gene side eliminate stage progression repeat silence decitabine decitabine production dosage acitvation would would would would would reactivate 
2.0@cancer cancer cancer cancer cancer inhibitor inhibition restore within within dnmt methyl island island probably find block md md quite tumour transferase hinder cgi previously class irreversibly help silence inhibit reduce pattern grow essential hypermethylation hypermethylation genome like like many cell cell use expression suppressor epigenetic replication certain therapy whole tumourigenicity type type type promoter cpg cpg dna dna dna important drug poor aml dnmts dnmts dnmts belong methylation methylation decitabine decitabine gene incorporate action action indicator 
2.0@dacogen cancer cancer article article dnmt dnmt dnmt use thereby appear agent epicentre myelodysplastic find economist leukemia leukemia hypermethylated treat cytosine inappropriately precursor demethylating biochimie reduce reduce reduce reduce hassler block block egger myeloid myeloid cell cell decitabine decitabine decitabine decitabine one action tumerogenisis tumerogenisis replication cause mutate epigenomics th april concept lecture magazine dna dna dna dna dna divide base acute syndrome sell mr rapidly emerge slide new methylation methylation methylation inappropriate incorporate form review methyltransferase alter 
2.0@could inhibitor dnmt manner reactivate areincorporated hypermethylated decrease island dna dna dna irreversibly work level level kind reduce tumor tumor tumor tumor usually many cell nuceloside expression expression one suppressor suppressor dependent cause replication analogue anti promoter promoter abnormally get thegenome bind dnmts cpg gene gene gene methyltransferase effect silence methylation methylation decitabine decitabine decitabine region tumorigenesis would 
1.33@cancer cancer inhibitor inhibitor class dnmt use analog d incorporation intodnaduring inhibit nucleotide irreversibly strand sequence lose belong thereby happen tumor presence release nucleoside demethylation cell cell cell cell much dependent transcription epigenetic aredividing replication cause ability body anti nab treatment treatment dna dna dna bind affect rapidly consequence methyltransferase methyltransferase methyltransferase copy division replicate methylation decitabine decitabine daughter mean mean action andrnaduring decitabineincorporates 
1.33@think class last fda myelodysplastic myelodysplastic analog myelogenous leukemia hypermethylated treat decrease island island nucleotide lead lead epigenetic strand decitabines precursor demethylating tumor week affect hypermethylation effectiveness effectiveness nucleoside cell cell cell cell rapid decitabine decitabine decitabine suppressor dependent replication replication permanently cancerous cancerous cancerous lecture presence dna dna dna dna dna dna acute bind bind syndrome syndrome act expression cpg cpg gene methyltransferase methyltransferase methyltransferase inhibitor inhibitor upon copy belong due methylation methylation would would daughter incorporate perhaps approve modify onto draw 
2.0@cancer cancer effect abnormal dnmt dnmt dnmt encounter progress tumour fda specific pattern mark mark myelodysplastic transcription transcription transcription useful back affect stop irreversibly strand strand particularly enzyme way research tumor tumor mechanism normal normal hypermethylation nucleoside daughter cell cell cell use suppressor also also high high erase analogue dose dose obscure switch low bring transcribe anti solid parent amp amp dna dna dna get non bind syndrome recent inhibitor still gene methyltransferase rate methylation decitabine decitabine decitabine decitabine decitabine decitabine mainly work incorporate approve action 
1.67@dna dna dna dna reduce suppressor use agent mdp suppression myelogenous leukemia generation methylated treat treat decrease something shut help syndrome precursor myelodysplastic demethylating demethylating demethylating gene gene gene gene effect tumor tumor tumor tumor increase thus thus methylation methylation methylation allow acute like like anti would decitabine decitabine 
1.67@cancer methyltransferases tumour direct cytotoxicity leukemia useful incorporation island aza often see inhibit inhibit myeloid hypermethylation myelodysplastic potent lead expression suppressor cytidine also replication analogue incorporate reverse unwanted covalent dna dna dna dna acute bind syndrome function cpg cpg gene aml inhibitor deoxycytidine reversal treatment treatment methylation decitabine decitabine decitabine regulate methyltransferase progression 
1.33@realeased cancer analogue faster daughter methyl cellsso fda dependent cause decitabine mean bind affect nucleotide dna dna dna dna dna divide strand wich fe inhibitor drug drug irreversible methyltransferase methyltransferase effect upon antineoplasic normal replicate rase longer nucleoside severely incorporate approve cell demethylation replication replication bound tra 
1.67@cancer cancer class class supression use characterize might myelodisplastic island work appropriately demethylating severely tumor tumor mechanism affect hypermethylation hypermethylation nucleoside case counteract cell cell replication supressor dependent also therefore drug analogue cause hypothesize low express particular dna dna dna dna dose kill bind syndrome dnmts cpg gene gene rapidly inhibitor belong replicate methylation decitabine decitabine decitabine irreversible incorporate methyltransferase 
1.33@dacogen class use manner agent process eisai analog myelogenous hypomethylates dnmti susceptible genetic treat inhibit epigenetic epigenetic strand precursor demethylating myelodysplastic although japanese way rna cytidine chemically drug mutation mean reaction chain company dna dna dna dna dna intervention acute syndrome sell function chemical nature similar decitabine decitabine incorporate incorporate leukaemia methyltransferase azacitidine azacitidine 
2.0@one earlier methylating target use fda island myelodysplastic myelogenous dnmti treat group first molecule lead dna dna epigenetic epigenetic development acute syndrome discuss dnmts cpg inhibit aml inhibitor tumor methyltransferase precursor belong machinary decitabine gene methylation approve supressor drug drug drug leukaemia 
2.0@inhibitor dnmt dnmt methyl fda myelodysplastic leave treat effectively lead irreversibly usage decrease thereby group proliferation tumor neoplastic style nucleoside align demethylation cell cell use expression suppressor therefore necessary replication analogue text incorporate anti prevent dna dna dna dna bind syndrome act important gene gene methyltransferase effect control due thus methylation decitabine decitabine decitabine work lay approve observe follow 
2.0@cancer cancer cancer restore dnmt dnmt dnmt much could mark dnmti hypomethylation hypomethylation md treat island island often irreversibly demethylating demethylating inhibit inhibit inhibit tumor hypermethylation nucleoside maintain cell cell replication replication replication replication suppressor analogue greater therefore decitibine decitibine decitibine decitibine drug drug tie cause cause mean cancerous like treatment dna dna bind le expression cpg cpg gene methyltransferase effect undergo methylation region incorporate approve action action 
1.33@could lower hypermutation island analogue activity dnmti anti overall inhibit level prevent gonome dna dna bind inhibitor dnmts dnmts cpg inreversibly methyltransferase effect tumor tumor silence methylation decitabine decitabine nucleoside possible incorporate supressors 
2.0@individing critical critical dnmt dnmt use proteasome cellgrowth agent xenograft analog myelogenous change covalently transplant treat response lead lead clinical sustain sustain degradation view bear precursor think demethylating observe enhance reduce tumor tumor mechanism clinically expression expression myelodysplastic aberrant enzyme passive cell demethylation leukaemia immunological cytidine therapeutic proteinonto drug drug tumorigenicity mouse acute support low low trapthe depletion theresulting promoterhypermethylation action responsesto dna dna dna reexpression dose dose antigen syndrome target gene gene gene methyltransferase effect relevant silence due decitabine decitabine decitabine azacitidine differentiation associate associate associate 
1.33@cancer cancer cancer class class dnmt regulation exposure hand phase methylating cytotoxicity reactivate inhibit play help enzyme tumor hypermethylation apoptotic aberrant caspase cdk cell cell cell cell cell cell cell cell de apaf decitabine decitabine decitabine decitabine suppressor also intra intra relate induction cause accomplish apoptosis role arrest arrest novo damage dnmts dna dna dna dna expression cycle cycle cycle consequence important ref ref inhibitor inhibitor induce induce induce death death belong vitro silence silence methylation complex gene gene gene form associate 
1.67@cancer methyltransferases methyltransferases restore induce methyl reversion mutation mark remain cannot reactivate normally resolve unction fundamental transferase inhibit addition recognize epigenetic lose inhibitor consequence proliferation compromise tumor tumor block hypermethylation hypermethylation metabolite metabolite silence silence substrate substrate role signal control machinery suppressor suppressor also bond bond relate adduction replication replication decitabine decitabine decitabine decitabine trap apoptosis result trigger become become become bind revert damage degradation dna dna dna dna dna dna dna dna dna dna dna covalently functionality covalent covalent function sensitivity methyltransferase enzyme enzyme enzyme epigenetically natural human thus methylation methylation methylation initiate gene gene gene incorporate incorporate form protein would play 
2.0@suppressor inhibitor inhibitor class dnmt dnmt dnmt tumour strand strand hemi low specific allow bind methyl prevent nucleus dna dna dna irreversibly dose methylated expression function drug group reduce attach increase enter methylation methylation parental daughter daughter incorporate actively correspond use decitabine decitabine 
1.33@mean cancer cancer inhibitor category within dnmt produce agent hypomethylating hypomethylates direct call decitabinealso nucleotide class irreversibly strand belong belong inhibit mechanism affect clear release case cell cell cell cell drug dependent antimetabolite antimetabolite seem replication cause cause apoptosis target number bind bind bind antineoplastic metabolism dna dna dna dna dna dna dna divide divide cytotoxic chemotherapy still rapidly rapidly effect upon interact cellular copy death division longer methylation methylation decitabine decitabine decitabine decitabine decitabine daughter incorporate incorporate come come action action methyltransferase methyltransferase methyltransferase methyltransferase 
2.0@cancer cancer cancer inhibition disrupt term reactivation use dnmts dnmts agent rich long probably also also reactivate substance direct hypermethylated treat hemimethylated inhibit inhibit previously achieve cytosine double promoter false attack demethylating dnmt dnmt tumor tumor mechanism normal fact substrate passive cell cell cell drug drug helix supressor supressor analogue therefore decitabine decitabine decitabine decitabine decitabine replication either could could novo specific subsequent prevent demethylation demethylation demethylation dna dna dna dna dna synthesis demethylates function cpg gene gene gene methyltransferase effect undirect suggest inactived due epigenetics methylation methylation antagonist em lead lead action side de 
0.0@myc myc suppressor cancer cause activate include tumour slow myeloma myeloma stop chromosomal myelodysplastic histone histone growth part methyl treat treat call group surround work shut syndrome use enzyme suffer proliferation gene gene gene jq uncontrolled protein silence decitabine methylates cell cell overactivity attach drive 
2.0@cancer cancer cancer cancer cancer characteristic characteristic specificity dnmt dnmt transcriptional activity may state agent exacerbate switch since since therapeutically growth growth tsg tsg back back affect affect inhibit degree interference methylated methylated hyper hyper island island tumor intergenic uncontrolled normal lack turn high exploit passive cell cell cell cell cell cell cell passively suppressor specifically methylating methylating drug drug instability could target result promoter genomic repetitive dna dna dna however hypo often often cpg cpg gene side effect effect rapid replicate methylation methylation methylation methylation decitabine decitabine decitabine region disproportionately account move would would would would de de de de 
2.0@cancer drug cure wilm useful demetilators decrease group dna dna dna call epigenecic name belong tumor accord hypermethylation methylation decitabine mainly drive case case level 
1.67@methyltransferases mitotical neoplasm use already myelodysplastic find de generation drug drug inhibit suppress work promoter methylated methylated involve inhibitor enzyme demethylating island island proliferation tumor tumor hypermethylation genome express cell cell cell tumour region suppressor suppressor also among cause novo mean see anti methyl subsequent group heredability dna dna mark wich wich syndrome inherit cpg cpg gene gene gene gene methyltransferase effect silence methylation decitabine daughter em lay action exist associate 
1.67@become become lock effect abnormal restore tumour agent agent specific hypomethylating normal gene anti cancer avoid group division division dna dna dna dna methyl bind le function demethylating hypomethylated methyltransferase rate fixation control belong dense decitabine high region region class express cell cell cell mention proliferation 
2.0@cancer inhibitor inhibitor inhibitor essentially dnmt dnmt dnmt dnmt dnmt include agent myelodysplastic dnmti dnmti incorporation affect island island island suppress suppress molecule lead epigenetic epigenetic dmnt demethylating demethylating severely take effective tumor tumor tumor tumor normal hypermethylation nucleoside like cell cell cell enzymatic dependent analogue therefore irreversibly alteration replication cause throughout appropriate target gene gene gene gene demethylate methylation methylation prevent dna dna dose reverse reverse bind bind syndrome syndrome syndrome act anti irreversible rapidly effect effect effect little cpg cpg cpg replicate regulator decitabine decitabine work would would small 
1.33@cancer cancer inhibitor unclear use likely generation inhibit irreversibly reduce mechanism block normal usually nucleoside demethylation cell cell cell cell replication replication machinery one specifically dependent epigenetic drug drug analogue subsequent target target low exact anti dna dna dna dna dna divide dose bind act function still methyltransferase methyltransferase methyltransferase effect upon antineoplastic due methylation decitabine decitabine incorporate rapidly prime 
2.0@cancer cancer methyl whose chromosomal myelodysplastic myelogenous change change dhank job epigenetic pass pass enzyme enzyme ezh nearby normal gsk doughter japanese tumour tumour suppressor also methylates work histone histone develop company package cell cell cell cell cell cell cell eisai gene gene gene division find actively decitabine decitabine deacetylase form attach effect effect substance lymphoma regulation use include growthing stop stop newly currently untill growth part thuse treat treat call call inhibit involve precursor refer dr reduce ereased factor kill leukaemia transcription cause acute uncontolled silencies apperent without unlike group return surround syndrome name inhibitor inhibitor protein terapies epigenetics activity hystone overactivity proliferation unmemorable granddoughter 
2.0@cancer cancer methyltransferases produce produce require could inactivation analog selective reactivate island inhibitor enzyme inhibit tumor hypermethylation contradictory genome demethylation cell cell drug region suppressor cytidine however epimutations epimutations replication certain level dna dna dna dna dna dna maintenance continuous reverse bind dnmts cpg gene gene hence effect induce methyltransferase methyltransferase global division division methylation methylation decitabine decitabine decitabine decitabine wide activity rather 
2.0@dacogen effect effect effect dnmt dnmt dnmt administration induce induce tumour tumour fda leukaemia silence anti analog myelogenous aza dnmti exert inhibit response addition lead cytosine degradation know treat enzyme become reduce reduce precursor model myelodysplastic nucleoside rest cell cell cell line food belong suppressor cytidine also proteosomal study drug drug drug deoxy subsequent deoxyribose activity sequestration u inhibitor depletion depletion show covalent dna dna dna dna dna divide non acute syndrome newly prove gene gene methyltransferase reexpression epigenetically result cellular division replicate mediate methylation methylation methylation decitabine decitabine decitabine decitabine decitabine incorporate approve form bound reactivate 
2.0@one suppressor cancer cancer effect depend dnmt tumour slow thus let irreversibly methylate methylate dnmti growth majorly methylation hence decrease lead treatment dna dna divide strand get division division division bind inhibitor dnmts dnmts gene rapidly activation tumor affect hypermethylation new dilute decitabine decitabine decitabine work incorporate come cell drug 
1.67@especially cancer reduce overmethylation regulation tumour agent process since drastically change susceptible make treat effectively epigenetic epigenetic epigenetic pass human demethylating research consumtion myeodysplastic future oppose gsk gsk propagation cell cell cell cell cell cell way leukaemia one dna dna destroy destroy also great use drug drug dectabine influence fell histone unique without become show ready damage unfortunately syndrome several however surround surround amaze chemotherapy sell inhibitor inhibitor inhibitor delete gene methyltransferase importantly truly division go decitabine method could could mean promise return form vicious alter tissue 
2.0@cancer cancer along class specificity dnmt dnmt use use order width really magnilancies probably hr dnmti leave md inhibit nucleotide often strand body belong severely effective tumor mechanism affect dnmtis hypermethylation style style release nucleoside align demethylation cell cell however much much much clear clear suppressor dependent dependent lower high therefore get seem replication replication analogue cause text anti toxic good island dna dna dna dna divide dose dose bind bind know inhibitor cpg irreversible br effect upon methyltransferase copy still still longer thus methylation decitabine daughter gene incorporate come action action rapidly haematological recently 
2.0@different cancer cancer myeloid higher outcome progress tumour tumour tumour tumour although include agent specific trialled myelodysplastic myelodysplastic currently treat inhibit inhibit incorporation lead irreversibly sequence common common well allow demethylating demethylating island effective mechanism feature hypermethylation nucleoside express many cell use decitabine decitabine decitabine decitabine decitabine decitabine older suppressor dependent analogue patient therefore fda replication promotors dose promotor bind solid primarily treatment treatment dna dna dna dna divide non acute cytotoxic syndrome syndrome dnmts cpg poor rapidly effect unclear leucaemia tolerate silence silence haematological gene gene gene approve action methyltransferase prognostic progression 
2.0@document cancer cancer cancer class dnmt dnmt dnmt much bigger repressive myelodysplastic myelogenous stage leukemia useful mother treat treat permanently inhibit inhibit might irreversibly strand strand uncontrollably lose responsible enzyme enzyme mechanism normal divide divide release disallow improvement cell cell cell cell replication replication belong faster patient patient therefore epigenetic epigenetic total work coincide impressive know demethylation dna dna dna dna dna dna get dose acute bind syndrome remission methyltransferase inhibitor inhibitor accumulate resuts copy division da methylation methylation decitabine decitabine decitabine decitabine decitabine daughter daughter em em em em em incorporate action mark mark 
2.0@cancer cancer restore dnmt dnmt dnmt dnmt use use include specific myelodysplastic hypomethylates growth leukemia md treat island lead strand strand sequence methylated thereby inhibit inhibit hypermethylation instability maintain demethylation cell cell recover decitabine decitabine chemical cytidine transcription anemia replication analogue cause mean hemi genomic dna dna dna kill syndrome cpg gene gene recognise inhibitor inhibitor increase division methylation deletion incorporate hypomethylator methyltransferase methyltransferase methyltransferase tissue 
0.67@cit kantarjian inhibitor abnormal abnormal class class lead use dnmts agent hypomethylating manero analog reactivate genetic treat achieve strand especially group reduce dilute jan high aberrant role pharmacother cell tumour tumour directly suppressor cytidine atallah decitabine decitabine decitabine via work dose dose extent hematopoietic myelodysplastic myelodysplastic low reference anti methyl expert treatment dna dna author bind syndrome syndrome act two gene gene methyltransferase effect opin death silence garcia thus methylation genome convalent em em em em incorporate 
1.0@suppressor cancer growth dnmt use loss specific myelodysplastic result currently hypomethylation oncogene hypermethylated treat inhibit dna dna dna acute syndrome gene rather effective tumor tumor tumor methyltransferase suggest myelogenous methylation decitabine decitabine decitabine work work role suppressive hypomethylator aml leukaemia 
2.0@cancer cancer cancer article restore restore restore incorrectly uncontrolled include agent agent agent mark also also economist silence growth growth part unnecessarily addition lead immune methylated methylated inhibitor functionality demethylating demethylating reduce tumor tumor tumor tumor accord normal thus count many cell cell cell cell cell control decitabine decitabine decitabine suppressor suppressor methylating consequently system cause know proper describe decitabines anti normally lecture dna dna dna divide divide histone function function function end gene gene gene gene target effect remove methyltransferase first increase especially extra extra methylation overactivity methylate activity incorrect rapidly rapidly 
1.33@cancer myeloid class dnmt dnmt progress use presently fda mark myelodysplastic dnmti change leukemia inhibit nucleotide epigenetic strand among involve enter effective mechanism normal give genome nucleoside case demethylation demethylation cell drug drug drug dependent analogue irreversibly replication replication cause pas toxic side target know know dna dna dna dose acute bind syndrome le inhibitor methyltransferase effect first methylation decitabine daughter come approve action action hence 
2.0@cancer cancer cannot inhibition malignancy malignancy dnmt dnmt dnmt use use hematological appear process myelodysplastic transfer hypomethylates frequently leukemia make treat inhibit inhibit lead strand severely take myeloid tumor tumor affect hypermethylation release nucleoside case cell cell cell methyl expression suppressor suppressor dependent deme therefore therefore presumably fewer replication analogue analogue limit acute become bind bind thy somatic treatment dna dna dna dna dna dna divide mark inhibitory ase syndrome inhibitor drug gene gene methyltransferase effect place cellular believe interfere since methylation methylation decitabine decitabine decitabine daughter come availability would 
2.0@cancer proliferate progressively restore dnmt dnmt use fda agent stop irreversibly dnmti make tumour tumour tumour marrow inhibit class epigenetic epigenetic strand reversible lose enzyme demethylating island normal normal hypermethylation hypermethylation thus myelodysplastic cell cell cell cell blood belong suppressor drug also patient antimetabolite get alteration replication cause frequent md md know dna dna dna dna divide bind bind syndrome function function cpg rapidly inhibitor inhibitor upon copy death division new methylation daughter bone incorporate approve methyltransferase onto enough 
2.0@cancer lower tumour tumour tumour agent agent loss growth growth anti restrict restrict amount island cpg dna dna dna common expression expression demethylating demethylating gene gene gene gene hence effect result increase hypermethylation methylation decitabine decitabine em icrs use supressor supressor 
2.0@suppressor instead action methyl agent specific subsequent unsilence effect generation normally decrease group greatest lead dna dna dna dna divide divide non rapidly bind le le enzyme enzyme demethylating inhibit inhibit methyltransferase function tumor tumor tumor tumor methylation methylation methylation decitabine gene incorporate cell cell cell cell add replication replication 
0.33@enzymatic cancer cancer methyltransferases therefore epigenetic analogue frequent dependent target normall whichbinds good often dna divide dose bind act belong dnmt division lower decitabine todrugs regulator cell cell cell nuceloside 
2.0@suppressor cancer impact high rat dnmt activate activate tumour probably necessary dnmti effect effect effect effective island reason dna dna dna dna dna bind inhibitor drug irreversible methyltransferase reduce analog normal cpg division division fight decitabine decitabine decitabine nucleoside gene incorporate methylation methylation demethylation cell cell minor tissue 
2.0@driver cancer cancer cancer growth tumour tumour tumour tumour activity sufficient analog major hypomethylation hypomethylation potential treat effectively island molecule lead cytosine demethylating hypomethlyation mechanism genomic hypermethylation apoptotic instability suppressor suppressor suppressor cytidine activation hallmark drug therapy suppression result type type counter prevent particular dna dna dna dna dna however mitigate cpg gene methyltransferase place increase productive due methylation decitabine drive incorporate though enable would small 
2.0@acid suppressor suppressor suppressor cytidine methyltransferases hypomethylation western transcriptional replication agent nucleic place result reside cytosine hypermethylation growth amount dna dna dna dna decitabine decitabine decitabine regulate abrogate methylated repression function demethylating gene gene eliminate tumor tumor tumor analog belong silence consequence reduce reduce region incorporate cell polymerase class class 
0.0@
2.0@cancer cancer cancer rate higher restore dnmt dnmt dnmt progress may agent myelodysplastic find block hypermethylated hypermethylated tumour tumour island previously class class class epigenetic body body inhibitor inhibitor inhibitor belong demethylating demethylating outcome round affect hypermethylation rely descend nucleoside thereby use suppressor irreversibly via drug drug analogue cell cell cell cell gene anti dna dna dna dna dna synthesis bind syndrome act suppression cpg poor aml aml effect remove division since methylation decitabine possible incorporate incorporate approve methyltransferase prognostic associate 
1.0@mean dependent cannot greater epigenetic use use cause agent agent cell cell cell analog since hypomethylation anti bind tumour affect arrive dna dna dna dna dna irreversibly strand copy cytidine inhibitor enzyme demethylating drug drug drug chemical rate methyltransferase normal neoplastic new methylation release region incorporate action way replication replication replication decitabine decitabine decitabine 
2.0@dna dna dna dna dna dna methyltransferases methyltransferases abnormal abnormal well inhibitor function hypomethylated proliferation reduce tumor tumor cause slow hypermethylation hypermethylation since decitabine decitabine decitabine make many cell inhibit treatment 
1.67@dacogen cancer methyltransferases change dnmt regulation baylin itis agent agent stop eisai find growth useful hypermethylated incorporation decrease decrease often epigenetic epigenetic even call irreversiblybinds involve hypermethylation demethylating demethylating dr penetration able tumor tumor tumor mechanism produce routine nucleoside evident case case cell example market suppressor oftumor efficiency therapeutic via drug analogue combination drugsalso japanesse histone somehow chemotherapeutic solid solid level company dna dna dna dna dna research act le still gene gene inhibitor inhibitor deacetylase silence due methylation decitabine decitabine decitabine facilitate active action enhance 
1.67@dacogen cancer risk use hematological place myelodysplastic leukemia myelogenous easier hypomethylation potential treat decrease inhibit act lead epigenetic see methylated candidate factor factor accessible tumour level suppressor transcription transcription transcription fight strike result problem become become help occur medical prevent root etc dna dna dna dna le acute syndrome sell important gene gene methyltransferase inhibitor ingredient condition first silence silence thus methylation decitabine decitabine decitabine active 
2.0@cancer wiley abnormal restore dnmt dnmt uncontrolled agent library online azacytidine growth clearly inhibit inhibit define international epigenetic work show allow demethylating em em tumor tumor tumor tumor normal normal hypermethylation mode mode directly nucleoside cell cell may expression suppressor suppressor also also although consequently study study drug cause cause information function function function mutation apoptosis result bond anti promoter prevent methyltransferase methyltransferase journal dna dna dna dna dna divide reverse demonstrate additional perform gene gene gene gene azanucleoside inhibitor induce analog human vitro vitro silence methylation decitabine decitabine decitabine decitabine decitabine stresemann create incorporate action action rapidly class 
2.0@cancer methyltransferases namelly restore determine tumour state state state agent decitabine decitabine island result result transcription certain growth growth growth effect anti usual inhibit cpg promote promote dna dna dna therefore le demethylating observe supressing gene gene turn aproximation normal increase heterochromatin longer methylation methylation methylation repair steady cell cell protein transcribe 
1.0@dacogen inhibitor restore reactivation remove methyl manner exhibit hypomethylating eisai hypomethylates similar japanese treat achievable decitabine decitabine decitabine decitabine play effective origin strand sequence know disease inhibit chromosome dnmt adjuvant clinically role role myelodysplastic although potent demethylation cell may may recover use cytosine transcription patient residue epigenetic presumably therapy agent agent property promoter group company dna dna dna dna dna dose inhibitory act sell function gene gene gene gene gene methyltransferase expression induce rare suggest silence silence silence silence rna advance possible incorporate incorporate malignancy form downstream antitumoral adrenocortical azacitidine azacitidine 
1.67@lung cancer cancer class last overmethylation activate tumour try agent agent silence silence de de de susceptible make treat patient patient epigenetic help belong demethylating demethylating reduce tumor tumor tumor react otherwise otherwise express cell way indicate supressor supressor dna dna dna dna dna methylating methylating researcher drug cause combination subsequent histone histone chemotherapeutic success anti type show furthermore good treatment treatment treatment standard reaction gene gene effect epigenetically deacetylase great thus thus methylation decitabine decitabine work alter 
0.67@cancer cancer cancer methyltransferases disrupt agent already probably de possibly oncogene exert island cpg epigenetic demethylases demethylating enhance downregulation block genome genome high hem cell stimulus proliferative also action action mitotic via either could likely destabilazation therby present effect effect occur novo prevent protect dna mark reverse dnmts unlikely multiply rapidly supressing demethylation demethylation demethylation deregulate production activity tumorigenesis methyltransferase would decatibine 
2.0@dna dna dna suppressor suppressor methylated cpg cpg inhibit methyltransferase promotors likely activate cancerous decitabine hypomethylates demethylation cell island island tumour tumour demythylating 
2.0@suppressor transfer therefore use use agent hypomethylating myelodysplastic myelogenous treat promoter inhibit previously lead lead dna dna dna acute methylated syndrome precursor expression group methyltransferase tumor decitabine decitabine gene demethylation demethylation methyl leukaemia 
1.0@allow cancer cancer inhibitor inhibitor class term dnmt progress use long myelodysplastic since malignancy dnmti susceptible methyl transferase irreversibly call belong effective normal hypermethylation nucleoside case demethylation cell cell cell cell cell cell cell tumour tumour decitabine decitabine decitabine suppressor suppressor dependent dependent therefore seem replication replication analogue epigentetic result largely demethylate type occur know dna dna dna however bind syndrome expression drug drug gene gene aml effect effect copy division replicate methylation would daughter incorporate come approve action rapidly haematological 
1.67@dna dna dna dna divide rapidly bind demethylating methyltransferase tumor agent result citotoxic decitabine hypomethylation covalently incorporate cell inhibit damage genome 
2.0@code dnmt dnmt activate tumour tumour agent agent stop stop transfer reactivate unmethylated unmethylated unmethylated transferase inhibit inhibit cytosine enzyme enzyme demethylating group group proliferation tumor tumor tumor essential contribute contribute demethylation cell cell cell cell cell removal methyl methyl methyl supressor supressor also replication icr result anti promoter insulator ctcf dna dna dna dna dna dna dna dna divide divide supressing bind bind bind example expression gene gene gene gene effect silence mother methylation methylation decitabine decitabine daughter region region mean modify protein 
2.0@older cancer cancer methyltransferases faster term outcome progress use manner agent specific long stag myelodysplastic myelodysplastic since apply leukemia md treat affect inhibit cpg significant noticeable irreversibly typical severe severe demethylating island myeloid mechanism reason normal hypermethylation usually side side cell cell cell tumour expression one suppressor dependent patient presumably include replication therapy likely limit positive without exact potentially show good treatment treatment dna dna dna non acute bind syndrome syndrome target still gene methyltransferase effect effect effect unclear division replicate hypothesis decitabine advance work response though action action aml 
1.0@cancer along class target dnmt dnmt progress use lt xml island methyltransferase analog dnmti regulatorssince possibly md treat urn prefix com irreversibly irreversibly strand readilytargeted microsoft inhibitor inhibitor inhibitor inhibitor enzyme severely effective myelodisplastic myelodisplastic due gt affect hypermethylation release nucleoside n cell cell methyl methyl ul ul enzymatic drug transfer transfer therefore epigenetic epigenetic epigenetic aml replication replication cause office office decitabine decitabine incorporate incorporate come bind bind prognosis division dna dna dna dna dna dna dna divide namespace upon syndrome syndrome dnmts cpg dependency current nucleotideto molecular dependant dependant copy belong replicate bindthat methylation longer daughter poor mean schema sign action machinery rapidly small 
1.67@unregulated cancer cancer restore restore within within produce activity way agent agent process major similar growth direct increase inhibit regulate regulate believe allow demethylating tumor mechanism normal normal anticancer demethylation demethylation cell cell cell cell cell cell cell cell control blockage expression suppressor suppressor also promote divide cause target result number become metabolism dna dna dna hypomethylating substance substance cytotoxic function gene gene gene rapidly effect effect interact cellular death division division interfere thus methylation methylation methylation decitabine decitabine decitabine work work incorporate methyltransferase 
2.0@different cancer cancer article standard dnmt start use use deme appear agent agent rich myelodysplastic acetylation currently economist apply ligand suggest inhibit suppress epigenetic promoter inhibitor inhibitor disease demethylating demethylating island enhance deacetylation tumor tumor tumor mechanism cod blood epigenome effectiveness least although trail trail afterwards cell cell demethylatedna decitabine lung lat also upregulate advance histone region combination apoptosis describe experiment solid thy together syndrome dna dna maintenance non catalysis chemotherapy site expression cpg cpg gene gene methyltransferase effect effect induce induce kb death fortreatment methylation locate transcription mitosis slow approve modify upstream showshistone progression 
1.67@abnormal effective produce way agent hypomethylating normally marrow marrow marrow addition sustain decrease step enzyme trap order heritability normal mutation complex genome cell cell cell cell blood therefore mitotic cause window therapy toxic result kill elimination help prevent unfortunately covalent dna dna catalysis degradation remove die must bone bone bone due thus methylation methylation decitabine decitabine decitabine decitabine work incorporate would small 
2.0@suppressor methyltransferases growth reactivation induction cause agent subsequent hypomethylating silent cytotoxicity hypomethylation solid prevent dna dna dna dna strand bind inhibit inhibit single tumor tumor methylation decitabine gene covalently differentiation methyltransferase 
0.33@dna dna epigenetic suppressor demethylating via may tumor agent methylation express inhibit control 
1.67@cancer toxicity areincorporated overdose tumour fda agent change hypermethylated decrease inhibit inhibit lead irreversibly epigentic demethylating happen normal turn turn replication ul ul specifically dependent suppresor therefore sustain drug therapy overgrowth result result result dosage type dna dna dna dna however reverse bind act dnmts gene effect formerely methylation methylation methylation methylation decitabine decitabine approve reinstatement tissue tissue tissue tissue 
2.0@cancer cancer inhibitor class dnmt progress methyl methyl myelodysplastic myelogenous silence leukemia hypermethylated treat transferase transferase inhibit epigenetic enzyme especially island untreated tumor tumor activation hypermethylation release nucleoside drug cell use suppressor enzymatic dependent irreversibly replication replication analogue target target result result anti demethylation dna dna dna dna get acute bind bind syndrome site dnmts cpg gene effect upon belong longer thus thus regulator decitabine decitabine incorporate active 
2.0@every progressively epigenetic epigenetic start n methyl certain inhibitor stop stop decitabine decitabine mark myelodysplastic since silence growth tra anti ase drug inhibit demethylases dna dna dna divide strand mantainance mantainance syndrome act lose demethylating gene effect uncontrolled divisionby contain activate new methylation methylation genome time mean cell tumour tumour tumour supressor 
2.0@suppressor suppressor cancer cancer inhibitor dnmt goal slow growth effect overall transferase island demethylation dna dna dna dna promoter typical enzyme cpg inhibit reduce reduce tumor tumor hypermethylation methylation methylation allow region gene gene express counteract methyl decitabine decitabine decitabine 
1.67@mean effect effect class eliminate order methyl attempt characterize characterize analog larger hypomethylation rate make normal normal normal dna dna epigenetic strand methylated inhibitor inhibitor belong take tumor tumor tumor tumor post nucleotide hypermethylation dilute nucleoside high cell cell several daughter irreversibly replication replication replication replication incorporate course anti amount know group reduction however dmnti bind bind function cpg cpg methyltransferase true place copy unavailable due methylation methylation decitabine decitabine decitabine decitabine decitabine sit dmnt dmnt eventually strong 
1.33@cancer rate dnmt dnmt dnmt dnmt dnmt dysregulation use use myelodysplastic currently malignancy hypermethylation lead increase malignant malignant see enzyme myeloid heritability replicate normal essential epigenome convert may may dilute genome genome factor regulate line episode leukaemia dependent patient patient mitotic cell cell cell cell cell acute dosage age variable prevent treatment dna dna dna understand reverse syndrome inhibitor inhibitor inhibitor inhibitor cpg methyltransferase effect effect effect preferentially death division additionally thus methylation methylation methylation decitabine decitabine mitosis context action 
2.0@specificity dnmt dnmt progress tumour tumour tumour tumour tumour tumour tumour myelodysplastic whilst growth sydndrome hypermethylated exert agentit island inhibitorie greatest irreversibly repression allow demethylating inherent impact impact mechanism block block normal lack generally gastrointestinal thus nucleoside actively primarily cell cell cell may tra suppressor suppressor dependent also become replication replication analogue gene gene anti methyl prevent dna dna dna divide divide bind fe expression cpg cpg hence aml effect hair tract hypermethylationsuch rase methylation methylation decitabine decitabine mucosa drive incorporate action rapidly tissue 
1.33@suppressor cancer hypometilation hypometilation drug drug cause could growth treat decrease group myelodyplastic reactive dna dna dna dna syndrome silence gene gene methyltransferase methyltransferase inhibitor tumor control belong decitabine decitabine like cell cell overactivity use 
0.67@myc dacogen cancer inhibitingdna activity class last regulation ncodes use title title manner agent agent hypomethylating myelodysplastic cell myelogenous one growth susceptible make treat call inhibit common expression epigenetic strand tumour tumour tumour involve precursor demethylating way block particular although factor factor decitabline italic leukaemia wrong standard slow successfully deploy system drug drug cause combination decitabine decitabine decitabine decitabine incorporate incorporate acute trade solid chain chemotherapy dna dna dna dna dna dna histone syndrome name function gene gene methyltransferase methyltransferase inhibitor similar deacetylase human go regulator rna transcription transcription em em another hypomethylates part protein alter azacitidine azacitidine azacitidine azacitidine 
1.67@plastic allow cancer cancer cancer cancer cancer etiology restore dnmt regulation use lod hat could acetyl major hypomethylates change genetic exert chromatin remodelers occur molecule molecule often epigenetic epigenetic development reversible currently repression inhibitor enzyme enzyme inhibit inhibit inhibit tumor tumor hdac hypermethylation hypermethylation hypermethylation fact utilize instability role express treatment etc expression suppressor suppressor suppressor transfer fda carry ability tet therapy therapy gene gene gene ase antitumor lead either involve dna dna dna dna dna dna histone histone histone histone thus syndrome demethylase hdm mi methyltransferase methyltransferase methyltransferase methyltransferase methyltransferase effect deacetylase hmt silence find regional decitabine decitabine methylation y malignancy approve various play 
2.0@cancer therefore action use myelodysplastic find growth gene gene gene anti treat inhibit inhibit dna dna dna acute reactived syndrome precursor expression demethylating hypomethylated methyltransferase effect supressor supressor silence myelogenous decitabine drugthat leukaemia decabine tumour tumour tumour associate 
1.67@growth dnmt dnmt dnmt dnmt methyl agent stand process meet reactivate hypomethylation unmethylated make hemimethylated hemimethylated apotosis class epigenetic methylate enzyme facilitate tumor tumor suppress although cpg cpg cell one transfer transfer cause novo dnmti arrest group particular family dna dna ase name dinucleotides gene inhibitor inhibitor belong belong silence methylation decitabine decitabine mitosis de 
1.33@dependent inhibitor dnmt tumour tumour tumour analogue agent align leave anti dna dna irreversibly bind dnmts demethylating severely effect effect affect feature belong methylation decitabine decitabine decitabine nucleoside aberrant incorporate demethylation thereby much replication replication 
1.33@cancer regain drug drug agent since hypomethylates gene gene tumour tumour group suppress suppress dna dna dna capacity allow demethylating inhibit methyltransferase remove hypermethylation silence decitabine region mean express methyl 
2.0@cancer cancer cancer think class dnmt dnmt transcriptional methyl fda phase silence dysregulated selective hypermethylation change change genetic tumour transferase locus aza lead lead irreversibly call export enzyme thereby group proliferation dnamis dnamis release many many cell cell use inhibit decitabine decitabine one suppressor tsgs tsgs epigenetic epigenetic excessive drug drug cause reactivate activity reverse ultimately arrest halt prevent potentially dna dna dna dna dna intervention synthesis synthesis bind syndrome myelodysplastic cpg gene methyltransferase inhibitor inhibitor induce deoxycytidine increase belong due thus methylation methylation methylation pathologically mainly incorporate approve death reprogramming associate 
0.0@cytidine itis abnormal via cause agent hypomethylating two result low cytotoxicity hypomethylation direct inhibition incorporation marrow inhibit analog dna dna dna dna dna death dose dose hematopoietic bone methyltransferase think induce mechanism antineoplastic source rna high activity hypomethylates cell cell decitabine 
1.67@cancer cancer cancer methyltransferases methyltransferases uncontrolled easily easily easily member frequently hypomethylation overall quite treat normal fastest promote irreversibly mention characteristic mechanism key affect clear thus nucleoside conclude conclude disable tumour one one one one one specifically specifically dependent dependent also patient replication replication replication analogue information focus anti dna dna dna dna understand cell cell cell cell bind use inhibitor still effect effect replicate replicate go decitabine decitabine decitabine incorporate action action 
0.67@class specificity dnmt way hematological analog claim dnmti recommend become treatment dna antineoplastic malignant bind irreversible effect tumor affect lack belong decitabine nucleoside incorporate drug 
2.0@suppressor suppressor suppressor impact identify class tumour agent agent silence describe describe cancerous hypermethylation effect effect anti anti abnormal amount inhibit dna dna dna dna dna dna epigenetic expression inhibitor hyper thereby gene gene gene demethlyating demethlyating reduce reduce tumor tumor tumor tumor result belong thus methylation methylation methylation methylation allow enzyme cell use decitabine decitabine decitabine decitabine decitabine decitabine 
2.0@effect effect dnmt dnmt use agent myelodysplastic myelogenous malignancy treat transferase inhibit inhibit irreversibly precursor enhance mechanism neoplastic hypermethylation hypermethylation clear nucleoside potent demethylation tumour tumour tumour leukaemia dna dna heamatological analogue yet dosage lie anti anti anti completely methyl basically reason acute bind syndrome smaller still gene inhibitor supressor main decitabine decitabine decitabine action propose 
2.0@suppressor cancer reduce class activate tumor tumor use ofdecitabine agent cause anti demethylated make level island cpg dna dna demethylating group effect remove nucleotidesand belong decitabine decitabine gene cell methyl 
2.0@could inhibitor dnmt dnmt dnmt dnmt dnmt unclear xml xml xml xml xml two analog analog hypermethylated make unmethylating adn effectively inhibit lead irreversibly unmethylation unmethylation see methylated en en en en en en en en en en responsible classic pair tumor tumor tumor tumor mechanism mechanism nucleoside second cell cell cell replication recover suppressor suppressor excessive total u u u u u u u u u u chemotherapeutic twin anti normally dna dna dna divide divide citidine unavailable bind site cpg gene methyltransferase attack lang lang lang lang lang lang lang lang lang lang copy gpc replicate methylation decitabine decitabine incorporate first action action action 
2.0@pronounce maybe cancer cancer inactivate dnmt dnmt progress use myelodysplastic dnmti might transferase lead body methylated kind inhibitor effective affect nucleoside like demethylation cell cell cell methyl see also replication analogue whole relatively low best best combine dna dna dose bind bind syndrome synergistic drug drug drug irreversible rapidly effect effect effect upon copy antineoplastic replicate thus methylation decitabine heavily incorporate aml 
1.0@cancer scientist may may agent benign myelodysplastic myelogenous element useful oncogene treat epigenetic despite demethylating intergenic precursor hypermethylation hypermethylation hypermethylation general express harmful use leukaemia market dna dna patient fewer drug drug certain yet like become type fully prevent region repetitive reason understand cell cell syndrome sound well side effect remove remove seem thus decitabine work associate 
1.33@cancer effect therewith therewith available dnmt dnmt dnmt dnmt slowdown analogue agent mean mean since bigger growth effective amount island want dna dna irreversabily bind act inhibitor cpg rapidly reduce reduce tumor devide normal normal division methylate methylation decitabine decitabine nucleoside incorporate demethylation cell cell cell cell cell 
1.33@cancer cancer inhibition restore use agent agent stop myelodysplastic analog leukemia md overall treat avoid inhibit inhibit suppress cytosine decrease component allow demethylating demethylating adna myeloid tumor tumor tumor tumor mechanism repair many disable may decitabine decitabine decitabine suppressor suppressor suppressor cytidine therefore divide divide excessive cause indefinitely deoxyribose cell cell present ribose amount chain dna dna dna dna dna dna apoptosis apoptosis ring acute syndrome least expression expression gene gene gene chemical methyltransferase cellular attach undergo methylation methylation rna incorporate aml without 
1.33@haematalogical cancer cancer cancer cannot depend depend dnmt dnmt replication replication agent since malignancy type overall decrease many dna dna dna dna irreversibly bind bind example inhibitor hyper demethylating affect affect take effect upon normal methylation methylation release incorporate like counteract cell cell cell cell decitabine decitabine 
1.33@suppressor could methylating inhibition restore start tumor tumor methyl agent anti transcription de sit sit group function cpg island effect effect remove remove normal hypermethylation decitabine counteract presumably 
2.0@cancer cancer proliferate dnmt use use agent process myelodysplastic hypermethylated treat treat island epigenetic particularly demethylating impact impact tumor due due normal nucleoside demethylation cell cell cell cell cell drug mode dependent greater patient patient irreversibly seem replication replication analogue success demethylate completely know involve dna dna future bind syndrome le dnmts cpg aml inhibitor increase increase possible replicate decitabine decitabine decitabine impactful incorporate action 
1.0@article apply activate slow agent agent process two growth infer deacetylase category kind well silence demethylating enhance reduce tumor tumor tumor tumor accord feature routine cell cell cell suppressor consequently drug drug exhibit moreover chemotherapeutic effect solid particular unfortunately dna dna dna histone histone name act inhibitor gene rate upon force remarkable belong methylation decitabine region hypermethyation combine 
1.33@cancer cancer dnmt use use fda myelodysplastic incorporate susceptible transferase inhibit chemotherapeutics irreversibly mechanism normal although antineoplasic demethylation cell cell drug drug drug drug machinery one nucleoside therefore epigenetic replication analogue four target constantly exact type methyl show dna dna dna dose bind syndrome still effect effect unclear global replicate low decitabine decitabine activity approve action 
1.33@cancer cancer cancer cancer article standard tumour cycle epicentre find economist hypomethylation participant test treat treat deploy inhibitor penetration affect anticancer improvement metabolic role cell cell process first one one dna also successfully epigenetic epigenetic drug drug drug drug drug apoptosis describe chemotherapeutic responsive anti arrest solid show several harder reaction thereafter methyltransferase important lung due decitabine decitabine decitabine activity various play 
1.33@maybe mean cancer cancer effect effect effect malignancy dnmt dnmt dnmt tumour specific analog since azacytidine dnmti dnmti inhibit nucleotide irreversibly strand well well belong severely way effective mechanism affect neoplastic hypermethylation clear vidaza nucleoside demethylation cell cell much release suppressor dependent dependent lower high get thats replication replication cause toxic suppose anti good dna dna dna dna divide dose dose bind bind act inhibitor gene rapidly along upon similar copy division longer methylation decitabine decitabine decitabine daughter incorporate come action methyltransferase methyltransferase haematological totally 
2.0@cancer cancer cancer cancer methyltransferases class biomarkers dnmt disease use serine agent long inactivation replace find malignancy aberration heritable unlike dna dna dna clinical epigenetic epigenetic work reversible methylated inhibitor hyper shift alter change tumor tumor neoplastic complex site cell trial drug drug drug machinery one suppressor dependent dependent residue therapeutic decitabine manner replication cause cause combination therapy mutation incorporate result result focus fda chemotherapeutic anti solid show approve diagnostic several dose covalent act act target irreversible rapidly effect stage replicate since since since haematological gene lethal promise active form prognostic 
1.67@cancer serve class dnmt induce fda currently reactivate reactivate hypomethylation possibly regulate phenotype epigenetic responsible reactivation tumor tumor mechanism normal hypermethylation genome program cell machinery one suppressor suppressor also therapeutic drug apoptosis u cancerous reverse away four modify modify act gene gene gene inhibitor epigenetically cellular death silence decitabine decitabine wide approve action dnmti 
1.67@suppressor suppressor cancer also supression tumour tumour overexpressed process demethylated effect effect effect effect anti normally methyl protein group lead dna histone help drug inhibit reduce tumor tumor enzyms developement methylation decitabine decitabine decitabine gene gene demethylation regulate attach 
2.0@cancer oncosuppressor inhibition dnmt dnmt dnmt relate tumour cause agent aim island cure hypermethylation gene make type might transferase prevent cpg division division dna dna dna dna dna irreversibly methyl bind bind belong belong demethylating inhibit rapidly important important dependant affect generally replicate main methylation methylation decitabine decitabine decitabine dependency mean case demethylation cell cell drug drug drug promoter 
1.67@cause mainly available dnmt dnmt dnmt tumour analogue fda add present inhibitor inhibitor bind transferase prevent class dna dna dna dna dna dna divide deciabine use enzyme enzyme drug group hence reduce hypermethylation replicate new methylation methylation decitabine decitabine decitabine nucleoside daughter approve cell cell methyl methyl manage belong 
0.67@concidered proliferate disrupt dnmt dnmt dnmt dnmt replication region include agent attempt process methylate incorporation lead dna dna dna irreversibly sequence bind inhibitor enzyme effect tumor tumor death thus actively release nucleoside couses homologue cell cell cell decitabine decitabine 
1.0@suppressor dnmt agent avoid myelodysplastic myelogenous leukemia especially inhibit act dna dna acute syndrome precursor enzyme demethylating prevent methyltransferase tumor hypermethylation methylation decitabine aberrant gene 
2.0@et cancer cancer class outcome administration blood agent whose hypomethylating myelodysplastic replace find therapeutically hypomethylation useful island lead cytosine date strand methylated issue proceed effective tumor tumor tumor myelodisplastic rely genome silence methylation cell hagop global suppressor cytidine transcription patient patient page improve april reference ribose promoter treatment dna dna dna ring kantarjian syndrome syndrome volume additional still gene allow analog cpg due thus al decitabine decitabine decitabine decitabine em incorporate heavily 
2.0@myc myc myc drag class dnmt activity agent silence eisai find de hypomethylation island lead involve human demethylating inhibit tumor block block contrary factor japanese incorporate incorporate decitabine decitabine one suppressor transcription researcher drug drug drug cause cause attempt target result encode depletion develop company dna dna dna dna expression expression cpg gene gene gene methyltransferase similar creation creation restore belong thus methylation rna another brd collaborator indirectly grug azacitidine 
2.0@et cancer effect effect growth dnmt activate tumour tumour tumour agent riley example already myelodysplastic myelogeneous since aza cellular hypomethylation leukemia make exert inhibit anderson lead epigenetic promoter dna dna treat scott demethylating hamilton daskalakis normal produce phosphorylation hematologic alteration like like cell cell control suppressor suppressor care critical literature initiative cdkn cdkn cdkn drug cause apoptosis encode anti type dual ink ink action metabolism kind expression acute cytotoxic syndrome use function gene gene gene aml inactivate methylation interact deoxycytidine report death al decitabine decitabine production return instance reactivate 
2.0@suppressor cancer instead greater dnmt tumour tumour require agent attempt hypomethylating cancerous gene anti copy prevent cpg island dna dna dna dna dna reverse bind example demethylating inhibit rapidly effect effect effect methyltransferase normal repeat hypermethylation replicate replicate methylation methylation decitabine decitabine decitabine daughter work work incorporate cell cell cell cell cell much much replication 
2.0@et et et disrupt haematologica wattel use agent vereecque myelodysplastic myelodysplastic myelodysplastic reactivate leukemia md md treat inhibit inhibit guillerm disease disease demethylating demethylating bauters tumor tumor tumor paper hypermethylation hypermethylation quesnel quesnel high high aberrant al al al voso secondary suppressor suppressor suppressor andacquired risk sydromes drug frequent teofili reference present present thata show dna dna dna dna prevalence blood syndrome syndrome syndrome gene gene gene gene methyltransferase methyltransferase lubbert myelodyspastic leone leone thus methylation methylation methylation decitabine ink ink associate preudhomme progression progression 
1.67@cancer cancer cancer methyltransferases dnmt uncontrolled agent myelodysplastic currently hypomethylates hypomethylation hypomethylation oncogene treat effectively inhibit lead lead lead strand proliferation proliferation reduce reduce demethylasing affect hypermethylation hypermethylation turn directly transference case cell cell cell cell tumour tumour tumour tumour region suppressor suppressor suppressor patient activation use use cause inhibtion activity result result underlie parent treatment dna dna dna dna dna non syndrome act gene gene gene hence effect similar hypomethylasing methylation decitabine daughter mitosis incorporate indirectly 
1.67@different fail higher dnmt dnmt dnmt agent hypomethylating event replace since cellular increase decrease decrease inhibit clinical irreversibly strand methylate chemical cytosine supportive supportive demethylating adna versus mechanism carbon carbon like cell cell try level level level decitabine decitabine decitabine decitabine decitabine decitabine dna dna cytidine care care patient patient sustain preclinical cause improve property myelodysplastic suggest free free number depletion best occur show group group syndrome several stick ring bind epigenetic risk dnmts average methyltransferase additional induce analog must evidence nitrogen nitrogen line due methylation methylation methylation methylation longer progression electron incorporate position expose survival reprogramming alter azacitidine 
2.0@dacogen inhibitor dnmt induce induce use hematological include agent aberrantly myelodysplastic analog also functional change leukemia morphological aza addition cytosine epigenetic epigenetic pass consequence demethylating tumor tumor tumor act methylgroups mature nucleoside cell cell cell way level suppressor commonly patient erase irreversibly drug slow trade thatbounds remission anti type type show prevent dna dna dna base powerful syndrome name cpg gene gene methyltransferase effect upon silencedgenes deoxycytidine progression division new actively decitabine decitabine decitabine region fact leukemic differentiation reactivate reactivate 
2.0@cannot agent hypomethylating since growth become hypermethylated inhibit dna dna dna prevent prevent enzyme demethylating island methyltransferase allow tumor tumor cpg methylation decitabine mean active repressor 
2.0@cancer cancer cancer cancer transfer therefore therefore able uncontrolled cause prove stop silence proliferate proliferate meet reactivate hypomethylation effect distinct normal inhibit dna dna dna divide rapidly rapidly inhibitor drug drug gene gene proliferation proliferation as methyltransferase control control feature division show since since methylation decitabine assume cell cell cell cell cell cell protein encode 
1.67@cancer inhibitor dnmt dnmt tumour tumour every tend remain hypomethylation unmethylated hypermethylated normal normal island development uncontrollably methylated allow reduce methylate affect usually rase release nucleoside nucleoside nucleoside cell cell methyl tra one one certain assume therefore however analogue analogue analogue strand strand strand strand strand cause cause cause incorporate describe decitabines amount dna dna dna dna divide alongside mind bind fe act cpg effect probably division division replicate replicate replicate thus methylation methylation decitabine decitabine daughter daughter daughter lay original restriction comprise dont would 
1.33@cancer methyl methyl correct since dnmti hypomethylation normally make transferase strand decrease methylated methylated enzyme group impact tumor block hypermethylation usually thus actively repetitive repetitive may region one would worsen cause suppose suppose decitabine decitabine cell cell condition case element promoter prevent potentially dna dna dna dna dna divide divide divide duplicate function gene inhibitor copy template new new methylation methylation expect expect work work onto 
1.67@cancer cancer cancer methyltransferases change change tumour tumour slow agent stop silence silence inhibit classify reactivate growth potential might might erase erase granddaughter epigenetic epigenetic epigenetic malignant malignant pass successfully contribute grow take deacetylation antimetabolite intravenously transformation give genetics actively justly cell cell cell cell cell first critical study therefore deploy drug drug drug combination therapy apoptosis kill without deacetylases anti solid show demethylation treatment dna dna alongside histone histone histone chemotherapy inhibitor time analysis effect induce place deacetylase division epigenetics methylation decitabine decitabine daughter gene gene return azacitidine 
1.33@specifically cancer suppressor decitabine decitabine tumour drive agent likely apoptosis reactivate possibly arrest lead dna dna help demethylating methyltransferase inhibitor gatekeeping mechanism hypermethylation repair reinstate cell cell cycle would associate 
1.33@mean cancer myeloid depend dnmt dnmt progress use cause inhibitor agent cell cell cell methyltransferase methyltransferase acute replication replication treat copy nucleotide dna dna dna dna get get strand body bind bind syndrome smaller myelodysplastic demethylating rapidly along along upon longer affect replicate methylation methylation release daughter incorporate come come action removal tumour decitabine decitabine 
2.0@cancer methyltransferases restore suppressor suppressor suppressor induce induce methyl title chemically mutation hypomethylating myelodysplastic analog hypomethylates reactivate reactivate leukemia leukemia md hypermethylated fundamental transferase inhibit aza epigenetic strand proliferation myeloid myeloid tumor tumor tumor hypermethylation role demethylation control compound sensitivity cytidine reversion patient patient therefore relate study drug ability agent apoptosis behind focus therapy therapy show treatment dna dna dna dna dna substantial acute acute syndrome function gene gene gene gene gene gene aml aml inhibitor inhibitor epigenetically methyltransferase deoxycytidine silence silence undergo potency demethylated decitabine decitabine decitabine decitabine revert em incorporate nucloeoside rationale play 
2.0@cancer cancer methyltransferases inhibition dnmt uncontrolled agent hypomethylating find reactivate growth growth tumour tumour tumour tumour normal irreversibly inhibitor severely reduce reduce due affect hypermethylation hypermethylation rase nucleoside cell cell methyl suppressor suppressor dependent dependent methylating run therefore drug analogue mean anti amount prevent prevent dna dna dna dna dna dna action bind act fe dnmts dnmts gene gene effect effect division replicate since since methylation decitabine decitabine decitabine hypomethylated beneficial incorperated dnmti dnmti dnmti 
2.0@cancer cancer inhibitor class slowly activate still use use drug defeat island myelodysplastic dnmti make oncogene treat know grow example dna dna dna epigenetic syndrome hypermethylation cpg gene methyltransferase reduce unclear mechanism mechanism belong silence methylation methylation decitabine decitabine decitabine like supressor tumour haematological associate 
1.33@cancer proliferate n methyl fda specific really daugter make island molecule irreversibly strand body og inhibitor human belong tumor tumor tumor myelodisplastic rely demethylation cell cell cell cell tra dependent therefore drug drug drug cause development lover impossible bind treatment dna dna dna dna dna divide dose kill ase syndrome important cpg effect effect effect copy division methylation methylation decitabine dosage approve small 
1.33@belong hypomethylation part produce tumor cell group suppress 
2.0@maybe cancer inhibitor dnmt dnmt produce way fda specific specific specific myelodysplastic find de decitavine hypermethylated dosis dosis avoid normalization irreversibly strand strand promoter island reduce reduce tumor mechanism clear nucleoside high drug cell methyl one suppressor dependent lower although replication replication analogue novo target toxic transferase approve family treatment dna dna dna however non bind bind syndrome act expression expression cpg gene gene gene effect effect copy belong methylation methylation methylation methylation decitabine decitabine decitabine daughter return action action frequently 
2.0@suppressor methylating class therefore attach tumour tumour tumour tumour cause inhibit ly become result histone histone histone meet effect effect anti anti methyl methyl decrease prevent nucleotide ezh ezh dna dna dna epigenetic lation cell lymphoma inhibitor hyper demethylating demethylating group group proliferation impact remove overactive affect belong silence methylation decitabine decitabine decitabine gene gene enzyme enzyme increasingly protein would 
1.67@inhibitoragent suppressor suppressor cancer methylating class epigenetic enzymatic tumour tumour tumour tumour tumour bigger agent stop epicentre effect generation bind lecture next dna dna divide pass help form inhibitor enzyme demethylating gene dnmt dnmt dnmt dnmt block normal hypermethylation methylation methylation release regulator drive lay like decrease cell cell ref nuceloside decitabine decitabine decitabine 
2.0@mean cancer cancer characteristic risksin activate activate ofchromesomes methyl possibly meanwhile agent long theenzymatic tackle article chance inreplication leave hypermethylated might island island cpg irreversibly however demethylating impact tumor tumor tumor accord normal give usually isin repetitiveelements cell cell cell cell much much nuceloside one suppressor suppressor suppressor drug also run therefore epigenetic epigenetic via recombination analogue potential suppose likely ofdna ofdna demethylate promoter group dna dna divide bind smaller target bydecitabine gene gene gene bindsdna inhibitor inhibitor methyltransferase methyltransferase methyltransferase methyltransferase illegitimate getdemethylated ascpg regulator decitabine lay form rapidly 
2.0@hypermethylations cancer cancer inhibition last reactivation use use include agent specific cure analog nevertheless md md genetic treat melodysplastic partially nucleotide lead cytosine even around help decade allow research tumor tumor tumor pattern epigenetics mitoses high high aberrant thousand demethylation demethylation cell way suppressor suppressor suppressor dependent also antimetabolite drug dose dose dose could cycle finally hypothetically without show dna dna dna base cytotoxic cytotoxic syndrome recent expression still gene gene gene methyltransferase effect effect effect effect effect explain antineoplastic silence low methylation decitabine decitabine decitabine decitabine decitabine decitabine mainly mainly present 
1.33@suppressor cancer cancer cancer dnmt tumor tumor tumor able hypomethylating silence gene gene gene gene grow suppress suppress act demthylating function interest inhibitor upon affect division thus methylation decitabine region cell enable would would would associate 
1.0@methyltransferases inhibition class dnmt dnmt dnmt synthesize use state chemically agent myelodysplastic aza de change unmethylated hypermethylated inhibit dna dna dna dna represent lead epigenetic maintain demethylating island myeloid tumor join normal hypermethylation genome icrs treatment tumour suppressor cytidine therefore irreversibly irreversibly imprint analogue novo case chain dnmts leukemia acute syndrome enzymesdna important cpg gene gene gene function evidently deoxycytidine belong methylation methylation decitabine incorporate return cpgs reactivate 
1.0@cancer effect effect inhibition disrupt able produce tumour tumour agent hypomethylating replace silence hypomethylation incorporation desoxicitidine cytosine strand strand strand methylated methylated methylated enzyme reduce tumor uncontrolled conclusion dntm turn new express cell cell cell union kinase paternal decitabine decitabine decitabine decitabine decitabine decitabine decitabine suppressor suppressor excessively activation daugther replication metylathion lay transcribe gene gene anti thedna could prevent genesthat dna dna dna process covalent guide drug patron methyltransferase eliminate place keep division replicate thus methylation methylation methylation inside possible incorporate active form form 
2.0@cancer cancer dnmt use use use slow regress irreversiblly myelodysplastic replace myelogenous deoxycytidine growth leukemia incorporation unlike aza lead methylated treat treat control consequently close turn turn may tumour tumour tumour suppressor lung cytidine cytidine cytidine preceed advance histone analogue combination synthesis occur show island island dna dna however acute bind syndrome methylase cpg cpg gene gene gene inhibitor inhibitor cellular deacetylase well decitabine decitabine decitabine decitabine return downstream 
2.0@suppressor cancer methyltransferases class therefore consequently tumor replication analogue cytidine cause island hypomethylates dnmti hypomethylation hypermethylated inhibit inhibit cpg dna dna dna dna enzyme drug gene gene proliferation inhibitor induce methyltransferase methyltransferase cellular repress belong decitabine decitabine nucleoside region region incorporate express demethylation cell differentiation control 
1.33@dna dna cancer methylate enzyme demethylating reduce agent epigenoma epigenoma normal make find methylation intergenic element activity like region cell cell inhibit decitabine repetitive 
2.0@cancer cancer cancer article abnormal restore able formation say agent stop mark mark probably economist island island island element make make inactive inactive inactive locus lead hypermethylation hypermethylation demethylating observe tumor tumor normal excess genome case tumour supressor supressor one suppressor transcription region shore present type amount specially repetitive dna dna dna dna lot eliminate eliminate cpg cpg cpg gene gene gene gene effect intergene methylation methylation methylation decitabine decitabine adna mean specific progression 
1.33@cancer effect cthat dnmt island island wide agent shore decitabine decitabine decitabine decitabine hypomethylating cancerous anti overall overall decrease decrease decrease inhibit genomic dna dna dna dna dna dna dna dna epigenetic strand promoter act cpg cpg observe methyltransferase impact tumor pattern similar hypermethylation methylation methylation methylation methylation rna reprogrammig incorporate incorporate hypomethylates cell cell drug drug region 
2.0@different hypermethylates cancer methyltransferases class suppressor uncontrolled agent growth growth growth restrict prevent prevent several lead dna dna dna dna epigenetic act hypermethylation demethylating inhibit inhibitor modifier belong thus methylation decitabine decitabine gene gene tumour tumour tumour 
1.33@could article use agent hypomethylating myelodysplastic growth hypermethylated treat decrease inhibit lead lead strand demethylating tumor neoplastic hypoactive claim read primarily cell cell unsilencing suppressor also greater drug mainlyhappening likely apoptosis phosphorolated dna dna dna dna syndrome act additional gene methyltransferase evidently silence thus decitabine incorporate proliferatingcells differentiation rapidly 
2.0@cancer inactivate inhibition growth dnmt regulation hypomethylate use include agent myelodysplastic hypomethylation md back back decrease treat lead irreversibly mention depend responsible demethylating order order normal normal normal hypermethylation turn fact nucleoside successful case cell cell blockage suppressor therefore via replication analogue apoptosis result bring bring inhibitor occur dna dna dna dna dna dna bind syndrome function function gene gene gene methyltransferase dnmts dnmts everything division due methylation decitabine decitabine decitabine decitabine decitabine work class differentiation combine decatibine 
2.0@suppressor suppressor cancer cancer also become gene gene dnmt dnmt drug analogue agent irreversibly cannot effect anti amount hemimethylated island suppress dna dna dna dna dna divide divide methylate bind maintain inhibitor dnmts cpg affect reduce reduce tumor tumor tumor tumor dependant normal hypermethylation silence dilute decitabine decitabine decitabine nucleoside region incorporate methylation methylation methylation active cell cell cell cell replication promoter mean mean mean 
2.0@dacogen inhibitor available dnmt tumor use leukemia agent hypomethylating two analog myelogenous azacytidine neutralize characterize hypermethylated hypermethylated transferase aza sup sup lead position strand strand eventually involve allow blast reduce optimal blastic transformation feature bind hematologic release aberrant express demethylation cell cell cell methyl one dna dna dna cytidine cytidine patient drug share deoxy deoxy md md cycle cycle apoptosis icovalently cod like become methylation solid older common common treatment several hematopoiesis dose acute myelodysblastic syndrome site expression gene gene gene gene inactivate induce control ineffective currently normal decitabine decitabine incorporate malignancy ink move differentiation myelodysplasia 
2.0@cease growth gradual dnmt dnmt dnmt activate tumor tumor tumor tumor tumor tumor tumor island island slow agent receive analog necessary decitadine decitadine decitadine hypomethylation inactive inhibit irreversibly strand strand around methylated involve allow allow demethylating parent proliferation heritability normal start access supressors nucleoside arrangement demethylation cell cell machinery suppressor suppressor transcription therefore activation mitotic replication cause cause suppression cancerous transcribe anti anti prevent prevent particularly dna dna dna dna dna dna dilute bind site expression cpg cpg gene gene gene transcriptional effect effect division methylation methylation methylation euchromatic incorporate hypomethylates methyltransferase reestablish 
2.0@compound suppressor cancer cancer methyltransferases class dnmt dnmt study use dnmts overexpressed agent cause cause decitabine decitabine decitabine silence result number hypermethylated catalyse inhibit previously titrate dna dna dna epigenetic epigenetic work reaction bind overexpression inhibitor hyper hyper demethylating gene gene gene enzyme enzyme tumor suggest expression belong thus methylation methylation methylation methylation reduce aberrant aberrant drug frequently 
1.67@cancer inhibition growth essentially enzymatic use state fda agent myelodysplastic myelogenous malignancy negative suppress lead epigenetic epigenetic know help regulator precursor give demethylating demethylating observe dnmt tumor tumor pattern hypermethylation hypermethylation feedback like like like counteract cell leukaemia one suppressor suppressor dependent hematological therefore drug drug certain cause target condition reactivation depletion type specially dna dna acute syndrome act irreversible methyltransferase effect suggest set silence aberration main methylation decitabine preneoplastic gene gene gene class approve tumorigenesis would 
2.0@cancer cancer cancer article class hypomethylate uncontrolled agent epicentre growth hypermethylated inhibit inhibit suppress lead epigenetic methylate enzyme demethylating reduce tumor tumor normal hypermethylation hypermethylation undo cell may belong suppressor refer fight drug cause gene gene caners dna dna dna dna histone histone histone histone allow expression expression economiist source inhibitor wikipedia word thus thus methylation decitabine decitabine work protein protein protein protein 
1.33@methyltransferases effective use onnormal agent actual pattern myelodysplastic analog analog cannot myelogenous nucleocide inhibit inhibit treat lead canceorus strand demethylating demethylating severely order mechanism affect release high cell cell cell cell cell drug drug leukaemia therefore replication dose dose toxic low type know dna dna dna dna dna dna dna non bind syndrome rapidly effect copy replicate replicate currently currently methylation methylation decitabine decitabine decitabine daughter incorporate approve action methyltransferase longterm 
2.0@cancer cancer along restore able upon use state state state agent hypomethylating myelodysplastic myelogenous dnmti hypomethylation hypermethylated back inhibit treat class epigenetic epigenetic epigenetic pass methylated precursor hypomethylated proliferation impact mutation genome nucleoside successful express cell cell control release leukaemia one suppressor suppressor lower become advance irreversibly replication analogue therapy subsequent revert acute cancerous healthy anti occur know prevent tumour tumour tumour syndrome dna dna dna dna dna get dose travel bind bind point inhibitor inhibitor drug gene gene methyltransferase methyltransferase methyltransferase methyltransferase effect epigenetically abnomal belong longer demethylated induce decitabine decitabine decitabine decitabine decitabine daughter incorporate incorporate 
1.0@abnormal class use differentiaton agent stop thecpg myelodysplastic transcription hypomethylates assocaites growth growth treat call island island wherein lose demethylating reduce tumor mechanism block cell cell cell cell blood machinery suppressor also epigenetic drug drug drug drug certain revert cancerous supposedly oncpg backbone know dna dna syndrome act hence hence effect induce belong thus methylation decitabine activity 
2.0@different suppressor cancer transcription class therefore therefore histone methyl dinucleotide stop lay transfer reactivate growth possibly inhibit inhibit inhibit inhibit prevent methyltransferase methyltransferase methyltransferase either dna dna dna dna dna dna dna dna kill bind expression expression act hyper cpg group group target target function tumor tumor tumor methylate deacetylase increase belong gene gene gene gene methylation methylation methylation decitabine decitabine decitabine factor incorporate hypo cell drug de 
2.0@different dacogen loss toxicity inhibition last et ni tumor kinase require cancer animal analog analog analog detail growth leukemia treat nucleotide lead clinical precursor interest tope anspecific preliminary induction neoplastic produce produce richard clonogenicity major schedule deoxcytidine adrug methylation demethylation cell cell trial use use suppressor leukaemia lung also patient year activation reactivation via drug drug inactivation dose activity myelodysplastic myelodysplastic nul consist model show dna dna dna dna however non acute moment syndrome syndrome sell eisai irreversible inhibitor moreover silent antineoplastic senescence myelogenous al decitabine decitabine gene incorporate gra differentiation phosphorylation small 
0.0@dna cancer methylated closer therefore order implimented gene gene may reduce fuction normal due find methylation methylation allow change express break break decitabine lead 
1.33@dacogen dacogen inhibition dnmt transcriptional transcriptional include agent agent specific specific event event myelogenous silence hypomethylation leukemia md inhibit dna dna dna dna dna dna dna dna dna lead precursor hypermethylation hypermethylation demethylating myeloid tumor tumor expression expression regulation leukemogenesis dac induction significant global suppressor leukaemia multiple turnback indicate decitibine via via require frequent treatement activity trade decrement treatment reduction apoptosis base acute acute syndrome syndrome name myelodysplastic myelodysplastic drug drug myeloblast aml aml effect effect induce methyltransferase methyltransferase human well methylation methylation methylation methylation methylation decitabine gene gene gene gene gene gene gene regulate regulate transcriptome single associate 
0.0@suppressor cancer methylates tumour cause include agent whose silence remain surround stop growth growth gene gene avoid group job properly dna histone histone histone methylated enzyme ezh ezh ezh inhibit inhibit overactive uncontrolled uncontrolled attach demethylating thus decitabine decitabine work activity cell cell methyl 
0.67@dna dna epigenetic could methylating promote demethylating tumour effect agent interngenic repeat methylation decitabine decitabine decitabine region anti element hypomethylated drug class 
2.0@cancer hypomethylation dnmt activate supression tumour analogue agent result hence cancerous growth drug know class dna irreversibly action bind epigenetic silence demethylating cgi rather inhibitor block belong replicate thereby thereby decitabine nucleoside gene daughter cell cell cell may would supressor 
1.67@cancer cancer cancer cancer methyltransferases class island chemically loss analog analog analog code code meet hypomethylation affect inhibit lead irreversibly enzyme severely as normal hypermethylation nucleoside cell cell cell cell cell cell drug drug faster transfer therefore replication cause trap incorporate ultimately know dna dna dna dna however bind act act cpg methyltransferase inhibitor pre belong replicate replicate thus decitabine decitabine activity activity methylating associate 
1.67@alt code class class abbriviated cancercells methyl idle dnmti dnmti md md incorparated incorparated leno leno nucleotide methytranferase methytranferase otherparts cytosine epigenetic strand src belong impact tinymce conversion aza thus thus release nucleoside potent methylation methylation methylation uncontrolled tra dependent ka irreversibly dcmp drug mi decitabine decitabine decitabine decitabine decitabine phosphorylation acute however img demethylated hg come replication suitable antitumour antitumour antitumour show show show prevent incase dna dna dna dna get deoxy action bind bind bind syndrome fe inhibitor inhibitor inhibitor gene aml effect effect effect place copy division division longer rase hypermethlyated follow daughter em activity dysplastic form analoges would azacitidine 
2.0@cancer inhibitor dnmt progress use slow myelodysplastic inhibiters growth treat transferase transferase nucleotide irreversibly strand belong replicate cell rapid dependent cause patient patient replication analogue tolerant mean result nuclear dnmtinhibitor methyl methyl show good dnamethyltransferase dna dna dna dna dna get dose bind bind syndrome drug aml aml along upon copy division division longer methylation methylation methylation decitabine decitabine decitabine daughter incorporate come action 
2.0@cancer methyltransferases class depend dnmt dnmt use amount acute decitabine decitabine decitabine myelodysplastic myelogenous effect treat act methyltransferase action dna dna dna dna get methylate bind bind syndrome precursor belong inhibitor rapidly reduce devide come division longer methylation ul ul ul ul ul ul incorporate enzyme cell cell drug drug leukaemia 
2.0@posit basis biochemically demethylates reactivation induction include subsequent mark probably transcription dnmti part generation inhibition clinically though dna dna apoptosis bind variety division inhibitor gene methyltransferase dnmt tumor mechanism cellular suppress antineoplastic complex thus thus dilute cytotoxin therapeutic methylation methylation interrupt cell demethylation passively decitabine 
1.67@cancer uncontrolled manner agent whose hypomethylating hypomethylates growth call inhibit job lead strand ezh proliferation reduce normal although cell cell cell tumour tumour rna suppressor include cause crucially surround stop chain dna dna dna dna histone function gene gene methyltransferase effect similar silence thus methylation decitabine decitabine decitabine incorporate incorporate azacitidine azacitidine overactivity nearby apparent 
0.67@cancer neoplastic abnormal effective synthesize hypomethylated concentration agent actual mark myelodysplastic myelodysplastic nonspecific aza dmt might normal superior treat epigenetic strand better well demethylating island island round affect life life hypermethylation high daughter side extremely tolerate several dependent lower quality patient get seem seem replication base toxic expectancy assimilate inhibitor inhibitor inhibitor inhibitor anti show show adequate cpg cpg treatment treatment dna dna dna dna divide dose cell cell cell bind syndrome syndrome act newly drug irreversible methyltransferase effect effect upon upon deoxycytidine copy contain division terrible decitabine decitabine decitabine mechanistically severely incorporate specific instance rapidly 
1.67@cancer cancer cancer cancer cancer abnormal disrupt dnmt dnmt dnmt activate tumor tumor order mutation mutation change oncogene characterize genetic propagate copy often epigenetic epigenetic see therefore well unaffected reduce heritability mechanism affect epigenome effectiveness dilute crucial propagation cell cell cell cell cell option genome one suppressor poorly depend therapeutic mitotic happily require mitosis progeny decitabine typically extant experiment without damage damage dna dna understand tumorigenesis demonstrate methyltransferase inhibitor epigenomes must must protein silence silence methylation methylation methylation methylation would daughter accompany disproportionately form rapidly alter 
1.67@cancer inhibitor higher change dnmt activate kinase agent myelodysplastic lower lower economist dnmti hypomethylation hypomethylation md quite quite affect inhibit cpg irreversibly hypermethylation demethylating island effective effective mechanism normal dnmtis dnmtis generally clear phosphorylation nucleoside triphosphate cell cell cell cell bind dependent dependent analogue although action action cause cause toxic apoptosis result gene type prognosis dnamethyltransferase dnamethyltransferase dna dna dna dna dose dose dose synthesis death syndrome expression still poor disease induce describe deoxycytidine increase division division replicate decitabine possible active form form differentiation dnmtisresult 
2.0@dna dna suppressor inhibitor bind nucleoside therefore dnmts gene goal reduce tumor tumor methyltransferase dnmt hypermethylation analogue reverse methylation decitabine growth act control 
2.0@dacogen dacogen inhibition dnmt transcriptional transcriptional include agent agent specific specific event event myelogenous silence hypomethylation leukemia md inhibit dna dna dna dna dna dna dna dna dna lead precursor hypermethylation hypermethylation demethylating myeloid tumor tumor expression expression regulation leukemogenesis dac induction significant global suppressor leukaemia multiple turnback indicate decitibine via via require frequent treatement activity trade decrement treatment reduction apoptosis base acute acute syndrome syndrome name myelodysplastic myelodysplastic drug drug myeloblast aml aml effect effect induce methyltransferase methyltransferase human well methylation methylation methylation methylation methylation decitabine gene gene gene gene gene gene gene regulate regulate transcriptome single associate 
2.0@one elod cancer cancer change overmethylation tumour certain agent precursor inactivation destruction myelogenous growth gene gene treat counter counter inhibit methyltransferase dna dna dna dna acute syndrome use demethylating hence plastic reduce mechanism enable hypermethylation methylation decitabine decitabine region y case active cell cell self may suppressor suppressor leukaemia 
1.67@cancer cancer inhibitor inhibitor dnmt methyl dnmts mutation mutation hypomethylating cure chance permanent genetic avoid suppress molecule prevention epigenetic development reversible involve hyper proliferation provoke tumor tumor intergenic transposition hypermethylation hypermethylation ing genome instability cell control one suppressor also therefore cause able trap apoptosis limit course repetitive dna reverse reverse enhance important gene gene methyltransferase effect induce silence main decitabine decitabine region activity chromosome small 
1.67@one cancer cancer dnmt dnmt use dependent contrast analog currently since since aberration come useful effectively inhibit cpg molecule molecule dna dna epigenetic strand methylate bind syndrome action action drug island methyltransferase inhibitor myelodisplastic hypermethylation replicate thus fastly permanentely nucleoside work second approve cell may replication replication decitabine decitabine 
2.0@cancer cannot lead class within able formation methyl hypomethylation affect inhibit inhibit cpg addition regulate epigenetic pass inhibitor demethylating group way normal rely release nucleoside express decrease cell cell cell cell cell tumour tumour tumour nuceloside suppressor high replication analogue dose dose toxic highly low cancerous yet anti bind amount prevent prevent prevent particular dna dna dna dna dna dna divide non synthesis often act suppression dinucleotides gene gene gene methyltransferase methyltransferase effect growth belong replicate methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine daughter work incorporate 
1.0@hypermethylations cancer inhibitor disrupt dnmt dnmt progress use fda build mark mark myelodysplastic strand transferase nucleotide nucleotide unable epigenetic epigenetic malignant pass heritability block normal ordinary nucleoside affect maternal cell cell cell cell may machinery one suppressor also promotors tumor irreversibly mitotic flow replication analogue icr pas however however target target fast sequence methyl show many dna dna dna divide divide move bind syndrome drug drug time side effect emerge substantial new methylation methylation decitabine decitabine decitabine daughter gene mean approve form enzymatic 
1.33@one enzymatic could could transfer transfer transfer transfer inhibition use fda dose methylations target low ea ea decrease group irreversiblely dna dna dna dna epigenetic four bind syndrome inhibitor myelodysplastic drug reduce mechanism hypermethylation methylation decitabine decitabine decitabine approve tumorigenesis methyl methyl methyl methyl 
2.0@suppressor suppressor inhibitor class dnmt activate remove drug drug cause cause decitabine decitabine decitabine anti anti since reactivation effect effect depletion call tumor tumor tumor tumor dna dna allow allow gene gene gene gene methyltransferase impact epigenetically produce silence silence methylation methylation genome wide demethylation demethylation robust 
1.33@cancer dnmt dnmt upon much island myelodysplastic analog little hypomethylation hypomethylation transferase inhibit inhibit effective irreversibly body severely reduce reduce tumor replicate question question affect hypermethylation hypermethylation fact release nucleoside tumorigenicity cell cell cell cell cell methyl suppressor dependent replication cause gene promoter dna dna dna dna divide bind syndrome cpg progressive rapidly inhibitor induce methyltransferase methyltransferase must division division longer decitabine decitabine decitabine bite incorporate witness action selectively 
1.33@dna dna cancer dnmt drug analogue hypomethylation anti show inhibit inhibit recive acytosine resuls expression demethylating gene effect tumor tumor paciente hipermethylation decitabine adna suppressor 
2.0@reduction reduction neoplastic neoplastic dnmt neoplasm tumour tumour hence correct dnmti anti anti anti bind inhibit somatic lead lead lead dna maintenance dose erroneous inhibitor thereof gene gene methyltransferase effect effect effect remove affect increase silence methylation methylation methylation decitabine decitabine work activity cell cell may suppressor expression 
0.67@rk erdmann ley jm jm width myelodysplastic size leave generation as epigenetic epigenetic pass demethylating impact sm hr align dh cell cell cell br transient dna dna dna dna cytidine deme deme erase cf meyer subsequent acute spencer anti thy thy correction genomic dagogen klco klco lamprecht whylie bind act dysregulated tl gene characterize dnmts dnmts upon syndroms wilson division treatment treatment methylation decitabine decitabine decitabine em em sarkaria hundal gilmore effect abnormal use title agent mardis townsend analog rr irreversibly lichti tj primary magrini walker myeloid replication transfer transfer drug target low patter leukemia dose ase expression aml inhibitor er regulator eventually varghese blood mr neoplastic 
2.0@cancer class progress use could myelodysplastic analog currently md treat transferase transferase inhibit nucleotide epigenetic epigenetic usage mt longer release nucleoside unless cell tumour drug drug drug replicative low dosage anti anti methyl methyl prevent dna dna dna dna dna dna dna get bind bind bind syndrome act act act hence aml inhibitor inhibitor inhibitor upon belong replicate thus thus methylation decitabine decitabine decitabine incorporate come methyltransferase methyltransferase replication 
1.67@dacogen cancer cancer restore dnmt dnmt dnmt dnmt dnmt dnmt dnmt use state fda activity phase eisai find md incorporation decrease decrease decrease decrease decrease tumorgenesis lead lead wherein pass would enzyme enzyme bone inhibit proliferation heritably block hypermethylation hypermethylation myelodysplastic genome genome nucleoside like cell cell control control dna dna dna also daughter irreversibly drug analogue analogue analogue marrow initiation apoptosis proper result demethylated trigger level level level approve syndrome lung pathway bind bind degradation function sensitivity methyltransferase pre silence thus thus decitabine decitabine disorder gene gene incorporate subsequently leukemic enhance follow associate 
2.0@dna cancer growth therefore dnmt dmnts enzymatic tumour tumour dependent irreversibly low more hypomethylation replication replication bind el epigenetic promote ted divide dose moment syndrome well suppression yaff gene inhibitor inhibitor induce ever decitabine decitabine decitabine regulator dmnt case areincorporated cell myleodysplastic use suppressor expression 
2.0@dacogen cancer effect effect effect use dnmts dnmts agent already myelodysplastic detail dnmti apply treat inhibit act cytosine inhibitor allow productive reduce reduce reduce tumor tumor tumor tumor block hypermethylation hypermethylation fact case primarily methyl suppressor depend remethylation cause cause could pathway suppression counter counter counter group dna dna various syndrome sell eisai cpg gene methyltransferase inactivate dinucleotides methylation methylation decitabine decitabine action would 
2.0@elod cancer cancer effect class dnmt dnmt progress use part part trap mark become become malignancy dnmti leukemia treat suppress epigenetic strand strand depend inhibitor inhibitor allow thereby myeloid tumor tumor tumor tumor mechanism hypermethylation hypermethylation thing although deactivation express express may suppressor suppressor methylating nucleoside nucleoside therefore replication analogue decoy reverse without exact come anti know prevent dna dna blood blood acute syndrome dmnti drug drug drug gene gene gene aml along unclear copy belong due go methylation methylation decitabine decitabine daughter daughter dmnt y la methyltransferase onto 
1.67@inhibitor class reactivation produce tumor blood link induce condition myelogenous silence hypomethylation leukemia useful treat marrow hypothemylation antitumour particularly dna dna acute syndrome precursor contribute deform gene methyltransferase effect epigenetically belong turn thus decitabine decitabine bone case cell myelodysplatic supressor 
2.0@methyltransferases abnormal incoporates agent rib hypomethylating two cytotoxicity cytotoxicity de hypomethylation direct inhibition incorporation incorporation marrow inhibit lead death bone mechanism high cell cell eoside cause via analogue subsequent hematopoietic result low asdecitabine prevent oxy dna dna dna dna dna dna dna dna dna dose dose synthesis bind covalent methyltransferase think induce antineoplastic decitabine activity hypomethylates chemical 
2.0@could cannot essentially able activate put yet slow appear agent myelodysplastic myelogenous leukemia treat island might irreversibly strand strand tumour well early demethylating dnmt tumor tumor mechanism hypermethylation clear nucleoside nucleoside demethylation cell cycle use suppressor suppressor dependent although action replication replication replication analogue toxic mean low inhibitor anti bind occur act prevent dna dna dna dna dna dose acute brake syndrome le dnmts cpg cpg gene methyltransferase effect effect stage word resemble silence replicate methylation methylation methylation decitabine decitabine decitabine incorporate approve tumorigenesis protein enough 
1.0@methyltransferases progress use analogue agent target fast replication inhibit dna dna dna bind syndrome act demethylating irreversible aml upon replicate decitabine nucleoside incorporate cell tumour myelodysplasic 
1.67@cancer characteristic suppressor adhesion use include rapid specific island island characterize myelogenous leukemia leukemia leukemia md md md treat locus epigenetic work help well disease inhibitor inhibitor inhibit proliferation myeloid tumor key precursor abnormality hypermethylation hypermethylation hypermethylation hypermethylation may may aberrant icrs methyl tra one hallmark imprint certain byfrequent shore type region prevent prognosis dna dna dna acute acute syndrome fe myelodysplastic cpg cpg poor aml feature control control rase methylation decitabine decitabine gene gene gene account progression associate 
1.67@mitotically cancer cancer cancer cancer activate use agent agent myelodysplastic find frequently change treat affect island island suppress open epigenetic epigenetic therefore allow demethylating demethylating tumor tumor tumor normal hypermethylation hypermethylation hypermethylation hypermethylation repair factor counteract cell cell cell cell cell heritable suppressor suppressor transcription transcription erase seem drug drug drive structure result result low reversal remission type occur promoter damage treatment dna dna dna divide reverse bind syndrome cpg cpg gene gene side effect advantage chromatin successfully decitabine decitabine decitabine daughter region return 
2.0@class dnmt check tumour dnmti dnmti transferase transferase inhibit irreversibly strand take hypermethylation release nucleoside cell cell methyl methyl suppressor metastasis therefore epigenetic require analogue novo proper cancerous replication occur prevent dna dna dna dna dna divide bind bind bind multiply rather inhibitor inhibitor place belong replicate replicate thus thus methylation methylation decitabine decitabine decitabine daughter gene incorporate come action rapidly de 
2.0@class depend dnmt dnmt progress may analogue agent myelodysplastic inhibit inhibit cpg dna dna bind syndrome act hypermethylation demethylating inhibitor tumor division methylation methylation decitabine work work incorporate maintain drug nuceloside belong 
1.33@cancer inhibitor class start methyl concentration find tumour tumour transferase island cpg lead irreversibly speed disease reduce replicate replicate hypermethylation release high case case many cell cell use use nuceloside decitabine lower large therefore however nucelotide analogue strand anti show properly later dna dna dna get get dose bind bind bind drug hence effect copy belong longer thus methylation methylation perfectly daughter work work work incorporate come methyltransferase 
1.67@suppressor provoke dnmt excessive methyl genic genic revert myelodysplastic transfer hypomethylation enhancer inhibit inhibit achieve dna dna decrease syndrome gene proliferation reactivation tumor cellular silence thus thus methylation decitabine decitabine mean treatment drug 
1.33@cancer inhibitor inhibitor class tumor tumor tumor tumor use slow agent become myelogenous de de growth growth leukemia decitibine restrict call warrant patient epigenetic even know methylated conduct respond research research positively bue generally fact addition although whereas may decitabine decitabine decitabine empolyed methylating methylating indicate therefore subside relate drug drug work combination subsequent result somehow susceptability show treatment treatment dna dna dna dna histone chemotherapy recent function function ostensibly interact deacetylase increase lung due methylation rna region cancerous abberant azacitidine azacitidine azacitidine 
1.67@different dna cancer article abnormal class medication suppressor produce tumour marrow agent agent stop jq normal histone hypomethylation hypomethylation higher suggest grow wokrs compare divide blood kill help expression switch switch bone bone gene methyltransferase inhibitor mechanism mechanism similar deacetylase due decitabine decitabine work gsk call call cell cell cell protein azacitidine 
2.0@mode dependent cause restore therefore dnmt start tumour analogue agent stop become methylating anti transferase transferase suppress tumoureffect dna dna dna dna dna dna dna dna irreversibly bind bind antimetabolite function gene inhibitor normal behave replicate silence methylation decitabine nucleoside work incorporate incorporate come action methyl methyl replication replication 
1.33@cancer cancer cancer along category specificity dnmt dnmt may fda could long myelodysplastic cannot affect island nucleotide unknown effective irreversibly strand particularly well belong provoke longer determine normal hypermethylation order release nucleoside term incoporated drug drug one get replication replication analogue stay however type demethylation demethylation treatment dna dna divide cell cell cell cell bind syndrome act act inhibitor cpg rapidly effect upon copy division replicate methylation decitabine decitabine daughter come approve couple 
2.0@abnormal activate may may may itis rib hypermethylized myelodysplastic workingby de hypomethylation possibly md md decrease inhibit nucleotide thesis cytosine usage reduce reduce tumor tumor mechanism methylgroups oxy case demethylation cell eoside suppressor analogue indicate activation drug cause stability toxic methylation methylation relative treatment dna dna dna syndrome act gene gene gene gene chemical effect effect consequent silence silence thus signal decitabine decitabine decitabine incorporate confer methyltransferase alsoremoving 
1.33@cancer impact lead dnmt dnmt epigenetically much great agent island analog necessary reactivate inhibit inhibit inhibit restatement irreversibly reversible inhibitor inhibitor gpc severely able longer affect neoplastic hypermethylation release nucleoside like cell cell cell cell drug drug recover index dependent lower high epigenetic mitotic replication activity activity body anti prevent good potentially dna dna dna dna dna divide dose function gene gene rapidly effect upon division replicate replicate thus methylation decitabine decitabine incorporate original silence silence silence action methyltransferase methyltransferase methyltransferase 
1.33@cancer effect effect higher class progress use isdivision fda specific myelodysplastic currently malignancy de leukemia inhibition treat nucleotide clinical irreversibly strand get get happen mechanism normal neoplastic dntm release nucleoside myeloid cell cell cell trial much dependent also consequently need analogue dose dose toxic low anti dna dna dna dna divide base acute bind bind syndrome inhibitor perform drug rapidly along upon copy belong longer since since decitabine decitabine decitabine decitabine daughter incorporate incorporate come approve action methyltransferase methyltransferase methyltransferase methyltransferase replication replication 
1.33@also inhibition restore apoptosis phosphorylation may cause cause agent hypomethylating suppression critical aza cellular cellular hypomethylation hypomethylation gene direct exert know inhibit incorporation dna dna dna dna dna neoplastic synthesis function believe proliferation effect induce methyltransferase deoxycytidine normal antineoplastic vitro major methylation decitabine decitabine decitabine decitabine em cell differentiation differentiation control 
2.0@dna dna epigenetic inhibitor inhibitor involve therefore reactivation via methyltransferase effect tumor tumor decitabine decitabine contribute silence allow hypomethylation hypomethylation gene anti exert group suppressor belong 
2.0@one one mitotically cancer state soon excessive alteration use slow manner agent agent stop mark mark key maintain tumour inhibit heritable rase dna dna dna dna epigenetic epigenetic development development point fe important remove outside normal candidate special methylation methylation methylation decitabine decitabine decitabine attractive demethylation regulation methyl tra 
1.67@decline reduce class histone classical cause prove along toxic mark approach describe low economist economist better non might transferase dna action achieve compare dose lot well establish hypermethylation inhibitor proliferation impact tumor mechanism little chemotherapeutics belong neigbouring decitabine decitabine therapeutic wariness come cell cell methyl 
1.0@one suppressor cancer term dnmt activate others tumour analogue agent long silence normal well treat among inhibit develop bad dna however know bind syndrome use important demethylating irreversible able unclear mechanism mechanism affect fight especially myelodysplastic decitabine decitabine nucleoside gene gene drug cell goal 
1.67@unregulated cancer cancer category within within produce activity use agent process two similar growth growth direct treat call decitabinealso restore restore death belong demethylating inhibit way tumor metabolism normal normal anticancer myelodysplastic demethylation regulate methyl blockage decitabine decitabine suppressor suppressor suppressor transfer block promote antimetabolite antimetabolite cause target result number gene gene gene become chemotherapy dna dna dna dna divide substance substance cell cell cell cell cell cell cell cytotoxic syndrome function believe rapidly effect effect interact cellular control increase division division interfere thus methylation methylation allow work incorporate 
2.0@cytosine cancer cancer become demethylates effective tumour tumour agent becomesincorporated myelodysplastic analog md promoter inhibit suppress suppress syndrome dna dna dna methylated particularly act allow demethylating gene gene gene hence reduce silence decitabine decitabine nucleoside region region express asa 
2.0@suppressor suppressor cancer inhibitor uncontrollable activate general tumour tumour analogue specific island course whose growth anti bind nearby prevent prevent cpg class dna dna dna dna irreversibly methylated hypermethylation hypermethylation hypomethylation locus methyltransferase methyltransferase effect tumor belong may may silence silence methylation decitabine decitabine nucleoside gene gene gene role cell global associate 
1.33@cancer cancer cancer cancer nature class medication medication medication medication dnmt dnmt dnmt progress use use fda mechanism epicentre myelodysplastic article already treat treat call inhibit unknown irreversibly strand currently available belong thereby thereby dramatically effective accord cell cell cell tumour expression one dependent become therefore replication reactivate target result effect anti show approve dna dna dna divide kill bind bind syndrome demethylating gene rapidly inhibitor upon methyltransferase methyltransferase copy division word epigenetics dnmti decitabine decitabine decitabine decitabine daughter work work work incorporate incorporate come active aml design 
1.67@cancer cancer inhibition inhibition regulation stimulate agent chromosomal hypomethylating analog change inhibit regulate epigenetic epigenetic epigenetic strand promoter hypomethylated proliferation tumor block develop instability cell cell repress cytidine transcription excessive drug cause cause development loss suppression result gene gene counter prevent damage either dna dna dna dna dna get transition histone histone bind bind expression expression irreversible methyltransferase methyltransferase methyltransferase methyltransferase methylations copy division replicate methylation methylation decitabine decitabine daughter region activity modify protein 
1.67@cancer inhibitor higher class essentially dnmt dnmt dnmt tumour lock specific lower synergistically hypomethylation susceptible hypermethylated call inhibit nucleotide nucleotide molecule cytosine epigenetic epigenetic effectively help well belong especially reduce normal normal normal hypermethylation routine genome regulator cell cell cell use suppressor decitabine decitabine decitabine decitabine specifically owe also also however however replication analogue extent target target target cancerous cancerous chemotherapeutic show cpg dna dna dna dna get dose bind function function drug drug drug drug drug gene rate resemble thereby thus methylation methylation recover wide incorporate incorporate decitbine enzymatic small 
1.33@cancer cancer cancer think think change able use slow appear agent conjunction conjunction conjunction conjuction growth susceptible generation treat significant epigenetic show enter penetrate cell cell cell cell far tumour tumour tumour tumour tumour tumour tumour tumour lung lung lung also patient erase cause subsequent result somehow type solid solid solid know treatment dna histone histone histone histone chemotherapy positive specifically inhibitor inhibitor inhibitor inhibitor deacetylase deacetylase deacetylase deacetylase apparently demethylating decitabine decitabine decitabine decitabine decitabine advance alter associate associate 
1.33@suppressor cancer class however tumor drug drug agent stop reactivate problem renew lose island dna dna epigenetic help name demethylating fall hence remove cpg methylation methylation methylation methylation methylation decitabine counteract 
2.0@suppressor suppressor cancer methyltransferases methyltransferases become gene gene gene gene gene drug agent decitabine decitabine decitabine suppression result find hypermethylated anti type occur occur promoter promoter group dna dna dna dna dna expression link demethylating unlikely unlikely effect tumor tumor tumor tumor tumor tumor grow hypermethylation hypermethylation hypermethylation hypermethylation hypermethylation due silence silence silence contribute possible hypomethylated express express many inhibit inhibit belong 
1.33@cancer cancer methyltransferases think methyl agent hypomethylating aza resolve call suppress recognize chemical attack thereby take guanine block normal carbon carbon carbon bond bond substrate substrate triphosphate cell machinery substitute substitute atom atom beta replication azacytosine azacytosine azacytosine metabolize result natural cytosine cytosine elimination become become become normally know group group dna dna dna dna away ring reaction reaction covalent dinucleotides gene gene azanucleosides enzyme decitabineare deoxycytidine nitrogen silence methylation allow establishment incorporate active nucleophilic initiate 
1.67@plastic plastic cancer cancer od od class suppressor suppressor tumor tumor tumor use state include agent stop myelogenous growth growth leukemia inhibit inhibit job job surround methylate methylated precursor enzyme enzyme demethylating hypo uncontrolled normal hypermethylation turn cell cell blood dysfunctional certain cause cause cause mutation condition acute whose amount el el treatment dna dna dna dna histone syndrome syndrome gene gene gene methyltransferase allow overactive overactive increase silence methylation decitabine decitabine y y return 
2.0@cancer cancer chemotheraputic activate activate advantage methyl methyl methyl susceptible load agent tend mark hypomethylates silence marker demethyalizing greater inhibit inhibit apotosis previously previously granddaughter issa pass naturally hypermethylation dr tumor tumor normal normal give turn cell cell cell cell cell much percentage suppressor run drug decitabine th number erasure dna dna fe gene gene induce hyomethylating rase methylation reliant daughter survival survival remove 
1.33@one dependent inhibition therefore dnmt use use analogue fda malignancy malignancy areincorporated md solid hypomethylated treatment dna dna irreversibly bind well dnmts drug hematologic decitabine mainly mainly work eventually approve trial replication nuceloside 
1.67@cancer cancer also dnmt dnmt dnmt dnmt replication replication dependent incorporate analog lower affect prevent prevent dna dna dna irreversibly get bind act act target inhibitor rate methylate preferentially normal replicate replicate methylation decitabine decitabine although work work lay cell cell nuceloside 
1.33@cancer restore use agent hypomethylating find hypomethylates growth leukemia make exert marrow inhibit treat unable help help bone take myeloid due normal normal normal hypermethylation interrupt cell cell cell cell cell cell tumour tumour suppressor also antimetabolite antimetabolite drug cycle anti show methyltransferase dna dna divide divide substance acute function cpg hence hence aml effect die similar control silence longer thus decitabine decitabine decitabine decitabine gene reproduce reproduction secondly 
2.0@one suppressor suppressor cancer article gent class dnmt dnmt methyl demethylate possibly anti anti transferase inhibit particular lead lead dna dna dna dna dna epigenetic inhibitor hypermethylation demethylating observe hence effect effect tumor tumor tumor tumor suggest belong modification thus directly case gene gene express demethylation demethylation action drug drug decitabine decitabine 
2.0@able attain use use mostly agent hypomethylating myelodysplastic major cytotoxicity functional overall genetic incorporation invitro inhibit inhibit inhibit adduct form normally thereby proliferation tumor normal phosphorylation assume treatment treatment thereon mode cytidine insert makeup action action chemically analogue ability rolein meoplastic lie quiescent supress though covalent dna dna dna dna dna dna dna divide dose cell cell cell syndrome act gene methyltransferase methyltransferase cellular especially due methylation methylation methylation decitabine decitabine reference various differentiation play 
2.0@suppressor suppressor reduce class tumour shore oncogene island island cpg cpg dna dna dna dose expression expression allow demethylating gene gene methyltransferase inhibitor tumor increase belong methylation decitabine decitabine demethylation drug abolish 
1.67@elod plastic cannot growth dnmt dnmt use order agent switch find de hypomethylation leukemia treat transferase inhibit back expansion lead irreversibly strand tumour tumour tumour methylated responsible enzyme thereby island proliferation reduce reduce normal normal hypermethylation cel release nucleoside myeloid cell cell cell methyl suppressor suppressor dna dna dna dna dna dna dna cause therefore analogue revert occur reduction acute bind bind bind syndrome site cpg gene gene hence inhibitor death silence methylation methylation methylation methylation decitabine decitabine y active enable would would 
1.33@dna one promoter allow demethylating gene suppressor reduce tumor tumor agent stop activate new methylation decitabine region restrict form exist 
2.0@cancer cannot class dnmt dnmt use appear agent myelodysplastic hypomethylates dnmti suppres susceptible treat inhibit nucleotide lead cytosine irreversibly strand tumour tumour tumour inhibitor belong demethylating block block hypermethylation convert divide release nucleoside triphosphate cell cell cell much ofnormal tra suppressor dependent isreplication epigenetic drug drug analogue longerbe body present depletion methyl know dna dna dna dna dna dna get tumorigenesis bind bind syndrome fe dnmts chemical along upon thenit copy division replicate rase methylation methylation decitabine decitabine decitabine decitabine decitabine daughter drive incorporate come action rapidly 
2.0@cancer methyltransferases inhibition dnmt dnmt tumour tumour build often irreversibly pass involve inhibitor inhibitor inhibitor silence consequently normal genome nucleoside reexpression reexpression intumour therebyupon cell cell cell cell cell cell rapid parental compare cause metastasis epigenetic epigenetic drug analogue reexpressed apoptosis suppression result result case anti promoter demethylation demethylation demethylation dna dna dna get bind act le dnmts gene gene gene target effect effect division division replicate methylation decitabine daughter machinery 
0.67@translocation cancer methylating decitabine decitabine methyl cause agent could intergenic hypomethylation effect element region region genomic lead dna dna reverse demethylating reduce insertion ion hypo instability methylation genome wide repetitive deletion 
0.33@cancer suppressor methyl near correct analog since preferentially oncogene transferase island irreversibly disease reduce tumor tumor tumor normal hypermethylation hypermethylation hypermethylation turn cell cell cell hallmark cytidine promote activation presumably replication cause dosage present occur level prevent dna dna dna dna divide divide repressor bind example demethylase cpg rapidly effect must increase division longer silence silence methylation methylation methylation decitabine decitabine decitabine incorporate incorporate return incorrect 
2.0@cancer methyltransferases class dnmt dnmt tumour tumour add become find reactivate oncogene call inhibit transport often cytosine irreversibly rapidly inhibitor enzyme enzyme enzyme hypomethylated happen mechanism fulfil dnmtis hypermethylation may nucleoside role express many cell methyl methyl decitabine decitabine decitabine decitabine decitabine suppressor dependent also also bond bond consequently cannot replication analogue base healthy product reverse anti bind promoter group group group unfortunately dna dna dna dna dna dna dna divide dose kill cytotoxic covalent covalent function drug gene gene continue effect methyltransferase methyltransferase time replicate methylation allow region incorporate strong form attach 
0.0@cancer restore restore within able produce use agent two also aza deoxycytidine growth direct regulatory incorporation affect inhibit dna dna dna dna dna epigenetic md sequence demethylating tumor anticancer normal bind may myelodysplastic cause cause substrate second demethylation demethylation demethylation treatment way suppressor decitabine decitabine decitabine decitabine decitabine chemical cytidine transcription antimetabolite replication analogue adversely target methylation group presence metabolism several divide substance cell cell cell cell cell cell cytotoxic syndrome function drug gene rapidly effect effect interact cellular control death belong interfere thus thereby rna rna rna methyltransferase work work incorporate incorporate first protein 
1.0@cancer cancer cancer along lymphoma use slow long already effectively effectively grow irreversibly methylate term block block block block divide demethylation cell cell cell cell cell cell methyl also dnats decitibine spread cause cause ability appropriate yet describe fact transferase develop dna dna get dose dose nucleosome bind bind bind act inhibitor drug drug drug rapidly rapidly effect dnat dnat due decitabine decitabine production incorporate come action aml 
2.0@class cancer cancer cancer inhibitor bind expression dnmt dnmt genome gene analogue could suppression suppression decitabine decitabine block block belong thus hypermethylation nucleoside otherwise cell cell lead 
2.0@mistake instead hypomethylation dnmt dnmt dnmt dnmt use agent hypomethylating myelogenous growth treat transferase inhibit lead tumour tumour methylated enzyme control genome express cell cell methyl leukaemia cytidine cytidine cytidine certain therefore necessary dectabine dectabine dectabine dectabine analogue structure result methylate dna dna acute le important gene gene gene aml inhibitor similar try keep silence silence silence since methylation mean enable enable 
1.33@cancer instead become dnmt use faster stop irreversibly analog since make make treat copy copy nucleotide dna dna divide divide body bind bind syndrome myelodysplastic stick methyltransferase inhibitor affect typically actively decitabine nucleoside work work work incorporate cell cell cell cell cell replication 
0.67@mean could methyltransferases class dnmt dnmt tumour require stop mark mark much dnmti say catalyse catalyse affect grow addition irreversibly methylated inhibitor enzyme thereby block normal necessary lay genome nucleoside nucleoside instability instability like like cell cell cell methyl genomic genomic one cause cause regular epigenetic epigenetic cannot cannot replication analogue proper result inactivate tumourigenic anti group chain dna dna dna dna dna dna however reaction bind death dnmts drug drug drug gene rapidly effect catalyze set replicate since methylation methylation methylation decitabine decitabine decitabine wide incorporate come action methyltransferase would 
1.33@suppressor suppressor cancer demethylates epigenetic epigenetic tumour tumour agent surround silence prevent suppress dna dna area area around expression demethylating gene gene proliferation division thus thus methylation decitabine decitabine express cell overactivity 
2.0@cancer cancer inhibitor demethylates activate uncontrolled system agent whose chromosomal hypomethylating declination growth growth part make tumour tumour tumour call inhibit job achieve enzyme enzyme ezh ezh protein mechanism normal include surround surround cell cell methyl suppressor suppressor consequently methylates cause cause mutation result histone histone histone stop anti immune group methyltransferase dna dna dna package lot act gene gene gene resume effect overactive control silence thus thus thus methylation methylation decitabine decitabine overactivity attach 
1.33@cancer inhibitor dnmt depedent replication analogue methylation avoid dna dna dna divide action bind bind act dnmts dnmts still severely ireversible unclear mechanism affect anyway actively decitabine nucleoside incorporate like cell drug 
1.33@dna dna inhibitor class reactivation knownn epigenetically methyltransferase effect tumor tumor link suppression contribute silence decitabine decitabine hypomethylation gene anti belong 
1.33@dependent transfer get use structure myelodysplastic meet azacytidine bind bind inhibit dna dna dna dna dna dna dna irreversibly ase syndrome inhibitor inhibitor division methyltransferase methyltransferase methyltransferase methyltransferase along upon similar belong longer release hypomethylates incorporate come approve action replication decitabine decitabine 
1.67@cancer methyltransferases inhibition restore formation methyl agent reactivate regulatory aza previously often cytosine absorbance strand sequence help enzyme demethylating prevent proliferation normal hypermethylation convert methylated demethylation cell cell cell cell tumour belong suppressor reductase epigenetic cause cause cause cause hemi apoptosis cancerous cancerous arrest promoter group good dna dna dna dna dna expression non diphosphate chemotherapy function absorb gene gene inhibitor remove deoxycytidine death silence decitabine decitabine decitabine another phosphorylates class 
0.0@cancer cancer inhibitor lymphoma regulation tumour tumour cluster mutation whose process two acetyl people growth susceptible genetic genetic call solid lead epigenetic epigenetic involve chromosome pattern question many way leukaemia atom slow breakage successfully deploy drug either combination support result reaction specific gene gene methyl know group reason dna dna intervention histone switch time chemical nature notable deacetylase lung epigenetics sort advance plaster mean first protein rather azacitidine 
2.0@totreat locus abnormal therefore dnaby activate drug chemically agent decitabine myelodysplastic analog myelogenous gene ortumour inhibit revoke chain dna dna dna epigenetic methylate cytidine syndrome demethylating demethylating right methyltransferase hypo hypermethylation demethylated andacute rna na incorporate leukaemia previous supressor 
2.0@cancer leukumia progress tumour likely specific hypomethylating hypomethylates type avoid inhibit demethylitate development development young give give carefully effective mechanism hypermethylation clear thus thus cell cell chromatin suppressor decitabine dntmi preriods patient action action drug agent inadvisable mylodysplastic dna dna reverse syndrome act act gene gene hence methyltransferase must germ completly would region malignancy sensitive period aml haematological help 
1.67@use likely agent myelodysplastic leukemia type treat island cpg dna syndrome expression demethylating inhibit enhance reduce tumor hypermethylation thus supressors action methyltransferase decitabine decitabine 
2.0@dacogen cancer cancer methyltransferases methyltransferases activate tumor yet clearly newly instead hypomethylation leukemia make tumour affect inhibit transport cytosine development culture enzyme demethylating research comercial guanine normal turn fact myeloid primarily cell cell cell cell use supressor phosphorylated also vitro via drug drug drug cause structural apoptosis experiment healthy normally show prevent treatment dna dna dna understand azacytosine dinucleotide dinucleotide bind syndrome name function myelodisplastic gene recognise recognise int due decitabine difference incorporate promise form mix membrane 
0.67@clear dependent along succes use concentration decitabine decitabine hypomethylating analog low th inhibit good myeloid myeloid threatment dna dna dna irreversibly irreversibly action bind bind bind dnmts drug drug methyltransferase methyltransferase effect unclear mechanism leucemia leucemia replicate longer nucleoside incorporate come cell replication replication release decatibine 
1.67@cancer cancer inhibitor methyl slow include mutation whose chromosomal medicine funtion growth growth part make call call job surround epigenetic lymphomascancers enzyme ezh ezh proliferation reduce people normal cell cell cell tumour tumour tumour systemare suppressor uncontrolled also advance attach methylates cause cause crucially lot stop immune group lung package histone histone histone gene gene effect overactive similar deacetylase silence thus decitabine nearby azacitidine overactivity protein apparent 
2.0@suppressor cytidine deoxycytidine restore restore appear methyl state answer answer agent hypomethylating myelodysplastic analog acute chemotherapeutic fda leukemia drug drug transferase hypomethylated aza treatment dna dna promoter island syndrome inhibitor among cpg gene effect tumor pattern question question normal thus decitabine decitabine incorporate myeloid approve cellular recently 
0.0@answer attach 
2.0@cancer cancer classify dnmt dnmt much much could dnmti hypomethylation hypermethylated affect previously unable irreversibly strand methylate methylate methylated allow severely order mechanism normal repair nucleoside demethylation cell cell cell de control dependent greater tsgs therefore replication replication analogue cycle mean result result anti dna dna dna dna dnafurther bind bind inhibitor methyltransferase rate rapid replicate methylation decitabine daughter incorporate incorporate action tumorigenic 
1.0@elod plastic cancer size mdr mdr drug agent methylating treat treat job properly dna syndrome demethylating gene reduce tumor tumor suppress thus decitabine create y use 
1.67@eliminate use inhibitor agent myelodysplastic myelogenous hypermethylation inactivate anti treat island dna dna dna acute syndrome precursor dnmts demethylating prevent prevent methyltransferase effect cpg methylation decitabine tumour leukaemia 
1.33@dacogen inhibitor inhibition growth reactivation produce use concentration eisai myelogenous cellular hypomethylation japanese treat inhibit aza promote cytosine death precursor tumor tumor gt myelodysplastic nucleoside via caspase program cell cell cell may leukaemia suppressor dependent high activation induction induction analogue acute syndrome apoptosis markedly result result result low acetylate level company dna dose histone histone cytotoxic mediate sell synergistic time methyltransferase effect effect deoxycytidine deacetylase increase belong senescence decitabine decitabine decitabine decitabine gene gene class differentiation selectively follow 
1.67@et silence myeloid blewitt round marnie use use use hematological fda gt gt interact jenuwein deoxynucleoside caparros reactivate md tranferase inhibit inhibit dna dna dna dna tumor dacogen epigenetic epigenetic david lecture phd involve inhibitor danny dctp dnmt daskalakis mechanism appropriate aza hypermethylation style style press thomas align align triphosphate cell control cshl suppressor justify justify also incorporation reinberg video drug drug therapy subsequent metabolize reference ultimately problem methylation methylation methyl text text group action syndrome allis replicate synthesis covalent marie expression gene gene dnmts intermediate deoxycytidine belong treatment epigenetics al decitabine laure incorporate dysplastic approve form 
1.33@dacogen cancer restore unregulated regulation regulation use use agent agent sit growth growth growth majorly treat normal normal inhibit suppress lead epigenetic epigenetic strand strand regulate belong demethylating demethylating impact tumor tumor pattern block affect hypermethylation govern myelodysplastic serious human may blockage expression suppressor promote epimutations drug cause ultimately anti among prevent dna dna dna dna dna dna dna antineoplastic cell cell act function function function gene gene gene effect effect increase division division interfere thus methylation methylation methylation methylation methylation decitabine decitabine decitabine mainly work class class 
2.0@cancer cancer cancer methyltransferases class within neoplasm methyl methyl add epigenome acetyl find hypomethylation leukemia oncogene call island molecule often proto epigenetic sequence involve responsible responsible enzyme enzyme enzyme myeloid block block block block block lack hypermethylation hypermethylation turn factor like cell cell control control transferase expression expression transcription antimetabolite methylates drug drug instability acute unchecked promoter group genomic repetitive dna dna dna dna dna however blood histone bind syndrome act act myelodysplastic cpg gene gene gene gene gene regulate remove growth growth belong go methylation decitabine decitabine decitabine disorder lead lead lead lead lead methylating small 
2.0@mitotically cancer cancer inhibitor inhibitor standard disease use use state state stop example process newly remain myelogenous meet epigenomic possibly treat treat treat inhibit heritable addition epigenetic strand better precursor respond thereby observe due epigenomical hypermethylation hypermethylation unmethylated aberrant island passive cell cell cell demethylation tumour tumour leukaemia one one suppressor transfer patient hallmark drug drug drug drug decitabine decitabine fashion anti try show furthermore presence syndrome dna dna dna dna dna dna acute ase chemotherapy myelodysplastic cpg methyltransferase inactivate explain division replicate since since methylation would would mean aml alter 
2.0@suppressor suppressor suppressor cancer cancer dnmt drug drug dependent agent hypomethylating de inhibit dna dna dna reverse use silence gene gene gene methyltransferase inhibitor activation hypermethylation methylation methylation decitabine deactivation tumour tumour 
1.33@cancer inhibitor faster class dnmt dnmt tumour dependent agent analog since dnmti anti affect dna dna irreversibly pass bind bind bind daughter division demethylating effect normal belong go decitabine decitabine nucleoside deitabine come cell cell cell replication replication 
2.0@suppressor restore therefore cause agent hypomethylating suppression methylate growth growth inhibit inhibit suppress class dna dna dna dna dna dna synthesis function gene methyltransferase methyltransferase allow tumor tumor vitro normal hypo interfere major methylation methylation decitabine decitabine decitabine demethylation demethylation cell cell control control 
1.33@dna belong cycle decrease decitabine hypermethylation demethylating cell cell tumor agent regulate 
1.67@suppressor transfer todna restore restore drug agent process hypomethylates growth inhibit dna dna dna ase function demethylating gene inhibitor tumor normal belong thus meet demethylation cell control 
2.0@suppressor cancer cancer effect depend methylates methyl methyl mitosis could could mark silence island possibly anti amount transferase prevent reactive dna dna dna dna strand promoter example inhibitor enzyme cpg gene reduce remove remove gradually hypermethylation interfere new methylation methylation methylation decitabine decitabine create lay tumor tumor use would drive 
1.67@cannot class nitrogen dnmt agent recur myelodysplastic member change change cytosine epigenetic reversible methylated demethylating gradually hypermethylation dilute express carbon repress therefore drug cancerous stop know prevent treatment dna dna however syndrome act gene gene gene rather inhibitor place repeat silence due thus methylation decitabine mitosis incorporate action 
2.0@cancer inhibitor think class dnmt dnmt activate use dnmts dnmts agent phase hypomethylating myelodysplastic myelodysplastic myelogenous hypomethylates treat inhibit targetting irreversibly precursor attack demethylating demethylating neoplastic hypermethylation nucleoside case interrupt cell tumour tumour tumour tumour tumour tumour expression suppressor suppressor suppressor dependent epigenetic replication analogue decitabine decitabine decitabine decitabine lay low across anti show treatment treatment dna dna dna dna maintenance dose acute bind bind syndrome syndrome function gene gene continue effect division replicate thus methylation allow work incorporate approve leukaemia machinery drive 
0.33@inhibitor class uncontrolled agent process also growth regulatory regulatory oncogene tumour call inhibit inhibit lead lead epigenetic epigenetic epigenetic epigenetic epigenetic epigenetic regulator regulator regulator responsible responsible responsible enzyme enzyme tumor mechanism block normal factor case demethylation methyl belong enzymatic transcription reguation drug drug add epigenectic gene gene anti group dna dna dna dna package surround bind bind expression affect effect supressor cellular cellular protein protein administer administer silence silence methylation methylation methylation decitabine decitabine decitabine region activity activity machinery overactivity express alter 
2.0@cancer proces dnmt dnmt dnmt methyl slow growth might transferase irreversibly strand malignanciesare video tumor coursera ological normal cel release nucleoside affect cell cell cell suppressor incorporeted onhypermethylation proccessneeds replication replication analogue haem prevent dna dna dna dna get bind bind inhibitor cpg cpg gene along upon dependant copy longer methylation methylation decitabine decitabine daughter daughter come islandsof 
2.0@mitotically cancer initial abnormal neoplasm progress tumour tumour build hypomethylating inhibit easily myelogenous growth leukemia leukemia hypermethylated back island island suppress lead epigenetic display allow group reduce reduce tumor mutation myelodysplastic express many cell cell cell blood expression suppressor carcinogenesis agent drug healthy likely reopen acute exact unchecked unchecked become methyl promoter prevent prevent example dna dna dna profile harmful often syndrome initially function cpg cpg multiply organism remove chromatin dinucleotides herited methylation methylation methylation methylation decitabine decitabine decitabine gene gene gene form incorrect 
2.0@plastic heavy cancer inhibitor inhibitor class class dnmt dnmt methyl fda mark mark dnmti molecule molecule epigenetic methylate belong belong impact mother nucleoside demethylation cell cell cell cell tumour tumour tra analogue identify patient use replication replication cause describe describe low present anti dna dna dna dna dna dose bind syndrome fe drug methyltransferase effect copy copy death myelodysplatic replicate rase methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine daughter daughter neo approve period 
1.33@dna dna dna cancer cancer cancer effect effect class use cause mutation mark myelodysplastic hypermethylation hypermethylation hypomethylation hypomethylation treat normal normal normal normal inhibit inhibit hystone often kind divide syndrome inhibitor inhibitor inhibitor dnmts ezh rapidly function affect antineoplastic belong methylation decitabine decitabine daughter daughter return cell cell cell cell cell methyltransferase methyltransferase dnmti 
2.0@cancer category within produce way agent myelodysplastic major hypomethylates treatment growth direct demethlation call inhibit restore regulate demethylating tumor mechanism metabolism normal anticancer cell cell cell cell cell control expression suppressor indicate antimetabolite drug cause target number gain know methyltransferase syndrome dna dna dna dna dna divide cytotoxic chemotherapy function gene gene rapidly effect effect interact cellular first death belong interfere methylation methylation decitabine decitabine decitabine work work incorporate secondly class 
2.0@cancer cancer cancer effect effect effect lead class effective way agent already disease probably dnmti growth island act unknown strand well generally demethylating tumor tumor hypermethylation conventional express many cell cell cell try decitabine decitabine older suppressor greater patient drug drug drug cause cause non whether attempt side low without know prevent demethylation demethylation dna dna dna dna dna divide divide dose bind syndrome le inhibitor cpg gene gene rapidly respond copy mylodisplastic belong replicate silence methylation allow daughter work incorporate give methyltransferase methyltransferase would 
2.0@suppressor could reduce activate drug agent mark number anti tumour tumour promoter group dna dna kind demethylating gene effect remove thus methylation decitabine methyl 
2.0@could restore dnmt dnmt dnmt dnmt use use deoxycytidine mechanism mark methyltransferase methyltransferase reactivate tsg island island aza recognize work work covalent lose carcer snare guanine block hypermethylation signal bond substrate substrate triphosphate demethylation process tumour tumour promoter machinery one suppressor adduction replication replication analogue entail metabolize decitabine decitabine decitabine result cytosine trigger anti know damage integrate dna dna dna dna dna however azacytosine dinucleotide degradation function function cpg cpg suffer azanucleoside inhibitor natural cellular must silence methylation methylation initiate gene gene capture chemical hit 
2.0@never dnmt dnmt use mostly probably island nucleotide lead silence tumor tumor replicate neoplastic release high demethylation unknown way supressor depend drug drug drug drug replication toxic fast low low dosage dosage anti good dna dna dose cell cell bind bind hypermethyation expression still inhibitsdna methyltransferase effect effect similar cpg due decitabine decitabine gene gene strong influence azatydine rather initiate decatibine 
0.0@mitotically cancer cancer cancer cancer inhibitor abnormal abnormal class dnmt dnmt dnmt dnmt inherit include agent dnmti useful inhibition exert carefully greatest physiological clone particularly particularly inevitably island myeloid pattern block affect affect give show demethylation cell cell cell cell cell control leukaemia association consequently solely require cause whether denovo condition see chemotherapeutic type know know prevent prevent denote dna dna divide divide divide divide acute bind rely cpg hence effect effect methyltransferase evidence antineoplastic thus methylation methylation methylation decitabine decitabine methylate empirical typically action rapidly rather 
2.0@cancer cancer inhibitor tumor tumor island agent analog since dnmti primary inhibit inhibit irreversibly strand methylated hypermethylation hypermethylation demethylating severely serve replicate replicate normal normal complex release nucleoside affect cell cell cell cell drug one specifically dependent suppresor need cause could novo mean mean anti type dna dna dna dna dna dna dna dna divide bind bind expression cpg gene rapidly effect copy division longer silence methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter lay action methyltransferase methyltransferase methyltransferase methyltransferase de 
2.0@aspect vivo synergy lymphoma effective regulation use include agent agent aberrantly aberrantly example hypomethylating myelodysplastic hypomethylates reactivate growth growth md inhibition inhibit lead epigenetic strand methylated methylated involve involve itfunctions tumor tumor tumor tumor tumor early although vorinostat emethylating cell cell cell cell cell cell decitabine decitabine decitabine decitabine decitabine one suppressor indicate manner combination development cycle apoptosis become treatment dna dna dna dna dna kill syndrome gene gene methyltransferase induce similar methylation rna incorporate incorporate malignancy mantle azacitidine azacitidine 
2.0@mitotically cancer cancer inhibitor inhibitor dnmt dnmt dnmt tumour alternative agent anucleoside neoplasic dnmti dnmti genetic heritable strand reversible silence demethylating severely order mechanism affect mutation nucleoside like demethylation cell cell use suppressor dependent dependent rreversibly high therefore get seem replication cause toxic mean analogue low body anti dna dna dna dna divide dose dose bind bind consequence drug drug gene rapidly effect upon copy division division replicate methylation methylation decitabine decitabine decitabine decitabine decitabine incorporate come action 
1.67@dna dna dna dna suppressor cancer cell expression demethylating gene drug reduce reduce tumor hypermethylation one methylation methylation decitabine decitabine mean level enhance regulate 
0.67@anomaly reduce reduce class use cause agent myelodysplastic leukemia treat treat inhibit dna dna dna dna epigenetic acute lose syndrome enzyme demethylating aml disease remove methyltransferase methylation methylation methylation decitabine decitabine decitabine decitabine myeloid cell drug drug 
2.0@cancer cancer cancer methyltransferases higher restore causal tumor tumor tumor state impact specific md analog signicant reactivate growth direct hypermethylated hypermethylated lead clinical clinical irreversibly strand silence silence proliferation dnmt optimal non inhibition normal hypermethylation nucleoside role demethylation cell cell cell control suppressor suppressor anomaly sensitivity dependent reversion patient patient therefore therefore get relate study deoxy therapy sever apoptosis low toxic bind show show dna dna dna dna divide dose dose disable benet dnmts gene gene gene gene gene gene aml inhibitor induce revert copy division undergo demethylated methylation methylation decitabine decitabine decitabine daughter incorporate azacytidine tumorigenesis rapidly play 
2.0@cancer methyltransferases within may may may agent aberrantly hypomethylating analog cannot hypomethylation hypomethylation direct hypermethylated treat inhibit inhibit dna dna dna dna dna dna previously lead lead cytosine overcome regulator silence demethylating severely tumor block generally apoptotic role case cell cell cell cell expression suppressor pathological nukleoside certain function cycle pathway hallmark express level etc standard non maintain maintain act dnmts dnmts time activator report belong methylation methylation methylation decitabine decitabine gene gene incorporate malignacies 
2.0@specifically methyltransferases suppressor suppressor suppressor formation spread promotors agent cause island become cancerous dnmti hypomethylation effect anti prevent prevent prevent prevent cpg dna dna dna dna dna dna help inhibitor demethylating inhibit way reduce tumor tumor tumor tumor tumor methyltransferase division silence silence methylation methylation methylation decitabine decitabine decitabine daughter daughter possible gene gene gene gene active cell cell cell cell may 
2.0@begin cancer standard within need part agent reactivate genetic anti methylated treat tumour regulatory dna dna dna duplicate help chemotherapy allow demethylating inhibit methyltransferase effect silence genome gene hypomethelates cell combine decitabine 
1.67@compound inhibitor class produce cause apoptosis result dnmti hypomethylation anti know inhibit molecule dna dna dna decrease chemical effect tumor belong celular decitabine decitabine decitabine methylation differentiation methyltransferase small 
2.0@inibition cancer cancer cancer change hipomethylation dnmt transcriptional progress may dnmts loss inactivation find meet dnmti growth genetic oncogene cellfrom decrease decrease decrease island island island lead lead epigenetic step particularly tumor tumor tumor tumor tumor tumor usually hypermethylation hypermethylation alteredto ase cell cell use suppressor suppressor suppressor suppressor path one dna dna dna dna agenethat transfer patient irreversibly commonly cause cause combination apoptosis result result anti arrest promoter protect reduction expression inibitor bind function cpg cpg cpg gene gene gene gene gene important silence modification methylation methylation decitabine decitabine region incorporate come tumorogenesis 
1.33@cannot cannot specificity dnmt dnmt dnmt dnmt dnmt progress use agent agent agent hypomethylating hypomethylating myelodysplastic methyilate leukemia normal inhibit irreversibly methylated belong demethylating myeloid tumor tumor tumor affect lack release nucleoside substrate maintain cell cell cell cell cell replication replication dependent also drug analogue hemi kill problem anti show dna dna dna dna dna acute bind syndrome aml effect effect division division methylation decitabine decitabine decitabine decitabine incorporate approve methyltransferase 
0.67@different mean cancer cancer inhibitor dnmt use agent disease also change hypermethylated treat inhibit act next irreversibly strand pass quicker demethylating island happen affect fact myelodysplastic lead drug drug one dependent discover erase epigenetic epigenetic replication replication support result developped treatment treatment dna dna dna dna dna divide concern cell cell cell bind bind syndrome recent approach cpg methyltransferase methyltransferase along upon copy division modification since since methylation methylation decitabine daughter incorporate come return dont 
0.33@dna epigenetic acute syndrome available namely demethylating use agent precursor myelodysplastic myelogenous one decitabine decitabine treatthe market drug leukaemia 
1.33@cancer reduce higher class therefore therefore dnmt dnmt use analogue acute dependant become result leukamia hypomethylation effect anti bind bind tumour call treatment dna dna dna dna dna irreversibly synthesis decrease act inhibitor drug drug suffer methyltransferase methyltransferase rate due inclusion belong replicate myelogenous methylation decitabine decitabine decitabine nucleoside dmnt incorporate cell cytodine replication 
2.0@specifically dependent dependent dnmt sometimes tumor methyl cause specific however highly analog dnmti hypomethylation anti drug inhibit dna dna dna epigenetic non action action bind syndrome syndrome fe inactivation tumoral gene inhibitor unclear hypermethylation rase myelodysplastic decitabine nucleoside incorporate tra replication suppressor belong 
0.67@cancer change remove remove tumour agent myelodysplastic probably myelogenous growth susceptible treat heritable next epigenetic epigenetic display efficient precursor respond demethylating adna actively give routine methymation although case many cell trial way leukaemia dna patient erase decitabine decitabine decitabine seem drug drug drug mytotically ability likely acute chemotherapeutic devoids good syndrome standard reaction chemotherapy use madethem employ advantage well hypothesis ul ul methylation return alter 
0.33@cancer cancer lymphoma uncontrolled eisai reside invasion leukemia island island suppress neighbor susceptibility tumor tumor tumor mechanism blood hypermethylation vicinity proliferative ensue program demethylation cell cell cell cell drug drug suppressor suppressor suppressor promote need suppression natural rescue el prevent prevent develop treatment treatment dna vessel tumorigenesis cpg gene gene gene result similar death division thus decitabine decitabine decitabine disorder efficacious action tissue 
2.0@aspect different cancer cancer cancer cancer article abnormal abnormal class term et cycle september silence silence since block note decrease un lead epigenetic methylated involve belong skip downregulation tumor mechanism aaron affect feature hypermethylation hypermethylation repair like hypo cell cell cell cell cell cell cell checkpoint line suppressor decitabine decitabine decitabine decitabine specifically dnmt dnmt activation general link link non therapy prior publish upregulation hypothetically gene gene gene gene gene methylation methylation damage action journal dna dna dna dna dna author reverse expression expression expression expression target differentiation inhibitor increase increase lung lung interfere interfere nguyen al allow pluripotent mitosis small propose azacitidine 
1.33@cytidine cause identify class interference disease tumour state suppression appropriate unblock support support analog methylization hypomethylation theoretically anti decrease hypomethylated disruption epigenetic repetitive dna dna process process form allow allow chemotherapy inhibitor function function impact tumor tumor describe describe block belong silence ul ul reproduction return cell drug drug drug would would would decitabine decitabine decitabine 
1.33@one suppressor cancer cancer employ promote therefore able methyl methyl carry agent process currently many bind treat transferase transferase prevent develop regulate dna dna dna action wich example establish dnmts demethylating gene proliferation function function tumor tumor correctly cellular adduct division turn pten decitabine create combat counteract cell drug drug drug 
1.33@inhibitor inhibitor class methyl methyl methyl silence silence lation originate make might transferase transferase transferase island suppress irreversibly promoter hyper myth tumor tumor tumor tumor tumor block hypermethylation fact nucleoside otherwise hypermthylation many replication decitabine decitabine decitabine decitabine suppressor suppressor cause epigenetic drug analogue denovo activity present anti know know prevent dna dna dna inhibitory bind expression dnmts dnmts cpg gene gene gene effect effect visualize belong due thus allow incorporate incorporate deactivate 
2.0@catalyze cancer methyltransferases higher higher growth growth target dnmt dnmt synthesize methyl agent hypomethylating newly hypomethylates hypermethylation hypomethylation hypomethylation part ofcpg transferase inhibit inhibit inhibit class cytosine cytosine nonreversible development inhibitor enzyme thereby proliferation tumor tumor tumor mechanism mechanism block normal normal essential link silence signal cell cell cell may dicitabine expression expression suppressor suppressor lower lower promote residue certain decitabine decitabine decitabine decitabine suppression result analogue immune dna dna dna dna dna dna dna dna dna however dose dose dose synthesis covalent dnmts gene gene gene gene methyltransferase inactivate induce control belong replicate thus methylation methylation methylation ul ul incorporate differentiation differentiation stimulation 
1.67@transient cancer cancer inhibitor inhibitor restore term suppressor produce tumour fda agent brown hypomethylating md growth direct treat affect molecule irreversibly body sensitisation longer normal regulation divide divide myelodysplastic decitabineis treatment much machinery one enzymatic dependent also set antimetabolite epigenetic epigenetic epigenetic window replication cause cause combination therapy target target low inproving become cytotoxic amp seriously dna dna dna process dose cell cell cell cell cell lyko syndrome function drug drug gene rapidly rapidly effect demethylation death division replicate regulator decitabine decitabine decitabine create incorporate first approve action methyltransferase small 
1.67@methyltransferases dnmt dnmt dnmt dnmt upon methyl potential concentration trap carcinogenesis analog deliver reactivate reactivate fda leukemia make addition lead recognize irreversibly promoter promoter methylated laboratory signature thereby myeloid myeloid tumor tumor tumor tumor tumor essential epigenome degrade unmethylated nucleoside substrate potent maintain control deplete suppressor suppressor suppressor suppressor stability drug certain overexpressed metabolize agent incorporate subsequent experiment inadvertently anti normally show group genomic treatment dna dna dna dna get citidine acute bind syndrome dnmts dnmts gene gene gene gene gene target inhibitor epigenetically cellular silence silence silence epigenetics methylation decitabine decitabine decitabine eventually dysplastic approve replication associate 
1.33@suppressor suppressor could effect use drug agent originally become since unmethylated express anti methyl methyl group group amount lead dna dna dna dna dna histone methylated expression expression allow demethylating demethylating gene gene gene gene reduce remove protein silence silence methylation methylation decitabine decitabine like removal tumour tumour tumour would associate 
0.0@dna package package cancer cancer histone ezh ezh ezh ezh group chromosome chromosome cause cause cause cause tumor activity silence silence thus decitabine decitabine growth gene gene lay methyle demethylation cell inhibit inhibit supressor 
1.67@different cancer inhibitor class dnmt dnmt activate tumour agent process overall decrease suppress irreversibly demethylating tumor due due normal dnmtis turn divide divide maintain cell cell cell cell cell cell supressor chemical cytidine silent greater however replication structure structure extent mean low cancerous anti hence know dna dna dna dna dna get dose bind le le expression end affect rapidly effect methyltransferase similar keep belong replicate methylation methylation methylation decitabine decitabine cant gene incorporate tumorigenesis continue 
2.0@effect suppresor order slow stop proper growth anti promoter dna dna dna epigenetic contribution expression gene gene inhibitor tumor tumor tumor belong methylation decitabine decitabine decitabine region demethylation demethylation ensure 
0.33@cancer cancer article change rogressive baylin slow agent epicentre acetyl since stephen growth make tumour tumour chromatin hdac hdac demethylating dr research bayling hopkins nucleosome say lung patient therefore combination cell deacetylases vulnerable show group dna medicine school histone histone histone chemotherapy inhibitor inhibitor inhibitor effect remove john similar deacetylase deacetylase decitabine decitabine decitabine modify azacitidine 
1.0@different dna dna dna cancer cancer cancer cancer cancer uneffective inhibiton igf relate seem drug cause agent demythlating phenotype highly body whereasenormal growth cnacer mechanic tumour affect island cpg promoter compare see methylated hyper unaffected gene gene gene proliferation reduce reduce reduce reduce importatnt normal normal generally methylation methylation methylation methylation decitabine high appparenly deacitvated cell cell cell cell cell cell cell cell dont acivate 
2.0@producer cause information prescribe hypomethylates hypomethylation anti inhibition exert inhibit incorporation dna dna dna dna dna dna neoplastic demethylating methyltransferase effect mechanism cellular believe phosphorylation ul ul action differentiation follow decitabine decitabine 
2.0@mitotically cancer whenever restore dnmt tumour tumour activity charge dnmti hypermethylated decrease inhibit irreversibly sequence enzyme enzyme enzyme severely mechanism block normal normal hypermethylation nucleoside case cell cell cell cell methyl methyl promoter promoter expression suppressor dependent analogue therefore therefore replication replication cause suppose incorporate incorporate methylation level group group dna dna dna dna dna dna divide bind bind mean dnmts affect affect methyltransferase inhibitor upon keep interfere actively decitabine decitabine decitabine decitabine decitabine gene gene lay lay active action action 
2.0@therapeutic therefore outcome tumour tumour cause agent likely mark suppression embody present reproduction generation subsequent group molecule often dna dna dna dna dna dna get get get strand strand strand cell cell site give methyltransferase methyltransferase inhibitor heritability permanently neoplastic belong replicate methylation methylation decitabine daughter lay come disable attach 
1.67@cancer cancer methylating incorrectly remove remove tumour cause inhibitor agent stop quantity de effect anti grow dna dna dna epigenetic help act function cpg island reduce induce hypermethylation methylation methylation decitabine decitabine cell cell spread 
2.0@cancer cancer inhibitor abnormal class uncontrolled agent become currently alternatively growth leukemia inhibit epigenetic know know inappropriately normally hyper demethylating island island tumor tumor tumor tumor methylated enzyme cell repress decitabine decitabine market suppressor suppressor suppressor therefore drug drug target express anti type type promoter treatment dna dna dna dna cpg cpg gene gene gene methyltransferase effect silence myelogenous methylation methylation allow region would associate 
2.0@unregulated cancer effect restore restore dnmt promote replication dependent irreversibly result silence silence growth growth become bind island cpg imply dna dna dna dna get regulate inhibitor function demethylates gene gene gene dnmts tumor normal increase division division thus methylation allow incorporate demethylation cell cell cell control suppressor suppressor suppressor decitabine decitabine 
1.0@dna dna acute syndrome precursor demethylating agent myelodysplastic myelogenous methylation decitabine decitabine decitabine treat decrease leukaemia 
0.67@suppressor cancer methyl activity histone histone histone methylates use cause cause include mutation whose chromosomal myelodysplastic lot stop growth part make treat immune group tumour surround package call call inhibitor enzyme enzyme ezh ezh inhibit lymphomascancers job overactive uncontrolled protein silence thus decitabine deacetylase gene gene cell overactivity attach systemare 
2.0@unregulated reduce dnmt dnmt produce uncontrolled decitabine hypomethylating ultimately growth unmethylated inhibit suppress lead dna dna dna strand allow function drug oncogensis methyltransferase effect tumor silence methylation methylation would daughter gene cell functionally replication suppressor without 
1.33@document cancer cancer cancer cancer cancer cancer inhibitor activity class class class class class class class progress use use appear agent process myelodysplastic myelogenous genetic genetic treat normal pave therapy often open epigenetic epigenetic epigenetic development tumour well disease demethylating severely research permanently hypermethylation much case regulate way leukaemia already understand irreversibly replication msonormal msonormal msonormal msonormal msonormal msonormal msonormal decitabine decitabine decitabine decitabine target acute number underlie country better dna dna dna dna divide blood cell cell syndrome drug drug affect chemical chemical nature upon methyltransferase due find allow implicit incorporate machinery machinery rapidly progression 
1.33@dnmt cause cause agent hypomethylating myelodysplastic myelodysplastic myelogenous hypomethylates hypomethylation gene gene anti bind treat inhibit dna acute methylated syndrome syndrome precursor prevent hence effect tumor methylation decitabine decitabine region leukaemia 
2.0@cancer cancer cancer effect restore suppressor suppressor tumour tumour tumour tumour include agent hypomethylating hypomethylating also growth direct regulatory inhibit regulate epigenetic lose antimetabolite belong demethylating take block normal hypermethylation hypermethylation thereby process methyl supressor dna dna dna dna dna dna transfer erase cause prompt result among several divide cell cell cell cell cytotoxic expression expression important gene gene gene gene rapidly function function control control death division division methylation decitabine decitabine decitabine class action hence hence 
1.33@enzymatic cancer effect higher dnmt dnmt much along target result cannot tighly inhibition effectively epigenic lead dna dna dna dna dna divide divide strand kill bind aninhibitor methyltransferase rate tumor move normal death division copy regulator decitabine decitabine decitabine daughter work anymore methylation demethylation cell cell cell cell cell cell thattargets attach 
1.67@cancer activate get methyl agent process newly change unmethylated eisai japanese treat inhibit inhibit act addition correspond epigenetic strand see methylated conservation enzyme demethylating island island conserve tumor tumor tumor pattern generally lay myelodysplastic previously high cell cell cell cell cell pharmaceutical suppressor suppressor commercialize also application relate general general drug page healthy suppression result result low help help company promoter promoter particularly dna dna dna dna dna mark dose dose division syndrome sell important cpg cpg gene gene methyltransferase methyltransferase consequence copy death death wikipedia clean silence decitabine decitabine daughter incorporate form recently 
1.0@cancer cancer methyltransferases able able uncontrolled agent whose transcription growth hypermethylated inhibit job addition lead epigenetic tumor nucleotide impairment regulate drug expression suppressor methylating replication cause add incorporate result stop methyl methyl group group dna dna dna dna dna cell cell cell important gene gene gene gene hence inhibitor induce induce condensation condensation chromatin chromatin silence decitabine decitabine decitabine decitabine characteristic activity active modify methyltransferase enzymatic 
2.0@mitotically cancer inhibitor inhibitor lymphoma tumour tumour include since change change heritable lead epigenetic wouldnt involve hyper ezh normal demethylation level supressor compound compound abrogate lower candidate drug ie decitabine suppression suppression type show prevent dna dna dna lysine ring histone histone act expression gene gene methyltransferase allow allow thus thus methylation methylation methylation methylation double activity activity promise return would would small 
1.0@cancer cancer rate differently healthy may agent mark two analog analog since since citosine citosine hypomethylation susceptible genetic lead open epigenetic epigenetic epigenetic epigenetic reversible demethylating effective replicate big affect neoplastic release high cell cell cell cell way decitabine market study dependent nucleoside replication replication replication therapy therapy low dosage present anti discovery show good dna dna dna intervention base bind bind covalent expression drug drug drug drug drug time chemical effect effect control provide modification modification modification new longer difference gene incorporate form methyltransferase methyltransferase azacitidine 
1.33@cancer inhibitor dnmt dnmt dnmt tumor tumor may trap mark reactivate unlike recognize irreversibly irreversibly lose functionality demethylating compromise subject mechanism normal repair signal cell cell cell machinery substitute suppressor faster also therefore replication replication cause cause could toxic toxic toxic incorporate result cytosine cytosine trigger anti nonspecific damage dna dna dna dna dna dna dna dna divide divide non bind bind degradation gene methyltransferase effect effect effect upon silence methylation decitabine decitabine decitabine another epigenetically 
2.0@mean mean cancer reduce reduce cgis able tumour tumour pattern myelodysplastic larger hypermethylated exert affect island previously lead effective irreversibly strand dnmt dnmt dnmt dnmt tumor mechanism activation normal hypermethylation nucleoside express demethylation cell cell try suppressor dependent dependent suppresor patient therefore therefore therefore get replication replication analogue inhibtion extent activity anti promoter prevent dna dna dna divide bind bind syndrome inhibitor cpg gene gene gene rapidly effect effect consequent replicate methylation methylation methylation decitabine decitabine decitabine decitabine daughter incorporate action 
2.0@dna cancer cancer certain promote within able relate close may cause agent could tumorogenesis mean easier growth growth hypermethylated promoter promoter island island suppress suppress suppress suppress tumor tumor open heterochromatin allow demethylating gene gene expression remove cpg cpg thereby usually methylation genome unexpressed unmethylate decitabine decitabine decitabine 
2.0@dacogen cancer classify overmethylation overmethylation tumour tumour cause agent stop cure result demethylated growth methylated previously dna histone help sell allow demethylating gene due decitabine drug suppressor 
0.67@cancer cancer inhibitor inhibitor inhibitor lower dnmt dnmt dnmt use use recently find find dnmti dnmti change treat call act molecule molecule molecule irreversibly transferase regulator enzyme enzyme order usually big neoplastic give atp readily release nucleoside like cell methyl enzymatic dependent analogue patient therefore divide replication replication replication cause target target target around anti group good treatment treatment dna dna dna dna dna dna dna get dose dose bind bind bind epigenetic epigenetic epigenetic site drug drug drug drug drug irreversible rapidly effect belong methylation decitabine decitabine incorporate past active move enable small 
1.67@dacogen mammalian methyl agent hypomethylating oly analog hypomethylation leukemia eisai japanese exert inhibit inhibit antineoplastic strand responsible enzyme myeloid mechanism conversion myelodysplastic directly synthesize triphosphate cell cell blood dicitabine dicitabine tra dysfunctional cytidine methylating andfor drug drug aclass result treatment dna dna dna dna dna dna apoptosis acute syndrome sell newly methyltransferase effect fe cellular believe rase decitabine decitabine incorporate incorporate differentiation aml follow 
0.67@standard cancer tumour cause promotorsii stop agent without change susceptible make heritable grow dna epigenetic kill chemotherapy methylaion demethylating gene decitabine cell cell removal alter 
2.0@dna dna suppressor cancer well enzyme let inhibit methyltransferase effect tumor tumor die agent hypomethylating belong methylation methylation decitabine gene anti cell prevent prevent lead 
1.33@dependent transfer tod dnmt anal replication tare ame g dnmti thy group dna see bind enzyme irreversible inhibitor upon er division taft nucleoside na incorporate action catalyze 
1.33@cancer cancer tumour tumour restore dnmt dnmt dnmt activate use myelodysplastic analog analog also hypomethylation leukemia incorporation transferase island island island island treat lead development promoter hypermethylation myeloid expression link act act nucleoside nucleoside instability drug methyl decitabine decitabine decitabine decitabine suppressor cytidine cause cause tsgs tsgs tsgs replication replication analogue structural incorporate incorporate anti show show prevent damage dna dna dna dna dna get acute syndrome site inhibitor inhibitor cpg cpg cpg cpg gene gene gene gene transcriptional transcriptional effect demethylation silence silence silence due thus thus methylation methylation methylation allow activity covalently obstruct class 
1.67@drug also inhibition restore incorporation rapidly rapidly regulation may may cause cause cycle antineoplastic apoptosis apoptosis critical cytotoxicity hypomethylation hypomethylation hypomethylation gene gene direct exert normal damage dna dna dna dna dna dna dna divide divide proliferation covalent function demethylating believe believe methyltransferase methyltransferase effect induce cellular cellular affect adduct formation phosphorylation decitabine decitabine decitabine decitabine decitabine attribute incorporate cell cell cell differentiation differentiation control expression 
1.67@several inhibitor high specificity dnmt dnmt use analogue agent toxic irreversibly administrate low cancerous anti drug promote dna dna neoplastic dose dose bind target demethylating side effect effect lack find decitabine nucleoside incorporate dnmtinhibitors replication 
2.0@completelylost cancer cancer methyltransferases methyltransferases dnmt dnmt synthesize way agent repressive proliferate reactivate treat treat tumor cytosine cytosine methylated methylated hyper instead divisiondna replicationcan round normal thus methylation methylation cell cell cell cell cell cell removal methyl methyl suppressor suppressor suppressor dna dna dna dna dna oftumor promote cannot analogue structure throughout add cancerous fromtumor promoter group several hypomethylating mark mark act inhibitor gene gene gene strandpreventing control new canthenrestore decitabine decitabine decitabine decitabine decitabine decitabine incorporate incorporate form 
1.67@suppressor cancer cancer cancer methyltransferases faster via blood dependent hypomethylating dnmti dnmti hypomethylation gene useful show inhibit cpg dna dna dna dna dna decrease decrease decrease mediate division drug island effect effect tumor tumor normal hypermethylation replicate thus methylation methylation methylation decitabine decitabine decitabine create mean cell cell cell cell cell cell global 
1.33@suppressor cytidine effect restore reactivation cg activity replication require agent know know irreversibly analog selective sit show inhibit methyltransferase methyltransferase lead dna dna dna divide divide strand hemimethylated bind inhibitor demethylating proliferation dnmt dnmt dnmt tumor preference hypermethylation reverse methylation decitabine decitabine decitabine high possible daughter original sensitive cell cell cell rapidly 
2.0@dna dna dna suppressor cancer dacogen involve sell expression demethylating inhibit tumour enzyme overexpressed agent hypermethylation result methylation decitabine gene might cell prevent 
2.0@allow cancer cancer instead dnmt dnmt much agent stop stop since decrease cytosine cytosine cytosine irreversibly development lose enzyme demethylating tumor normal methylated express demethylation demethylation cell cell cell tumour tumour tumour tumour suppressor suppressor decitibine methylates replication replication structure hemi result present anti normally promoter develop dna dna dna dna dna bind gene gene rapidly effect place similar replicate replicate methylation methylation methylation methylation decitabine decitabine decitabine incorporate cpgs chemical 
1.33@dna dna suppressor tumorigenesis block inhibitor dnmt tumour byhypermethylation cause methylation methylation decitabine decitabine case decrease suppress oftumour 
1.67@cancer effect restore use near agent shore cpi myelodysplastic analog low unmethylated anti hypermethylated treat kb island cpg cpg dna dna understand dose promoter cytidine syndrome act demethylating cgi cgi methyltransferase inhibitor condition normal normal tumoral decitabine gene asocaited cell cell cell associate 
2.0@growth growth unregulated cancer cancer category within within produce activity way agent process member similar substance substance direct call call restore restore believe belong demethylating twofold tumor block normal normal expression anticancer demethylation demethylation regulate regulate control blockage decitabine decitabine decitabine one suppressor suppressor suppressor also promote antimetabolite antimetabolite drug cause target result number become metabolism dna dna dna dna divide cell cell cell cell cell cell cell cell cytotoxic chemotherapy function gene gene gene gene rapidly effect effect interact cellular death division division interfere thus methylation methylation methylation allow work incorporate 
0.67@body cancer cancer cancer regulator devision dnmt dnmt drug cause tide dependent methylations methylations since since dnmti come bind subgroup affect severly action dna dna epigenetic strand cell cell cell cell cell cell death hurt le devisions methyltransferase inactivate inactivate tumor methylate din deviding lack belong irreversibily methylation decitabine decitabine decitabine decitabine daughter enzyme disrups rapidly enzymatic 
1.67@cancer cancer myeloid class dnmt use neopastic fda myelodysplastic since hypomethylation useful treat transferase transferase irreversibly precursor enzyme enzyme thereby transeferases nucleoside cell methyl methyl methyl leukaemia dependent also teratment drug drug analogue cause acute anti show prevent develop dna dna dna dna dna dna divide dose synthesis bind bind syndrome inhibitor hence effect belong low actively decitabine decitabine decitabine decitabine incorporate approve replication replication replication 
1.67@dna dna dna cancer impact think selectively dnmt dnmt dnmt deactivate significantly result irreversibly irreversibly hypomethylation decatabine fully effectively action compare divide divide divide divide kill bind inhibitor enzyme enzyme rapidly rapidly rapidly reduce mechanism block normal understand methylation methylation decitabine decitabine work incorporate cell cell cell cell cell cell protein 
1.67@dependent inhibitor higher class dnmt replication replication analogue agent irreversibly result constantly become hypermethylated previously dna dna dna dna epigenetic strand strand bind bind daughter silence demethylating gene methyltransferase methyltransferase effect tumor mechanism copy belong replicate methylation decitabine nucleoside em incorporate demethylation cell drug drug expression 
1.67@different different dacogen cancer cancer article use slew stop process md say leukemia make make treat treat treat decrease decrease regulate regulate epigenetic body help help precursor disease disease inhibitor inhibitor notably happen happen tumor tumor tumor go least render factor many dont dont way one one suppressor myleogenous drug could useless target present type methylated develop develop develop example dna dna dna dna away acute syndrome sell suppose continue rate human thus methylation methylation methylation methylation decitabine decitabine decitabine myleodysplastic heavily sure sure 
1.33@maybe cancer inhibitor inhibitor class able much every myelodysplastic analog dnmti might affect affect island thendnmt lead effective irreversibly get belong severely outcome dilution hypermethylation release nucleoside demethylation cell cell cell cell dependent depend epigenetic seem replication cause ofof low cpg dna dna dna dna dna dna dna divide dose bind syndrome syndrome function perform poor rapidly allow upon division division longer longer methylation decitabine decitabine interest incorporate action methyltransferase methyltransferase methyltransferase prognostic 
1.33@suppressor suppressor cancer cancer tumour tumour unmethylated frequent agent uncontroled normal hypermethylation hypermethylation come treat promoter island back dna dna divide function demethylating hypomethylated take place affect division division silence regulator cpg allele active cell cell drug drug azacitidine 
1.0@cancer methyltransferases methyltransferases methyltransferases start methyl fda agent maximum maximum myelodysplastic methylating dnmti dnmti dnmti make call inhibit inhibit lead epigenetic epigenetic epigenetic reversible despite hyper hyper demethylating clear key hypo hypo may may vital much enzyme cell far way lower divide drug drug drug classic combination today actually mutation mutation describe toxic dna future dose dose dose reverse bind chemotherapy use use important rapidly effect effect first division ti abbreviate methylation methylation decitabine importance approve methyltransferase beneficial 
1.0@cancer therefore use cause agent hypomethylating hypomethylates decrease inhibit demethylation lead dna dna hypermethylation gene gene methyltransferase tumor tumor silence silence due decitabine production many supressor supressor ul ul 
2.0@suppressor reduce activate remove methyl methyl agent specific hypomethylating growth promoter group island dna dna dna transferase prevent act cpg cgi inhibitor tumor tumor methylation decitabine gene drug level 
1.33@cancer cancer myeloid class class target dnmt dnmt dnmt may mark newly meet silence leukemia treat stabilize cytosine cytosine cytosine cytosine irreversibly strand strand strand strand help inhibitor enzyme end reduce tumor tumor task normal epigenome clear myelodysplastic much role primarily cell cell cell cell yet suppressor drug also although residue replication analogue analogue match incorporate trialed become solid parent dna dna divide divide acute bind syndrome use important perform gene aml along methyltransferase must belong replicate thus methylation methylation methylation decitabine decitabine decitabine daughter daughter work lay move rapidly play 
2.0@methyltransferases methyltransferases class dnmt dnmt dnmt dnmt tumour tumour tumour tumour dnmts dnmts fda agent process probably classify dnmti hypomethylation hypomethylation job irreversibly strand inhibitor enzyme enzyme reactivation mammal hypermethylation thus thus nucleoside nucleoside maintain many drug decitabine decitabine decitabine one suppressor suppressor cause epigenetic replication analogue analogue novo incorporate anti occur treatment dna dna dna dna dna bind function perform gene gene methyltransferase effect along belong longer since methylation allow em lay approve arrive hence de 
0.0@vivo series infusion upon assess median agent specific hypomethylating hypomethylating hypomethylating analog change change change change leukemia treat decrease aza indicate cytosine epigenome blast myeloid detect mechanism conclusion link dac dac dac directly distinct imply line scarcely patient patient patient patient study mrna myeloblast early sequentially occur day dna dna dna dna dna already non acute primary expression gene aml aml effect effect induce deoxycytidine global methylation methylation methylation methylation complex first transcriptome analysis 
1.67@cancer cancer inhibitor term dnmt dnmt use use appear attempt specific myelogenous fda approve treat affect irreversibly strand copy sure well consequence severely myelodisplastic longer longer normal precursor leukaemia release nucleoside population methylation methylation cell cell cell cell cell methyl tra dependent analogue high seem replication cause dectabine dose dose toxic good relative dna dna dna dna divide divide divide therefor acute bind bind syndrome fe still rapidly effect upon must first antineoplastic division replicate rase lower decitabine daughter much much incorporate prove action 
2.0@methyltransferases methyl require agent add hypomethylating become meet transfer free chemotherapeutic replication occur avoid assignment regulate dna dna dna dna dna write action ase strand strand drug group division new methylation decitabine daughter factor incorporate cytotoxicity cell cell may inhibit hypomethylates 
1.67@dacogen cancer reduce restore messenger methyl loss specific silence direct mir dnmti md inhibit act addition translation silencer epigenetic enzyme ezh ezh ezh ezh partially impact tumor tumor expression expression expression turn microrna microrna lead lead decitabine suppressor suppressor consequence three encode encode amount group dna dna lysine lysine histone histone histone histone deciabine syndrome least myelodysplastic gene gene gene gene gene methyltransferase methyltransferase inhibitor inhibitor induce condensation chromatin increase belong thus methylation methylation methylation rna class 
2.0@cancer myeloid higher class dnmt progress tumour fda induce induce induce myelodysplastic collectively growth leukemia inhibition inhibit require lead irreversibly malignant inhibitor inhibitor division reactivation affect hypermethylation hypermethylation consequently demethylation demethylation cell cell cell tsg use epimutations epimutations dependent dependent basis tsgs therefore epigenetic epigenetic replication replication replication cause therapy therapy activity result reverse occur promoter dna dna dna dna dna maintenance acute bind syndrome dnmts dnmts azanucleoside rate epigenetically condition pre belong silence silence methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine em incorporate approve form methyltransferase frequently 
1.33@plastic cannot cannot class target dnmt activity activity tumour tumour tumour tumour tumour mutation stop mark mark find dnmti dnmti growth growth lation inhibit grow previously often often epigenetic epigenetic belong hyper island reduce pattern hypermethylation hypermethylation silence silence myeloid cell cell cell cell uncontrolled supressor supressor require cause mutate y largely infuse introduce math occur dna however continuous bind syndrome dnmts dnmts dnmts dnmts dnmts dnmts cpg gene gene aml inhibitor induce methylations methylations division division division undergo since methylation decitabine decitabine decitabine daughter lay lay lay inhibted hence reactivate 
1.67@lead methyltransferases inhibition tumour agent agent aberrantly aberrantly event transcription reactivate hypomethylation hypomethylation unfavoured island provide irreversibly know methylated methylated enzyme demethylating demethylating inhibit inhibit reduce tumor tumor tumor lack corporated factor cell cell ofdnmt use nuceloside decitabine one suppressor analogus also epigenetic seem drug drug drug cause cause pas result low dosage physical anti promoter group genomic dna dna dna dna dna dna dna reverse bind bind site conciderably dnmts cpg gene gene expression critical belong silence silence methylation methylation blockage daughter region propose 
1.33@compound cancer cancer methyltransferases mode jul remain currently azacytidine azacytidine covalently aza recognize epigenetic inhibitor inhibitor attack nucleophilic guanine block carbon bond substrate substrate triphosphate replication machinery substitute atom advance drug analogue deoxy therapy decitabine decitabine decitabine natural cytosine cytosine cytosine reference metabolize become bind dna dna dna dna dna dna dna azacytosine azacytosine reaction lyko covalent function function dinucleotides irreversible methyltransferase methyltransferase methyltransferase enzyme enzyme enzyme result deoxycytidine int thus methylation initiate stresemann incorporate ring action establishment 
2.0@suppressor restore dnmt remove drug result probably make hypermethylated improperly group suppress dna dna dna dna allow act function inhibit resume inhibitor tumor tumor methyltransferase protein thus methylation vital gene gene incorporate cell removal methyl replication decitabine 
2.0@blewitt cancer cancer cancer cancer article article irrevocably dnmt dnmt marnie tumour tumour agent epicentre become become economist reactivate useful regulatory area lecture methylated video egger demethylating demethylating dr biochimie magazine hassler normal hypermethylation source thus nucleoside implicate suppressive cell methyl suppressor specifically transfer use analogue april incorporate course concept epigenetics prevent external treatment dna dna dna mark bind act function mr aml inhibitor th copy emerge silence epigenomics new methylation decitabine daughter gene activity come erroneously review methyltransferase dnmti 
1.67@specifically cancer cancer inhibitor dnmt tumour tumour cause dependent dependent agent mean reduction suppress dna dna dna dna divide tumorigenesis division division demethylating rapidly reduce reduce hypermethylation methylation methylation decitabine decitabine convenient demethylation cell suppressor dnmti 
1.67@mean inhibitor disrupt suppressor suppressor methyl fda druggable protection major logical dnmti might test island nucleotide molecule molecule molecule achieve effective epigenetic tumour tumour tumour component provide proliferation reduce reduce mechanism mechanism block block normal aberrant like small define way level one one dna dna indeed physiology necessary drug drug drug dnbti target cytosine present amount promoter group rb treatment several regulate regulate cell cell cell act function function function function cpg pathophysiology methyltransferase dnmts increase epigenetics methylation methylation decitabine possible lay approve form would important 
1.0@dacogen effect restore erase tumor tumor agent hypomethylation make change call inhibit inhibit dna dna cell cell cell hyper demethylating methyltransferase function induce normal neoplastic methylation methylation decitabine decitabine decitabine decitabine form continue azacitidine 
1.67@hypermethylations demethlylating use agent epigenteics mark ability aberration know important dna dna get inhibitedna epigentic function drug methyltransferase reduce reduce methylations normal increase belong contribute case lead tumour tumour decitabine 
1.0@dacogen methyltransferases class dnmt activate use manner agent agent irreversiblly eisai analog myelogenous cytotoxicity treat inhibit incorporation lead strand covalent precursor demethylating way tumor neoplastic myelodysplastic although demethylation japanese tumour leukaemia suppressor dependent nucleoside therefore replication function hypomethylating subsequent activity activity result result acute inhibitor anti anti prevent company dna dna dna dna dna dna dna dnaand synthesis bind bind syndrome sell dnmts gene methyltransferase effect similar belong decitabine decitabine decitabine decitabine incorporate incorporate hypomethylates azacitidine 
2.0@cancer cancer todna excision aid agent apobec tend myelodysplastic hypermethylated oxidation treat island island cpg cpg cytosine tumour silence demethylating take impact mechanism hypermethylation repair mc hydroxymethyl demethylation demethylation possible use andis patient via via cause tet thymine underlie become ber promoter prevent family dna dna base cell syndrome expression anti gene gene effect belong modification decitabine decitabine hmc deamination propose protein follow 
2.0@one cancer cancer cancer cannot identify class dnmt dnmt dnmt dnmt dnmt drug cause cause hemi decitabine decitabine decitabine decitabine decitabine decitabine decitabine hypermethylation unmethylated unmethylated unmethylated useful bind bind inhibit inhibit division division dna dna dna dna dna dna dna dna get strand strand methylate methylated methylated methylated inhibitor enzyme methyltransferase methyltransferase effect effect permanently belong replicate thus methylation methylation release daughter daughter daughter incorporate incorporate maintain cell cell cell cell cell cell exist dnmti 
2.0@cancer cancer cancer methyltransferases methyltransferases growth suppressor progress use use fda fda agent hypomethylating myelodysplastic design hypomethylation normal disruption previously epigenetic epigenetic see inhibitor inhibitor allow severely myeloid affect affect hypermethylation fact methylation methylation demethylation cell cell cell cell process tumour leukaemia one dna dna dna dna dna dna replication certain mutation incorporate result anti type type several divide divide acute bind syndrome act expression drug drug gene rapidly effect upon control silence regulator decitabine decitabine lay approve approve approve methyltransferase methyltransferase 
1.67@plastic elod cancer cancer way slow break transfer myelogenous since silence growth treat inhibit inhibit suppress lose precursor allow demethylating island island dramatically reduce tumor tumor tumor tumor cell cell cell cell cell cell replication leukaemia one one suppressor methylating regain spread ability cycle y cancerous dna dna acute bind syndrome syndrome use function drug drug drug gene gene methyltransferase rate cpg cpg new methylation methylation methylation methylation decitabine decitabine daughter create reproduce form accelerate 
1.67@allow cancer cancer inhibitor inhibitor cgis change dnmt regulation use use appear specially major malignancy dnmti dnmti growth useful hypermethylated avoid homolog molecule irreversibly development see enzyme cgi proliferation order uncontrolled uncontrolled test demethylated cope thus nucleoside role cell cell tumour tumour determinant one suppressor also therefore epigenetic epigenetic seem seem replication drive decitabine decitabine decitabine mean reversible free anti promoter treatment dna dna however bind expression drug drug gene gene methyltransferase effect haematological passively new methylation reestablish proceed incorporate restriction comprise hypermethylation hypermethylation small 
1.67@cancer classify dnmt behave exposure concentration agent agent agent anti hypomethylation hypomethylation hypomethylation hypomethylation hypomethylation exert lead lead antimetabolite enzyme interest tumor encounter proliferative high like control suppressor cytidine lower therefore drug drug analogue low chemotherapeutic become promoter dna dose dose dose cytotoxic inactivate gene effect effect similar vary produce decitabine incorporate active indirectly would behavior 
1.0@article able use use part agent myelodysplastic way dnmti dnmti change penetrate infer treat transferase inhibit dna dna weaken irreversibly work demethylating group group group proliferation em tumor tumor tumor block epigenome may may susceptible cell methyl suppressor specify drug drug cause add become dnm solid prevent chemotherapy standard bind syndrome gene effect remove thus decitabine decitabine possible incorporate action acitidine would enough 
0.33@suppressor inhibition lymphoma overmethylation drug cause unmethylates agent stop thank growth make many dna histone histone expression demethylating gene gene tumor belong decitabine active cell tumour 
1.67@cancer methyltransferases methyltransferases progress drug reexpressed silence myelodysplastic result sundrome dnmti hypomethylation treat treat previously dna dna dna dna irreversibly bind dnmts gene aml inhibitor upon hypermethylation thus allow cell line decitabine decitabine 
1.33@myc cancer substance activate activate system system system mutation mutation faulty capable change regulatory genetic avoid inhibit suppress regulate epigenetic development call methylated responsible responsible enzyme enzyme enzyme ezh tumor affect turn overexpress factor gsk case case control transcription therefore activation activation drug information information three suppose methylate mute express protein prevent site gene continue inhibitor inhibitor jq malignant defect thereby regulator regulator decitabine possible brd form generate generate effector 
0.33@suppressor cancer cancer cancer cancer cancer class target activation general drug drug cause agent stream upregulation easily since cancerous change anti hypermethylated tumour suprressor inhibit solid lead dna dna divide blood blood surround belong demethylating demethylating gene gene proliferation effect tumor tumor mechanism affect death quickly thus methylation decitabine cell cell cell cell cell use reach 
2.0@cancer cancer classify abnormal dnmt activity activity agent agent agent reversibilty example hypomethylating hypomethylating rule need also also meet silence potential potential microchemical achieve area area opposite methylated enzyme demethylating demethylating as tumor affect expression epigenome metabolite cause attractive cell cell catalyze decitabine compound compound suppressor transfer tsgs divide general drug certain therapy appropriate ly highly reaction anti lead particular intend reverse dna dna dna apoptosis illustrate bind epigenetic le target target gene gene rapidly effect epigenetically increase increase division methlylation methylation rna work disproportionately definition elevate selectively associate associate 
2.0@suppressor cancer instead gene dnmt dnmt dnmt tumour note cycle phase result body quantity healthy hypomethylation clearly hence decrease aza dna dna irreversibly intracellular get bind inhibitor cgi rapidly reactivation upon methyltransferase deoxycytidine deoxycytidine affect belong replicate severely em incorporate cell cell cell replication decitabine 
0.33@cancer inhibitor available regulation use agent stop example myelodysplastic myelogenous change change treat cutaneous unlike might granddaughter epigenetic epigenetic epigenetic pass therefore lymphoma demethylating grow transcription histone precursor factor cell cell cell tumour leukaemia also successfully deploy drug therapy acute erase erase without solid though involve dna kill syndrome gene effect deacetylase division actively decitabine daughter return form form azacitidine 
2.0@cancer characteristic restore dnmt uncontrolled loss shore decacitabine since de hypomethylation incorporation normal island lead lead irreversibly strand repression tumor affect hypermethylation genome nucleoside icrs cell cell cell suppressor consequently imprint analogue property potentially dna dna bind site function cpg gene methyltransferase inhibitor division decitabine work active tumorigenesis differentiation follow associate 
2.0@emphasis cancer cancer inhibitor restore suppressor produce withe use fda agent inactivation also meet dnmti md md overall treat call inhibit incorporation strand marrow think demethylating proliferation tumor tumor tumor affect affect thus thus myelodysplastic demethylation cell cell cell cell blood supressor one mode transfer ase antimetabolite relate abnromal decitabine decitabine decitabine apoptosis apoptosis target result gene gene gene lyko promoter dna dna dna dna dna dna divide reverse cytotoxic syndrome function sensitivity rapidly effect effect effect effect effect control death bone main work rna stresemann compound compound approve action methyltransferase methyltransferase methylating azacitidine 
0.33@cancer cancer abnormal abnormal class produce hypomethylate use leukemia agent phase hypomethylating md md myelogenous cytotoxicity hypomethylation leave direct inhibition treat marrow marrow inhibit clinical increase blast percent clinically effectiveness cell cell cell cell cell cell cell fast blood blood blood blood blood blood decitabine decitabine fewer cause healthy healthy prove target result result damged damage damage example dna dna dna acute syndrome myelodysplastic trial aml die rare death death bone bone develope production methyltransferase methyltransferase 
2.0@mitotically cancer stable reactivation use could mark since de de generation hypermethylated heritable island island island irreversibly pass pass methylated onto allow dnamt tumor tumor normal cell cell cell cell cell replication replication nuceloside dnamti suppressor suppressor therefore epigenetic require analogue subsequent subsequent result methylate hypomethylated dependendent dna dna dna dna bind cpg cpg cpg gene gene methyltransferase inhibitor methylation methylation decitabine decitabine decitabine daughter incorporate active active would 
2.0@growth growth unregulated cancer cancer classify category within produce way agent process similar substance substance direct restore restore believe inhibitor belong twofold tumor block normal normal anticancer demethylation demethylation cell cell cell cell cell cell may blockage one suppressor suppressor suppressor also promote antimetabolite antimetabolite antimetabolite cause incorporate result number become target metabolism dna dna dna divide cytotoxic death function gene gene gene rapidly effect effect interact cellular control increase division division interfere thus methylation methylation decitabine decitabine decitabine regulate methyltransferase 
2.0@suppressor upregulate agent decitabin decitabin result hypermethylated conjunction inhibit dna reaction bind expression demethylating gene gene enzyme tumor silence methylation methylation work otherwise action catalyze azacitidine 
1.67@cancer cause growth irreversibly use analogue dependent myelodysplastic result currently hypomethylation replication treat normal inhibit incorporation incorporation epigenetic class dna dna dna dna dna divide sequence bind syndrome inhibitor thereby drug rapidly effect methyltransferase methyltransferase methyltransferase cellular cellular affect belong interfere decitabine decitabine nucleoside incorporate demethylation cell cell differentiation tumour 
1.33@rate rate devision term dnmt dnmt dnmt progress tumour tumour tumour slow agent specific long mark irriversibly growth unknown epigenetic help demethylating heritability mechanism mechanism disproportionate may although like cell cell cell cell drug drug drug dependent nucleoside mitotic replication analogue incorporate demethylated exact type halt prevent dna dna dna get bind typical inhibitor still methyltransferase effect rapid decitabine decitabine work mean action exist 
2.0@different effect able activate tumour tumour tumour system agent stop hypomethylating reactivate previously allow pattern normal formation dilute genome express demethylation cell cell cell cell cell suppressor suppressor reexpress regain require regulation cycle apoptosis result occur prevent prevent damage dna dna dna reverse act function function time time methyltransferase inhibitor copy silence silence silence word methylation methylation decitabine decitabine daughter gene gene gene mean would progression 
2.0@cancer cancer classify category within within dnmt produce n methyl agent process ul ul ul ul ul ul hypomethylates similar growth direct call decitabinealso restore restore believe strand strand inhibit tumor normal normal anticancer frase demethylation demethylation demethylation cell cell cell cell cell way tra suppressor antimetabolite antimetabolite divide cause inhibts decitabine decitabine decitabine target number anti metabolism dna dna dna dna hypomethylating substance substance cytotoxic cytotoxic chemotherapy chemotherapy function gene rapidly effect effect interact cellular control antineoplastic belong interfere thus methylation rna work incorporate incorporate death 
2.0@suppressor inhibitor restore restore dnmt dnmt close replication patter since dnmti anti copy nucleotide tumor tumor dna get strand bind act expression gene effect upon normal hypermethylation due fact methylation methylation release daughter incorporate come decitabine 
1.67@specifically cancer methyltransferases suppressor thing uncontrolled analogue agent stop silence analog hypermethylation growth gene bind drug avoid island cpg action lead dna dna dna dna dna irreversibly see cytidine epigenetic act among demethylating inhibit methyltransferase division go methylation decitabine decitabine nucleoside could could incorporate cell cell ref tumour 
1.67@slightly cancer cancer cancer cancer use unmethylated concentration concentration specific myelodysplastic myelodysplastic myelogenous dnmti dnmti growth leukemia overall treat cytosine irreversibly methylated particularly responsible thereby tolerate reduce reduce tumor least nucleoside high cell cell cell methyl ensure suppressor either patient residue however decitabine decitabine decitabine decitabine drug analogue toxic low bring well replication help promoter group develop syndrome syndrome dna dna dna dna le acute bind act methylase dnmts dnmts gene hence inhibitor transfer control administer replicate correspondingly methylation methylation genome genome incorporate incorporate 
2.0@suppressor hypomethylation also inhibition restore restore remove remove slow agent specific ideally mark result since growth growth case back island occur class dna dna dna epigenetic consequence inherit demethylating gene gene methyltransferase like tumor tumor tumor tumor location normal normal normal expression division turn methylation methylation decitabine possible cpg express cell cell cell cell cell would would belong 
2.0@dacogen effect daughter diseased overmethylation mitotic appear agent healthy cell cell cell remain marker limit dna epigenetic epigenetic histone chemotherapy sell respond demethylating continue reduce remove little normal normal division modification decitabine decitabine conventional modify 
1.67@one suppressor cancer cancer cancer silent category consequently activate archive certain agent island anti tupor hypermethylated make type region decrease inhibit promoter lead dna dna dna dna epigenetic level particularly important demethylating involve methyltransferase effect tumor tumor mechanism demetylating belong word methylation methylation decitabine decitabine gene gene cpg cell require hypermethylation supressor 
1.67@cancer cancer cancer cancer cancer eliminate able regulation aid agent correct design growth growth growth growth growth genetic hypermethylated restrict inhibit dna dna dna dna epigenetic silence demethylating reduce tumor tumor tumor tumor directly case case many suppressor one specifically drug drug work suppression suppression express promoter promoter develop several act act expression expression expression gene gene gene gene inhibitor inhibitor remove protein thereby methylation methylation methylation decitabine decitabine decitabine region typically enable 
2.0@cancer class dnmt dnmt use agent specific mechanism process myelodysplastic myelogenous dnmti generation generation treat inhibit dna dna lead epigenetic pass demethylating tumor pattern pattern afffects hypermethylation next leukaemia one specifically action drug could acute type better prognosis reduction however transmit syndrome act function still gene precusors inhibitor unclear cellular cellular antineoplastic belong word methylation methylation decitabine decitabine decitabine another supressor 
0.67@mean cancer cancer along weaken daughter therapeutic tumour analogue dependent target susceptible make bind bind bind affect nucleotide action treatment dna dna irreversibly strand copy help chemotherapy inhibitor dnmt dnmt dnmt upon permanently division division thus methylation decogen nucleoside incorporate come cell cell cell far rapid replication decitabine 
2.0@important inhibitor inhibition restore phosphorylated phosphorylated activate methyl purpose make differentiation hypomethylation hypomethylation hypomethylation md treat transferase inhibit inhibit dna dna dna dna dna dna dna dna dna achieve direct proliferation tumor tumor tumor normal myelodysplastic directly insensitive affect demethylation demethylation lead control control ensure suppressor drug cause role anti treatment split however cell cell cell cell cell contribution contribution function gene gene gene methyltransferase methyltransferase effect effect effect effect dead dead syndrome vitro nonproliferative methylation decitabine decitabine decitabine decitabine decitabine possible differentiate enhance play 
0.33@compound enzymatic supression tumour include agent result hypermethylated prevent previously dna histone group enzyme demethylating inhibit inhibit expression induce attach ezh silence methylation decitabine decitabine gene gene gene activity overactivity methyl supressor 
1.33@reduction restore drug reversion reversion agent already probably apoptosys island good tumorogenic promote dna even action demethylating tumor pattern control division methylation methylation methylation methylation decitabine possible cpg case cell generate 
1.67@cancer cancer along along class dnmt tumor tumor uncontrolled could could could whose analog cellular change nucleotide addition granddaughter irreversibly strand belong demethylating job replicate normal release nucleoside regulate supressor suppressor dependent epigenetic epigenetic replication cause pas mean demethylated demethylated stop dna dna dna dna dna get get cell cell cell cell cell bind bind bind gene gene methyltransferase methyltransferase methyltransferase inhibitor inhibitor upon growth growth growth copy division division longer disappear methylation decitabine decitabine decitabine decitabine daughter daughter incorporate come come action 
2.0@cancer inhibitor restore dnmt dnmt dnmt dnmt tumour tumour hematological could mark preservance reactivate preserve lead lead irreversibly permit hyper permanently necessary thus thus nucleoside deactivation often suppressor suppressor duplication deactivate greater high status relate replication analogue novo antitumour level chain dna dna dna bind act important dependence gene gene effect new methylation methylation methylation methylation methylation methylation decitabine decitabine mainly incorporate malignancy active de 
1.67@cancer cancer sucseptible demethylates dnmt dnmt much state fda mark analog dnmti dnakeeping absence irreversibly belong inhibit maintanance mechanism block hypermethylation although cell cell cell strandafter drug one faster lower nucleoside divide replication stability non healthy toxic inheritance introduce fully genomic dna dna dna understand dose epigenetic inhibitor allow probably division methylation decitabine decitabine decitabine daughter incorporate approve would 
2.0@suppressor cancer cancer cancer cancer cancer methyltransferases available dnmt tumour dnmts impact impact allow decitabine since bind effect sit conjunction drug permit particular expression dna dna dna dna irreversibly methylate dependent chemotherapy use belong thereby thereby thereby gene rapidly reduce reduce reduce mechanism increase hypermethylation hypermethylation replicate methylation methylation longer cpg cell cell cell control replication ensure 
1.67@cancer glioma class dnmt others use include agent hypomethylating myelodysplastic pathogenesis characterize decrease decrease island lead lead irreversibly consider demethylating tumor tumor tumor hypermethylation hypermethylation hypermethylation may may tumorigenicity role icrs neuroblastoma tumour patient therefore anti type prevent treatment treatment dna dna dna dna dna dna dna dna dna antineoplastic bind syndrome colorectal inhibitor cpg methyltransferase methyltransferase effect increase belong methylation methylation methylation decitabine decitabine incorporate play 
1.67@cancer inhibitor comparison effective use include agent myelodysplastic myelodysplastic analog possibly treat decrease island island degree irreversibly strand demethylating tumor tumor normal hypermethylation hypermethylation nucleoside cell cell cell may daughter depend depend mostly drug drug anti dna dna dna divide bind syndrome syndrome cpg cpg rapidly effect effect copy apparently division methylation decitabine decitabine cant much come sensitive methyltransferase methyltransferase replication 
1.67@heavy pathogenesis restore dnmt supression use agent whose myelodysplastic analog find hypomethylation island lead lead effective irreversibly development demethylating neoplasia tumor tumor hypermethylation reduce nucleoside case replication supressor dependent lower therefore therefore drug describe prognosis dna dna dna expression dose bind syndrome act dnmts cpg poor inhibitor thus methylation methylation decitabine decitabine gene incorporate recently 
1.33@cancer cancer proliferate restore dnmt dnmt tumour tumour tumour tumour agent agent heighten mark contributor classify growth island suppress class epigenetic see consider hyper thereby thereby inhibit inhibit due tumourogenesis major high like demethylation cell cell cell belong suppressor suppressor also drug cause loss loss number counter dna dna dna dna dna divide inhibitor cpg gene gene gene rapidly effect effect effect effect remove result must division replicate find methylation methylation methylation decitabine decitabine mitosis methyltransferase 
2.0@suppressor tumour activity enzymatic progress methyl trap aberrantly myelodysplastic analog cytosine reactivate leukemia sit incorporation transferase inhibit treat dna dna dna dna acute syndrome inhibitor consequence gene gene methyltransferase myeloid result silence probably methylation decitabine decitabine nucleoside nucleoside heritable incorporate express demethylation use deplete dnmti 
2.0@begin cancer cancer cancer cancer cancer activate use use agent stop stop stop silence myelodysplastic myelogenous dnmti growth treat inhibit development precursor enzyme become hypermethylation rase repressor repressor tumour tumour leukaemia suppressor run patient drug result connect dnmtinhibitor completely methyl example dna dna acute syndrome fe dnmts gene gene induce control control increase demethylating demethylating since methylation methylation decitabine work dnmtinhibitors active 
2.0@suppressor cancer analogue analogue dnmt dnmt tumour tumour cause dependent along decitabine decitabine epigentically reactivate hypomethylation hypomethylation come anti know inhibit methyltransferase action dna dna dna dna get get body bind inhibitor drug gene gene rapidly activation mechanism stage affect increase epigenome replicate silence longer nucleoside nucleoside incorporate replication replication cell cell way alter release 
1.67@several cancer effect responsive term may near agent long analog standard without growth make drug environmental achieve dna dna dna dna kill cytidine chemotherapy demethylating time methyltransferase regulate block normal cumulative thus mitoses genome incorporate methylation many cell differentiation stimulus level decitabine decitabine 
2.0@cancer inhibitor specificity dnmt activate use use agent agent agent irreversible syndrom myelodysplastic analog chance growth treat thecopy pressor adna tumor mechanism affect turn nucleoside demethylation demethylation cell cell cell control clear dependent lower replication cause could could bind bind dna dna dose moment gene methyltransferase along upon division replicate decitabine decitabine time incorporate come action 
2.0@blewitt cancer cancer cancer cancer article article abnormal also dnmt marnie tumour tumour hypomethylating contributory lower economist dnmti hypomethylation direct incorporation marrow inhibit lead epigenetic university think wikipedia causative decitibine hypermethlation katiegreigof high factor cell cell cell may may supressor cytidine analogue coursera cause hematopoietic result anti conjunction traditional level treatment dna dna dna epicentre dose expression inhibitor melbourrne gene gene gene methyltransferase effect control death bone thus methylation decitabine decitabine incorporate cytotoxicity azacitidine 
1.33@mitotically cancer cancer cannot formation methyl methyl mutation myelodysplastic analog additional dnmti leukemia transferase lead irreversibly pass group myeloid tumor nucleoside often epimutations dependent therefore replication replication cell cell prevent prevent prevent dna dna dna dna dna divide divide acute bind bind syndrome act dnmts aml inhibitor attach thus methylation decitabine decitabine decitabine incorporate strongly approve methyltransferase alter 
0.67@inhibitor class transposon activate tumour cytidine mark anti azacytidine hypomethylation effectively inhibit passively methylated enzyme demethylating demethylating alone tumor aza dilute render like demethylation cell global suppressor dependent also drug drug analogue combination cause agent tet express contrast group either dna dna dna dna histone act act dnmts gene effect globally deoxycytidine deacetylase division methylation decitabine decitabine decitabine decitabine mechanistically work active 
2.0@eliminate erythocytes hipomethylation produce use cycle myelodysplastic analog growth specialization marrow inhibit lead epigenetic strand involve allow bone pattern cell cell cell control recover decitabine suppressor cytidine also antimetabolite drug certain malignant toxic permit dna dna syndrome platelet gene methyltransferase effect quantity lymphocyte division silence rna differentiation 
1.0@cancer inhibition class effective regulation tumour agent detrimental methyltransferase de change inhibit benefit cytosine development provide fall reduce reduce tumor tumor hypermethylation supressors instability role case case may reduction methylating alteration analogue cause context result gene gene genomic island dna dna dna dna dna dna however action le cpg sensitivity chemical dependant similar increase methylation methylation methylation methylation decitabine decitabine drive another period attach would would would azacitidine 
1.0@hematologic include include agent aberrantly hypomethylating analog myelogenous myelogenous hypomethylates reactivate hypomethylation leukemia leukemia md broad inhibit inhibit methylcytosine cytosine consequence cml tumor sickle nucleoside express cell incorporate deplete suppressor anemia cause chronic target promoter dna dna dna dna acute demonstrate gene gene gene aml range silence methylation decitabine decitabine decitabine decitabine disorder activity indirectly methyltransferase 
1.67@cancer faster erase tumor replication agent hemi mark decitabane decitabene decitabene decitabene affect inhibit division dna dna dna dna dna dna divide strand methylated enzyme demethylating methyltransferase methyltransferase upon mechanism normal belong dependent methylation methylation lay cell cell cell 
1.33@myc myc impact inhibition lymphoma overmethylation activate activity use use slow agent jq animal transcription treat treat treat test inhibit expression tumour culture involve well human demethylating protein proliferation proliferation research tumor block normal model myelodysplastic factor gsk gsk enzyme cell cell cell cell cell methyl neighbour supressor reduction plan myeloma drug animalmodels know decitabine approach shut encode show show show group dna histone histone histone decrease syndrome inhibitor gene gene gene gene gene target rate overactive deacetylase ezh due silence methylation drastic another brd attach 
2.0@suppressor suppressor suppressor cancer analogue dnmt may may hematological add cause also malignancy dnmti normally normally anti bind call damage lead lead dna dna dna irreversibly improperly dependent inhibitor dnmts gene gene gene effect effect tumor tumor tumor tumor tumor death hypermethylation silence decitabine decitabine nucleoside incorporate express demethylation cell cell cell survival survival 
1.33@mitotically could hypomethylation able tumour tumour agent decitabine island island result result silence growth growth gene bind methyl better prevent heritable lead dna dna dna dna dna see irreverislbly responsible enzyme demethylating inhibit activation dmt demethylation cpg cpg thus methylation methylation methylation ensure region transferase cell control control suppressor suppressor important 
2.0@critical restore able formation way cytotoxicity hypomethylation hypomethylation regulatory incorporation affect inhibit inhibit exert neoplastic sequence thereby proliferation conversion normal adduct may may directly nucleoside substrate triphosphate demethylation cell cell cell control decitabine decitabine decitabine decitabine decitabine decitabine decitabine cytidine also drug cause adversely apoptosis analogue present antineoplastic methyltransferase methyltransferase methyltransferase dna dna dna dna dna dna dna dna divide bind covalent function gene chemical effect induce result cellular cellular protein believe rna rna rna attribute incorporate incorporate differentiation differentiation rapidly follow 
2.0@dacogen cancer use agent island myelodysplastic myelodysplastic characterize transferase inhibit inhibit inhibit cytosine irreversibly methylate demethylating eisai tumor tumor block normal normal hypermethylation case cell tumour suppressor depend get drug anti normally methyl somatic somatic dna dna dna dna divide bind syndrome sell dnmts dnmts dnmts cpg gene syndome effect effect fork thus methylation decitabine decitabine decitabine incorporate active rapidly replication replication tissue tissue tissue 
2.0@methyltransferases restore restore restore dnmt dnmt dnmt dnmt dnmt dnmt likely growth direct recognize epigenetic strand strand promoter methylated methylated reduce tumor factor like accessible control suppressor duplication transcription replication hemi mutation cell result dinucleotide reversal case fully level treatment dna dna dna dna dna dna dna maintenance reverse maintain le gene methyltransferase methyltransferase inhibitor inhibitor induce death silence undergo methylation methylation methylation methylation methylation decitabine decitabine decitabine daughter daughter region lay full follow 
1.33@suppressor suppressor cancer cancer cancer restore able activate imprint tumour tumour tumour cause cause agent agent shore loss hypermethylation hypermethylation hypermethylation normally oncogene treat call group cpg cpg division dna epigenetic cell cell cell cell cell function demethylating demethylating island island hence inhibitor upon uncontrolled normal belong silence decitabine decitabine gene gene class icrs thereby removal methyl remove without 
1.33@dna dna inhibitingdna syndrome demthylating methyltransferase reduce agent myelodysplastic hypomethylates decitabine leukemia cell blood dysfunction 
1.33@mean cancer along decetabine class able much dependent decitabine decitabine decitabine decitabine irreversibly methyltransferase methyltransferase methylate replication replication normal group nucleotide action lead dna dna dna dna divide strand strand get bind bind daughter daughter severely rapidly dnmt dnmt upon longer affect belong replicate copy methylation addition nucleoside incorporate come active cell cell cell methyl release 
2.0@cancer cancer methyltransferases hypomethylation hypomethylation dnmt may include likely specific island de growth avoid locus factor absense prevention cytosine wide provide observe enhance tumor tumor tumor tumor mechanism aza opportunity hypermethylation hypermethylation genome imprint population demethylation cell cell rapid decitabine one suppressor suppressor also promote therefore general drug drug cause novo loss shore anti anti prevent either either dna dna dna maintenance maintenance greatly inhibitor cpg gene gene effect effect effect result deoxycytidine division methylation methylation would em accelerate associate associate 
2.0@cancer precursos therefore therefore use certain agent therapy decitabine decitabine leukimia hypermethylation hypomethylation methylaiton anti type treat counter island island cpg cpg imply dna epigenetic action prevent act name function demethylates gene gene resume inhibitor tumor demethylation silence thus shore genome express active prevention enable follow path 
2.0@cancer cancer cancer inhibitor restore dnmt dnmt system agent agent process generation eroneously inhibit disruption disruption disruption epigenetic even body division demethylating demethylating effective tumor affect ont passive cell cell drug suppressor undo require result result result redundant normally occur successive demethylation demethylation together treatment dna dna correct lot multiple expression gene methyltransferase allow copy silence silence longer methylation decitabine work work 
2.0@methyltransferases dnmt dnmt activate tumour tumour tumour tumour displastic cannot dnmti make absence myelo strand methylate methylated silence effective mechanism life reduce reduce reduce nucleoside cell cell removal use earlier suppressor suppressor suppressor replication analogue limit low exact know treatment dna dna dna dna dna dna dose bind bind isincorporated gene methyltransferase inhibitor consequent unavailable replicate thus methylation methylation methylation daughter tumorigenesis decatibine decatibine decatibine 
0.67@beleived daughter erase action use cause agent agent syndrom myelodysplastic kill change contrast traditional demethlating inhibit treatment dna dna dna epigenetic pass chemotherapy act anit demethylating methyltransferase effect tumor stark division decitabine decitabine becuase mechonism eventually return cell cell cell cell 
2.0@suppressor cancer class therefore irreversibly upon replication analogue dependent agent significantly malignancy growth affect prevent act dna dna dna dna dna dna divide bind epigenetic well demethylating gene rapidly inhibitor inhibitor inhibitor tumor tumor normal hypermethylation hematologic decitabine nucleoside work incorporate methylation cell cell cell methyltransferase methyltransferase methyltransferase 
2.0@cancer within activate others tumour tumour tumour tumour agent tend myelodysplastic myelodysplastic hypomethylation overall treat treat decrease decrease decrease inhibit inhibit suppress epigenetic level available demethylating island island usually hypermethylation hypermethylation act genome genome instability methyl decitabine decitabine decitabine decitabine suppressor suppressor suppressor patient therefore therefore tumourgenesis drug cause add result demethylated number become chromosomal group dna dna dna dna dna dna dna syndrome syndrome use cpg cpg gene gene methyltransferase methyltransferase effect silence thus thus methylation methylation anti drive drive drive 
1.0@suppressor cancer cancer also greater restore effective tumour cause require toxic since drug drug affect inhibit methyltransferase methyltransferase dna dna dna dna divide strand strand bind inhibitor function thereby gene rapidly allow upon longer order normal normal death due release daughter daughter create incorporate active active cell cell cell cell replication replication replication decitabine decitabine 
2.0@suppressor cytidine methyltransferases inhibition therefore therefore tumour analogue could remain hypomethylates exact inhibit dna dna dna irreversibly bind act dnmts dnmts prevent unclear mechanism hypermethylation decitabine although gene incorporate counteract action 
1.67@dacogen cancer cancer cancer receive standard last activate say slow agent stop cutaneous eisai myelogenous stephen growth growth susceptible make illness call treat treat lead epigenetic epigenetic decrease sure lymphoma precursor demethylating dr way tumor tumor tumor tumor people job early whose routine speculate japanese trial baylin baylin leukaemia suppressor uncontrolled researcher successfully deploy use use drug drug drug cause combination acute histone histone chemotherapeutic reaction company show show show good syndrome dna dna cell cell cell cell chemotherapy sell myelodysplastic gene inhibitor inhibitor rare deacetylase deacetylase solid lung go methylation decitabine decitabine decitabine advance time response first alter azacitidine azacitidine 
0.33@though cancer cancer employ change change lymphoma regulation tumour tumour tumour slow agent stop without two growth penetrate treat grow might next epigenetic epigenetic epigenetic pass therefore demethylating unlike granddaughter people response unexpectedly routine participant factor second good cell cell cell trial much kill leukaemia lung transcription advance successfully deploy drug drug drug combination therapy result reaction erase erase chemotherapeutic solid solid show show show reason involve dna harder histone example inhibitor gene rather effect notable deacetylase division go actively daughter time first return form azacitidine 
0.0@cancer ivolved restore apply agent tend stag also growth oncogene oncogene overall tumour illegitimate island nucleotide lead lead status methylate therefore treat division tumor intergenic intergenic transposition transposition evasion aberrant aberrant repetitive repetitive drug hypomethylation hypomethylation methylating methylating metastasis residue excessive excessive recombination recombination region restoration later apoptosis whole element occur promoter repression dna dna dna however cell act use expression cpg cpg involve prevention condensation chromatin increase angiogenesis methylation methylation methylation methylation decitabine gene gene 
2.0@dna bind particularly dnmts relate haemopoietic inhibitor tumor tumor agent mutation itirreversibly demethylating decitabine incorporate dntm level 
1.0@cancer inhibitor promote promote dnmt dnmt dnmt activity tumour dependent irreversibly hypomethylation anti normal blockyng class dna dna dna divide quickly function drug inhibit methyltransferase effect affect hypermethylation longer decitabine decitabine mainly incorporate cell cell replication belong 
2.0@catalyze silence inhibitor inhibitor inhibitor inhibitor class dnmt dnmt dnmt dnmt activate progress methyl methyl leukemia tranfer process lower since dnmti preserve antitumiur epigenetic strand get enzyme thereby thereby myeloid mechanism affect nucleotide bind ensure nucleoside formation maintain maintain good cell cell cell tumour tumour tumour genomic tra funtions dependent cause suppresor therefore irreversibly fda replication replication analogue stability express normally know group presence treatment dna dna dna dna dna dna dna dna dna dna divide dose acute every syndrome fe gene rapidly effect upon cellular copy come belong replicate rase methylation methylation methylation methylation methylation methylation methylation decitabine decitabine decitabine daughter case incorporate myeoldysplastic approve methyltransferase 
2.0@dna dna dna irreversibly could inhibitor bind act dnmts gene replication effect tumor tumor hypermethylation dnmt anti analogue methylation decitabine decitabine nucleoside incorporate inhibit inhibit suppressor 
1.67@classify abnormal dnmt dnmt dnmt activate tumour tumour likely azacytidine dnmti dnmti dnmti dnmti hypomethylation higher inhibit irreversibly strand methylate affect may nucleoside cell cell use hen machinery suppressor cause epigenetic replication replication replication analogue novo target etc dna dna bind bind act inhibitor drug drug gene methyltransferase rate upon try silence methylation decitabine decitabine daughter incorporate incorporate de 
1.0@suppressor cancer also change therefore effective methylates slow slow slow agent cause shut shut without growth growth effect could lead lead treatment dna dna development histone help expression demethylating demethylating gene gene gene gene proliferation impact tumor tumor tumor tumor overactive overactive overactive silence surround methylation decitabine decitabine decitabine cell cell 
2.0@dacogen cancer inhibitor nonessencial dnmt dnmt progress use appear agent stem find dnmti dnmti say leukemia might e demethylating biochimie myeloid hassler hassler hassler mechanism recruitment egger egger egger egger hassle implicate demethylation cell cell cell de methyl embryonic drug mutate mutation tet tet epigenomics describe reference transpherase concept maintance novo presence family treatment dna dna dna dna dna however acute syndrome syndrome sell myelodysplastic aml especially frequently emerge belong new methylation methylation methylation decitabine disorder myelod differentiate protein protein associate 
1.67@especially dnmt dnmt decitabine methlation agent rich promotor limit cytosine hypermethylation growth like contrast avoid inhibit inhibit cpg molecule molecule dna dna dna base bind function demethylating gene tumor mean mean normal normal thereby methylation methylation genome nucleoside region incorporate express small cell control supressor 
1.0@anomaly suppressor cancer cancer targetted restore able fight agent apoptosis demethylate reactivate trigger anti hypermethylated back island properly dna cell cell cell example demethylating gene gene effect tumor tumor pattern normal cpg turn methylation decitabine choose present 
2.0@cancer cancer cgis class class class dnmt could analog find dnmti dnmti dnmti inhibit phenotype strand strand strand strand methylated common cgi reduce tumor tumor tumor tumor mechanism dnmtis hypermethylation hypermethylation nucleoside express cell one suppressor suppressor hallmark replication replication cause hemi suppression suppression promoter promoter prevent prevent dna dna dna dna dna dna get bind site gene gene gene methyltransferase inhibitor copy copy copy copy silence thus methylation methylation methylation methylation decitabine daughter daughter daughter daughter incorporate incorporate enable would 
1.67@class methyl methyl agent member reachable decrease response response response noticeable irreversibly work transferase transferase consider allow interest penetration eradication tumor tumor tumor tumor tumor amp show show thus nucleoside cell may decitabine decitabine decitabine suppressor dependent also patient activation need certain certain improve possess therapy activity activity analogue chemotherapeutic favor antitumor specially conclusion later dna dna dna bind chemotherapy le drug drug gene inhibitor advantage solid solid find methylation alter power observation unexpected tissue replication draw 
1.0@dacogen restore use agent decitabine decitabine decitabine eisai myelogenous similar hypomethylation azacitidine methyl treat transferase inhibit bindi company dna dna dna dna acute methylated syndrome sell function demethylating gene proliferation induce mechanism cellular normal essential precursor may myelodysplastic rna hypo japanese differentiation control leukaemia 
2.0@cancer cancer cancer cancer excess island island island island state agent shore shore hypomethylating analog since almost hypomethylation hypermethylated apototsis inhibit area strand help enzyme grow research tumor tumor hypermethylation hypermethylation genome express express express cell cell cell cell pre decitabine decitabine decitabine suppressor hypermetlyated cause cause cytindine suppose program show show show prevent sign dna dna dna reverse death cpg cpg cpg cpg gene gene gene gene gene methyltransferase defective believe silence undergo methylation methylation rna work incorporate return 
2.0@dacogen cancer methyltransferases methyltransferases higher growth dnmt synthesize use state manner agent agent hypomethylating newly analog myelogenous azacytidine hypomethylation hypomethylation leukemia eisai treat treat inhibit inhibit previously lead nonreversible decitabines precursor link thereby proliferation tumor tumor tumor mechanism block expression hypermethylation myelodysplastic nucleoside express cell cell cell line decitabine decitabine decitabine decitabine suppressor suppressor cytidine lower promote deoxy suppression sequestration acute inhibitor inhibitor become methylation immune prevent covalent covalent dna dna dna dna dna dna dna dna dna dna maintenance dose dose synthesis bind syndrome sell dnmts dnmts dnmts irreversible methyltransferase consequence upon stimulation demethylating silence induce ul ul gene gene gene incorporate hypomethylates differentiation eg 
1.0@maybe reversible dependent transfer patient patient irreversibly epimutations epimutations tumour analogue agent selective meet bind treat decrease inhibit reverse dna dna dna dna dna epigenetic lot ase dnmts demethylating interest methyltransferase inhibitor speficially increase replicate regulator decitabine decitabine nucleoside incorporate methylation cell survival replication 
1.33@cancer cancer dnmt dnmt dnmt use state agent mark generation citosine de make treat call inhibit next clinical epigenetic epigenetic methylate responsible enzyme enzyme enzyme demethylating way way affect transference maintain cell cell cell cell cell cell methyl belong one several transfer erase position drug drug drug drug novo reversible without anti tumour group presence dna dna kill bind syndrome myelodysplastic cpg irreversible effect practice division division division epigenetics methylation decitabine decitabine daughter daughter em em activity 
2.0@toxicity hypometylates cancer also activity promote therefore suppressor suppressor tumor tumor tumor tumor cause classify cytidine agent cyto analog find anti inhibit inhibit cpg dna dna dna dna divide antimetabolite act demethylating island rapidly induce hand death hypermethylation clear methylation decitabine decitabine decitabine gene gene incorporate cell cell cell methyltransferase blockage 
0.67@cancer inhibitor class term epigenetic drug drug agent stop decitabine decitabine decitabine cancerous chemotherapeutic hypomethylation make grow lead dna dna dna dna status kill demethylates demethylating hypomethylated effect belong thus routine permanent prone cell cell cell without 
1.0@cancer cancer tumour agent mark easily andby inhibit dnmtsdecitabine granddaughter epigenetic doesnt pass responsible demethylating demethylating grow proliferation impact normal turn maintain demethylation thereby status status drug healthy cell cell cell cell cell cell cell demethylated bring anti prevent dna dna dna divide kill bind bind act dnmts rapidly effect remove division thus thus methylation decitabine decitabine decitabine daughter cancerous influence action hence would 
1.33@class tumour state agent mark local chemotherapeutic anti drug drug landscape dna epigenetic derepressing decrease pressor demethylating effect remove remove natural thereby methylation methylation methylation decitabine decitabine decitabine tumourigenic return repress 
2.0@suppressor cancer able induction tumour useful reactivate hypomethylation leukemia become treat hypomethylated dna dna dna syndrome gene methyltransferase inhibitor epigenetically silence methylation decitabine decitabine activity myelodysplatic inhibit 
1.67@cancer methyltransferases class lower epigenetically use use appear agent specific silence myelodysplastic discover reactivate md treat effectively irreversibly strand decitabne belong demethylating facilitate tumor tumor mechanism hypermethylation nucleoside alteration cell way supressor also rapid depend epigenetic induction replication analogue combination dose toxic apoptosis present gene type type solid show show show prevent good action degradation dna dna dna dna dna dna get non histone bind syndrome act act act inhibitor inhibitor still poor methyltransferase effect effect effect unclear deacetylase antineoplastic division new methylation decitabine decitabine much incorporate first cpgs indicator prognostic 
1.33@cancer cancer cancer myelodisplasic dnmt administration use use slow agent syndrom silence silence unmethylated hypermethylated treat treat avoid island island lead epigenetic strand decrease enzyme demethylating inhibit proliferation tumor tumor start process suppressor suppressor patient general drug target inheritance show prevent presence dna dna already cpg cpg gene gene especially longer thus methylation methylation decitabine decitabine decitabine decitabine decitabine instance 
1.0@cancer cancer class class specificity dnmt enzymatic use use use example malignancy consist characterize treat island incorporation molecule irreversibly severely inherent mechanism block affect lack hypermethylation clear continually nucleoside small underway methylation cell trial tumour tumour myelodysplasic dna dna dna dependent therefore epigenetic replication analogue target moreover fact introduce completely region cpg treatment several several bind syndrome dnmts dnmts dependence drug drug drug drug methyltransferase inhibitor inhibitor expecially propensity solid belong replicate new regulator decitabine decitabine possible action haematological recently 
1.33@suppressor cancer effect reactivation activate tumour tumour deactivate agent anti might island cpg lead dna dna demethylating gene gene gene hence reduce reduce hypermethylation hypermethylation thus methylation decitabine dectiabine work cell 
1.0@suppressor suppressor cytidine promote use analogue agent agent stop process myelodysplastic myelodysplastic myelogenous reactivate leukemia treat dna dna carcinogenesis acute syndrome syndrome act act demethylating demethylating gene gene tumor tumor tumor block precursor hypermethylation decitabine decitabine activity progression 
2.0@unregulated restore hypomethylate use use include agent myelodysplastic growth treat call inhibit regulate kind belong demethylating tumor normal source isa many cell cell tumour tumour toa suppressor suppressor promote therefore drug drug result responseto become solid group demethylation dna dna dna syndrome function anti gene gene andpromotes expression increase division division silence methylation decitabine decitabine work methyltransferase 
1.33@cancer enzime becose depend depend dnmt use drug evolve agent acute mark analog myelogenous myelodysplactic anti treat affect island methil dna divide hypermehylation bind syndrome syndrome act demethylating cpg methyltransferase effect effect effect tumor normal mantein belong thus decitabine nucleoside demethylation cell cell replication replication leukaemia 
1.67@reason inhibitor class dnmt seem cause myelodysplastic anti unknown dna dna irreversibly kill bind syndrome dnmts still effect tumor neoplastic belong efective decitabine decitabine decitabine incorporate methylation cell 
1.67@mitotically could could restore manipulate use manner agent mark myelodysplastic myelogenous aberration leukemia treat island island suppress say expression methylated methylated precursor demethylating effective tumor tumor tumor mechanism mechanism normal hypermethylation new genome reinstate hereditable case cell cell cell cell removal blood decitabine suppressor method relate rightly target cancerous excellent express dna syndrome le inherit cpg cpg gene gene gene function remove methylations methylations control main expect daughter mean mean action 
2.0@heavy transferease inhibitor inhibition class target efficacy methyl methyl although pattern myelodysplastic probably mimetic dnmti marker leukemia tumour tumour transferase subsequently unknown irreversibly strand methylated operation well inhibit proliferation myeloid mechanism normal hypermethylation hypermethylation hypermethylation rely rely may supressors nucleoside affect cell cell cell myelodysplatic decitabine decitabine decitabine suppressor cytidine also indeed therefore replication drug adjacent ability highly cancerous ultimately gene become know dna dna dna dna dna divide acute bind bind syndrome syndrome dnmts dnmts cpg right rapidly effect copy thus methylation reliant daughter poor incorporate dosage towards prognostic tissue 
2.0@dacogen cancer cancer cancer article class regulation remove methyl impact eisai instead economist hypomethylation treat importantly inhibit previously expression epigenetic epigenetic development tumour tumour tumour tumour tumour tumour help involve inhibitor inhibitor contribute demethylating proliferation reduce longer hypermethylation addition genonome name demethylation japanese unsilencing global decitabine decitabine decitabine decitabine suppressor suppressor cause activation fight disease certain promotor promotor result hypermethylationand ledsilencingof express anti anti know group company dna dna dna dna dna sell act important important gene gene gene gene gene gene effect induce belong produce silence silence silence silence methylation methylation allow allow region region activity andexpression adverse associate 
2.0@cancer decitabine decitabine todemethylate suppresing analogue analogue agent tend hypomethylating replication hypermethylated depedant promoter inhibit cpg island dna dna dna dna dna dna lot help particularly silence provide irreversible methyltransferase methyltransferase remove longer longer control bind bind division replicate methylation sensitive nucleoside nucleoside gene gene incorporate drug drug drug cell cell cell cycle tumour release 
2.0@cancer myeloid nucleoside progress methyl fda dependent myelodysplastic myelodysplastic since leukemia intense drug transferase island lead epigenetic methylated efficient inhibitor inhibitor inhibitor research tumor tumor clear normal hypermethylation mode although cell cell cell cell cell use suppressor expression dna dna dna faster dnmt dnmt indeed irreversibly replication replication analogue could target become promoter action action reduction acute bind syndrome syndrome act dnmts cpg affect field believe replicate methylation decitabine decitabine decitabine decitabine oncology gene gene gene incorporate approve machinery enable require 
1.67@cancer inhibitor inhibitor faster dnmt regulation progress tumour agent specific methylome selective dnmti myelodisplastic molecule epigenetic involve well think demethylating severely impact tumor tumor pattern pattern affect neoplastic hypermethylation consequently dilute genome although small methylation methylation methylation treatment decitabine decitabine decitabine decitabine suppressor dependent establishment depend irreversibly seem replication drive low anti type family particularly dna dna dna dna dna dna divide divide dose cell cell cell cell bind syndrome act dnmts perform gene aml effect effect methyltransferase belong due thus regulator would mainly wide incorporate action rapidly alter tissue 
1.67@dacogen cancer article suppressor regulation use agent myelodysplastic since economist silence growth part might might might island back back amount promoter treat source demethylating group way reduce normal hypermethylation turn cell cell cell cell tumour leukaemia dna dna dna return region apoptosis proper sequence precursor become type methyl lecture prevent damage reduction syndrome act act cpg cpg gene gene gene gene gene remove death division thus methylation methylation decitabine decitabine decitabine proceed active action badly play 
1.67@intend patient drug drug cause agent mutation demethylated problem might might level group class dna dna methylated silence take reduce correctly downregulated belong decitabine region region region region express methyl 
2.0@cancer critical restore methyl proliferate hypomethylation hypomethylation inhibit irreversibly sequence inhibitor thereby proliferation normal neoplastic may proliferative nucleoside insensitive differentiate demethylation cell cell cell fast control tra cause replication analogue apoptosis relatively become dna dna dna non bind fe function gene methyltransferase dnmts die cellular cellular result rase decitabine decitabine daughter incorporate differentiation differentiation 
2.0@cancer slow usual tumour tumour certain change demethylate decrease dna area reverse allow precursor hypermethylation hypermethylation gene gene inhibitor silence methylation decitabine express demethylation supressor 
1.67@could inhibitor dnmt dnmt relate drug every supperession new reactivate growth might decrease group dna bind expression belong cpg island effect tumor onco mitotic potentiate thus methylation supressors demethylation demethylation cell enable decitabine 
1.67@cancer cancer methyltransferases efficacy dnmts use state agent mark make analog analog analog find susceptible useful hdais inhibit epigenetic inhibitor disease demethylating effective effective affect late methylation cell removal decitabine decitabine one lung cytidine cytidine cytidine individual drug drug cause combination deactylase pathway result cancerous chemotherapeutic chemotherapeutic antitumour show fact together treatment dna dna dna base histone chemotherapy synergistic scrutiny effect effect stage well hypothesis expect work mean azacitidine combine combine combine would recently 
2.0@dna dna irreversibly inhibitor bind expression cpg cpg methyltransferase dnmts tumor tumor tumor increase activity result methylation methylation decitabine decitabine incorporate hypermethylated prohibit decrease decrease island island replication suppressor suppressor 
1.67@cancer methyltransferases inhibition restore suppressor suppressor suppressor uncontrolled situation demethylate cannot reactivate hypomethylation hypermethylated island island achieve irreversibly strand class common inhibitor silence silence silence inhibit reactivation tumor tumor tumor pattern pattern feature hypermethylation hypermethylation inactivation repair nucleoside express lead lead way release one namely turn endogenous disrupt drug analogue apoptosis result reverse anti promoter promoter dna dna dna dna dna dna dna base cell cell bind act dnmts dnmts cpg cpg gene gene gene gene gene methyltransferase along growth belong methylation methylation decitabine decitabine decitabine daughter incorporate incorporate tumorigenesis neoplastic dnmti 
1.33@cancer inhibitor inhibitor dnmt use agent myelodysplastic myelogenous treat stpo aza irreversibly strand body precursor demethylating severely replicate nucleotide release align align align align cell cell cell much leukaemia justify justify justify justify dependent divide replication mean dna dna dna dna dna get acute bind bind bind syndrome affect methyltransferase methyltransferase methyltransferase along along upon deoxycytidine copy division division longer methylation decitabine decitabine daughter incorporate come come action rapidly 
2.0@elod plastic cancer instead discriminant use slow agent tend since formy decrease inhibit luckily unfortunate demethylating reduce reduce tumor intergenic methylation methylation thing genome genome gene gene express treatment drug leukaemia older specifically also patient aprecursors stability ly moreover suppressive element amount repetitive dna dna dna understand acute syndrome rest right methyltransferase effect effect silence due myelogenous unsilenced decitabine advance region y dosage side would small 
1.67@mean cancer cancer cancer inhibitor dnmt hypomethylate methyl tend mark currently block md hypermethylated test island solid solid irreversibly decitabines easy reduce tumor tumor people know know hypermethylation nucleoside methylation cell cell cell cell cell cell cell cell removal blood blood reach compare actively actively drug analogue ability ability target relatively yet maintain anti occur show dna dna dna divide divide bind act dnmts cpg trial methyltransferase effect result al decitabine decitabine decitabine incorporate modify 
2.0@althouugh appear serum use include agent selectve hypomethylating myelodysplastic hypomethylates growth inhibit inhibit aza cytosine injury strand pyrimidine enzyme head tumor tumor tumor tumor intracellularly block clinically convert implicate transient triphosphate cell expression decitidine suppressor cytidine cause liver manner analogue analogue jaundice therapy therapy decitabine decitabine decitabine decitabine decitabine decitabine apoptosis result low azacitidine azacitidine azacitidine become antineoplastic chain dna dna dna dna dna dna deoxyribose deoxy form wich syndrome function gene gene gene rate induce similar increase silence silence methylation rna elevation em em em em em em incorporate incorporate incorporate apparent associate 
2.0@vivo cancer cannot cannot atom synthesize tumour tumour tumour require aberrantly process newly analog compaction island island nucleotide whereas cytosine cytosine cytosine position position strand methylated methylated methylated pyrimidine precursor thereby dctp close carbon factor triphosphate cell cell may may machinery substitute suppressor suppressor daughter map replication cause wherever base result reverse maintain prevent presence preparation dna dna dna dna dna dna dna ring synthesis synthesis heterochromatin expression cpg cpg gene gene nitrogen division replicate go methylation decitabine decitabine decitabine decitabine decitabine motif em incorporate form discriminate initiate recruit 
1.67@dacogen cancer effect effective progress use possibly mostly eisai since since malignancy leukemia make make affect island irreversibly strand sequence well gpc inhibitor inhibitor severely myeloid tumor mechanism normal hypermethylation although many cell cell cell trial drug drug drug drug drug drug dependent also also patient get fda replication target body know prevent point dna dna dna dna divide divide acute bind bind syndrome sell myelodysplastic aml aml along upon methyltransferase methyltransferase methyltransferase division methylation decitabine daughter incorporate come approve rapidly 
0.0@la baby hasta vista 
2.0@cancer cannot methyl methyl state could stop mark dnmti potential decrease island island irreversibly inhibitor inhibitor give demethylating inhibit normal hypermethylation nucleoside express cell cell tumour tumour tumour one one suppressor cause insert patient therefore spread analogue agent occupy activity anti know group dna dna dna dna bind bind example dnmts dnmts dnmts cpg cpg affect methyltransferase effect remove replicate methylation methylation decitabine decitabine decitabine decitabine gene incorporate return 
2.0@methyltransferases areincorporated effective use hematological oftumor stop stop silence myelodysplastic analog since malignancy dnmti dnmti growth unmethylated sit treat island unknown ofareas precursor think especially thehypermethylation tumor mechanism hypermethylation hypermethylation whichirreversibly often suppressor dependent dependent either although therefore replication leukemia incipient suppression formerare exact normally halt hypomethylated dna dna dna dna acute bind syndrome nucleoside dnmts end gene gene aml inhibitor cpg myelogenous decitabine decitabine decitabine action methyltransferase reactivate 
2.0@mean cancer cancer inhibitor inhibitor class progress tumour tumour tumour hematological fda agent specific island myelodysplastic find malignancy transferase inhibit cpg epigenetic get disease demethylating severely affect hypermethylation hypermethylation fact nucleoside cell cell cell use decitabine decitabine suppressor suppressor dependent dependent therefore irreversibly replication analogue revert compose body underlie anti methyl promoter dna dna dna divide bind syndrome dnmts drug drug gene gene gene rapidly effect effect belong due silence methylation ul ul incorporate approve aml 
1.33@suppressor suppressor cancer cancer cancer also mode activate drug agent could relation suppose silent desmethylation element decrease island genomic action repetitive dna saw saw methylated methylated methylated density density act cpg gene gene tumor tumor intergenic question question normal increase increase demethylating produce go go methylation exist assume region region region cell cell cell cell level decitabine decitabine 
1.33@myeloid rate class specificity dnmt dnmt progress arenucleotide agent long hypomethylating myelodysplastic since malignancy dnmti leukemia molecule sincethese irreversibly term effective tumor tumor mechanism normal dnmtis dnmtis hypermethylation although high cell cell cell drug suppressor dependent dependent dependent also indicate therefore replication replication replication analogue target describe lack hence show dna dna acute bind syndrome inhibitor gene aml effect innhibitors desease belong decitabine decitabine incorporate action methyltransferase haematological small 
1.67@cancer participate disrupt activate tumour tumour tumour cluster agent agent whose mark phenomenon wrong growth growth part inhibit regulate igf epigenetic promoter would demethylating demethylating locus happen mechanism lack hypermethylation may main role icrs demethylation use use decitabine decitabine decitabine suppressor suppressor depend activation solve result specific specific like demethylate normally normally know island dna dna dna dna example expression cpg gene gene gene gene gene gene effect increase silence silence silence since methylation methylation methylation locate establishment usually mean active active restriction reestablish 
1.0@cancer methyltransferases abnormal dnmt dnmt dnmt fda maintened augment cisplatin survivin survivin cytotoxicity de upregulating might might folate resistant often lay repression repression inhibitor hypermethylation hypermethylation demethylating reduce tumor mechanism mammal nuncleoside apoptotic factor factor role cell cell cell drug methotrexate expression suppressor dependent also therefore agent agent agent replication analogue downregulation uptake novo support anti permit protect proapoptotic dna dna dna dna dna dna dna reverse reverse reverse bind bind chemotherapy chemotherapy chemotherapy dnmts irreversible target carboplatin cellular sensitize silence methylation methylation methylation methylation decitabine decitabine decitabine resistance resistance gene gene incorporate approve various protein follow play 
1.67@plastic plastic cancer inhibitor higher effective use fda lower neoplasic dnmti dnmti possibly dosis superior might irreversibly myelodys treat division island tumor due affect life life improvement nucleoside side demethylation cell cell cell cell much much dependent dependent also quality patient therefore action drug drug drug analogue cause toxic expectancy kill anti better good dna dna dna divide dose hypermehylation bind syndrome syndrome act dnmts cpg rapidly effect effect range tolerate belong replicate terrible decitabine decitabine severely incorporate approve administer methyltransferase myelod 
2.0@allow cancer critical restore able synthesize way include agent process newly structurally methylating similar hypomethylation regulatory affect inhibit sequence responsible enzyme demethylating proliferation tumor tumor tumor mechanism normal may may directly nucleoside convert triphosphate demethylation cell cell cell cell cell control suppressor decitabine decitabine decitabine decitabine decitabine specifically cytidine transcription promote induction replication adversely initiation apoptosis result result body number effect anti anti damage dna dna dna dna bind function function gene gene gene methyltransferase methyltransferase reexpression cellular repress division rna rna rna incorporate differentiation protein present 
1.0@dacogen cancer cancer inhibitor inhibitor lower able activity use use use fda mutation hypomethylating eisai myelogenous hypomethylates japan make make treat treat treat inhibit inhibit addition patient patient clinical epigenetic epigenetic epigenetic usage around precursor enzyme enzyme enzyme dnmt mechanism nowadays neoplastic life life extend readily molecule nucleoside trial independent machinery machinery market enzymatic drug drug drug analogue quality high therefore replication cause know agent expectancy result reversible anti better better begin dna dna dna dose dose acute syndrome target target still myelodysplastic methyltransferase effect unclear overactive undergo since decitabine decitabine decitabine incorporate approve action small 
1.33@cancer cancer drug drug instability add mutation silence linfomas surround present presence cue cue methyl group treat kind histone histone heterochromatin epigenome inhibit rate gene result result result block protein protein protein increase hypermethylation new methylation decitabine high region action action use 
2.0@mitotically lock inhibitor therefore therefore dnmt epimutations use cause cancer limit remain growth heritable incorporation dna dna dna dna dna divide divide divide lot bind particularly dmti dmti dmti dmti silence gene methyltransferase effect normal effective effective methylation methylation would mean restrict cell cell cell cell cell demethylation tumour tumour suppressor decitabine 
2.0@different different tendency cancer cancer cancer cancer class progress way slow could stop probability hypermethylated call island island molecule often cytosine cytosine position even silence silence hypermethylation hypermethylation usually cell removal tumour tumour suppressor suppressor promote drug drug unblock result result present type promoter promoter develop dna dna mark reverse example expression cpg cpg gene gene gene methyltransferase inhibitor increase belong methylation decitabine mean specific would would would 
0.0@one cancer component acid acid acid depakote et regulation use recently inhibitor inhibitor likely specific blocker process synaptic autism insomnia direct treat chromatin inhibit epilepsy expression expression expression depression depression even plasticity cox establish enzyme sexual observe change change affect malformation genome substrate methylation skeletal crucial contraceptive risk wang epigenetic epigenetic epigenetic epigenetic compound drug drug drug drug drug drug structure side result reaction citation example example valproic valproic valproic methylphenidate nsaid genomic potentially dna understand histone histone histone osteoporosis consume tolerance list hyperglycemia ssri effect effect induce induce induce condition range deacetylase increase increase diabetes produce epigenetics al adverse gene gene gene mortality widely cardiovascular deacetylease acetylation alter alter alter dysfunction 
2.0@inhibitor inhibitor class unwarranted methyl inactivation malignancy hypermethylation hypermethylation island sup sup sup sup sup sup demethylates epigenetic preclude enzyme enzyme enzyme inhibit inhibit tumor tumor pattern reflect contribute aberrant catalyze belong suppressor transfer certain cause number anti promoter group family dna dna dna dna dna dna dna dna dna cpg gene methyltransferase methyltransferase methyltransferase methyltransferase methyltransferase effect undergo increase human website website website thus thus methylation methylation decitabine decitabine decitabine decitabine region activity hypomethylates tumorigenesis associate 
2.0@dna dna suppressor cancer transcription allow demethylating gene work agent mean classify decitabine factor demethylate open expression 
1.33@cancer employ restore last outcome baylin slow agent process myelodysplastic charge member growth susceptible make treat might researcher clinical epigenetic epigenetic epigenetic epigenetic show show inhibitor inhibitor demethylating dr tumor people normal unexpectedly routine speculate successful decitabineis cell standard way suppressor trial patient drug drug drug drug drug drug drug drug combination combination could good good reaction chemotherapeutic solid know tumour tumour tumour syndrome dna dna histone chemotherapy use use function gene effect effect effect deacetylase lung interfere methylation advance time another another first combine alter 
1.0@dna dna cancer methylate enzyme demethylating reduce agent epigenoma epigenoma normal make find methylation intergenic element activity like region cell cell inhibit decitabine repetitive 
1.0@cancer inhibitor highreplication dnmt tumour analogue tothe ucleoside decitabinecauses selective growth normal suppress dna ofnormal bind dnmts hence cellscompared rate affect due methylation decitabine effectivenessis cell cell may 
1.67@suppressor suppressor ofepigenetic therefore inhibitor experience use cause link agent island myelodysplastic result myelogenous reactivate hypomethylation hypomethylation leukemia anti treat promoter group cpg previously dna dna epigenetic acute syndrome precursor contribute demethylating gene gene effect tumor tumor tumor calleddna belong silence decitabine decitabine counteract drug drug drug drug hypermethylation hypermethylation 
1.67@cancer cancer inhibitor use agent mark myelodysplastic hypomethylation treat lead precursor demethylating tumor pattern decogen essential contribute may high maintain passive cell cell cell similarity compound cytidine also due replication analogue ability loss across structural anti know treatment dna dna dna dna dna dna deoxy point view aml effect effect induce methyltransferase hand syndrome death interfere epigenetics methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine daughter mitosis mitosis incorporate dosage survival chemical 
1.67@one suppressor critical restore restore methyl exposure agent stop activity activity result block hypomethylation hypomethylation anti oncogene drug decrease grow grow dna dna dna dna fe function demethylating gene gene proliferation effect tumor tumor mechanism cellular normal neoplastic may rase actively actively decitabine possible incorporate cell cell cell differentiation control tra 
0.33@suppressor promotors inhibition medication tumour tumour analogue therefore anti low reactivate antineoplatic replication methyl transferase methyltransferase hyopmethylation dna dna dna irreversibly dose bind pyrimidine act act stabilise gene way effect pattern give give methylation methylation decitabine decitabine carcinogenic independent dnmti 
2.0@cancer cancer classify restore dnmt dnmt tumor agent mark cure cure myelogenous since dnmti dnmti growth rate direct class irreversibly nonspecific help precursor inhibitor inhibitor put normal give myelodysplastic nucleoside reinstate demethylation demethylation demethylation cell cell cell cell control leukaemia one suppressor also analogue large high antimetabolite antimetabolite decitabine decitabine decitabine decitabine decitabine drug cause toxic target relatively low bind level prevent dna dna dna dose acute cytotoxic syndrome act function gene methyltransferase effect epigenetically interact belong replicate prescribe methylation inside incorporate kill 
2.0@earlier specifically cancer cancer transfer methyl cause agent agent island island inhibit inhibit apply tsg tsg hypermethylated hypermethylated might group suppress dna dna dna dna dna development reverse discuss enzyme demethylating demethylating prevent methyltransferase allow tumor tumor cpg cpg methylation decitabine decitabine work work gene express catalyze 
2.0@suppressor suppressor higher therefore reactivation seem drug cause agent hypomethylation especially inhibit tumor tumor tumor tumor dna dna dna dna promoter gpg act hypometylation demethylating island methyltransferase epigenetically accumulate silence induce decitabine decitabine gene gene mean methylation lead level progression 
2.0@cancer cancer inhibitor dnmt dnmt activate methyl methyl agent mark mark since dnmti hypermethylated transferase lead lead epigenetic strand regulator demethylating severely tumor tumor tumor affect dnmtis divide onto much case demethylation cell cell cell cell cell may suppressor suppressor faster irreversibly drug carry normal dosage anti bind promoter promoter transfetase dna dna dna dna dna dna dna get action dependent target gene hence effect copy division division thus methylation methylation decitabine decitabine decitabine decitabine decitabine daughter daughter incorporate arrive enzymatic azacitidine 
2.0@ctr ul ul ul ul ul ul use manner agent agent acute decitabine decitabine decitabine decitabine hypomethylating myelodysplastic myelogenous hypomethylates augment azacitidin methyle treat transferase inhibit chain dna dna dna dna dna dna strand decrease syndrome precursor function demethylating expression mechanism similar belong methylation methylation rna although incorporate incorporate leukaemia independent azacitidine 
2.0@cancer cannot restore within administration may may may may agent agent mechanism already disappear economist de hypomethylation note note generation dilution inhibit inhibit additionally involve responsible enzyme demethylating demethylating island island island tumor tumor accord normal hypermethylation go repair repair recommend case many disable drug drug drug drug decitabine decitabine suppressor hallmark essentially prior novo apoptosis apoptosis cell cell regardless halt damage dna dna dna dna dna dna divide mark mark reverse inhibitor cpg cpg cpg gene gene methyltransferase eliminate place growth copy increase silence website thus methylation methylation methylation allow mitosis article 
2.0@higher class specificity dnmt use analog since dnmti diminish transferase inhibit previously irreversibly enzyme demethylating reactivation tumor tumor tumor tumor develop hypermethylation mode nucleoside nucleoside cell cell cell replication replication one suppressor dependent dependent drug drug base toxic low anti methyl good dna dna divide dose dose bind concentrate gene rapidly effect effect increase silence due new decitabine incorporate action action would would 
2.0@suppressor classify necessary may analogue cycle specific dnmti hypomethylation anti lead dna irreversibly non bind drug time methyltransferase effect tumor tumor tumor inactive increase hypermethylation clear thrive decitabine decitabine nucleoside gene replication 
2.0@growth cancer cancer reexpression abnormal abnormal restore restore within transcriptional induce induce methyl inhibitor inhibitor island dinucleotides also invasion hypomethylation inhibit inhibit suppress important cytosine epigenetic epigenetic development sequence certain silence demethylating control proliferation downregulation tumor normal cg cg may may may otherwise methylation methylation methylation methylation many cell cell cell cell cell demethylation tumour expression critical transcription become residue sustain presumably presumably alteration cause therapy result reverse effect effect anti type promoter promoter promoter group damage dna dna dna dna dna remethylated inhibitory carcinoma example act dnmts ofdecitabine ofdecitabine gene gene gene gene gene gene methyltransferase function remove preferentially global classic interfere thereby decitabine decitabine decitabine decitabine decitabine activity associate downstream adrenocortical reactivate 
2.0@heterodimer cancer cancer super class drug drug cause agent xl pro member bcl bcl anti anti family demethylates dna area belong demethylating demethylating gene effect tumor epigenome apoptotic decitabine 
1.67@dacogen cancer cancer unrestricted could dnmt uncontrolled loss dnmti growth growth growth growth might inhibit lead igf inhibitor contribute reduce tumor tumor tumor tumor block normal hypermethylation cause case case cell cell cell express expression expression suppressor suppressor suppressor also promote promote imprint imprint either whether upregulation result maintain amount know prevent prevent dna dna dna therefor therefor limit gene gene gene gene gene gene methyltransferase allow control silence methylation methylation methylation decitabine decitabine decitabine region action would would 
1.33@suppressor suppressor transfer transfer erase n drug slow agent stop methy growth anti anti hypermethylated methyl methyl avoid avoid inhibit dna dna dna dna use inactivation demethylating group group hence effect effect tumor tumor tumor tumor decitabine decitabine gene gene gene gene active tumour tra 
1.67@cancer class class dnmt methyl state agent also growth characterize hypermethylated hypermethylated decrease decrease hinder act regulate demethylating island island proliferation tumor normal contribute rase nucleoside role demethylation cell cell suppressor tra specifically cause indicate therefore decitabine decitabine decitabine decitabine drug drug analogue revert know dna dna dna dna expression expression bind fe name dnmts cpg cpg gene gene gene inhibitor belong capable methylation central irreversible 
1.67@cancer cancer article think dnmt dnmt use agent tend myelodysplastic dnmti treat hemimethylated irreversibly strand see inhibitor enzyme demethylating mechanism hypermethylation nucleoside cell cell cell cell blood specifically methylating successfully hallmark replication analogue cause novo target target describe methylate healthy halt tumour tumour prevent prevent dna dna dna divide action bind bind syndrome act dnmts drug time hence disease unclear methyltransferase evidence division methylation decitabine decitabine daughter progression rapidly de 
1.33@plastic elod cancer rate dnmt dnmt dnmt use inhibitor inhibitor inhibitor agent specific really myelodysplastic myelogenous leave leave leave treat call island lead irreversibly controversially methylated precursor demethylating tumor additionally normal generally style style style nucleoside align align align case cell cell cell incorporate leukaemia one dependent high replication replication replication replication analogue strand text text text otherwise mean fast show dna dna dna dna non acute bind syndrome syndrome act important cpg affect dnmts belong replicate find methylation decitabine daughter y action heavily 
1.67@mean mean cancer cancer proliferate restore restore dnmt dnmt use order cytidine myelodysplastic analog classify dnmti dnmti hypomethylation hypomethylation hypomethylation md change nucleotide regulate epigenetic inhibitor neoplasia tumor longer spesifically normal hypermethylation may release insensitive cell cell cell cell cell cell cell cell control blockage suppressor suppressor dependent transfer induction drug drug cause cause target relatively bind methyl treatment dna dna dna dna dna non ase syndrome function gene gene rapidly effect result result growth growth copy division division replicate replicate methylation methylation decitabine decitabine decitabine activity 
0.67@methyltransferases abnormal class ul ul height independent exposure agent agent consequence hypomethylating size deciatabine hypomethylation exert gent antitumoral recognize theupregulation responsible enzyme demethylating demethylating demethylating suchas dnmt tumor tumor mechanism complex style may ation line font explanation cell cell cell cell cell methyl inside dependent transfer relate induction drug cause cause phospho metabolize cycle cycle apoptosis apoptosis incorporate result chemotherapeutic rylated arrest px px degradation dna dna dna dna dna base action covalent dnmts gene gene effect induce sensitizethem suggest belong caspase silence methylation decitabine decitabine decitabine decitabine bydna strong apaf form hypermethyl associate 
1.67@mitotically cancer cancer cancer cancer methyltransferases deacetyase dnmt activate tumor tumor tumor tumor tumor use use use inhibitor prove myelodysplastic hypomethylation methyation treat treat treat treat erase meyloid restrain class promoter lukaemia responsible silence silence silence demethylating derive serve mechanism uncontrolled thus counteract cell cell line region region region one suppressor suppressor also also successfully drug drug drug cause cause free anti conjunction solid know dna histone syndrome inherit gene gene hence eliminate demethylates thereby thereby thereby main methylation methylation decitabine decitabine decitabine decitabine em proliferation azacitidine 
2.0@inhibitor inhibitor dnmt dnmt dnmt activate tumour tumour tumour proteasome include block block growth growth avoid lead cytosine cytosine nov methylate source biochimie conversion complex aug degrade nucleoside like like like try supressor compound activation relate doi anti promoter promoter pmid external dna dna dna decrease mediate dnmts gene gene gene chemical effect methyltransferase cellular control methylation decitabine decitabine decitabine decitabine work work incorporate action epub 
1.67@dna dna dna cancer cancer cancer inhibitor dnmt dnmt replication replication analogue result chance decrease treatment compare reverse bind bind kind methyltransferase methyltransferase effect longer repaidly normal normal replicate thus methylation decitabine decitabine decitabine work work incorporate cell cell cell cell far nuceloside 
1.67@inhibitor neoplasm neoplasm agent myelodysplastic methylating malignancy de hypermethylated treat usedto irreversibly therefore adna tumor tumor tumor neoplastic suppressor exploit many drug nuceloside specifically dependent also large depend depend replication replication analogue toxic toxic target dosage dosage fact anti anti though dna dna dna divide divide loose bind syndrome dnmts gene rapidly effect rapid word since methylation methylation decitabine incorporate sensitive hence small 
2.0@cancer cancer methyltransferases methyltransferases methyltransferases lymphoma methyl include agent whose eisai growth make enzimes grow job consequence demethylating inhibit tumor methylates like like japanese uncontrolled suppressor general drug cause cause mutation cell histone histone stop stop case group company dna dna dna surround sell gene gene overactive attach silence decitabine hypometilates activity overactivity protein 
2.0@cancer dnmt activate methyl fda reasonable malignancy dnmti effectively inhibit achieve decrease decrease decrease naturally enzyme island effective tumor mechanism mechanism order although cell level one suppressor analogue nuceoside seem drug drug deactivate trasnferases mean exact gene promoter approve treatment dna dna dna bind bind dnmts dnmts cpg irreversible unclear still replicate methylation methylation decitabine decitabine work incorporate active action haematological 
2.0@blewitt cancer inhibitor inhibitor inhibitor inhibitor hypomethylation lymphoma able marnie baylin order agent hypomethylating myelodysplastic lower functional growth balance make deacetylation decrease chemotherapeutics class epigenetic epigenetic show consider functionality demethylating control severe dnmt tumor tumor block lack compensate factor stephen case cell cell cell cell tumour machinery lung transcription researcher drug cause target result kill affective vulnerable traditional lecture reason chemotherapy dna dna dna dna dna get dose dose histone syndrome suitable expression gene side effect effect describe deacetylase solid division decitabine decitabine decitabine another blood mix methyltransferase methyltransferase methyltransferase dnmti 
2.0@cancer inhibitor restore produce use myelodysplastic also growth direct treat call lead strand strand methylated therefore belong group reduce normal maintain demethylation cell cell cell cell cell cell tumour tumour suppressor methylating antimetabolite cause hemi subsequent target fast number occur prevent syndrome dna dna dna divide cytotoxic chemotherapy function methyltransferase methyltransferase effect interact control death division division methylation decitabine daughter incorporate 
2.0@loss methyltransferases class specificity dnmt use inhibitor agent specific myelodysplastic myelogenous dnmti treat inhibit irreversibly tumour tumour common precursor hypermethylation demethylating haemotological lack mechanism mechanism malignanies feature give nucleoside may supressor dna dna dna dna dna dependent rise high therefore action action action replication analogue dose dose toxic lay result result low anti anti anti reduction non acute bind syndrome dnmts still gene effect effect effect unclear little thus thus thus thus methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine incorporate leukaemia inherent neoplastic neoplastic 
1.33@one fix essentially dnmt tumour agent hemi result anti inhibit prevent prevent nucleotide basically dna dna dna pass methylated responsible time demethylating adna methyltransferase effect inhibitting dilute decitabine decitabine daughter mitosis methylation methylation methylation cell way 
1.67@dacogen cancer cannot cgis cgis restore dnmt use agent place hypomethylating decatabine md copy aza aza class cytosine cytosine cytosine irreversibly strand strand strand therefore division effective tumor pattern pattern hypermethylation hypermethylation hypermethylation rase myelodysplastic reduce maintain cell cell cell cell cell cell methyl tra suppressor toinhibit lower patient rat rat abherant replication replication replication analogue analogue analogue analogue toxic eventually low reprograming occur act dna dna dna le dose reverse bind bind syndrome fe target gene rather effect remove tumorogeninsis deoxycytidine deoxycytidine rapid successfully belong replicate new methylation methylation decitabine decitabine daughter daughter incorporate kill side 
2.0@mitotically cancer cancer cancer cancer cancer inhibitor growth uncontrolled include specific myeloplastic since dnmti hypomethylation treat effectively locus incorporation often irreversibly methylated silence silence thereby inhibit inhibit proliferation change tumor tumor invert nucleotide hypermethylation whose daughter express cell cell cell cell cell control continuously suppressor suppressor drug promotors promotors patient therefore abberant replication analogue pas stop normally severe cpg cpg treatment dna dna dna dna dna dna dna dna divide bind syndrome le le dnmts decelerate gene gene gene aml effect global administer methylation methylation methylation methylation decitabine decitabine decitabine rich rich incorporate tissue downstream methyltransferase associate 
1.67@dacogen lead also inhibition activation use agent eisai myelodysplastic lower growth treat know prevent company dna dna dna expression syndrome sell contribute demethylating subsequently disease interfers belong methylation methylation decitabine decitabine gene gene japanese tumour tumour tumour suppressor suppressor progression 
1.67@
1.67@cancer inhibitor dnmt hypomethylate replication analogue nucloside dependent decitabine mean dna dna bind adna methyltransferase happen longer affect division due release severely incorporate cell rapid irriversible 
2.0@one one dacogen cancer cancer effect effect greater class able myelodysplastic drug agent epicentre epigenome describe currently economist anti promoter market response aspect treatment dna expression demethylate syndrome discuss belong cpg island reduce tumor tumor tumor result question become demethylating hypermethlyated genome genome article methylation methylation suppressor suppressor decitabine decitabine decitabine 
1.33@specifically cancer effect class dnmt methyl methyl exhibit transfer agent member number gene anti decitibine decitibine drug drug call island many dna dna epigenetic strand promoter group group name demethylating prevent reduce tumor tumor suggest hypermethylation nascent decitabine work cpg replication counteract way suppressor 
0.67@cancer cancer class able tumour tumour could shore tend myelodysplastic currently frequently treat treat island island island suppress suppress epigenetic methylate help help help belong reduce reduce longer affect hypermethylation hypermethylation hypermethylation nucleoside primarily cell drug drug drug drive drive analogue replication replication cause cause mean demethylation example dna dna dna dna dna get bind bind syndrome use dnmts dnmts cpg cpg cpg irreversible inhibitor believe quickly replicate methylation decitabine gene gene incorporate 
1.67@suppressor suppressor suppressor suppressor cancer negate growth growth activation activate tumour tumour tumour tumour tumour cause agent result hypomethylation act lead lead dna kill demethylates name allow demethylating demethylating gene gene gene gene gene expression suggest turn accordingly express demethylation cell cell control decitabine decitabine decitabine decitabine 
1.0@cancer check use agent could decitabine decitabine decitabine mark reactivate methyl supress island island dna process reverse methylated act allow demethylating gene gene supressing remove eg cpg cpg thus genome progress tumour tumour tumour supressor 
2.0@inhibitor class administration tumour tumour mostly something metil lower dnmti transferase island see consider hypermethylation impact tumor tumor tumor give reduce reduce reduce high de suppressor suppressor suppressor also drug cause novo result highlight anti amount good treatment dna dose moment tumoural important cpg gene gene gene effect effect pogression increase belong antineoplasic silence silence methylation methylation decitabine decitabine active progression 
0.67@could classify inhibition class available produce use use agent specific process process hemoglobin aza hypomethylation leukemia leukemia treat marrow locus morphological phenotype epigenetic work help help help bone inactive chromosome myeloid stimulate normal dir many cell cell cell blood malign malign malign one dependent cause cause cause zati suppression kill infusion reverse reverse dna dna dna intervention dose dose histone short right right methyltransferase inhibitor inhibitor inhibitor induce deoxycytidine modification methylation methylation decitabine decitabine decitabine decitabine decitabine ltr irreversible widely modify differentiation 
2.0@mean cancer dnmt dnmt dnmt use agent stag newly analog myelogenous leukemia treat island molecule strand tumour tumour tumour tumour precursor administer demethylating way reduce block neoplastic neoplastic hypermethylation suspect myelodysplastic nucleoside cell cell blood supressor earlier suppressor methylating relate drug cause development development cycle highly reverse type dna dna dna dna get acute syndrome act act incorporate cpg gene gene aml aml aml aml inhibitor division replicate silence silence decitabine decitabine daughter em activity active methyltransferase small 
0.0@dacogen cancer cancer cancer methyltransferases class japanese mitotically use unmethylated agent agent agent cure probably myelogenous hypermethylated eisai catalyse treat inhibit previously lead lead status pass methylated precursor enzyme demethylating demethylating demethylating tumor name name cell cell belong market suppressor suppressor transcription activation compound compound therapy cycle result result reaction bring prevent company dna dna dna dna acute bind syndrome sell myelodysplastic gene gene gene gene expression division silence silence methylation methylation methylation decitabine decitabine daughter work active leukaemia 
1.67@one suppressor suppressor cancer thatdnmt within phosphorylated accord drug cause viability induce phase subsequent learn hypomethylation anti uptodate amount knockout inhibit essential addition lead dna dna dna dna dna utero decrease methylated methylated allow demethylating demethylating gene gene methyltransferase expression tumor tumor tumor die death death silence methylation week could could incorporate cell cell cell cycle decitabine decitabine decitabine decitabine decitabine 
2.0@growth cancer inhibition marker dnmt dnmt activate progress yet slow agent agent receive hypomethylating myelodysplastic transfer dnmti hypomethylation tumour tumour call hemimethylated lead lead irreversibly decrease silence demethylating proliferation mean dmt calleddna may mechnisms regulator cell cell methyl expression suppressor deme therefore understand replication replication behind bind thy approve dna dna dna dna divide ase syndrome use thus drug gene gene gene target inhibitor cellular control cpg new methylation decitabine decitabine work incorporate active differentiation enzymatic class 
1.33@dacogen use manner agent agent decitabine decitabine hypomethylating eisai myelogenous hypomethylates treat strand chain company dna dna dna dna dna decitabinesold acute syndrome precursor function demethylating inhibit methyltransferase similar belong myelodysplastic rna although incorporate incorporate japanese azacitidine azacitidine 
2.0@unregulated kantarjian critical inhibition restore correct may chemically agent hypomethylating manero analog hypomethylates cellular hypomethylation opin inhibit inhibit inhibit garcia lead cytosine epigenetic promoter involve wikipedia island proliferation proliferation tumor mechanism uncontrolled normal neoclassic dec repair role role hm cell cell control control investig suppressor cytidine transcription metastasis residue fj fda drug cause information appropriate block prescribe free know expert giles dna dna dna dna dna dna carcinogenesis expression function cpg decitaine methyltransferase important growth bt encyclopedia modification methylation methylation methylation methylation methylation methylation decitabine decitabine decitabine gene gene gene gene gene gene gene malignancy action differentiation full haematological play 
2.0@hypomethylating action specificity act dnmt gene gene tumour inhibitor unclear mechanism lack thus reactivate supressor promoter though decitabine 
1.33@mitotically cancer critical restore synthesize tumour newly methyltransferases cytotoxicity hypomethylation leave change transferase inhibit exert addition achieve methyldated epigenetic methylated proliferation reduce reduce normal thus thus bond maintain cell cell cell inheritable global promote ability hypothesize hypothesize activity activity result anti methyl presence treatment dna dna dna dna dna divide supressing greatly covalent le gene rapidly effect cann cellular division vitro since methylation decitabine decitabine decitabine decitabine decitabine strangds incorporate incorporate form differentiation continue would 
0.33@different different dacogen cancer methyltransferases dnmt dnmt synthesize cite cite state manner cycle cycle aberrantly newly analog eisai azacytidine hypermethylation hypomethylation hypomethylation md treat inc aza previously lead set covalent methylated involve inhibitor consequence bone group marrow heterogeneous anticancer normal contribute apoptotic dac dac dac dac nucleoside nj express drug drug cell cell cell cell cell cell stem control expression expression cytidine become although modulate myelodysplastic lake clinically cause viability apoptosis sequestration gene gene gene depletion prevent damage treatment dna dna dna dna dna dna dna maintenance deoxy bind syndrome use dnmts dnmts get nsclc effect effect pathway line line believe silence woodcliff methylation decitabine disorder irreversible incorporate upon differentiation 
2.0@inhibition lower dnmt dnmt dnmt progress slow stop stop also generation hypermethylated previously next irreversibly even pass allow able tumor hypermethylation nucleoside cell suppressor dependent state newunmethylated area mitotic drug analogue incorporate whichis type heritability level dna dna dna dna tumorigenesis bind expression downor methyltransferase inhibitor inhibitor silence methylation methylation decitabine daughter activity activity towards replicationand would would 
1.67@cancer cancer larger effective sometimes methyl dependent analog also call rest irreversibly inhibitor inhibitor division division tumor replicate normal dnmtis produce nucleoside enzyme demethylation cell cell cell cell belong faster transfer replication decitabine decitabine low oppose anti anti group group dna dna dna dna dose dose kill bind dnmts suffer methyltransferase effect join great modification allow active neoplastic important 
1.33@article drug agent suppose tumo undestanding promoter say dna dna dna methylated example act gene gene reduce thus methylation decitabine decitabine although much express demethylation may supressor 
1.33@dacogen cancer cancer classify use slow fda agent eisai also growth leukemia treat treat transferase precursor enzyme demethylating severely tumor tumor affect epigenome may release much japanese methyl transfer therefore cannot replication syndrome cause cell cell acute reference inhibitor type know group company dna dna dna divide donor acceptor sell methylase myelodysplastic irreversible rapidly effect upon explain impede replicate myelogenous methylation decitabine decitabine decitabine decitabine incorporate approve form methyltransferase methyltransferase methyltransferase bound azacitidine 
1.0@different cancer cancer cancer cancer inhibitor inhibitor dnmt dnmt use dnmts fda mutation specific andactually know de leukemia methyl genetic dosis transferase unlike treat analogous important irreversibly even show show involve myeloid myelodisplastic good high alteration demethylation tumour tumour reversible one see dependent nucleoside epigenetic epigenetic epigenetic candidate study study drug drug drug cause therapy novo precurosr target low anti universal toxic reason treatment dna dna dna dose acute bind syndrome recent replicant effect effect effect modification modification main methylation possible approve machinery protein 
1.33@fail cancer cancer inhibitor inhibitor blastocyst produce tumour view appear prove stop tend silence currently coordinate generation genetic primary inhibit epigenetic strand reproduction reproduction attack island way way effective mechanism block test abnormality hypermethylation may may new dilute dilute vidaza evidence allele maternal cell cell cell cell cell use decitabine decitabine decitabine decitabine one suppressor mitotic drug elaborate reaction exhibit haploid inheritance cancerous like protect dnmi dnmi dna dna away histone develop important cpg gene chain many many similar deacetylase division find methylation methylation methylation methylation inappropriate safe action methyltransferase 
2.0@suppressor inhibitor dnmt tumour tumour tumour decitabine really lation meet hypermethylation anti bind inhibit job island dna dna lose hyper cpg gene gene methyltransferase effect heritability block suppress division longer longer silence methylation group daughter mean express cell cell belong 
2.0@dna dna suppressor effect class therefore allow demethylating demethylating gene expression tumor tumor agent belong methylation decitabine decitabine decitabine anti decrease 
0.67@elod plastic discover tumour agent decitabine decitabine decitabine mark y myelogenous occur island treat syndrome dna see particularly demethylating prevent remove chromatin hypermethylation methylation ul ul cpg leukaemia luekaemia 
2.0@gene suppressor suppressor suppressor cancer cancer become transform necessary activity agent promotor mark mark inactivation hypomethylation synthesed newly maintaned change know inhibit active active decitabine repetitive dna dna dna dna dna apoptosis strand strand common hypermethylation cpg island proliferation tumor tumor tumor die normal belong methylation methylation methylation methylation locate make case mean allele newlysynthesed cell cell cell methyltransferase methyltransferase irreparable 
2.0@hand as activity activity medical neoplasia remove methyl posibly agent agent tend already already inhibit easily transfer untill reactivate possibly tsg treat call perfect suppress lead epigenetic epigenetic epigenetic pass introdused enzyme demethylating demethylating trigering take impact impact tumor tumor tumor extravagant activelly significant extraneous fact high patern patern methylation methylation many cell cell cell cell methyation market also suppresor tsgs tsgs therefore therefore understand due drug apoptosis massive massive mind elimination introduce maintain tymorgenesis know generally approve extremely dna dna dna dna dna dna offspring occasion accessible environment translational cpg gene gene gene gene effect effect effect proportion suppresions provide modification modification induce decitabine decitabine decitabine arise antitumor antitumor widely acquire reverse alter azacitidine 
2.0@suppressor cytidine also restore depend dnmt induce may cause cause cause toxic analog low hypomethylation hypomethylation effect effect anti nonspecific inhibit lead dna dna dna dna irreversibly dose dose dose bind kind inhibitor function gene methyltransferase dnmts dnmts tumor tumor tumor mechanism death decitabine decitabine high incorporate cell 
0.0@cancer nanomolar genomewide gene gene epithelial reactivation produce induce induce use exposure include agent deacetylase stem myelogenous cytotoxicity key change regulatory treat decrease antitumor antitumor sustain promoter culture precursor tumor tumor inhibition primary link high reexpression like cell cell experimentally rapid leukaemia immediate lat pome clinically cause acute without case antitumour thy hypothemylation damage subpopulation dna dna dna relevant dose dose histone syndrome myelodysplastic ah methyltransferase effect effect epigenetically cellular memory silence methylation decitabine decitabine accompany response hypomethylates supressor inhibitingdna leukemic 
1.67@irreversable demethlylase cancer transfer class dnmt much analogue dependent metal dnmti effect effect effect know nucleotide dna dna dna divide get bind inhibitor inhibitor inhibitor drug rapidly apon y mean normal belong replicate genome although incorporate cell cell cell replication replication decitabine decitabine 
2.0@unregulated cancer methyltransferases growth dnmt dnmt o use dnmts agent myelodysplastic since de hypomethylation hypomethylation treat inhibit aza lead irreversibly even analogon regulate inhibitor inhibitor inhibitor allow demethylating severely reactivation tumor block affect nucleoside program often nu blockage suppressor suppressor suppressor cytidine promote induction replication replication analogue activity result result low become promoter id oxy dna dna dna dna dna divide dose cell cell cell cell cell bind syndrome function gene gene gene gene methyltransferase effect deoxycytidine increase division division senescence methylation decitabine dependency incorporate death differentiation selectively follow 
1.67@inhibitor dnmt dnmt use leukemia fda faster hypomethylating myelodysplastic myelogenous growth susceptible sit transferase inhibit cytosine irreversibly malignant precursor enzyme possibly tumor tumor normal normal nucleoside demethylation cell cell methyl decitabine decitabine decitabine suppressor dependent methylating methylating therefore necessary replication replication replication analogue agent result prevent prevent supressed treatment dna dna dna dna acute bind syndrome act function cpg gene effect replicate since since allow incorporate approve 
2.0@inhibitor growth within progress use include include agent myelodysplastic myelogenous change change unmethylated generation generation treat transferase transferase transferase island island island lead irreversibly pass pass demethylating tumor tumor uncontrolled hypermethylation nucleoside express many cell cell cell cell methyl methyl methyl leukaemia suppressor dependent methylating become erase epigenetic epigenetic favorable replication analogue target target anti occur prevent prevent dna dna dna dna dna dna acute bind syndrome cpg cpg cpg gene aml aml effect upon silence thus decitabine decitabine decitabine decitabine daughter daughter return machinery machinery onto 
1.33@critical abnormal abnormal restore dnmt dnmt blood blood dnmts dnmts trap silence silence silence useful methyltransferases since de characterize decrease inhibit inhibit lead md md md promoter inappropriately inhibitor hyper demethylating reduce tumor tumor tumor tumor pattern block normal hypermethylation hypermethylation genome nucleoside aberrant regulator hypo cell cell cell repress obstruction suppressor suppressor transcription identify disorder instability structural agent result result reverse anti solid level syndrome dna dna dna dna dna dna dna synthesis degradation function function gene gene gene effect belong thus methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter region incorporate approve differentiation 
1.33@cancer cancer myeloid dnmt dnmt dnmt dnmt progress use dependent easily functional rate enzyme impact myelodyspastic turn reduce render maintain demethylation cell cell cell cell cell cell cell cell release leukaemia faster greater nucleoside replication replication analogue healthy healthy healthy know know though dna non acute bind bind syndrome inhibitor still effect dependant chromatin replicate methylation decitabine decitabine decitabine decitabine decitabine decitabine incorporate incorporate action action generally 
1.0@cancer cancer cancer growth dnmt dnmt gear susceptible agent marker clearly make epigentic inhibit define epigenetic epigenetic demethylating tumor tumor tumor mechanism standard cell replication enzymatic dependent analogue advance erase irreversibly drug cause nucloside target show together dna dna dna histone bind chemotherapy act act dnmts inhibitor inhibitor inhibitor deacetylase lung regulator decitabine decitabine decitabine incorporate action action delay 
2.0@cancer silent class supression use certain agent methylases strand reactivate growth leukemia replication tumour tumour tread myelodyplastic demethylates dna dna dna dna dose bind syndrome expression demethylating drug effect methylations restablish belong new decitabine decitabine gene eventually terapeutical cell control azacitidine 
2.0@effect effect class specificity specificity dnmt still tumour tumour aim medicine inhibit lower dnmti many might transferase island cpg concer main promoter efficient inhibitor inhibitor thereby observe reactivation mechanism good lack hypermethylation clear new repair high prognosis cell standard methyl chemiotherapy suppressor dependent discover patient patient however replication work toxic toxic toxic low low dosage dosage better develop dna dna dna dna process dose bind le dnmts positive gene gene gene taxicity inactivate mititically increase belong thus methylation methylation decitabine decitabine decitabine much much action full recently 
1.33@cancer cancer cancer proliferate higher class dnmt tumour agent aberrantly since dnmti rate methyl methyl transferase transferase subsequently irreversibly inhibitor silence inhibit word normal dnmtis upcoming release express profound much specifically dependent methylating replication replication apoptosis moreover anti occur dna dna dna dna cell cell cell cell cell bind inherit gene hence effect effect upon belong longer methylation decitabine decitabine decitabine daughter embody action action continue de 
2.0@cancer methyltransferases restore restore dnmt synthesize way state manner cytidine aberrantly process newly analog dnmti growth treat previously lead methylated involve inhibitor hypermethylation twofold tumor anticancer anticancer normal normal contribute apoptotic dac dac dac nucleoside express demethylation demethylation cell cell cell control control decitabine decitabine one suppressor hypomethylation consequence drug work cycle pathway sequestration effect effect become prevent dna dna dna dna dna dna dna dna maintenance bind covalent dnmts dnmts irreversible methyltransferase function upon line believe believe silence interfere thus methylation methylation rna gene gene gene incorporate incorporate differentiation 
2.0@hypermethylations reduction reduction could inhibitor inhibition reactivation cause cause cause noticeable overall previously treatment dna irreversible methyltransferase dnmt tumor silence replicate replicate methylation methylation decitabine decitabine gene actively cell cell would supressor 
1.67@suppressor cancer cancer article large magazine sometimes tumor tumor tumor agent april epicentre anti economist silence concept dna dna dna egger demethylating portion biochimie effect hassler turn epigenomics emerge hypermethylation rely new decitabine hypomethylates gene mean th mr 
1.33@lower high get behave methylates analogue likely specific toxic base fashion biinds better prevent nucleotide patient dna dna dna dna dna irreversibly dose dose copy initially le enzyme inhibitor methyltransferase methyltransferase effect effect malignant give methylation methylation directly nucleoside incorporate cell cell tolerate nuceloside decitabine 
0.33@file see answer answer attach question 
2.0@methyltransferases order activate induce use agent agent mark mark tackle methyl methyl oncogene oncogene oncogene oncogene normal normal absence absence addition methylated methylated methylated methylated methylated hyper hyper hyper inhibit proliferation turn uncontrolled affect affect tumerogenic tumerogenic tumerogenic hypo hypo hypo hypo hypo hypo may ensure ensure pro cell cell cell cell cell tumour tumour tumour tumour tumour tumour suppressor suppressor suppressor suppressor suppressor already methylating methylating drug cycle result result cancerous cancerous anti anti respective presence presence dna dna however reverse act gene gene gene gene gene gene hence remove place silence methylation methylation decitabine decitabine method activity active take 
1.67@cancer cancer cancer inhibitor term term partly long process myelodysplastic since dnmti dnmti dnmti hypermethylated call call supply aim severely hypermethylise neoplastic improvement high alteration anymore side cell cell cell toxicity suppressor also depend regain drug function agent target idea anti though treatment dna dna dna demethylised dose syndrome important short irreversible methyltransferase methyltransferase effect effect unclear range division replicate demethylase decitabine gene gene hence apparent 
2.0@analogue analogue inhibition dnmt encounter state otherwise dnmti doesnot occur decrease inhibit dna dna dna dna dna establish reset inhibitor methyltransferase dnmts ingredient cellular normal replicate methylation methylation allow incorporate enzyme active cell cell decitabine decitabine decitabine 
2.0@cancer cancer cancer cancer inhibitor inhibitor class dnmt dnmt tumour tumour tumour tumour tumour dnmts agent stop myelodysplastic silence change might transferase island island fulfill development decrease methylated methylated enzyme demethylating demethylating inhibit tumor pattern block hypermethylation methyl methyl supressor supressor suppressor suppressor suppressor suppressor methylating residue work therapy promotor promotor number gene gene gene gene gene gene treatment dna dna dna get syndrome use function cpg cpg proceed effect remove belong longer thus thus methylation methylation decitabine decitabine decitabine region region enable 
1.33@
2.0@different article promote activation regulation say agent actually abstract apoptosis myelodysplastic find growth growth regulatory treat promoter inhibit syndrome dna dna dna tumour involve use source demethylating demethylating gene gene methyltransferase list paper hypermethylation silence decitabine decitabine region region cell may supressor 
0.0@prc transfer bind site others drug as acetylation process ncrna u meet number metylation make like anormal promoter recruitament alter 
2.0@plastic cancer reduce effective use stop much leukemia treat irreversibly strand tumour silence dnmt dnmt serve normal typically genome nucleoside nucleoside myeloid myeloid cell cell cell replication suppressor therefore status require analogue incorporate methylate dna divide acute bind bind syndrome capacity gene inhibitor upon copy quickly replicate thus methylation decitabine decitabine decitabine daughter work y hypomethylator 
1.0@cytosine cancer myeloid class blood white cell analog hypomethylation leukemia inhibit syndrome dna hypomethylating acute problem involve inhibitor myelodysplastic aml reduce hypermethlation belong thus decitabine lead treatment methyltransferase etc 
1.0@igf drug tumour cause agent could icr overgrowth wilm myelogenous genetic treat counteract demthylate dna acute syndrome precursor hypermethylation demethylating turn contribute may myelodysplastic decitabine utilize region allele maternal childred use leukaemia 
2.0@suppressor suppressor cancer dnmt drug cause cell cell express normal inhibit dna dna decrease help expression gene gene rapidly inhibitor tumor tumor affect lack hypermethylation replicate thus methylation methylation decitabine decitabine decitabine case instance enable 
1.67@cancer cancer cancer reduce restore dnmt dnmt dnmt dnmt methyl agent stop stop mark find mutagenic back inhibit inhibit treat amount area strand strand body epigenome demethylating group enhance able tumor normal normal hypermethylation genome aberrant maintain human expression dependent epigenetic replication cause mutation virtually inheritance anti old lessen level prevent dna dna dna dna dna cell cell cell cell cell act function gene gene methyltransferase effect effect effect farther division replicate new methylation methylation methylation methylation decitabine decitabine decitabine decitabine add beneficial 
2.0@unknown inhibitor growth term term suppressor administration use cytidine long already analog hypomethylation leukemia hypermethylated treat test amount lead clinical epigenetic well take myeloid normal although drug drug drug drug regulate trial tumour tumour tumour food dna dna dna dependent also insert replication replication cause preclinical toxic cell cell result anti type solid good several however dose acute bind dnmts still gene methyltransferase effect effect unclear demethylation demethylation approve great decitabine normally small 
2.0@could dnmt dnmt dnmt hypomethylate use agent situation myelodysplastic silence hypomethylation treat inhibit often epigenetic tumour tumour help enzyme demethylating aberrant demethylation cell require decitabine decitabine decitabine suppressor suppressor transfer drug result cancerous demethylate methyl group potentially dna dna dna dna dna dna reverse syndrome act expression gene gene methyltransferase inhibitor characterise unnatural thus methylation allow instance 
1.67@cancer cancer methyltransferases higher growth dnmt dnmt tumour tumour agent process article epigenomic enzimes broad inhibit inhibit specificly lead generaly help link hypermethylation demethylating control impact accord epigenome may case cell cell cell catalyze belong suppressor general stability throughout speak inheritance genomic aberrate island dna dna mark wich wich expression cpg asociated inhibitor evidence division silence silence methylation methylation decitabine gen gene strong tissue 
2.0@dna dna dna suppressor effect syndrome inhibitor inhibitor myelodysplastic gene tumour reactivation tumor methyltransferase methyltransferase belong see decitabine decitabine hypomethylation hypomethylation link anti class call drug lead 
1.67@heavy cancer cancer cancer cancer article category dnmt dnmt dnmt continue may agent myeloplastic myelodysplastic since frequently epigenomic restrict effectively island island treat benefit irreversibly strand strand methylate kind well concern demethylating categorize interfere interfere interfere interfere normal general methylation methylation methylation methylation methylation cell cell cell tolerate impede older enzymatic methylating patient interference relate seem replication certain attempt target low low dnmti dnmti type lecture prevent cpg cpg dna dna dna dose dose bind syndrome syndrome drug methyltransferase eg larger belong replicate replicate regulator decitabine decitabine decitabine decitabine decitabine daughter daughter activity operate attach associate associate 
2.0@reduce abnormal class class activate tumour tumour process two cytotoxicity dnmti hypomethylation direct inhibition incorporation marrow weaken epigenetic silence silence bone impact mechanism mechanism hypo turn high signal demethylation cell cell may may may ul ul ul ul ul ul suppressor transfer activation via cause cause stability prior decitabine decitabine decitabine decitabine hematopoietic result low anti occur demythylation relative dna dna dna dna dna dose dose methyl death inhibitor inhibitor gene gene gene methyltransferase effect effect induce antineoplastic belong belong thus methylation methylation methylation rna activity confer follow 
2.0@cancer cancer cancer cancer cannot class slowly able whose correct sit also dnmti generation grow molecule next epigenetic methylated methylated enzyme enzyme island affect dnmtis genome successful methylation methylation cell cell cell cell cell cell one one compare transcription greater patient divide divide divide drug drug healthy healthy target course present present opposition treatment dna dna dna dna dna however mark bind act act site function cpg methyltransferase methyltransferase inhibitor proportion copy replicate actively decitabine decitabine decitabine facilitate facilitate active action incorrect heavily 
2.0@cancer restore restore within within produce way agent process hypomethylates similar substance substance direct call inhibit category death twofold tumor normal normal anticancer demethylation demethylation cell cell cell cell cell control one suppressor also antimetabolite antimetabolite divide cause target number metabolism dna dna dna dna hypomethylating cytotoxic chemotherapy function gene rapidly effect effect interact cellular believe belong interfere thus methylation decitabine decitabine work incorporate incorporate methyltransferase 
2.0@cancer inhibitor get much faster since normal prevent lead dna dna divide copy chromosome dnmt affect methylation decitabine daughter factor incorporate cell cell methyltransferase 
1.67@dna epigenetic inhibitor demethylates demethylating gene impact tumor agent belong class methylation decitabine decitabine decitabine demethylate supressor 
1.33@suppressor could effect individual demethylator use state decitabine mean cancerous case many type amount better island prognosis dna dna epigenetic hypermethylation drug gene reduce remove affect pre silence methylation reliant work cpg across return tumour tumour genome genome 
2.0@cancer methyltransferases restore within use slow include hand hand make growth susceptible direct nevertheless germ inhibit act lack malignant sequence sequence methylated specificity inhibitor enzyme tumor tumor intergenic particular particular feature aberrant term repetitive control expression one suppressor also consequence imprint drug drug drug instability instability could apoptosis loss region region region region type occur promoter prevent genomic genomic genomic impossibility potentially dna dna dna cell cell cell every well element organism suffer single effect induce explain increase silence due methylation methylation methylation decitabine gene delivery normally progression complete beneficial 
1.67@answer 
1.33@methyltransferases reactivation use mostly analog hypomethylation methylationrather inhibit lead lead lead strand give thereby replicate key hypermethylation passive cell tumour tumour tumour tumour suppressor suppressor cytidine lower therefore divide drug toxic mean anti cytotoxic traditional promoter demethylation dna dna dna maintenance dose bind chemotherapy le gene gene force interfere interfere methylation decitabine drive incorporate replication replication 
2.0@cancer inhibitor think class dnmt dnmt dnmt methyl precise myelodysplastic remain methylating reactivate change transferase irreversibly strand hypermethylation aim effective tumor tumor mechanism epigenome clear clear nucleoside potentially drug suppressor dependent association epigenetic replication analogue therapy result cancerous anti show prevent treatment dna dna mark reverse bind syndrome gene effect unclear belong due silence decitabine decitabine daughter incorporate action 
2.0@undesirable cancer cancer cancer toxicity methyl fda agent already myelodysplastic probably reactivate hypermethylated characterize quite quite treat avoid inhibit inhibit might worth achieve epigenetic epigenetic mention erase useful useful reduce expression mpd side demethylation cell cell cell cell cell tumour tumour tra suppressor suppressor lower therefore divide recurrence require require pas low low level return dna dna dna dna syndrom dose act fe inhibitor drug drug gene gene rapidly effect effect hand approve division division rase methylation methylation decitabine decitabine daughter active active cpgs cpgs methyltransferase would 
2.0@cancer rate abnormal subsequent dnmt dnmt dnmt much favor hypomethylation generation permanently molecule epigenetic kind inhibitor enzyme tumor tumor tumor tumor block normal hypermethylation may thus nucleoside role case demethylation cell cell cell cell methyl expression suppressor suppressor transfer therefore mitotic replication information nonspecific activity result result inheritance anti bind promoter group somatic dna dna dna dna dna dna moment important gene gene methyltransferase effect catalyze increase silence new new decitabine decitabine decitabine work reproduce reproduction enzymatic play 
1.0@body cancer cancer inhibitor inhibitor irreversibly use dependent acute decitabine decitabine myelodysplastic analog myelogenous dnmti dnmti replication treat affect nucleotide dna dna dna dna divide strand nucleosid bind bind syndrome precursor quickly methyltransferase methyltransferase methyltransferase methyltransferase along upon longer copy division word methylation release daughter incorporate come cell cell cell much leukaemia 
2.0@cancer cancer cancer regard inhibition class suppressor methyl methyl methyl agent specific trasferase oncogene decrease locus lead epigenetic transferase hyper hyper hyper thereby thereby island island reduce tumor tumor dilution expression expression give divide nucleoside cell cell tumour tra dna dna dna dna dna dna methylating large patient irreversibly drug drug analogue icr icr know low anti level level reduction get hypo bind le fe inhibitor cpg cpg hence effect belong due rase methylation methylation methylation methylation methylation methylation decitabine decitabine decitabine decitabine incorporate 
2.0@net methyltransferases methyltransferases restore dnmt activity inhibitor cytidine analog also also sit hypermethylated incorporation call inhibit inhibit degradation epigenetic epigenetic epigenetic reversible catalytic belong demethylating demethylating severely decitibine tumor tumor tumor mechanism block affect abnormality anticancer bond demethylation cell cell cell suppressor machinery dna dna dna dna dna dna dna dependent lower proteosomal therefore irreversibly alteration replication function agent pathway target reverse trigger anti promoter lead treatment treatment treatment several replicate dose various covalent dnmts dnmts dnmts gene gene gene gene rapidly effect effect effect division due methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine reexpresion class form methyltransferase would 
1.67@myeloid dnmt dnmt encounter tumor tumor baylin fda specific myelodysplastic analog since azacytidine stephen leukemia md md epimutation transferase locus act lead lead effective irreversibly methylate inhibitor enzyme dr rarely close mechanism aza lack hypermethylation carbon nucleoside case methyl isolation reinforce mode cytidine indicate epigenetic combination decitabine decitabine decitabine acute idea conjunction solid solid show prevent approve relative treatment dna dna get histone bind syndrome use synergistic aml aml effect replace deoxycytidine deacetylase nitrogen thus thus deplete position action reverse interrelate 
2.0@mitotically cancer cancer cancer cannot growth activate tumour tumour tumour include agent shore overmethylated change generation heritable island island cpg cpg epigenetic development pass common well attack demethylating tissue reduce tumor hypermethylation hypermethylation role many cell cell cell cell cell cell control occurrence suppressor suppressor relate imprint could suppression result bring facilitate gene anti halt dna dna dna future overexpression least overgrowth perform time effect shrink due thus methylation decitabine decitabine decitabine decitabine decitabine region another perhaps perhaps form would would azacitidine 
2.0@one suppressor suppressor cancer carry promote therefore epigenetic tumour tumour tumour tumour tumour tumour tumour slow activity decitabine silence myelodysplastic characteristic frequently growth growth possibly drug drug permit island island suppress treatment dna dna area syndrome act act inhibitor demethylating gene gene demethylates reduce methyltransferase expression hypermethylation hypermethylation find allow cpg cpg often use would would would would would supressor 
1.33@cancer dnmt dnmt yet add mark detail growth unmethylated regulatory hemimethylated inhibit lead increase strand portion tumor mechanism although maintain demethylation cell methyl manage expression suppressor replication cycle result demethylate know group passive island dna dna function cpg gene rapidly effect cellular believe perform replicate methylation methylation 
2.0@cancer inhibitor dnmt progress methyl fda myelodysplastic analog currently treat treat back addition epigenetic strand enzyme enter tumor tumor mechanism hypermethylation turn nucleoside demethylation may one suppressor use drug drug target result exact anti prevent particular dna dna dna four reverse bind syndrome site still gene aml effect unclear thus decitabine decitabine daughter approve action methyltransferase replication 
2.0@dacogen cancer cancer methyltransferases dnmt dnmt dnmt dnmt island appear agent specific mark epigenome inhibit inhibit irreversibly strand methylate establish generally demethylating observe effective tumor tumor affect hypermethylation nucleoside maintain counteract cell cell cell cell cell cell incorporate affets suppressor faster cytotocix therefore get replication replication analogue non healthy healthy trap lay low inhibitor promoter example dna dna dna dna dna divide divide dose reverse dependent epigenetic act important cpg gene gene methyltransferase methyltransferase methyltransferase effect effect effect range try thereby silence decitabine decitabine decitabine decitabine daughter protective activity strongly 
1.67@plastic cancer cancer inhibitor growth dnmt much dnmts neo agent island island island inactivation since dnmti hypomethylation hypermethylated affect inhibit cpg cpg cpg often irreversibly demethylating notably tumor mechanism normal essential hypermethylation hypermethylation severely nucleoside demethylation cell cell control expression suppressor dependent dependent analogue seem replication replication cause cause cause cause apoptosis mean result low anti dna dna dna divide dose bind syndrome myelodysplastic drug drug drug gene gene gene rapidly effect upon belong replicate decitabine adna incorporate action differentiation methyltransferase class 
1.67@dacogen also abnormal promote suppressor suppressor tumour tumour agent situation gene gene better lead dna dna reaction chemotherapy sell expression demethylating esai reduce reduce reduce hypermethylation silence silence methylation methylation decitabine decitabine drive 
1.33@suppressor cancer oncogenic within reactivation decitabine tumor drug state healthy revert irreversibly analog cytosine overall hypomethylation potential depletion genetic back show previously lead lead lead dna dna profile towards bind target gene methyltransferase disease tamp mean mimcs allow hypermethylated cell cell class 
2.0@cancer cannot class dnmt dnmt dnmt cell use manner attempt myelodysplastic way myelogenous sit decrease inhibit imply epigenetic methylate methylate methylated contribute demethylating demethylating island proliferation effective block permanently hypermethylation genome genome nucleoside name lead tumour tumour tumour leukaemia suppressor suppressor dependent therefore irreversibly replication replication analogue analogue decitabine decitabine incorporate anti exactly promoter treatment dna dna dna dna dna dna expression base acute bind bind syndrome site inhibitor cpg gene gene gene effect remove belong methylation methylation allow another action 
2.0@targetting cancer silent patient haematogical dnmt dnmt dnmt dnmt activate use drive epigentic activity know lay around drug drug underlie wrap type treat tumour tumour tumour class dna dna dna completely histone demethylates gene gene methyltransferase inhibitor inhibitor mechanism normal thus methylation methylation methylation decitabine decitabine decitabine render successful athough counteract counteract much suppressor suppressor 
1.33@cancer cancer impact class dnmt dnmt dnmt dnmt use agent myelodysplastic hypomethylates hypomethylation treat treat inhibit nucleotide irreversibly strand however demethylating fall effective neoplastic fact nucleoside demethylation cell cell far drug dependent lower high epigenetic replication analogue cause toxic mean anti good dna dna dna dna dna dna divide dose dose bind bind syndrome inhibitor inhibitor rapidly effect upon copy division decitabine decitabine daughter severely incorporate come action methyltransferase onto 
1.67@cancer along inhibition class class lower tumour tumour tumour chemically agent find find hypomethylation hypomethylation sit inhibit benefit imply epigenetic initiate inhibitor belong demethylating island question hypermethylation hypermethylation genome nucleoside case counteract cell use decitabine decitabine decitabine decitabine one suppressor cytidine certain amongst cause could commonly apoptosis result anti occur dna dna dna dna dose allow example name expression cpg gene methyltransferase effect effect similar division longer abbreviate rna hypomehylation would azacitidine 
1.33@dna histone inhibitor overmethylation drug dnmt dnmt link belong analogue decitabine nucleoside incorporate decrease 
2.0@blewitt methyltransferases slide dnmt marnie agent agent treat decrease decrease inhibit lead irreversibly lecture belong demethylating island island able tumor tumor tumor hypermethylation rely thus nucleoside anymore thereby control suppressor suppressor lower high epigenetic drug analogue decita cell methylate toxic hypomethylated dna dna dna dna dna dose dose anything bind expression expression cpg gene gene gene demethylated increase division respectively methylation methylation decitabine incorporate incorporate subsequently bine 
1.67@one one suppressor cancer cancer mean mean slowly irreversibly remove drug agent target result reverse cancerous anti occur inhibit dna dna dna dna dna divide divide non tumour tumour bind demethylating severely rapidly effect effect effect upon methyltransferase affect silence methylation methylation methylation decitabine decitabine decitabine gene gene incorporate cell cell much replication replication 
2.0@et cancer effect disrupt produce continue tumour tumour require yan september silence significantly myleloid reactivate hypomethylation predominantly treat notice island post release strand marrow differential react aim reduce paper pre anticancer genome aberrant methylation methylation methylation methylation methyl host region suppressor suppressor leukaemia patient patient diseased disorder relate induction drug drug mitosis methylsomes activity vol em show group group day treatment dna dna dna dna profile profile blood blood acute recent pearly cpg gene gene aml aml inactivate bone suggest belong normalisation find al decitabine decitabine decitabine sit wide incorporate cpgs section would would 
2.0@dna dna dna dna dna suppressor either upregulate promote expression demethylating methyltransferase methyltransferase effect agent methylation methylation decitabine decitabine decitabine growth factor factor anti downregulation decrease decrease inhibit inhibit tumour tumour lead 
2.0@cancer cancer cancer cannot class dnmt dnmt progress use cytidine myelodysplastic currently dnmti leukemia generation normal normal irreversibly methylated myeloid tumor tumor affect affect feature hypermethylation hypermethylation nucleoside express cell cell cell cell cell cell suppressor suppressor dependent daughter replication analogue mean reverse without become lose promoter treatment dna dna dna acute bind syndrome gene gene chemical inhibitor remove methyltransferase replicate since methylation methylation methylation decitabine decitabine decitabine method incorporate approve action rapidly affectiveness 
0.67@dna syndrom transfer ase patient decitabine meet use inhibitor mielodysplastic treatment 
2.0@larger dnmt impact transfer transfer find dnmti sit sit hypermethylated effectively island island unknown irreversibly strand quickly take happen tumor tumor normal dnmtis dnmtis genome nucleoside like demethylation cell cell cell cell decitabine decitabine analogue daughter cause demethylated largely gene later dna divide divide bind inhibitor cpg cpg affect methyltransferase effect effect end since methylation allow method possible come action attach onto 
2.0@interaction reduce class effective tumour tumour hence growth generation generation change island island imply open rather principal consequence inhibitor facilitate pair mechanism demethylation demethylation lead may suppressor reduction also demthylated replication cell cell become euchromatin successive successive dna dna dna base histone bind name dnmts cpg gene chemical effect upon believe positive silence methylation decitabine incorporate active methyltransferase associate associate 
2.0@cancer cancer rate higher classical inestability agent mark mark mark mark analog dnmti high affect affect inhibit lead irreversibly strand better inhibitor demethylating way heritability normal lack possibility cell cell cell cell cell cell methyl level dependent also nucleoside epigenetic epigenetic drug drug pas pas low introduce antitumour know genomic dna dna dna dna dose bind chemotherapy dnmts methyltransferase effect division division division methylation decitabine decitabine daughter daughter work work mean mean come combine important 
1.67@mitotically cancer cancer cancer supressing suppressor suppressor use state agent decitabine decitabine hypomethylating myelodysplastic myelogenous reactivate growth hypermethylated treat locus heritable often dna dna dna dna acute methylated syndrome precursor demethylating demethylating island reduce tumor tumor silent cpg epigenome methylation methylation locate gene gene lead cell leukaemia 
2.0@one dacogen effect excessive fda name manner agent hypomethylating hypomethylating mean trade hypomethylation gene gene gene anti anti anti approve myelodsyplastic responsible prevent suppress dna dna dna dna dna strand u methylated syndrome sell inhibit methyltransferase reduce tumor tumor tumor block administer methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine work work activity express bring hence 
2.0@dependent cause cause dnmt replication analogue cycle cycle cancerous avoid inhibit demethylation dna dna divide decrease time inhibitor go methylation ul ul nucleoside repeatedly many cell cell cell cell checkpoint decitabine decitabine 
2.0@cancer cancer cancer cancer inhibitor abnormal dnmt dnmt replication replication replication fda dependent mark myelodysplastic analog selective free growth maintain treat act island might might epigenetic epigenetic syndrome dna dna irreversibly get bind repression le hypermethylation cpg methyltransferase effective upon nucleotide contain belong new decitabine decitabine incorporate overgrow approve cell cell cell cell cell trial drug drug drug 
2.0@cancer rate activity activity term dnmt progress tumour although fda agent specific long myelodysplastic currently malignancy inhibit unknown irreversibly well hypermethylation demethylating subsequently comparatively normal neoplastic moderate mode mode nucleoside myeloid demethylation cell tolerate suppressor leukaemia compare dependent high high replication replication replication analogue non side target result low inhibitor anti good dna dna dna dna understand dose dose acute bind syndrome dnmts still gene methyltransferase effect effect dependence due decitabine decitabine incorporate approve approve action action action selectively haematological tissue 
2.0@cancer cancer cancer methyltransferases inhibition class reactivation induce induce use agent silence silence silence reactivate hypomethylation hypermethylated subsequently methylcytosine transcriptionally epigenetic global global belong demethylating proliferation tumor tumor tumor hypermethylation contribute cell cell cell require supressor suppressor suppressor epimutations epimutations epimutations whichreduces link therapy loss level hypothemylation dna dna dna maintenance continuous reverse dnmts dnmts gene gene gene methyltransferase effect epigenetically epigenetically control division thus decitabine decitabine accompany activity 
2.0@myc myc class class class class subsatnce activity activity tumour agent agent acute island inhibit myelogenous gene gene anti treat call itdemethylates isused dna epigenetic know syndrome name belong belong demethylating ademethylating effect sincedecitabine jq block block precursor cpg thus myelodysplastic decitabine decitabine em em em em thusdecitabine regulator brd indirectly italic italic leukaemia 
1.67@effect abnormal class dnmt agent hypomethylating myelodysplastic analog member growth growth increase increase island island demethyating epigenetic promoter well inhibit inhibit inhibit tumor tumor tumor tumor tumor tumor tumor tumor tumor mechanism grow hypermethylation hypermethylation suppressor suppressor suppressor suppressor suppressor locate dna dna dna dependent dependent due product type level prevent reduction reduction cytidine syndrome site function function cpg cpg gene gene gene gene gene methyltransferase inhibitor inhibitor upon explain believe word methylation methylation decitabine decitabine decitabine decitabine decitabine incorporate interfere beneficial 
2.0@suppressor cancer cannot restore dnmt tumor replication dependent medicine analog bind decrease demethylation dna dna dna irreversibly level help daughter function severely methyltransferase inhibitor upon affect division replicate thus methylation release nucleoside gene incorporate mature approve cell cell decitabine decitabine 
2.0@suppressor cancer methyltransferases activate imprint tumour tumour agent stop stop result therapy growth growth gene gene gene decrease inhibit cpg lead dna dna dna dna density disease demethylating island reduce hypermethylation methylation decitabine decitabine progress restriction expression 
1.33@cancer methyltransferases uncontrolably dividng way healthy apoptosis natural dnmti part anti inhibition inhibit inhibit dna dna dna divide prevent inhibitor allow drug severely methyltransferase impact tumor go methylation methylation methylation genome work overgrow cell cell cell catalyze would decitabine decitabine 
1.33@article think indeed use cause hide actually leukemia mention hystone class dna acute syndrome precursor inhibitor end impact deacetylase myelodyslastic belong methylation deeply although case muelogenous towards demethylation drug decitabine 
1.67@intend article activate tumor tumor methyl methyl methyl possibly possibly agent agent originally event remain extra economist hypermethylation growth growth potential useful back mention island dna benefit stabilize igf epigenetic discuss hyper demethylating demethylating close question question normal give genome genome allele maternal cell cell cell control assign wilms one suppressor identify patient therefore decitabine decitabine drug drug could could could could zati product product demethylated problem occur level group group deal several dose two cpg time eliminate remove remove combat double mean elevate review previous enough enough enough enough 
1.67@growth dacogen cancer activity category within produce cell cell cell cell cell cell cell agent process eisai member similar antimetabolic direct call restore believe dual belong demethylating tumor metabolism normal normal anticancer demethylation regulate control blockage decitabine decitabine one suppressor suppressor promote antimetabolite drug drug cause cause approach target number know company dna dna divide substance substance japanese cytotoxic chemotherapy sell function gene gene rapidly effect effect interact cellular increase division longer new methylation allow incorporate death class 
2.0@inhibitor inhibitor standard lymphoma reactivation reactivation produce induce use leukemia include agent agent hypomethylating myelodysplastic myelogenous cytotoxicity silence silence hypomethylation susceptible make illness call inhibit inhibit treat class epigenetic tumour last precursor link deform dr way dnmt tumor neoplastic contribute high cell cell cell cell baylin supressor specifically speculate drug drug marrow condition low antitumour dual hypothemylation syndrome dna dna dna dna dna dna dna dose dose acute chemotherapy demethylating gene gene methyltransferase methyltransferase effect effect epigenetically rare cutaneous belong belong thus methylation methylation decitabine decitabine decitabine decitabine bone hypomethylates blood differentiation alter alter 
1.33@transcription translation methylates tumour tumour agent april promotor product depletion result economist hypomethylation anti occur inhibit methylcytosine dna dna dna dna position ezyme fe tan demethylating gene effect mechanism srands rase decitabine decitabine em em incorporate methyl supressor 
1.33@unregulated cancer transfer restore restore suppressor suppressor suppressor deme agent process result growth growth become thy inhibit allow regulate dna dna dna dna ase demethylates belong demethylating gene gene gene function tumor block normal increase division division thus methylation blockage activity demethylation cell cell cell control promote decitabine 
1.33@effect identify class activation tumour agent myelodysplastic describe describe hypomethylates anti treat inhibit suppress dna dna dna dna epigenetic syndrome inhibitor allow demethylating gene methyltransferase impact tumor belong methylation ul ul ul ul ul ul use decitabine decitabine decitabine decitabine 
2.0@growth cancer class activate kinase agent analog analog malignancy reactivate hypomethylation incorporation transferase inhibit suppress irreversibly get silence demethylating demethylating take change pattern complex nucleoside aberrant methyl inhbitor mechanistically depend epigenetic relate replication photophosphorylation result result dna dna dna dna dna modulate action bind covalent site cytogenetic gene gene gene methyltransferase upon place deoxycytidine deoxycytidine antineoplastic belong due methylation methylation decitabine decitabine mainly activity active form eg 
1.0@dacogen cancer effect inhibition restore regulation n methyl agent agent eisai myelogenous leukemia treat call class epigenetic see precursor demethylating tumor tumor normal frase name japanese use blockage tra suppressor via drug drug offer cell anti company dna dna dna acute decrease syndrome sell myelodysplastic gene function division methylation decitabine decitabine action 
1.33@dacogen cytidine transcription present able cell cell way analogue agent agent cause decitabine decitabine decitabine precursor eisai myelogenous adversely replication regulatory incorporation inhibit presence treatment dna dna dna dna dna dna sequence acute syndrome sell function demethylating chemical inhibitor methyltransferase methyltransferase affect bind thereby myelodysplastic rna rna rna rna nucleoside substrate incorporate demethylation leukaemia protein hypomethylising 
1.0@one mitotically cancer effect effect effect think standard erase overmethylation drug drug agent stop change without negative susceptible make treat market amount treatment treatment dna epigenetic epigenetic epigenetic epigenetic histone last inherit demethylating grow proliferation reduce tumor tumor tumor normal normal actively decitabine mean cell cell cell 
1.33@cancer activation cause expressionand hemi decitabine zad myelodysplastic result myelogenous synergistically reactivate hypomethylation treat inhibit isused oxy regulate dna dna dna dna epigenetic histone acute syndrome precursor gene gene gene methyltransferase modifier chromatin contribute remodel tid activity decitabineis demethylation demethylation demethylation demethylation demethylation combine leukaemia 
2.0@one cancer cancer inhibitor regulation disease uncontrolled deme agent agent might might leukemia treat myelodsyplastic lead see inappropriately involve precursor contribute demethylating demethylating demethylating proliferation proliferation mechanism suppress hypermethylation parental aberrant many occurrs control promoter andis suppressor suppressor lat imprint certain could could cycle mean loss anti anti methylated antitumour tumour tumour tumour tumour tumour tumour prevent prevent genomic genomic mylegenous dna dna cell cell cell syndrome act expression gage gene gene gene effect effect effect belong thy methylation decitabine decitabine decitabine another 
2.0@dacogen cancer methyltransferases encounter activity tumour reversion require loss myelodysplastic analog proliferate since reactivate sit sit treat affect resume lead phenotype susceptibility reduce normal hypermethylation degrade inhibito stall cell cell use mtases supressor cytosine bond drug promotor apoptosis target result cancerous cancerous without mtase covalent dna dna dna dna dna dna dna non synthesis synthesis synthesis syndrome function cpg irreversible rapidly expression frequently methyltransferase deoxycytidine increase silence currently methylation methylation decitabine gene gene incorporate commercially active form differentiation proliferation associate 
2.0@cancer cancer cancer cgis restore medication transcriptional epigenetically use reversion mutation myelodysplastic silence silence silence silence silence silence growth growth tumour tumour inhibit significant transcriptionally epigenetic epigenetic development tomour tomour tumourigenesis hypermethylation hypermethylation hypermethylation aberrant aberrant role demethylation cell interfers suppressor suppressor become spread cause ability agent apoptosis result therapy anti show treatment dna dna dna dna syndrome sensitivity sensitivity methyltransferase methyltransferase inhibitor inhibitor induce induce reactiviating revert control reversal substiantial potency methylation methylation methylation decitabine decitabine decitabine gene gene gene gene gene gene gene influence play associate associate 
1.33@cancer methyltransferases disrupt progress use every include agent hypomethylating myelodysplastic also also also leukemia sit incorporation call molecule class irreversibly enzyme severely myeloid intergenic normal normal normal normal larger cystidine cystidine divide divide genome genome nucleoside methylation methylation cell cell cell cell drug vidaza analogue analogue epigenetic replication replication certain indefinitely cycle highly detrimental normally region prevent though dna dna dna get dose acute bind syndrome inhibitor inhibitor inhibitor perform affect methyltransferase effect similar copy repeat belong replicate since since combat decitabine decitabine portion incorporate 
2.0@cancer cancer rate faster available mode manner likely tend cpg overall overall hypermethylated incorporation island nucleotide nucleotide irreversibly strand methylate reduce reduce normal neoplastic genome disproportionate daughter cell cell cell cell replication level level level reduction dependent also nucleoside therefore therefore regular analogue base appropriate low across anti receive prevent particular see see dna dna dna dna dna dna dose bind bind act inhibitor drug drug drug methyltransferase methyltransferase methyltransferase effect effect place try believe division replicate new methylation methylation methylation methylation methylation decitabine compare cancerous action 
2.0@cancer reduce reduce reduce dnmt tumour tumour tumour tumour tumour also de hypomethylation hypomethylation permanently tumorgenesis suppress enhance effective tumor affect hypermethylation genome nucleoside instability cell cell cell cell may drive drive suppressor analogue therefore drug cause cause apoptosis chomosomal low present depletion depletion amount prevent dna dna dna dna dna dna however dose bind dnmts rapidly inhibitor death replicate replicate methylation methylation methylation methylation methylation decitabine decitabine wide incorporate 
1.67@rate class comparison dnmt dnmt fda mark mark mark dnmti correlate epigenetic strand deadlocked tumor tumor mechanism mechanism normal clear crucial nucleoside nucleoside passive cell cell cell one high mostly drug analogue result across erasure antitumor demethylation dna dna divide establish concrete inhibitor deciatbine copy belong replicate thus daughter incorporate come approve action enough 
1.0@cytidine methyltransferases abnormal activity cause chemically agent hypomethylating two result synthesis cytotoxicity cytotoxicity hypomethylation direct inhibition incorporation marrow prevent amp amp analog lead dna dna dna dna dna dna dna dna dna death strand covalent bind ii hematopoietic demethylating inhibit methyltransferase methyltransferase think induce mechanism antineoplastic bone decitabine incorporate hypomethylates cell cell 
2.0@cancer instead inhibition effective haematopoietic spar hypomethylating newly transfer malignancy hypomethylation possibly incorporation inhibit nucleotide nucleotide irreversibly responsible enzyme especially island as normal neoplastic hypermethylation convert manufacture really suseptible triphosphate cell cell cell cell cell release dependent dependent methylating disorder therefore replication replication replication analogue analogue attempt cause agent apoptosis ensue relatively low occur dna dna dna dna dna dna dna dna dna divide divide dose bind bind act inhibitor cpg time rapidly effect cellular copy division longer methylation decitabine decitabine decitabine decitabine decitabine decitabine daughter incorporate meet methyltransferase methyltransferase methyltransferase 
2.0@cancer abnormal growth multiple use state agent hypomethylating hypomethylating myelodysplastic capable de change change change change might inhibit therapy lead phenotype epigenetic epigenetic strand sequence help involve reset blunt order tumor tumor pattern pattern primary blood cell cell cell control expression expression expression persistent dysfunctional methylating drug drug drug certain cause pathway pathway condition low withdraw proeminent anti medical treatment treatment treatment dna dna dna dna dna dose tumorigenesis syndrome ffect important gene gene gene methyltransferase effect cellular word word new new signal signal decitabine decitabine accompany incorporate instance reprogramming without 
2.0@suppressor suppressor inhibition inhibition class dnmt apoptosis cause agent pas mark result result since ability hypomethylation inhibitsthe promoter lead dna dna epigenetic epigenetic development development common responsible issue demethylating fall methyltransferase inhibitor tumor tumor tumor tumor tumor block death death hypermethylation decitabine decitabine decitabine daughter gene gene program demethylation cell cell cell cell expression 
1.67@cancer cancer article article dnmt progress use use state stop myelodysplastic analog myelogenous de possibly treat transferase irreversibly inhibitor allow way able tumor tumor accord block neoplastic neoplastic reduce nucleoside cell cell cell methyl one suppressor suppressor demethylator drug drug novo mean luekemia replication know prevent dna dna dna dna acute bind dnmts gene gene rapidly expression silence replicate methylation methylation methylation decitabine disorder incorporate action aml would 
1.67@suppressor suppressor cancer methylating live dnmt dnmt mitotic tumour tumour tumour promotors agent hypomethylates dnmti decrease decrease prevent protect dna dna dna dna dna level help inhibitor enzyme demethylating inhibit methyltransferase methyltransferase allow pattern division division silence silence methylation methylation methylation decitabine decitabine gene gene gene gene lay express cell cell cell drug manage 
1.67@cancer class available reactivation activity activity tumour near agent analog hypomethylation hypomethylation call island aza lead cytosine irreversibly methylate involve belong impact mechanism block abhorent clear genome genome profoundly read many try tra tra induction cause apoptosis incorporate anti methyl methyl promoter dna dna dna dna decrease fe fe important cpg gene gene deoxycytidine silence rase rase methylation methylation decitabine decitabine decitabine region another action 
1.67@cancer cancer cancer determine way eisai find de de hypomethylation japan make hypermethylated hypermethylated might island island island methylate allow especially tumor tumor essential turn genome genome express many leukaemia always drug drug cause cause strategy exasperate suppression suppression suppression result problem demethylate best exactly know hypomethylated demethylation treatment dna however act rest rest cpg cpg cpg gene gene gene methylation decitabine decitabine decitabine work work work 
1.33@enzymatic cancer cancer inhibitor land dnmt dnmt dnmt need need cause agent actually form mark irreversibly cancerous growth anti occur prevent dna dna divide divide tumour bind bind epigenetic target demethylating inhibit effect belong replicate thus methylation decitabine regulator incorporate case drug cell cell cell cell rapid azacitidine 
2.0@cancer cancer effect inhibition class dnmt tumour tumour malignancy dnmti decrease island island irreversibly methylate inhibitor enzyme affect hypermethylation hypermethylation nucleoside cell cell much belong suppressor dependent therefore relate drug analogue body number anti type dna dna divide bind capacity act dnmts cpg cpg gene rapidly supressing division decitabine decitabine incorporate action methyltransferase haematological 
1.67@therefore fight remove methyl cause agent mark growth growth become suppress suppress previously dna dna sequence allow demethylating gene gene gene tumor tumor thereby silence decitabine work typically express active cell replication 
0.67@suppressor cancer growth methylayion use drug agent mark mark myelogenous silence hypomethylation type restrict tumour inhibit treat promote dna dna dna dna epigenetic acute syndrome establish enzyme demethylating gene gene methyltransferase precursor consequent hypermethylation thus decitabine decitabine myelodysplatic 
2.0@cancer characteristic restore target use use agent agent study two epimutations critical economist hypomethylation hypomethylation make suggest inhibit lead date reversible help allow demethylating resource normal normal whilst epigenome may access genome recommend read often much expression specifically rat seem drug cycle cell cell cell cell cell cell cell chemotherapeutic excellent slower lecture later dna dna dna divide divide histone prolieferation maintain act function gene rapidly inhibitor induce preferentially deacetylase belong vitro main actively decitabine decitabine decitabine class class differentiation methyltransferase neoplastic neoplastic 
1.33@dacogen think abnormal restore restore unregulated produce produce may agent hypomethylating eisai decitabane growth direct treat marrow marrow inhibit strand decitabines help allow demethylating unlike twofold tumor mechanism normal normal misshapen anticancer myelodysplastic demethylation cell cell cell cell cell control decitabine decitabine one suppressor also antimetabolite use via cause result body cytotoxic chain dna dna dna dna dna dna dna divide blood blood kill unhealthy syndrome sell function gene rapidly effect effect methyltransferase death bone interfere thus methylation rna incorporate incorporate hypomethylates wherebone azacitidine 
0.67@dna dna dacogen acute syndrome sell eisai ethylatingagent use treat leukaemia precursor myelodysplastic myelogenous hypomethylates decitabine decitabine hypom japanese inhibit methyltransferase company 
1.67@loss inhibitor inhibitor inhibition class dnmt dnmt adhesion stimulate may cycle cycle cycle place inactivation analog oncogene decrease inhibit inhibit lead lead epigenetic strand promoter generally island remain tumor tumor tumor tumor tumor tumor encounter repair nucleoside program regulate repress suppressor suppressor suppressor suppressor suppressor cytidine cytidine metastasis promote promote activation apoptosis apoptosis result result present present become know damage damage damage dna dna dna dna dna dna dna dna cell cell cell cell cell bind death act expression cpg gene gene chemical inactivate methyltransferase methyltransferase increase belong methylation methylation decitabine decitabine decitabine incorporate incorporate progression progression protein initiate irreparable 
2.0@cannot cgis cgis never dnmt dnmt dnmt tumour tumour tumour tumour tumour include myelodysplastic find hypermethylated affect class methylated silence outcome replicate normal normal hypermethylation reduce nucleoside substrate maintain possible drive suppressor suppressor certain release analogue hemi incorporate u level good dna dna dna dna dna dna divide divide dose cell cell cell bind syndrome le gene rapidly inhibitor belong longer longer since methylation methylation methylation decitabine decitabine decitabine work lay come prognostic tissue tissue 
2.0@dacogen cancer cancer activate use chemically agent eisai myelogenous growth genetic genetic treat inhibit lead epigenetic epigenetic work precursor demethylating island enhance tumor tumor tumor uncontrolled difficult turn repair regulate control control leukaemia suppressor suppressor drug lower however spread create mutation switch anti treatment dna dna dna dna dna get acute syndrome sell myelodysplastic cpg gene gene gene gene gene methyltransferase effect solution solution silence methylation methylation decitabine possible malfunction tumorigenesis 
0.67@et et et possible toxicity hagermann stimulate able transcriptional induce induce use state agent augment myelodysplastic find invasion hypomethylation cortisol make decrease often effective hagemann inhibitor disease demethylating proliferation downregulation adjuvant pattern stewart dac dac together nucleoside factor demethylation treatment treatment ctr incorporate recover decitabine decitabine study study study also also advance remethylation secretion seem drug analogue therapy genome highly bond chemotherapeutic investigate replication show show relative syndrome dna dna expression expression cell demonstrate covalent dnmts dnmts gene target effect upon evidence thereby replicate silence al al al conclude wide another suh specific azacitidine 
1.33@suppressor cancer condition excessive tumor methyl leukemia agent april epicentre myelodysplastic edition myelogenous th marker perhaps treat decrease dna epigenetic acute syndrome precursor print demethylating drug remove online normal thereby silence decitabine gene gene economist active use 
0.67@one suppressor cancer cancer also disrupt dnmt dnmt healthy may cause cause dependent specific agent silence behind dnmti novo avoid unseen dna dna epigenetic effectively bind inhibitor however drug gene target effect tumor belong main main methylation methylation decitabine decitabine mainly em class side cell replication de 
2.0@cancer rate term dnmt dnmt yet possibly long precise since block susceptible hypermethylated diminish dna dna unknown epigenetic even although belong tumourigenesis mechanism later normal normal contribute irreversible effectiveness parental nucleoside nucleoside nucleoside enzyme enzyme cell cell cell cell cell tumour compound suppressor dependent high therefore cannot seem replication replication replication analogue analogue analogue strand strand strand strand incorporate amount specially group though treatment compare get act inhibitor gene effect copy division longer new methylation methylation methylation decitabine daughter daughter work elucidate arrive pattern 
1.33@cancer cancer inhibitor restore activate induce induce use fda cycle phase myelodysplastic silent cytotoxicity dnmti dnmti dnmti marker md md md emea rassf affect treat correlate promoter well disease blast research normal normal hypermethylation hypermethylation respectively count contribute high high demethylation cell cell cell cell cell mlh may dependent discover patient patient patient however improve acute apoptosis low low moreover arrest arrest hoxa hoxa level damage dna dna dna dna pathway dose decitabineleads syndrome aza survival aml aml effect synthesis myelogenousleukemia deoxycytidine death death human senescence terminal methylation decitabine decitabine decitabine decitabine gene gene incudce dosage dosage dosage approve differentiation methyltransferase independent progression 
2.0@cancer methyltransferases epigenetic consolidate methyl cause inhibitor however process dnmti hypomethylation effect anti hypermethylated inefficient example dna dna dna dna dna dna dna irreversibly anddecitabine anddecitabine anddecitabine fe act tra drug drug affect reduce tumor nowadays bind replicate rase knock methylation many cell zacitidine tumour tumour would azacitidine azacitidine 
2.0@dacogen cancer cancer standard dnmt tumour state agent agent shore shore irreversible process inhibit inhibit hypermethylation hypermethylation hypomethylation contiunual retract hence utilise resume previously island island dna dna expression region bind act act sell enzyme cpg cpg prevent chemical allow pattern cellular belong methylation methylation decitabine decitabine aberrant indicative demethylation cell say suppressor class 
2.0@mean cancer cancer inhibition class methyl methyl agent stop correct sit since silence silence change part generation heritable transferase inhibit inhibit inhibit inhibit suppress suppress irreversibly reversible allow demethylating island island take mechanism linkage hypermethylation act myelodysplastic aberrant like treatment tumour tumour tumour one enzymatic involvement therefore epigenetic epigenetic drug carry msonormal subsequent target result low occur know know know group cpg cpg cpg potentially dna dna dna dose cell cell cell bind covalent inheritance dnmts dnmts dnmts dinucleotides gene gene enzyme place syndrome division longer thus methylation methylation methylation decitabine decitabine decitabine hypomethylated action indirectly protein progression progression 
0.67@cancer cause cause inhibition ltr ltr dnmt use analogue dependent stop agent agent process myelodysplastic fade leukemia occur dna acute syndrome dir dir demethylating demethylating irreversible meyolid decitabaine hypermethylation thus methylation nucleoside cell replication 
0.67@one market cancer cancer restore hypermetylation epigenetic seem use agent suppression myelodysplastic unmethylated anti treat promoter island dna dna dna dna dna often normalize status decrease syndrome function cpg affect hence impact tumor tumor suppress demethylating due silence silence methylation methylation decitabine decitabine decitabine possible gene gene gene action drug drug expression expression 
1.67@cancer cancer methyltransferases dosage dosage dosage affectation dnmt produce use could toxic apoptosis myelodysplastic uncontrollably azacytidine without introduce like useful useful bind treat affect grow look dna dna irreversibly strand kill kill methylated syndrome methyltransferase inhibitor inhibitor tumor due cellular normal normal replicate decitabine high daughter come cell cell cell cell cell cell cell drug drug drug small small 
1.0@www dna cancer true javascript patient use cause chd cdata lt text lower dosage actually http http http toxic group treatment script script dose kill help var var var function aid objectify side effect tumor gt chaid belong methylation decitabine high ca cell dont dnmti dnmti 
0.0@different suberoylanilide cancer nanomolar itmay class class pxd toare use fk prove tacedinaline acetyldinaline hydroxamic hydroxamic belinostat useful genetic treat decrease inhibit higher zolinza epigenetic tumour help help also formerly becausedecitabine impact tumor tumor tumor tumor epigenome may genome vorinostat potent potent toget hdacs cell way decitabine decitabine decitabine decitabine acid acid classification lower identify infection infection fight seem wide cause mutation nonselective istodax body anti type type level could saha dna dna dna dna dna profile blood blood analogy inhibitor romidepsin methyltransferase effect accumulate ci belong selective methylation methylation methylation methylation micromolar em reference clot follow follow progression 
2.0@incorporation cancer cancer inhibitor within able nova use use state fda disease almost dnmti methyl back grow treat previously expression epigenetic body lose involve epigenome remittance impact pattern drop normal hypermethylation myelodysplastic progress cell cell tumour leukaemia study patient patient diseased abberant replication cause therapy limit result result decitabines bring anti occur group approve disappearance dna dna dna acute syndrome recent function drug drug gene aml effect methyltransferase silence undergo half methylation decitabine decitabine decitabine daughter work return complete rapidly myelod 
1.67@mean inhibitor higher class dnmt need toxic myelodysplastic describe low dnmti dnmti anti anti bind know tumergenesis irreversinly treatment dna dna dna divide dose dose uncontrollably lay syndrome use drug drug derive effect effect dependant must neoplastic aml thus becasue becasue methyltransferase incorporate replication replication demethylation tumour decatabine decitabine decitabine 
2.0@blewitt cancer cannot class dnmt find find dnmti dnmti dnmti hypermethylated island island job granddaughter dr lecture prevent allow allow inhibit tumor tumor tumor tumor accord grow grow hypermethylation often drug suppressor suppressor therefore replication lay know parent dna dna replicate cell cell cell cell bind cpg cpg gene gene methyltransferase inhibitor remove try belong word silence methylation methylation methylation methylation decitabine daughter daughter work incorporate form frequently 
1.33@cancer lower inhibator syndrome economist dnmt tumour reduce reduce could myelodysplastic describe article methylation decitabine decitabine say effect effect anti overall develop chance 
1.67@myc totreat activate use slow myeloma agent myelodysplastic myelogenous group acute syndrome precursor demethylating adna proliferation remove byshutting decitabine gene cell methyl leukaemia 
2.0@cancer methyltransferases methyltransferases restore able tumour agent analog block drug decrease nucleotide recognize display silence trap proliferation tumor tumor mechanism key pirimidine hypermethylation style carbon supressors substitution align cell justify control decitabine decitabine substitute atom cytidine therefore relate demethilating ring ability text result cytosine anti consist revert group dna dna dna dna dna base reaction reaction bind succesful gene gene azanucleosides effect induce nitrogen belong methylation methylation methylation analong drive incorporate action 
2.0@cancer cancer class reactivation tumour thee since ofsilenced reactivate growth change suppress epigenetic en hypermethylation demethylating impact tumor tumor throught therapydrugs supressors mitoticallyhereditable pig rant theinhibition suppressor tical drug agent ly lea anti ber promoter correction isactive dna dna dna deoxy cell cell cell dnmts theepigenetic methyltransferase effect er thecancer belong silence methylation decitabine decitabine decitabine daughter gene gene azacytidine andna 
2.0@cancer promotion tumour tumour tumour agent agent agent specific hypomethylating hypomethylating myelodysplastic silence growth growth growth growth leukemia useful treat marrow locus nucleotide lead correlate correlate correlate area island island precursor disease provide group reduce positively uncontrolled factor icrs cell methyl inhibit suppressor transcription promote imprint result shore like impritn bind occur prevent prevent syndrome dna dna dna process process often chemotherapy use general general cpg gene think negatively negatively epimutation control control bone ascpg methylation methylation methylation methylation methylation methylation decitabine decitabine decitabine region region reproduction adjunct 
2.0@mitotically cancer cancer cancer cancer inhibitor ascribe dnmt progress epigentics mutation supressors supressors two acetylation find dnmti growth leukemia genetic treat affect unlike afford epigenetcs epigenetic epigenetic reversible selectively chromosome tumor tumor tumor tumor uncontrolled uncontrolled permanently effectiveness directly favorably heritable otherwise stabilize stabilize cell cell cell methyl demythylating dependent transfer identify indicate therefore therefore therefore irreversibly via suppresors either structure support result acute bind treatment dna dna dna dna histone often syndrome myelodysplastic effect effect overactive control division division modification silence silence methylation methylation methylation methylation decitabine arise work work active form protein would 
2.0@dacogen cancer methylating methylating become marker therefore unregulated uncontrolled drug agent hypomethylating hypomethylating myelodysplastic myelogenous cancerous growth make type treat responsible lead epigenetic syndrome dna dna dna dna dna correct acute involve sell enzyme demethylating inhibit inhibit methyltransferase methyltransferase error precursor awry go methylation decitabine decitabine decitabine hypomethylates prone cell use leukaemia 
2.0@dna dna dna cancer cancer rate growth le function demethylating much reduce agent transerase ihibiting strand hypomethylates without evolution usage rapid methyl decitabine decitabine 
1.33@cancer faster therefore dnmt use duplication specific demethylated replication replication treat inhibit action action action dna non body bind act responsible enzyme drug drug gene inhibitor tumor undergo affect affect silence replicate methylation methylation decitabine much stablishing strong cell cell cell cell cell blood haematological supressor 
0.67@suppressor use drug agent whose purpose silence overmethylate histone histone mutate leukemia treat affect inhibit tail dna area around precursor contribute demethylating gene gene reduce tumor overactive suppress ezh myelogenous methylation locate work activity enzyme enzyme form form heavily decitabine 
1.0@suppressor tumour tumour slow agent anti overmethylated reactivate possibly demethylate reactive dna help example reenabling gene effect chemoteraphy demetylating death division decitabine make cell cell cell may 
1.33@cancer cancer cannot class dnmt get tumour along tend irreversibly result inhbitors dnmti anti analog dna epigenetic kill bind bind effect fast affect belong replicate thus release nucleoside incorporate come cell cell replication decitabine decitabine decitabine decitabine 
1.67@cancer cancer cannot class term dnmt dnmt dnmt dnmt activate may hematological long silence myelodysplastic myelogenous aza frequently hypomethylation potential methyl treat transferase resultant epigenetic strand strand precursor belong effective tumor tumor normal hypermethylation release nucleoside actively cell cell cell cell cell cell use use leukaemia suppressor cytidine cause therefore replication analogue also gene gene depletion occur show illegitimately treatment treatment dna dna dna divide divide divide acute bind bind syndrome act act act inhibitor drug drug time side effect upon upon upon copy solid division thus methylation decitabine decitabine decitabine decitabine daughter irreversible incorporate malignancy 
2.0@critical inhibition restore low dnmt dnmt proliferate induce use slow concentration agent metabolit myelodysplastic myelogenous cytotoxicity cellular hypomethylation leukemia md md treat inhibit incorporation achieve epigenetic precursor enzyme demethylating proliferation myeloid normal neoplastic may may substrate insensitive triphosphate cell cell cell control leukaemia aza aza also suicide drug cause cause non chronic suppression relatively acute acute hypomethylations favor methylation mazin dna dna dna dna dna dna divide dose synthesis syndrome act function gene rapidly inactivate deoxycitidine deoxycytidine zalihi major al decitabine decitabine decitabine decitabine decitabine decitabine attribute zdc zdc covalently differentiation methyltransferase progression 
2.0@suppressor restore tumour agent analog hypermethylation amount island cpg class dna dna reverse function demethylating inhibit reduce belong silence methylation decitabine nucleoside gene lead may expression 
1.67@cancer switch myelogenous hypomethylation isused inhibit inhibit treat lead dna dna acute methylated syndrome precursor myelodysplastic demethylating gene methyltransferase belong thus methylation decitabine decitabine angents leukaemia 
1.67@one suppressor cancer myelodisplasic inhibition inhibition therefore use agent subsequent hypomethylating result neoplasic important important growth methyl antineoplasic treat hypomethylated incorporation expression expression expression dna dna dna apoptosis strand leukaemia overexpression fe function gene gene gene gene proliferation effect effect tumor due cellular counterbalance rely rase decitabine decitabine disorder cell differentiation control tra 
1.67@suppressor momparler also metin dnmt include cancer therapy agent karahoca upregulation deaditabine design effect pharmacokinetic inhibit aza previously dna dna dna dose methylated act enzyme gene analysis activation tumor deoxycytidine andbinding antineoplastic pharmacodynamic richard methylation methylation repair schedule work incorporate deacitabine decitabine 
1.67@suppressor suppressor cancer cancer methyltransferases methyltransferases methyltransferases think cant thus thus tumour tumour tumour analogue analogue add silence part anti type exert prevent action mode dna dna dna irreversibly methylate dependent bind bind act enzyme enzyme enzyme enzyme inhibitor group effect upon upon hypermethylation replicate unhindered genome nucleoside nucleoside gene gene gene incorporate come cell methyl decitabine 
1.33@user effect effect available dnmt dnmt upon use although although appear mutation alteration remain process myelodysplastic exceed selective malignancy marker susceptible susceptible genetic drug drug unlike effective irreversibly strand reversible particularly division island take myeloid mechanism prognosis hypermethylation high progress fda methylation cell cell cell cell cell far replication replication replication majority leukaemia enzymatic extremely dosage nucleoside epigenetic epigenetic epigenetic seem need analogue u non non non subsequent target target low cancerous cancerous cancerous hence experience potentially dna dna dna dose acute bind syndrome inhibitor cpg poor side rate unclear methyltransferase classic longer thus regulator decitabine decitabine decitabine decitabine daughter incorporate undergo approve action indicator absolute haematological require 
1.33@cancer cancer along along class dnmt dnmt progress use fda myelodysplastic azacytidine treat inhibit nucleotide epigenetic strand body division severely impact replicate replicate affect release much cell cell cell tumour dependent irreversibly replication anti dna dna dna dna dna dna dna divide bind bind bind syndrome act inhibitor inhibitor inhibitor get aml effect upon methyltransferase methyltransferase methyltransferase methyltransferase methyltransferase similar copy belong longer methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine daughter incorporate come come approve action rapidly 
2.0@cancer effect class administration use thereby mostly agent agent hypomethylating hypomethylating event event analog transcription block growth growth abnormally tsg tumour tumour inhibit multiplication regulate epigenetic epigenetic help inhibitor inhibitor belong demethylating island island take shape normal myelodysplastic many lead control region one suppressor cytidine also become tsgs tsgs tsgs require certain loss drug drug anti methylated methylated promoter promoter prevent prevent demethylation together treatment dna dna blood blood cell cell cell syndrome act function cpg cpg gene inactivate place cellular cellular cellular demethylates division modification thus thus methylation decitabine production uncontrolled 
2.0@suppressor suppressor cancer methyltransferases class therefore able sometimes drug stay agent could result inhibit inhibit inhibit job dna dna dna dna allow demethylating hypomethylated methyltransferase tumor tumor tumor suppress turn turn decitabine decitabine gene gene like machinery 
2.0@rate disrupt dnmt yet manner specific specific precise since clearly incorporation dmnt inhibit benefit benefit clinical bear inhibitor proportional proliferation reduce tumor mechanism mechanism fact nucleoside cell trial rapid region namely analogue pathological therapeutic replication replication suicidally somewhat moreover become inibitor know dna dna dna non action bind example dnmts effect suggest methylation methylation methylation decitabine decitabine possible incorporate cancerous covalently 
2.0@dna open transcription help methyltransferase inhibit tumour tumour agent hypomethylating thus decitabine decitabine suppressor gene gene generation case cell prevent rapid would 
1.67@cancer cancer able negatively use agent inhibit myelogenous growth leukemia treat normal normal normal normal grow lead lead lead effective irreversibly level involve certain demethylating island island island impact tumor mechanism affect hypermethylation hypermethylation high methylation demethylation cell cell cell cell cell cell cell rapid suppressor drug lower however partly cause cause could toxic cancerous ultimately replication wont potentially dna dna dna dna divide divide acute bind integrate myelodysplastic myelodysplastic cpg cpg cpg gene gene gene rapidly expression remove syndrome syndrome death due actively decitabine decitabine decitabine decitabine possible activity dosage subsequently methyltransferase 
1.0@dacogen cancer cancer along able others use use fda myelodysplastic azacytidine dnmti dnmti regulatory incorporation effectively inhibit previously clinical irreversibly strand sequence way way dnmt dnmt mean affect neoplastic effective much substrate like like license cell cell cell tumour decitabine decitabine decitabine decitabine unmethylation dependent transcription get seem replication target result low tradename anti usa dna dna dna dna dna dna divide dose dose bind bind syndrome smaller inhibitor inhibitor perform rapidly effect upon methyltransferase methyltransferase copy division methylation rna rna rna daughter work incorporate come action protein haematological 
1.33@suppressor lower activate remove remove use agent mark myelodysplastic anti treat level group dna dna dna syndrome demethylating gene effect tumor tumor silence thus methylation decitabine decitabine methyl 
1.33@cancer article consumption helpfull term able scientist use state break tend economist cellular hypomethylation clearly md tp clinical sultant write inhibitor inhibitor chromosome disrupt clinically modest general ig cell cell cell negative ignore phosphorylated transfer therefore profile failure drug drug drug healthy toxic result remission long fairly wth dna dna dna dna divide non ase act function positive review aml effect effect practice chromatin death division advers methylation decitabine incorporate meet survival side side 
1.67@cancer cancer cancer methyltransferases dnmt dnmt dnmt haematopoietic concentration frank azacytidine reactivate hypermethylated carlo island international issue ineffective reduce reduce tumor tumor vitro render cell cell may may may suppressor suppressor mode also therefore imprint need analogue loss cytosine bind bind show develop journal dna dna dna dna dna july lyko volume cpg irreversible irreversible methyltransferase methyltransferase inhibitor inhibitor pg replicate silence silence decitabine decitabine decitabine decitabine decitabine stresemann gene gene incorporate action indirectly associate 
2.0@aspect misshapen cancer methyltransferases abnormal class medication transcriptional use use dnmts small agent agent inactivation since hypomethylation associate treat call island molecule transcriptionally development development reversible help involve inhibitor inhibitor demethylating subject methylate normal produce produce produce aberrant many cell cell cell cell blood blood blood promoter transfer via work marrow marrow marrow mutate condition sequence healthy become tumour group reverse dna dna dna dna histone ase syndrome myelodysplastic cpg gene gene gene rather inactivate epigenetically bone bone bone silence silence modification modification methylation decitabine decitabine decitabine possible kill enough 
2.0@cancer todna class within dnmt use agent agent hypomethylating hypomethylating silence diminish call island propagate lead lead irreversibly strand methylate enzyme observe tumor tumor react thus repair methylation methylation methylation cell cell cell drug belong suppressor suppressor cytidine lower patterncannot consequently decitabine decitabine replication replication analogue cycle apoptosis maintain gain arrest amount promoter particular later dna dna dna process expression cpg gene gene gene allow try division new regional locate region region incorporate incorporate 
1.33@mitotically cancer cancer yet myelodysplastic myelogenous economist heritable constanlty epigenetic strand establish impact mechanism description hypermethylation genome although explanation japanese removal tumour tumour tumour belong dna dna dna dna dna dna also also high relate general analogue information non structural obvious acute express anti occur company process base cell cell cell cell cell cell cell cell bind gene gene upon division division additionally methylation methylation methylation methylation methylation decitabine decitabine difference possible possible mean mean leukaemia irreversable dacogen could characteristic class lower dnmt dnmt progress use susceptible order modification epicentre eisai since growth offently treat mention incorporation effect lead lead involve unclarified due strictly nucleoside nucleoside like like demethylation demethylation replication replication supressor mode speicific transfer establishment activation drug drug drug drug cause toxic result result result result reason decitabicine decitabicine kind dose dose syndrome sell rapidly inhibitor silence silence replicate would would daughter daughter attribute activity activity activity action action mark 
1.67@suppressor suppressor dependent inhibitor inhibitor class malignancy epigenetic use cause could myelodysplastic myelogenous since dnmti anti treat call dna dna dna irreversibly acute bind syndrome precursor dnmts gene gene methyltransferase effect hypermethylation currently decitabine decitabine decitabine decitabine incorporate free demethylation tumour tumour tumour haematological leukaemia 
1.67@dna suppressor become active demethylating gene tumour cause demethylation agent decitabine 
0.67@decline genens reduce patient methylates drug add mutate cell withdecitabine cancerous become treat treat histone greatly enzyme ezh ezh gene gene supressing supressing tumor tumor decitabineinhibits silence methylation methylation methylation activity express active saw 
1.33@suppressor suppressor cancer large disrupt immature use cause red specific agent proper loss number part restoration treat tumour inhibit occur lead lead dna dna dna blood blood sequence syndrome syndrome disease demethylating myelodysplastic methyltransferase expression tumor normal hypermethylation due may methylation decitabine decitabine production gene cell cell control level associate 
1.67@cleareal cancer cancer rate rate inhibition restore produce methyl methyl agent agent specific hypomethylating transcription silence hypermethylated inhibit island island lead cytosine promoter regulate belong demethylating group group happen mechanism normal normal source thus high case cell incorporate transfer residue target target become level hypomethylated dna dna dna dna dna dna get cpg cpg gene gene methyltransferase methyltransferase inhibitor division catalizes decitabine decitabine region class hence hence tissue tissue tissue 
1.67@cancer effect effect high therefore dnmts use analogue dependent myelodysplastic myelogenous dnmti leukemia anti anti transferase adequate good family treatment dna dna irreversibly acute bind low precursor belong inhibitor rate tumor syndrome neoplastic give since decitabine nucleoside incorporate cell methyl replication replication 
1.67@faster cause daughter therefore order uppon may analogue healthy methyltransferases irrevesibly demethyliation copy nucleotide dna dna dna dna dna get strand methyliation bind bind incoporated methyltransferase methyltransferase inhibitor tumor tumor tumor replicate affect longer release nucleoside replecated come cell cell cell cell replication decitabine decitabine decitabine decitabine 
1.67@specifically cannot dnmt dnmt dnmt tumour tumour tumour tumour tumour analogue shore island island island island irreversibly result growth maintain maintain replication hypermethylated drug prevent cpg cpg cpg cpg integrate dna dna dna dna dna divide dose division particularly give demethylating inhibit inhibit inhibit dnmts gene gene expression bind hypermethylation dilute decitabine decitabine nucleoside methylation methylation express cell cell cell cell use suppressor suppressor small 
2.0@growth mitotically cancer cancer restore restore tumour tumour tumour state process process disease find find silence apply unmethylated make restrict call inhibit inhibit act oncogenic epigenetic pass give change benign expression dnmtis hypermethylation effectively aberrant aberrant cell cell cell cell methyl tra suppressor suppressor suppressor also patient replication replication replication cause decitabine decitabine decitabine decitabine result low low without responsive damage reverse dna dna dna dna dna dna originally dose dose shut shut chemotherapy fe function gene gene gene gene methyltransferase inhibitor inhibitor cellular belong longer rase methylation methylation methylation methylation methylation sequence daughter incorporate class 
2.0@cancer cancer show class dnmt dnmt tumour analogue decitabine decitabine decitabine irreversibly methylating dnmti anti transferase prevent nucleotide dna dna dna epigenetic get get bind bind integrate inhibitor inhibitor thereby rapidly effect upon normal normal belong replicate thus ul ul nucleoside much incorporate come cell cell cell cell methyl replication release 
1.67@substitute cancer toxicity class last dnmt dnmt methyl bigger concentration stop mark disease dnmti dnmti dnmti aberration susceptible genetic genetic genetic tumour decrease nucleotide nucleotide addition epigenetic epigenetic epigenetic development opposite belong rate impact entire block normal neoplastic epigenetics genome substitution cell cell cell cell much reversible one compare also patient therefore irreversibly fda replication strand decitabine decitabine target result result decade effect discovery show group methyltransferase dna intervention rethink bind drug chemical inhibitor highest fast exclusive division modification low cod allow daughter mitosis activity approve action protein 
1.33@cancer cancer methyltransferases dnmt dnmt use agent myelodysplastic analog myelogenous enzimes inhibit treat epigenetic epigenetic tumour consider precursor belong demethylating way release nucleoside japanese methyl kill leukaemia enzymatic dependent transfer patient therefore need toxic low anti act group group good company dna dna dna dna get dose cell cell cell bind syndrome sell function drug irreversible effect effect division replicate replicate regulator decitabine decitabine decitabine work incorporate action replication 
0.67@mitotically cancer cannot dnmt dnmt dnmt dnmt progress use slow agent stop stop myelodysplastic since decitabane growth leukemia heritable expression well quickly quickly thereby myeloid tumor tumor tumor normal cell cell cell decitabine suppressor also mean allow relative dna dna dna dna dna divide acute bind bind syndrome act inhibitor inhibitor gene aml effect remove division replicate replicate demethylization permanent daughter incorporate hypomethylates methyltransferase 
2.0@dna mitotically cancer histone methylated syndrome inherit demethylating stay use use reduce remove remove remove agent myelodysplastic methylation methylation methylation decitabine decitabine decitabine cpg many island treat class 
1.67@dna dna suppressor inhibitior fe reactivation cpg prevent tumour rase methylation decitabine gene lead island methyl tra 
1.67@growth cancer cancer cancer cancer class class essentially effective persist way slow could stop tend mark become probably change change potential potential sit treat might open area pass help involve division demethylating tumor tumor tumor affect methylation methylation methylation effectiveness supressors markedly express cell cell cell removal methyl genome suppressor also patient relate drug drug drug drug drug certain gain type group particular decitibane dna dna act allow allow remove must control increase increase belong actively regulator possible active active indirectly 
1.67@especially cancer cancer inhibitor inhibitor class dnmt activate progress use use title agent tend myelodysplastic currently hypomethylation leukemia md md hypermethylated treat inhibit leukamie expression expression irreversibly well silence demethylating island island myeloid myeloid tumor tumor normal dnmtis dnmtis nucleoside aberrant cell cell machinery one one suppressor suppressor patient epigenetic epigenetic drug drug analogue could target result acute acute look show treatment treatment dna dna however reaction bind syndrome dnmts cpg cpg aml effect induce explain enter positive thus methylation decitabine decitabine decitabine decitabine possible methyltransferase alter recently 
2.0@mean cancer cancer inhibitor higher class specificity dnmt regulation progress use use could stop faulty since dnmti dnmti dnmti dnmti growth growth leukemia transferase lead lead irreversibly strand strand therefore responsible silence silence myeloid tumor tumor contribute usually nucleoside aberrant treatment methyl suppressor suppressor dependent rat replication replication replication analogue suppression result acute promoter involve dna dna dna dose cell cell cell bind syndrome myelodysplastic drug right aml effect belong methylation methylation methylation decitabine daughter daughter gene gene gene gene incorporate associate 
1.67@mean cancer cancer class dnmt dnmt dnmt tumour agent specific process become silence oncogene heritable meitotically nucleotide nucleotide irreversibly quickly demethylating subsequently affect affect abhorrent release nucleoside maintain thereby dependent analogue epigenetic replication replication cause cause cause non lay low anti prevent dna dna dna dna dna divide divide dose cell cell cell bind bind gene inhibitor inhibitor belong replicate new methylation methylation methylation decitabine decitabine daughter incorporate modifier 
1.33@myeloid last summary produce methyl unmethylated agent agent suppression hypomethylating myelodysplastic since deoxycytidine growth leukemia transferase inhibit aza aza patient cytosine epigenetic involve involve silence efficacy tumor tumor source clear allele cell way promote expression dna dna dna subset replication analogue cdr low remission reappear show reverse reverse several dose acute maintain month gene gene gene eliminate induce induce cellular elderly division methylation methylation methylation methylation decitabine decitabine mtase differentiation differentiation differentiation associate 
2.0@cancer effect eg tumour tumour tumour agent stop myelodysplastic silence leukemia decrease decrease decrease island island island rate rate irreversibly strand methylate methylated particularly give demethylating mechanism mechanism hypermethylation hypermethylation high otherwise express cell methyl methyl leukaemia leukaemia suppressor suppressor silent therefore malignant context result demethylated specific anti occur level transferase transferase common dna dna dna dna bind syndrome act inhibitor cpg cpg cpg gene gene nature relevant division longer new methylation methylation decitabine decitabine decitabine decitabine mitosis mean protein would 
0.0@standard decline class chemotherapy last epigenetic tumour belong way decitabine susceptible make cell drug alter azacitidine 
1.67@occurrence suppressor suppressor cancer cancer cancer cancer epigenetic activate tumour tumour tumour agent agent mark newly cancerous silence island island island gene gene anti hypermethylated treat promoter prevent prevent prevent cpg cpg cpg previously synthesise dna dna dna dna maintenance strand action help common target demethylating demethylating inhibit methyltransferase formation thus often decitabine decitabine decitabine decitabine region incorporate methylation methylation many cell drug associate 
1.67@cancer impact class alteration tumour tumour tumour tumour cycle cell cell administrate effect anti know dna dna daughter transmit inhibitor inhibitor hypermethylation drug drug drug methyltransferase reduce stage first life belong show show developement methylation methylation decitabine high high high period replication level level level 
1.0@transient nitrogen may trap since malignancy change potential md md md hypermethylated inhibit inhibit indicate clinical epigenetic strand see return impact clinically hematologic therapeutic carbon demethylation granddaughter trial substitute atom transfer patient erase erase disorder answer answer answer answer malignant substitutin deoxyribose incorporate pass powerful occur group though dna dna dna dna dna dna cell cell ase dnmts gene aml inhibitor inhibitor place contain division actively decitabine decitabine decitabine decitabine decitabine daughter methylation methylation class meet active active azacitidine 
1.0@effect become therefore dnmt dnmt synthesize methyl cause agent novo island newly transfer de anti hypermethylated group dna dna dna dna dna dna dna dna dnmts dnmts dnmts demethylating inhibit target reduce tumor tumor function cpg methylation methylation methylation maintain cell methyltransferase methyltransferase decytitabine decytitabine decytitabine 
2.0@cancer inhibitor dnmt dnmt dnmt dnmt synthesize use manner process newly treat inhibit lead irreversibly strand strand strand strand methylate silence demethylating reactivation may nucleoside cell tumour tumour suppressor one dna dna dna dna dna get replication replication analogue mean result anti parent genomic reduction mark bind bind epigenetic drug methyltransferase methyltransferase effect remove similar thereby replicate methylation decitabine decitabine decitabine decitabine daughter daughter region incorporate incorporate 
2.0@methyltransferases restore restore tumour tumour tumour tumour tumour slow agent anti growth growth decitiabine island lead irreversibly severe demethylating normal turn nucleoside demethylation cell cell cell control expression suppressor suppressor cause replication promotors function analogue become bind level level dnmts dna dna dna dna dna decrease decrease inhibitor cpg gene gene rapidly effect effect enable increase replicate methylation methylation decitabine decitabine decitabine decitabine incorporate incorporate methyltransferase 
2.0@cancer cancer inhibitor dnmt dnmt dnmt dnmt dnmt state attempt myelodysplastic analog since reactivate hypermethylated inhibit nucleotide lead irreversibly strand slyly particularly island island tumor mechanism normal normal normal hypermethylation genome nucleoside passive cell cell cell cell cell decitabine decitabine decitabine decitabine decitabine decitabine suppressor action methylates methylates replication replication replication suit cancerous occur show hypomethylated demethylation dna dna dna dna get reverse bind bind syndrome function positive gene rapidly effect effect copy cpg cpg replicate methylation longer daughter incorporate return slip methyltransferase methyltransferase 
0.67@one one market cancer cancer methyltransferases therefore therefore suppressor suppressor tumour tumour agent agent already major hypermethylation hypermethylation type drug call prevent lead dna dna action action dnmts dnmts demethylating inhibit inhibit effect feature epigenome silence decitabine decitabine gene gene gene treatment use present 
1.33@bloc alt could also decitanbit epigenetic fda say modulator include stop decitabin decitabin classify anti src nucleotide action lead dna dna dna irreversibly base cell bind bind hypomethilation drug drug first proliferation dnmt dnmt hma administer methylation metabolic transcription mitosis img come approve analogy global nuceloside 
2.0@cancer cancer cannot cannot class synthesize methyl methyl myelodysplastic analog leukemia newly hypermethylated elsewhere lead irreversibly strand strand see methylated postitions well enzyme demethylating island myeloid tumor particular blood divide release nucleoside nucleoside demethylation cell cell use use decitabine decitabine decitabine decitabine dna dna dna dna dna dna patient epigenetic favorable drug drug incorporate result low bind prevent prognosis reason get get dose kill group group syndrome victim target cpg suffer methyltransferase methyltransferase methyltransferase inhibitor belong poor onto daughter daughter possible lay lay perhaps approve would would associate 
1.67@suppressor cancer cancer center patient fewer use near agent result result result since demethylate back better suppress dna dna dna dna dna dna histone histone recovery treat treat silence silence demethylating demethylating gene gene gene gene effect tumor tumor tumor hypermethylation hypermethylation turn demethylated release way would decitabine decitabine decitabine 
2.0@inhibitor cgis dnmt synthesize tumour tumour chemically cytidine analog dnmti leukemia might transferase strand well way able pattern genome bond evidence demethylation demethylation demethylation yet suppressor dependent therefore activation mitotic replication kidnap result highlight anti methyl know dna dna covalent gene effect copy new methylation decitabine irreversible incorporate arrive 
0.33@cancer cancer cancer inhibitor inhibitor class term dnmt dnmt dnmt dnmt progress use every fda mutation mutation myelodysplastic analog change make genetic treat broad unlike molecule lead epigenetic epigenetic epigenetic epigenetic strand get consequence tumor longer affect abnormality release nucleoside potent cell cell cell drug machinery machinery therefore irreversibly replication mutate target spectrum type occur dna dna divide dose reverse bind bind syndrome function methyltransferase along copy aml replicate low methylation decitabine decitabine decitabine decitabine daughter incorporate come approve downstream rapidly mistake 
1.33@functionally cancer cancer cancer also faster restore anticancer suppressor suppressor spread monitor expand agent dependence toxic toxic methyl transferase order dna dna dna epigenetic expression inhibitor generally demethylating demethylating gene effect effect tumor tumor due cellular normal hypermethylation replicate silence longer possible mean prone demethylation cell cell survival may decitabine decitabine 
1.67@standard untreated tumour tumour tumour tumour agent cell cell cell cell myelogenous susceptible anti treat syndrome dna acute chemotherapy precursor myelodysplastic demethylating effect remove due methylation decitabine demethylation modify use leukaemia 
2.0@suppressor cancer reduce insert successfully may stop decitabine decitabine result growth growth methyl transferase dna dna dna irreversibly reverse bind expression dnmts gene gene gene take inhibitor tumor circulation hypermethylation turn silence methylation genome wide cell cell uncontrolled promoter promoter associate 
1.67@cancer cancer cancer abnormal class uncontrolled leukemia agent stop stop generation myelogenous hypomethylates change susceptible make make make pregnancy treat treat grow act act sup sup epigenetic epigenetic epigenetic epigenetic epigenetic even child precursor division division ezh inhibit inhibit contraindicate research tumor tumor early style style may may routine align align cell cell cell cell methyl kill expression expression childhood assessment continuance detail che use use via drug drug cause build embryo pas text text suppression result u center center rd strand solid protein good gametogenesis dna dna dna histone syndrome least development myelodysplastic ape effect methyltransferase growth control penetrate demethylating mother new decitabine decitabine pgc gene gene sensitive period add reprogramming 
1.33@cancer cancer methyltransferases restore reactivation tumour tumour likely silence myelodysplastic irreversibly frequently growth useful might transferase inhibit act significant epigenetic level help hypermethylation hypermethylation hypermethylation demethylating island island island change dmt normal normal epigenome nucleoside behaviour cell cell cell cell cell cycle may suppressor dna dna dna dna dna dna indicate dmts replication analogue md agent target chemotherapeutic gene bind toxic prevent prognosis example reduction divide divide dose reverse affect affect syndrome le important drug poor allow cpg cpg cpg thus methylation decitabine much much incorporate alter 
0.33@dacogen cancer inhibitor inhibitor use agent aberrantly eisai myelogenous malignancy malignancy functional growth potential md japanese treat expression clinical malignant precursor deacetylation tumor clinically hypermethylation hematologic hematologic treatment may leukaemia certain therapeutic cause apoptosis cell acute arrest occur show company dna histone syndrome sell myelodysplastic gene gene along induce silence methylation decitabine decitabine decitabine disorder activity active azacitidine azacitidine 
1.33@inhibitingdna use information hypomethylating myelodysplastic myelogenous economist chemotherapeutic make treat dna acute syndrome precursor enzyme reduce responsiven routine methylation decitabine decitabine article hypomethylates cell drug leukaemia 
1.33@class class dnmt hypomethylate phase analog azacytidine reactivate growth ijc inhibit refer methylators responsible enzyme thereby tumor tumor block block issue nucleoside cell cell suppressor decitabine decitabine one one mode cytidine cytidine methylating intra drug vol amp dna dna dna dna dna four july lyko function function gene specifically inhibitor synthesis division silence rna stresemann epigenetically action methyltransferase 
1.0@cancer methyltransferases cgis standard specificity dnmt slow agent long hypomethylating newly analog currently malignancy people growth susceptible make inhibit inhibit aza advance irreversibly term inhibitor leukemia inherent myeloid tumor tumor tumor mechanism paper normal lack hypermethylation hematologic nucleoside treatment trial secondary example suppressor dependent subtypes indicate combination md novo cell myelodysplastic acute solid subsequent chemotherapy dna dna however histone bind syndrome act dnmts gene aml effect deoxycytidine deacetylase lung replicate go decitabine decitabine decitabine incorporate action de 
1.33@cancer cancer cancer cancer myeloid faster progress use abrupting phase process myelodysplastic frequently leukemia might transferase precisely unknown irreversibly body inhibitor impact mechanism normal hypermethylation decibaine much methylation cell cell cell cell cell removal methyl dependent hematopoetic mytotic structure precise particulary tumorous cycle cycle mean see anti bind occur dna dna divide divide acute cytidine syndrome act dnmts dnmts still average effect highest similar due thus actively decitabine incorporate active action action 
2.0@reduce reduce identify promote island island island include agent describe describe demethylated epigenomic theoretically anti anti inhibit suppress suppress class dna dna dna dna epigenetic inhibitor belong demethylating gene gene resume effect effect tumor tumor tumor tumor impact thus methylation methylation methylation decitabine decitabine decitabine decitabine cpg cpg cpg methyltransferase expression 
1.67@cancer cancer cancer impact growth growth mode tumour slow could instablity dnmti hypomethylation hypomethylation element increase increase transferase inhibit nuleoside addition lead lead lead lead igf irreversibly help responsible way reduce may factor factor many cell cell cell removal methyl expression expression suppressor dependent also promote imprint replication replication analogue mainintaing apoptosis repetitive become type genomic treatment dna dna dna divide inhibitory bind dnmts dnmts gene gene rapidly inhibitor remove remove global death silence methylation methylation methylation decitabine decitabine mitosis incorporate active action action follow progression 
1.33@dna cancer cancer effect hypermethylation demethylating gene reduce reduce tumor agent result inactivation cpg turn decitabine growth cell cell island suppress suppress 
2.0@suppressor dependent instead therefore mission tumour tumour tumour carry structure agent agent cure cytosine cytosine hypomethylation promoter inhibit lead dna dna dna dna dna dna irreversibly bind bind enzyme demethylating gene chemical similar hypermethylation decitabine decitabine hematopoietic incorporate methyltransferase methyltransferase 
2.0@et cancer cancer cancer proliferate proliferate growth term dnmt decline yet slow include could long considerably analog since since sharma hypomethylation surface heritable inhibit inhibit previously epigenetic concern onto enzyme activation tumor tumor raise normal concurrently genome nucleoside ensue al cell cell cell cell cell cell drug drug drug drug belong suppressor get get concentration replication succeed decitabine target result demethylated free like methylation occur particular acceptable dna dna dna dna dna divide dose bind consequence risk dnmts dnmts gene rapidly effect division silence actively follow incorporate restriction adverse 
1.67@class class medication activate kinase state rib hypomethylating azacytidine reactivate vulnerable make overall overall transferase nucleotide previously recognize level enzyme derive tumor tumor drop normal routine molecule substrate repressor prodrugs may may eoside substitute specifically lower successfully via replication replication analogue structure result cytosine cytosine chemotherapeutic become type methyl obtain group genomic oxy treatment dna dna dna dna dna deoxy reaction name drug drug time deoxycytidine nitrogen belong belong silence methylation methylation methylation decitabine decitabine gene incorporate incorporate complete de 
2.0@cancer methyltransferases hypomethylation use use add add since change change inhibit molecule expression epigenetic allow grow enhance reduce reduce tumor tumor tumor hypermethylation hypermethylation usually like cell cell methyl supressor one suppressor also antimetabolite drug drug cause cause cause cause cause could histone environment environment group dna dna dna dna divide surround cytotoxic chemotherapy act act inhibitor gene gene gene chemical effect effect protein similiar silence methylation methylation decitabine decitabine decitabine work incorporate incorporate influence death rapidly rather 
2.0@heavy along depend covalently tumour tumour mostly agent course effect anti call dna dna dna dna dna dna get level bind inhibitor enzyme demethylating methyltransferase methyltransferase reduce permanently methylation methylation decitabine incorporate come cell replication 
2.0@heavy cancer slow class drug drug analogue agent cause myelodysplastic specifaclly island synonymous division dna dna divide action syndrome act hypermethylation cpg time rapidly inhibitor particular belong decitabine nucleoside disruption demethylation cell cell methyltransferase genomic progression 
1.0@dna cancer form overmethylation methyl reduce block block cell result methylation decitabine hypomethylation effect activity modify transferase drug 
1.33@cancer effect effect devision dnmt dnmt tumour likely process two de rate generation hemimethylated hemimethylated inhibit job epigenetic epigenetic strand strand strand methylated methylated methylated firstly twofold consequently longer block affect maintain maintain cell cell cell cell cell cell cell much seperate one reason faster become become therefore status alteration cause normal anti successive mitotis dna dna dna mark mark mark reverse bind dnmts dnmts hence methyltransferase inhibitor inhibitor preferentially secondly replicate replicate work methylation methylation methylation decitabine decitabine decitabine daughter create lay undergo attract symmetrically 
1.0@dacogen cancer cancer stronger dnmt use dependent eisai myelogenous strand precursor inhibitor inhibitor impact normal normal usually name japanese leukaemia faster divide necessary replication replication analogue cell cell cell cell cell cell company dna dna dna get acute bind syndrome sell myelodysplastic aml nuceotide upon copy division replicate since methylation decitabine decitabine decitabine daughter incorporate methyltransferase methyltransferase nusceloside 
1.33@cancer size dnmt dnmt methyl state likely analog since since dnmti dnmti growth decrease inhibit irreversibly latter pass refer demethylating effective effective tumor tumor tumor affect may nucleoside cell cell cell cell cell cell replication transferase profile general require whether mean lecture prevent dna dna dna divide bind point inhibitor drug current effect unclear copy keep division methylation methylation decitabine daughter work incorporate rapidly 
1.67@specifically specifically could could reduce suppressor suppressor adna methyl cause agent since dnmti effect anti hypermethylated transferase island cpg dna tumorigenesis silence demethylating inhibit inhibitor tumor tumor tumor tumor tumor tumor hypermethylation methylation decitabine decitabine decitabine drive gene gene cell 
2.0@cancer inhibitor class class western western dnmt activate may myelodysplastic probably md md md exert lead lead irreversibly effective effective tumor tumor tumor tumor mechanism normal besides hypermethylation nucleoside behave cell cell cell replication decitabine decitabine decitabine decitabine decitabine suppressor suppressor dependent patient therefore drug drug certain whether extent low anti anti experience dna dna dna dna dna dna dna divide divide dose reverse bind syndrome dnmts gene gene rapidly effect effect analog demethylation demethylation demethylation demethylation demethylation believe silence due expect drive incorporate administration action methyltransferase 
1.33@cancer inhibitor patient tumour cause fda could myelodysplastic currently malignancy anti clinal dna dna divide divide dose help syndrome well rapidly effect affect demethylationwhen since decitabine approve cell cell cell trial methyltransferase small 
2.0@different mean cancer cancer nuber lymphoma dnmt progress methyl mostly soid currently currently malignancy part md approve might transferase island treat unknown epigenetic strand methylate well enzyme treatmnet tumor tumor mechanism test ireversibly supressors nucleoside demethylation cell cell use one hemathological fda drug drug analogue suppose exact type chain dna dna divide four bind act cpg aml inhibitor inhibitor dependant replicate selective decitabine decitabine incorporate come active action leukemyas 
2.0@cancer cancer methyltransferases class term dnmt dnmt check yet agent long cannot reactivate growth unmethylated hypermethylated treat hemimethylated inhibit suppress suppress suppresser irreversibly strand call help silence demethylating inactive dilute release cell cell cell tumour tumour tumour tumour epigenetic epigenetic replication loss result effect normally normally occur know dna dna dna dna dna dna divide bind bind bind point use use dnmts dnmts dnmts drug gene gene rapidly rapidly inhibitor keep belong replicate since methylation methylation methylation decitabine decitabine decitabine decitabine incorporate 
1.33@lock abnormal dnmt dnmt agent mark mark mark mark find de layer useful correspond irreversibly methylate methylated well enzyme tumor tumor replicate thus genome nucleoside potent case often methylating epigenetic epigenetic drug drug drug drug could type treatment dna dna dna dna dna dna divide cell cell cell bind bind analouge remove remove methyltransferase combine longer since since decitabine decitabine decitabine method work incorporate incorporate incorporate rapidly would 
1.67@market suppressor suppressor drug abnormal uncontrolled slow agent stop myelodysplastic result currently cancerous reactivate growth growth hypermethylated treat demethylation dna dna epigenetic tumour tumour tumour methylated syndrome precursor demethylating demethylating gene gene gene gene normal silence myelogenous decitabine work acute active cell cell use leukaemia 
2.0@specifically cancer impact restore therefore maintenance dna dna dna progress island include agent specific accord myelodysplastic methylization application inhibit inhibit apotosi greatest hallmark converion action bind syndrome faa enzyme demethylating observe methyltransferase functionality mechanism cellular normal cpg drugbank decitabine decitabine decitabine decitabine incorporate triphosphate approve cell cell cell cycle cycle aml 
1.33@epigenetic cancer cancer class belong demethylating grow methyl state remove remove agent stop mark hypermethylation thus methylation decitabine change know group drug common 
1.67@elod elod plastic plastic inhibitor class dnmt dnmt supression supression use agent myelogenous treat island expression irreversibly precursor demethylating demethylating adna tumor tumor tumor mechanism block affect neoplastic hypermethylation nucleoside demethylation demethylation cell drug leukaemia dna dna dependent dependent therefore replication replication analogue activity acute y y anti reason reverse bind syndrome syndrome dnmts cpg gene gene effect induce silence silence decitabine decitabine mainly incorporate enable 
2.0@cancer cancer cancer cannot think class dnmt dnmt produce methyl since call effectiveness irreversibly strand transferase responsible human effective tumor tumor divide release nucleoside nucleoside cell cell cell cell cell copy belong suppressor dependent therefore maintenance drug drug drug drug drug analogue healthy effect anti dna dna dna get bind bind act gene gene rapidly inhibitor along division division division methylation methylation decitabine daughter incorporate come supressor 
2.0@inhibitor class reactivation produce induce blood link condition myelogenous silence hypomethylation leukemia useful treat marrow hypothemylation antitumour particularly dna dna case acute syndrome precursor contribute ezh gene methyltransferase effect tumor deform belong turn thus decitabine decitabine bone epigenetically cell myelodysplatic supressor 
1.33@enzymatic could inhibitor suppresor methylates way work ability hypomethylating currently dnmti supress know inhibit inhibit though dna dna dna dna exactly think ezh gene methyltransferase methyltransferase effect tumor block thus methylation decitabine decitabine decitabine general drug nucleosomes yet 
0.0@epigenetic result histone act tumor drug decrease inhibit enzme deacetylase 
1.67@cancer cancer cancer inhibitor inhibition disrupt uncontrolled agent pdf hypomethylation useful assignment class epigenetic write among display responsible belong demethylating chromosome stimulate mechanism block hypermethylation signal signal cell cell may blockage decitabine decitabine one one dna dna dna dna dna dna become promote therefore status drug decitabines anti type know several several important important gene methyltransferase effect effect growth growth upstream division interfere thus thus methylation methyltraferase region action action accelerate 
1.67@dacogen cancer cancer cancer produce produce uncontrolled agent essai myelodysplastic myelogenous growth oncogene oncogene treat back promote proto japanese demethylating demethylating tumor tumor normal usually aberrant name lead use leukaemia suppressor tsgs tsgs drug drug could cell condition case anti anti act company dna dna dna dna modulate acute syndrome overexpression function time hence expression remove remove result result result thereby brand silence methylation methylation methylation methylation decitabine decitabine decitabine decitabine gene activity activity return action 
2.0@cytosine relate tumour tumour tumour pression deaththat stop incorporate pro reactivate reactivate trigger ion inhibit dna dna lifer establish expression gene gene analog normal death silence decitabine nucleoside eventually eventually like cell cell cell methylationwhen protein 
2.0@cancer methyltransferases inhibition inhibition prolifirating reactivation dna dna dna use fda agent agent myelodysplastic analog toxicity possibly seem tumour tumour affect affect consecuently lead sequence well concern demethylating proliferation due deviding conventional conentration side primarily cell cell tolerate tra tra higher suppressor cytidine lower nucleoside depend fewer drug drug drug target exact fully group treatment treatment compare dose syndrome gene demethylaton characterise cellular mechanims belong ti decitabine decitabine decitabine hence incorporate approve action rapidly 
1.0@cancer transfer identify class dnmt dnmt cytocine tumour die anti describe describe number effect become methyl call group dna dna dna dna epigenetic inhibitor inhibitor function drug inhibit inhibit inhibit methyltransferase impact severy affect belong belong replicate methylation methylation methylation decitabine decitabine decitabine nucleoside unstable cell cell analoges 
1.67@supresor inhibitor inhibitor restore restore reactivation methyl appear agent process inhibit dnmti growth might might locus lead epigenetic sequence silence demethylating island tumor tumor tumor intracellularly normal contribute convert triphosphate demethylation demethylation demethylation cell control suppressor suppressor enzime therapeutic target promoter group treatmentthere example dna dna dna dna dna mediate function cpg gene gene gene gene gene methyltransferase methyltransferase effect remove belong thus methylation decitabine decitabine decitabine decitabine decitabine decitabine observe incorporate pacients class 
1.33@cancer cancer cancer cancer methyltransferases growth medication use myelodysplastic deoxynucleoside deoxynucleoside substance genetic genetic treat marrow fundamental lead class methyltransferaseinhibitors call component responsible enzyme bone block block block convert triphosphate cell cell cell blood belong cytidine cytidine certain promote spread analogue development activity body body type tumour dna dna dna syndrome dnmts dnmts similar death division interfere material material decitabine decitabine decitabine decitabine decitabine decitabine em incorporate active progression 
1.0@dna dna cancer cancer cancer either patient patient therefore suppressor use use leukemia agent subsequent find encourage demethylate treat show solid treatment lung better help decrease expression demethylating gene single inhibitor tumor tumor tumor deacetylase ul ul demethylators reaction cell withhistone would decitabine decitabine 
2.0@suppressor cancer methyltransferases dnmt synthesize tumour tumour agent newly fast effect anti drug specially prevent addition dna dna dna strand avoid act allow demethylating inhibit rate activation mechanism silence silence thus molecule gene gene mean cell methyl replication decitabine decitabine 
2.0@cancer cancer methyltransferases specifically uncontrolled inhibitor agent stop silence since since since since dnmti dnmti dnmti growth hypermethylated affect dna dna dna dna dna dna dna dna dna irreversibly methylate responsible enzyme enzyme demethylating reduce reduce tumor tumor intergenic block normal hypermethylation release nucleoside case cell cell cell cell tumour decitabine decitabine decitabine decitabine decitabine decitabine suppressor suppressor dependent cause cause run therefore therefore cannot replication analogue function incorporate moreover like anti methyl hypomethylated reduction divide region bind lay act act dnmts dnmts dnmts gene gene gene rather effect upon fe must repeat division rase methylation methylation methylation methylation allow hence work mean rapidly 
0.67@interaction cancer cancer cancer cancer cancer cancer cancer cancer characteristic term promotion supression may may may may may likely specific island andthus find hyper hypomethylation normally useful instability decrease decrease locus lead lead lead lead see disease inactive tumor tumor particular particular oftransposons hypermethylation hypermethylation genome imprint role hypo genomic expression expression suppressor suppressor dependent general region frequent md activity loss specifictumor shore element via promoter biology dna however cell cell demethylase positive gene gene effect effect result result progression increase increase increase cpg cpg thus thus methylation decitabine decitabine wide another play associate 
1.33@cancer classify dnmt dnmt use chemically agent mark myelodysplastic analog back luckily irreversibly strand methylated allow demethylating mitoticheritability normal feature nucleoside nucleoside maintain cell cell cell cell process blockage specifically get syndrome therapy novo novo mean prevent epiphenotype treatment dna dna dna divide moment typical inhibitor actuate patron effect join replicate new methylation methylation decitabine decitabine daughter incorporate would 
2.0@clear reason cancer methyltransferases inhibition dnmt dnmt use analogue mean mean cause cause myelodysplastic myelodysplastic entirely hypomethylation hypomethylation demonstrate island nucleotide treatment dna dna dna dna dependence development bind syndrome syndrome syndrome cpg effective interfere block hypermethylation due decitabine decitabine decitabine decitabine decitabine possible incorporate lead 
2.0@different cancer cancer cancer effect effect dnmt methyl inhibitor agent myelodysplastic myelodysplastic easily easily since malignancy dnmti growth leukemia sit might transferase suppress molecule irreversibly nonspecific get precursor demethylating effective tumor tumor neoplastic hypermethylation divide nucleoside regulator drug cell cell use suppressor dependent lower high epigenetic relate replication replication analogue cause toxic target target result kill anti type severe approve dna dna dna dna however dose dose acute bind syndrome act thus cpg gene aml myelogenous demethylation belong find actively decitabine decitabine much incorporate active blood side enzymatic small 
1.67@cancer cancer cancer methyltransferases dnmt encounter methyl process analog analog instead authentic apply part treat inhibit irreversibly strand strand methylate consequence hypomethylated effective effective hypermethylation nucleoside nucleoside like like like cell cell cell cell insert divide answer information case lecture group treatment dna dna dna dna dna dna dna dna mark base bind epigenetic dnmts rapidly along increase division division replicate replicate new new new decitabine decitabine decitabine decitabine decitabine come chemical chemical would would 
1.0@one mean cancer inhibitor inhibitor dnmt dnmt need dependent irreversibly body replication replication halt copy inhibit nucleotide dna dna dna dna dna divide strand cell cell cell bind bind methyltransferase methyltransferase methyltransferase methyltransferase division severely rapidly along upon longer affect belong replicate replicate methylation release daughter incorporate come action much decitabine decitabine 
2.0@loss methyltransferases inhibition dnmt dnmt use state could mark mark mark myelodysplastic analog generation generation generation enzimes inhibit inhibit nucleotide lead phenotype epigenetic epigenetic methylate display responsible tumor tumor block contribute go genome genome next next way tra stabilize get drug syndrome prior wont introduce methyl methyl group treatment dna dna dna dna maintenance cell cell bind mediate fe effect rase methylation decitabine decitabine therapeutical action delete 
2.0@cancer cancer cancer inhibition methyl state agent agent stop switch charge since growth characterize back island island island status status demethylating demethylating uncontrolled feature demethylation cell cell cell tumour tra one cause base base epigenetic drug drug caner non non ability demethylated bring demethylate antitumor family treatment dna dna dna dna therefor nameddna suitable cpg cpg cpg overproliferating effect effect fe increase belong rase methylation methylation methylation decitabine decitabine gene gene supressor 
2.0@suppressor inhibition restore oncogenic drug apoptosis pro tumorigenic susceptible anti treatment dna dna reverse sensitivity methyltransferase inhibitor tumor tumor death hypermethylation methylation proliferative render gene cell control decitabine decitabine 
2.0@decline critical restore overmethylation formation use use myelodysplastic similarly cytotoxicity hypomethylation hypomethylation leukemia treat inhibit inhibit inhibit adduct amount rapidly strand strand inhibitor dramatically reduce tumor tumor tumor normal normal neoplastic hypermethylation may may although proliferation proliferation cell cell cell cell control attribuited supressor find also also drug drug cause decitabine decitabine decitabine decitabine decitabine decitabine decitabine apoptosis result acute dicitabine anti methyl nearby group syndrome dna dna dna dna dna dna dna dna dna divide histone histone histone covalent act function gene gene aml effect effect induce methyltransferase methyltransferase methyltransferase cellular cellular antineoplastic silence myelogenous methylation methylation rna incorporate incorporate incorporate azacitidine azacitidine differentiation differentiation attach apparent 
2.0@mitotically methyltransferases class within dnmt tho agent mark heritable hemimethylated island nucleotide cytosine methylate methylated particularly enzyme demethylating adna block di express replication suppressor un need mitosis nucelotides effect anti occur promoter tumour tumour dna dna dna maintain act cpg cpg cpg gene gene methyltransferase inhibitor inhibitor methylation decitabine region action would 
2.0@different cancer cancer cancer proliferate use state fda add add suspect myelodysplastic analog change incorporation island molecule cytosine involve inhibitor attack thereby tumor pattern normal hypermethylation anticancer contribute cell cell cell drug drug drug suppressor cytidine activation combination replication viability could could dectabine target target cancerous type traditional level treatment treatment dna dna dna dna base bind syndrome inactivate gene methyltransferase methyltransferase effect place gpc synergistic methylation decitabine decitabine decitabine incorporate approve instance 
2.0@suppressor suppressor cancer methyltransferases growth dnmt dnmt may certain could stop mark analog low de hypomethylation hypermethylated amount improperly prevent nucleotide lead dna dna dna dna dose action methylated variety allow inhibit inhibit reduce tumor tumor tumor inheritance methylation methylation decitabine decitabine decitabine daughter gene gene express many cell cell 
2.0@suppressor cancer cause tsgs dnmt dnmt dnmt inherit lock place proper replace allow part hypermethylated decitiabine inhibit charge achieve dna dna pass methylated bind inhibitor function gene methyltransferase effect tumor pattern pattern block first hypermethylation effectively genome daughter daughter daughter daughter methylation methylation read active cell cell cell cell try decitabine decitabine 
1.67@faster cancer cancer cancer rate higher demethylates dnmt remove use use agent specific specific scale myelodysplastic myelogenous leukemia treat affect inhibit inhibit latter methylate repression inhibitor inhibitor demethylating island decitibine normal normal neoplastic precursor apoptotic go although cell cell cell cell may region dna dna dna dna dependent certain certain bond therefore activation replication cause acute kill kill consequently antitumor action reason divide divide dont bind syndrome dnmts dnmts cpg gene gene rapidly effect effect upon believe believe since decitabine decitabine decitabine decitabine decitabine irreversible incorporate instance duplication enable enzymatic 
1.33@dna therefore myelodisplasic bind syndrome inhibitor dnmts still irreversible replication dnmt fda mechanism analogue depent decitabine nucleoside incorporate unclear approve action 
2.0@tumour cause suppression part promoter island treatment dna dna methylate syndrome allow cpg gene methyltransferase inhibitor silence myelodysplastic rna region activity demethylation use decitabine decitabine decitabine 
1.67@cancer effect class dnmt dnmt dnmt much methyl stop process since dnmti dnmti growth might inhibit nucleotide often strand belong tumor affect nucleoside cell cell cell ade faster transfer depend daugther replication replication replication analogue healthy embed particular dna dna dna dna dna divide bind act act irreversible methyltransferase inhibitor copy copy division longer thus thus methylation methylation decitabine decitabine decitabine possible arrive 
2.0@cant class dnmt dnmt formation may agent stop de growth growth possibly island lead irreversibly methylated inhibit inhibit inhibit tumor tumor tumor tumor mechanism release cell cell cell uncontrolled uncontrolled one suppressor suppressor methylating promote epigenetic replication replication incorporate promoter though dna dna dna dna tumorigenesis bind bind expression expression cpg gene gene continue inhibitor belong methylation methylation decitabine decitabine decitabine daughter region lay action heavily 
2.0@cancer critical activate epigenetically way manner agent characteristic malignancy generation inhibit inhibit suppress regulate malignant methylate lose common enzyme enzyme enzyme enter island proliferation tumor tumor dmt dmt opportunity hypermethylation hypermethylation contribute cell cell cell methyl decitabine decitabine suppressor require strand apoptosis result normally successive dna dna greatly act cpg gene gene gene allow remove remove control demethylating silence silence group daughter mitosis perhaps active passively 
2.0@cancer myeloid dnmt dnmt use hematological prove nucleic analog analog malignancy hypomethylation leukemia myelodisplastic recognize irreversibly particularly inhibitor source research tumor clinically feature hypermethylation nucleoside aberrant cell cell replication deplete supressor acid cytidine effective therefore point substrate decitabine another result antimetabolite group worthy treatment dna get acute bind syndrome act target gene enzyme induce belong silence rna incorporate 
1.33@cancer effect class intercalate dnmt dnmt dnmt methyl methyl agent hypomethylating bring anti transferase transferase inhibit dna dna dna dna dna dna bind bind allow allow thereby gene inhibitor tumor belong silence methylation decitabine decitabine cell expression 
2.0@cancer class dnmt use state agent myelodysplastic analog since since reactivate leukemia back affect island treat irreversibly neighboringcancer precursor silence silence demethylating normal normal hypermethylation islandscan nucleoside demethylation cell cell incorporate suppressor dna dna bereverted moiety epigenetic replication suppression result become know hypomethylated reduction divide acute bind syndrome act dnmts cpg gene gene inhibitor inhibitor preferentially consequent belong myelogenous decitabine decitabine decitabine decitabine activity methylating frequently 
1.67@saft reduce islandswith therefore dnmt inhibitor could correct myelogenous itbinds isused suppress dna dna area acute precursor hypermethylation still methyltransferase research tumor mechanism er cpg belong methylation decitabine incorporate treatthe active action leukaemia 
2.0@mitotically cancer cancer cancer cancer inhibitor able produce methyl include transfrease make tsg tsg might decrease explain lead epigenetic know know hyper hypo hypo mechanism better better inactive inactive neoplastic give role cell cell cell cell global one tsgs get need first agent potent describe paradoxical anti promoter promoter amp dna dna dna dna dna dna understand mtase mtase bind bind act use function drug irreversible hence hence hence enzyme remove control silence methylation methylation methylation methylation methylation decitabine decitabine decitabine pathology gene incorporate selectivity active activate 
0.67@class way agent prolific apoptosis methalation methalation methalation result result result hypomethlation anti regulatory inhibit emulate dna dna divide sequence especially rapidly effect effect tumor methyltransferase interfere interfere decitabine decitabine demethylation cell drug 
0.67@cancer cancer effect dnmt dnmt activate use agent specific specific myelodysplastic analog transfer hypomethylates hypomethylation affect inhibit inhibit nucleotide epigenetic strand copy division demethylating reduce longer good release high side demethylation cell cell cell cell however replication decitabine malignance cytidine also irreversibly need cause stability dose dose likely result low without methyl toxic genomic syndrome dna dna dna dna dna dna dna divide non kill bind bind example function dependence gene methyltransferase methyltransferase inhibitor upon along quickly replicate replicate methylation haematological daughter incorporate come action modifier bound 
2.0@one suppressor suppressor cancer cancer cancer state abnormal cause cause agent inhibitin characteristic might especially island cpg hypemethylation prevent prevent prevent dna dna dna dna methylated allow demethylating inhibit methyltransferase methyltransferase tumor tumor amount demethylation hypermethylation silence decitabine gene gene gene many cell cell genomer 
1.33@cancer inhibition restore use fda ribonucleosides myelodysplastic myelodysplastic analog hypomethylation class class proliferation dezocitidine normal normal convert crucial nucleoside insensitive triphosphate lead lead triazine may may etc tid cytidine cytidine transcription subtypes antimetabolite replication msonormal decitabine decitabine decitabine zad ribnucleotides relatively british american present oxy treatment dna dna dna dna apoptosis therefor cell cell cell synonym syndrome syndrome function drug gene chemical cellular belong rna rna azadc french incorporate approve differentiation differentiation methyltransferase 
2.0@cancer methylating methylating dnmt progress replication replication analogue dependent myelodysplastic fast myelogenous de bind affect whereas action action treatment dna dna irreversibly acute cytidine syndrome usefull inhibitor inhibit methyltransferase effect normal afterwards replicate principally decitabine decitabine fewer incorporate cell cell 
1.67@market suppressor cancer inhibitor higher epigenetically use cause dependent already myelodysplastic analog constantly reactivate hypomethylation hypomethylation normally anti bind tumour transferase inhibit dna dna dna epigenetic covalently cytidine syndrome precursor ncbi ncbi drug gene methyltransferase effect effect effect tumor accord accord division due decitabine decitabine decitabine region region many cell cell cell methyl replication leukaemia 
1.67@suppressor suppressor cancer transfer inhibition tumour tumour tumour tumour tumour metylation anti ace methyl promoter island suppress suppress suppresser dna dna dna towards kind kind le inhibitor drug gene effect enable cpg act methylation decitabine decitabine drive case active cell cell cell use 
1.67@suppressor suppressor cancer cancer methyltransferases methyltransferases class class activate drug include hence overgrowth relatively lower reduction inhibit dna dna substantial surround consequence gene gene gene proliferation inhibitor tumor tumor tumor tumor result result suggest belong silence methylation methylation genome ensue case methyltransferase decitabine 
2.0@cancer toxicity disrupt determine dnmt regulation methyl prove already myelodysplastic methyltransferases hypomethylation catalyse lead open epigenetic speed rapidly help differential disease either take myeloid pattern pattern pattern affect blood epigenome genome bond expression expression attachment cell cell cell cell cell may leukaemia correct effective patient depend decitabine decitabine need certain structure healthy toxic apoptosis highly acute cancerous present replication bind nucleosomes level group family syndrome dna dna dna divide mark histone careful covalent dnmts dnmts drug irreversible chemical inhibitor induce place chromatin death division thus methylation allow allow gene class dosage form incorrect protein 
1.33@cancer inhibitor inhibitor term progress use fda long really two analog say leukemia dosis dosis affect treat irreversibly body know demethylating myeloid tumor mechanism normal neoplastic myeodysplastic release nucleoside demethylation cell cell cell cell methyl methyl kill one dependent transfer transfer get replication drug acute low low anti anti show furthermore good dna dna dna dna dna divide action action bind syndrome act still rapidly effect effect effect effect unclear range division longer thus decitabine much incorporate upon approve tumoral would recently 
1.67@heavy dependent methylating devision depend suppressor presumably drug drug cause suppression since de de proliferate primarily class dna dna often highly poor target tumor tumor tumor mean prognosis due methylation methylation methylation decitabine transcription gene correlate active cell cell 
1.67@dna dna dna dna irreversibly impact bind act inhibitor demethylating methyl methyl effect agent neoplastic belong anti nucleoside incorporate transferase transferase decitabine decitabine 
1.67@cancer cancer cancer cancer cannot way manner remodelling without characterize methyltransferases malignancy dnmti change imputation generation effectively grow nucleotide maternal epigenetic epigenetic epigenetic methylate methylated methylated inhibitor cellswill proliferation reduce reduce hypermethylation consequently new dilute proliferative regularization hem hem cell cell cell cell cell cell tumour dependent irreversibly candidate drug analogue therapy passive highly result stop methyltransfera methylation methylation methylation prevent prevent good treatment dna dna dna dna dna dna kill bind integrate act function methyltransferase effect status similar pre division division since regional decitabine decitabine decitabine sensitive action todecitabine 
1.0@cause abnormal class intra dnmt mammalian acytidine analogue agent phase hypomethylating activity result result low cytotoxicity hypomethylation hypomethylation potential direct arrest incorporation marrow inhibit dna dna dna dna dna dna dna dna antineoplastic dose dose antimetabolite hematopoietic bone methyltransferase methyltransferase methyltransferase inhibitor mechanism inhibition death belong ul ul high incorporate cell cell replication decitabine decitabine decitabine 
2.0@dna dna dna dna suppressor suppressor inhibitor help demthylating demethylating perform gene methyltransferase methyltransferase reduce agent agent fight silence methylation methylation reactivate hypermethylation type tumour tumour tumour tumour inhibit use decitabine 
2.0@suppressor cancer cancer use agent april epicentre myelodysplastic myelogenous economist leukemia treat grow dna dna acute prevent prevent syndrome precursor demethylating inhibit methyltransferase tumor turn methylation decitabine gene activity th cell 
1.67@mean drug critical decitabinecan restore hypomethylated tumor methyl methyl cause controlof agent ofdna apoptosis cellulardifferentiation hypomethylation anti inhibition exert group group class class dna dna dna dna dna dna dna believe function demethylating inhibit inhibit proliferation effect remove remove word cellular normal neoplastic belong may may may methylation methylation ul ul gene simply cell differentiation methyltransferase inducedhypomethylation decitabine decitabine decitabine decitabine 
1.67@growth unregulated cancer category within within produce activity way agent process major similar substance substance direct call restore restore believe belong demethylating twofold tumor mechanism block normal normal anticancer thus decitabineis regulate regulate control blockage expression one suppressor suppressor suppressor chemotherapy promote antimetabolite antimetabolite drug cause target result number allow become know demethylation demethylation metabolism dna dna dna dna divide cell cell cell cell cell cell cell cell cytotoxic death function gene gene gene gene rapidly effect effect interact cellular increase division division interfere new methylation methylation methylation member work incorporate class 
2.0@cancer methyltransferases methyltransferases methyltransferases within within within effective methyl order order stop silent island island also dnmti dnmti lifespan manageable inhibit lead methylate methylated methylated silence silence group impact tumor tumor tumor tumor tumor grow grow affect dnmtis dnmtis dnmtis mehylation genome serious offspring suppressor suppressor suppressor transfer therefore therefore consequently regular indefinitely cancerous cancerous become become promoter promoter prevent prevent properly dna dna dna dna dna dna dna dna dna dna divide divide cell cell cell cell cell cell bind short gene gene gene gene gene methyltransferase inhibitor must must keep cpg cpg replicate since since since since since methylation decitabine decitabine work active 
2.0@underpin cancer cancer inhibitor dnmt progress way manner selective de potential treat treat decrease subsequently disruption accesible avoid efficient silence liquid proliferation tumor tumor tumor tumor tumor block block myelodisplastic myelodisplastic include high express cell cell control supressor kind dependent lower metastasis therefore cancerigen replication certain dose novo apoptosis harness become nucleus dna dna dna non acute bind syndrome syndrome act dnmts drug drug gene employ division myelogenous methylation methylation methylation decitabine decitabine decitabine decitabine activity sensitive leukaemia progression 
2.0@cancer cancer cancer inactivate activate remove remove may may slow manner could mark since growth rate hypermethylated drug island epigenetic take tumor tumor tumor tumor otherwise like demethylation cell cell cell cell inheritable methyl decitabine decitabine one suppressor suppressor dependent imprint replication replication cause cause anti group example dna dna dna expression expression inhibitor cpg gene gene gene methyltransferase effect advantage increase silence methylation reestablish daughter alter 
1.0@cancer cancer tumor tumor reactivation formation cell cell cell methyl methyl region agent useful growth make amount show island promoter promoter molecule treatment dna dna dna increase around decrease particularly act act suppression suppression demethylating group group allow remove cpg especially methylation methylation decitabine decitabine gene gene lead many expose removal would expression 
2.0@dna dna dna eliminate suppressor suppressor activate drug certain pathway result block growth effect anti inhibit reduction whereby gene gene methyltransferase methyltransferase inhibitor tumor tumor tumor tumor activation neoplastic neoplastic methylation decitabine activity come cell cell cell hence 
2.0@cancer suppressor suppressor methyl methyl could decitabin dmt dmt change hypermethylated generation generation oncogene heritable transferase transferase island island island might next pressor tumor tumor block suppress contribute dilute regain maintain cell cell cell cell control dna dna also dmti imprint normalization itcan occur promoter normalize cpg cpg cpg gene gene inhibitor methylations methylations tumorigenecity thus thus decitabine daughter daughter region activity hypermethylation 
2.0@cancer rate higher class activate use slow agent island myelodysplastic dnmti dnmti theoretically treat affect grow unknown epigenetic know inhibitor inhibitor belong demethylating group demethylates tumor tumor tumor mechanism normal dnmtis hypermethylation high cell cell cell methyl suppressor dependent irreversibly replication replication cause toxic lay low anti nonspecific prevent prevent dna dna dna dna dna dose dose reverse bind syndrome dnmts cpg gene gene rapidly rapidly effect still replicate decitabine decitabine decitabine decitabine incorporate methyltransferase 
0.67@dna suppressor decitabiine todna posibally demethylating gene way tumor tumor agent belong methylation methylation growth cpg inhibit inhibit island suppress 
2.0@maybe alt cancer cannot higher class dnmt dnmt dnmt use use use use concentration cytidine myelodysplastic analog analog hence hence part treat decrease island amount lead irreversibly even transferase wikipedia myeloid tumor tumor mechanism rapidly normal neoplastic nucleoside nucleoside img demethylation cell cell cell methyl leukaemia earlier dependent lower become patient residue divide fda replication replication today toxic methylate reference age anti old solid src hypomethylated figure figure dna dna dna dna dna get acute bind syndrome inhibitor inhibitor affect aml effect globally eg belong decitabine decitabine pg come approve attach attach 
2.0@cancer cancer cancer impact restore dnmt upon tumour hypomethylating malignancy hypomethylation island irreversibly methylated effective affect blood hypermethylation may nucleoside nucleoside read repressor replication neighbour analogue analogue drug cause offer healthy mean mean become dna dna dna dna dna divide mark cell cell cell cell bind inhibitor inhibitor cpg gene rapidly effect remove remove incorrectly silence methylation methylation decitabine decitabine region incorporate incorporate chance methyltransferase methyltransferase 
2.0@epigenitically suppressor cancer transfer synthesize uncontrolled analogue whose newly cytosine methylating meet reactivate growth replication incorporation transferase inhibit job stop dna dna dna dna responsible enzyme inhibitor gene chemical as tumor silence thus decitabine cause mammalian incorporate cell cell methyl 
0.67@dacogen dacogen inhibition dnmt transcriptional transcriptional include agent agent specific specific event event myelogenous silence hypomethylation leukemia md inhibit dna dna dna dna dna dna dna dna dna lead precursor hypermethylation hypermethylation demethylating myeloid tumor tumor expression expression regulation leukemogenesis dac induction significant global suppressor leukaemia multiple turnback indicate decitibine via via require frequent treatement activity trade decrement treatment reduction apoptosis base acute acute syndrome syndrome name myelodysplastic myelodysplastic drug drug myeloblast aml aml effect effect induce methyltransferase methyltransferase human well methylation methylation methylation methylation methylation decitabine gene gene gene gene gene gene gene regulate regulate transcriptome single associate 
1.67@dna act demethylating function cpg cpg gene tumour effect remove agent activate due chromosome methylation methylation supressors part island island drug decitabine 
1.67@inhibitor class reactivation produce tumor blood link induce condition myelogenous silence hypomethylation leukemia useful treat marrow hypothemylation antitumour particularly dna dna acute syndrome precursor contribute deform gene methyltransferase effect epigenetically belong turn thus decitabine decitabine bone case cell myelodysplatic supressor 
2.0@cancer inhibitor inhibitor restore activate methyl could specific significantly goal transcription reactivate hypomethylation hypomethylation part part generation treat decrease decrease researcher cytosine body methylated principal disease tumoral adenosine tumor new methylation say percentage suppressor transfer patient residue need cause sensor anti family dna dna dna dna get drug drug drug gene gene effect effect effect epigenetics combat decitabine decitabine region downstream protein would 
1.33@dysfunctional myeloid methyltransferases regulator class class dnmt use certain agent hypomethylating target analogue also hypomethylates leukemia inhibit epigenetic treatment dna dna dna dna irreversibly blood acute bind syndrome inhibitor dnmts drug drug methyltransferase enzyme condition belong myelodysplastic decitabine decitabine decitabine decitabine nucleoside incorporate case cell aml enzymatic 
1.33@document partner cancer cancer effect effect restore restore within suppressor produce produce methyl leukemia myelodysplastic growth potential direct hypermethylated affect inhibit response lead clinical clinical origin well island twofold myeloid tumor substance normal normal life hypermethylation anticancer approval hdacs metabolism trial increase one compare hypomethylation transcription quality antimetabolite therapeutic drug cause improve md md target acute cytosine number gene bind genomic treatment dna divide domain cell cell cell cell cell cell cytotoxic syndrome function cpg cpg believe rapidly rate demethylation interact cellular control death belong interfere thus methylation methylation decitabine decitabine decitabine work incorporate attract protein recruit 
0.0@drug decitabine good 
2.0@cancer cancer cancer methyltransferases higher restore tumour tumour agent agent specific hypomethylating switch proliferate hypomethylation call addition lead phenotype class strand quickly thereby normal normal inactivation hypermethylation nascent fact nucleoside nucleoside harmful drug suppressor cytidine methylating divide replication analogue analogue analogue non toxic limit recognise slower know prevent properly dna dna dna dna dna dna mark dose cell cell cell cell cell bind function affect rapidly effect effect methyltransferase preferentially unable belong due thus methylation decitabine decitabine decitabine gene incorporate incorporate incorporate protein would associate 
0.67@celgene dacogen cancer leukaemia abnormal bone bone produce use work agent acute form epicentre eisai myelogenous summit japanese treat marrow marrow decitabine company dna kill help syndrome sell sell myelodysplastic demethylating normal precursor jersey new vidaza em cell cell blood azacitidine 
1.67@mean could cannot cannot inhibition dnmt dnmt tumour tumour tumour tumour way azacytidine dnmti growth useful might might transferase transferase suppress irreversibly strand derive decibabine pattern hypermethylation nucleoside maintain cell cell methyl methyl suppressor suppressor cytidine reconstitute daughter therefore replication incorporate incorporate effect analoge analoge dna dna dna dna dna bind act act gene gene inhibitor similar replicate methylation methylation methylation decitabine decitabine decitabine mainly drive lay original 
1.33@cancer cancer cancer inhibitor dnmt dnmt dnmt dnmt dnmt activate use use myelodysplastic analog treat affect inhibit inhibit lead irreversibly strand reversible methylated group tumor tumor normal normal hypermethylation hypermethylation release nucleoside substrate cell cell cell cell cell tumour suppressor suppressor transfer therefore divide replication region region region hemi result anti methyl promoter promoter promoter prevent dna dna dna dna dna dna dna get get bind syndrome gene gene gene rapidly effect epigenetically methylations silence silence longer decitabine decitabine decitabine decitabine decitabine decitabine observe incorporate incorporate action action methyltransferase methyltransferase 
1.33@essence cancer proliferate tumor tumor tumor suppressor suppressor anit use drug drug drug drug agent myelodysplastic result transmit bring generation generation expression expression treat occur naturally dna epigenetic histone methylated syndrome hyper hyper demethylating gene gene effect effect remove suggest prevention silence modification may methylation allow daughter article across across demethylation cell cell cell protein decitabine 
1.33@myc myc myc myc myc cancer transcription transcription growth produce ammount cause cause mouse agent stop overproduce histone myeloma block block block permit permit gene gene gene gene gene gene gene avoid grow chain decitabine decitabine decitabine expression expression expression expression epigenetic among involve involve involve act act inhibitor time proliferation proliferation em tumor jq big normal silence regulator ul ul factor like brd brd cell demethylation demethylation protein protein protein supressor 
1.67@heavy lower lower decibatine decibatine agent myelodysplastic currently characterize overall island island suppress previously dna dna syndrome allow demethylating gene tumor cpg cpg silence methylation methylation methylation decitabine express approve 
1.67@activate tumor tumor tumor drug drug drug cause agent cycle inhibit fuction silence normally treat promoter prevent act regulate dna epigenetic development action syndrome use important thereby group proliferation allow remove hypermethylation new myelodysplastic decitabine decitabine gene gene gene express demethylation cell methyl supressor supressor 
2.0@exclude cancer cancer methyltransferases growth growth growth term suppressor suppressor tumour tumour tumour tumour tumour problematic inhibitor consequence mitotic mitotic myelodysplastic myelogenous dnmti negative treat inhibit inhibit inhibit inhibit act lead irreversibly intensely methylated involve precursor hypermethylation ineffective silence mechanism uncontrolled uncontrolled affect generally feedback additionally nucleoside seem side demethylation cell cell may may leukaemia specifically high depend fight via spread spread analogue retain toxic low reference citation long dna dna dna dna dna however dose dose acute bind syndrome le dnmts unknown unknown gene rather effect effect methyltransferase division division word inheritance inheritance methylation decitabine decitabine decitabine decitabine daughter incorporate active action aml 
2.0@dacogen inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor class class specificity dnmt progress use dnmts fda agent long eisai acetyl myelogenous malignancy dnmti dnmti might treat epigenetic tumour depend enzyme demethylating neoplasmic effective mechanism normal lack hypermethylation hypermethylation myelodysplastic nucleoside like term treatment hdmi suppressor belong dna dna dna dna dna dependent dependent transfer therefore irreversibly disease replication replication analogue acute cell cell cell histone histone histone histone anti bind company act prevent demethylation action action potentially several japanese ase syndrome sell demethylase drug drug gene methyltransferase methyltransferase effect effect hmti deacetylase division division hati decitabine decitabine decitabine decitabine incorporate hdaci approve leukaemia haematological 
2.0@suppressor cancer inhibitor todna restore able sodecitabine oftumor find growth part thedna decrease decrease inhibit dna promoter bind enzyme gene methyltransferase methyltransferase function tumor tumor normal hypermethylation hypermethylation usually suppressorsdecitabine decitabine incorporate cell control level 
1.33@cancer cancer intercalate formation blood cycle hypomethylating decitabe hypomethylation hypomethylation useful fosfoliracin epigenetic epigenetic strand know help bone bone proliferation route normal normal hypermethylation cell cell cell cell cell cell however alteration regulation apoptosis plasma bind covalent maintenance base synthesis cytotoxic act dnmts gene gene gene methyltransferase methyltransferase function cellular antineoplastic antineoplastic belong vitro methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine work classify classify abnormal abnormal restore within produce produce produce concentration agent agent agent agent aberrantly medicine cytotoxicity reactivate change call inhibit inhibit inhibit inhibit treat attribute marrow marrow involve negligible neoplastic bond demethylation demethylation control one destroy antimetabolite antimetabolite wherein drug drug drug drug cause property elimination antitumor promoter metabolism dna dna dna dna dna dna dna dna dna divide chemotherapy important rapidly inhibitor product silence region incorporate incorporate differentiation differentiation protein azacitidine 
2.0@suppressor cancer reduce abnormal therefore dnmt relate could myelodysplastic hypomethylates hypomethylation effective island island lead dna dna dna irreversibly bind syndrome inhibitor cpg cpg gene methyltransferase methyltransferase effect tumor activation hypermethylation hypermethylation thus decitabine decitabine cell 
1.67@cytosine could methyltransferases suppresor suppresor restore able excessive tumour tumour tumour analogue hence newly synthesise since growth inhibit prevent prevent lead dna dna dna dna dna dna irreversibly strand bind inhibitor function function proceed methyltransferase dnmts dnmts normal normal increase formation methylation decitabine decitabine decitabine nucleoside gene gene incorporate cell replication methylating expression 
0.67@decline cancer cancer effect refer overmethylation uncontrolled include mutation whose chromosomal newly currently growth part make breakthrough might call call conceptual surround amount immune culture laboratory treat enzyme ezh ezh take reduce job normal thus place proliferation gsk gsk gsk case justly cell cell cell cell tumour tumour systemare suppressor also indeed appear methylates cause cause crucially histone histone histone stop inhibitor happen methyl lymphomascancers group develop treatment package alongside lot name epigenetics animal gene gene analysis genetics overactive truly protein silence find find unmemorable nearby apparent overactivity attach would dramatically 
2.0@interaction cancer methyltransferases methyltransferases class phosphorylated activate upon may chemically cycle stop inactivation inactivation analog analog reactivate decrease island aza aza lead level thereby dctp dctp tumor cell cell cell repress decitabine decitabine decitabine decitabine suppressor cytidine subset via shore apoptosis encode become among dna dna dna dna dna synthesis dnmts cpg cpg gene gene inhibitor induce death belong thus methylation inside incorporate covalently attach 
1.67@dna dna epigenetic reduce allow class inhibitor inhibitor dnmt gene drug effect hypomethylating belong methylation reactivate anti express tumour tumour inhibit methyltransferase suppressor decitabine decitabine 
2.0@methyltransferases dnmt still relieve state state manner cytidine dinucleotides analog leukemia hypermethylated inhibit molecule methylate inhibitor inhibitor think island island myeloid affect epigenome mode myelodysplastic although small population maintain cell cell cell cell tsg tumour decitabine decitabine decitabine suppressor dependent tsgs replication ability appropriate result cancerous hypomethylated treatment dna dna dna divide non bind syndrome dnmts cpg cpg cpg irreversible aml aml function unclear progression division thus andacute allow gene incorporate dosage approve action haematological recently 
2.0@several cancer hematopoietic abnormal restore suppressor use cause cause agent stop direct low cytotoxicity growth myelogenous treat inhibit expression dna dna dna dose dose acute help syndrome precursor myelodysplastic demethylating gene gene methyltransferase allow uncontrolled silence thus decitabine decitabine high hypomethylates cell cell tumour tumour leukaemia 
1.67@cytidine also inhibition growth lymphoma dnmt dnmt methyl analogue cause cause decitabine decitabine hypomethylation maintance transferase inhibit inhibit inhibit class dna dna dna daughter strand covaletly bind inhibitor death belong replicate methylation directly nucleoside incorporate cell cell replication genome 
0.0@growth unregulated cancer category within within produce activity way agent process member similar substance substance direct call restore restore death belong demethylating twofold tumor block normal normal anticancer thus decitabineis regulate control blockage one suppressor suppressor suppressor promote antimetabolite antimetabolite drug cause target result number gene gene gene become know demethylation demethylation metabolism dna dna dna divide cell cell cell cell cell cell cell cytotoxic chemotherapy function believe rapidly effect effect interact cellular increase division division interfere new methylation methylation allow work incorporate class 
1.67@mean cancer inhibitor inhibition mark disease decrease inhibit disruption disruption treatment dna dna dna dna epigenetic mehtylation consequence establish enzyme group methyltransferase methyltransferase reduce characterise normal lack belong due methylation decitabine decitabine activity lead lead tissue 
2.0@cancer methyltransferases dnmt dnmt categorize may agent mark analog dnmti treat permanently inhibit possess tumour tumour inhibitor inhibitor demethylating severely heritability pattern normal nucleoside cell cell use decitabine decitabine decitabine decitabine specifically dependent irreversibly mitotic pas anti prevent dna dna dna bind bind epigenetic act act function rapidly effect effect division replicate thus methylation methylation longer daughter much much incorporate 
1.67@mean cancer slow therefore action seem require analogue dependent cause highly also chemotherapeutic growth like make type show methyltransferaseinhibitor treatment dna dna dna dna irreversibly lot bind enzyme whichdivide treatable methyltransferase tumor tumor normal division longer methylation release nucleoside incorporate affect demethylation cell cell drug drug decitabine decitabine decitabine 
0.67@elod mitotically drug therefore therefore suppressor decibatine tumour tumour carry agent mark mark y growth halt nearby group group group heritable lead dna epigenetic epigenetic syndrome act act enzyme demethylating gene gene plastic additional remove later division silence decitabine daughter work work work lay express cell cell cell removal methyl methyl methyl onto expression 
2.0@demethylate cancer cannot class dnmt methionine epigenetically use include sam anti anti also reactivate leave leave leave leave treat transferase inhibit inhibit aza cytosine epigenetic ade know methylated methylated certain silence inhibitor inhibitor island precursor nosy style style style style nucleoside align align align align demethylation methyl methyl leukaemia suppressor cytidine transfer action decitabine decitabine decitabine seem drug drug analogue analogue hemi text text text text apoptosis condition demethylated become promoter group tumour tumour tumour dna dna dna dna dna process acute syndrome act myelodysplastic cpg cpg cpg gene methyltransferase methyltransferase methyltransferase effect effect induce deoxycytidine belong myelogenous dinucleotides position mitosis precancerous cpgs modifier azacitidine azacitidine 
2.0@suppressor transfer nucleoside nucleoside tumour tumour meet reactivate effect anti methyltransferasescan level island dna dna dna dna dna irreversibly strand methylate bind bind bind bind inhibitor cpg itmaydecrease as division longer thus thus methylation methylation methylation reduce daughter gene cell replication decitabine decitabine 
2.0@cancer methyltransferases higher growth enzymatic activate mediator island every include loss specific specific regard de hypomethylation rate rate sit demethylation locus epigenetic inappropriately regulator responsible consequence inhibit inhibit effective tumor tumor tumor tumor tumor experience experience hypermethylation hypermethylation genome instability icrs passive cell cell cell cell removal rapid suppressor suppressor dependent cause promote permanantly imprint replication function shore novo target result maintanence anti methylated demethylator genomic dna dna dna dna dna dna however non bind example example act act act dnmts dnmts cpg gene gene gene resume effect relevant division due well methylation methylation methylation decitabine decitabine decitabine decitabine wide context 
1.67@suppressor cancer methylating methylating patient aptosis may agent know offer mean cancerous reactivate exact change better prognosis class promoter help chemotherapy inhibitor tissue reduce tumor mechanism increase belong new methylation decitabine although region activity cell cell drug drug would de de 
2.0@cancer instead class progress tumour fda agent stop event dnmti treat grow act act epigenetic inhibitor demethylating myeloid epigenome rely thus myelodysplastic demethylation cell drug market dependent therefore irreversibly replication cause actually purpose focus therapy anti anti good dna dna dna dna get acute bind syndrome sell dnmts effect effect range belong epigenetics decitabine decitabine mitosis incorporate approve kill neoplaisc 
1.67@reduction cancer cancer methylating class suppressor drug cause agent could could could slow result result result reverse de growth might decrease island antitumor previously dna dna dna dna know expression cpg gene gene effect tumor tumor silence demethylated methylation methylation methylation decitabine decitabine cell promoter supressor 
1.67@rase rase transfer greater arise irreversibly upon much much dependent anti analog member sit inhibition tumour prevent methyltransferase molecule disrupt dna dna dna dna dna dna dna divide divide cell cell bind epigenetic act inhibitor inhibitor group rapidly rapidly effect effect tumor fe fe normal contain go methylation decitabine decitabine decitabine nucleoside incorporate le tra tra methyl methyl methyl replication replication class 
2.0@cancer inactivate category specificity dnmt dnmt dnmt methyl semi since dnmti tumour transferase molecule molecule never epigenetic strand strand decrease methylated enzyme order tumor pattern affect lack release methylation methylation methylation cell cell way decitabine decitabine decitabine decitabine specifically large rat divide replication analogue analogue healthy result methylate fade anti dna dna dna dna dna however dose dose bind bind act use use inhibitor inhibitor inhibitor drug drug continue effect sustain division thus sort double daughter incorporate noucleotide noucleotide small small 
2.0@unregulated cancer inhibitor restore restore within produce way exhibit process disease myelogenous myelogenous growth growth leukemia leukemia regulate cytosine malignant sequence antimetabolite belong twofold tumor substance block normal normal anticancer thus myelodysplastic second demethylation demethylation cell cell cell cell methyl blockage one one suppressor suppressor residue seem acute chronic property result low success become antitumor show group promoter promoter dna dna dna dose inhibitory category syndrome act act function gene gene gene effect remove similar control increase division division interfere focus methylation methylation methylation decitabine decitabine decitabine activity first 
1.67@loss inhibitor insert person dnmt dnmt myelodysplastic methyl ability decitabine mark mark proper analog analog decitabane transferase prevent nucleotide nucleotide lead dna dna irreversibly form bind syndrome newly cpg island chromosome chromosome chromosome along tumor time copy division methylation methylation methylation parental daughter daughter gene come cell cell may reestablish supressor 
1.0@kind lower todna depend seem use cause strand dnmti anti nucleotide copy good decitabinegets dna dna dna dna irreversibly dose dose action bind bind bind inhibitor belong dgus methyltransferase methyltransferase methyltransferase effect upon longer along along neoplastic division replicate methylation methylation release daughter incorporate come come cell cell much replication decitabine decitabine 
0.33@dna dna dna epigenetic inhibitor identify class belong belong methyltransferase impact agent hypomethylating inactivation describe describe decitabine decitabine decitabine decitabine anti tumour 
1.0@cancer methyltransferases restore restore within within produce use process two hypomethylates treatment substance substance potential direct call inhibit inhibit category believe malignant silence tumor normal normal anticancer myelodysplastic gene gene decitabineis metabolism way one suppressor antimetabolite antimetabolite cause md apoptosis cell cell cell cell cell cell target number deacetylases hypomethylated demethylation demethylation chemotherapy dna dna dna dna divide histone cytotoxic syndrome function fold rapidly effect effect induce interact cellular control death belong interfere thus methylation decitabine decitabine work incorporate similar differentiation reactivate 
2.0@cancer inhibitor inhibition dnmt tumour tumour tumour become replace since dnmti hypermethylated transferase island suppress irreversibly allow group group chromosome chromosome reduce demethylated hypermethylation substrate many cell cell methyl methyl methyl expression compare cytidine transfer transfer suppresor residue divide replication replication analogue parent product result inheritance cgis anti furthermore dna dna dna dna dna however bind dnmts cpg cpg gene gene rapidly effect place deoxycytidine deoxycytidine deoxycytidine silence thus methylation decitabine decitabine decitabine decitabine daughter incorporate incorporate hence associate 
2.0@cancer cancer inhibitor class dnmt dnmt methyl agent newly newly newly newly member dnmti unmethylated overall island unable irreversibly work methylate help demethylating inhibit inhibit reduce reduce reduce tumor tumor tumor tumor affect hypermethylation thus nucleoside cell cell cell cell cell cell cell cell drug drug expression suppressor suppressor transfer metastasis therefore epigenetic favorable need analogue anti know dna dna dna dna dna divide divide profile bind bind act create cpg gene rapidly effect methyltransferase replicate replicate replicate replicate new methylation methylation methylation methylation decitabine decitabine decitabine decitabine daughter production incorporate form enable 
2.0@dacogen cancer cancer activate use use use cluster agent agent hypomethylating myelodysplastic hypomethylates silence silence change leukemia genetic treat call erase erase previously lead epigenetic epigenetic pass involve involve involve hypermethylation demethylating inhibit myeloid turn normal regulation apoptotic go contribute express many cell cell cell cell methyl tra dysfunctional also therefore decibatine drug drug drug drug certain could cycle pathway do anti wont either treatment dna dna dna dna blood acute syndrome fe epigenetics gene gene gene effect control division rase actively decitabine daughter return differentiation 
1.0@dna suppressor suppressor classify dcitabine activation demethylating gene gene effect tumor tumor tumor agent promotor anti result decitabine demethylate show 
1.33@allow cancer instead apply dnmt dnmt dnmt regulation heritability use slow resemblance whose process process salvage since hypomethylation potential oncogene suppress suppress molecule tumor tumor tumor cytosine cytosine irreversibly strand strand get bear enzyme enzyme helpful accord block normal normal hypermethylation rase ensure much like cell methyl antagonist tra extend polymerase epigenetic mitotic replication drive decitabine decitabine yet result transcribe effect type show dna dna dna dna dna dna dna mark mark bind fe function gene gene gene rather go methylation methylation growth silence mother thus suppresion rna region selectivity action previous azacitidine 
1.33@red abnormal patient patient lymphoma produce use use severe agent agent heal heal white myelodysplastic analog myelogenous leukemia become old inhibit inhibit marrow strand class dna dna dna dna epigenetic blood blood acute syndrome platelet bone ah aml inhibitor cystidine rare cutaneous thy methylation methylation decitabine decitabine lat incorporate cell cell cell pome methyltransferase 
2.0@cancer cancer proliferate cgis class dnmt use analog dnmti change treat irreversibly belong way tumor tumor tumor pattern hypermethylation nucleoside demethylation demethylation demethylation cell may expression suppressor dependent promote therefore epigenetic replication cause target fast anti promoter dna dna dna dna dna dna bind suitable inhibitor gene methyltransferase methyltransferase effect effect division thus decitabine decitabine decitabine decitabine decitabine incorporate action relieve associate 
2.0@unregulated critical stable growth reactivation transcriptional tumour tumour include include agent hypomethylating analog pathogenesis malignancy hypomethylation catalyse inhibit inhibit previously lead cytosine epigenetic class inhibitor enzyme demethylating proliferation key hypermethylation hematologic nucleoside role regulator proximity regulate control belong suppressor transfer tsgs tsgs tsgs appear certain result result become arrest methyl promoter group dna dna dna dna dna dna cell cell expression expression expression important gene gene gene gene gene methyltransferase refer cellular progression division division silence silence silence silence methylation methylation methylation decitabine decitabine incorporate play differentiation differentiation associate 
2.0@demethylate suppressor cancer along large daughter therefore dnmt dnmt get tumour tumour analogue strand severe irreversibly result low dnmti anti show nucleotide dna dna dna dna divide dose dose effectively bind bind inhibitor gene methyltransferase effect effect upon copy body quickly longer silence methylation methylation release nucleoside incorporate come cell replication decitabine decitabine decitabine 
2.0@proliferate dnmt continue may may may may agent agent hypomethylating probably hypomethylation md tumour act lead lead irreversibly strand consequence demethylating hypomethylated proliferation outcome unintended normal hypermethylation fact genome although case propagation cell cell cell cell replication ubiquitination suppressor proteosomal nucleoside seem need analogue improve tumourogenicity apoptosis caution demethylate methylation methylation prevent prevent prevent dna dna dna dna dna however reverse bind degradation degradation least hence rather refer induce induce report increase silence actively decitabine daughter daughter gene incorporate associate survival aml generally 
0.0@dysfunctional cytidine abnormal class produce blood blood certain chemically myelodysplastic analog acute trade leukemia ati marrow marrow aza treatment kill help syndrome bone bone aml myeloid tumor condition deoxycytidine normal defect contribute decitabine work cell cell cell drug namedacogen 
2.0@methyalted becouse methyltransferases inhibition activate use analogue analogue agent process myelodysplastic fast fast treat inhibit incorporation dna dna dna dna dna divide bind syndrome dnmts dnmts dnmts demethylating gene gene tumor tumor division irraversibly decitabine decitabine decitabine nucleoside nucleoside incorporate incorporate cell cell replication supressor 
2.0@cancer cancer higher progress progress methyl slow frequently growth hypermethylated quite suppress addition lead rapidly even quickly discuss allow tumor tumor tumor tumor tumor block block response hypermethylation passive cell cell cell suppressor suppressor let drug downregulating course trigger level group demethylation dna dna dna divide expression gene gene methyltransferase inhibitor obviously death division decitabine decitabine activity activity return resume question 
1.67@cancer rate overdose fda specific process myelodysplastic dnmti dnmti effectively island nucleotide strand body belong impact hypermethylation show high demethylation cell cell drug drug dependent dependent daugther replication cause toxic nonspecific good treatment dna dna dna get dose bind syndrome act inhibitor cpg irreversible methyltransferase effect upon copy division division methylation decitabine decitabine decitabine incorporate approve 
1.67@mitotically cancer cancer reduce reduce reduce stable restore dnmt dnmt dnmt tumour tumour possibly significantly analog analog hypomethylation part hypermethylated transferase inhibit molecule molecule irreversibly pass functionality island island able hypermethylation genome many cell cell cell cell methyl suppressor suppressor cytidine cytidine result methylate methylate number promoter dna dna dna dna dna divide bind bind act least cpg cpg irreversible eliminate try replicate methylation methylation methylation decitabine decitabine decitabine decitabine daughter daughter gene gene incorporate onto associate 
1.0@suppressor cancer restore overmethylation overmethylation overmethylation regulation tumour cause agent stop growth amount amount misregulations dna dna dna histone histone example silence demethylating demethylating gene reduce reduce affect produce decitabine cell uncontrolled 
1.67@cancer cancer cancer happen effective effective yet build dependant process myelodysplastic myelodysplastic probably dnmti dnmti might place inhibit epigenetic island island take dnmt dnmt dnmt dnmt mechanism block affect hypermethylation hypermethylation clear nucleoside nucleoside drug drug drug drug drug cell cell cell cell much machinery one faster patient irreversibly seem replication replication cause cause whether therapy target healthy healthy prevent demethylation dnamethyltransferase dna dna get action bind bind syndrome syndrome act cpg cpg suffer aml inhibitor analog elderly replicate methylation methylation decitabine come form form form 
1.33@cancer cancer inhibitor dnmt dnmt dnmt yet mark myelodysplastic guarantee adjustment hypomethylation hypomethylation inhibit important strand establish issue island effective tumor tumor normal feature hypermethylation nucleoside role cell cell cell may suppressor dependent cause cause high however drug drug drug analogue toxic proper low problem solid prevent treatment treatment dna blockquote blockquote dose dose dose bind syndrome use highly cpg gene target target target effect division replicate find methylation decitabine decitabine daughter action side 
1.0@dna reverse decrease demethylating cpg cpg cpg use effect tumor agent feature hypermethylation hypermethylation excessive since methylation expect anti find promoter island island island tumour decitabine decitabine 
1.67@cancer methyltransferases methyltransferases miss therefore therefore dnmt use reproduce fast cannot become dna dna dna dna strand transmit le le inhibitor irreversible methyltransferase methyltransferase effect affect replicate methylation methylation decitabine daughter daughter anymore cell cell cell cell attach 
2.0@inhibitor class reactivation produce tumor blood link induce condition myelogenous silence hypomethylation leukemia useful treat marrow hypothemylation antitumour particularly dna dna acute syndrome precursor contribute deform gene methyltransferase effect epigenetically belong turn thus decitabine decitabine bone case cell myelodysplatic supressor 
1.0@one cancer regard abnormal therefore able activate monitor include agent result result cancerous without growth growth diminish suppress suppress suppress dna histone histone unlock allow demethylating gene gene gene gene tumor tumor tumor tumor tumor silence methylation inappropriate work theory cell cell control would decitabine 
1.67@cancer restore dnmt regulation methyl decitabinecauses meet dnmti growth decrease island addition lead cytosine position hyper thereby proliferation tumor tumor tumor tumor tumor pattern block normal hypermethylation turn carbon hilum methylationsilences cell cell supressor suppressor suppressor hypomethylation therefore decibatine cause cause apoptosis trigger promoter group supressed dna dna dna dna dna dna dna dna reverse expression expression cpg gene gene gene gene gene methyltransferase methyltransferase methyltransferase inhibitor inhibitor inhibitor silence ti methylation methylation methylation methylation decitabine activity differentiation na 
1.0@cancer activate kinase potential concentration agent phase process inactivation analog since reactivate hypomethylation leukemia incorporation incorporation methylcytosine enzyme silence tumor formation dac dac dac dac dac dac dac dac schedule aberrant cell dependent dependent bond tope ring photophosphorylation result result low nul specific ni curative model show treatment dna dna dna dna dna dose covalent animal prodrug azacytosine methyltransferase effect place deoxycytidine deoxycytidine antineoplastic antineoplastic antineoplastic end due major methylation decitabine gene gra sensitive action action action side leukemic 
2.0@dependent also daughter therefore get alteration much slow agent likely methyltransferase dnmti growth make drug drug drug inhibit nucleotide dna dna dna dna divide bind chemotherapy fe function demethylating island rapidly inhibitor tumor tumor longer affect affect hypermethylation may rase decitabine conventional cpg replication demethylation cell cell cell cell methyl iscopied tra 
2.0@cancer pcr dnmt administration tumour interact repressive silence part affect inhibit possess complex demethylating hmtase proliferation reduce reduce block normal hypermethylation hypermethylation cell cell attatch methyl suppressor suppressor also patient methylates drug mutate polycomb target without antitumour show group lysine histone histone thetumour gene gene effect induce overactive ezh ezh ezh thus thus decitabine decitabine decitabine dmnt dmnt activity various recently 
1.67@cancer cancer cancer article think influence dnmt include agent specific analog de note enzyme proliferation reduce tumor tumor tumor tumor mechanism repair nucleoside express primarily cell cell cell cell cell impact drug suppressor suppressor specifically dependent methylating replication decitabineisa cycle apoptosis incorporate effect anti lecture particular dna dna dna dna dna divide bind act inhibitor gene gene rapidly inactivate reversal division silence methylation methylation decitabine decitabine drive lay active action methyltransferase per 
2.0@dna dna dna dna dna dna dna dna dna cancer methyltransferases methyltransferases daughter irreversibly mitotic heritability methyl unmethylated incorporate analog cannot cannot growth case occur inhibit recognize divide strand methylate bind maintain maintain responsible responsible inhibitor drug gene gene rapidly suppressor suppressor tumor tumor tumor methyltransferase methyltransferase silence thus methylation methylation methylation decitabine decitabine nucleoside eventually express cell replication replication would would expression 
2.0@prelude accidental class activation methyl methyl cause cause manner agent specific hypomethylating myelodysplastic finally hypomethylation leukemia useful treat transferase transferase locus dna dna dna dna dna irreversibly decrease bind syndrome enzyme demethylating inhibit hence inhibitor tumor tumor inactive belong methylation decitabine decitabine decitabine render gene suppressor 
2.0@suppressor cancer cancer lower become class much strand acute myelodysplastic myelogenous leukemia anti treat inhibit good example dna dose kill methylated syndrome precursor gene aml effect methyltransferase copy neoplastic demethylated methylation decitabine decitabine daughter case cell tumour tumour 
1.0@enzymatic dnmt may island island myelodysplastic myelodysplastic analog find become become bind inhibit inhibit suppress epigenetic dna dna dna dna dna dna irreversibly prevent syndrome syndrome cpg cpg poor methyltransferase methyltransferase effective tumor prognosis hypermethylation replicate replicate regulator decitabine decitabine nucleoside incorporate methylation methylation drug associate 
1.33@unregulated cancer cancer cancer critical category within alt produce use agent demythlating de growth growth treat call interaction ass restore height epigenetic src exp consequence fall impact tumor tumor substance cyotoxic normal decibatine decibatine decibatine img width often demethylation may blockage suppressor suppressor suppressor promotion final antimetabolite antimetabolite antimetabolite regain drug cause structure restoration result low peer disrupt introduce anti know reason methylizing metabolism dna dna dna dna block dose cell cell cell cell cell cell cell cytotoxic chemotherapy gene gene gene gene effect effect effect cellular control increase division division methylation methylation methylation cntrl work regulate similar death follow class 
1.67@epi 
1.33@subtituted abnormal class dnmt formation use agent deoxycytidine deoxycytidine deoxycytidine call inhibit aza aza targetting strand strand hemimethylated demethylating tumor round convert phosphorylation phosphorylation substitution triphosphate demethylation cell cell kinase decitabine decitabine decitabine one study commonly inside action trap drug drug drug supresses uptake subsequent result incorporate incorporate natural diphosphate cytosine like become powerful show presence dna dna dna dna dna dna dna dna dna base synthesis synthesis cytotoxic inhibitor inhibitor methyltransferase effect place cellular death belong thus thus methylation methylation methylation double another form full 
2.0@different alt cancer inhibitor dnmt dnmt activate activate blood chemically example angiogenic signal dacitabine dacitabine de de growth generation embolic inhibit inhibit response cytosine position know methylated methylated well pol tumor tumor senecense ion regulation may may thus thus thus repair bond factor factor img like cell cite supressor un silent metastasis activation ch cause cause answer md pathway cdr th become src prevent prevent prevent covalent dna dna apoptosis bind bind bind chemotherapy cpg cpg irreversible collateral induce creb cellular supply since methylation allow allow transcription transcription gene gene gene activity activity mecp delay asa 
1.33@dna dna epigenetic epigenetic cancer cancer kill help help devision erase demethylating use agent pas without methylation stop daughter therapy actively change cell cell cell cell grow decitabine decitabine 
1.33@cancer methyltransferases class dnmt dnmt dnmt use agent process myelodysplastic code dnmti treat previously precursor demethylating tinymce affect dacitabine pre pre irreversibily nucleoside cell tumour leukaemia dna dna dna dna dependent therefore replication analogue novo incorporate incorporate hg fact anti reason divide acute bind syndrome rapidly effect explain replicate myelogenous methylation decitabine lay severily 
2.0@suppressor use hypomethylating myelodysplastic result reactivate treat promoter island island demethylation dna syndrome silence cpg cpg gene methyltransferase inhibitor tumor division due methylation decitabine region attenuation passive cell 
2.0@cancer cancer cannot class dnmt dnmt encounter methyl specific mark mark entirely since dnmti transferase island job lead irreversibly strand strand produce belong tumor tumor mechanism mechanism uncontrolled normal hypermethylation although metylation cell cell cell cell cell cell cell cell yet one one hallmark dependent transfer nucleoside therefore epigenetic replication replication work subsequent theory anti know parent cpg dna dna dna v bind le le inhibitor inhibitor drug drug drug affect affect methyltransferase effect analog along division replicate methylation methylation decitabine decitabine decitabine daughter daughter possible incorporate come action 
1.67@cancer cancer cannot dnmt dnmt progress use toxi myelogenous dnmti dosis dosis nucleotide irreversibly help belong myelodisplastic neoplastic release high like demethylation cell leukaemia dependent lower nucleoside get replication cause analogue anti group treatment dna dna dna dna dna divide acute bind bind syndrome inhibitor inhibitor aml effect effect effect upon methyltransferase methyltransferase methyltransferase division replicate decitabine decitabine incorporate come action rapidly would 
2.0@dna dna cancer characteristic abnormal methyltransferase epimutations tumour frequent agent mutation areable reverse becamecancerous make avoid unlike cpg die thephenotype reversible decrease inhibitor demethylating island proliferation reduce epigenetically mechanism hypermethylation silence decitabine gene many cell cell cell may supressor 
2.0@class dnmt activate use include process dnmti myelodisplastic island island lead epigenetic strand strand pass partially tumor affect hypermethylation turn nucleoside demethylation demethylation demethylation cell replication one analogue irreversibly drug cause cause malignant suppression result know dna dna dna dna kill bind syndrome cpg cpg gene methyltransferase inhibitor belong thus methylation decitabine decitabine daughter incorporate onto 
1.33@cancer growth lymphoma transcriptional transcriptional use agent silence myelodysplastic reactivate hypomethylation treat decrease grow lead variety enzyme ezh downregulation tumor uncontrolled normal hypermethylation overeactive human global dna dna cause cause mutation upregulation low dosage treatment several cell cell cell syndrome expression gene gene gene gene induce induce demethylating well methylation decitabine decitabine decitabine modify associate 
1.67@cancer cancer code change melbourne suppressor suppressor behave use include include ten tend process md reactivate growth make tumour tumour call university granddaughter epigenetic epigenetic development transferase transferase inhibitor silence silence bone control proliferation tinymce affect epigenome homolog access aredna pten cell cell cell cell cell cell methyl methyl majority expression expression multiple also patient erase histone methylates drug drug marrow mutation myelodysplastic myelodysplastic pass course example gene gene gene gene gene contain tensin header treatment hg surround syndrome syndrome phosphatase important time topbanner allow overactive cellular pre pre believe division thus actively decitabine daughter august activity reference migration delete chromosome class 
1.67@vivo could inhibitor restore effective activate state concentration concentration limit specific inactivation analog azacytidine azacytidine stage stage overall inhibit dna dna dna addition epigenetic disease proliferation tumor mechanism biochemical normal normal hdac hdac hdac hypermethylation terminal high demethylation demethylation demethylation cell cell recover suppressor also individual drug apoptosis target low gene gene antitumor dual reason dose inhibitory cytotoxic reveal function time methyltransferase effect effect deoxycytidine senescence new methylation decitabine decitabine difference performance activity activity differentiation 
2.0@plastic suppressor cancer cancer methylating actsby tumor say certain agent tend economist de de useful useful treat transferase inhibit though benefit dna dna blood example silence group might remove hypermethylation methylation methylation decitabine gene y elod methyl methyl associate 
2.0@determine dnmt dnmt drug analogue order inactivation experiment impossible must make methylation promoter inhibit inhibit aza fulfill integrate dna however base action bind covalent function perform gene resume enzyme enzyme mechanism deoxycytidine expression complex thus degrade genome nucleoside region case active cell methyltransferase methyltransferase decitabine decitabine 
2.0@cancer cancer cancer cancer nature efficacy formation tumour tumour tumour tumour likely eradicate dnmti useful transferase transferase inhibit suppress suppress suppress methylated proliferation block block affect contribute contribute factor many cell cell cell cell cell methyl methyl region region specifically dependent drug drug certain subsequent highly demethylate type type demethylation treatment dna dna dna least gene rapidly inhibitor unclear replicate thus methylation decitabine decitabine decitabine decitabine daughter work replication replication 
2.0@market inhibitor restore methyl agent process myelodysplastic remain since growth issold treat inactive island amount amount lead irreversibly nonspecific methylated belong demethylating consequently tumor tumor affect hypermethylation thus although demethylation japanese control ofdnmt tra one suppressor large nucleoside epigenetic drug drug drug analogue appropriate anti isused toxic company dna dna dna already cell bind syndrome fe dnmts cpg gene effect become division due rase decitabine decitabine decitabine class active 
1.33@suppressor suppressor cancer promote therefore hopefully activate tumour tumour tumour track agent stop mark gene gene island cpg dna dna dna reverse common act silence demethylating inhibit methyltransferase remove hypermethylation methylation overproliferation region cell would decitabine decitabine 
1.67@suppressor cancer cancer formation tumor tumor methyl agent stop stop probably cancerous become occur decrease grow suppress divide group demethylating island island nearby remove cpg turn methylation decitabine gene gene gene active cell cell cell would 
1.33@dna allow cpg gene tumour remove silence methylation decitabine demethylator become active inlands supressor 
0.0@cancer cancer marker able start may loss stop mark mir mir negative part useful island sup sup patient correlate team hypermethylation observe tumor early conclude methylation methylation methylation methylation soto soto expression mirnas mirnas transcription indicate therefore therefore conduct spread proximal could result result boundary reference element show furthermore ctcf ctcf potentially dna dna dna repressive histone bind site function function cpg gene effect epigenetically increase silence silence silence experiment breast breast locate mechanistically class reyes reyes 
1.0@dacogen cancer inhibitor inhibitor class class use chemically myelodysplastic analog hypomethylation leukemia treat inhibit aza epigenetic wikipedia impact trade aug may metabolic nucleoside myeloid cell tumour dysfunctional cytidine drug certain condition reference anti treatment dna dna blood acute syndrome name aml effect deoxycytidine belong methylation decitabine decitabine decitabine decitabine decitabine decitabine em free encyclopedia methyltransferase 
1.67@cancer cancer cancer critical critical disrupt available heritability methyl appear appear appear process inhibit dnmti battle transferase subsequently job irreversibly strand effectively inhibitor enzyme parent finish tumor pattern normal normal mitotic conversely nucleoside interrupt interrupt cell cell cell cell cell cell drug decitabine decitabine decitabine decitabine one faster transfer transfer high epigenetic epigenetic presumably regain replication replication analogue albeit toxic low dosage appropriate group acceptable dna dna dna mark mark dose dose dose bind act dnmts dnmts methyltransferase rate rate replicate thus methylation methylation allow daughter daughter incorporate action grind 
2.0@mitotically effect change change change unwarranted suppressor suppressor suppressor activate tumour tumour tumour tumour tumour tumour agent stop myelodysplastic inheritance chance growth anti treat decrease suppress dna dna form syndrome heterochromatin inherit inherit demethylating demethylating gene gene gene gene gene gene gene last activation notable lifetime traditionally silence silence methylation decitabine daughter daughter express active cell cell cell organism 
2.0@suppressor suppressor cancer cancer cancer silent establishment dnmt induce replication include apoptosis irreversibly analog hypomethylation overall anti increase decrease inhibit inhibit inhibit dna dna dna dna divide effect effect bind expression expression act dnmts inhibitor gene gene gene gene rapidly reactivation tumor tumor tumor death senescence methylation methylation expect nucleoside instrumental propagation cell cell cell cell methyltransferase would would decitabine decitabine 
1.33@dna dna suppressor suppressor cancer inhibitor cpg gene gene tumour tumour tumour tumour effect effect methyltransferase silence demethylated methylation decitabine hypermethylated anti anti impair promoter island express 
2.0@cancer cannot stable class dnmt dnmt dnmt dnmt tumor tumor tumor tumor blood agent agent hypomethylating myelodysplastic myelodysplastic myelogenous myelogenous reactivate hypomethylation might inhibit methylcytosine expression cytosine maintain maintain demethylating detect hypermethylation hypermethylation aberrant role regulator proximity cell suppressor suppressor suppressor leukaemia leukaemia dysfunctional cause cause therefore require certain condition express promoter promoter dna dna dna dna dna dna acute acute syndrome syndrome act important important gene gene gene gene gene gene gene gene methyltransferase methyltransferase inhibitor remove result progression silence silence silence silence silence methylation methylation methylation decitabine decitabine decitabine incorporate play indirectly associate 
1.67@inhibitor inhibition class activate kinase build inactivation major reactivate hypomethylation incorporation methylcytosine lead belong tumor tumor block dcl formation dapk bond aberrant enzyme etc decitabine decitabine decitabine decitabine decitabine analogue cdkn ofdecitabine azacytosine photophosphorylation result anti treatment dna dna dna dna dna dna dna ring cell covalent gene chemical effect place deoxycytidine deoxycytidine silence due methylation methylation rna em incorporate methyltransferase methyltransferase 
2.0@dacogen transcription therefore relate relate tumour tumour tumour likely agent suppression suppression anti occur decitabine dna dna involve act demethylating gene effect remove hypermethylation methylation methylation methylation reduce reduce reduce arise aberrant cell cell overproliferation 
1.67@loss antileukemic dnmt dnmt dnmt dnmt produce activity leukemiogenesis concentration agent agent specific hypomethylating transfer aza aza aza aza range hypomethylation inhibition inhibit inhibit suppress lead epigenetic pharmacology responsible silence dctp mechanism inhibing momparter momparter terminal readily aberrant potent triphosphate demethylation cell cell global decitabine decitabine dependent micromolars action relate replication analogue cdr cdr result phase depletion methyl level seminar dna dna dna dna dna dna dna dna synthesis soluble gene gene ic inhibitor inhibitor induce induce methyltransferase methyltransferase deoxycytidine protein protein reversal human interfere clonogenicity methylation supl incorporate incorporate incorporate active form differentiation hematology rl leukemic 
1.33@dna dna dna acute syndrome precursor demethylating methyltransferase agent myelodysplastic myelogenous decitabine treat leukaemia inhibit use demethylates 
2.0@suppressor inhibitor dnmt dnmt way specific island azacytidine dnmti anti preclude tumour transferase inhibit nucleotide dna non prevent well silence tumoral gene effect mechanism especially thus methylation vidaza di cpg methyl decitabine decitabine decitabine 
1.67@ezh cause restore dnmt tumor tumor tumor tumor way certain agent agent suppression novo significantly histone histone de anti completely decrease decrease transferase act lead lead dna surround involve inhibitor function demethylating group overmethylation remove provide silence methylation decitabine decitabine decitabine gene gene gene enzyme methyl methyl expression expression 
1.33@cancer cancer irreversibly get much dependent specific replication island cpg dna dna dna dna divide strand see bind example act act important drug drug methyltransferase methyltransferase inhibitor tumor copy division methylation decitabine daughter incorporate upon demethylation cell cell cell cell cell rapidly 
2.0@cancer inhibition dnmt dnmt dnmt use use chemically agent irreversible myelodysplastic analog analog hypomethylation inhibit inhibit inhibit lead lead lead lead recognize discuss complex demethylating island reactivation tumor tumor question particular hypermethylation metabolite genome nucleoside nucleoside like cell cell may expression suppressor suppressor anemia replication region strategy could cycle mean subsequent look promoter good dna dna dna dna dna divide action dnmts cpg gene gene gene rapidly inhibitor division silence methylation methylation methylation decitabine decitabine decitabine wide incorporate selectivity form methyltransferase important 
2.0@cancer cancer cancer cancer cancer cancer abnormal restore dnmt dnmt dnmt neucleoside shore newly since growth inhibit epigenetic strand repression establish allow island island reduce reduce reduce tumor tumor tumor tumor hypermethylation repair render methylation methylation methylation cell cell cell cell cell cell cell cell control etc suppressor suppressor transcription need analogue even cause cycle apoptosis loss demethylated healthy healthy reproduction become vulnerable promoter promoter metabolism dna dna dna dna divide kill kill chemotherapy drug drug shrinkage rapidly rapidly increase cpg cpg replicate regulator decitabine daughter drive gene gene dysplastic methyltransferase 
1.33@lung cancer cancer inhibitor advance therefore suppressor decitabine decitabine decitabine decitabine slow combination agent likely hypomethylating myelodysplastic analog myelogenous growth precursor demethylate demethylate isused itacts inhibit dna dna dna intend preventacute strand body cytidine syndrome treat function thereby histone methyltransferase allow tumor tumor people deacteylase contribute act anti gene incorporate leukaemia 
1.67@mitotically lead reduce reduce greater growth suppressor inherit include promotor change regulatory treat inhibit potentially dna dna epigenetic expression function gene gene methyltransferase effect tumor tumor treatment methylation allow region cell cell decitabine decitabine 
1.67@cancer inhibitor inhibitor class tumour tumour tumour tumour tumour tumour tumour slow mutation exsessive chromosomal also meet penetrate many treat solid suppresser epigenetic hypermethylation ezh reduce harder link vital successful enzyme decitabineis cell cell cell decitabine decitabine suppressor suppressor suppressor transfer genesdecitabine activation excessive stability result anti methylation condense group genomic treatment dna dna package histone ase chemotherapy sell important believe sensitivity label effect remove increase increase belong silence silence combat allow allow gene gene gene response form protein alter associate 
1.67@cancer cancer methyltransferases inhibition activate progress use trap aberrantly precise anti anti dnmti growth leukemia dosis grow dna dna dna dna dna dna dna lead inhibit myeloid tumor tumor tumor tumor mechanism neoplastic nucleoside unclear demethylation demethylation cell cell cell cell cell say kill inside suppressor drug cause cause cause therefore get decitabine decitabine decitabine decitabine decitabine replication analogue mylodysplastic low case depletion know particular reduction divide acute syndrome inhibitor still gene aml effect effect induce methyltransferase silence methylation methylation onto incorporate approve action rapidly hit 
1.67@cytidine patient intra use analogue agent phase myelodysplastic result myelogenous hypomethylation antimetabolite arrest treat inhibit dna dna dna dna dna acute syndrome precursor demethylating methyltransferase decitabine incorporate replication leukaemia 
1.33@suppressor cancer cause cause tumour analogue include agent whose inorporation result histone meet dnmti growth lation ye ver inhibit dna dna dna stop surround hallmark divide divide synthesis silence demethylating gene gene rapidly job death hypo methylation decitabine nucleoside work cell cell cell cell uncontrolled 
1.67@cancer critical restore effective induce may agent agent analog since since hypomethylates hypomethylation hypometylating inhibit inhibit irreversibly strand inhibitor demethylating severely proliferation longer normal normal give release nucleoside affect cell cell cell cell control dependent also divide replication know dna dna dna dna dna dna dna dna get bind bind function drug gene rapidly along upon cellular copy division replicate methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine daughter incorporate come action differentiation methyltransferase methyltransferase methyltransferase methyltransferase 
2.0@reduction cancer inhibitor level dnmt activate use drug dependent irreversibly myelodysplastic since since dnmti growth might decrease island island approve division dna dna divide know bind syndrome dnmts cpg cpg severely methyltransferase consequently dependant affect hypermethylation replicate methylation methylation genome gene incorporate influence cell cell need suppressor decitabine decitabine decitabine 
1.67@cancer effect dnmt dnmt dnmt progress yet fda faster also malignancy leukemia affect affect represent epigenetic decrease inhibitor inhibitor belong demethylating way myeloid tumor tumor normal hypermethylation may may vidaza nucleoside like demethylation cell cell cell myelodysplatic decitabine decitabine decitabine decitabine suppressor dependent dependent discover therefore irreversibly drug analogue cause anti bind group treatment dna dna dna dna however however acute approbed syndrome act dnmts cpg gene methyltransferase along division replicate methylation would work incorporate haematological 
1.33@dna dna dna reactivation gene tumour effect epigenetically agent hypothemylation activity induce silence hypomethylates decitabine decitabine associate anti supressor inhibit inhibit methyltransferase tumor 
1.67@cancer cancer cancer cannot faster hdac dnmt dnmt dnmt dnmt dnmt sometimes remove methyl include furher two since dnmti majorly inhibit inhibit inhibit nucleotide daughter even help inhibitor inhibitor inhibitor enzyme instead day affect life main nucleoside lifestyle cell cell cell use kind dependent thing quality aalogue fda need cause cause cause improve therapy people mean do replication old prevent severly methylationof treatment dna dna get get bind driugs function suffer hence rate upon try division division replicate replicate thus thus thus methylation methylation methylation methylation decitabine decitabine decitabine mainly work work incorporate come approve bound transferace 
0.0@cancer inhibitor growth hyperacetylation multiple ntrk use hematological agent agent specific stag two acetylation hypomethylation hypomethylation treat lead clinical epigenetic epigenetic epigenetic development sequence sequence sequence well tumor vitro amp amp cyclin skm skm kinase decitabine decitabine suppressor dependent also bisulfite bisulfite cg cdkn therapy cell cell type know genomic treatment treatment dna dna dna dna pik histone histone cgs gene gene amplify induce deep chromatin contain inhabit modification new methylation ul ul ul ul ul ul disorder ell approve various aff primer azacitidine azacitidine 
1.33@cancer dnmt start progress use deme agent process myelodysplastic leukemia back might tumor irreversibly strand help demethylating put pattern normal normal usually genome nucleoside like cell cell cell tumour supressor one dependent transfer divide replication frequent unmethylated anti bind occur thy prevent syndrome dna get acute ase myeoloid act important drug drug gene apporved effect methylation methylation decitabine daughter incorporate analouge 
0.33@dna dna epigenetic cancer decrease chemotherapy demethylating methyl state remove agent methylation ul ul suciptible make amount cell group alter 
2.0@one umethylated suppressor methyl agent island island find unmethylated generation generation occur promoter inhibit suppress next next dna dna dna help fe hypermethylation demethylating gene gene proliferation inhibitor tumor tumor tumor keep belong rase methylation decitabine decitabine cpg cpg express cell cell cell methyltransferase tra 
1.67@cancer cancer restore restore dnmt use state state likely myelodysplastic myelogenous chance leukemia treat island island island lead even precursor silence demethylating demethylating tumor tumor tumor tumor normal normal hypermethylation effectiveness gene gene gene gene gene like may decitabine decitabine suppressor brac drug either development agent agent target result unmethylated express anti anti level treatment dna acute syndrome act expression cpg cpg cpg numerous effect increase increase belong since breast locate region mean class 
2.0@cancer compromise class irreversibly use analogue inhibitor inhibitor likely cause cause constantly course hypermethylation decrease dna dna dna dna divide strand reverse bind bind epigenetic act dnmts dnmts dnmts drug drug time methyltransferase methyltransferase happen tumor affect division interfere work methylation methylation decitabine nucleoside could daughter demethylation cell cell global belong 
0.67@kind cancer cancer also therefore progress may since effect anti decrease island island dna dna development histone histone methylated inhibitor thus cpg cpg reduce tumor tumor deacetylase increase usually acetylase lower decitabine probibality mean methylation methylation methylation methylation active supressor supressor 
1.67@theincorporation silence critical restore dnmt dnmt may fda agent hypomethylating hypomethylating malignancy malignancy malignancy cellular hypomethylation island adduct lead lead irreversibly reversible regulate inhibitor undeterred especially inhibit proliferation tumor normal neoplastic hypermethylation hypermethylation act rase nucleoside cell cell process methyl methyl ing dueto suppressor dependent run epigenetic epigenetic alteration replication analogue actually however target number bind bind promoter action action dna dna dna dna dna divide hypo cytotoxic covalent fe dnmts cpg gene gene gene gene rapidly function induce growth control human thus thus methylation decitabine decitabine decitabine decitabine decitabine decitabine hematoligical incorporate approve tissue differentiation methyltransferase associate 
2.0@allow cancer inhibitor inhibitor class much tend de call whendna unable epigenetic hyper tumor tumor may release express cell cell cell cell replication belong dependent irreversibly regular target describe type good dna dna dna divide reverse bind suppression drug drug gene rapidly effect copy division replicate go methylation methylation methylation decitabine daughter incorporate methyltransferase methyltransferase 
1.67@allow cancer cancer restore restore induce uncontrolled uncorrected inhibit inhibit transfer forapoptosis sit afford affect forth heritable heritable unrecognized regulate status sequence division division proceed tumor tumor tumor tumor normal normal lack lack give repair repair aberrant program propagation cell cell cell cell cell cell cell cell ref control decitabine decitabine suppressor suppressor suppressor suppressor carry candidate replication analogue apoptosis apoptosis unmethylated gene gene gene anti normally demethylation dna dna dna dna dna future citidine ase mediate function divisionsreactivating time effect epigenetically methylations cellular cellular line line death advantage advantage methyltransferasecausing methylation methylation rna transcription inthese slow differentiation remove 
2.0@cancer cancer cancer methyltransferases vulnerabe class methyltransferase methyltransferase tumour include agent hypomethylating analog cannot azacytidine similar hypermethylated island island aza epigenetic strand decitabines common responsible belong accord affect feature hypermethylation usually work silence cell cell process much one one suppressor cytidine dependently divide replication cause cause apoptosis underlie promoter prevent cpg cpg treatment dna dna dna dna dna get bind well name function function drug drug gene gene gene rapidly inhibitor inhibitor upon structurally deoxycytidine copy division main methylation decitabine decitabine decitabine daughter irreversible incorporate chemical alter 
1.33@different dacogen cancer inhibitor term dnmt dnmt formation use use use include agent agent agent agent interrelate hypomethylating hypomethylating inactivation phenomenon also hypomethylates cod stably treat inhibit inhibit epigenetic epigenetic epigenetic precursor japanese demethylating demethylating remodel chromosome tumor mechanism heterochromatin new investigation investigation vidaza maintain treatment treatment drug leukaemia celgene summit cytidine basis identity imprint need jersey decitabine decitabine decitabine decitabine cell myelodysplastic acute family company dna dna dna dna dna dna non histone syndrome sell sell eisai methyltransferase effect analog cellular division modification myelogenous methylation methylation methylation rna undergo form conserve azacitidine 
1.67@older cancer cancer neoplastic inhibition dnmt dnmt dnmt use use use although inhibitor inhibitor inhibitor agent myelodysplastic analog myelogenous hypomethylation leukemia treat promote irreversibly strand sure precursor demethylating impact tumor mechanism life nucleoside nucleoside case demethylation cell cell cell much one dependent greater greater patient successfully cause prove expectancy relatively low anti anti know good treatment dna dna dna dna dna dna dose surround bind bind syndrome act act behind methyltransferase methyltransferase methyltransferase effect effect effect fast try division replicate replicate decitabine decitabine daughter incorporate side 
1.67@vivo cancer cancer methyltransferases last reactivation way dl dl stop analog selective change change susceptible make might grow granddaughter irreversibly pass therefore belong dnmt tumor though ing unexpectedly routine demethylation demethylation lead tumour suppressor standard dependent erase erase epigenetic epigenetic epigenetic drug drug cause combination therapy cell cell cell cell cell reaction chemotherapeutic replication show good pyrimidine dna dna dna dna dna histone bind chemotherapy inhibitor inhibitor consecutive gene methyltransferase effect epigenetically deacetylase division vitro silence actively decitabine decitabine daughter incorporate return kill dt dt alter without 
2.0@suppressor cancer reduce therefore imprint tumour tumour state icr decitabine effect anti know island dna dna area see inhibitor drug methyltransferase initial cpg methylation methylation methylation genome region demethylation control recover associate 
1.33@dna histone histone allow gene gene methyltransferase reduce tumor process silence decitabile methylation decitabine decitabine antioncogenic express supressor reverse lead 
2.0@dna dna dna cause cause become translation activation activate tumor tumor tumor tumor tumor methyl deme agent agent agent place mark protien result transfer hypomethylation effect effect epression thy open ase act inhibitor anti anti gene gene gene gene take reduce remove turn transcriptional produce decitabine decitabine decitabine transcription factor case demethylation demethylation methly supressor supressor 
0.0@could sorry notattempt correctly 
0.0@decline cancer cancer cancer cancer cancer article substance lymphoma overmethylation use system mutation mutation chromosomal process process economist growth part make treat call inhibit lead lead epigenetic epigenetic tumour tumour tumour enzyme enzyme enzyme ezh ezh ezh group group proliferation impact turn uncontrolled normal normal epigenome may reduce methylates affect cell cell cell methyl methyl suppressor several identify attach appear include include epicentre cause cause cause answer activity activity describe describe describe histone histone histone reference nearby effect effect effect anti immune prevent reason dna package surround point inhibitor drug gene gene gene hyper overactive explain belong silence methylation decitabine decitabine decitabine decitabine decitabine decitabine usually class protein follow 
2.0@suppressor suppressor dependent effect effect effect apply reactivation relate tumour tumour tumour cause agent toxic silence relatively low dosage dosage hypermethylation hypomethylation possibly might lead lead demethylation demethylation demethylation demethylation fulfill patient dna dna dna dna cytidine inhibitor function function cpg inhibit inhibit hence dnmt analog antineoplastic division since methylation allow high gene gene fuctions island active cell cell cell decitabine decitabine decitabine 
2.0@cancer cancer cancer inhibitor dnmt dnmt excess use agent already myelodysplastic myelogenous chance nucleotide treat normal precisely suppress analogous lead epigentic hyper hyper demethylating inhibit affect feature give strongest nucleoside suppressive cell cell cell tumour tumour leukaemia although get decibatine replication drug subsequent zati zati incorporate type methyl methyl decibitabine island dna dna dna dna dna divide acute bind syndrome act cpg gene gene rapidly rapidly enzyme remove suppressent replicate silence decitabine activity action action methyltransferase methyltransferase 
2.0@cancer critical class able regulation regulation use cycle transcription reactivate play suppress suppress demethylates epigenetic inappropriately inappropriately allow provide interest block otherwise may role case cell tumour tumour tumour suppressor methylating methylating modify target effect anti methylated dna dna histone important gene gene gene gene gene gene inhibitor overactive belong methylation decitabine right bypass form would de de 
2.0@mitotically cancer cancer able way since reactivate heritable transferase island island nucleotide nucleotide irreversibly strand methylated enzyme tumor tumor tumor hypermethylation release factor factor factor anymore express cell methyl suppressor fight replication analogue analogue help know prevent dna dna dna dna dna repressor repressor bind act cpg cpg gene gene gene methyltransferase inhibitor epigenetically copy silence silence methylation methylation methylation decitabine decitabine decitabine daughter daughter incorporate 
1.0@heavy cancer cancer cancer article dnmt use could stop process epigenome economist de growth treat copy island island nucleotide irreversibly even see inhibitor wil control dependend turn affect hypermethylation may depressor cell epicentre replication dna dna promote epigenetic regular drug drug strand mean describe low reference come solid tumour tumour good together treatment several get get dose bind bind syndrome myelodysplastic cpg cpg gene methyltransferase effect effect effect upon thatis explain administer demethylated methylation decitabine decitabine decitabine decitabine decitabine daughter work incorporate give 
2.0@cancer cancer classify restore restore dnmt dnmt produce use fda agent hypomethylating two hypomethylates dnmti growth treat inhibit inhibitor inhibitor demethylating way way tumor normal myelodysplastic nucleoside nteract cell cell cell tumour one suppressor cause become get replication analogue target reference anti anti bind bind syndrome dna dna dna dna dna divide cytotoxic cytotoxic chemotherapy function drug gene rapidly effect effect upon control antineoplastic thus decitabine decitabine decitabine decitabine thedeath incorporate come methyltransferase methyltransferase 
2.0@suppressor dependent reduce tumour island dnmti methyl antitumor level prevent dna dna dna dna irreversibly transferase bind inhibitor dnmts thereby gene effect cpg methylation methylation decitabine decitabine nucleoside incorporate maintain active replication would would 
1.33@cancer impact growth tumour agent contributor hypomethylation change change call inhibit exert class epigenetic epigenetic development responsible enzyme demethylating reduce tumor tumor block neoplastic may high many thereby try expression expression suppressor suppressor let drug drug cause structure result cancerous anti type dna dna dna dna dna dna dna important gene gene recognise effect increase belong due methylation methylation methylation methylation decitabine decitabine decitabine decitabine rectify methyltransferase 
1.67@effect class suppressor produce induce blood impact mylogeneous hypomethylation hypomethylation leukemia useful treat marrow incancer cytosine position strand particularly precursor belong especially take reactivation tumor tumor strategic contribute beenlinked cell cell myelodysplatic ecitabine also therefore anti dna dna dna syndrome syndrome syndrome gene methyltransferase inhibitor epigenetically place deform replicate silence decitabine decitabine decitabine bone 
2.0@especially cancer myeloid effective stimulate use cluster appear agent agent specific decitabin decitabin myelodysplastic myelodysplastic leukemia myelogenous fda potential md treat inhibit response molecule regression establish hyper demethylating island reduce tumor tumor tumor tumor precursor ing genome regain cell cell cell methyl leukaemia ctl also activation necessary induction elicit mouse mouse cd cd apoptosis result result low gadd gene anti show show approve osteosarcoma treatment treatment treatment treatment dna dna dose acute acute cytotoxic syndrome syndrome expression expression expression cpg differentiation aml induce induce methyltransferase lymphocyte control human oncogenesis methylation decitabine decitabine decitabine decitabine decitabine wide return survival protein recently 
2.0@cancer impact impact inhibition class class dnmt dnmt activate tumor tumor tumor may could hypomethylating md trasferase myelogenous de unmethylated unmethylated ofcpg treat ofmds island island surround irreversibly malignant dependance precursor inhibitor prevent reduce detect maintenancemethyltransferase affect hypermethylation much cell cell cell cell cell cell cell use leukaemia suppressor suppressor drug drug drug drug therefore therefore ofmethyltransferase due replication ofdecitabine novo normal result decitabinebinds oppose nature bind methyl ready somatic dna dna dna dna acute likelihood syndrome act myelodysplastic cpg cpg gene gene aml aml effect rapid belong replicate replicate replicate thereforeis methylation methylation decitabine possible kill methyltransferase methyltransferase 
2.0@one one cancer cancer reduce action way drug drug drug drug order agent myelodysplastic currently cancerous leukemia treat treat inhibit act example dna dna dna epigenetic acute syndrome recent demethylating proliferation research mechanism modifier precursor human interfere interfere myelogenous methylation methylation methylation expect possibility highlight cell cell trial use use decitabine 
1.67@cancer cancer able able activate may may may may agent specific example hypomethylating hypomethylating cure growth completely effectively chaces start help hypermethylation hypermethylation take reduce tumor tumor tumor tumor tumor activte good certian genome express many supressor also suppresor patient consequently cause cause actually stop normally normally occur prognosis potentially reverse point gene gene gene gene gene rate place increase shrink silence silence methylation decitabine decitabine mean 
1.67@cancer dnmt formation may agent specific sustaied avoid inhibit lead irreversibly enzyme demethylating tumor tumor affect proliferative nucleoside methylation methylation maintainence cell cell cell cell cell rapid suppressor sustain replication analogue apoptosis normal normal serverely prevent prevent prevent dna dna dna dose bind gene rapidly advantage division replicate silence signal decitabine decitabine decitabine daughter lay confer methyltransferase 
0.67@suppressor cancer cancer effect myelodysplastic imprint use include agent acute demethylate loss myelogenous hypermethylation hypermethylation change leukemia sit treat lead act act potentially dna dna dna dna dna epigenetic cell cell syndrome precursor enzyme demethylating inhibit methyltransferase reduce tumor thereby silence methylation decitabine decitabine decitabine gene gene activity counteract various aml 
1.67@cancer cancer article isa dnmt dnmt upon use epicentre week tohave myelodysplastic analog myelogenous replicate treat longer irreversibly strand get precursor severely order tumor mechanism affect neoplastic divide release nucleoside cell cell cell tocopy much kill leukaemia lower takenat replication body reference effect anti completely lecture good dna dna dna dna dna replicationdependent dose acute bind bind syndrome inhibitor still aml along unclear methyltransferase methyltransferase methyltransferase methyltransferase explain word methylation decitabine decitabine decitabine daughter incorporate come action rapidly 
2.0@suppressor suppressor dependent transfer inhibition inhibition class therefore dnmt dnmt dnmt dnmt tumor tumor tumor methyl agent analog normally inhibit call prevent dna dna dna irreversibly bind bind epigenetic demthylating function still group inhibitor inhibitor unclear mechanism belong clear methylation methylation decitabine decitabine decitabine decitabine nucleoside gene gene incorporate action bite replication 
1.33@cancer overmethylation overmethylation overmethylation much agent tend carcinogenesis since tumorigenic growth decrease island suppress position step demethylating tumor tumor block variegation cell towards suppressor suppressor certain histone excessive cause mean shut pev occur promoter promoter protect dna form heterochromatin expression cpg gene gene gene gene effect remove keep thereby respectively methylation methylation decitabine decitabine learn active instance 
2.0@cancer effect effect class activation tumor tumor tumor tumor agent agent anti result since gain lessen inhibit suppress suppress dna dna dna dna dna epigenetic strand body allow inhibitor hyper demethylating demethylating island methyltransferase impact remove belong silence methylation methylation methylation methylation genesis gene gene cpg many control decitabine decitabine decitabine decitabine 
1.67@standard standard cancer cause cause growth epigenetic may may slow employ employ effect result chemotherapeutic dispense irreversibely better inhibit previously treatment treatment dna dna dna dna divide divide dose bind alternatively act enzyme provide affect methyltransferase reduce tumor normal epigenome thus methylation decitabine decitabine severely incorporate demethylation cell cell cell drug alter small 
2.0@suppressor suppressor cancer effect therefore dnmt dnmt tumor tumor tumor uncontrolled agent hypomethylating reactivate growth anti bind promoter group regulate dna dna irreversibly dependent inhibitor demethylating inhibit methyltransferase rate remove effective due decitabine gene gene incorporate reproduction cell cell cell methyl replication 
1.33@blewitt cancer cancer cancer critical condition restore essentially dnmt tumor tumor use use every agent agent myeloplastic find reality little drugbankthis wikipedia treat class elation hyper demethylating demethylating dr proliferation myeloid put question normal marvelous hypermethylation knowledge silence silence aberrant many cell cell cell cell cell control suppressor leukaemia dysfunctional hypomethylation cause cause room certain answer prior could decitabine decitabine decitabine decitabine target result immunity depletion normally normally occur myth damage treatment treatment dna dna blood acute syndrome function gene gene gene gene aml genetics place must death shrink word epigenetics instructor inappropriate attribute active differentiation 
2.0@unregulated cancer cancer cancer inhibitor restore restore rid process anti major growth growth normal regulate regulate allow severely tumor mechanism block affect neoplastic high decitabineis cell cell cell cell cell control blockage belong suppressor suppressor suppressor dependent promote cause cause cause toxic mean result low become nonspecific good good dna dna dna dna dna dna get dose dose expression act function gene gene gene gene methyltransferase effect range demethylation demethylation demethylation demethylation increase division division division replicate thus methylation methylation decitabine decitabine decitabine activity 
2.0@cancer able activate use include agent stop myelodysplastic remain currently hypomethylates growth genetic treat inhibit lead epigenetic methylated demethylating proliferation tumor tumor tumor uncontrolled overly role many cell control leukaemia suppressor suppressor histone histone drug cause cause dectabine dectabine prior mutate mutation surround whose demethylate could counteract dna dna dna acute syndrome gene gene methyltransferase silence myelogenous decitabine decitabine continue 
2.0@cancer methyltransferases methyltransferases restore available tumor tumor goal code agent brown analog instead diminish decrease ting jnci class recognize epigenetic epigenetic development around methylated demethylating island serve serve tinymce necessary vital nucleoside substrate lead methyl expression suppressor cytidine cytidine candidate replication cause therapy trap target hg anti promoter pool treatment dna dna dna dna hypo lyko degradation dnmts dnmts cpg gene effect resemble methylation methylation decitabine decitabine incorporate promise covalently would would 
1.33@mean cancer cannot class term dnmt use long myelodysplastic probably dnmti dnmti negative affect nucleotide unknown irreversibly strik belong effective tumor normal dir ing reduce cell cell cell cell drug drug release one dependent patient divide divide consequence consequence replication suppose low dna dna get dose kill bind bind syndrome inhibitor still rapidly effect division decitabine decitabine ltr incorporate strongly action methyltransferase 
1.33@cancer cancer toxicity higher class depend epigenetic get methyl methyl incorprate result result irreversibly analos since dnmti hypomethylation transferase transferase dna dna dna dna dna divide call bind bind rapidly inhibitor inhibitor mechanism belong decitabine decitabine decitabine nucleoside cell cell cell replication replication 
2.0@mitotically cancer dnmt dnmt use use mark myelodysplastic find reactivate growth part part make treat decrease decrease decrease inhibit heritable lead methylated methylated enzyme enzyme enzyme enzyme tumor tumor tumor mechanism reproduct hypermethylation anymore cell cell cell cell methyl decitabine decitabine decitabine decitabine decitabine suppressor suppressor block indeed therefore therefore methylates cause overexpressed mutate amount act group example dna dna dna dna dna divide syndrome syndrome overexpression gene gene methyltransferase methyltransferase inhibitor place control silence silence silence methylation methylation methylation ul ul activity activity 
1.67@cancer article class lymphoma formation much slow include mutation myelodysplastic myelogenous malignancy reactivate incorporation previously patient irreversibly recovery precursor enzyme enzyme demethylating demethylating severely tumor tumor tumor affect life hypermethylation extend like cell cell way suppressor suppressor dependent methylating quality promote action appear replication replication cause cause cause agent mean mean result surround anti better prevent prevent dna dna dna dna divide acute bind syndrome gene gene gene methyltransferase inhibitor upon overactive become silence silence decitabine decitabine work incorporate economist period survival rapidly chance 
2.0@dna dna dna suppressor dnmt start gene methyltransferase methyltransferase inhibitor inhibitor tumor agent block ofdna hypomethylates work activity normally inhibit 
1.67@dacogen cancer cancer overmethylation overmethylation may may may include agent stop eisai currently since growth growth treat tumour tumour precursor reset demethylating happen pattern pattern normal epigenome case japanese unregulated uncontrolled leukaemia suppressor suppressor use drug cause decitabine decitabine cell cell cell cancerous like balance develop company dna acute syndrome sell myelodysplastic gene gene gene gene gene along remove name keep silence silence longer myelogenous methylation methylation methylation allow daughter return maintain 
2.0@cancer cancer methyltransferases think summary progress fda mark myelodysplastic remain myelogenous hypomethylation hypermethylated treat island island lead epigenetic particularly hypermethylation hypermethylation demethylating reduce reduce tumor mechanism generally usually genome although aberrant passive cell cell promote leukaemia find suppressor nucleoside therefore therefore decitabine decitabine drug analogue mitosis acute cancerous contrast level prevent demethylation potentially dna dna dna inhibitory syndrome act inhibitor cpg cpg gene aml effect unclear revert silence replicate replicate thus methylation expect wide approve action decatibine 
2.0@cancer cancer inhibitor dnmt dnmt tumour useful treat normal inhibit incorporation unable irreversibly strand methylate lose enzyme island able round affect hypermethylation nucleoside nucleoside nucleoside maintain cell cell cell cell drug drug suppressor dependent methylating patient replication replication analogue analogue analogue cause mitosis incorporate promoter parent cpg dna dna dna dna dna dna dna dna dna divide bind bind function function perform gene gene methyltransferase dnmts dnmts contain quickly longer silence methylation decitabine daughter severely eventually follow 
2.0@cancer dnmt may may could malignancy growth transferase island island silence silence silence provide inhibit way reduce due block affect aberrant cell cell tumour tumour tumour suppressor suppressor specifically certain healthy activity activity result methyl promoter prevent underexpression dna dna greatly act overexpression dnmts dnmts dnmts cpg cpg gene gene gene gene gene inhibitor characterise control quickly replicate thus methylation methylation decitabine decitabine region incorporate nuclear haematological associate 
2.0@dna dna dna suppressor expression gene gene tumour inhibitor include increase methylation methylation methylation decitabine decrease decrease would lead lead 
1.67@dnmt drug agent mutate toxic quantity body dosage might show group dna dna epigenetic better example act demethylating affect affect inhibitor normal replicate low decitabine decitabine decitabine high work incorporate cell cell far control azacitidine 
2.0@atom destroy instead inhibition nitrogen dnmt dnmt dnmt dnmt dnmt variation methyl concentration cytidine cytidine cytidine cytidine decitabine decitabine analog finally azacytidine azacytidine azacytidine gt part methylated decrease decrease group aza lead dna contain level help bind bind expression gene inhibitor tumor quantity deoxycytidine increase methylation go want vidaza em em em em another like cell supressor 
1.67@suppressor cannot class dnmt dnmt dnmt still tumour analogue inhibitor inhibitor agent irreversibly hypomethylation hypomethylation come bind bind bind copy inhibit nucleotide lead dna dna dna dna dna get get strand upon act contribute demethylating gene methyltransferase methyltransferase reactivation unclear mechanism along belong silence methylation ul ul nucleoside work incorporate epigenetically action replication decitabine decitabine decitabine decitabine 
1.33@cancer instead dnmt dnmt progress use fda cpgi disease normal inhibit nucleotide irreversibly strand know know well hypermethylation severely effective mechanism affect neoplastic give give usually copy release nucleoside good cell cell demethylation much decitabine decitabine decitabine dependent dependent analogue quality patient tolerate replication replication cause whether life life expectancy low dnamethylase anti try show prognosis dna dna divide dose bind bind syndrome syndrome myelodysplastic myelodysplastic poor aml effect unclear order elderly replicate thus methylation longer longer daughter incorporate perhaps approve action rapidly 
2.0@cancer methyltransferases patient available irreversibly use analogue dependent cause form methyltransferase since malignancy dnmti part part replication replication occur decrease group tumour treatment dna dna dna dna dna dna dna divide blood transferase transferase bind bind therefore enzyme drug drug drug rapidly inhibitor methylate affect longer methylation decitabine decitabine decitabine nucleoside incorporate demethylation cell cell cell cell methyl methyl methyl kill 
1.33@inactivate higher growth growth dnmt agent hypomethylating hypomethylation inhibit dna dna class immune allow thereby tumor tumor tumor mechanism block normal essential show cell cell control ofdnmt decitabine decitabine decitabine suppressor suppressor lower promote drug drug apoptosis suppression know study dose dose dose cytotoxic expression expression gene gene gene methyltransferase inhibitor dependant belong methylation byblocking itinduces activity activity activity causehypermethylation action differentiation differentiation stimulation 
1.33@mitotically cancer cancer breast tumour tumour state likely shore island island island break transcription frequently growth growth growth catalyse hypermethylation hypermethylated heritable unlike select lead lead igf epigenetic covalent methylated involve involve enzyme demethylating utilise brca gene gene gene gene conversion mutation difficult may bond factor hdacs removal removal control reversible suppressor also promote aberrant overexpressed agent tet result cytosine reinstatement wiedermann depletion bind occur occur prevent primarily potentially dna dna however methyl methyl methyl group group syndrome beckwith expression expression cpg cpg cpg aid rapidly intermediate demethylation demethylation silence thus decitabine decitabine method region original active various protein 
2.0@suppressor effect abnormal daughter get cannot irreversibly since especially anti bind bind effectively island cpg dna dna dna dna dna dna divide strand know methylated decrease inhibitor inhibitor division demethylating gene methyltransferase methyltransferase methyltransferase rate tumor tumor tumor copy hypermethylation thus methylation methylation decitabine decitabine decitabine decitabine high mitosis incorporate many cell cell cell cell associate 
1.67@dna dna dna dna cancer cause demethylating demethylating may effect tumor agent belong methylation decitabine decitabine work anti hypomethylates inhibit 
0.0@mielodisplsicas cit inhibitingdna comportado sndromes semelhante um um utilizado uma quais hypomethylates apenas quimicamente podem ele adn adn embora azacitidina lma decitabina decitabina decitabina clulas para medicamento aguda leucemia pode na na na na font font font font font font font font tratamento toazacitidine sanguneas cadeias cadeias lat transfer pome funciona meet disfuncional certas aa thy id dna incorporados incorporados ase por ah mielide doenas arn num ser ser classe enquanto de de de de 
1.0@current cancer inhibitor effective use specific mark probably malignancy useful transferase irreversibly strand strand enzyme dnmt dnmt mechanism affect hypermethylation may nucleoside side cell cell cell tumour older suppressor dependent patient get replication replication analogue incorporate low tolerable methyl know dna dna dna divide divide dose dose bind bind epigenetic drug gene aml effect effect dependant increase methylation methylation decitabine daughter lay action action rapidly haematological 
1.67@critical inhibition restore neoplasia web may concentration agent sit myelogenous de de hypomethylation hypomethylation leukemia direct exert call inhibit incorporation achieve antineoplastic decrease methylated default default default default default leukocyte hyper nih proliferation dailymed tumor tumor normal neoplastic phosphorylation major gene gene gene eventual cell control expression one suppressor methylating methylating drug drug cause cause cause cause u acute apoptosis suppression suppression preceeds reference dysplasia dna dna dna dna dna dna dna dna synthesis site function believe methyltransferase effect induce presume cellular cellular nim increase silence vitro since methylation methylation methylation decitabine decitabine decitabine decitabine pathology em em em em em em em em article differentiation differentiation would class class class class class 
1.33@several cancer effect responsive term may deme cytidine long analog standard without growth make drug environmental achieve dna dna dna dna kill chemotherapy gage time methyltransferase regulate block normal near cumulative thy thus mitoses genome lat incorporate methylation many cell differentiation stimulus level decitabine decitabine 
1.67@myelodisplasic restore lower effective unclear methyl dnmts fda agent alteration transcription neoplasic dnmti high treat inhibit molecule cytosine epigenetic epigenetic epigenetic see diagnostics inhibitor demethylating impact mechanism adnmt asanti progress drug drug drug drug extremely use use machinery machinery dependent transfer nucleoside residue irreversibly biomarker replication analogue therapy toxic target meet sequence chemotherapeutic anti promoter promoter group tumour reverse dna dna dna dna dna however dose dose inhibitory bind syndrome act important still gene effect remove demethylation selective methylation methylation decitabine decitabine decitabine incorporate as approve action downstream prognostic small 
2.0@suppressor eliminate class histone histone consequence induce drug decitabine distinas course silence silence change make antitumor level island island island lead dna dna epigenetic epigenetic desatecilasa expression inhibitor inhibitor inhibitor inhibitor cpg cpg cpg gene gene gene methyltransferase methyltransferase effect tumor normal hypermethylation hypermethylation consequently thus methylation allow possible express demethylation etc reversible 
2.0@dacogen cancer methyltransferases restore dnmt cycle analog silence hypermethylated save island aza fulfill lead ribonucleoside methylate methylated discuss enzyme inhibitor unlike proliferation happen tumor tumor undergo block normal normal fail bind bind band vidaza high ang like like passive cell cell cell cell cell cell try supressor supressor one cytidine cytidine transcription replication decitabine decitabine decitabine decitabine apoptosis become become moment promoter demethylation dna dna dna dna deoxy earlier act function cpg gene gene gene rate remain deoxycytidine division longer thus thus methylation allow region incorporate incorporate return covalently break azacitidine azacitidine 
2.0@cancer cancer inhibitor inhibitor class class subsequent dnmt progress use slow fda exhibit silence md find systemically hypermethylation hypermethylation hypermethylation treat call acommon effective effective irreversibly tumour tumour tumour tumour particularly enzyme demethylating demethylating treatmentwould activation deacetlylase rapidly contribute divide demethylators demethylation cell cell may suppressor suppressor belong hallmark patient therefore epigenetic drug drug combination know agent agent intumours limit result low progressive anti show dna dna dna dna dna dna however dose histone bind bind act act dnmts cpg irreversible side effect effect remove methyltransferase division since decitabine decitabine decitabine gene gene gene approve islandsof aml progression 
1.0@appearance reduction cancer article restore use use state first agent agent likely event growth normally make type level play several lead dna dna see expression le important demethylating demethylating gene gene gene reduce tumor tumor tumor tumor question normal normal death hypermethylation hypermethylation may may methylation methylation decitabine decitabine role express cell far control supressor supressor supressor 
1.33@et et et et et et inhibitor inhibitor class interaction blood abcb oncol int hypomethylates leukemia generation decrease reactive nov intracellular specie mechanism anticancer anticancer onda onda although hdacis cell tumour tumour tumour several ro thorugh depend study drug drug mrna apoptosis shin shin reference kalac kalac anti anti type show oxygen dna dna author histone demonstrate deacetylase act expression sensitivity methyltransferase effect induce briefly suggest increase belong al al al al al al decitabine decitabine decitabine decitabine decitabine gp context re action differentways 
1.33@maybe cancer along dnmt dnmt dnmt tumor tumor myelodisplastyc demonstrate drastically normally quite effective epigenetic dependet icorporated inhibitor inhibitor enzyme total lack reduce subject methylate block casusing hypermethylation hypermethylation nucleoside like like like like bloking cell cell cell nonspecicific blockign suppressor dependent high high high irreversibly replecation analogue toxic highly low anti bind amount prevent prevent damage dna dna dna dna dna dna dna specifity dose dose dose wich wich syndrome act act dnmts dnmts drug drug gene methyltransferase effect due due methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine affliction activity action hit 
1.33@cancer cancer restore wide methyl methyl slow agent specific already myelodysplastic growth part sit hypermethylated treat island repression demethylating tumor tumor pattern normal genome genome cell use leukaemia suppressor therefore drug certain evolve revert loss gain group dna dna mark syndrome least expression cpg gene gene remove remove methylation methylation decitabine decitabine region incorporate instance would 
1.67@cancer cancer cannot dnmt dnmt dnmt use appear specific specific anti analog high lead effective irreversibly strand body methylated normally thereby reduce rapidly dilution neoplastic readily release release nucleoside cell cell cell cell cell cell drug dependent lower although fda replication replication information information dose hemi subsequent result result depletion best toxic treatment dna dna dna dna divide divide non bind bind inhibitor inhibitor methyltransferase effect copy impact impact longer thus methylation methylation methylation decitabine decitabine daughter daughter work incorporate approve action aml enough 
2.0@cancer inhibition able activate tumour tumour tumour state agent exacerbate dnmti growth hypermethylated hypermethylated treat treat island island demethylating group inactive tumourcells cell cell suppressor suppressor suppressor silent patient activation drug drug result result result become type promoter promoter hypomethylated presence dna dna dna divide act cpg cpg gene gene gene gene remove fast belong methylgroups mainly mean tumourgrowth beneficial indication decatibine decatibine 
1.67@elod plastic cancer use agent stop myelogenous reactivate lead cytosine epigenetic intracellular covalent repression precursor commit demethylating reduce reduce tumor tumor conversion neoplastic source bond triphosphate cell methyl leukaemia suppressor suppressor dependent cause suicide irreversibly fight drug analogue add apoptosis target todecitabine y anti group treatment dna dna dna dna acute cytidine syndrome gene gene methyltransferase induce belong methylation methylation decitabine work incorporate come action machinery attach 
2.0@dacogen also restore restore suppressor suppressor uncontrolled fda agent process cell cell myelodysplastic dnmti growth treat know inhibit inhibit inhibit thedna dna dna acute syndrome inhibitor dnmts demethylating gene gene aml function tumor tumor tumor methyltransferase activation normal division word thus methylation decitabine decitabine mean myeloid approve leukaemia demethylation control belong 
2.0@fail inhibitor activity hypomethylation specificity reactivation synthesize yet fda agent long hypomethylating togenome nonetheless growth make insert treat affect widedemethylation previously lead lead effective irreversibly inhibitorscontribute help term well especially cgi cgi last dnmt dnmt dnmt dnmt tumor tumor mechanism block normal life life extend thus instability cell cell cell way decitabine decitabine decitabine decitabine decitabine older suppressor patient patient quality tolerate epigenetic mitotic seem replication youngerpatients md likely expectancy inheritance fully genomic example dna dna dna understand understand bind chemotherapy chemotherapy newly drug time aml effect control approve belong new new methylation methylation reestablish gene class sensitive action enable alter 
1.33@cancer cause therefore dnmt replication replication analogue dependent agent affect action dna dna irreversibly lot bind dnmts demethylating adna inhibitor upon normal replicate decitabine decitabine nucleoside incorporate demethylation cell cell 
2.0@suppressor suppressor cancer methylating inhibition use region hypomethylating de de growth gene gene near hypermethylated occur island treat dna dna work methylate syndrome allow drug drug drug inhibit methyltransferase expression myelodyspastic methylation decitabine aberrant cpg many cell tumour tumour 
2.0@dna dna suppressor methylated restore function gene methyltransferase tumor agent normal hypomethylating thus hypomethylates decitabine express inhibit previously 
2.0@cancer investigate growth available reactivation produce induce induce uncontrolled stop inactivation myelogenous silence hypomethylation hypomethylation hypomethylation useful treat treat marrow class precursor contribute deform tumor tumor tumor link may ing case cell blood leukaemia market suppressor suppressor silent drug cause md intreat anti dna dna acute syndrome use use inhibitor inhibitor gene gene methyltransferase myeloblastic epigenetically epigenetically belong thus decitabine decitabine bone methylating 
1.67@think restore restore slowly dnmt island exposure appear agent focal process affect inhibit aza epigenetic promoter belong tumoral tumoral tumoral appropiate pattern normal normal hypermethylation clear dilute dilute genome cpg behaviour cell cell cell semiconservative expression general replication carry proper desmethylation without spot anti know presence treatment dna dna dna lot demethylating drug methyltransferase effect deoxycytidine line division division replicate go methylation methylation methylation decitabine decitabine region previous 
1.67@cancer class able methyl agent specific hypomethylating anti hypomethylates de growth hypermethylated hypermethylated treat call island dna dna dna dna dna help enzyme inhibit inhibit tumor tumor tumor may myelodysplastic like cell use suppressor drug drug drug could add result rich demethylate methylated promoter group example kind responsble lot syndrome important cpg gene gene gene methyltransferase methyltransferase effect unecessarily control belong methylation decitabine decitabine region hence hence 
2.0@inhibitor class dnmt dnmt dnmt tumor way inherit mark mark analog since dnmti generation exert exert decrease island next incorpurated methylated methylated belong tumoral stick reversable longer normal hypermethylation nucleoside methylation methylation often therefore daugther replication function cell cell cell cell anti normally amount amount severly dna dna get reverse bind bind bind bind point dnmts cpg methyltransferase effect effect effect dependant copy division replicate thereby decitabine decitabine decitabine decitabine mean active side side irriversible 
2.0@cancer cancer cancer methyltransferases class neoplasia progress use include likely shore tend stag proliferate exhibit silence unmethylated locus prevalent actively methylated well hyper hyper demethylating inhibit proliferation tumor tumor tumor pattern normal generally thus genome much read hypo increasingly similarly methyl suppressor suppressor suppressor dysfunctional metastasis hyperplasia imprint region icr agent limit stop dysplasia especially group island island island island dna dna cell cell cell cell cell cell cpg cpg cpg cpg gene gene gene allow allow control increase thereby strip methylation methylation methylation decitabine decitabine daughter wide specific beneficial 
1.67@one cancer inhibitor dnmt methyl certain fda novo myelodysplastic de growth predominant transferase inhibit inhibit syndrome dna dna profile help involve dnmts gene reduce reduce tumor tumor tumor hypermethylation methylation methylation decitabine decitabine approve suppresoor 
2.0@dacogen cancer cancer methyltransferases disrupt use slow exhibit pattern myelodysplastic myelodysplastic growth treat inhibit suppress irreversibly tumour tumour efficient thereby island severe heritability mechanism dilution hypermethylation mitoses case many cell cell cell cell way market reason dependent therefore seem mitosis result number become type halt promoter parent dna dna dna dna bind syndrome syndrome act inhibitor cpg gene gene rapidly effect silence replicate methylation methylation methylation methylation decitabine daughter time methyltransferase 
2.0@suppressor suppressor unwanted dnmt dnmt dnmt dnmt use state agent agent acute island island myelodysplastic result myelogenous hypomethylates growth anti treat effectively prevent prevent prohibit previously dna dna dna dna pass syndrome precursor division cpg cpg inhibit inhibit inhibit methyltransferase effect tumor tumor tumor job demethylating demethylating silence silence methylation methylation methylation methylation decitabine decitabine decitabine daughter maintain cell cell drug leukaemia 
0.67@cancer cancer change action drug stop hypermethylation growth generation next dna epigenetic epigenetic pass lose consequence demethylating function division decitabine decitabine daughter possible cell cell cell belong 
1.33@suppressor suppressor suppressor promote able activate tumour tumour tumour tumour agent growth anti promoter island dna expression demethylating demethylating gene gene hence effect cpg usually decitabine region cell control 
2.0@mitotically cancer cancer cancer inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor tumor tumour remodelling mark acetyl collectively hdmti generation hypermethylated heritable transferase transferase transferase transferase dna dna benefit igf epigenetic epigenetic help help kind allow control remain reduce reduce demthyl u u give chromatin like like cell cell cell cell use expression expression suppressor quantity also also imprint certain approach kill cancerous cancerous without gene gene anti methylation methyl methyl context definition several histone histone histone histone thereafter right effect hmti first increase administer demethylated hati daughter deacetylase mean hdaci dnmti dnmti 
1.0@cancer cancer cancer methyltransferases higher dnmt maturation use appear exhibit specific contrast since mitigate de fda leukemia decidable inhibit nucleotide regulate epigenetic epigenetic malignant damage enzyme inhibitor inhibitor severely proliferation myeloid tumor tumor replicate permanently neoplastic metabolic nucleoside acute like cell cell cell cell drug drug kill ul ul faster although therapeutic therapeutic seem replication replication analogue strand ability mean result low low oppose effect effect anti level level good dna dna dna dna reverse bind bind target target target aml collateral accumulate presume copy dependent methylation methylation methylation onto daughter dmnt incorporate dosage approve machinery alter progression 
1.67@inhibitor inhibitor underlie produce tumour tumour cause add mark result result dnmti hypomethylation anti methyl call prevent class dna dna dna dna dna epigenetic strand group allow control methyltransferase methyltransferase effect remove growth normal belong thus thus methylation incorportation daughter gene express cell cell cell protein replication decitabine decitabine decitabine 
2.0@suppressor suppressor also restore cytocine activity activity may agent toacute die myelodysplastic analog methyltransferases reactivate leukemia characterize hypermethylated apoptotic partially suppress treatment dna syndrome least demethylating inhibit think tumor tumor describe precursor hypermethylation vitro myelogenous ul ul gene article cell propose shutdown alter decitabine 
1.67@one suppressor suppressor cancer analogue activity growth dnmt unclear may hematological dependent precise irreversibly loss malignancy malignancy dnmti negative effective treat prevent dna dna dna divide action bind although inhibitor methyltransferase effect tumor tumor mechanism hypermethylation due hematologic decitabine nucleoside possible incorporate explanation cell cell cell cell methylation expression 
2.0@cancer methyltransferases higher able much dnmts dnmts dnmts faster newly since silence hypermethylated abnormal inhibit cpg lead irreversibly strand help dosagedecitabine responsible generally inhibitor island way reduce tumor tumor tumor tumor normal normal normal hypermethylation hypermethylation demethylation demethylation demethylation cell cell cell cell cell cell cell far replication replication replication suppressor dependent dependent therefore revise cause cause cause hypermethylationand low synthesise dna dna dna dna dna divide bind catalytic function still drug effect effect effect tolerate human thus methylation methylation decitabine decitabine decitabine decitabine complete 
2.0@cancer cancer cancer cancer article use use include agent agent shore epicentre economist regulatory might decrease inhibit back cytosine work methylated hypermethylation wikipedia island island island island tumor tumor accord affect epigenome turn turn tumorigenicity increasingly methyl suppressor suppressor promotors promotors drug drug certain certain strand describe become type prevent develop dna dna dna dna group expression cpg cpg cpg gene gene gene gene gene gene rather effect usually demethylating demethylating demethylating demethylating cleave methylation decitabine decitabine decitabine decitabine decitabine daughter mitosis methyltransferase would 
1.0@different mitotically cancer cancer cancer article class use slow agent epicentre myelodysplastic major reactivate growth possibly treat call suppress lead epigenetic methylated precursor demethylating change change tumor tumor tumor aberrant demethylation cell heritable leukaemia one also erase future drug cause decitabine highlight underlie anti type develop treatment dna mark acute syndrome gene gene effect silence myelogenous methylation desire promise 
2.0@inhibitor disrupt supressors supressors island unmethylated problem dnmti growth growth express bind effectively inhibit lead dna dna irreversibly body prevent biomechanics dnmts cpg cgi methyltransferase allow tumor tumor tumor tumor hypermethylation hypermethylation silence methylation methylation decitabine combat root treatment genome 
1.33@cancer cancer cancer cannot inhibition class class specificity dnmt dnmt synthesize use attempt island newly remain dnmti treat treat affect grow unknown irreversibly strand strand strand enzyme severely effective mechanism mechanism normal dnmtis hypermethylation parental parental nucleoside nucleoside demethylation cell cell cell cell cell tumour tumour release dependent dependent analogue analogue epigenetic replication replication cause result exact become think think dna dna dna dna dna however action bind bind syndrome syndrome myelodysplastic myelodysplastic cpg drug rapidly inhibitor inhibitor copy death belong replicate methylation decitabine decitabine decitabine decitabine daughter incorporate incorporate form methyltransferase methyltransferase 
2.0@unregulated cancer inhibitor abnormal class dnmt hypomethylate blood myelodysplastic dnmti growth growth leukemia specialization treat island cpg addition regulate irreversibly see antimetabolite precursor belong myeloid block normal normal dnmtis give nucleoside cell cell cell cell use blockage suppressor suppressor suppressor cause promote promote therefore spread analogue result tumour tumour dna dna dna dna acute bind syndrome dnmts drug gene gene gene aml function increase division division interfere thus methylation methylation decitabine decitabine decitabine decitabine incorporate death 
2.0@inhibitor available dnmt dnmt dnmt cycle cycle myelodysplastic analog growth response cytosine cytosine irreversibly strand well allow duration seven tumor block normal thus dilute cell drug suppressor lower get replication replication replication lieu apoptosis amount dna dna dna dna dna maintenance bind syndrome least month average methyltransferase expression passively consequent temporarily new methylation methylation methylation decitabine gene incorporate return differentiation 
0.33@cut dna chemotherapy demethylating heva methyl effect tumor tumor agent belong elterning cytosine decitabine anti cell group sensitiv 
1.67@tumour tumour appear agent shore increase process myelodysplastic myelogenous hypomethylation susceptible oncogene island island mayenhance mainlydriven lead lead disruption decreaselocus reversible methylated precursor pressor demethylating demethylating adna activation activation activation intergenic transposition suppress suppress hypermethylation hypermethylation instability genome cryptic icrs drug neighbour leukaemia one suppressor also andlossing indeed epigenetic epigenetic epigenetic alteration recombination wide ofdna specific depletion type region promoter promoter genomic repetitive dna intervention acute syndrome le function cpg cpg cpg gene gene chemical status illegitimate repeat repeat methylation decitabine decitabine decitabine poor tumorigenesis alter 
1.67@could could could class dnmt dnmt tumour tumour tumour sorry add specific thank honestly dnmti dnmti dnmti unmethylated make block locus locus suppress transport transport transport methylated well allow p express transportation locate guy suppressor replication create answer decitabine target idea gain complicate example dna dna dna domain methyl methyl methyl point function gene gene methyltransferase inhibitor inhibitor contain belong longer thus cop region would straightforward 
2.0@cancer proliferate restore tumour tumour tumour tumour tumour state could stop analog functional hypomethylation potential hypermethylation hypermethylated locus nucleotide lead cytosine class reactivate particularly refer thereby thereby inhibit reduce gene gene normal dnmtis give directly high cell methyl suppressor suppressor also therefore drug region inhibitiors apoptosis suppression result cancerous facilitate effect effect anti anti cytotoxic promoter promoter group dna dna dna dose environment dnmts time target function methyltransferase cellular belong methylation decitabine decitabine decitabine create incorporate attach would would dnmti 
2.0@suppressor analogue lymphoma dnmt activate tumour certain agent entire hypomethylates illness inhibit treat dna dna dna strand act epigenome demethylating gene gene along unclear mechanism rare cutaneous still may may silence decitabine decitabine decitabine incorporate like cell use 
2.0@net cancer reduce growth blood blood leukemia fda specific process inactivation dnmti hypomethylation hypomethylation potential class inhibitor allow ineffective impact impact tumor tumor tumor normal hypermethylation rely express cell cell removal drug drug suppressor suppressor include replication certain result know prevent treatment dna dna divide mark acute bind act function positive gene gene methyltransferase methyltransferase myeloid condition belong methylation methylation decitabine decitabine decitabine decitabine production approve hence 
2.0@inhibitor dnmt dnmt molecular use appear specific newly replace hypomethylation leukemia md treat island island strand methylated methylated take myeloid tumor tumor mechanism block hypermethylation hypermethylation fact nucleoside counteract cell decitabine decitabine decitabine decitabine suppressor analogue become due cause cause hemi anti occur hypomethylated dna dna dna acute bind syndrome act myelodysplastic cpg cpg gene effect unclear silence replicate longer incorporate action 
1.33@increse could methyltransferases abnormal order use agent glioma hypomethylates hypotised generation block inhibit possibile molecule molecule next next epigenetic epigenetic mgmt mgmt methylated inhibitor think demethylating interest reduce tumor conversion rmove temozolomide temozolomide nucleoside cell cell cell drug suppressor efficiency require analogue geneation pas therapy promoter adiuvant example dna dna dna dna chemotherapy act act dnmts gene gene gene effect remove remove silence methylation methylation methylation decitabine decitabine daughter region active form form 
1.33@dacogen cancer cancer cancer cancer classify activity cytidin cytidin metabolise restore use agent process process process growth growth category interference analogon tumor block normal metabolite demethylation demethylation demethylation lead lead control control blockage expression suppressor suppressor suppressor promote regain replication nucleosid cell cell cell cell cell cell cell disturb synthetical anti anti show dna dna dna dna get duplicate cytotoxic chemotherapy act function drug gene gene gene gene rapidly effect similar increase division division division methylation methylation decitabine decitabine decitabine regulate influence death 
2.0@growth growth unregulated cancer cancer category within within produce activity way agent process major similar substance substance direct call decitabinealso restore restore believe belong demethylating twofold tumor mechanism block normal normal expression anticancer thus decitabineis regulate regulate control blockage decitabine one suppressor suppressor suppressor chemotherapy promote antimetabolite antimetabolite drug cause target result number allow become know demethylation demethylation metabolism dna dna dna dna divide cell cell cell cell cell cell cell cell cytotoxic death function gene gene gene gene rapidly effect effect interact cellular increase division division interfere new methylation methylation methylation member work incorporate class 
2.0@unregulated cancer restore restore way include agent process member hypomethylates hypomethylation incorporation inhibit regulate regulate regulate believe allow demethylating twofold tumor mechanism block normal anticancer thus demethylation demethylation cell cell cell cell control blockage expression one suppressor suppressor suppressor promote relate induction drug activity result become know damage dna dna dna dna dna dna dna dna dna point function gene gene gene gene methyltransferase effect molecular growth growth increase division division interfere new methylation methylation methylation decitabine decitabine decitabine work class 
1.33@class therefore dnmt drug drug agent therapy tend mark dnmti occur island island cpg cpg dna dna dna epigenetic see bind demethylating inhibit inhibit reduce tumor tumor hypermethylation methylation methylation decitabine decitabine incorporate tissue tissue 
2.0@cancer cancer inhibitor dnmt dnmt unclear tumour tumour tumour state state fda myelodysplastic analog analog malignancy affect island cpg effective daughter strand division reduce reduce mechanism normal hypermethylation hypermethylation release nucleoside nucleoside enzyme cell cell cell drug drug suppressor dependent dependent methylating although relate replication gene anti basically dna dna divide bind bind syndrome act important still irreversible rapidly effect upon first impede word methylation methylation decitabine decitabine decitabine decitabine decitabine cant possible incorporate approve action action action haematological 
2.0@one risk cancer cancer cancer methyltransferases action alteration cycle could agent methylate de growth effect effect hypermetylation normal prevent many benefit etc dna dna epigenetic development know consider involve inhibit reduce tumor tumor inactive increase increase hypermethylation hypermethylation methylation supressors tumorigenicity gene gene active cell cell cell cell cell global decitabine 
1.67@inhibitor patient therefore epigenetic tumor use slow u u u u agent therapy certainly reverse unnexpectedly growth gene call xml xml cpg dna dna get work histone en en en en silence demethylating demethylating island chemo effect lang lang lang lang deacetylase apparently give new new routine decitabine decitabine promotor demethylisation side sensitive drug associate 
1.67@cancer critical restore synthesize use agent newly methyltransferases hypomethylation hypomethylation exert inhibit treat antineoplastic particularly responsible enzyme demethylating proliferation normal neoplastic precursor thus myelodysplastic nucleoside mammalian cell cell cell cell may leukaemia cytidine transcription replication analogue decitabine decitabine decitabine decitabine decitabine apoptosis activity result present presence dna dna dna dna dna dna dna acute syndrome function gene chemical effect induce fast cellular cellular control believe replicate replicate myelogenous rna rna incorporate incorporate sensitive differentiation differentiation methylating 
2.0@cancer cancer cancer rate growth specificity dnmt synergic may include could could find thatare susceptible susceptible make hypermethylated incorporation island chemotherapeutics molecule lead recognize irreversibly doesnt display enzyme proliferation reduce affect epigenome rely spite nucleoside like like like hdacs cell cell cell cell insert tumour suppressor decitabine decitabine decitabine dna dna dna dna dna inasmuch improve promote epigenetic manner replication replication able generalize therapeutic effect effect become background furthermore cpg treatment reduction get use inhibitor drug drug drug gene inactivate demethylation division thus methylation methylation accelerate action antitumoral would 
2.0@reduce become much cause cause agent decitabine decitabine decitabine hypomethylating suppression cannot anti hypermethylated promoter promoter suppress suppress company dna dna dna dna strand strand sell eisai demethylating demethylating gene gene effect develop silence methylation methylation rna region region incorporate incorporate express japanese tumour tumour tumour tumour tumour important 
2.0@cancer thetumor higher class target dnmt dnmt upon methyl fda leukaemia specific myelodysplastic myelogenous dnmti dnmti treat transferase whendna exert analoguesirreversibly epigenetic strand body precursor silence inhibitor severely comparatively longer longer affect release nucleoside cell cell cell dive tumour region one dependent decitabinebelongs therefore therefore replication analogue decitabine decitabine reactivate normal effect anti among dna dna dna dna get acute bind bind syndrome use function function drug gene rapidly rate epigenetically copy set division replicate methylation ul ul daughter much much incorporate first approve supressor machinery methyltransferase design 
1.67@aid abnormal class manifest use slow slow agent apoptosis anti result repetitive pathogenic genetic treat marrow locus malformed malformed dna blood blood blood tumour help involve suppression demethylating demethylating effect normal increase division decitabine decitabine decitabine bone malfunction malfunction cell cell cell cell myelodysplasia 
2.0@specifically class suppressor use drug drug drug economist underlie part sit occur effectively treat dna epigenetic aim hyper demethylating gene effect remove apr shrink may methylation allow express cell tumour tumour would decitabine 
2.0@cancer think dnmt tumour tumour include two dnmti growth incorporation lose way outcome block reduce high demethylation cell may suppressor cytidine lower relate analogue function apoptosis upregulation bind promoter dna dna dna dose dose kill cytotoxic inhibitor inhibitor hence effect methyltransferase methyltransferase reversal methylation methylation methylation decitabine decitabine possible activity covalently side associate 
0.33@series class class class class class class class class dacogen td td td td use chemically agent agent hypomethylating eisai analog de md japanese treat treat previously patient patient strand amino demethylating first myeloid insufficiency insufficiency pentofuranosyl case leukemi tbody tbody erythro secondary one tr tr cytidine researcher untreated include formula structure inhibts therapy novo table table old company dna dna dna deoxy acute syndrome myelodysplastic triazin chemical methyltransferase report treatment decitabine incorporate feasibility renal renal aml 
2.0@suppressor could hypomethylating histone hypomethylates tightly become inhibit inhibit dna dna pack around le gene gene tumor tumor thus methylation decitabine eventually like cell express kill 
1.33@abnormal bone bone dnmt produce use agent hypomethylating myelodysplastic myelogenous myelogenous make treat decrease island irreversibly marrow marrow help precursor demethylating grow tumor normal neoplastic hypermethylation may release regulator demethylation cell cell cell blood leukaemia leukaemia dnaso dependent also replication analogue epigentic low anti dna dna dose acute bind syndrome act act dnmts cpg effect remove division longer methylation decitabine decitabine nucleloside incorporate kill kill enzymatic associate 
1.33@cancer lower high dnmt dnmt seem use analogue build thing myelodysplastic since become inhibit good degree dna dna irreversibly cell cell cell bind syndrome inhibitor hypermethylation cpg island demethylated enzyme get division new new new methylation methylation methylation decitabine nucleoside thereby 
1.67@strain specifically effect depend get tumour unmethylated manner irreversibly analog part anti hypermethylated avoid inhibit dna dna dna divide bind bind least inhibitor drug methyltransferase dnmt dnmt dnmt copy believe due al decitabine decitabine decitabine nucleoside methylation incorporate incorporate come demethylation cell replication 
2.0@cancer along along dnmt n methyl methyl faster myelodysplastic analog find de leukemia nucleotide molecule irreversibly strand rate severely myeloid tumor longer outside affect release nucleoside progress case demethylation cell cell cell replication tra tra one dependent dosage use use need actually acute course dna dna dna dna dna dna divide kill bind bind bind syndrome fe inhibitor inhibitor drug right aml effect upon range copy antineoplastic division replicate rase rase methylation decitabine daughter incorporate come come approve action methyltransferase methyltransferase 
2.0@different mean cancer methyltransferases administration tumor tumour tumour tumour tumour tumour tumour every loss dnmti growth growth growth restrict inhibit lead epigenetic common inhibitor allow demethylating island enhance reduce reduce subject affect affect feature hypermethylation hypermethylation alteration express express cell uncontrolled decitabine decitabine one suppressor suppressor suppressor lower therefore imprint drug drug could extent limit case case anti type show group dna dna however expression expression important cpg gene gene gene gene single organism systemic control belong thus thus methylation methylation icrs icrs region context tumorigenesis would would 
1.67@cancer cause large although tumor tumor analogue agent toxic suppression cannot bigger dnmti bind faster dna dna dna dna irreversibly dose dose dependent effecton smaller inhibitor demethylating methyltransferase methyltransferase effect optimal division replicate suppresion release nucleoside demethylation cell decitabine decitabine decitabine decitabine 
2.0@suppressor cancer inhibitor class therefore irreversibly relate induction much apoptosis apoptosis favor result since reactivation dnmti hypomethylation anti dna dna dna divide dose bind expression dnmts gene gene rapidly effect tumor methyltransferase normal neoplastic source low methylation decitabine nucleoside incorporate silence cell cell replication belong 
1.33@suppressor cancer cancer inhibitor run becuase therefore irreversibly tumour analogue dependent dependent result result hypomethylation hypomethylation replication normal dna dna dna divide bind fe dnmts drug gene rapidly decitibine affect hypermethylation rase nucleoside incorporate cell cell cell methyl would would 
1.67@dacogen instead dnmt dnmt enzymatic use appear agent situation hypomethylating myelodysplastic myelogenous leukemia overall treat inhibit end molecule cytosine position position see particularly precursor demethylating stick reduce tumor normal hypermethylation vidaza nucleoside cell incorporate suppressor expression atom cytidine lower residue decitabine drug drug drug analogue cause attempt suppression result methylate cancerous level alike island dna dna dna dna get ring acute syndrome target cpg aml along similar tolerate contain azacitadine well well methylation methylation would work activity advantageous protein hit small 
1.67@mitotically inhibitor within dnmt dnmt progress tumour tumour likely forbid since since incorporation island epigenetic enzyme able replicate affect affect neoplastic hypermethylation release nucleoside nucleoside case cell cell cell cell genome also therefore decitabine decitabine decitabine decitabine replication replication analogue analogue analogue stay trap mean low anti prevent dna dna dna dna dose bind degradation inherit cpg methyltransferase effect effect longer methylation methylation allow daughter drive incorporate 
1.33@cancer instead inhibition dnmt dnmt dnmt dnmt dnmt may stop analog treat decrease nucleotide irreversibly tumour help mechanism separate affect hypermethylation hypermethylation nucleoside like propagation cell use one enzymatic epigenetic replication stay target anti consider methyl methyl group group dna dna bind bind methyltransferase effect try division longer go regulator decitabine decitabine work copy copy action 
1.33@suppressor suppressor cancer irreversibly relate tumor tumor replication analogue agent agent typically island island proper growth hypermethylated decrease prevent cpg cpg regulate dna dna dna dna divide bind allow demethylating demethylating time methyltransferase methyltransferase inhibitor remove decitabineare give methylation methylation decitabine nucleoside gene gene gene incorporate like excess cell cell cell would expression expression 
2.0@cancer effect reactivation use use syndrom dnmti hypomethylation treat accesible lead theese durring well tumor tumor tumor tumor tumor affect hypermethylation hypermethylation hypermethylation therfore although like cell cell cell supressor supressor supressor hardest discover therefore replication cause anti myelodysplatsic treatment dna dna divide dnmts gene gene gene methyltransferase inhibitor inhbition must reversal reversal replicate decitabine decitabine decitabine decitabine incorporate malignancie rapidly hit sofar 
1.67@dacogen cancer cannot use every trasnferases agent mark eisai myelogenous dnmti island tumorcells treat transferase inhibit heritable typical establish allow demethylating thismitotically tumor tumor precursor capable hypermethylation hypermethylation new like japanese methyl methyl methyl demethylated suppressor suppressor therefore drug cause isold cell cell acute inhibitor group company dna dna dna divide dose reverse syndrome act myelodysplastic cpg gene side effect remove silence low methylation decitabine decitabine time 
1.0@cancer cancer methyltransferases able tumour tumour likely process become since dnmti decrease island effective area methylate happen affect hypermethylation reduce nucleoside methylation methylation many cell cell cell promoter suppressor cytidine high irreversibly replication replication analogue structure toxic highly result result low anti show dna dna dna dna dna dna divide dose dose bind inhibitor cpg gene chemical effect methyltransferase similar silence longer normal decitabine decitabine decitabine decitabine incorporate rapidly associate 
2.0@heavy heavy methyltransferases inhibition nucleoside progress tumour tumour hematological agent myelodysplastic analog regard since since leukemia myesdysplastic treat inhibit solid irreversibly body body currently demethylating island island research hypo hypermethylation although methylation methylation cell cell cell use use dependent patient consequently outcome require ongoing add target condition methyl know group dna dna divide divide acute bind syndrome syndrome dnmts dnmts cpg cpg poor hence result result preferentially still myelogenous actively decitabine decitabine wide prognostic progression 
2.0@maybe cancer cancer cannot abnormal dnmt use every agent myelodysplastic reactivate say leukemia cancel treat inhibit molecule molecule achieve contribute demethylating demethylating myeloid tumor tumor mechanism affect hypermethylation release anymore like unknown bind suppressor suppressor drug cell cell fast replication vulnerable promoter dna dna dna acute greatly syndrome gene methyltransferase replicate thus methylation decitabine decitabine decitabine incorporate 
1.67@dna dna cancer cancer cancer cannot class suppressor mitotic remove remove drug require silence become since hypermethylation part sit bind occur effectively repetitive hallmark hallmark divide strand often inhibitor belong cpg methyltransferase effect tumor combine division inheritance methylation methylation decitabine daughter case cell cell methyl replication replication machinery 
0.67@reason cancer cancer cancer preferably decibatine methyl cause agent therapy cytoxicity fast healthy slower transferase lead dna dna dna bind covalent demethylating side effect replicate replicate dnmtib decitabine decitabine decitabine incorporate cell cell cell replication without 
1.0@cit cancer fix problem covalentbind bad much sorry faster cause bine mark fast de hypomethylation replication try copy lead dna dna dna dna dna strand ezyme fe thus suffer methyltransferase inhibitor upon english normal normal belong rase decitabine daughter devide devide incorporate cell cell cell cell deth methyl methyl tra 
0.67@kind cancer methyltransferases inhibition class use agent specific anti myelogenous characterize treat call prevent treatment dna dna dna dna acute syndrome precursor enzyme demethylating effect tumor hypermethylation hypermethylation thus myelodysplastic decitabine decitabine region leukaemia 
1.67@cancer cancer cancer myeloid myeloid restore essentially dnmt progress way way hematological include activity stop myelodysplastic myelodysplastic since since malignancy reactivate leukemia make regulatory treat effectively grow effective inhibitor inhibitor inhibit able tumor tumor tumor normal normal normal count nucleoside methylation demethylation cell cell cell cell cell cell cell blood blood suppressor suppressor also lower greater indicate fda replication cause adversely toxic target analogue therapy gene gene anti damage treatment dna dna dna dna dna dose acute bind bind syndrome syndrome function drug affect methyltransferase methyltransferase methyltransferase methyltransferase effect effect induce silent replicate dnmti decitabine decitabine decitabine decitabine decitabine decitabine irreversible incorporate epigenetically approve form protein de 
2.0@suppressor inhibitor class tumour tumour trigger effect anti inhibit island dna dna dna expression cpg gene gene methyltransferase impact belong word silence methylation methylation decitabine decitabine demethylation demethylation recover 
2.0@reativation hipomethylation mdr mdr mdr mdr blocksdna use agent hypomethilating analog find genetic decrease aza aza cytosine epigenetic know pyrimidine take reactivation tumor besides hypermethylation celular adm program demethylation repressor tumour tumour expression expression suppressor mielodisplasic suppresor suppresor resistance drug cause cause cause cause apoptosis low encode promoter dna dna dose cell bind bind syndrome site dnmts irreversible methyltransferase decrese induce place deoxycytidine death silence methylation decitabine decitabine decitabine decitabine desoxicitidina gene gene gene gene gene gene gene incorporate differentiation 
1.0@suppressor rebound patient may phenotype low treat level island dna reverse methylated hyper cpg prevent methyltransferase inhibitor tumor tumor methylation decitabine decitabine activity case 
0.67@myc inhibitor class last activate use state agent already two myelogenous meet threshold treat decrease decrease inhibit epigenetic epigenetic epigenetic error precursor attack demethylating proliferation tumor ezhz neoplastic sort leukaemia market suppressor quote slow drug drug drug reactivate target target result dosage like anti dna dna applicable base acute example gene gene effect increase silence thus methylation methylation decitabine decitabine machinery protein follow dnmti 
1.67@cancer cannot higher class class dnmt progress use use dnmts dnmts myelodysplastic since leukemia inhibition treat treat provide epigenetic strand strand inhibitor inhibitor administer demethylating proceed myeloid block release nucleoside nucleoside demethylation cell tumour analogue analogue demethylators therefore irreversibly drug drug cause cause low prevent prevent dna dna dna dna dna dna dna dna get dose dose acute bind bind syndrome function perform methyltransferase effect belong new methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine incorporate action modifier 
1.33@suppressor dependent lower class lymphoma activation tumor tumor agent hypomethylating suppression hypomethylates oncogene level inhibit lead dna dna counter hyper ezh gene methyltransferase effect upon overactive wikipedia wikipedia methylation methylation decitabine decitabine hypo overactivity methylator initiate associate 
1.0@distinguish suppressor suppressor cancer cancer way certain certain agent ability precursor myelogeneous de leukemia oncogene myelodisplatic important dna dna acute syndrome name give demethylating demethylating gene gene reduce reduce tumor tumor mechanism suggest hypermethylation methylation decitabine activity like like cell may belong 
0.0@cancer cancer class inhibting check use part agent agent stop chromosomal myelodysplastic myelogenous growth susceptible make make make pf treat call inhibit epigenetic tumour easy enzyme ezh ezh proliferation tumor tumor uncontrolled precursor access ensure factor cell cell methyl systemare supressor suppressor transcription chromosome methylates lymphomascancers cause cause acute mutation lot free basically immune group syndrome dna package histone histone histone chemotherapy expression drug drug gene gene hence rate overactive protein keep demethylating silence decitabine activity leukaemia attach 
1.33@mean mean cancer neoplastic able tumour require agent since dnmti transferase transferase molecule epigenetic body enzyme demethylating severely reduce longer dnmtis typically consequently divide readily release demethylation cell cell cell use enzymatic owe analogue irreversibly replication cause neucleoside target target result anti anti bind methyl good dna dna dna dna get dose dependent inhibitor inhibitor inhibitor greatly rapidly effect effect effect upon division replicate replicate regulator decitabine decitabine decitabine incorporate action generate small 
1.33@procsses epigenetic tumorous methyl include agent ability ability decitabine decitabine island target result demethylated transcribe growth hypermethylated drug drug drug among group group develop tumor tumor dna dna dna area area mehtylation silence silence demethylating inhibit able remove remove cpg genome gene gene gene mean multiplication cell cell mehtyl attach neighbour supressor 
1.0@cannot dacogen cancer methyltransferases inhibition nucleoside therefore future myelodysplastic use agent precursor irreversibly analog myelogenous leukemia bind treat affect assignment dna dna dna dna divide write write acute dependent syndrome sell dnmts dnmts demethylating inhibit rapidly impact normal division since methylation release method incorporate name cell cell cell cell replication decitabine decitabine 
1.33@cancer cancer investigate inhibition nucleoside produce use dnmts fda agent inactivation meet substance high treat avoid inhibit methylcytosine unable epigenetic reversible enzyme enzyme enzyme ezh proliferation proliferation effective tumor tumor nowadays contribute myelodysplastic substitution alteration many cell cell cell methyl suppressor transfer although include include analogue toxic test solid tumour tumour tumour group treatment dna dna however dose dose histone bind syndrome demethylating irreversible inhibitor overactive human silence silence decitabine decitabine decitabine gene gene activity approve survival small 
2.0@cancer cancer able tumour tumour unmethylated agent substantially newly round round hypermethylated genetic treat treat dna dna dna dna lead lead area strand strand pass methylated well time demethylating reduce longer question affect hypermethylation hypermethylation dilute silence vicinity potentially possible expression expression suppressor patient certain hereafter suppression describe methylate level level parent synthesise several divide cell cell cell cell cell function gene gene gene gene gene gene methyltransferase inhibitor place first increase division treatment disappear methylation methylation methylation decitabine decitabine decitabine decitabine mitosis original influence complete hence follow associate 
2.0@suppressor suppressor suppressor cancer cancer transcription transcription transcription inhibition dnmt dnmt dnmt dnmt mecpg mecpg drug slow agent hypomethylating transcribe growth possibly replication condense decrease decrease decrease inhibit inhibit occur act act tumor tumor tumor tumor dna via promoter promoter bind le site thereby gene gene gene inhibitor inhibitor induce chromatin increase may may work methylation methylation methylation methylation decitabine decitabine aberrant cell cell control would region 
2.0@cancer cancer cannot produce use use agent process myelogenous hypomethylates de de treat inhibit molecule position strand methylate methylated precursor allow island island pair guanine hypermethylation hypermethylation carbon although cell cell cell cycle cycle myelodysplatic leukaemia suppressor suppressor suppressor cytidine carry necessary hallmark replication analogue decitabine decitabine decitabine decitabine continuous ability add product typically reverse promoter prevent tumour tumour tumour dna dna dna dna dna dna dna base acute syndrome expression cpg cpg drug methyltransferase inhibitor silence methylation inappropriate gene gene gene incorporate downstream protein methylating associate associate 
1.67@cancer cancer classify within effective cytoplasm progress leukemia fda long myelodysplastic myelogenous action action dnmti change normality incorporation treat unknown unknown irreversibly pass term well inhibitor severely undesired mechanism neoplastic hypermethylation thus thus medium nucleoside actively cell cell cell cell cell cell example market dependent transfer dosage erase epigenetic selective drug drug analogue acute subsequent result low cancerous whether meet anti bind prevent unwanted nucleus dna dna dna divide kill ase syndrome dnmts effect effect effect relatively division continually methylation methylation decitabine decitabine decitabine decitabine daughter work moreover approve towards reverse frequently 
1.33@suppressor cancer use use use drug agent myelodysplastic natural acute treat decrease decrease prevent dna dna dna body inappropriately syndrome precursor allow demethylating gene impact mechanism silence defense myelogenous methylation methylation decitabine decitabine work tumour leukaemia 
2.0@mitotically often neoplastic inhibition class dnmt dnmt dnmt dnmt dnmt adhesion use include agent sam md md md characteristic de hypomethylation leukemia characterize treat hemimethylated inhibit response form regulate cytosine epigenetic epigenetic clonally demonstrate establish hypermethylation demethylating island enhance change block though feature methionine may myelodysplastic greatest methylates case primarily treatment global indicate leukaemia one drug drug patient action concentration cancer take novo success methylation methylation occur know experience together syndrome dna dna dna dna mark methyl greatly adenosyl function cpg cpg gene methyltransferase methyltransferase heritable induce increase dinucleotides good thus choice decitabine decitabine decitabine decitabine activity donor proliferation tissue 
1.0@dacogen cancer metastasis therefore regain agent suppression growth growth gene know island demythelation dna better involve function cpg prevent prevent tumor control death methylation decitabine region program cell cell cell enable 
1.67@cytosine also abnormal abnormal high therefore tumor tumor either agent agent decitabine decitabine decitabine apoptosis cell cell chromatine low reactivate hypomethylation treat marrow inhibit inhibit reverse dna dna dna dna dose dose kill myelodysplastic demethylating demethylating gene methyltransferase induce induce similar hypermethylation synodromes silence methylation repair utilize aberrant supressor would would would azacitidine 
2.0@elod plastic specificity mitoric tumour ofren agent demethylating normalcells myelogenous dnmti change iscurrenly effective irreversibly consider responsible enzyme risksof adna proliferation reduce heritability ordnmtinhibitor affect lack nucleoside expression decitabineis cell use use precedeacute leukaemia suppressor dependent also epigenetic replication analogue combination withan slow y solid show dnmtiswere dna dna especially bind syndrome dnmts decitabinerestores gene inhibitor deacetylase antineoplastic division thus thus methylation decitabine incorporate hystone 
0.0@dacogen substance lymphoma activity activity methyl include agent stop chromosomal silence eisai myelogenous reactivate growth part make treat call inhibit inhibit tumour tumour precursor enzyme enzyme ezh ezh uncontrolled normal japanese use use leukaemia suppressor suppresor histone histone histone histone methylates cause mutation cell acute demethylate know group company dna package surround syndrome sell myelodysplastic gene gene gene remove overactive protein protein demethylating thus decitabine decitabine theory overactivity attach 
2.0@suppressor cannot cannot dnmt use analogue inhibitor agent decitabine decitabine mark target reactivate growth tumour tumour tumour tumour transferase nucleotide molecule potentially dna dna dna irreversibly bind act act enzyme demethylating continue reduce reduce reduce replicate methylation methylation genome incorporate maintain cell cell methyl methyl hyper small 
1.33@cancer cancer cancer characteristic also also dnmt adhesion activity use use agent myelodysplastic analog find de potential hypermethylation treat transferase island lead cytosine show involve enzyme thereby take efficacy tumor tumor tumor block block hdac formation repair aberrant demethylation cell cell cell cell cell cell cell methyl suppressor cytidine methylating drug cause combination could could cycle apoptosis context anti arrest promoter hypomethylated dna dna dna dna dna divide divide non reverse reverse bind syndrome inhibitor cpg irreversible rapidly effect induce increase silence replicate replicate since decitabine decitabine resistance gene gene incorporate differentiation selectively 
1.67@mean cancer cancer methyltransferases class outcome methyl add mark newly dnmti hypermethylated tumour tumour tumour unable dmnts epigenetic even show inhibitor inhibitor silence undergo block permanently usually nucleoside case cell blood suppressor become become patient excessive replication analogue strand strand defend incorporate result cancerous anti solid know group good dna dna dna dna dna trialled bind well site dnmts drug gene gene methyltransferase effect belong replicate methylation decitabine decitabine decitabine work lay active form onto functional 
2.0@suppressor drug effect lymphoma dnmt dnmt dnmt tumor tumor tumor say cause cause inhibitor agent add md analog since hypomethylates anti tsg treat group group action dna dna epigenetic cytosine acute act allow demethylating gene gene reexpression remove block belong silence decitabine myeloid thereby methyl methyl machinery 
2.0@suppressor suppressor patient able use analogue md md example sufficient cytosine make hypermethylated treat marrow demethylation common dna dna dna epigenetic many many syndrome expression bone gene gene methyltransferase inhibitor tumor tumor normal division silence myelodysplastic allow disorder disorder work incorporate ink ink cell cell cell differentiation blood blood decitabine decitabine 
2.0@elod dacogen critical inhibition restore proliferate use concentration agent eisai myelogenous cytotoxicity hypomethylation hypomethylation direct exert inhibit adduct achieve antineoplastic covalent treat demethylating proliferation brand plastic normal neoplastic precursor phosphorylation insensitive cell cell cell may may formation leukaemia commercialize also incorporation drug cause cause apoptosis suppression relatively acute syndrome dna dna dna dna dna dna dna dna divide non synthesis decetabine name function gene methyltransferase methyltransferase effect induce cellular cellular control believe y vitro major methylation decitabine decitabine decitabine decitabine decitabine decitabine attribute incorporate differentiation differentiation rapidly 
0.67@dna dna suppressor transfer ase allow gene tumour agent hypomethylating meet hypomethylates decitabine express better inhibit 
2.0@cancer cancer cancer methyltransferases methyltransferases able methyl methyl slow agent epicentre myelodysplastic instead economist growth treat decrease inhibit nucleotide previously advance cytosine epigenetic epigenetic work tumour tumour enzyme group group people inactive like like way suppressor lung dna dna dna dna dna dna dna transfer transfer indeed drug drug analogue combination hypomethylating describe describe reaction normally furthermore island several process mark histone bind bind syndrome use cpg affect chemical inhibitor inhibitor inhibitor remove deacetylase catalyze methylation methylation decitabine decitabine decitabine decitabine decitabine gene article methyltransferase azacitidine 
0.67@think class start say slow agent stop process process trigger anti promoter many dna dna development cell name hypermethylation demethylating demethylating effect tumor belong methylation contrary counteract tumoral drug drug would decitabine decitabine 
1.67@cancer cancer cancer cancer usual methyl methyl agent agent agent agent agent specific tend cellular growth growth hypermethylated island island suppress cytosine cytosine enzyme demethylating demethylating demethylating demethylating inhibit tumor tumor tumor grow normal hypermethylation hypermethylation usually maintain maintain cell cell cell cell suppressor suppressor locus depend replication could add limit limit express type group group dna dna dna dna dna divide divide act cpg cpg cpg cpg cpg gene gene gene rapidly allow allow remove remove remove stage silence silence methylation methylation methylation methylation decitabine decitabine decitabine methyltransferase operate 
0.33@methylating suppresor demethylates consequently tumour mutation anti surround make methyl lympomas inhibit ezh ezh ezh dna histone histone enzyme demethylating group effect tumor overactive block protein belong silence decitabine activity activity attach 
1.33@cancer restore therefore compact agent switch eventually hypomethylation normal inhibit lead lead dna dna dna dna dna dna level bind responsible enzyme demethylating gene gene methyltransferase methyltransferase expression expression growth chromatin hypermethylation methylation ul ul daughter incorporate cell cell cell control decitabine decitabine 
1.33@cancer inhibitor inhibitor dnmt use myelodysplastic myelogenous treat nucleotide irreversibly strand body precursor severely replicate affect divide release nucleoside cell cell drug leukaemia specifically dependent therefore epigenetic replication analogue mean mean dna dna dna dna dna get acute bind bind syndrome methyltransferase methyltransferase methyltransferase methyltransferase along upon copy division longer methylation decitabine daughter much incorporate come action rapidly 
2.0@suppressor loss methylating dnmt necessary use hematological agent hypomethylating target since malignancy sit transferase inhibit dna dna dna divide pass syndrome act myelodysplastic especially gene expression tumor increase thereby methylation methylation decitabine decitabine decitabine cell methyl 
2.0@cancer methyltransferases class tumour agent transfer example mark since hypomethylates overall inhibit inhibit epigenetic development methylate involve establish enzyme as pattern contribute reduce alteration read demethylation cell level machinery sense also suppresor decibatine either tumout usage mutate mutation version express anti could prevent promoter dna dna dna dna decitabin expression dnmts gene gene effect effect belong thus methylation methylation methylation meet alter 
2.0@cancer cancer cancer cancer cancer article class dnmt dnmt administration progress use use fda reversible process myelodysplastic critical economist hypomethylation sit approve treat dna epigenetic epigenetic epigenetic epigenetic strand tumour shrink myeloid word question question affect affect lack epigenome may count manufacture push knowledge role regulator minimal cell cell cell cell cell tissue food leukaemia one enzymatic patient however necessary alteration epicentre cause healthy decitabine decitabine decitabine decitabine side target target describe low reference maintain replication replication develop company several divide dose acute syndrome inhibitor drug drug drug drug drug drug drug rapidly effect effect explain belong due epigenetics methylation pharmaceutical daughter work incorporate active play machinery pattern recently 
0.67@suppressor returnig dmti cncer may state state apoptosis tumor capable functional wich group family lead epigenetic histone help drug gene remove previous belong decitabine toits toward express return cell cell cell methyl 
2.0@cancer transfer dnmt dnmt relate tumor replication cause island suppression analog meet hypermethylated inhibit inhibit nucleotide action dna dna dna dna irreversibly sequence ase bind inhibitor enzyme drug drug drug gene reduce reduce heritability cpg mitotic methylation methylation decitabine nucleoside tumorigenicity integral demethylation cell incorporate 
1.33@aspect cancer cancer inhibition restore commonly list model unclearly include agent agent originally stem analog member reactivate reactivate growth clearly xenograft tsg grow response breast epigenetic development shrink demethylating demethylating inhibit chemosensitizer tumor affect repair nucleoside induction role high cell cell cell cell checkpoint control exposure tsgs window drug drug implicate answer cause cause apoptosis renew low without trigger cytotoxic antitumor could damage family subpopulation dna dna dna dna pathway dose dose mechanistic chemotherapy act function function differentiation expression expression expression cellular resemble belong silence decitabine decitabine decitabine decitabine decitabine develop gene gene activity self alter azacitidine azacitidine 
0.0@manifestation spanish code inhibition disease attempt specific thank thank cure since since raise visible genetic quite treat decrease deeper regulate mention mention discuss health research p link turn professional role read read read significant try mistake study transcription pathological future drug drug either ie product approach stop problem type level level treatment treatment treatment superficial medicine domain plane plane example expression expression expression source symptomatic symptomatic true talk talk systemic minimize apologize possible language protein question 
2.0@suppressor cancer effect irreversibly replication include dependent anti since silence inhibitor overmethylation bind copy island nucleotide nucleotide dna dna dna dna get strand methylated le division cpg gene gene methyltransferase methyltransferase inactivate tumor tumor along increase belong thus decitabine decitabine decitabine decitabine daughter incorporate come cell 
2.0@methyltransferases dmta tumor may may note agent mark mark since since reactivate apply potential hyponethylation decrease inhibit inhibit suppress lead repsobsible epigenetic methylated methylated demethylating detect dmtas hypermethylation hypermethylation turn unusual genome instability cell cell cell cell cell screen lower wild amount hemi epigenomes cancerous anddecitabine demethylate type fully promoter parent parent genomic dna dna dna dna act act important cpg cpg gene gene inherit inherit sincedecitabine globally methylation methylation methylation decitabine decitabine daughter region mean mean across easier 
2.0@reactivation reactivation progress trip agent hypomethylating myelodysplastic analog myelogenous de hypomethylation treat inhibit fosforylated lead demethylating intracellularly nucleoside role case cell cell tumour tumour tumour supressor supressor leukaemia hate ho decitabine decitabine decitabine apoptosis result ultimately cytostatic prevent oxy dna dna dna get acute syndrome act function gene gene methyltransferase inhibitor onset normalisation selective tid genepromoter incorporate progression differentiation play 
2.0@dna one cell class theb produce methyltransferase inhibitor deform belong condition decitabine marrow blood toa 
1.67@ogioing use include prove since since malignancy tumour tumour tumour transferase irreversibly anologue decitabinein myelodyspastic hypermethylation nucleoside many trial methyl supressor beleived dependent dependent lower high therefore therefore replication inhibotrs toxic tuours solid good dna dna dna dna however dose dose bind syndrome incorpared gene aml effect effect scientifically decitabine decitabine decitabine decitabine decitabine decitabine decitabine much incorporate approve methyltransferase haematological 
1.0@could could could demethylates overmethylation use state manner agent specific myelodysplastic myelogenous hypomethylation normally make treat response class malignant sequence methylated precursor give demethylating effective tumor tumor epigenome although instability demethylation tumour help help leukaemia dna also patient drug cause slow reverse anti suscpetible occur severe genomic syndrome standard acute chemotherapy act gene effect effect upon growth belong thus decitabine decitabine region eventually supressor generate would would would associate 
1.67@dna area demethylating tumour effect intergenic agent remoove remoove methylation methylation genome region anti element repetetive 
1.67@suppressor cause unwanted include dnmti growth gene gene partially dna dna development allow prevent prevent continue inhibitor tumor normal hypermethylation methylation methylation genome wide mean express many cell methyltransferase decitabine 
1.33@myc cytidine transcription lower lower malignancy use agent anti analog major hypomethylates gene gene derivative definitely drug level group regulate regulate dna dna dna dna epigenetic deoxy contribute demethylating inhibit methyltransferase expression expression mechanism belong epigenetics epigenetics decitabine factor incorporate like brd cell control azacitidine 
1.67@important important distinguish cancer cancer cancer cancer cancer similarly class methyl encourage fda likely specific specific myelogenous accordingly characterize breakthrough might transferase inhibit decogel epigenetic epigenetic development promoter leukaemia inhibitor enzyme demethylating demethylating hypomethylated research tumor develop feature hypermethylation spite genome demethylation company de first belong one specifically methylating large deleterious action myelogenic general drug drug drug em novo cell result acute commercially novel region among progression damage damage treatment dna dna authorize japanese syndrome sell epigenetics effect effect jq generic realization ezh since decitabine decitabine wide contrary beneficial azacitidine 
2.0@dacogen cancer cancer myeloid cgis heavy activate progress use agent myelodysplastic analog eisai dnmti dnmti leukemia md md md japanese tumour effectively nucleotide irreversibly strand copy well demethylating cgi dnmt dnmt longer affect hypermethylation style style release nucleoside factor hypermethylated cell cell cell cell much decitabine decitabine decitabine decitabine decitabine justify justify suppressor dependent divide replication text text align align kill body come act act methyltransferase company dna dna dna get acute bind bind syndrome sell inhibitor poor rapidly along upon characterise tolerate division replicate methylation prognostic daughter severely incorporate perhaps approve action aml would 
1.0@cancer inhibitor inhibitor term progress use fda long really two analog say leukemia dosis dosis affect treat irreversibly body know demethylating myeloid tumor mechanism normal neoplastic myeodysplastic release nucleoside demethylation cell cell cell cell methyl methyl kill one dependent transfer transfer get replication drug acute low low anti anti show furthermore good dna dna dna dna dna divide action action bind syndrome act still rapidly effect effect effect effect unclear range division longer thus decitabine much incorporate upon approve tumoral would recently 
2.0@cancer myeloid restore gradual dnmt dnmt dnmt activate tumour tumour appear agent become analog carcinogeneis decrease decrease decrease decrease island dna dna dna dna dna dna often irreversibly effectively help well allow demethylating grow effective week suppress give turn cell cell cell level level level level level several cytidine cytidine activation excessive activity low low anti show promoter reduction dose dose bind cpg gene gene gene methyltransferase effect place must silence silence silence methylation methylation methylation methylation decitabine decitabine work incorporate incorporate active 
1.67@dacogen cancer cancer cancer article stable class tumor tumor use use inhibitor inhibitor agent willstop epicentre eisai myelogenous change change treat grow often epigenetic epigenetic anepigenetic precursor belong demethylating granddaughter mechanism hypermethylation turn turn turn myelodysplastic many japanese tumour leukaemia one suppressor suppressor pigenetic drug cell cell cell cell cell cell describe finally without anddecitabine anti company dna dna expression acute syndrome sell inherit gene gene gene effect control division methylation decitabine decitabine decitabine decitabine decitabine daughter kill would would 
2.0@suppressor suppressor suppressor cancer cancer cancer able via drug inherit destroy stop agent really irreversibly fast hypomethylation methyl affect affect act whereas dna dna dna dna dna divide divide mark bind responsible le division gene gene methyltransferase methyltransferase methyltransferase methyltransferase inhibitor tumor tumor tumor pattern generate normal belong silence silence methylation decitabine decitabine decitabine work incorporate cell cell cell cell cell cell far protein switch 
1.33@cancer along use fda agent hypomethylating myelodysplastic daugter hypomethylation inhibit act strand differentation happen replicate nuclesoside demethylation incoporated methyl methyl tra tra dependent race thats replication cause cause low need good treatment dna dna dna dna dna dose cell bind bind syndrome fe fe irreversible aml effect upon analog cellular copy division antineoplasic rase methylation decitabine progressive come approve recently 
2.0@dacogen inhibitor restore dnmt regulation tumour tumour analog effectively inhibit class silence silence proliferation proliferation downregulation dysregulation hypermethylation hypermethylation thus thus thus role cell cell suppressor central market sensitivity cytidine excessive cause apoptosis apoptosis downregulating bring anti prevent dna reverse expression gene gene gene gene methyltransferase effect induce induce cellular belong tumourogenesis methylation decitabine decitabine decitabine action differentiation play 
1.67@cancer cancer rate restore specificity dnmt use although fda specific myelodysplastic analog toxicity md drug drug drug drug transferase irreversibly strand methylate orderly provide reduce mechanism normal neoplastic hypermethylation genome nucleoside like demethylation cell cell methyl decitabine one cause high epigenetic replication replication replication certain improve dose mean result low come anti methylation better prognosis dna dna dna dna profile non bind syndrome inhibitor dependence progressive effect effect due main main sort expect daughter much incorporate confer approve action protein 
2.0@tendency cancer methyltransferases dnmt tumour tumour tumour myelodysplastic methyltransferase lower dnmti leukemia md island epigenetic strand reversible precursor consequence inhibitor impact hypermethylation reduce nucleoside myeloid demethylation cell cell cell cell drug suppressor cause become depend depend replication carry analogue anti promoter adequate somatic treatment dna dna dna dna dna divide divide dose acute bind bind syndrome dnmts cpg gene aml important fast methylation methylation decitabine decitabine decitabine daughter mitosis incorporate action rapidly 
1.33@dacogen cancer rate higher devision effective use untouched include agent receive myelodysplastic myelodysplastic remain almost treat transferase island incorporation lead irreversibly strand strand severe therefore allow proliferation happen tumor normal normal lack hypermethylation dilute nucleoside demethylation cell cell cell cell cell methyl methyl dependent rat replication analogue finally moreover level group presence dna dna dna dna dna dna dna bind syndrome syndrome cpg drug drug continue effect dependant death division division replicate low methylation methylation decitabine daughter daughter much cancerous 
2.0@et cancer cancer cancer randomize outcome use manner kantarjian phase hypomethylating myelodysplastic myelodysplastic hypomethylates treat treat inhibit dna dna dna dna dna jp issa strand methylated tumor tumor although express many rna suppressor suppressor withdecitabine iii patient c promotors improve april result demethylated study rosenfeld syndrome syndrome function gene gene similar epigenetics al decitabine decitabine decitabine em em incorporate incorporate cpgs azacitidine azacitidine 
2.0@heavy cancer cancer inhibitor dnmt prove malignancy dnmti regulatory affect island island regulate irreversibly around particularly inhibit proliferation reduce normal normal hypermethylation hypermethylation nucleoside cell cell cell cell cell promoter dna dna dna dependent replication replication analogue likely activity activity fast see see differentially promise concomitant prevent damage reduction bind syndrome cpg cpg gene gene rapidly myeloblastic silence replicate replicate thus decitabine haemopoietic incorporate incorporate strongly action methyltransferase associate 
2.0@elod loss larger abnormal abnormal growth use use agent specific cancause methyltransferases cytotoxicity hypomethylation leukemia direct treat locus disruption lead lead trna tumour icrswhere precursor demethylating hypermethylation polyribosomes high factor express cell causesapoptosis supressor cute azacitidinein also incorporation incorporation incorporation decitabine imprint drug drug overexpressed extent pal activity low caninhibit y case case bind prevent covalent dna dna dna dna dna dna dna dna dose dose synthesis acceptor syndrome function gene methyltransferase induce tic antineoplastic ofthe myelogenous methylation rna rna rna hematopoietic incorporate endinhibition form protein azacitidine azacitidine 
1.0@dna myelodysplastic acute leukaemia syndrome precursor demethylating use myelogenous agent treat 
1.67@cancer cancer cancer class dnmt upon use analog currently inhibit dna dna dna dna dna dna irreversibly quickly hypermethylation tumor prerequisite nucleotide blood blood moderate turn genome high counteract cell drug manage belong suppressor fight seem replication replication toxic typically demethylation demethylation reason divide dose dose bind act methyltransferase inhibitor induce preferentially global global administer since methylation decitabine decitabine decitabine decitabine drive incorporate incorporate action 
2.0@suppressor suppressor cancer therefore therefore formation tumor tumor tumor tumor cause cause agent stop overgrowth anti hypermethylated could dna dna demethylating gene gene gene gene gene proliferation effect remove remove silence silence methylation decitabine decitabine otherwise cell cell hence would would 
2.0@dna dna cancer cancer reactivation regulation regulation biological agent aberrantly cycle apoptosis derivative significance recognize deoxy cell powerful involve involve expression demethylating gene gene gene inhibitor silence ofazacitidine methylation methylation decitabine decitabine role increasingly 
1.67@suppressor cancer action seem use analogue manner agent hypomethylating target myelogenous largely type treat inhibit act tumor tumor dna strand acute bind syndrome precursor dnmts still gene methyltransferase unclear mechanism similar permanently blood hypermethylation silence remove decitabine many leukaemia trial replication nuceloside azacitidine 
1.67@cancer methyltransferases methyltransferases term excess may agent tend myelodysplastic since substance overall drug inhibit irreversibly strand level responsible demethylating reduce normal normal long life genome high maintain many cell cell cell cell mimic use care dna dna dna dna dna dna dna dna dna however relate study need need dose dose likely yet low therapeutic toxic particular kind divide base base bind bind bind syndrome cpg methyltransferase effect copy end replicate well methylation methylation methylation methylation decitabine decitabine daughter work work typically 
0.0@myc myc myc myc myc myc transcription promote epigenetic epigenetic myeloma drug state include cause mitosis slow myelodysplastic result encode hypomethylation overactivating hypermethylated decrease hypomethylating call syndrome function gene gene gene gene gene proliferation overactive block block block regulator decitabine decitabine decitabine promotor factor activity case brd brd brd brd cell protein alter 
2.0@cancer methyltransferases loss cytosin mark analog proliferate decrease island lead irreversibly even methylated hyper instead inhibit proliferation tumor tumor round hypermethylation propagation cell cell cell cell cell fast pathologically suppressor suppressor cytidine decitabine decitabine decitabine induction replication replication cause silencedtumor trap result dna dna dna dna dna dna dna divide covalent expression cpg gene methyltransferase inhibitor apoptosisof belong senescence silence methylation methylation complex incorporate form 
1.67@suppressor suppressor cancer inhibition therefore dnmt dnmt dnmt dnmt island cause cause precede since occur decrease inhibit inhibit dna dna dna dna divide strand strand uncontrollably methylated responsible hyper cpg gene take inhibitor tumor tumor methylations keep division replicate replicate methylation methylation decitabine decitabine decitabine active cell cell cell control 
1.67@occurrence incorporatedinto cancer suppresor class decatibine agent result silence silence gene useful hypermethylated might effectively inhibit dna dna overcome involve hypermethylation hypermethylation demethylating island methyltransferase tumor demethylationand belong thus thus decitabine nucleoside region demethylation instance associate 
1.33@market cancer effect dnmt use use already myelodysplastic myelogenous dnmti dosis nucleotide irreversibly strand treat division demethylating severely replicate affect precursor directly cell cell cell cell far tumour belong one epigeneticaly replication replication mean lot anti group aproved dna dna dna dna dna dna get four acute bind bind syndrome act act act inhibitor inhibitor drug drug drug drug drug methyltransferase methyltransferase methyltransferase methyltransferase along upon dependant copy great longer methylation decitabine daughter incorporate come action small 
0.33@cancer cancer hypermtylated tumour cause likely could inibit apoptosis anti administrate growth make hypermethylated drug island island cpg cpg cpg dna mark even mind act impede demethylating hypomethylated take effect division methylation decitabine gene gene gene limit like cell cell cell control 
0.0@lat inhibitingdna pome use agent myelodysplastic acute cytotoxicity treat thy damage dna dna dose histone syndrome precursor ah methyltransferase induce deacetylase myelogenous decitabine high hypomethylates experimentally rapid leukaemia 
1.67@et et cancer cancer cancer cancer cancer randomize outcome uncontrolled include agent stop april myelodysplastic myelodysplastic myelogenous myelogenous hypomethylates growth leukemia hypermethylated treat call inhibit aza surround jp issa decrease therefore precursor silence demethylating adna reduce hypermethylation hm cell cell cell tumour suppressor suppressor iii patient patient c brien cause improve therapy chronic result result acute thetumour phase doi doi methylation immune pmid pmid dna dna dna blood histone rosenfeld syndrome syndrome use gene gene methyltransferase cortes deoxycytidine especially kantarjian kantarjian al al decitabine decitabine decitabine august study 
2.0@cancer inhibitor dnmt dnmt others use manner agent stop find reactivate growth leukemia resist treat locus response tp strand tumour tumour tumour tumour proliferation myeloid affect hypermethylation turn incorporate nucleoside demethylation may may cystosine specifically destroy also promote need analogue novo proper local anti arrest damage dna dna reverse cytidine cytidine suppression drug drug gene target expression expression induce similar methylation decitabine eventually eventually hence de 
1.67@cannot class class western western dnmt dnmt dnmt dnmt relieve every include mark dnmti overall tumour tumour effectively island irreversibly adult methylated enzyme enzyme demethylating inhibit inhibit dilute release substrate cell cell methyl nuceloside suppressor therefore replication analogue hemi mean anti dna dna dna dna dna dna maintenance bind act inhibitor cpg gene gene methyltransferase methyltransferase effect effect division division due silence silence silence methylation methylation methylation decitabine decitabine incorporate action require 
0.67@dna development disrupt demethylating provoke tumor agent pattern belong methylation decitabine influence indirectly cancer 
1.67@cancer class dnmt tumour tumour stop stop myelodysplastic reactivate growth hypermethylated island island cpg cpg cpg cpg cpg strand methylated methylated belong inhibit tumor maintain propagation propagation cell cell cell cell cell expression expression suppressor suppressor divide hemi prevent particular dna dna dna dna dna get dinucleotide bind syndrome act dnmts dinucleotides gene gene methyltransferase methyltransferase methyltransferase methyltransferase inhibitor inhibitor inhibitor copy division replicate new new new methylation methylation methylation decitabine decitabine daughter action 
2.0@mean cancer cancer toxicity class summary epigenetically use dnmts dnmts trap stop decitabines myelodysplastic reactivate change regulatory hemimethylated inhibit inhibit significant epigenetic epigenetic epigenetic epigenetic strand body inhibitor inhibitor silence especially severely tumor round affect expression nucleoside second demethylation cell cell way belong one suppressor dependent lower high decitabine decitabine decitabine decitabine alteration replication analogue therapy nonspecific target result result reversible become methylation methylation antitumor presence treatment dna dna dna dna dna divide dose dose synthesis bind syndrome function drug drug gene gene rapidly effect proportion methyltransferase growth division regulator double much activity upon action full enzymatic 
2.0@elod plastic cancer cancer article class seven activate marnie use state stop stop economist magazine surpressor treat copy epigenetic tumour methylated enzyme dr expressionmodule acknowledgment thus name cell cell methyl decitabine decitabine decitabine see transfer dnmt april upontumour meet suggest th withheavy anti group dna dna maintenance ase syndrome act inhibitor gene gene gene effect control belong mother epigenetics methylation ul ul daughter region y bring action blewitt 
1.0@higher higher growth effective tumor tumor use agent suppression myelodysplastic response response hypomethylation hypomethylation treat inhibit acc addition promote clinical epigenetic show hypermethylation demethylating protein proliferation adjuvant mechanism mechanism mechanism block normal expression expression expression link induce hematologic stimulation demethylation cell cell cell may recover decitabine decitabine decitabine decitabine decitabine decitabine decitabine suppressor lower lower patient depend nonreversible pharmacologic therapy exhibit property synthesis gene gene gene immune covalent dna dna dna dna however dose dose dose dose dose reverse syndrome support right methyltransferase disease dual establishment suggest silence silence treatment thereby allow advance possible incorporate ink ink ink action differentiation antitumoral associate 
0.67@think abnormal use second agent two cytotoxicity hypomethylation direct inhibition incorporation mention inhibit treat weaken marrow involve silence silence demethylating reduce mechanism mechanism hypomethylates signal demethylation cell cell may may activation cause stability prior result gas occur group relative dna dna dna dna dna dna dna methyl syndrome myelodysplastic gene gene methyltransferase effect remove first death bone thus methylation decitabine decitabine confer action 
2.0@cancer class activate induce methyl mostly repliction hamper analog since since transferase island nucleotide unreversably development common demethylating reduce tumor tumor tumor tumor tumor affect feature hypermethylation high many cell cell cell replication suppressor suppressor also therefore concentration spread cause cause agent transcribe promoter promoter demethylation demethylation iteracts dna dna dna dna dna dna dna divide cytotoxic dnmts dnmts cpg gene gene inactivate upon death belong citotoxic decitabine decitabine decitabine decitabine mainly incorporate action organism 
1.33@dysfunctional cancer transcription suppressor include tumour tumour chemically hypomethylating result find similar hypomethylation effect make drug drug inhibit inhibit demethylation molecule regulate dna dna dna dna process component act silence demethylating gene methyltransferase methyltransferase reduce big epigenome turn structure rna rna region replication active cell similarity would decitabine decitabine decitabine decitabine decitabine 
1.33@cancer cancer cancer similarly excess use dnmts duplication inhibit inhibit analog find make treat inactive string suppress azacitidina cytosine cytosine development body inhibitor inhibitor think instead severely reduce tumor conversion affect affect turn myelodysplastic although role cell cell cell cell cell may decitabine decitabine decitabine decitabine split dependent nucleoside activity portion normally methyl methyl group group chain dna dna dna dna dna dna dna action syndrome act act function gene gene gene rapidly inactivate increase division silence methylation methylation rna work incorporate incorporate incorporate hypomethylationdna form methyltransferase methyltransferase methyltransferase azacitidine azacitidine 
1.67@effect class class dnmt dnmt methyl agent anti dnmti dnmti make enzimes enzimes enzimes island tumour tumour prevent prevent inhibitor silence inhibit inhibit put block inactive besides grup turn turn turn use suppressor enzime enzime indicate drug letter mean sequence need methylated know group turmours name act important cpg gene gene gene gene gene function function function function function function function belong belong due decitabine decitabine decitabine decitabine decitabine decitabine decitabine region region region hypomethylated hypomethylated classe active active operate 
0.67@plastic cancer article use drug agent stop cell myelogenous without battle level grow treat acute epigenetic kill help syndrome dnd refer demethylating precursor belong act leukaemia decitabine y lod tumour would azacitidine 
2.0@cancer reexpression dnmt use clearly loss shore mark myelodysplastic analog leukemia inhibit disruption epigenetic epigenetic belong island island myeloid tumor tumor tumor mechanism hypermethylation cytidine demethylation cell tumour suppressor suppressor suppressor dependent irreversibly replication frequent promotor result result anti occur action treatment dna dna dna dna understand acute bind syndrome inhibitor inhibitor gene gene gene methyltransferase methyltransferase effect upon division methylation decitabine decitabine decitabine incorporate cpgs cpgs 
0.33@cancer cause greater patient assist tumour tumour slow slow agent prove prove seek methylating growth success hardimpenetrable treatment treatment lung histone consider chemotherapy chemotherapy inhibitor demethylating rate deacetylase increase shrink allow advance advance otherwise cell use decitabine decitabine 
0.67@dacogen cancer cancer cancer cancer inactivate use agent example myelodysplastic myelogenous hypomethylates treat island lead precursor demethylating inhibit tumor hypermethylation cell cell line leukaemia one dna dna dna drug reexpressed prove apoptosis apoptosis gadd gadd type prevent treatment reason acute wich syndrome sell eisai cpg gene gene methyltransferase effect induce decitabine decitabine decitabine regulate various 
1.67@cancer cancer methyltransferases restore able dna dna dna dna dna optimal tumour tumour tumour sub fda protection overall overall incorporation island suppress class irreversibly strand help enzyme outcome serve mechanism block hypermethylation maximal reduce nucleoside methylation methylation cell prevalent suppressor suppressor drug drug drug analogue throughout highly occur reduction reduction dose bind act inhibitor cpg gene gene methyltransferase inactivate cellular combat decitabine decitabine activity activity approve follow 
1.33@cancer critical togenesthat restore dnmt dnmt produce progress use agent hypomethylating myelodysplastic analog proliferate cytotoxicity cellular cellular hypomethylation hypomethylation leukemia direct exert inhibit inhibit adduct irreversibly treat thereby proliferation myeloid normal neoplastic formation phosphorylation orapoptosis insensitive like cell cell cell may may cytidine also incorporation cause relatively inhbitors chlorosugar hence benzoyl protect syndrome dna dna dna dna dna dna divide non acute bind covalent act function believe rapidly effect induce aza deoxycytidine control antineoplastic belong decitabine decitabine decitabine decitabine decitabine decitabine attribute incorporate differentiation differentiation methyltransferase methyltransferase methyltransferase 
1.67@cancer also devision serenely dnmt dnmt tumour analogue dependent along island anti affect inhibit nucleotide action dna dna decitabines bind bind inhibitor cpg irreversible methyltransferase effect upon longer normal hypermethylation replicate copy methylation release nucleoside incorporate come cell cell may replication decitabine 
2.0@maybe cancer cancer able may add unmethylated make hypermethylated hemimethylated inhibit consider genone well allow dnmt dnmt tumor tumor tumor tumor express cell cell drug drug incorporaed therefore activation need methol allele normally methyl group group dna dna bind expression dinucleotides gene gene gene gene methyltransferase inhibitor remove die die cpg replicate methylation decitabine decitabine wide active supressor supressor supressor supressor 
1.33@suppressor lower reset therefore tumor improve become value efect make lifespan decrease decrease lead regulate dna dna methylate expression expression inhibitor enzyme tumoral gene gene methyltransferase function usualy onco normal normal normal division methylation methylation decitabine establishment possible cell cell tissue tissue 
2.0@cancer along restore within within dnmt produce use agent hypomethylating myelodysplastic myelogenous similar growth leukemia direct call decitabinealso nucleotide achieve irreversibly strand precursor inhibitor inhibit tumor longer normal normal bind bind release demethylation metabolism control suppressor antimetabolite antimetabolite get replication cause target result acute number cytotoxic syndrome dna dna dna dna dna divide substance substance cell cell cell cell cell category chemotherapy function drug gene rapidly effect interact cellular copy death belong belong treatment thus methylation decitabine decitabine daughter work incorporate incorporate come methyltransferase methyltransferase methyltransferase class 
2.0@dna suppressor cpg cpg gene cause tumor tumor agent demethylating demethylating decitabine decitabine decitabine growth activate island island demethylation suppreses 
2.0@elod plastic cancer along dnmt dnmt tumour tumour hematological mean specific disease probably similarly malignancy dnmti dnmti drug avoid strand transferase sure inhibitor consequence effective due normal feature hypermethylation hypermethylation clear fact nucleoside affect cell cell frequently methyl belong suppressor dependent dependent get general replication analogue incorporate suppressorsgenes like know hypomethylated dna dna dna however mind bind bind syndrome important end irreversible effect upon copy keep division replicate go methylation decitabine decitabine decitabine decitabine daughter gene y come active action de 
0.33@suppressor cancer remove methyl agent stop myelodysplastic make treat group develop dna histone syndrome gene gene surroding tumor demethlyhing thus decitabine work express use 
1.67@compound cancer inhibitor promote dnmt dnmt use analogue dependent become since course replication drug drug demethylation class dna dna dna divide bind bind slide especially irreversible rapidly effective belong material decitabine nucleoside incorporate incorporate passive cell cell way 
1.67@cancer cancer stable able activate n methyl agent though mark find find unmethylated generation hypermethylated tumour tumour tumour tumour island island act next irreversibly pass pass know silence demethylating inhibit inhibit normal hypermethylation rase contrary nucleoside methylation methylation many cell cell cell cell cell cell cell cell cell curb use tra suppressor suppressor analogue erase epigenetic epigenetic need cause could kill promoter promoter particular dna dna dna dna dna mind bind point fe dnmts dnmts cpg cpg gene gene gene gene eliminate division division undergo since unless decitabine decitabine daughter incorporate return action action reprogramming would would 
1.33@cancer restore determine suppressor regulation remove remove methyl methyl chemically intend stop mark mark block change change susceptible make genetic transferase transferase grow lead epigenetic epigenetic epigenetic epigenetic epigenetic development pass erase erase enzyme demethylating facilitate key permanently may genome factor like demethylation cell cell cell cell cell tumour tumour standard transcription therefore mitotic actively drug drug restoration restoration mean mean cancerous without therapy methylation methylation better though involve involve dna dna kill chemotherapy le function function gene gene gene gene inhibitor induce cellular cellular overall division silence material decitabine decitabine class return form enable alter alter 
2.0@cancer cancer cancer cancer cancer restore restore restore dnmt bad methyl state could pattern mark dnmti generation transferase island cpg class epigenetic promoter promoter promoter establish enzyme enzyme provide inhibit inhibit reduce tumor tumor tumor mechanism grow hypermethylation predictor maintain cell cell cell cell cell cell cell transcription transcription promote however mitotic expand loss result inheritance anti know successive dna dna dna divide repressor repressor outcome gene gene inhibitor division division new methylation methylation methylation methylation methylation methylation decitabine decitabine decitabine daughter daughter daughter region activity 
2.0@suppressor suppressor inhibitor dnmt tumour tumour tumour effect anti hypermethylated decrease decrease island dna dna dna dna promoter establish expression cpg prevent impact gene gene increase methylation methylation methylation methylation ul ul region replication decitabine decitabine decitabine 
1.67@suppressor suppressor cancer cancer lower irreversibly tumor tumor tumor may cause agent target prescribe growth become occur decrease inhibit though often dna divide divide dose inhibitor allow demethylating gene rapidly effect serve affect hypermethylation thus methylation methylation decitabine decitabine adna incorporate incorporate past dnamethyltransferase cell cell far replication expression 
1.33@cancer cancer effect restore suppressor suppressor may may likely specific tend myelodysplastic epimutations myelogenous myelogenous growth specify make affect affect locus suppress margin margin margin margin margin often igf adult kind precursor demethylating island common effective tumor tumor primary hypermethylation hypermethylation style style style style style effectiveness factor factor many leukaemia leukaemia one sense also indicate imprint drug cause agent describe reverse fact age age become type type promoter though example dna dna bottom bottom bottom bottom bottom acute acute syndrome le important cpg gene gene gene gene function function remove methylations apparently since methylation methylation methylation methylation decitabine decitabine decitabine work would associate 
1.67@cancer cancer cancer inhibitor within within dnmt tumour rapid probability analog growth hypermethylated affect island island nucleotide nucleotide dmnts irreversibly strand strand see well severely consequently tumor tumor normal hypermethylation nucleoside cell cell cell cell cell cell replication replication suppressor suppressor dependent lower therefore therefore future require could therapeutic anti prevent prevent prevent particular dna dna dna dna dna divide bind bind typical cpg cpg gene gene rapidly effect effect upon copy division methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine daughter daughter impart incorporate action action methyltransferase methyltransferase methyltransferase methyltransferase 
2.0@blewitt cancer instead instead higher dnmt marnie much attempt currently reactivate affect island lead cytosine cytosine cytosine epigenetic strand destruct tumor normal resource may nucleoside progress interrupt cell cell cell cell cell control myelodysplasic suppressor let lower lower coursera drug analogue apoptosis result present bind hence parent treatment dna maintenance maintenance frequency syndrome expression cpg gene aml inhibitor copy division go methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine daughter daughter mitosis mitosis incorporate approve self methyltransferase methyltransferase dnmti 
1.33@cancer abnormal class western progress way sorry stop transcribe island dna dna help function cpg inhibit methyltransferase tumor tumor english methylation decitabine gene cell supressor 
2.0@cancer cancer inhibitor dnmt dnmt dnmt dnmt methyl mark mark myelodysplastic since since since generation island cytosine irreversibly body particularly involve especially effective affect hypermethylation hypermethylation particular genome genome nucleoside maintain cell cell cell try chemcially also divide need analogue cause however lay methylate across come replication replication prognosis treatment dna dna dna dna get get shut bind syndrome fe well cpg cpg poor rapidly effect upon similar copy replicate rase methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine daughter work work incorporate incorporate perhaps though tra methyltransferase associate 
1.0@cancer cancer toxicity class tumor may agent agent agent phase hypomethylating hypomethylating excite durable lower malignancy leukemia characterize marrow response response represent patient patient death md md md md well supportive ineffective myeloid thrombocytopenia mechanism transformation expression improvement hematologic schedule role option tolerate american american care suppressor also foundation anemia hematopoiesis combination neutropenia therapy decitabine decitabine decitabine decitabine decitabine myelodysplastic myelodysplastic show group treatment compare profile dose acute syndrome syndrome recent additional society society time aml aml allow result result suggest emerge bone new new expect disorder gene learn delay study study associate 
2.0@suppressor inhibition histone histone excessive tumour tumour phenotype silence upregulation result result result result result aberant aberant cancerous cancerous cancerous reduction catalyse decrease decrease decrease particular dna dna lysine cell cell methyltransferase overal expression expression shift gene gene gene proliferation proliferation inhibitor supressor lymphocyte increase increase ezh ezh ezh ezh thus thus methylation methylation methylation methylation decitabine decitabine pathological towards survival inhibtiion associate 
1.33@cancer myeloid todna class class suppressor suppressor tumour manner agent stop silence silence myelodysplastic hypomethylates similar growth leukemia inhibit inhibit inhibit aza epigenetic strand methylate inhibitor enzyme enzyme demethylating impact tumor tumor tumor uncontrolled although cell cell blood decitabine decitabine decitabine decitabine decitabine decitabine dysfunctional cause identify include drug drug certain acute condition surround whose anti anti decitabineor chain treatment dna dna dna dna dna dna dna histone syndrome function function gene gene gene aml effect effect deoxycytidine belong belong thus methylation rna incorporate incorporate overactivity overactivity methyltransferase methyltransferase azacitidine azacitidine 
1.67@cancer classify antimetabolite use agent myelodysplastic hypomethylates growth growth md tumour inhibit syndrome dna dna dna body cytotoxic chemotherapy demethylating methyltransferase block antineoplastic treatment anti cell drug decitabine decitabine decitabine 
1.67@heavy cancer cancer inhibitor target effective effective methyl agent cytotoxicity dnmti susceptible make make treat island unknown area precursor however however demethylating myeloid mechanism normal hypermethylation may nucleoside demethylation lead use leukaemia dependent lower irreversibly replication analogue subsequent cell cell cell cell synthesis well prevent action dna dna dna dna dna divide divide dose acute bind bind syndrome fe dnmts cpg rapidly rapidly effect unclear methyltransferase myelodysplatic rase decitabine malignancy tra aml haematological 
2.0@cancer cancer inhibitor class dnmt may stop island dnmti change change transferase transferase grow nucleotide granddaughter epigenetic epigenetic strand pass methylated belong severely impact longer affect divide release nucleoside actively cell cell cell cell cell tumour tumour decitabine decitabine decitabine decitabine faster erase erase irreversibly replication analogue therapy mean mean mean without anti methyl methyl dna dna get kill bind bind cpg hence rapidly effect effect upon dependant copy division division replicate methylation methylation dn dn daughter daughter incorporate return heavily 
1.67@dna dna dna dna continuous normally silence demethylating hypomethylated drug tumor tumor protect division hypomethylates decitabine gene gene mean methylation active cell inhibit methyltransferase supressor supressor 
1.67@suppressor cancer cancer cancer reduce reactivation stabilise use agent attempt suppression result lower silence growth growth anti hypermethylated drug drug level genomic lead lead dna dna dna dna dna sodecitabine demethylating demethylating gene effect amount demethylation feature hypermethylation thus methylation methylation genome genome instability limit many often tumour tumour decitabine 
1.67@abnormal abnormal epigenetic metyl remove drug information regulation mutate repressive hypermetylated number like affect inhibit damage tumor dna dna dna tet speed act division provide gene gene gene essential induce usually demetylators protein death belong particular repair decitabin metylation activity program cell cell cell cell control mark supressors 
2.0@cancer methyltransferases methyltransferases growth suppressor use use add island myelodysplastic currently dnmti hypomethylation treat mention inhibit inhibit previously irreversibly development promoter prevent epigenome cgi proliferation myeloid tumor tumor tumor mechanism uncontrolled neoplastic hypermethylation strictly role cell cell cell cell considerated leukaemia market dna dna dna dna epigenetic replication drug drug activity result anti methyl among group treatment reason base syndrome dnmts cpg gene aml inhibitor upon increase interfere methylation decitabine decitabine decitabine incorporate action continue alter play 
1.0@mean mean cancer inhibitor class dnmt dnmt dnmt dnmt use since dnmti dnmti normally tumour transferase previously irreversibly strand level level belong mechanism affect neoplastic understand release nucleoside case demethylation cell cell cell cell cell cell methyl dependent lower lower divide divide replication replication cause target analogue dosage dosage like anti methylation know dna dna dna dna however however kill bind act drug drug drug drug drug effect copy division longer normal decitabine decitabine decitabine decitabine decitabine decitabine daughter much incorporate strongly nucloeoside action action full hit 
1.67@cancer cannot class dnmt methyl agent agent demethlyating hypomethylating become become analog analog dnmti make hypermethylated transferase inhibit often irreversibly island island island reduce reduce tumor tumor tumor mechanism affect affect nucleoside cell cell cell may may expression cytidine therefore therefore epigenetic suppression suppression anti dna dna dna dna dna dna dna divide bind inhibitor cpg cpg gene continue effect upon copy belong methylation methylation methylation decitabine decitabine possible incorporate active duplication attach exist 
2.0@cancer cancer cancer effect abnormal abnormal class able produce produce way slow agent mark mark make make silence silence growth growth part sit heritable call suppress epigenetic epigenetic epigenetic pass methylated belong demethylating dnmt tumor tumor normal nucleoside cell cell cell cell cell cell decitabine decitabine certain become become daughter daughter daughter drug analogue pas exhibit target reverse impossible prominently subsequent prevent nucleus dna dna dna dna dna dna dna divide synthesis bind bind bind expression inhibitor inhibitor inhibitor inhibitor anti anti gene gene methyltransferase methyltransferase methyltransferase methyltransferase methyltransferase along epigenetically division thus methylation inside cant work protein 
2.0@cancer transfer transfer dnmts dnmts dnmts progress island certain prove acute process myelodysplastic find deme deme leukemia useful ase thy thy prevent play dna dna dna dna irreversibly belong bind syndrome inhibitor function cpg inhibit inhibit hence as hypermethylation hypermethylation decitabine decitabine drive role myeloid tumorigenesis incorporate promoter generally 
1.67@cancer cancer methyl methyl state irreversably agent significantly dnmti dnmti growth growth leave overall might effectively island island back back regulate phenotype area strand transferase particularly demethylating group typical hypermethylation genome many cell cell cell one one specifically slow hallmark certain combination add target loss cancerous vulnerable promotor prevent return treatment dna dna dna bind chemotherapy site cure cpg cpg gene effect revert division methylation decitabine region hypomethylated active towards full would 
1.67@suppressor cancer kind use agent whose decitabine decitabine decitabine myelodysplastic myelogenous stop growth treat inhibit job dna dna acute syndrome precursor demethylating gene methyltransferase inhibitor tumor hypermethylation ul ul couses cell uncontrolled leukaemia 
1.67@cancer classify tumour tumour agent hypomethylation hypomethylation susceptible make clasification inhibit development attack demethylating pattern genome genome instability massive like many many cell methyl tra one promote year drug drug drug cause disaster anti specially dna dna chemotherapy overexpression expression gene gene effect fe control death due rase methylation decitabine decitabine drive action generate totally 
2.0@functionally toxicity inhibition effective may may hematologic hematologic include include agent aberrantly hypomethylating analog find hypomethylates reactivate leukemia md manageable broad cml cml workingin patient cytosine strand well issue inhibit tumor tumor hypermethylation turn sickle nucleoside role express cell tolerate indicate leukaemia suppressor suppressor also anemia safety manner play decitabine decitabine decitabine decitabine decitabine decitabine decitabine chronic activity show chain dna dna dna dna dna dna however similar acute numerous aml consequence range silence silence myelogenous myelogenous methylation rna disorder gene gene gene incorporate incorporate incorporate malignancy malignancy various methyltransferase study azacitidine azacitidine 
1.33@cancer inhibitor usual restore tumour tumour growth growth aninterference category epigenetic thereby impact normal normal create like demethylation cell suppressor suppressor identify antimetabolite via drug turmour fuctionality proper fast restoredalong anti em em em decitabineis basically dna dna divide kill function gene gene chemo effect describe describe cellular cellular belong methylation methylation decitabine decitabine decitabine work class 
1.67@suppressor suppressor cancer attach tumor tumor tumour agent decitabine decitabine decitabine become demethylated reactivate gene gene gene anti drug normal group addition dna dna dna dna promoter promoter methylated act function function demethylating island island effect remove remove remove affect cpg cpg thus methylation methylation previously region return cell cell methyl genome 
2.0@strain cancer inhibitor inhibitor inhibitor restore restore progress use agent hypomethylating myelodysplastic dnmti growth leukemia affect inhibit nucleotide nucleotide demethylates irreversibly body help ill severely myeloid replicate normal release much control cell cell cell cell tumour decitabine suppressor dependent divide replication analogue come type dna dna dna dna dna dna dna get bind bind syndrome function drug drug gene aml along upon methyltransferase methyltransferase methyltransferase methyltransferase methyltransferase copy division interfere methylation methylation longer daughter incorporate theyre approve action rapidly 
1.33@cancer methyltransferases tumour process analog dnmti dnmti treat inhibit nucleotide irreversibly strand inhibitor inhibitor silence affect neoplastic release high transferation side cell methyl dna dna dna dna dependent nucleoside divide low effect effect anti group reason get dose dose bind bind bind use important time methyltransferase methyltransferase along along copy division longer thus methylation decitabine daughter incorporate come come enable 
2.0@cancer cancer size abnormal breast lower disease use agent stop metastatic hypomethylating two transfer reactivate possibly drug block grow response response amount help well functionality inhibit way research tumor mechanism reason normal feature cease myelodysplastic reduce high high aberrant many cell cell cell cell cell cell methyl repair dna dna let also supply excessive spread cause dose dose dose eventually eventually result dosage cytotoxic antitumour show expert develop family treatment treatment standard blood blood cancerous syndrome act stem positive colon effect die lung due display methylation methylation methylation decitabine decitabine decitabine hematopoietic gene activity malfunction small small 
1.67@growth regulation put much concentration agent result since hypomethylation tumour decrease inhibit inhibit important dna dna dna dna pretty demethylates establish function demethylating gene proliferation effect induce cellular normal neoplastic website thus methylation methylation decitabine decitabine decitabine dacogens class cell cell mention uncontrolled 
0.67@dacogen deliver term effective use concentration agent long hypomethylating sequester remain myelogenous hypomethylates dnmti dnmti hypomethylation perscribed grow grow supress unknown higest child comparison precursor hyper inhibit inhibit pregnant tumor tumor normal normal hypermethylation hypermethylation ing readily incresed behaviour minimal minimal minimal theraputic methyl supressor woman pick also seem drug drug drug drug drug acute ability toxic side side property result result low leukeamia anti type effectivness show damage treatment dna dna dna dose cell cell cell cell cell syndrome myelodysplastic gene rapidly rapidly effect effect effect effect effect induce dependant thus decitabine decitabine decitabine decitabine possible malignancy methyltransferase methyltransferase haematological 
2.0@transfer dnmt dnmt dnmt general general general general use work work work sever irreversibily dnmti dnmti dnmti dnmti effect bind bind bind enzimes inactive group methyltransferase methyltransferase supressed dna dna dna dna dna dna divide decrease methylated inhibitor enzyme enzyme inhibit way reduce reduce tumor tumor tumor longer longer activation normal normal contain replicate thus methylation methylation methylation decitabine decitabine decitabine much gene gene cell cell cell cell cell methyl follow supressor 
1.0@mean cancer cannot dnmt dnmt progress methyl methyl methyl methyl methyl fda analog malignancy dnmti leukemia nucleotide irreversibly strand severely affect myelodyspastic vidaza vidaza others cell cell cell trial blood commercially release dependent transfer transfer transfer transfer transfer therefore get fight replication replication preclinical hematopoietic course nucleosisde dna dna dna dna dna divide acute bind bind bind syndrome syndrome inhibitor inhibitor inhibitor drug drug aml along along upon copy division longer methylation decitabine decitabine daughter work incorporate come come approve approve action rapidly decitadine 
1.0@suppressor check drug drug cause become without unchecked make sure lead tumor dna divide divide methylated allow demethylating gene gene rapidly remove methylation genome express express cell cell decitabine 
1.33@maybe dna dna dna cancer methyltransferases patient patient say slow combination agent could activity analog asazacitidine growth desacetylase anti treat show inhibit hdaci hdaci lung effect histone cytidine inhibitor demethylating drug reduce reduce tumor tumor tumor briefly similar methylation decitabine decitabine decitabine work article withazacitidine imply combine progression 
0.33@dacogen cancer cancer methylating target mitotically decitabine decitabine use agent know toxic yet myelogenous dosage dosage specific leukemia replication bind treat integrate group action lead dna dna irreversibly non minimum dependent dependent syndrome division aml dnmts mechanism mechanism must belong effectiveness myelodysplastic vidaza high acute active active cell cell may azacitidine 
1.67@suppressor suppressor suppressor methyltransferases determine dnmt malignancy tumor tumor tumor tumor tumor require analogue whether originally result since since moreover reactivate effect effect methylation promoter inhibit inhibit particular dna dna dna irreversibly cytosine ant involve silence silence gene gene gene able able epigenetically division hematologic decitabine decitabine decitabine decitabine nucleoside depend incorporate incorporate case active cell first region 
2.0@fail cancer cancer restore able synthesize tumour whenis could could specific silence make make normal normal inhibit often recognize strand strand hemimethylated hemimethylated methylated repression establish establish enzyme enzyme inactive take dnmt dnmt dnmt dnmt style permanently clear dilute release nucleoside cell cell cell cell br inside suppressor turn cant get fight drug analogue ability decitabine decitabine decitabine present gene gene gene help dna dna dna however bind capacity heterochromatin expression expression affect conformation conformation cellular chromatin keep division replicate new methylation methylation methylation methylation would daughter transcriptionally incorporate come action heavily reestablish 
2.0@heavy cancer cancer methyltransferases methyltransferases tumour agent island analog classify reactivate inhibit lead irreversibly strand strand strand body methylated naturally demethylating group reduce severity affect much maintain cell cell cell cell cell cell methyl suppressor faster maintenance replication improve prior condition focus cancerous bind prevent prevent dna dna dna dna divide divide cytidine function cpg gene methyltransferase effect copy division replicate since since methylation methylation methylation decitabine decitabine decitabine daughter daughter daughter daughter incorporate strong indicator onto progression 
1.67@cancer cancer restore neoplasm progress use include agent shore island island myelodysplastic growth leukemia md hypermethylated incorporation normal normal inhibit aza lead cytosine position body pyrimidine belong demethylating severely myeloid tumor tumor tumor affect essential hypermethylation hypermethylation show supressors demethylation cell cell cell cell much cute suppressor suppressor drug analogue replication cause apoptosis hematopoietic sequence promoter pmid presence treatment dna dna dna dna divide ring reverse syndrome function cpg cpg gene gene gene aml inactivate methyltransferase deoxycytidine control silence replicate thereby decitabine decitabine decitabine decitabine decitabine incorporate approve modify differentiation rapidly 
1.67@cancer inhibitor restore restore dnmt dnmt tumour tumour tumour tumour add complementary hypomethylation hypomethylation transferase transferase island island suppress unable irreversibly strand level methylated silence silence thereby observe reduce reduce detect normal hypermethylation hypermethylation hypermethylation genome methylation methylation methylation methylation methylation methylation methyl methyl methyl expression expression suppressor suppressor therefore epigenetic mitotic replication hemi subsequent target condition ultimately maintain maintain anti occur promoter promoter group dna dna dna dna dna alongside bind bind dnmts dnmts drug gene gene gene gene gene gene effect remove result result cpg cpg regional decitabine decitabine decitabine decitabine wide activity active associate 
0.0@myc myc decline cancer overmethylation regulation tumour system animal wrong substance part treat call call inhibit common epigenetic culture laboratory proliferation reduce block normal go factor factor gsk cell cell cell one surprisingly also cause crucially activity encode amount know particular involve dna histone name expression gene gene effect jq protein human find find regulator transcription transcription nearby another brd dramatically apparent 
2.0@clinical cancer proliferate faster class consequently use use improve agent revert hypomethylating inhibit analog analog myelogenous cyclea replication regulatory treat affect hypomethylated dna dna dna acute syndrome precursor hypermethylation demethylating severely methyltransferase upon normal belong turn thus myelodysplastic decitabine decitabine nucleoside gene incorporate cell cell cell control prognostic leukaemia 
1.33@cannot class unclear tumour tumour fda dnmti high make hypermethylated drug drug drug decrease decrease whereas irreversibly level display proliferation consequently mechanism neoplastic fact release nucleoside demethylation cell global suppressor lower although activation replication analogue toxic result anti know dna dna dna dna dna get dose dose bind inhibitor still gene gene methyltransferase methyltransferase effect effect effect upon die explain belong longer methylation decitabine much incorporate approve action 
2.0@cancer cancer cancer cancer inhibitor dnmt dnmt may appear mutation stop stop silence silence myelodysplastic objective transfer malignancy hypermethylation hypermethylation growth tumour tumour tumour regulate effective irreversibly methylate enzyme especially reduce reduce hypermethlation affect neoplastic give possibility cell cell cell cell cell drug suppressor suppressor suppressor also promote daugter regain spread spread heamatological cause cause cycle ly low cancerous without anti anti bind occur promoter lead properly ezh dna dna future dose kill ase syndrome proliferatively gene gene gene methyltransferase effect effect overactive control unable division treatment thus methylation decitabine decitabine decitabine work mean meet replication reactivate 
1.67@cancer restore dnmt others agent hypomethylating funtion growth statue call island lead methylated involve hyper demethylating inhibit tumor mechanism normal essential dir dir dir cell control mainly regain cause procedure suppression dna dna dna dna health expression expression cpg cpg gene methyltransferase methyltransferase enzyme nclrna methylation decitabine ltr ltr ltr region mean action protein 
1.67@cancer inhibitor category within within produce activity tumour agent hypomethylating major cellular growth growth direct increase call inhibit restore restore epigenetic work regulate regulate belong belong demethylating twofold tumor mechanism normal normal directly demethylation cell cell cell cell cell cell cell way blockage expression one suppressor suppressor hypomethylation also antimetabolite antimetabolite cause cause cause target result number anti metabolism dna dna dna dna dna dna divide substance substance cytotoxic chemotherapy function believe rapidly effect effect interact similar control death division thus methylation methylation decitabine decitabine decitabine decitabine gene gene gene incorporate methyltransferase class 
2.0@cancer effective use use certain agent prove since prophylaxis hypomethylation useful treat inhibit men treatment dna acute disease wikipedia methyltransferase myeloid bloodbourne acknowledge decitabine disorder create case blood leukaemia 
1.67@one suppressor suppressor suppressor cancer demethylates use slow agent april myelodysplastic result myelogenous economist growth treat promoter promoter island island dna acute syndrome precursor silence demethylating gene gene gene gene gene tumor tumor tumor tumor mechanism cpg cpg turn methylation decitabine decitabine decitabine tumorigenesis 
1.0@dna dna dna loss methylating hypermethylation hypermethylation cpg island methyltransferase tumor agent belong due hypomethylates decitabine gene avoid inhibit inhibit suppress 
2.0@lock desoxycytidine higher growth reactivation formation synthesize leukemia fda mutation correct newly hypomethylation potential island aza class igf irreversibly strand see inhibitor division severely dnmt dnmt tumor tumor tumor affect hypermethylation hypermethylation myelodysplastic architecture monoallelic cell cell cell control control suppressor decitabine decitabine decitabine decitabine decitabine dna dna dna dna dna iii rat divide imprint imprint mitosis improve hemi subsequent apoptosis overexpression result result result result rearrange anti myeloic promoter prevent ii reduction probability acute bind syndrome heterochromatin expression cpg gene gene gene rapidly effect prevention prevention increase belong methylation ul ul region incorporate nuclear approve covalently differentiation methyltransferase methyltransferase associate 
1.0@cancer classify restore restore within within produce use agent process two similar growth direct treat demethylating tumor normal normal contribute myelodysplastic demethylation cell cell cell cell cell tumour suppressor also antimetabolite antimetabolite cause target number anti metabolism dna divide substance substance cytotoxic syndrome function gene rapidly effect effect interact cellular control death thus decitabine work work incorporate anddna 
2.0@dna dna suppressor suppressor cancer inhibitor expression expression cpg gene gene gene dnmt dnmt tumor tumor increase result methylation methylation methylation decitabine decitabine decitabine hypermethylated inhibit decrease decrease decrease island lead 
2.0@dacogen cancer cancer restore unregulated formation use agent agent leukamia myelodysplastic major growth growth treat epigentic inhibit credit regulate regulate src belong demethylating mechanism block block normal precurser thus interering img name demethylation cell cell cell cell control decitabine decitabine decitabine market suppressor suppressor methylating methylating suppresor regain drug drug em image become type know lead dna dna dna dna dna dna expression blood hypo hypo syndrome sell function gene gene gene gene methyltransferase effect alt increase division division new methylation methylation methylation methylation allow work activity form class 
1.67@dacogen cannot regulation regulation use cytidine mark myelodysplastic proliferate change change treat marrow marrow marrow inhibit lead lead epigenetic methylated precursor disease composition proliferation consequently normal turn implicate myeloid myeloid myeloid myeloid cell cell cell cell cell blood blood blood leukaemia undermethylated leukocyte leukocyte perturb disorder diseased activation decitabine decitabine drug drug analogue acute cause correct myeloblast result demethylated number become develop lineage treatment dna dna dna dna dna package migrate syndrome accessibility expression gene gene gene methyltransferase accumulate accumulate chromatin increase increase division methylation pathologically transcription bone bone bone incorporate differentiate differentiate efficiently 
2.0@cancer cancer effect standard last use use slow agent stop though myelodysplastic myelogenous growth susceptible make treat erase erase might granddaughter epigenetic epigenetic epigenetic epigenetic pass therefore precursor demethylating grow happen tumor people people response response may may routine much good cell cell cell cell trial way kill leukaemia lung advance successfully drug drug drug combination therapy acute without solid show show tumour tumour syndrome dna histone chemotherapy inhibitor change change employ deacetylase division actively decitabine decitabine daughter first return instance alter chemotherapeutic 
1.67@cancer cancer cancer characteristic dnmt progress use use use every order methyltransferases dnmti leukemia overall normal inhibit epigenetic inhibitor especially island island island myeloid tumor longer longer affect thus thus nucleoside nucleoside hypermethylated hypermethylated methylation methylation demethylation cell cell cell cell cell cell cell cell myelodysplatic enzymatic dependent irreversibly spread analogue analogue incorporate result result replication normally prevent prevent dna dna dna dna acute bind syndrome dnmts cpg cpg cpg methyltransferase inherit inherit inherit division division replicate since since regulator decitabine decitabine decitabine decitabine decitabine daughter daughter daughter lay would would would 
2.0@class use agent agent island property hypomethylates hypomethylation anti treat act underlie cpg deacetylas dna dna dna henceforth histone syndrome myleodysplatic administer demethylating inhibit methyltransferase inhibitor enable belong silence decitabine decitabine decitabine gene hypermthylation lead tumour 
2.0@cancer cancer cancer cancer cancer characteristic dnmt order specific since normal inhibit strand strand inhibitor inhibitor inhibitor inhibitor silence island activation tumor replicate replicate affect affect hypermethylation fact demethylation cell cell cell cell cell far try decitabine risk dependent downside decitibine cause cause non target anti bind bind allmark promoter dna dna dna dna dna realesed bacause maily suppression suppression cpg gene gene gene methyltransferase methyltransferase methyltransferase important copy division division undergo decitabile decitabile methylation allow daughter incorporate 
2.0@elod hasbeen effect class reactivation produce aprecursor blood link induce tohypomethylation decitabine decitabine lation condition myelogenous leukemia useful treat marrow antitumour syndrome dna dna case acute particularly inhibitor silence deform gene methyltransferase platic tumor belong turn thus contribute bone y epigenetically hypo cell supressor 
1.67@cancer inhibitor class class tumour agent hypomethylating hypomethylating stem hypomethylates change potential hypermethylated inhibit inhibit suppress suppress epigenetic epigenetic impact maintain cell cell removal increase identify drug caner target loss low anti know treatment dna dna dna dna dna dose expression gene gene methyltransferase methyltransferase effect accumulate describe describe contain belong belong oncogenesis methylation decitabine decitabine decitabine decitabine decitabine region malignancy complete 
2.0@cancer cancer also restore note regulation regulation drug cause cause agent cycle major hypomethylates silence silence growth growth growth leukemia anti decrease suppress class dna dna dna dna substance know consider integrate responsible division demethylating gene gene gene expression tumor tumor similar normal normal increase belong senescence metabolite thereby decitabine decitabine decitabine factor learn methylation methylation activate cell cell cell cell cell 
1.33@lead change change acquisition decitabine decitabine agent cycle mark mark mark myelodysplastic apply connect useful hypermethylated might group group representative dna clean clean cell syndrome belong demethylating gene side effect tumor tumor normal abnormality hypermethylation usually genome progression expression treatment associate associate 
1.67@suppressor transcription activate use agent decitabine apoptosis myelodysplastic myelogenous treat inhibit lead dna dna even acute syndrome precursor enzyme demethylating prevent methyltransferase tumor tumor belong silence methylation complex gene gene gene cell leukaemia 
1.67@growth growth enzymatic mor mor methyl fe agent silence silence demethylating dnmti apply decrease decrease job irreversibly hypometylating tra enzyme traeat overmetylation tumor tumor tumorsupressor normal myelodysplastic nucleoside role like like control control cell cell cell cell tumour belong kind block epigenetic epigenetic metyl metyl need analogue precursores decitabine decitabine target group group dna dna dna dna divide histone bind syndrome act dnmts drug drug drug drug drug gene gene rapidly inhibitor methyltransferase responsable protein division rase methylation ul ul regulator affect leukaemia attach attach supressor 
1.67@cancer dnmt dnmt indnaandrna much rnasubstrate md transcription methyl regulatory incorporation intodnaduring bit nucleotide patient irreversibly strand sequence thereby able longer affect affect hi copy release cause demethylation cell cell cell way example nucleoside nucleoside cytidine transfer indicate replication replication analogue analogue adversely present nain bind bind bind thedna presence treatment dna dna dna dna divide ase syndrome myelodysplastic drug time chemical inhibitor methyltransferase methyltransferase protein replicate methylation decitabine decitabine decitabine decitabine daughter incorporate incorporate come andrnaduring rapidly 
2.0@exclude alt alt cancer cancer cannot higher negative term height height picture picture picture fda width width specific long process two entirely since cytotoxicity hypomethylation hypomethylation hypomethylation direct might affect affect incorporation epigenetic work work src src wide therefore division especially especially severely dnmt dnmt dnmt tumor mechanism normal source usually vidaza high instability img img like like cell cell cell cell drug drug drug genome one suppressor dependent rat irreversibly replication cause cause dosage exact bind bind occur know know prevent genomic mode dna dna however substance substance substance cytotoxic inhibitor irreversible methyltransferase effect effect similar first believe silence decitabine gene approve action 
1.67@inhibitor inhibitor class dnmt produce induce induce blood hematological myelodysplastic myelogenous malignancy hypermethylation hypomethylation hypomethylation leukemia md marrow inhibit epigenetic precursor enzyme deform effective tumor tumor link nucleoside demethylation cell deplete belong suppressor suppressor dependent dependent therefore irreversibly dnnts replication analogue ability condition reactivation antitumour dna dna dna dna dna acute bind syndrome gene gene methyltransferase methyltransferase effect epigenetically bone silence methylation decitabine decitabine incorporate reprogramming 
2.0@suppressor also indicate effective activate use ability myelodysplastic article hypomethylation antitumour inhibit inhibit treat previously adernocortical dna dna carcinoma syndrome recent dnmts dnmts gene methyltransferase inhibitor hypermethylation due silence methylation decitabine decitabine decitabine activity primarily lead tumour 
2.0@proliferate restore formation may newly methylating hypomethylation hypomethylation md inhibit adduct indicate sequence responsible enzyme enzyme proliferation tumor normal normal myelodysplastic insensitive demethylation cell cell cell cell control decitabine decitabine decitabine decitabine transcription patient replication cause apoptosis relatively synethesized come anti treatment dna dna dna dna divide non bind covalent function drug gene rapidly effect induce result result cellular cellular syndrome additionally thus rna attribute incorporate safe differentiation differentiation methyltransferase methyltransferase important 
1.0@suppressor insert class irreversibly tumour tumour tumour phase inactivation analog reactivate anti dna dna dna dna epigenetic base reverse bind typical act provide gene methyltransferase effect block increase give thus methylation methylation drug 
1.67@methyltransferases higher growth progress use state agent myelodysplastic analog myelogenous hypomethylation rate treat normal inhibit act epigenetic kind demethylating reduce affect much instability cell cell cell cell cell tumour tumour tra tra specifically dependent bigger irreversibly replication cause free anti bind methyl methyl level genomic dna dna dna dna dna dna dna acute cytidine syndrome fe fe drug drug effect effect replicate rase rase decitabine decitabine decitabine decitabine incorporate incorporate leukaemia 
1.67@dna dna maybe belong cpg island methyltransferase tumor decitabine decitabine hypermethylation methylation ul ul gene dnmti decrease decrease inhibit suppressor lead 
2.0@specifically inhibitor dnmt may agent hypomethylating cancerous unmethylated anti incorporation lecture lecture dna dna dna dna bind dnmts demethylating proliferation effect tumor tumor methyltransferase keep allow bring demethylation cell control suppressor decitabine decitabine 
1.67@suppressor cancer tumor say agent stop inactivation probably useful treat show group lead dna epigenetic syndrome disregulation demethylating gene effect remove mechanism thus myelodysplastic decitabine many methyl 
2.0@abnormal growth tumor use currently hypomethylates reactivate change leukemia leukemia md treat marrow inhibit aza epigenetic epigenetic strand reversible well disease bone cml myeloid myeldysplastic normal react suppress aberrant otherwise cell cell blood supressor myeliod promote specialisation toxic chronic promoter rectivate dna dna dna dna dna acute syndrome gene gene aml effect deoxyctidine modifer silence methylation methylation decitabine decitabine decitabine decitabine decitabine work incorporate methyltransferase 
1.33@mitotically cancer cancer cannot class dnmt dnmt dnmt regulation state mostly cycle cpgi foremost since since unmethylated heritable affect suppress represent epigenetic strand strand strand strand reversible reversible methylated methylated involve inhibitor inhibitor silence provide summary tumor tumor tumor longer normal normal hypermethylation hypermethylation reduce cell cell cell cell incorporate compare commonly area manner replication replication cause subsequent suppression loss number anti promoter cpg dnmts dna dna dna dna dna divide bind target drug gene gene rapidly effect first belong replicate new methylation methylation methylation decitabine decitabine daughter lay return return 
2.0@decline cancer overmethylation activate use part mutation become charge myelogenous dnmti normality useful back regulate regulate epigenetic methylate particularly well enzyme enzyme enzyme reduce chemistry program cell cell tumour suppressor leukaemia dna dna dna ofmethyltransferase methylates drug certain overmethylates decitabine property result else genesmay disassemble normally amount particular something andin consequence function gene gene gene inhibitor overactive death silence silence silence due decitabile methylation inappropriate time form antitumoral 
1.33@dacogen cancer cancer critical mitotically produce methyl chemically agent agent hypomethylating eisai sometimes mythylation chance chance hypomethylation japanese call molecule even promoter responsible demethylating reduce reduce tumor tumor mechanism lack hypermethylation turn turn suppressor suppressor genome genome nucleoside cell cell cell cell control azacitidline decitabine decitabine decitabine specifically cytidine also activation relate trademark hypermetylation know group family company dna dna dna process kill name inherit still gene gene gene gene molecular place place similar simple none word extra methylation methylation pharmaceutical daughter wide mean attach beneficial 
2.0@cancer cancer lymphoma methyl include agent stop chromosomal myelodysplastic myelogenous growth growth growth part make make tsg tsg tsg tumour call treat surround precursor enzyme demethylating control tumor may cell cell cell uncontrolled supressor suppressor histone histone histone histone restablishing system certain mutation hypermetylated normally normally immune group dna package acute syndrome use gene gene gene overactive protein ezh ezh silence silence silence methylation controll demetilates leukaemia attach 
2.0@mean cancer cannot get undo replication agent irreversibly since copy island nucleotide dna dna dna divide strand bind bind division demethylating rapidly dnmt upon dependant affect cpg hypermethylation methylation decitabine decitabine decitabine daughter incorporate cell cell 
1.67@cancer also dnmt tumour analogue cytidine cause decitabine decitabine decitabine decitabine contributor myelodysplastic dosage hyper leukemia md type inhibit prevent nucleotide dna dna dna dna dna acute bind syndrome inhibitor dnmts dnmts right methyltransferase effect therapeutic systemic incorperated methylation methylation rna serious em em incorporate myeloid hypo aml replication progression 
1.67@cancer inhibition restore dnmt maturation use include agent inhibit inhibit stem analog analog analog azacytidine tumorigenic leukemia md treat decrease island lead irreversibly strand copy involve demethylating observe myeloid mechanism neoplastic hypermethylation genome nucleoside nucleoside program decitabineis cell cell cell cell demethylation may reach repair covalently become signal replication replication cycle pathway pathway suppression result result number success anti tumour passive promoter dna dna dna dna dna expression expression deoxy acute bind syndrome act myelodysplastic cpg gene gene decitabene effect pro suggest death division thus methylation methylation methylation decitabine daughter wide incorporate action differentiation methyltransferase 
2.0@cancer cancer effect effect effect lower lower tolerable dna dna progress much much mostly agent toacute myelodysplastic also malignancy dnmti fda make quite treat nucleotide longer irreversibly strand strand well take effective mechanism normal neoplastic release nucleoside tumorigenicity cell cell cell blood leukaemia mode dependent dependent methylating patient therefore fewer replication analogue pas subsequent anti cause cause reduction divide divide dose u bind bind syndrome act function drug rapidly rate upon upon division division division division duringcell myelogenous methylation methylation decitabine decitabine daughter incorporate come approve whendnmt side de de 
0.67@prevention cancer class formation cell cell cell tumour tumour tumour include mutation process myelodysplastic silence transferase whendna nucleotide nucleotide lead lead irreversibly strand decrease involve enzyme enzyme demethylating severely tumor tumor due affect expression expression express thereby trial methyl belong suppressor suppressor replication cause suppression loss surround bring dmlt dmlt dmlt methylation methylation methylation prevent prevent presence treatment dna dna get mark histone histone bind bind syndrome act control drug drug gene gene gene inhibitor inhibitor upon copy ezh ezh replicate thus actively daughter come 
1.67@reason cancer inhibitor patient dnmt dnmt outcomeis use drug could irreversibly probably treat inhibit rapidla dna divide divide action bind syndrome syndrome well myelodysplastic myelodysplastic cpg island methyltransferase effect unclear dependant affect besides hypermethylation decitabine decitabine work demethylation cell cell yet 
2.0@specifically higher suppressor suppressor formation formation tumour tumour tumour tumour agent ie growth methyl methyl effectively group group suppress often dna dna dna dna hypermethylation demethylating gene gene gene gene rate remove remove attach administer silence silence decitabine decitabine occur may expression 
1.0@suppressor suppressor suppressor cancer effect activity restore decibatine uncontrolled cause agent cell cell cell cell growth growth lead dna dna dna kill function demethylating gene gene impact tumor tumor tumor mechanism mechanism block increase division methylation methylation methylation reduce factor regulate demethylation form control decitabine decitabine 
0.0@
2.0@inactivate growth reactivation synthesize may slow fda exhibit newly dnmti hypomethylation md treat previously lead lead lead irreversibly strand well enzyme enzyme enhance enzymemethyltransferase tumor tumor tumor tumor catergorized nucleoside cell asdna suppressor sensitivity drug drug analogue agent apoptosis chemotherapeutic anti quiescent solid treatment dna dna bind bind act inhibitor gene methyltransferase effect death decitabine incorporate approve 
1.67@cancer cancer classify abnormal restore restore target regulation regulation tumor may include agent agent agent hypomethylating member since silence silence silence growth growth growth normal lead lead epigenetic epigenetic metabolite refer demethylating interest dysregulation mechanism mechanism mechanism affect significant new major demethylation demethylation regulate control control expression suppressor suppressor suppressor nonspecific incorporate result result chemotherapeutic anti activity dna divide cell cell cell cell cell function gene gene gene gene gene gene rapidly allow interact cellular division division thus thus methylation methylation decitabine decitabine decitabine class cytotoxicity alter important 
1.33@cancer methyltransferases growting dnmt use use dnmts dnmts dnmts agent specific specific easily lower treat inhibit irreversibly strand reversible inhibitor enzyme demethylating tumor neoplastic readily release high side much nuceloside machinery enzymatic dependent dependent also therefore epigenetic epigenetic epigenetic decitabine decitabine decitabine decitabine decitabine decitabine decitabine alteration replication replication analogue dose dose dose could toxic target target target thefunction stop anti methyl severe group develop dna dna dna dna dna however non bind bind function drug drug methyltransferase effect effect effect upon transfer longer thus thus regulator regulator rna daughter incorporate generate 
1.0@methylating although within irreversibly inhibitor tumour tumour tumour analogue mostly probably new aberration icrs generation type occur dependends island suppress dna divide action exactly epigenetic act funcion cpg gene dnmt dnmt mechanism lack hypermethylation clear main methylation methylation decitabine nucleoside daughter enzyme enzyme demethylation cell cell cell bind 
1.67@mean could restore target others way agent agent since hypomethlation predominantly change inhibit class class sequence chemical epigenome demethylating demethylating tumor tumor normal hypermethylation hypermethylation show conventional case demethylation demethylation cell may decitabine decitabine suppressor suppressor drug drug also patient understand need cause improve therapy unexpected replication completely promoter promoter treatment treatment dna future reaction act function positive gene gene continue effect induce hold belong find find methylation desire incorporate promise protein 
1.67@cancer restore restore effective tumor use agent carcinogenesis myelodysplastic major de growth treat normal achievable regulate epigenetic precursor silence silence adjuvant mechanism clinically may thus role demethylation cell cell control recover leukaemia suppressor methylating patient decitabine decitabine decitabine decitabine therapy exhibit property dna dna process dose acute syndrome function gene gene gene gene expression expression suggest belong myelogenous methylation ul ul possible class antitumoral 
2.0@cancer cannot available dnmt dnmt dnmt dnmt progress agent chromosomal process process analog de normally grow suppress irreversibly strand quickly inhibit enhance tumor tumor tumor tumor tumor normal hypermethylation act act release release nucleoside instability cell cell myelopoastic suppressor dependent dependent methylating therefore decitibine replication replication cause cause context result present vulnerable dial either dna dna dna dna dna dna bind syndrome le le inhibitor aml effect effect upon copy division replicate methylation methylation methylation decitabine decitabine daughter incorporate approve tumorigenesis methyltransferase methyltransferase delete 
1.33@cancer methyltransferases lead total agent pattern hypomethylating ofdna leukemia type level inhibit treatment dna show act benign methylation methylation decitabine activity cell drug itdecrease 
1.33@dacogen dependent dnmt use analogue agent anclear toxic eisai myelogenous treat nonspecific action company dna dna irreversibly acute bind syndrome sell dnmts still inhibitor mechanism precursor demethylating myelodysplastic decitabine nucleoside incorporate japanese replication leukaemia 
0.67@cancer irreversibly progress use fda dependent myelodysplastic incorporation normal acutemyeloid dna dna divide bind syndrome capacity dnmts drug rapidly inhibitor methyltransferase affect belong replicate go vidaza nucleoside analoue mean approve cell cell cell tumour decitabine 
1.67@suppressor cancer cancer turn activate tumor tumor methyl word cytosine reactivate growth promoter inhibit dna dna base base counter hypermethylation demethylating demethylating group effect remove remove presume belong due silence methylation methylation decitabine decitabine decitabine gene gene mean cell cell may supressor 
1.67@please page see 
1.33@market cancer cancer cancer cancer along class last effective use slow agent stop myelodysplastic myelogenous growth treat grow granddaughter epigenetic epigenetic epigenetic pass help precursor division demethylating way reduce tumor people like many cell cell cell cell tumour tumour kill belong one one dna dna cancern advance erase erase actively drug drug drug drug drug combination therapy prove acute without type type colon though etc reduction histone syndrome inhibitor change change methyltransferase effect similar deacetylase contain lung methylation decitabine daughter learn return leukaemia ovarian alter azacitidine 
2.0@happen dnmt dnmt progress methyl methyl methyl myelodysplastic probably decitabane dnmti dnmti md md hypermethylated transferase island effective epigenetic strand help inhibitor group group group oncosuppressor tumor may regulator cell cell use expression enzymatic transfer transfer promote drug target anti among prevent dna divide syndrome act important cpg gene gene aml effect remove division thus methylation decitabine decitabine decitabine daughter region active action 
1.67@cancer cancer also run tumor methyl deme include lat decitabine decitabine decitabine island protection probably demethylate math region thy group protect lead dna dna dna lation promoter tra fe fe hyper demethylating inhibit hypomethylationagents intergenic demethylation cpg act rase rase wayperform gene role maintain active supressor supressors 
2.0@inhibitor class dnmt dnmt relate use cause order analoga result low dnmti dnmti hypomethylation hypomethylation anti anti tumour lead dna dna dna dna dna dose methylate bind bind enzyme irreversible methyltransferase effect effect effect neoplastic belong decitabine incorporate nucleosid replication reach 
1.33@cancer cancer cancer cancer size inhibition intercalate tumor tumor tumor use include agent lower growth hypermethylated effectively island lead lead irreversibly work work methylate demethylating inhibit threat reduce reduce helpful affect high demethylation cell cell cell cell try level suppressor dependent methylating drug certain could could appropriate mean dosage dosage healthy bind toxic prevent dna dna dna dna dna dna dna divide base action often death cpg gene rapidly rate reversal division methylation decitabine decitabine decitabine decitabine decitabine severely incorporate form methyltransferase methyltransferase methyltransferase 
2.0@mean cancer along dnmt class get much dependent msonormal irreversibly analog group methyltransferase methyltransferase methyltransferase action action division dna dna dna dna dna divide pt body bind bind inhibitor inhibitor belong demethylating severely rapidly bottom upon replicate affect generally style margin decitabine decitabine nucleoside incorporate come cell cell replication 
1.67@dacogen cancer article class tumour tumour slow agent myelodysplastic myelogenous hypomethylates growth penetrate treat inhibing epigenetic strand demethylating accord people cell blood leukaemia thesetumoursare dysfunctional advance successfully deploy drug drug drug certain combination condition histone derivative solid treatment dna dna dna dna harder deoxy acute syndrome sell time methyltransferase inhibitor deacetylase lung decitabine decitabine incorporate first azacitidine azacitidine 
1.33@ce study cancer cancer hematopoetic class dnmt fda use combination make somehow change susceptible anti treat call fully standard epigenetic epigenetic histone chemotherapy target inhibitor inhibitor inhibitor tumor tumor deacetylase neoplastic belong decitabine approve cell drug machinery 
1.0@restore restore agent anti anti transfer meet reactivate growth part back normal normal normal normal normal inhibit as tumor tumor tumor affect metabolite hypomethylates architecture regulator demethylation cell cell cell cell cell cell control control suppressor suppressor also also mythelating antimetabolite stability drug structure apoptosis bring nuclear become dna dna gene operational cellular silence interfere methylation decitabine decitabine work work activity come return de 
1.67@cancer cgis cgis suppressor suppressor agent agent rich rich intergenic inactivation inactivation neighbor hypomethylation hypomethylation hypomethylation hypomethylation inhibit lead lead cytosine work responsible enzyme demethylating island tumor tumor tumor tumor pattern hypermethylation hypermethylation genome genome genome genome instability methylation accessible global global region region region specifically methylating therefore activation activation recombination cause throughout subsequent cell dinucleotide become become occur promoter promoter promoter hypomethylated genomic dna dna dna however kill expression transpose gene gene gene gene methyltransferase allow allow dinucleotides dinucleotides illegitimate repeat repeat repeat cpg cpg cpg signal decitabine wide downstream downstream alter associate 
1.67@advantageous silent identify class dnmt use use drug inhibitor md myelodysplastic probably reverse dnmti exact anti exert consistent island treat dna however profile syndrome precursor hypermethylation hypermethylation demethylating gene gene aml effect mechanism stage still thus methylation decitabine aberrant cpg express action tumour tumour suppressor belong 
2.0@plastic elod cancer classify andthe dnmt dnmt administration tumour fda agent shore island island predominantly analog reactivate hypomethylation md isvia aza againstdna clinical strand canbe silence demethylating adna chromosome normal cpg cpg kinase phosphorylation repair nucleoside aberrant potent effectsoccurred cell control food supressor suppressor antimetabolite activation activation decitabine decitabine decitabine subtelomeric drug syndrome directaction actually trap andafter property u overgrowth present study methyl several degradation dna dna dna dna synthesis demonstrate fe act function prodrug prodrug gene gene inhibitor hypermetilation deoxycytidine deoxycytidine antineoplastic y dck rase methylation rna incorporate incorporate directly approve tra inthe actionscan 
2.0@onto suppressor suppressor cancer cancer cancer dnmt activate methyl agent stop island island island island become gene anti treat could group cpg cpg cpg cpg common dna dna dna strand therebypreventing division demethylating inhibit inhibit effect tumor tumor tumor copy copy produce thus methylation methylation decitabine daughter daughter work activity active active cell cell protein would would 
2.0@cancer cancer inhibitor class dnmt disease tumour tumour tumour host tend agentis lower dnmti change island cpg epigenetic severe enzyme epigenomic normal generally release nucleoside methylation methylation cell cell cell cell cell genome suppressor suppressor methylating rat replication analogue decitabine target result result anti promoter prevent prevent genomic treatment dna dna dna reverse bind expression act myelodysplastic end gene gene methyltransferase effect increase division replicate silence spare allow region region incorporate register modifier haematological associate 
2.0@cancer cancer cancer effect class dnmt dnmt dnmt use use mostly dependent probably since malignancy dnmti treat treat normal normal inhibit irreversibly strand belong longer affect affect neoplastic release nucleoside case cell cell cell cell cell tumour tumour hypermethylates enzymatic faster also also therefore epigenetic epigenetic seem replication cause target low anti methylation methylation solid good dna dna dna dna dna divide dose kill bind bind inhibitor inhibitor inhibitor drug drug drug methyltransferase methyltransferase along upon copy division replicate regulator decitabine decitabine daughter incorporate come action haematological 
2.0@cancer cancer cancer critical restore target reactivation tumour tumour inhibitor agent depletion anucleoside myelogenous silence hypomethylation useful treat inhibit act class irreversibly strand strand body responsible division demethylating proliferation dnmt dnmt normal precursor accurately myelodysplastic demethylation cell cell cell control suppressor leukaemia sensitivity dependent methylating relate synthesise analogue decitabine decitabine decitabine decitabine apoptosis incorporate result effect anti bind know treatment dna dna dna dna dna dna divide acute cytidine syndrome use function drug drug gene gene specifically enzyme epigenetically methyltransferase methyltransferase cellular belong thus newly daughter mean differentiation rapidly replication 
1.67@cancer methyltransferases daughter therefore use analogue dependent cause decitabine decitabine myelodysplastic myelogenous replication replication replication bind bind treat know nucleotide dna dna dna dna irreversibly strand action acute syndrome precursor dnmts dnmts dnmts severely methyltransferase inhibitor inhibitor upon affect incorporat methylation release cant copy demethylation cell rapid nuceloside leukaemia 
2.0@occurrence implement daughter dnmt dnmt requirement agent agent agent ie appropriate become strand frequently replication replication vulnerable incorporation tend unable dna dna dna dna dna dna irreversibly dose kill bind function demethylating affect rapidly enzyme tumor tumor methyltransferase normal normal normal provide replicate methylation methylation decitabine decitabine high work copy cell cell cell cell cell cell cell cell cell use 
2.0@cancer cancer cannot last dnmt dnmt dnmt dnmt progress use agent md find susceptiple make hypermethylated tumour tumour epigentic island nucleotide epigenetic strand machinery demethylating severely way affect affect neoplastic release regulator good cell cell cell cell cell methyl tra enzymatic dependent dependent get study replication analogue baylins target low anti irreversably cpg nuceloscide chemotherapy dna dna dna dna divide dose kill bind bind syndrome fe inhibitor drug aml along upon copy division replicate replicate rase methylation decitabine decitabine daughter dr incorporate come action myleodysplastic rapidly alter 
2.0@suppressor suppressor withdecitabine restore molecular use cause agent ability inhibit experiment dnahypomethylation apply gene gene gene derivative treat know extensive aza expression dna dna level common demethylating ubiquitously prevent proliferation inhibitor tumor tumor tumor methyltransferase methyltransferase force normal normal hypermethylation hypermethylation reasonable funciton observe demethylation cell cell cell may remove decitabine 
1.33@cancer effect dnmt dnmt decitabine decitabine progress tumour peak peak toxic target fast anti phi dosis dosis dosis dosis place disease dna dna dna irreversibly bind syndrome inhibitor inhibitor dnmts myelodysplastic take impact dependant weak weak belong replicate methylation tempo high incorporate demethylation demethylation cell aml play 
1.67@dna dna dna deactivate inhibitor dnmt activate gene reduce reduce tumor agent demethylating methylation methylation decitabine decitabine oppose suppress 
1.0@cancer methyltransferases tumour tumour concentration agent specific hypomethylating myelodysplastic reactivate suppress lead cytosine see round apoptotic nucleoside implicate like cell cycle independent closely dna dna dna carry carry therapeutic mitotic require analogue extent apoptosis condition without trigger show repetitive study action function gene methyltransferase inhibitor epigenetically supressor silence thus thus signal decitabine activity activity activity decatibine decatibine couple 
0.67@elod suppressor platic class dnmt produce tumour tumour acute myelogenous hypomethylates leukemia become hypermethylated treat marrow lead treatment dna dna decitabines syndrome inhibitor allow deform inhibit methyltransferase effect bone silence thus decitabine decitabine gene y license cell cell blood expression 
1.33@one suppressor cancer cancer cancer cancer inhibitor dnmt dnmt n methyl cause maintenance switch fra lation math affect rase dna dna divide lesser level level level fe responsible hyper drug gene gene rapidly reduce reduce reduce normal division usually new methylation methylation methylation decitabine decitabine time mean enzyme cell cell cell cell use belong 
1.33@growth unregulated cancer category within within produce activity way agent process major similar substance substance direct call restore restore believe belong demethylating twofold tumor mechanism block normal normal anticancer thus decitabineis regulate regulate control blockage expression one suppressor suppressor suppressor chemotherapy promote antimetabolite antimetabolite drug cause target result number allow become know demethylation demethylation metabolism dna dna dna dna divide cell cell cell cell cell cell cell cell cytotoxic death function gene gene gene gene rapidly effect effect interact cellular increase division division interfere new methylation methylation methylation member work incorporate class 
2.0@cancer methyltransferases inhibition inhibition produce produce synthesize use dnmts dnmts agent newly charge find meet growth growth md md md istrough treat decrease unlike controldescribed lead cytosine strand methylate methylated therefore hyper hyper demethylating demethylating tumor tumor tumor tumor mechanism normal feature hypermethylation myelodysplastic hilum cell cell methyl decitabine decitabine decitabine decitabine critical suppressor residue action cause global apoptosis incorporate gent consider better dna dna dna dna dna escape hypo allow syndrome inactivation atinga expression control control ti methylation rna gene gene another progression progression differentiation azacitidine 
1.67@cancer cancer cancer methyltransferases class tumour tumour tumour tumour include hand hypermethylate characteristic dnmti rate oncogene oncogene oncogene decrease decrease island island lead lead lead development avoid common silence silence silence silence ezh nearby hypermethylation hypermethylation high maintain many cell may supressor supressor supressor supressor general drug cause present present integrity like type prevent chain dna dna dna histone expression expression expression inhibitor cpg cpg gene gene gene gene gene gene effect belong methylation decitabine decitabine create safeguard associate associate 
2.0@cancer article inhibition class class mode enthusiasm inhibitor agent ther hypomethylating md md major azacytidine reactivate hypomethylation direct exert report emergence incorporation antineoplastic see cellular establish especially impact tumor accord life difficult potency manufacturer beyond tolerate suppressor quote poorly patient patient substantial jain drug cause phosphorylation therapy apoptosis expectancy era fact cytotoxic garcia treatment dna dna dna dna godley stressman lyko vitro target management gene methyltransferase methyltransferase effect effect epigenetically onco int believe silence website new new decitabine decitabine action differentiation generate 
2.0@cancer reduce suppressor way slow slow slow chemically agent specific process since growth growth treat normal grow suppress suppress benefit neighbor epigenetic hyper demethylating able tumor tumor tumor due affect hypermethylation hypermethylation case cell say one namely duplication drug drug nothing target stop slower level dna dna histone histone act function gene gene induce silence word thus methylation methylation decitabine mean accelerate 
2.0@cancer critical dnmt dnmt dnmt dnmt tumor tumor tumor use state state state agent de generation hypermethylated hypermethylated treat inhibit previously next strand strand strand see methylated well allow allow allow thereby thereby conserve heritability normal like passive cell cell cell blood suppressor suppressor methylating identify mitotic either either add presently pass effect anti methylation methylation methylation methylation methylation methylation methylation occur parent parent myelodyplastic example dna dna dna maintenance histone histone histone syndrome gene gene gene inhibitor inhibitor demethylation increase silence silence silence demethylated combat decitabine decitabine daughter daughter daughter active active maintain protein 
2.0@loss inhibitor inhibition class dnmt induce use dnmts fda agent specific hypomethylating myelodysplastic analog hypomethylation hypomethylation hypomethylation leukemia direct exert inhibit incorporation previously nonproliferating covalent brake hypermethylation proliferation myeloid tumor tumor tumor tumor aza neoplastic contribute bond insensitive cell cell cell cell cycle cycle may may suppressor suppressor suppressor cytidine also cancer cause cause restoration restoration subsequent apoptosis relatively phase anti arrest methyltransferase methyltransferase treatment dna dna dna dna dna divide acute cytotoxic syndrome act function function drug gene gene aml effect effect deoxycitidine result cellular cellular secondary belong senescence silence principally decitabine decitabine decitabine decitabine drive approve form differentiation rapidly 
2.0@suppressor suppressor cancer transcription insert growth tumour tumour tumour cause agent hypomethylating ultimately change effect effect anti level inhibit inhibit inhibit promote dna dna dna dna dna dna dna process process promoter act enzyme cpg island proliferation reduce reduce reduce increase increase epigenome thus thus methylation methylation methylation methylation methylation decitabine decitabine decitabine decitabine silence gene gene activity counteract cell methyltransferase methyltransferase methyltransferase associate 
1.67@cancer inhibitor inhibitor epigentic class class target enzymatic enzymatic uncontrolled include agent whose mark mark myelodysplastic find meet growth replicant treat call job epigenetic epigenetic epigenetic strand around atp belong demethylating mechanism therfore cause site many cell use nuceloside suppressor suppressor suppressor transfer irreversibly drug drug analogue overexpressed function april incorporate histone stop solid tumour tumour tumour tumour tumour ecomonist dna dna dna nucleous surround bind bind bind syndrome act dnmts gene gene copy effect remove dependant deacetylase ezh silence regulator decitabine decitabine decitabine daughter lay come active move alter 
2.0@et dnmt dnmt agent agent rich leone hypomethylation hypomethylation hypomethylation analoque island cytosine position pyrimidine diffrentiation enzyme demethylating demethylating inhibit inhibit inhibit tumor tumor mechanism complex nucleoside signal cell expression transient suppressor analogue antimetabolite cause decitabine decitabine decitabine result anti promoter group dna dna dna dna dna ring bind dnmts cpg gene gene methyltransferase effect induce classiffied cellular death thereby da al ul ul region modify 
1.67@suppressor suppressor effect todna reactivation reactivation epigenetically agent analog cytosine anti promoter lead lead lead dna dna act silence demethylating gene gene methyltransferase inhibitor tumor tumor tumor belong decitabine demethylation 
0.67@methyltransferases methyltransferases abnormal translation fa cause defective methyl concentration agent way transcription azacytidine er covalently treat inhibit inhibit inhibit inhibit cytotoxicity cytotoxicity similar lead lead trna e thereby thereby derive myeloid proliferative high n case cell cell cell cell use tra cytidine also also also also insert commonly analogue dose ability decitabine decitabine decitabine highly low chemotherapeutic derivative bind bind show dna dna dna dna dna dna dna deoxy synthesis often syndrome function function ribonucleotide remove hematopoetic death death vitro methylation methylation rna rna em incorporate incorporate incorporate dysplastic action azacitidine azacitidine azacitidine azacitidine azacitidine 
2.0@et inhibition dnmt tumour analogue agent hypomethylation lead dna dna dna irreversibly bind act dnmts demethylating gene activation santi silence thus al decitabine nucleoside incorporate replication suppressor 
1.67@one inhibitor class reactivation produce tumor use induce specific condition myelogenous silence hypomethylation leukemia treat marrow hypothemylation antitumour dna dna blood acute syndrome precursor link deform gene methyltransferase effect epigenetically contribute member decitabine decitabine decitabine hence bone respect cell myelodysplatic supressor 
1.67@dna epigenetic drug methylated demthylates demethylating gene gene chemical effect tumor agent stop stop stop runaway give decitabine growth growth growth become antitumor cell proliferation demethylates 
2.0@mitotically cancer cancer methyltransferases hereditably therefore epigenetic promote tumour decitabine decitabine decitabine apoptosis modifier dnmti inhibit furthermore lineage lead dna dna dna dna divide methylated act selectively inhibitor gene methyltransferase effect mother normal replicate reach daughter interact hypomethylated cell cell cell cell cell cell may suppressor reactivate 
2.0@specifically cancer cancer cancer classify within suppressor suppressor use information interact target whereit chemotherapeutic md approve metabolism dna dna divide kill syndrome function drug gene gene rapidly antimetabolite antimetabolite normal silence treatment treatment myelodysplastic decitabine decitabine decitabine work incorporate demethylation demethylation demethylation cell cell cell cell tumour tumour 
1.0@alt cancer methyltransferases todna class reactivation consequenceof methyl methyl andprogrammed selective deoxinucleosyde reactivate dosis inhibit aza expression epigenetic promoter methylated silence key fact img hypo tra cause action induction analogue role low src tranferase dna dna citidine cell cell cell tumoural fe important gene gene gene inhibitor inhibitor inhibitor deoxycytidine death belong treatment rase decitabine decitabine decitabineas supressor differentiation play 
0.67@dna cancer methylating dnmt necessary via use instability lesser scale inhibit cancerous methyl transferase prevent genomic open decitabin development histone histone bind inhibitor upregulated gene effect effect effect normal increase silence epigenetics methylation wide cell may expression 
1.67@cancer cancer inhibitor category specificity dnmt dnmt produce use agent process myelodysplastic since hypomethylates block growth md md call inhibit restore restore irreversibly particularly belong belong demethylating efficient effective mechanism metabolism normal lack although methylation demethylation treatment treatment tumour suppressor dependent also antimetabolite replication cause mean bind antineoplastic good chemotherapy dna dna dna dna dna dna divide dose cell cell cell cell cytotoxic syndrome function function drug gene rapidly rapidly effect effect devide cellular control death unaffected replicate thus lower decitabine decitabine decitabine decitabine decitabine decitabine much incorporate incorporate action methyltransferase class 
2.0@cancer cancer cancer inhibitor inhibitor inhibitor class dnmt dnmt dnmt dnmt dnmt dnmt activate tumour tumour tumour tumour agent also growth growth oncogene multiplication nucleotide lead lead lead lead lead irreversibly belong demethylating severely enhance enhance activation modification affect turn successful deactivation demethylation cell cell cell cell cell way suppressor suppressor suppressor methylating therefore epigenetic replication deactivate surround anti normally dna dna dna divide histone histone histone bind bind le gene gene gene gene gene rapidly effect upon copy division division additionally silence methylation decitabine decitabine daughter incorporate methyltransferase 
2.0@inhibitor inhibitor abnormal class tumour tumour tumour tumour tumour agent myelodysplastic reduction unmethylated hemimethylated inhibit suppress recognize epigenetic strand belong demethylating island hypermethylation nucleoside daughter cell methyl drive suppressor suppressor dependent transfer ase therefore irreversibly replication analogue mean anti consist cpg cpg dna dna dna dna dna bind syndrome dnmts dnmts dinucleotides gene effect catalyze division methylation methylation methylation decitabine decitabine decitabine mainly tumourigenesis incorporate action action dnmti dnmti dnmti 
2.0@mitotically cancer cancer inhibitor demethylates dnmt dnmt dnmt reactivation uncontrolled include stop mark myelodysplastic dnmti dnmti growth generation treat transferase inhibit previously next irreversibly pass common enzyme demethylating parent activation tumor tumor affect dnmtis typically nucleoside cell cell cell cell removal methyl suppressor suppressor destroy transfer epigenetic replication analogue overgrowth result result result cancerous tumour prevent dna dna dna dna dna kill bind bind syndrome function drug drug gene gene gene gene gene dnmts upon silence silence silence thus methylation methylation methylation methylation decitabine decitabine decitabine daughter work incorporate whatever onto 
1.0@cancer inhibitor higher dnmt general much much function include agent mostly since since growth affect deprive often dna dna kill act act functionality demethylating rate tumor tumor normal normal essential replicate methylation decitabine decitabine eventually cell cell cell cell cell cell replication 
2.0@suppressor suppressor cancer transfer transfer inhibition excessive agent loss result meet meet silence hypomethylation unchecked promotor promotor inhibit cpg often dna dna dna dna expression see ase ase act establish allow allow thereby island proliferation proliferation effect tumor tumor cellular cellular excess thus methylation methylation locate region region gene gene gene suppressive would decitabine decitabine 
2.0@article oncogenic others cite cluster place decitabin myelodysplastic analog myelogenous economist unmethylated sit recognize promoter step precursor enzyme remain happen tumor substrate express cell cell beyond pre leukaemia suppressor cytidine cytidine drug drug number replication among hypomethylated treatment dna acute syndrome syndrome inhibitor cpg cpg methyltransferase methyltransferase allow allow remove probably great go methylation inside region incorporate perhaps 
1.67@cancer dnmt dnmt tumour tumour tumour information agent stop anymore irreversibly replication supress lecture grow dna dna dna divide strand bind dilution le dnmts demethylating demethylating inhibit everytime pattern copy hypermethylation require new methylation methylation decitabine arise gene activity case cell incorporate supressor 
2.0@cancer proliferate higher dnmt dnmt use transfer pattern pattern pattern myelodysplastic myelodysplastic myelogenous normally treat island effective irreversibly strand strand particularly enzyme enzyme outcome hypothesise mechanism affect hypermethylation dilute nucleoside case cell cell cell cell cell tumour leukaemia one understand rat get drug analogue healthy yet type develop example dna dna dna dna divide divide divide acute bind bind syndrome syndrome cpg poor methyltransferase methyltransferase inhibitor copy longer methylation methylation methylation decitabine decitabine decitabine decitabine daughter incorporate action full prognostic 
1.67@suppressor suppressor cancer cause restore therefore epigenetic excess tumour tumour certain effective agent know activity probably effect genetic drug drug drug drug drug drug decrease decrease island island island cpg cpg cpg treatment dna feature call act demethylating gene gene reduce amount myelodysplasia increase increase belong anticancer potency methylation methylation methylation methylation genome class like cell part use level level decitabine decitabine decitabine decitabine 
2.0@suppressor restore restore use agent process myelodysplastic hypomethylates growth treat inhibit dna dna dna syndrome function demethylating gene methyltransferase tumor normal thus decitabine decitabine demethylation cell control 
2.0@cancer cancer rarely restore restore neoplasia tumour tumour tumour tumour tumour appear agent specific reactivate hypomethylation change locus regulate know methylated methylated methylated belong demethylating island island proliferation happen question normal essential genome insensitive program cell cell cell cell may suppressor suppressor suppressor suppressor suppressor promote divide drug apoptosis result result become show dna dna dna dna profile demethylates function function cpg cpg gene gene gene gene gene gene methyltransferase inhibitor epigenetically control death division silence silence methylation decitabine decitabine decitabine decitabine class differentiation 
1.0@dacogen cancer cancer company promote suppressor suppressor suppressor activity total carry carry agent heighten process role role myelodysplastic myelogenous growth growth leukemia anti methylation treat call group presence lead cell cell syndrome sell division division drug hinder happen tumor control belong thus normal decitabine decitabine decitabine gene gene gene regulate demethyation demethylation japanese use 
2.0@et et et cancer inhibition induce use agent apl make hypomethylates reactivate leukemia md inhibit epigenetic demethylating hagemann hagemann tumor besides apoptotic extrinsic bond dac treatment treatment suppressor indicate successfully activation epimutations therapy apoptosis cell result low nb show covalent dna dna dna pathway dose acute syndrome dnmts myelodysplastic methyltransferase epigenetically die soncini silence al al al decitabine decitabine gene reverse promyelocytic associate 
2.0@mistake inhibitor class within dnmt theability n methyl fda exhibit penetrative hypomethylating myelodysplastic methylating methylating dnmti growth tra md tsg tsg transferase solid irreversibly promoter promoter lose lose conduct hyper stick tumor tumor tumor tumor tumor due genome transcriptionof cell cell curb belong study cytidine also agent incorporate nature occur show good andhave treatment dna dna hypo hypo bind syndrome property gene resume effect approve generational replicate epigenetics methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine possible activity activity activity influence supressor enable would per 
1.67@cancer inhibitor effective get include analog malignancy md might affect island clinical irreversibly body consequence severely tumor mechanism normal hypermethylation release speculate cell cell cell cell trial decitabine reason dependent also nucleoside divide seem seem cause number solid know know dna dna dna dna however bind bind cpg rapidly along still replicate methylation longer incorporate come action methyltransferase methyltransferase methyltransferase azacitidine 
2.0@inhibitor inhibitor dnmt progress use place myelodysplastic analog azacytidine azacytidine dnmti leukemia cutaneous inhibit nucleotide clinical irreversibly strand take myeloid longer vidaza vidaza nucleoside methylation cell trial pre release one dna dna dna dna dna also dmti replication machine hdaci type kind get acute bind bind bind syndrome act additional drug drug drug methyltransferase methyltransferase methyltransferase methyltransferase along along upon hmti similar copy hdmi modification epigenetics hati decitabine decitabine daughter incorporate come come approve approve 
1.0@cancer myeloid higher dnmt dnmt dnmt dnmt blood worst myelodysplastic malignancy hypomethylation leukemia md decrease inhibit synonymous lead thigh level level level subunit enzyme ezh ezh ezh ezh ezh research research due complex case case demethylation often catalyze prc also drug drug prolong toxic target histone dosage maintain show show show show good dna dna dna dna dna dna dna acute frequency syndrome act expression expression end methyltransferase increase dnmtp replicate methylation methylation methylation methylation methylation methylation decitabine hematopoietic mean mean mean survival sequestrate recruit 
1.33@dna dna dna irreversibly dependent analogue bind low inhibitor dnmt demethylating replication dnmts agent cause dose thus nucleoside nucleoside incorporate demethylation 
1.67@heavy cancer cancer cancer methyltransferases shen long stem key renew back act act epigenetic epigenetic epigenetic know methylated enzyme literally tumor tumor tumor mechanism hui mammal cell cell cell peter atom cease today ie effect effect contratrary bind landscape reshape kill cytotoxic abandonment volume gene gene methyltransferase memory belong treatment methylation methylation decitabine decitabine decitabine decitabine work enable laird clonogenic dca class dnmt use use state agent agent rule supresser unmethylated direct convince call island island addition lead cytosine methylate display thereby alone issue fact carbon high case reprogram supressor one associate associate deleterious date drug drug combination therapy therapy therapy location low low healthy traditional traditional promoter prevent poison dna dna dna dna dose dose dose unmethyated chemotherapy le cpg cpg rather inhibitor demetylating administer past covalently self tissue 
1.33@elod plastic cancer individual agent healthy y myelogenous cytotoxicity ultimately become quite inhibit lead treatment dna dna dna dna dna dna divide bind syndrome function demethylating prevent rapidly enter methylation andacute decitabine decitabine successful incorporate hypomethylates active cell cell cell far methyltransferase methyltransferase methyltransferase 
2.0@cancer cancer classify abnormal restore within produce produce use dnmts thebone attempt process myelodysplastic hypomethylates growth covalently direct treat marrow marrow inhibit aza rapidly help well bone happen tumor anticancer block block normal normal bipartite convert phosphorylation triphosphate demethylation demethylation demethylation cell cell cell cell cell cell cell tumour metabolism suppressor antimetabolite antimetabolite drug cause cause therapy substance cdr target number gene anti bind syndrome dna dna dna dna dna divide blood kill cytotoxic cytotoxic chemotherapy function change change chemical effect effect interact cellular control death decitabine decitabine work incorporate form methyltransferase behavior 
1.67@cancer cancer effect class dnmt administration methyl remain unmethylated transferase island epigenetic decrease methylated silence silence demethylating inhibit tumor tumor tumor tumor tumor block hypermethylation hypermethylation express cell retinoblastoma decitabine decitabine decitabine suppressor suppressor necessary general drug appropriate result result result anti colon particular dna dna dna dna dna dna expression cpg gene gene inhibitor keep belong methylation methylation allow mean active would would would would would would would would would 
1.67@cancer methyltransferases methyltransferases inhibition methionine use process myelodysplastic currently dnmti hypomethylation higher treat inhibit incorporation incorporation lead covalent island enzyme provide proceed mechanism hypermethylation utilize second cell cell tumour leukaemia commercialize via drug cause result result result low perspective anti bind syndrome dna dna dna dna dna dna dna dna sam dose dose acute mechanistic adenosyl cpg methyltransferase effect death death myelogenous methylation decitabine decitabine decitabine decitabine eventually 
2.0@cancer cancer cancer inhibitor inhibitor abnormal abnormal abnormal class dnmt dnmt dnmt dnmt may susceptible agent stop stop mark mark mark mark growth preserve make epigentic previously strand call call well think demethylating effective tumor tumor tumor normal express cell cell cell cell suppressor transfer transfer drug pass anti prevent treatment dna dna dna dna divide form chemotherapy gene methyltransferase effect silence new new new new new methylation methylation methylation methylation methylation decitabine decitabine decitabine action part protein 
1.33@myc myc cancer cancer cancer inhibitor class effective way slow system myelogenous amenable dnmti change leukemia generation generation regulatory call erase disruption epigenetic epigenetic epigenetic msd pass involve belong demethylating proliferation tumor affect outright epigenome epigenome anticancer thus conventional like cell cell cell cell one transcription factoir render therefore fda drug drug drug drug cause cause myeloma therapy therapy pathway cancerous encode completely endure treatment treatment dna dna dna four shut act eliminate gene gene methyltransferase effect division main decitabine decitabine somehow approve 
1.0@cancer inhibitor disrupt disrupt within much healthy island disproportionately analog since cancerous dnmti change replication transferase prevent cpg decetibine dna dna dna dna irreversibly development bind reproduce expression thereby gene rapidly effect tumor methyltransferase affect hypermethylation methylation nucleoside incorporate cell cell cell cell cell methyl 
2.0@cancer cancer proliferate uncontrolled size growth growth growth cm cm transferase inhibit lead lead lead hyper chromosome reduce tumor style style affect hypo sysnthesis nucleoside font font font font cell cell cell incorporate supressor suppressor also bottom bottom excessive drug proper inhibitted inhibitted bring serif methyl prevent dna dna dna dna get non histone margin margin face gene gene deoxycytidine onset silence thus methylation methylation methylation decitabine decitabine eventually progression 
1.67@cancer class transferasa overmethylation produce produce methyl methyl agent stop neighbor silence silence silence growth avoid aza surround irreversibly call enzyme enzyme demethylating way reduce reduce uncontrolled hypermethylation high dntm demethylation cell tumour tumour suppressor suppressor cytidine cause epigenetic analogue toxic cancerbecause low number group ezh dna dna dna dose dose histone histone histone histone bind act gene gene gene gene inhibitor overactive deoxycytidine attach belong thus methylation decitabine decitabine cant overactivity protein 
2.0@cancer methyltransferases promote use analogue first cytidine cytidine agent activity deoxynucleoside deoxynucleoside transfer hypomethylates tumour group dna dna dna dna dna dna dna dnmts dnmts demethylating inhibit methyltransferase enzyme block block block catalyze division convert methylation decitabine decitabine decitabine decitabine substitude incorporate triphosphate cell methyl 
1.67@cancer inhibitor nucleoside use concentration cycle specific myelodysplastic dnmti dnmti dnmti dnmti dnmti dnmti dnmti fda treat primary island chemotherapeutics molecule often irreversibly even transferase standart enzyme inhibit sideeffects test hypermethylation clear thus vidaza high general cell cell methyl belong belong dependent patient therefore therefore seem need analogue combination toxic normal replication act prevent approve dna dna however bind syndrome site function cpg poor effect globally rapid indicator division due completly work work decitabine em em incorporate active survival le prognostic small 
2.0@suppressor cancer inhibitor dnmt hypomethylated tumour state myelodysplastic currently hypomethylation leave treat inhibit aza treatment dna dna syndrome methylase drug gene gene reactivation deoxycytidine cml methylation decitabine decitabine lead cell use 
0.67@heavy myeloid dacogen progress use eisai dnmti leukemia might island island island nucleotide irreversibly strand inhibitor hypermethylation hypermethylation hypermethylation effective generally release japanese drug decitabine cute dependent identify replication possible mean know amp company dna dna dna dna dna get bind bind bind syndrome syndrome syndrome sell myelodysplastic myelodysplastic myelodysplastic cpg cpg cpg poor aml along along upon copy dnmt methylation outcome daughter work incorporate come come nt methyltransferase methyltransferase methyltransferase methyltransferase prognostic 
0.67@celgene dacogen cancer suppressor methylates uncontrolled cause include agent whose decitabine decitabine decitabine silence eisai cell cell myelogenous surround stop growth azacitidine demethylate treat call tumour tumour company dna dna histone acute syndrome sell sell myelodysplastic demethylating gene gene proliferation reduce job precursor thus vidaza like japanese overactivity use leukaemia 
2.0@plastic dacogen cancer cancer inhibitingdna growth growth dnmt use drug agent acute suppression condition myelogenous hypomethylation leukemia treat inhibit develop lead lead dna see syndrome sell eisai demethylating island methyltransferase y hypermethylation decitabine gene cpg like elod may suppressor leukaemia 
1.0@suppressor therefore order regulation system trait agent agent apoptosis strengthen anti anti inhibit regulate dna dna epigenetic epigenetic histone gene gene effect tumor tumor tumor give methylation methylation decitabine maintain cell cell cell 
2.0@suppressor suppressor suppressor lat methylating dnmt dnmt methylates use deme agent mean cytosine proliferate bring dnmti express bind methyl transferase inhibit act dna dna dna dna dna however decrease methylated particularly normally function inhibitor gene gene gene gene proliferation proliferation enzyme tumor tumor tumor contribute thy silence silence methylation decitabine decitabine decitabine reproduce cancerous cell cell cell cell control control control without 
0.67@misshapen cancer cancer article abnormal abnormal growth growth medication able produce produce produce use use appear agent epicentre make economist hypomethylation specialization treat treat call class epigenetic body help think bone bone bone control normal normal epigenome may metabolite myelodysplastic cell cell cell cell cell cell cell cell cell blood blood blood blood blood blood dna red also promote seem drug marrow marrow marrow md toxic white describe reference healthy gene anti better group several process kill syndrome act platelet affect affect effect effect condition explain decitabine decitabine decitabine decitabine work work enough 
1.67@cancer cancer toxicity class class dnmt dnmt dnmt much since analouges quite normal inhibit lead transferase transferase help accect enzyme take effective effective permanently high cell cell cell cell cell methyl methyl methyl transfer nucleoside depend get use replication replication methylate dna dna dna dna dna divide divide dose dose point consume drug drug rather inhibitor upon attach set belong low methylation decitabine decitabine decitabine decitabine decitabine decitabine work incorporate come rapidly 
2.0@cancer inhibitor class dnmt dnmt general dependent decitabine decitabine process process since anti normal nucleotide division strand transferase bind hypermethylation affect rapidly effect tumor longer copy belong replicate methylation methylation severely daughter create cell release 
1.33@dna dna suppressor cancer classify restore restore function demethylating demethylating gene drug tumor agent interfere thus methylation decitabine growth work anti cell control 
2.0@mitotically methyltransferases cell tumour tumour tumour agent mark analog since reactivate heritable cytosine epigenetic epigenetic development enzyme demethylating demethylating rid nucleoside purpose like offspring express decitabine decitabine suppressor suppressor therefore use either accomplish target result introduce case methylation methylation methylation methylation dna dna dna get mind act gene gene gene gene inhibitor keep silence silence silence regulator allow daughter dnmti 
2.0@one expresed cancer histomes class lymphoma methylates tumour tumour tumour slow agent silence suppression histone chance de growth ezh amount better call dna dna methyliizig decrease enzyme demethylating gene gene supressing overactive belong turn especially especially methylation decitabine surround cused many cell cell overactivity proliferstion would would expression 
2.0@suppressor cancer happen start region agent revert suppression result result hypomethylation hypermethylated dna dna allow demethylating gene gene methyltransferase inhibitor tumor normal silence decitabine work activity express cell differentiate combine expression 
2.0@class able activate demethylated cancerous growth growth inhibit inhibit suppress suppress dna dna dna dna divide malignant especially prevent methyltransferase methyltransferase inhibitor tumor tumor belong methylation decitabine gene gene hypomethylates cell cell catalyze 
2.0@dna dna suppressor mean therefore activation demethylating gene tumour allow allow remove agent mark hypermethylation methylation transcribe hypomethylated normally decrease island cpg decitabine decitabine 
0.67@suppressor could cause demethylates essentially supression use drug agent suppression myelodysplastic free growth unmethylated sit normally inadequate especially island treat example dna syndrome function demethylating demethylating gene gene remove mean mean uncontrolled control hypermethylation hypermethylation hypermethylation combat decitabine decitabine decitabine region cpg express cell cell tumour tumour tumour replication 
2.0@inhibitor class reactivation tumour decitabine decitabine anti acute silence silence hypomethylation hypomethylation tumori useful treat ed sup dna dna leucemia precursor pressor bone gene methyltransferase aliment epigenetically link effectiveness al contribute narrow form belong 
2.0@cancer cancer as inhibition restore specificity dnmt use use fda aberrantly well myelodysplastic myelogenous meet functional growth part treat perfect silence silence achieve achieve toxicity remember precursor respond inhibitor proliferation rarely tumor tumor mechanism normal lack also high retain methylation cell cell cell cell tolerate leukaemia one suppressor dependent transfer patient therefore excessive replication analogue cause apoptosis target low derepress effect therapy arrest prevent extremely dna dna expression dose dose acute syndrome nucleoside function function drug drug gene gene methyltransferase important induce join relevant antineoplastic division currently currently lower decitabine approve action generate dnmti dnmti 
2.0@cancer along restore gradual dnmt continue use include tend myelodysplastic analog myelogenous dnmti dnmti fda leukemia tumour nucleotide class irreversibly strand body precursor time inhibitor cgi em em tumor affect release nucleoside demethylation demethylation cell cell cell cell cell much suppressor transcription regular depend get induction replication replication cause restoration novo novo apoptosis result anti promoter dna dna divide acute bind bind syndrome expression drug drug drug gene gene gene gene rapidly effect upon copy division longer since methylation decitabine decitabine decitabine decitabine decitabine daughter severely incorporate come approve action action action downstream methyltransferase methyltransferase de de 
1.33@cancer inhibition dnmt dnmt use every agent remain de unmethylated treat myelodisplastic inhibit lead irreversibly strand strand strand body methylated demethylating tumor affect hypermethylation nucleoside demethylation cell cell cell drug dna dna dna dna dna depend get daugther replication analogue novo mean occur treatment kind divide bind syndrome act progressive rapidly copy division division methylation decitabine decitabine decitabine daughter daughter much much incorporate come approve methyltransferase 
2.0@mean cancer proliferate class dnmt methyl cytoxicity specific dmntis find hypomethylation high tumour tumour tumour tumour often locus stop lead cytosine irreversibly inhibitor enzyme inhibit reduce mechanism normal normal dnmtis dnmtis dnmtis hypermethylation hypermethylation nucleoside drug cell way expression suppressor suppressor destroy patient divide replication replication analogue dose healthy decitabine decitabine decitabine target ultimately anti anti cytotoxic promoter group unfortunately dna dna dna get non reverse dependent bind function perform gene gene resume effect effect effect upon methyltransferase time attach belong methylation allow region incorporate covalently rapidly equally 
2.0@suppressor cancer substance methylates tumour cause include agent whose chromosomal silence surround stop growth part methyl call call group job dna package histone histone enzyme enzyme demethylating inhibit uncontrolled protein ezh thus decitabine gene gene activity cell overactivity attach 
2.0@suppressor could analogue abnormal high depend dnmt tumour tumour cause cause inhibitor agent agent specific toxic become low effect effect effect anti type know island dna dna dna dna irreversibly dose bind act hyper demethylating demethylating gene methyltransferase activation non antineoplastic cpg decitabine decitabine nucleoside incorporate like demethylation cell methyl 
2.0@epigenitically cancer cancer undesired inhibition apart reactivation o use use agent aberrantly inactivation toxicity silence growth decitabene decitabene precusrrors treat treat transferase inhibit occur lead lead aplastic epigenetic strand methylated overactivation reduce hypermethylation myleogenous decithin cell cell cell cell cell tumour tumour belong high drug drug drug cause prolong toxic role low gene methyl hypomethylated damage reverse dna dna dna dna dna dna dna dose acute syndrome demthylating highly irreversible hence y concenterations control control repeat division thus thus methylation decitabine decitabine decitabine work work incorporate supressor class 
1.33@methyltransferases inhibition use state cycle mechanism myelodysplastic hypomethylation epigenetic help enzyme enzyme take tumor pattern hypermethylation although maintain cell cell cell methyl recover one suppressor transfer relate drug result explanation group group treatment dna donor acceptor syndrome expression still gene gene methyltransferase inhibitor unclear control thus decitabine possible action would 
0.67@housekeep suppressor lead restore cangerogenic drug drug cycle decitabine decitabine apoptosis myelodysplastic remain remain demethylated change leukemia treat treat prevent heritable company dna dna dna epigenetic epigenetic japanese syndrome sell expression demethylates gene gene tumor tumor prescibed precursor death division division housekeepind repair active active cell cell cell cell cell control supressors 
1.67@suppressor cancer promote dnmt tumour cause include agent whose surround stop growth call inhibit job dna dna dna show silence silence demethylating gene gene gene belong usually thus methylation methylation methylation decitabine decitabine demethylation cell uncontrolled 
2.0@vivo cancer deliver abnormal restore restore dnmt cytoplasm heritability agent agent exacerbate disease member hypomethylation hypomethylation hypomethylation covalently inhibit class epigenetic import division demethylating contraindicate tumor tumor tumor normal neoplastic hypermethylation intragenic instability enzyme passive repetitive suppressor suppressor dna dna dna dna dna mitotic mitotic likely result result result gene gene proliferate promoter promoter genomic nucleus reduction mark non cell cell bind bind act inactivate progressive methyltransferase methyltransferase eliminate induce induce relatively suggest unaffected since methylation decitabine decitabine decitabine decitabine decitabine region region incorporate action action action would would phosphorylated 
1.33@cancer cancer cancer faster dnmt dnmt activate activate heritability tumour analogue manner agent repressive irreversibly hinder maintain replication bind prevent previously unable dna dna dna dna divide dependent act silence demethylating island methyltransferase tumor normal cpg replicate thus methylation methylation methylation decitabine decitabine nucleoside gene gene gene like cell cell cell cell much progression 
0.67@unregulated cancer code code code restore restore within within produce way activity process number hdac growth growth associate direct decitabes similar regulate epigenetic inhibitor belong tumor tinymce tinymce tinymce block normal normal expression model jul marci demethylation demethylation cell cell cell cell cell cell cell control blockage scotto suppressor suppressor suppressor unique promote antimetabolite divide dlbcl cause decitabine decitabine highly result reference kalac effect become target metabolism dna dna blockquote blockquote substance substance histone cytotoxic death function gene gene gene gene rapidly synergistic interact cellular deacetylase increase division division interfere thus methylation methylation allow work incorporate hg hg hg profile class class class 
2.0@suppressor suppressor cancer inhibitor therefore dnmt dnmt hypomethylated tumour tumour tumour hence hence island island result dnmti hypomethylation become oncogene inhibit cpg cpg dna dna dna dna irreversibly strand strand cell cell bind involve involve division drug gene gene methyltransferase activation copy copy hypermethylation usually silence silence methylation methylation decitabine decitabine daughter daughter daughter incorporate action replication associate 
1.0@suppressor toxicity class agent agent agent decitabine decitabine decitabine decitabine hypomethylating excite hypomethylates acc show inhibit represent treatment dna dna profile carcinoma expression expression well allow gene gene methyltransferase effect tumor tumor antineoplastic silence new hyponethylating adrenocortical chromosome cell option tolerate recover expect 
1.67@mean mean cancer category dnmt regulation remove remove uncontrolled state order mark mark analog growth growth potential direct increase decrease island nucleotide restore irreversibly strand disease demethylating severely impact tumor tumor tumor affect hypermethylation unmethylated nucleoside regulator cell cell cell cell cell may may expression suppressor dependent epigenetic epigenetic replication replication normal result result cancerous anti occur promoter cpg dna dna dna get bind bind target target target drug drug drug drug gene continue effect upon must copy contain division division replicate methylation methylation methylation methylation methylation decitabine decitabine decitabine daughter region region incorporate come incomplete enzymatic class 
2.0@suppressor cancer cancer improper class commonly epigenetic synthesize use syndrome island highly myelodysplastic since hypermethylation newly treat treat normal prevent prevent prevent lead dna dna dna dna divide strand bind particularly inhibitor inhibitor belong demethylating irreversible rapidly important tumor methyltransferase methyltransferase affect cpg treatment thereby decitabine decitabine decitabine daughter gene methylation methylation cell cell cell cell control replication 
1.67@dacogen cancer cancer methyltransferases restore term dnmt dnmt progress use bigger activity long way deoxycytidine hypomethylation hypomethylation aza molecule lead irreversibly well enzyme inhibitor take tumor normal normal normal neoplastic much much like decitabineis treatment may deplete one suppressor faster necessary study drug drug analogue promotor cell cell cell cell cell myeloblastic dna dna dna divide deoxycytydine bind syndrome function gene gene aml effect effect induce cellular control belong decitabine decitabine decitabine decitabine decitabine region incorporate account differentiation proliferation class 
2.0@cytosine cytosine could inhibitor way analogue agent hypomethylating become reactivate anti factor dna get get get strand methylated antiproliferation tumoral methyltransferase effect similar decitabine decitabine although work incorporate case methyleted 
0.33@methyltransferases think use use hematological drugis specific saft myelodysplastic myelodysplastic find malignancy hair grow greatest irreversibly help inhibitor disease onother prevent tumor tumor tumor hypermethylation hypermethylation inhibitormay nucleoside small intestine like like follicle cell line example suppressor dependent dependent lower bond replication analogue havegreater toxic toxic mechanismof fast antineoplastic fastergrowing treatment dna dna dna dna however minimum syndrome syndrome soit function drug gene methyltransferase methyltransferase methyltransferase effect effect effect effect unclear relatively er keep decitabine decitabine incorporate action tissue tissue 
1.67@appear methyltransferases growth neoplasm synthesize include include agent newly classify hypomethylation hypomethylation leukemia md md hypermethylated treat marrow inhibit response addition expression expression correlate essential antimetabolite inhibitor bone tumor tumor mechanism blastic normal autorized hypermethylation hypermethylation hematologic signal demethylation cell cell cell control blockage supressor multiple also residue action appoptosis drug drug drug cycle hematopoietic result reverse cytosine encode myelodisplastic dual good syndrome dna dna dna replicate acute cytotoxic chemotherapy leukemic gene gene gene gene gene inactivate catalyze treatment dacitabine methylation methylation methylation decitabine decitabine production ink ink myelod differentiation protein associate 
1.67@unknown cancer methyltransferases class mean classical could could could specific malignancy malignancy dnmti affect locus imply irreversibly work work depent enzyme inhibit reduce tumor methylate dmt severly isunspecific hypermethylation inhibtors cell cell cell yet machinery dependent heamatological block block thes divide divide replication replication certain ly target describe finally dependency try know good dna dna dna dna however nucleosid epigenetic name inhibitor inhibitor drug drug som analouge analouge effect effect effect effect effect remove fast explain belong hypermethylationand methylation decitabine decitabine decitabine possible incorporate incorporate methyltransferase methyltransferase hit 
2.0@inhibitor inhibitor class dnmt dnmt administration upon may myelodysplastic analog reactivate vulnerable hypermethylated tumour tumour tumour tumour tumour island island unable epigenetic strand level belong thereby inhibit inhibit inhibit pattern hypermethylation divide genome nucleoside cell curb methyl go release dna dna dna dna dna dna drug transfer get get replication replication wide suppressor suppressor anti ease lecture several maintenance bind syndrome act cpg cpg gene gene rapidly effect effect remove remain copy division due thus thus methylation methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter em em em incorporate come period methyltransferase onto 
1.33@dependent methyltransferases class specificity dnmt use use analogue inhibitor irreversibly since problem come anti bind bind treat dna dna divide dose tumour every syndrome act act myelodysplastic drug drug time methyltransferase effect optimal longer lack belong replicate may release nucleoside replication replication cell rapid neoplastic decitabine 
1.0@suppressor suppressor effect class class unwarranted check tumour certain agent cancerous growth anti drug drug call group tumor tumor dna allow demethylating gene gene proliferation eliminate remove keep belong thus decitabine decitabine express cell cell methyl 
1.33@inhibitor inhibitor fda agent novo already myelodysplastic myelogenous dnmti anti anti treat particular family dna dna epigenetic acute syndrome precursor demethylating aml effect effect tumor tumor belong decitabine decitabine decitabine work approve leukaemia methyltransferase de 
2.0@suppressor suppressor cancer reduce inhibition tranferases produce methyl fda result since hypomethylation anti hypermethylated promoter inhibit often dna dna dna action dnmts dnmts gene gene effect tumor tumor tumor silence methylation methylation allow transcription maintain approve treatment drug initiate decitabine decitabine decitabine 
2.0@cancer supressing restore dnmt dnmt dnmt methyl state manner specific rule malignancy malignancy block block block block exert transferase achieve clinical well allow inhibitor inhibitor inhibitor take tumor tumor question normal hypermethylation fact case cell cell cell trial control compound compound hematological depend divide general result express hypermetylation type solid show good dna dna dna dna however bind bind site expression irreversible effect effect methylation methylation methylation cellular try silence thus thus hypothesis decitabine decitabine decitabine gene gene account approve previous would would 
1.0@code therefore hematopoiesis use drug agent hypomethylating product myelodysplastic myelodysplastic transfer element methylated treat act group amount lead dna dna dna dna correct correct non acute help syndrome syndrome precursor expression disorderly inhibit methyltransferase effective normally normally normal catalyze myelogenous methylation decitabine decitabine region return methyl would leukaemia 
1.33@mean cancer along dnmt dnmt dnmt dnmt use analogue dependent sever myelodysplastic myelogenous treat copy nucleotide dna irreversibly strand acute bind bind syndrome precursor inhibitor inhibitor drug rapidly effect longer normal replicate methylation release daughter incorporate come cell cell replication decitabine 
1.33@cancer methyltransferases methyltransferases dnmt dnmt dnmt hand induce induce kinase concentration concentration cycle cycle specific analog analog reactivate hypomethylation covalently incorporation suggest absence aza lead cytosine cytosine position inhibit inhibit intracellularly usually high triphosphate triphosphate cell cell cell methyl study cytidine replication cause preclinical trap product incorporate incorporate low unique without arrest arrest group dna dna dna dna dna dna dna dna apoptosis reverse reverse degradation dnmts end gene gene inhibitor synthesis place deoxycytidine deoxycytidine global silence methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine work eventually modify differentiation attach phosphorylated 
2.0@cancer cancer inactivate abnormal dnmt dnmt dnmt dnmt dnmt use appear activity specific mark mark analog since hypomethylation transferase locus lead irreversibly strand copy inhibit take affect hypermethylation hypermethylation hypermethylation hypermethylation nucleoside maintain demethylation cell cell cell cell cell cell cell tumour suppressor one hallmark therefore divide epimutations replication normal normal normal normal detrimental methyl prevent island dna dna dna dna dna maintenance continuous synthesis bind inhibitor cpg gene rapidly effect explain division main methylation decitabine decitabine decitabine decitabine decitabine decitabine daughter incorporate come hence require 
1.0@elod heavy cancer cancer cancer cancer cancer cancer methyltransferases methyltransferases abnormal progress progress much slow fda add growth leukemia characterize mother inhibit island cpg regulate irreversibly depend enzyme group impact replicate affect yn isa blood blood nucleoside myeloid drome methyl dependent unlock therefore therapeutic replication analogue non y acute cancerous type prevent dna dna dna dna dna however dose cell cell cell cell cell cell cell cell cell bind inhibitor drug drug gene plastic effect copy copy quickly interfere interfere interfere new methylation methylation methylation methylation decitabine decitabine daughter daughter production incorporate perhaps approve administer heavily 
1.33@mitotically cancer cancer cancer last tumour tumour unmethylated agent agent agent stop currently susceptible make heritable island dna dna deacetylse epigenetic demethylating demethylating grow way tumor mean hypermethylation may demethylation demethylation cell cell cell rapid one one suppressor promote histone hallmark drug combination progeny shore overgrowth overgrowth result finally without type standard kill chemotherapy act act cpg gene continue inhibitor deacetylase silence thus methylation decitabine decitabine eventually cellsthe alter 
2.0@cancer cancer inactivate dnmt dnmt tumour tumour tumour concentration attempt phase reactivate hypomethylation hypomethylation hypomethylation unlike dna dna achieve dntp methylate therefore enzyme dctp reduce suppress link convert divide nucleoside cell cell cell cell cell cell use majority decitabine decitabine decitabine dose suppressor cytidine also residue cys via analogue non target result low low anti normally pool somatic several maintenance base kill act principle inhibitor end irreversible side effect effect replicate thus thus actively deplete gene incorporate incorporate incorporate incorporate active covalently would 
2.0@suppressor suppressor cancer effect class way analogue agent decitabine decitabine decitabine decitabine ofdna decrease hyper hyper anti level island nucleotide reactive dna dna irreversibly shut bind kind inhibitor dnmts dnmts demethylating gene gene methyltransferase reduce tumor tumor tumor tumor gradually cpg belong go methylation methylation methylation ul ul region incorporate replication many lead lead use deplete ordna 
2.0@mean cancer cancer inhibitor restore restore enzymatic use agent process myelodysplastic analog myelogenous silence growth growth treat call inhibit regulate epigenetic epigenetic transferase regulator precursor belong demethylating severely tumor normal thus nucleoside case demethylation cell cell cell cell tumour leukaemia suppressor suppressor dependent also promote divide replication decitabine decitabine target result body gene gene anti specify methyl dna dna dna dna dna dna get acute syndrome act function drug affect methyltransferase effect upon control increase division division interfere since methylation methylation allow much incorporate rapidly class 
1.67@dna dna suppressor suppressor reduce methylated demethylating demethylating gene gene gene effect tumor agent job opportunity since decitabine absent express express promoter promoter suppress suppress 
1.67@dna dna dna dna cancer methylating advance suppressor tumour slow inhibitor inhibitor agent agent enhnace chromatine pack de growth case make overall promoter acetylation lung histons histone expression expression le contribute demethylating gene gene reduce reduce reduce tumor deacetylase deacetylase hypermethylation turn methylation decitabine attractive hystone form combine azacitidine 
1.67@myc transcription class tumour em agent whose anti inhibit inhibit basically dna dna involve human demethylating gene effect block belong turn methylation decitabine decitabine decitabine factor activity brd expression 
1.0@cancer provoke class slowly agent mark mark become metil genetic significative nucleotide molecule epigenetic epigenetic methylated kind well hypermethylation hypermethylation demethylating reduce tumor later normal normal normal normal life health turn cell cell drug drug mistake mistake suppressor cytidine cause cause arise divide replication analogue could could could expectancy loss demethylated consequently problem gain lose level tentative treatment dna dna dna dna dna however le gene effect place hope belong silence decitabine difference possible incorporate 
2.0@growth critical restore dnmt proliferate may fda cycle phase myelodysplastic analog analog methyltransferases cytotoxicity hypomethylation inhibit inhibit regulate irreversibly show silence demethylating island tumor tumor tumor normal hypermethylation nucleoside aberrant insensitive cell cell cell cell cell drug drug suppressor cytidine also thats replication agent apoptosis result result know treatment dna dna dna dna dna dna dna divide non syndrome function cpg gene gene rapidly dnmts relatively cellular division interfere member methylation decitabine decitabine decitabine work incorporate approve towards differentiation class 
2.0@elod plastic inhibitingdna promote application tumor tumor region agent specific y decabine anti call treatment dna dna show methylated methylated syndrome inhibitor demethylating gene methyltransferase effect induce belong decitabine decitabine create class hypo hypo suppressor expression 
1.33@cancer cancer article change overmethylation overmethylation overmethylation activate methyl agent mark mark economist growth normality normal island epigenetic epigenetic sequence involve involve tissue demethylating prevent minimize affect implicate hereditable cell cell cell cell may may several erase erase drug cycle describe aminoacids problem effect group return return lineage lineage treatment dna surround act expression time chemical along cellular cellular control oocyte silence silence due signal decitabine gene gene gene activity hystone cpgs gamete andna 
1.33@dna dna dna dna strand fe dnmt methyl tan similar belong rase hypomethylates incorporate methylation decrease inhibit azacitidine 
1.0@mitotically characteristic inhibition specificity dnmt progress use hematological fda long process myelodysplastic since malignancy malignancy dnmti dnmti leukemia md treat transferase inhibit lead irreversibly interfere promoter term inhibitor enzyme especially island provoke nowadays key normal lack hypermethylation require access myeloyd nucleoside hereditable often methyl decitabine decitabine dna dosage patient patient soon tolerate drug drug analogue acute novo low cancerous know oncosuppressors develop assessment non cell bind syndrome act dnmts cpg gene youger effect effect discontinue aml due methylation longer selectivity approve side de 
1.0@thuscan cancer inhibitor use use agent acute decitabine myelodysplastic loss myelogenous growth orderly treat inhibit lead dna dna dna dna methylate syndrome precursor suppose demethylating adna methyltransferase methyltransferase effect tumor hypo methylation methylation anti create ofcontrolofdna cell uncontrolled leukaemia 
2.0@reversible class isin use use precursor myelodysplastic acute hypomethylates treat treat know inhibit azacitidineare dna dna dna dna epigenetic histone syndrome variety demethylating methyltransferase inhibitor inhibitor tumor deacetylase belong myelogenous methylation decitabine decitabine decitabine like form drug leukaemia 
0.67@loss effect turmour anti hypomethylates growth md inhibit inhibit dna dna dna dna dna dna profile orderly expression gene take happen advantage mechanism due thus methylation methylation methylation reduce create cell control decitabine decitabine decitabine 
1.67@elod cancer toxicity standard effective methyl fda celllymphoma formy evaluate leukemia make adjust well bone myeloid tumor tumor tumor mechanism cell suppressor dependent dependent also large anemia drugis dlbcl neutropenia suppression effect effect anti discovery study acute bind areactivation methyltransferase unclear must tolerate methylation decitabine decitabine decitabine decitabine decitabine y malignancy side dnmti plastic could could inhibitor class maximize hematological include zati md becorrection marrow island irreversibly transferase en hypermethylationof question thromocytopenia genehypermethylation replication one suprisingly drug cause describe diffuse toavoid beeffective dna dna dna dna dose decrease syndrome cpg smad mo chemotherapymore aml thus asagents che incorporate approve action 
2.0@dna dna area demethylates therefore demethylating methylates drug effect tumor agent demehtlyated result epigenome additionally methylation de gene hypermethylated suppress suppress decitabine 
1.33@cancer cancer cancer article start bad agent agent de growth back test suppress mention enzyme demethylating take tumor tumor tumor tumor affect epigenome turn turn like many cell drug lung one suppressor methylating methylating patient assumption cause healthy suppression histone without slower become occur show basic family dna dna effort rest gene gene gene effect overactive ezh methylation methylation methylation decitabine decitabine decitabine decitabine active lymphome restrict restrict 
2.0@cancer methyltransferases dnmt dnmt use agent hypomethylating newly result hypomethylation normal inhibit severly dna dna dna dna dna divide divide inversibly bind whichin prevent rapidly affect apotosis turn methylation decitabine decitabine decitabine inihit incorporate cell cell cell methyltransferase 
2.0@one dna dna dna dna dna cancer cancer cytadine available available irreversibly tumour tumour tumour analogue inhibitor dependent place process methyltransferase methyltransferase methyltransferase result silence growth susceptible replication bind island island resultant action reduction divide development rapidly associate fe tan cpg cpg gene gene gene take reduce mechanism hypermethylation rase methylation decitabine decitabine incorporate express cell cell methyl supressor supressor 
1.33@cancer inhibitor higher within unclear use exhibit myelodysplastic irriversibly myelogenous dnmti treat island precursor mechanism normal hypermethylation may release nucleoside demethylation cell cell drug drug rapidlt leukaemia dependent therefore divide decitabine theraputic replication replication analogue toxic exact demonstrate level dna dna dna however acute bind syndrome dnmts cpg methyltransferase effect effect effect upon range antineoplastic due since longer incorporate 
0.67@dna epigenetic epigenetic cancer clear drug could normal mark turn thus decitabine toxic create demethylate back cell cell 
2.0@suppressor cytidine myeloid condition reactivation use cause stability agent hypomethylating event analog leukemia inhibit aza treatment treatment dna acute particularly function drug myelodysplastic methyltransferase reduce tumor mechanism deoxycytidine syndrome reversal silence silence silence thus methylation allow gene gene gene role signal demethylation may decitabine 
1.67@mean cancer effect effect effect effect specificity nucleoside fda already dnmti dnmti might dna dna dna irreversibly despite tumor tumor mechanism lack hypermethylation high demethylation cell drug suppressor dependent analogue although favorable replication cause toxic target low anti type nonspecific kind however dose dose bind dnmts still gene methyltransferase inhibitor unclear decitabine decitabine incorporate approve 
2.0@unregulated cancer cancer cancer cancer effect restore dnmt agent become since explain nucleotide suppresser lead mean irreversibly strand belong demethylating tumor tumor tumor replicate block hypermethylation accordingly nucleoside regulate control decitabine decitabine suppressor dependent dependent daughter replication replication replication analogue support come anti occur nucleus dna dna dna dna expression cell cell cell cell cell cell bind bind integrate act act act inhibitor drug gene gene gene along must copy increase division division division interfere methylation methylation longer mainly class undergo 
1.67@blewitt blewitt cancer cancer cancer myeloid specificity dnmt progress methyl fda neucleoside myelodysplastic online malignancy apply demethlation transferase island astrong irreversibly university get available lymphoma patientsafter inlow happen tumor tumor mechanism august life hypermethylation dmnti divide heavy high access cell cell cell toincrease decitabine decitabine decitabine decitabine enzymatic drug indicate epigenetic epigenetic actively replication analogue acute know target incoperated reference inhibitor anti show expentancey dna dna dna dna effectivein kill bind syndrome expression cpg gene aml effect upon tumorsmight control administer due regulator melbourne hematopoietic demethlyation activity dosage approve action rapidly 
2.0@methyltransferases cgis restore target dnmt proliferate proliferate may exposure exhibit hypomethylating myelodysplastic major cytotoxicity cellular hypomethylation hypomethylation leukemia sit treat island response important correlate epigenetic level demethylating cgi proliferation change tumor tumor anticancer normal neoplastic hypermethylation hypermethylation hypermethylation tumorogenisis bond insensitive myeloid cell cell cell cell cell global expression dna dna dna also incorporation drug drug non prolong agent agent agent role low cytosine gene gene gene effective show prevent covalent reduction dose acute syndrome act function cpg irreversible aml effect induce induce localize control increase belong methylation methylation decitabine decitabine decitabine decitabine decitabine attribute class influence form differentiation rapidly play 
1.67@one suppressor suppressor cancer cancer inhibitor tumour tumour tumour tumour promotors dependent specific become effect anti hypermethylated hypermethylated amount island island dna dna dna area contribution cpg cpg locus methyltransferase reduce reduce methylation methylation decitabine gene active global 
1.67@dna dna demethylates dnmt decitabine use situation reactivate work demethylate approve normal inhibit drug azacitidine 
2.0@mean cancer cancer cancer cancer growth growth dnmt dnmt dnmt dnmt produce enzymatic use attempt mark contributor since since de hypomethylation md unmitigated treat grow significant effective epigenetic epigenetic epigenetic epigenetic see see responsible research block block normal hypermethylation hypermethylation genome indicative regulator minimal cell cell cell control majority machinery surprisingly dependent fight seem replication certain novo target target target result body success type dysfunctional contribution dna maintenance fruitful reverse bind syndrome myelodysplastic prove drug inhibitor inhibitor molecular line methylation methylation decitabine incorporate come influence action alter small 
1.67@cancer cannot dnmt use mark myelodysplastic myelogenous hypermethylation make treat affect island important irreversibly strand well well disease inhibitor aremost normal precursor nucleoside side cell cell cell cell tolerate leukaemia dna dna drug drug analogue daugther replication cause low show reduction dose acute syndrome act dnmts dnmts cpg methyltransferase effect copy increase division go methylation decitabine decitabine work attach 
0.67@cancer differents ul ul relate may state agent revert whole find meet architecture change might decrease decitabine treatment dna dna hyper demethylating demethylating gene effect pattern chromatin ti methylation genome hilum cell drug expression 
2.0@cancer cancer cancer inhibitor higher restore dnmt say every could specific probably de part affect previously class irreversibly methylated belong tumor inactive nucleoside cell cell cell cell cell expression one suppressor therefore replication analogue novo normal relatively become amount dna dna dna dna dna dna divide bind le dnmts gene methyltransferase inactivate upon division silence methylation decitabine decitabine decitabine decitabine incorporate incorporate rapidly 
1.33@myc misshapen cancer ul ul produce produce tumour agent hypomethylating myelogenous substance call call inhibit inhibit epigenetic strand marrow precursor bone block myelodisplastic cell cell blood blood leukaemia wrong drug healthy target condition anti group brd treatment dna dna dna acute syndrome gene methyltransferase effect jq go regulator decitabine decitabine decitabine activity unmethylate indirectly enough 
2.0@dacogen cancer class depend dnmt need analogue agent agent acute incorboration precursor eisai myelodysplastic myelodysplastic myelogenous hypermethylation replication treat treat treat decrease island company dna dna dna irreversibly cell bind syndrome sell demethylating demethylating cpg drug methyltransferase tumor tumor affect belong replicate methylation decitabine decitabine nucleoside mean like specificlly japanese use use leukaemia 
1.33@one different could could could could also also standard depend suppressor activate remove drug slow agent agent agent chromosomal susceptible make instability might inhibit inhibit suppress suppress addition tumor tumor tumor tumor tumor tumor tumor tumor tumor dna dna dna harmful development development opposite chemotherapy ineffective demethylating demethylating demethylating island effect effect accumulate stage stage stage progression progression hypermethylation hypermethylation gene methylation methylation decitabine decitabine decitabine decitabine drive drive cpg cell may may alter beneficial 
1.33@cancer transfer todna able activate tumour tumour tumour tumour cause cause agent finally hypomethylates anti inhibit inhibit effectis dna dna dna dna methylated degradation silence demethylating demethylating hypomethylated methyltransferase dnmt molecular mechanism belong rase decitabine decitabine decitabine gene gene return methyl supressor supressor 
1.67@cancer inhibitor dnmt dnmt dnmt dnmt produce epigenetically methyl replace reactivate silincing catalyse inhibit antitumor addition effective irreversibly show og enzyme enzyme proliferation reduce tumor tumor contribute apoptos degrade nucleoside maintain suppressor suppressor expression specifically cause epigenetic via drug analogue target result cytosine cytosine cytosine methyltranferse amount amount methyltransfer group dna dna dna bind dnmts gene gene gene effect induce induce cellular cellular silence silence silence thus thus methylation decitabine decitabine incorporate decitbine as differentiation progression 
2.0@decline methylating class specifically methyl agent neighbor drug call call group dna epigenetic histone histone act enzyme enzyme ezh gene gene reduce tumor attach silence silence longer methylation methylation decitabine protein suppressor 
1.33@suppressor cancer cancer usual therefore use cause cause include agent add surround growth growth methyl methyl tumour prevent damage damage dna histone histone group group treat demethylating drug happen remove uncontrolled uncontrolled protein protein silence decitabine decitabine gene gene cell cell attach 
1.67@allow cancer cancer myeloid dnmt dnmt cell cell use dnmts dnmts trap trap alteration mark methyltransferase reversibility island often recognize epigenetic epigenetic epigenetic lose inhibitor inhibitor enzyme unknown tumor block feature hypermethylation turn bond substrate signal demethylation treatment drug decitabine compound enzymatic also however consequence via replication structure healthy zad target result trigger anti type damage oxy covalent dna dna dna divide base reverse bind degradation act function still chemical effect effect effect natural cpg methylation tid mean modifier 
2.0@cancer cancer cancer methyltransferases class lower suppressor activate use cycle long myelodysplastic myelogenous dnmti hypomethylation direct overall incorporation affect affect analogous regulate irreversibly body replacement change tumor tumor tumor pattern normal normal neoplastic may may nucleoside cell cell cell cell cell much leukaemia one dna dna dna dna dna dna dependent methylating high epigenetic epigenetic replication replication cause cause cause cause evolve toxic kill dosage dosage anti prevent though treatment several divide acute bind bind syndrome dnmts drug drug drug gene gene rapidly effect effect death belong methylation decitabine decitabine dnmtinhibitors machinery 
0.67@one focus dnmti function approve drug fda decitiabne 
2.0@suppressor cancer cancer methyltransferases untreated tumour tumour certain agent result lower effect effect anti hypermethylated treat level inhibit cpg cpg often dna dna promoter consequence act hypermethylation demethylating island reduce reduce gene gene increase thereby find methylation decitabine decitabine decitabine transcription region activity cell cell cell cell 
2.0@inhibitor stable standard last dnmt dnmt tumour tumour tumour tumour leukemia concentration long myeloplastic md md way lower dnmti susceptible make hypermethylated treat heritable molecule open irreversibly get depend well belong possibly might myeloid precursor neoplastic nucleoside passive cell cell cell demethylation demethylation methyl reversible suppressor dependent transfer therefore therefore epigenetic epigenetic epigenetic alteration replication analogue target result result result result acute excellent anti anti occur show group good treatment dna dna mark mitoticaly kill bind chemotherapy use still drug aml effect effect similar syndrome division thus regulator decitabine decitabine possible incorporate cpgs enzymatic small 
2.0@cancer classify available dnmt activate use use inhibitor agent irreversible myelodysplastic myelodysplastic myelogenous dnmti hypomethylation treat transferase island copy currently establish time demethylating take tumor tumor normal hypermethylation effectiveness nucleoside affect decrease cell cell cell methyl formation leukaemia toxicity suppressor syndromescan therefore relate cellswhich replication analogue could precursor result low dosage dependency anti carcinoma promoter prevent whenmost transferasesto dna dna dna dna divide dose acute bind syndrome act dnmts cpg gene effect explain division due new methylation methylation methylation decitabine decitabine decitabine decitabine decitabine fasterare incorporate previous study small 
2.0@cancer level decitabine methyl region agent could revert process elimination gene anti hypermethylated pehaps inhibit previously dna dna decrease methylated involve allow demethylating group effect tumor tumor methylation genome cancerogenesis mean express demethylation drug would supressor 
2.0@loss growth dnmt methyl methyl agent process detail hypomethylation hypomethylation hypomethylation inactive inhibit inhibit decrease decrease island class cytosine area mention display establish enzyme enzyme observe tumor tumor tumor ion hypermethylation turn turn turn render constitute many cell firstly catalyze level expression expression suppressor suppressor transfer rat irreversibly drug cause cause cause normal result type promoter promoter group dna dna dna dna dna dna dna mark base hypo bind epigenetic incorporate cpg gene gene gene gene methyltransferase methyltransferase rate control division methylation methylation decitabine decitabine decitabine decitabine region lay 
1.67@myc methyltransferases inhibition class lymphoma lymphoma transcriptional activity use use use include include agent process myelogenous hypomethylation direct incorporation cutaneous inhibit exert epigenetic epigenetic epigenetic repression inhibitor inhibitor enzyme ezh proliferation tumor block affect orcell phosphorylation suppress gsk treatment treatment treatment leukaemia also drug drug drug cause myeloma cell cell acute number anti involve involve dna dna dna dna histone name dnmts gene effect jq cellular deacetylase death demethylating novel regulator decitabine decitabine decitabine em another brd form differentiation azacitidine 
2.0@suppressor cancer effect insert researcher term dnmt decibatine decibatine blood toxic analog since high overall drug drug long island cpg treatment dna dna explore dose dose allow expression act inhibitor inhibitor still gene methyltransferase reduce tumor block permanently increase give methylation methylation genome genome nucleoside side counteract unknown combine small 
2.0@could could could dnmt dnmt dnmt dnmt use every agent stop hypomethylating myelodysplastic malignancy growth leukemia md hemimethylated island decrease decrease responsible belong inhibit inhibit inhibit proliferation proliferation myeloid mechanism anticancer anticancer express cell cell cell cell tumour tumour tumour tumour tumour succesful suppressor suppressor hematological indeed divide methylates drug drug drug association likely kill kill like hypomethylated hypomethylated dna dna dna dna dna dna maintenance maintenance acute syndrome still gene gene methyltransferase inhibitor unclear cpg new methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine case another action 
2.0@kantarjian article inhibition inhibition tumour fda cancer cancer irreversible myelodysplastic myelogenous economist leukemia md md transformation abdulhaq point epigenetic epigenetic strand covalent proliferation impact tumor tumor mechanism affect hypermethylation cell cell may may may suppressor suppressor dna dna dna dna dna also high high incorporation answer diana cycle apoptosis reference anti treatment process acute cytotoxic dnmts dnmts gene gene increase belong methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine work form follow et et et effect effect effect indirect class reactivation transcriptional use use include epicentre direct analog reduction growth characterize treat adduct lead cytosine involve epigenome nucleoside miszczuk control identify atallah methyltransferases drug drug describe describe describe prevent several prevalence dose syndrome expression inhibitor explain al al al approve action propose delay leukemic 
1.67@cancer cancer cancer methyltransferases methyltransferases lower effective use use agent epicentre myelodysplastic since economist dnmti dnmti dnmti dnmti call nucleotide molecule depend inhibitor enzyme demethylating way accord nowadays neoplastic particular release nucleoside side cell cell cell much much belong toxicity dependent cause high therefore cannot seem replication replication analogue decitabine decitabine decitabine normal result anti good article dna dna dna dna dna dna dna dose dose bind syndrome site function drug irreversible target effect effect effect upon range treatment division replicate methylation ul ul ul ul ul ul incorporate similar active action action methyltransferase methyltransferase small 
1.67@dacogen cancer class realeased use chemically agent mostly hypomethylating myelodysplastic analog growth overall hypermethylated treat call island effective epigenetic epigenetic strand know firstly dnmt dnmt hypermethylation usually copy bond drug drug cell cell demethylation repress supressor cytidine certain become promote therefore consequently manner replication cause base speak result low gene anti hypomethylators promoter tumour tumour treatment dna dna dna however dose region bind syndrome function cpg irreversible methyltransferase inhibitor anolog character belong longer methylation decitabine decitabine decitabine decitabine daughter create incorporate follow 
2.0@acid cancer cancer classify dnmt dnmt dnmt synthesize tumour tumour nucleic hypomethylating newly aza make tsg incorporation decrease inhibit inhibit adduct adduct cytosine strand sequence methylated therefore therefore amino enzyme thereby recent reduce reduce gene gene affect t fact mammalian pentofuranosyl triphosphate demethylation cell cell cell erythro supressor one like also promote promote antimetabolite format methylates drug drug drug cause apoptosis incorporate incorporate iupac express anti know act dna dna dna dna dna divide deoxy covalent tumoural expression triazin methyltransferase induce deoxycytidine generate antineoplastic division methylation decitabine decitabine decitabine decitabine decitabine deregulation work demethylaling rapidly 
2.0@dacogen lymphoma neoplasm use use dysplasia include agent agent hypomethylating since mt growth inhibit inhibit act act even involve enzyme demethylating control myeloid tumor lymphocytic uncontrolled blood blood hypermethylation factor intiated cell cell cell methyl tra dna dna dna dna excessive excessive relate drug drug cause myeloma strand mutation tratment histone trade like initiation prevent prevent name methylationof kind non lot lot wich syndrome sell gene gene gene andproliferation supressing limitter fe myelodysplatic rase methylation decitabine decitabine production incorporate context modify progression 
2.0@suppressor inhibitor class reactivation produce tumor blood link induce myelodysplastic condition myelogenous silence hypomethylation hypomethylation leukemia useful treat marrow antitumour syndrome dna dna acute particularly precursor contribute deform gene methyltransferase effect epigenetically bone belong turn thus decitabine decitabine em em case cell 
1.33@cancer excessive tumour frequent agent generation location anti group dna dna dna dna epigenetic pass principal demethylating effect remove mechanism derangement epigenome methylation methylation decitabine aberrant cell removal methyl follow 
2.0@shapen dacogen inhibition demethylates effective produce remove remove remove blood blood blood likely stop myelodysplastic continue myelogenous hypomethylation tohypermethylation treat marrow market lead methylated precursor silence demethylating inhibit due normal cell cell cell cell cell cell aremis tumour tumour tumour tumour tumour leukaemia one suppressor suppressor suppressor red also agent replication mutate mutate prove white mean result acute cancerous prevent damage damage damage treatment dna dna dna divide divide use dependent syndrome syndrome le two drug gene gene gene aml aml platelet upon bone replicate methylation decitabine decitabine decitabine decitabine decitabine incorporate form myleodysplastic methyltransferase switch 
1.33@cancer cannot cannot class dnmt dnmt dnmt tumour tumour tumour cimps outccome mark myelodysplastic inefficiency hypermethylated effectively island island lead phenotype epigenetic better methylated methylated cimp silence proliferation outcome typically go release nucleoside cell cell cell promoter supressor suppressor dependent discover therefore therefore replication replication analogue cause incorporate become region know dna bind syndrome cpg cpg poor methylator inhibitor increase belong thus methylation decitabine decitabine daughter gene gene gene lay active hence associate 
1.0@cancer cancer restore afundamental suppressor suppressor suppressor epigenetically reversion mutation hypomethylating agent reactivate inhibit play epigenetic silence silence silence decitabinehave proliferation tumor tumor hypermethylation hypermethylation hypermethylation role decitabineis control several therefore tumer relate ability ability revert apoptosis behind behind therapy therapy type show demethylation demethylation dna dna dna sensitivity methyltransferase methyltransferase inhibitor induce induce human potency ul ul gene gene gene gene gene hypomethylates tumorigenesis rationale rationale associate 
2.0@dacogen cancer cancer cancer cancer cancer methyltransferases class dnmt dnmt use include agent diminish tend mark mark two growth genetic treat effectively suppress suppress often epigenetic silence demethylating enhance effective tumor tumor tumor primary expression myelodysplastic genome like counteract cell cell cell drug drug vidaza one suppressor suppressor depend consequently abnormalies either mutate decitabine decitabine decitabine suppression result whether express type know name name capability dna dna divide syndrome sell sell function time effect remove remove demethylation demethylation belong brand brand especially methylation methylation allow daughter gene gene activity enable would azacitidine 
1.33@one lower available dnmt tumour dnmts intensely target since frequently growth transferase inhibit greatest divide donor involve aggressive drug effect heavily division methylation decitabine inhibiton cell cell cell availability methyl methyl generally 
1.33@inject inject unregulated cancer cancer cancer toxicity category target gender way add long hour hour arthralgia substance substance increase back normal normal detect hepatic clinical medical common demethylating nurse tumor mechanism block conclusion produce anticancer hypokalemia o draw cell cell cell cell cell cell cell cell hypomagnesemia may may promote suppressor suppressor suppressor nonwhite also slowly patient patient relate powder work pression office vein cycle cycle cycle number number age headache el day treatment treatment study four cytotoxic least additional gene gene gene gene diarrhea function interact cellular believe division division interfere new methylation methylation methylation blockage difference hyperglycemia class enrol continue constipation pain restore restore within within manifest every every include agent decide process event major major growth growth direct febrile call call rash insomnia anemia repeat doctor doctor doctor belong twofold thrombocytopenia cough give usually usually edema benefit recommend member demethylation demethylation regulate regulate control decitabine decitabine decitabine decitabine decitabine decitabine decitabine one renal antimetabolite antimetabolite come safety neutropenia neutropenia drug cause sword week activity result insufficient intravenously become fever know metabolism dna dna dna dna divide nausea fluid chemotherapy expression petechia rapidly effect effect outpatient similar trial death thus clinic allow vomit incorporate period hospital adverse dysfunction 
1.67@cancer arise activate tumour tumour agent agent acute ultimate myelogenous hypomethylation hypermethylated treat inhibit suppress suppress previously dna dna dna histone histone methylated syndrome precursor silence silence demethylating demethylating end methyltransferase impact myelodysplastc overly gense decitabine decitabine method gene action use leukaemia 
1.67@cancer also growth epigenetic methyl methyl suppression suppression tend process irreversibly result result since since change susceptible anti transferase group previously involve involve dna dna dna dna divide divide bind particularly act act enzyme enzyme enzyme inhibitor gene gene gene methyltransferase effect tumor tumor tumor affect expression hypermethylation silence silence allow express demethylation demethylation cell cell cell cell cell removal drug drug decitabine decitabine 
1.67@proliferate restore formation tumour concentration agent hypomethylating major cytotoxicity hypomethylation hypomethylation inhibit inhibit adduct incorpates achieve demethylating conversion normal neoplastic insensitive triphosphate cell cell cell may may also replication cause cause suppression result anti dna dna dna dna dna dna dna dna divide non synthesis covalent function gene rapidly effect induce cellular cellular control thereby methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine attribute incorporate differentiation differentiation methyltransferase methyltransferase follow important 
2.0@cancer effect class therefore tumor tumor tumour agent agent agent decitabine mark mark growth anti supress prevent cpg dna dna dna dna epigenetic expression silence demethylating island inhibitor remove remove normal silenciated belong thus methylation methylation methylation allow allow gene gene gene express demethylation supressor 
2.0@suppressor cancer tumour tumour tumour agent mean focus frequently hypermethylated anti type occur decrease island island island suppress previously dna various expression demethylating gene effect increase hypermethylation thus decitabine cpg cpg cpg demethylation cell 
1.67@cancer class dnmt activate use agent myelodysplastic myelogenous treat call locus epigenetic decrease decrease involve involve well disease demethylating inhibit myeloid tumor tumor primary regulator cell cell blood blood blood leukaemia suppressor drug certain healthy methlyation anti promoter treatment dna dna dna dna acute syndrome act function gene gene gene methyltransferase effect thus thus methylation methylation decitabine decitabine decitabine aml hypomethylator 
2.0@suppresor suppresor remove tumour tumour agent support deatht anti methyl protein group tumor dna dna dna dna dna cell involve sell demethylase demethylating gene gene effect induce normal belong may decitabine japanese assossiated 
1.0@myc cancer methyltransferases methyltransferases growth reactivation axacydine activity use trap myelodysplastic degradation myelogenous hypomethylation treat avoid absence suppress regulate cytosine epigenetic methylated precursor enzyme enzyme inhibitor inhibitor reduce tumor htert htert regulation wt cell cell leukaemia transcription drug analogue target result synthesis anti promoter transcriptase reverse dna dna dna expression deoxy acute syndrome dnmts gene gene effect telomerase telomerase silence decitabine decitabine decitabine daughter accompany eventually 
1.33@cancer cancer cancer control control agent process process newly find growth arrest myelogenous modality treat status malignant precursor demethylating demethylating histone happen tumor tumor normal normal hypermethylation insure treatment stress leukaemia suppressor suppressor disturbance epigenetic epigenetic relate failure drug either cell cell myelodysplastic acute type type isused desitabine desitabine develop develop syndrome dna reverse mediate function function gene gene gene resume expression repress silence silence modification major methylation work return 
1.33@one suppressor could effect transform transform thus thus transcriptional tumor tumor drug drug either agent apoptosis anti signal transcription chemotherapeutic make affect damage dna dna respond demethylating gene reduce reduce induce pattern internal silence go methylation decitabine decitabine prone cell cell 
2.0@compound cytosine cytosine effect dnmt dnmt dnmt relate tumour tumour tumour proteasome include decitabine decitabine decitabine decitabine cellular growth growth anti methylation avoid lead dna dna dna block block methylate decrease mediate inhibitor inhibitor dnmts gene gene gene chemical activation methyltransferase conversion try activate degrade complex nucleoside work incorporate like like like control promoter promoter supressor 
0.0@several kind cancer cancer characteristic however study study drug drug agent agent clinical characterize demethyl demethyl resistant resistant dna dna epigenetic reaction reaction consider effect effect set possibility many cell cell cell modifier 
1.67@mitotically cancer tumour able improve use stability agent agent agent therapy decitabine hypomethylating target since leukemia type basically decrease group heritable addition treatment dna dna dna dna dna dna epigenetic development acute consider syndrome well myelodysplastic demethylating inhibit methyltransferase myeloid amount nucleotide contribute act methylation methylation methylation methylation genome gene azacitidine methyl supressor 
2.0@dna dna spg demethylates demethylates suppressor wikipedia gene methyltransferase reduce tumor agent decitabine decitabine hypomethylating mean methylation ul ul make active inhibit island 
2.0@mean mean mean cancer cancer effect effect dnmt dnmt supressors supressors methyl susceptible manner agent analog dnmti dnmti part transferase analogous inhibitor attack able tumor tumor tumor tumor normal normal reduce reduce reduce case many many cell cell cell cell supressor faster also enzyme enzyme replication replication replication actually incorporate anti traditional though potentially dna dna base bind chemotherapy le le important rate tumorigenisis dependant replicate thus thus thus methylation methylation methylation decitabine dmnt dmnt activity activity activity active 
0.0@loss also identify patient patient md inhibitor imprint imprint tumour certain load impact alsoreduce example stem analog exam hypomethylation answer describe describe stemcells class dna epigenetic write reverse act azacytadine hypermethylation blast proliferation reduce ofhypermethylation result growth normal belong allow factor dysplastic cell anti may may decitabine decitabine decitabine 
2.0@et kantarjian inhibitor inhibitor randomize class outcome tumour tumour tumour tumour cancer phase hypomethylating hypomethylating myelodysplastic myelodysplastic inhibition might inhibit inhibit jp issa hyperplasia enzyme neoplasia mechanism block hypermethylation hypermethylation express express use supressor suppressor suppressor iii patient c epigenetic decitabine decitabine decitabine decitabine study drug work improve april agent agent result result result reverse reference anti anti consist occur show action treatment dna dna dna intuitively rosenfeld syndrome syndrome gene gene gene methyltransferase methyltransferase methyltransferase effect methylation belong word thus al allow allow em em promise tumorigenesis 
1.33@cancer cancer cancer cancer article higher nova use use agent therapeutic goal currently reactivate change change susceptible md back treat open epigenetic epigenetic epigenetic epigenetic severe silence demethylating derive reduce reduce tumor tumor tumor pattern normal life much demethylation cell cell cell cell cell cell cell cell cell may lower therefore touch need cause therapy therapy toxic expectancy bring without better better treatment dna dna dose dose kill chemotherapy expression drug drug drug drug gene gene side effect effect effect dependant division replicate decitabine work action enough 
1.33@inhibitingdna use manner agent decitabine decitabine myelodysplastic myelogenous hypomethylates treat chain dna dna dna dna strand acute syndrome precursor function demethylating similar rna although incorporate incorporate leukaemia azacitidine azacitidine 
1.67@different cancer cancer effect effect class dnmt methltranphrase agent stop also since dnmti overmethylation call inhibit nucleotide irreversibly get get get well plasty happen hypo release demethylation cell methylating epigenetic replication replication certain skill mean dosage inibitors best know dna dna dna dna dna divide kill bind name inhibitor time rate increase belong longer thing methylation decitabine decitabine decitabine neo incorporate incorporate would 
0.0@also proteosomal promote dnmt dnmt produce cause cause hypomethylating result reaction hypomethylates cellular know inhibit inhibit damage damage dna dna dna dna dna synthesis decrease degradation chemical effect methyltransferase deoxycytidine aza death anticancer methylation decitabine decitabine decitabine decitabine cell protein 
2.0@et et kantarjian kantarjian proliferate class class western western formation use include agent aberrantly myelodysplastic analog myelogenous cytotoxicity reactivate hypomethylation treat inhibit adduct cytosine precursor consequence demethylating tumor methylcytosine neoplastic nucleoside insensitive express cell cell cell may deplete leukaemia suppressor also cause target relatively methylation promoter covalent dna dna dna dna dna divide non acute syndrome gene gene gene rapidly silence al al decitabine decitabine decitabine decitabine decitabine decitabine attribute incorporate incorporate indirectly methyltransferase 
1.67@myeloid lymphoma multiple progress yet near require myelodysplastic member since dnmti dnmti dnmti leukemia sit treat transferase island suppress effective irreversibly feasible hyper thereby hinder way dnmt tumor tumor tumor tumor tumor normal mode nucleoside enzyme drug drug cell cell cell cell methyl suppressor dependent also replication analogue pertain oppose anti know know family dna dna dna dna dna acute syndrome inhibitor cpg cpg affect aml effect attach division division division find methylation methylation decitabine decitabine decitabine gene incorporate prone action heavily 
1.33@transfer category antimetabolite produce use agent apoptosis myelodysplastic reference ease treat call decitabinealso syndrome dna dna divide divide chemotherapy inhibit rapidly rapidly demetyhlation belong decitabine em incorporate incorporate cell cell methyl 
0.0@interaction ao synergy murine activate induce use use system investigate center evaluate xenograft microarrays treat represent xenagrafting bisulfite sequence inhibitor time germinal derive derive tumor tumor pattern inhibition primary model model effec induction caspase like like cell cell cell cell cell cell tolerability tolerability expression explore dependent basis large patient patient vitro vitro activation via dlbcl dlbcl dlbcl grwth combination combination limphoma apoptosis apoptosis result experiment experiment number confirm confirm confirm acetylate level analyze panobinostat study xenografting histone histone validation mediate synergistic synergistic gene effect effect effect molecular deacetylase increase line produce diffuse hdacis hdacis hdacis decitabine decitabine decitabine decitabine methylation activity activity 
2.0@fail cancer cancer cancer cancer dnmt dnmt dnmt dnmt dnmt tumour mark remain therapeutically methyl transferase inhibit inhibit halt area area decrease decrease kind enzyme prevent prevent primary hypermethylation genome genome case cell cell cell cell cell cell cell cell cell drug one driver therefore irreversibly daugther require result occur show group particular particular dna dna dna dna bind epigenetic act act important gene expression consequent division division division methylation methylation methylation decitabine decitabine daughter daughter daughter hypomethylated original action action 
1.67@cancer cause therefore dnmt dnmt analogue include agent hypomethylayion lower hypomethylates surpressor affect inhibit surround dna dna dna dna dna irreversibly histone bind inhibitor demethylating gene gene proliferation overmethylation tumor tumor dependant cellular normal division repicate silence reduce nucleoside incorporate cell cell cell differentiation methyltransferase decitabine 
1.67@methyltransferases restore tumor tumor blood whose interact stag myelodysplastic deoxynucleoside deoxynucleoside extrapolate growth md inhibit inhibit malignant know enzyme triphosphates triphosphates close activation activation transformation give give factor many cell way way expression suppressor also divide drug therapy therapy subsequent product type promoter demethylation syndrome dna dna dna dna dna dna dna dna get synthesis covalent site site inhibitor inhibitor gene gene gene gene gene methyltransferase effect effect induce intermediate methylation methylation methylation decitabine decitabine decitabine transcription incorporate incorporate desirable form differentiation 
1.33@cancer class epigenetic replication replication replication analogue member meet part become normal hypomethylated dna dna dna dna irreversibly bind act thereafter methyltransferase methyltransferase inhibitor inhibitor affect methylation decitabine nucleoside active cell cell 
2.0@dacogen bone use include agent aslo decitabinereverses myelodysplastic find aza deoxycytidine hypomethylation leukemia md md md hypermethylated treat marrow inhibit response response involvement clinical status strand decrease precursor disease demethylating mechanism mechanism blastic normal hypermethylation ofazacitidine hematologic nucleoside demethylation cell expression multiple also call indicate successfully pharmacologic decitabine decitabine decitabine decitabine analogue cycle cytosine allow chain action dna dna dna dna dna acute associate syndrome correlate gene gene aml aml inhibitor methyltransferase similar similar protein increase belong myelogenous methylation methylation rna possible incorporate incorporate ink ink ink ink ink progression chemical azacitidine azacitidine 
0.67@cancer erase tumour cause combination combination leukaemia relation histone chemotherapeutic change solid show inhibit good granddaughter reation epigenetic epigenetic wiche pass lymphoma important gene rather inhibitor medicament deacetylase division orblocks unexpectedly regulator decitabine decitabine daughter activity actively many cell cell azacitidine 
1.67@dependent effect therefore epigenetic activate remove methilation methilation near mark dnmti mithotic preserve anti bind tumour tumour prevent hypomethilated methilase dna dna dna irreversibly lose inhibitor belong group dnmt gene division decitabine decitabine decitabine daughter case incorporate replication cell cell may recover supressor 
1.0@dna dna factor factor cause promote expression demethylating hence effect tumor tumor tumor agent lack hypermethylation suppressor suppressor methylation decitabine region anti decrease propose production would 
1.67@myc market cancer cancer restore restore within suppressor suppressor scientist use two hypomethylates hypomethylates similar substance oncogene inhibit inhibit inhibit inhibit inhibit regulate epigenetic available enzyme enzyme demethylating twofold tumor tumor tumor normal normal turn second human dive control decitabine decitabine one one one one dna dna dna dna cause cause antimetabolite drug drug drug drug certain indirectly target like anti type develop treatment treatment hallmark cell cell cell cell act function gene gene rapidly effect interact growth first death ezh thus regulator ul ul ul ul work activity activity brd various overactivity overactivity methyltransferase 
2.0@dacogen cancer methyltransferases within tumour tumour tumour agent epicentre article economist hypomethylation hypermethylated might might decrease inhibit inhibit inhibit keep refer demethylating island accord hypermethylation hypermethylation clear cell cell cell way suppressor suppressor commonly therefore via cause cause dir dir indefinitely apoptosis trade occur antineoplastic hypomethylated dna dna dna dna divide name name cpg gene gene effect cellular suggest repeat silence silence methylation decitabine decitabine decitabine decitabine ltr ltr work cancerous differentiation 
1.67@restore restore dnmt phosphate agent process de de growth growth regulatory call inhibit aza class cytosine strand responsible hyper trap tumor normal hypo convert phosphorylation carbon substitution triphosphate cell control control suppressor expression substitute atom dan reductase activation drug subsequent natural dnmts dna dna dna base di function ribonucleotide inhibitor place place deoxycytidine nitrogen belong thus methylation methylation methylation methylation methylation methylation decitabine decitabine gene gene gene incorporate silence form 
1.67@heavy cancer cancer cancer cancer cancer inactivate class dnmt dnmt dnmt fda agent myelodysplastic myelodysplastic analog myelogenous growth treat hemimethylated inhibit incorporation epigenetic decrease particularly precursor enzyme demethylating put nucleoside methylates cell cell cell cell leukaemia dependent dependent greater patient therefore seem replication replication replication cause could could could subsequent hematopoietic brake fully particular dna dna dna dna dna dna divide divide acute bind syndrome syndrome act inhibitor inhibitor inhibitor cpg irreversible rapidly rapidly effect effect due thus methylation methylation decitabine decitabine decitabine daughter work incorporate incorporate approve methyltransferase follow beneficial 
2.0@inhibitor condition class reactivation produce tumor blood contributiong induce useful result myelogenous hypomethylation leukemia make antitumour marrow hypothemylation syndrome dna dna acute particularly precursor silence deform gene methyltransferase effect epigenetically supressor link decitabine decitabine hence bone case cell part myelodysplatic otreating 
0.33@reduction cancer trigger suppressor regulation via drug agent hypomethylation need back back dna dna dna epigenetic act silence demethylating gene gene gene enhance inhibitor induce hypermethylation turn turn methylation decitabine decitabine work tumour enough 
1.0@hypermethylations cancer cancer cancer methyltransferases may aid manner break myelodysplastic remain azacytidine hypomethylation leukemia recognize epigenetic strand strand covalent establish myeloid tumor guanine normal cell cell cell cell cell cell substitute dependent also high divide divide azacytosine cycle apoptosis pace trigger hypomethylated damage damage mediate abnormally deoxy acute bind degradation dnmts dnmts dnmts dinucleotides function cellular control defect division methylation methylation methylation decitabine decitabine decitabine decitabine hence yield dnmt dnmt regulation use cytidine analog since treat response cytosine irreversibly prominent carbon bond demethylation line activation fight drug cause cause cause loss azacytisine azacytisine level dna dna dna dna dna dna dna dna dna get ring syndrome site rapidly inhibitor nitrogen human signal double incorporate covalently 
1.0@deivide dependent inhibitor daughter tumor methyl analogue faster normal dnmti make transferase dna dna irreversibly bind bind act dnmts dnmts anti effect upon mean copy belong methylation decitabine decitabine decitabine nucleoside incorporate cell cell replication replication 
2.0@one suppressor restore restore use agent process myelodysplastic hypomethylates growth gene anti treat inhibit dna dna dna dna syndrome function demethylating control twofold effect tumor tumor methyltransferase normal believe interfere thus methylation decitabine decitabine work demethylation demethylation cell way 
2.0@elod plastic cancer analogue inhibition dnmt way cause fda stop y cytosine drug reactivate hypomethylation therapy occur previously division dna dna dna dna strand covalently bind syndrome complex demethylating irreversible methyltransferase tumor belong silence methylation decitabine decitabine decitabine gene incorporate approve cell may suppressor 
2.0@cancer inhibitor growth dnmt progress use tightly fda repressive repressive currently dnmti hypomethylation characterize oncogene oncogene hinder suppress irreversibly uncontrollably generally grow take pair tumor tumor tumor tumor tumor hypermethylation hypermethylation thus silence factor express express cell myodysplastic drug one one suppressor suppressor epigenetic epigenetic necessary spread cause ability however dangerous cancerous encourage demethylate infect unstoppable dna dna dna dna mark bind syndrome dnmts metastasize aml allow allow allow place selectively ofthe since since methylation methylation methylation decitabine decitabine gene gene free approve approve form methyltransferase would tissue 
2.0@cancer cancer class dnmt dnmt dnmt tumour process useful irreversibly strand pass involve well enzyme replicate affect hypermethylation supressors nucleoside like like cell cell cell replication belong dependent analogue bond tranfered alteration drug drug cause promoter dna dna dna dna bind act replicant rapidly inhibitor inhibitor copy impede impede word epigenetics methylation methylation methylation methylation decitabine decitabine decitabine daughter daughter work incorporate alter 
1.67@dna dna supresor inhibitor use dnmt gene hence effect inactive belong methylation methylation methylation hypermethylation enzimes drive anti overall tumour tumour tumour decrease drug decitabine 
1.67@cause relate drug drug state agent apoptosis hypomethylation hypomethylation direct incorporation inhibit dna dna dna dna base act function demethylating control methyltransferase effect induce cellular cellular normal antineoplastic decitabine gene differentiation differentiation proliferation reestablish 
1.33@cancer effect order sometimes sometimes may slow growth useful inhibit calledezh calledhistone epigenetic work enzyme enzyme enzyme enzyme ezh ezh ezh ezh group reduce reduce tumor tumor normal methylation methylation methylation need suppressor certain drug cause pression histone histone cancerous gene gene gene become prevent silencetumor important surround surround inhibitor inhibitcancerous ahigher rate rate deacetylase belong silence silence combat decitabine decitabine decitabine production active 
1.0@dacogen nutshell effect effect hypomethylation remove tumour tumour agent anti since therapeutically growth call transcriptionally epigenetic reversible silence silence anticancer dnmtis hypermethylation hypermethylation turn maintain demethylation option use use suppressor therefore drug drug drug bring decreasingly methylation methylation occur family treatment dna dna dna dna inhibitory sell act perform gene gene methyltransferase inhibitor epigenetically belong actively decitabine decitabine decitabine usually would 
1.33@mitotically cancer methyltransferases dnmt induce hematological fda cytidine actual xml hypomethylating analog since malignancy malignancy growth unmethylated incorporation hemimethylated select next irreversibly strand pass survive en en allow demethylating cgi cgi reactivation tumor mechanism dilution hypermethylation hypermethylation prior nucleoside heritable cell cell cell cycle first decitabine decitabine decitabine decitabine suppressor dependent dependent therefore action action replication replication cause precede progeny therapy agent apoptosis lang lang ability become arrest fully promoter prevent prevent good dna dna dna dna dna u u bind act act dnmts dnmts still gene gene inhibitor unclear division division methylation methylation double response approve heritage 
1.33@cancer cancer cancer effect dnmt dnmt dnmt use use hence specific methylases substantially sister malignancy leukemia tumour hemimethylated incorporation clinical clinical irreversibly strand strand transferase inhibitor inhibitor inhibitor inhibitor enzyme enzyme reduce mechanism inactive acetylases act divide pproved le side cell numero methyl compound suppressor doesns trial epigenetic epigenetic replication analogue base actually target result acute peer underlie deacetylases type occur better approve treatment treatment dna dna dna dna process dose histone histone bind syndrome site organism hipermethylation gene chemical myeloblastic myeloblastic submit catalyze apparently pregunta methylation decitabine decitabine decitabine wide incorporate citosine active action rapidly del 
1.0@myc article work agent result methylating economist anti oncogene oncogene oncogene prevent previously example dna bind theerby enzyme demethylating gene gene methyltransferase allow tumor affect give silence silence silence silence regulator regulator decitabine methylation express express express brd thereby expression 
0.67@cancer research restore use use agent mark myelodysplastic methylating de make treat treat act often area common conserve reduce pattern normal silencingdecitabine aberrant signal many cell cell cell pharmaceutical dna dna dna also epigenetic epigenetic relate via involve reduction divide cytotoxic syndrome name expression differentiation rapidly effect methylation methylation methylation methylation methylation decitabine daughter gene gene azacitidine tantalize associate 
1.67@cancer freely available dmta use agent hypomethylating analog action leukemia catalyse treat decrease inhibit disfunctional addition often amount cytodine cytodine strand promoter tumour enzyme especially group myeloid access promotor cell methyl methyl methyl methyl methyl transferase transferase machinery mode nucleoside irreversibly via transciption transciption groupd result incorporate relatively loss occur subsequent prevent prevent prevent gaiining family island dna dna dna dna dna dna mark blood acute bind example important drug gene gene gene gene hence function trasciption trasciption trasferase cpg silence silence methylation methylation decitabine decitabine region deitabine baulky supressor associate 
0.67@inhibitor decitabine dnmt 
1.67@cancer inhibitor inhibitor higher dnmt use use appear mutation analog analog cytotoxicity genetic affect unlike achieve recognize irreversibly reversible interest order pattern normal normal release nucleoside nucleoside aberrant like like demethylation often dependent divdiding valid therefore epigenetic anal alteration replication certain approach approach result low th therapeutic reaction cytotoxic antitumor know dna dna dna dna dna dna dose dose cell cell bind overexpression least dnmts rapidly effect upon methyltransferase little division longer methylation methylation methylation decitabine decitabine establishment incorporate undergo action protein associate 
1.67@cancer myeloid class therefore therefore dnmt dnmt dnmt seem tumour leukemia fda technically lt lt decitabine decitabine decitabine island currently impossible catalyse make type prevent properly expression dna dna dna dna dna acute dependent syndrome syndrome inhibitor function cpg inhibit methyltransferase effective inhbition myelodisplastic myelodisplastic bind hypermethylation methylation methylation methylation release progress th approve supressor drug belong 
1.33@myc cancer cancer inhibitor inhibitor inhibitor inhibitor overmethylation activate use use state agent two analog neoplasic hypomethylation susceptible make treat treat azacitine inhibit molecule lead epigenetic copy wide enzyme tumoral tumoral tumor tumor demethylated genome like cell cell cell cell may decitabine decitabine decitabine decitabine decitabine decitabine decitabine standard dependent also study drug mitosis healthy target target transmit promoter tumour syndrome dna dna dna dna dna base histone histone cytidine chemotherapy act myelodysplastic gene gene methyltransferase effect overmethylated deacetylase demethylating epigenetics methylation methylation ul ul daughter possible eventually azacitidine 
1.67@cancer inhibition devision use cause cause agent myelodysplastic myelogenous hypomethylation treat restore dna dna status acute syndrome precursor demethylating methyltransferase normal belong thus methylation decitabine cell cell leukaemia 
1.67@cancer cancer inhibitor inhibitor higher class nd upon tumour require since reactivate inhibit inhibit nucleotide whereas irreversibly strand body belong severely proliferation dnmt replicate block affect release nucleoside cell cell cell much dependent lower replication analogue anti dna dna dna dna dna divide dose dose synthesis bind bind expression gene rapidly effect induce methyltransferase methyltransferase methyltransferase methyltransferase methyltransferase copy division longer silence methylation methylation decitabine decitabine decitabine decitabine daughter incorporate come action hence 
2.0@elod plastic cancer cancer ischromosomal abnormal heritability use include agent apl chromosomal mark leukemia leukemia leukemia dangerous hypermethylated hypermethylated treat affect loss suppress molecule lead epigenetic epigenetic help responsible responsible responsible disease disease demethylating adna chromosome reduce reduce close test feature mitotic factor case often stress stress example one one multiple translocation tumor abnormality relate certain solve ability mutation pathway y result loose cancerous number problem methylation methylation show treatment apoptosis blood cell cell cell cell cell syndrome function gene gene allow resistant chromatin chromatin death especially due silence hypothesis decitabine decitabine extreme clonal active differentiate associate 
1.33@cancer cancer cancer inhibitor change essentially regulation use slow medicine growth report grow present present say often open epigenetic epigenetic epigenetic epigenetic even show component erase hyper demethylating tumor substance substance people people experience chemotherapeutic routine case many significant way lung couldstop also researcher successfully drug drug association first school pharmacological good cell histone without azaticidine among group particular dna dna intervention author reaction act gene chemical reserchers john deacetylase belong thus hypothesis decitabine advance methylation hopkins return kill dont azacitidine 
1.33@cancer cancer cancer as as higher lower effective use use deme deme could agent stop originally transfer transfer dnmti make treat affect inhibit inhibit traditional work work work pass sure know know inhibitor hyper severe reduce gradually blood may nucleoside demethylation dont tumour leukaemia enzymatic dmnt also dnmt dnmt need analogue doesnt ability yet acute anti solid show group good dna dna divide divide dose dose cell cell cell bind chemotherapy target drug aml effect effect belong thy thy myelogenous methylation methylation methylation decitabine decitabine daughter much action side onto 
1.67@suppressor cancer cancer methyltransferases inhibition get activate tumor tumor use aberrantly decitabinecauses analog dosage dnmti growth replication among inhibit dna dna dna dna divide bind epigenetic inhibitor silence drug gene rapidly dnmt induce first belong methylation decitabine decitabine nucleoside incorporate demethylation cell cell propose way 
1.67@specifically methyltransferases application methylating via kinase induce phase silent specific potential show action facilitate facilitate dna dna dna effect form inhibitor enzyme enzyme prodrug prodrug gene hence inactivate tumor mechanism turn division convert since methylation decitabine decitabine decitabine deoxcytidine upon active cell differentiation phosphorylation suppressor expression 
1.67@cancer inhibition hypomethylation hypomethylation hypomethylation summary tumour concentration significantly analog class cytotoxicity cellular cellular growth direct incorporation inhibit exert achieve death body thereby proliferation disrupt adduct apoptotic may may nucleoside nucleoside cell cell cell cell require disruptive also promote promote spread cause restoration apoptosis activity result anti dna dna dna dna dna dna dna dna dna divide divide synthesis cytotoxic covalent function believe rapidly rapidly effect effect methyltransferase methyltransferase deoxycytidine control antineoplastic belong interfere decitabine decitabine decitabine gene incorporate differentiation differentiation phosphorylation associate 
1.67@suppressor suppressor cancer methyltransferases gene synthesize drug cause agent sequester commonly de hypomethylation hypomethylation effect newly happen prevent molecule treatment dna dna dna dna covalently consider bind dnmts ezh inhibit inactivate tumor tumor tumor block inactivation cytidine methylation methylation methylation methylation anti nucleoside work incorporate lead decitabine decitabine 
1.67@one suppressor cancer transcription transcription within un tumor tumor use cause ch destruction cod growth methyl methyl methyl methyl group group group group regulate dna dna dna dna cell demethylase gene gene gene gene gene enzyme remove remove remove result control control increase silence silence turn organism methylation genome typically case many upregulated way decitabine decitabine 
1.33@along never dnmt dnmt methyl methyl include since dnmti dnmti inhibit class irreversibly sequence tumor tumor tumor release nucleoside methylation profound replication replication tra specifically transfer depend epigenetic epigenetic drug incorporate mimic halt know prevent dna dna cell cell bind bind fe inhibitor inhibitor rapidly effect set belong replicate replicate rase regulator decitabine decitabine decitabine decitabine work activity come action enzymatic 
2.0@mean mean methyltransferases slowly dnmt dnmt agent newly find de unmethylated sit sit transferase island island often strand methylated methylated determine silence demethylating inhibit inhibit inhibit inhibit tumor tumor tumor tumor affect particular genome express express thereby thereby suppressor faster create novo whole anti severly normal dna dna dna divide divide divide cell cell cell cell cell cell cell cpg cpg cpg gene gene gene effect division methylation methylation methylation decitabine decitabine decitabine daughter mitosis lay 
2.0@cancer cancer proliferate proliferate inhibition restore dnmt dnmt synthesize methyl methyl agent rea newly since growth growth generation hemimethylated inhibit tumor tumor recognize strand silence thereby island reduce reduce heritability dilution dilute aberrant maintain cell cell cell cell tra suppressor mitotic se subsequent normal result n cancerous loss loss unchecked group dna dna dna dna dna dna dna get function function cpg gene eliminate demethylating methylation methylation methylation methylation methylation decitabine work work add 
1.67@cancer methylating become become dnmt replication cause agent agent could myelodysplastic analog analog instead useful useful amount decrease island treatment dna dna dna dna divide bind syndrome act cpg cpg hypermethylation find methylation decitabine decitabine nucleoside nucleoside incorporate demethylation demethylation cell cell would 
1.33@dacogen cytidine myeloid inhibition class methyltransferase methyltransferase use cause agent hypomethylating myelodysplastic analog finally commercially hypomethylation leukemia treat inhibit exert action dna dna dna apoptosis acute syndrome sell function aml effect mechanism antineoplastic phosphorylation decitabine incorporate cell occur blood dysfunction 
2.0@different effect nd much appear correct sit probably lower dnmti dnmti unmethylated unmethylated generation generation affect next irreversibly strand strand strand strand strand strand body methylated parent parent dnmt though typically release daughter daughter daughter daughter methylation methylation methylation demethylation cell cell cell cell cell use nuceloside analogue become patient rat however replication replication cause throughout match lay pass ie introduce age rd antitumor prevent good dna dna dna dna divide dose bind maintain inhibitor cpg methyltransferase decitane decitane decitane range germ division division longer new incorpated advance mitosis degree sensitive period recently 
1.67@elod plastic cancer cancer cancer effect restore suppressor suppressor induce use reversion mutation theycan lower azacytidine reactivate growth treat inhibit fundamental epigenetic international irreversibly inhibitor inhibitor inhibitor silence silence demethylating proliferation tumor tumor tumor genesin neoplastic hypermethylation nucleoside role demethylation cell cell control mode dependent also therefore therefore divide relate replication analogue improve ability agent apoptosis behind therapy y anti show vitro journal dna dna dna dna dna substantial dose action bind syndrome function cpg sensitivity rapidly dnmts epigenetically methyltransferase methyltransferase methyltransferase revert line human replicate potency decitabine decitabine resistance gene gene gene incorporate deamination tumorigenesis rationale enzymatic play 
0.67@inhibitor problem dnmt dnmt use hematological specific mean mecanism malignancy thar make divsion solid group action dna need tumour bind drug irreversible trat analog clear farmac decitabine nucleoside work incorporate cell trial yet 
0.0@term produce unclear tumour prove long malignancy make make transferase strand consequence mechanism affect neoplastic hypermethylation clear although demethylation cell cell cell methyl decitabine suppressor dependent dependent also nucleoside depend replication analogue normal normal low yet gene anti dna dna dna dose bind bind dnmts still irreversible effect effect upon copy division division work methylation would daughter possible incorporate incorporate perhaps action action haematological 
1.33@inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor thatare thechromatin thechromatin dnmt fda mark scurrently currently swi de dnademethylases copy histonemethyltransferase andalso clinical clinical clinical epigenetic strand inpre ezh ezh remodelers remodelers verysimilar effective pre pre vidaza trial trial variousclasses release one kind methylationto transfer typeclass drug drug drug either tet target bind bind bind dnamethyltransferase dna dna snf histone histone histone ase ase demethylase methyltransferase methyltransferase along along remove acetyl acetyl chromatin longer thatnucleotide decitabine daughter come come approve irreversiblyand clinicaltrial protein 
2.0@cancer effect abnormal class dnmt use correct myelodysplastic myelogenous leukemia treat partially aza lead epigenetic epigenetic silence ezh myeloid tumor tumor due deoxcytidine unsilencing desire suppressor suppressor therapeutic target target result result histone problem anti dna dna dna acute syndrome act gene gene methyltransferase methyltransferase inhibitor inhibitor ml temporarily main methylation methylation decitabine decitabine decitabine decitabine work leukaemia leukaemia aml aml 
2.0@mean cancer classify restore within dnmt dnmt produce dnmts agent agent process process make dnmti growth susceptible direct call regulate open irreversibly inhibitor inhibitor inhibitor tumor tumor interfere normal bind divide myelodysplastic nucleoside demethylation demethylation metabolism drug drug example suppressor also antimetabolite epigenetic epigenetic replication analogue cause dependentthat target number anti discovery know know fact syndrome dna dna dna intervention cell cell cell cell cytotoxic chemotherapy function gene chemical effect effect interact cellular consequentially division treatment treatment methylation decitabine decitabine decitabine work incorporate incorporate death rapidly 
0.67@cancer cancer society stable target target target process process activity phase myelodysplastic myelodysplastic pathogenesis malignancy hypomethylation leukemia leukemia leukemia md md md play tumour methylcytosine clinical epigenetic epigenetic epigenetic epigenetic assignment hypermethylation impact tumor tumor tumor anticancer key affect pharmacodynamic leukemogenesis aberrant sickle proximity cell trial may deplete suppressor patient pharmacologic include include include page answer synthesis reference reference express anti arrest expert several syndrome syndrome however effect effect acute acute demonstrate gene gene gene gene gene gene gene methyltransferase judson appleton range belong myelogenous myelogenous methylation methylation methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine disorder economist follow important et inhibitor inhibitor describe describe describe class transcriptional use appear aberrantly epicentre make analog analog reactivate helen potential potential treat broad cml anemia cytosine cytosine write kim consequence inhibit inhibit detect epigenome hematologic hematologic nucleoside nucleoside role al control control transcription identify therapeutic drug cause frequent indirectly therapy therapy chronic incorporate incorporate result result vol american solid promoter promoter dna dna dna dna dna dna dna dna dna dna doi reverse point expression expression expression review aml carboplatin mackay ian explain silence silence regulator oncology august article progression differentiation associate 
1.67@suppressor suppressor tumor tumor tumor tumor progress spread agent growth hypermethylated back effectively effectively group develop often dna dna dna dna dna expression expression demethylating demethylating remove affect increase turn turn suppress decitabine decitabine region methylation thesis methyl 
2.0@dna suppressor could reverse syndrome cure activate use tumor agent decitabine demethylating myeodysplastic genome part mean demethylation lead promote leukaemia 
2.0@suppressor suppressor dnmt dnmt tumour tumour tumour cause useful become become bind demethylation example dna dna around help common gene gene inhibitor hypermethylation thus thus decitabine decitabine region incorporate active cell 
1.0@dna dose cancer become gene allow demethylating demethylating right effect tumor agent expression give silence genome part anti hypermethylated island cpg decitabine 
2.0@suppressor suppressor methyltransferases use agent restoration myelodysplastic myelogenous decitadine growth treat inhibit act lead dna dna increase acute help syndrome precursor function demethylating hypomethylated allow tumor tumor normal keep word methylation decitabine gene gene cell control would leukaemia 
2.0@mean cancer cancer cancer larger may faster anti anti myelogenous dnmti tumour normal normal molecule particularly precursor enzyme inhibitor inhibitor happen mechanism mechanism affect neoplastic hypermethylation nucleoside demethylation cell cell cell cell cell use leukaemia specifically dependent lower replication replication analogue toxic target fast yet demethylate know myelodyplastic treatment dna dna dna dna dna dna divide dose dose acute bind bind syndrome dnmts irreversible methyltransferase methyltransferase effect effect effect everything replicate find find decitabine incorporate action small 
2.0@dna dna suppressor suppressor cancer inhibitor class use hypermethylation hypermethylation gene gene methyl cause know affect belong methylation decitabine decitabine anti transferase inhibit inhibit tumour tumour tumour basically 
1.0@several cancer restore use cause include agent result growth type level dna dna demethylating gene gene reduce supressor uncontrolled control silence grouth decitabine high methylation methylation cell cell tumour alter associate 
2.0@cancer cancer dnmt use leukemia agent event currently malignancy reactivate change change change potential md treat treat inhibit play epigenetic epigenetic epigenetic reversible reversible prominent enzyme myeloid tumor leukemogenesis investigation aberrant role cell expression suppressor lat methylating pome frequent therapy novo target target type thy good syndrome dna dna dna acute chemotherapy myelodysplastic ah aml important silence methylation methylation decitabine decitabine decitabine decitabine gene tumorigenesis de 
1.33@suppressor association activation produce use deactivate precedent agent myelodysplastic myelogenous anti treat decrease dna dna dna epigenetic syndrome demethylating gene gene effect silence methylation methylation methylation decitabine decitabine demethylation leukaemia tumour tumour azacitidine 
1.33@cancer cancer methyltransferases class class class comparison methyl fda agent process myelodysplastic myelogenous since dnmti leukemia make treat treat call inhibit act epigenetic epigenetic strand tumour precursor demethylating impact kill neoplastic epigenome may high case cell use use use economist tra one dna dna dna dna dna dna dna become patient irreversibly replication cause specfically hypomethylates acute decitabine decitabine decitabine decitabine incorporate describe low reference anti family basically several epicentre dose li li li li li li bind bind syndrome fe inhibitor drug affect methyltransferase effect effect stage explain believe belong rase methylation methylation ul ul ul ul ul ul daughter sick article dosage approve instance 
1.67@cancer cancer cancer cannot higher incorporation dnmt dnmt get much mostly strand analog since identify occur copy group nucleotide division division dna dna dna dna however speed transmit bind bind epigenetic hypermethylation demethylating observe hence effect undergo normal belong replicate methylation complex daughter daughter irreversible incorporate incorporate cell cell cell cell cell cell cell cell drug drug decitabine decitabine decitabine decitabine 
2.0@dacogen cancer cancer code demethylates include exhibit scale growth growth loosen md marrow hypemethylation expression disease reduce tumor tumor tumor tumor tumor tumor mechanism hypermethylation mug factor fda express many genome genome cod greater ec supressing supressing decitabine decitabine decitabine decitabine appear mylodysplastic suppression lukemia free gene gene anti among demethylation myeloid treatment treatment dna acute syndrome name inhibitor irreversible methyltransferase effect obviously entire thing allow wide sledgehammer approve approve protein accross 
1.67@dacogen cancer class mean regulation firm uncontrolled chemically chemically agent mark mark mark eisai analog since dnmti growth leukemia make treat phenotype irreversibly rapidly precursor demethylating myeloid tumor tumor tumor replicate normal produce nucleoside japanese removal supressor suppressor suppressor erase epigenetic drug drug cycle precancers proper result result acute cancerous without without dna dna dna dna dna divide cell cell cell cell cell cell bind bind expression dnmts dnmts gene gene aml inhibitor induce methyltransferase belong modification methylation methylation decitabine daughter daughter incorporate incorporate precancerous return return return myelodysplasia functional functional 
1.33@cancer instead class reactivation produce produce synthesize use use part part build analog analog aza hypomethylation leukemia methyluridine inhibit suppress molecule molecule correspond correspond adenosine guanosine possibly effective tumor mechanism block normal nucleotide nucleotide thus genome nucleoside nucleoside nucleoside nucleoside cell cell cell pre belong phosphorylated dependent although polymerase decitabine decitabine decitabine due drug structure structure subsequent suppression result present exact become become chemistry know know nucleus dna dna dna dna dna divide cytidine lifecycle uridine gene methyltransferase effect compatible deoxycytidine division replicate new rna rna action action 
1.0@dna cancer cell action demethylating methyl agent revert hypermethylation methylation decitabine much case show inhibit antitumoral transferase normal 
1.67@dysfunctional cytidine improper class sugar use certain agent cause hypomethylating suppression condition cytosine hypomethylates reactivate hypomethylation anti tumour tumour marrow treatment dna dna blood synthesis syndrome inhibitor myelodysplastic bone gene methyltransferase effect epigenetically belong due may analong silence pentose cell way decitabine decitabine 
0.0@cancer cancer genetics regulation appear stop change change breakthrough might might grow conceptual granddaughter epigenetic epigenetic pass erase erase unlike take happen factor gsk case justly cell cell cell transcription therefore therapy without though treatment alongside kill example gene analysis effect place truly division involve epigenetics actively daughter return form would 
1.33@cancer along class reactivation epigenetically tumour hypomethylation nucleotide lead irreversibly strand belong severely replicate replicate affect contribute release nucleoside cell cell cell much supressor dependent consequently replication analogue fashion dna dna dna dna dna divide bind bind gene methyltransferase methyltransferase methyltransferase inhibitor upon copy division longer silence methylation decitabine decitabine daughter incorporate come action rapidly 
1.33@standard methyltransferases class last use speculation agent agent agent hypomethylating myelodysplastic hypomethylates futhermore say susceptible make treat dna dna dna chemotherapy demethylating way inactivate aters belogs decitabine decitabine decitabine cell tumour 
1.67@cancer instead class dnmt dnmt use use use really myelodysplastic appertain nucleotide irreversibly strand body quickly tumor replicate replicate affect neoplastic release high cell cell cell cell much dependent lower divide replication answer toxic dosage dosage effect anti good dna dna dna dna get dose kill bind bind syndrome inhibitor inhibitor inhibitor methyltransferase methyltransferase methyltransferase along copy division longer methylation decitabine daughter come approve action combine recently 
1.33@cancer demethylates use slow agent myelodysplastic remain lose silence growth old treat inhibit lead epigenetic strand strand strand strand methylated methylated enzyme big gradually hypermethylation unmethylated unmethylated second cell cell cell cell cell tumour tumour majority third one suppressor methylating activation drug drug cause target loss demythelating ctivates type dna dna dna dna dna dna blood syndrome gene methyltransferase methyltransferase methyltransferase result first division division division half methylation methylation decitabine decitabine decitabine daughter daughter original would would would 
1.67@cancer methyltransferases restore reactivation reactivation formation activity nonrandom cycle phase degradation critical cytotoxicity cytotoxicity treatment hypomethylation hypomethylation hypomethylation absence lead cytosine cytosine tbond inhibitor inhibit proliferation dnmt tumor replicate normal neoplastic neoplastic convert directly high triphosphate demethylation cell cell cell cell control expression bond resumption replication analogue apoptosis highly covalen low specific specific dual dnmts dnmts dnmts dnmts dnmts dna dna dna dna dna dna dna get get dose dose synthesis stall covalent act function gene gene gene gene target effect effect induce induce result result cellular cellular silence due methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine em em em em em incorporate incorporate form differentiation differentiation differentiation 
2.0@inhabitation cannot dnmt dnmt dnmt dnmt much cancer phase phase newly inhibit nucleotide analogous lead lead lead irreversibly strand methylate island able tumor tumor tumor tumor replicate replicate normal normal genome hypo drug suppressor suppressor release compare faster methyaltion methyaltion activation replication replication decitabine decitabine decitabine effect effect anti dna dna dna dna dna dna dna maintenance maintenance cell cell cell cell cell bind inhibitor cpg gene methyltransferase rate silence dependent methylation methylation longer incorporate incorporate action hence hence hence hence 
1.67@cancer dnmt dnmt uncontrolled whose myelodysplastic myelogenous growth treat transferase transferase inhibit job lead epigenetic epigenetic methylated involve precursor enzyme turn style nucleoside align demethylation cell tumour tumour tumour tumour leukaemia suppressor suppressor suppressor justify cause irreversibly drug analogue therapy text stop stop anti methyl methyl action dna dna dna dna dna dna unmethylation acute bind syndrome use use expression gene gene gene gene gene methyltransferase inhibitor inhibitor belong methylation decitabine decitabine decitabine decitabine incorporate tumorigenesis 
1.67@cancer cancer cancer cancer available use leukemia agent specific process myelodysplastic myelogenous stage reestablishment regulatory genetic tumour demethylation island suppress previously lead open epigenetic epigenetic even redirect hypermethylation demethylating observe outside tailor early repair factor interrupt accessible option control machinery one depend drug drug drug could mutation apoptosis unmethylated demethylate methylated promoter promoter develop treatment dna dna dna already cell often syndrome stag cpg gene gene reexpression epigenetically multitude multitude pre especially due currently decitabine influence instance protein 
2.0@undesirable article available dnmt administration supressors every appear stop already myelodysplastic dnmti hypomethylation administred overall treat superiority grow might benefit lead lead cytosine epigenetic epigenetic methylate inhibit reactivation tumor tumor tumor tumor block normal normal hypermethylation rely fact chemotherapics tumorigenesis passive cell cell cell cell cell machinery acitivty market nonetheless residue therapeutic alteration drug drug instability tumorous ability approach result low without anti traditional dependecy genomic dna dose kill syndrome uncertain inhibitor still methyltransferase effect effect effect describe demethylation demethylation increase division decitabine decitabine decitabine decitabine decitabine coleteral come supressor drive present 
2.0@suppressor suppressor cancer methyltransferases restore therefore action use analogue agent myelodysplastic proliferate depend hypermethylation inhibit decrease decrease partially dna dna dna level level syndrome least dnmts demethylating severely rapidly effect tumor tumor tumor dependant affect death division methylation methylation decitabine nucleoside gene activity drug cell cell protein expression 
1.33@lead critical restore remove tumour tumour tumour agent anti find reactivate hypomethylation hypomethylation hypomethylation epimutation previously class igf epigenetic methylated involve inhibitor silence group proliferation impact normal neoplastic program demethylation cell cell may may prevent suppressor also identify imprint wilm restoration apoptosis result cytosine icrs become methyl methyl wrongly example dna dna dna act overexpression function gene gene gene gene effect effect induce describe describe cellular control death belong due thus methylation decitabine decitabine decitabine decitabine decitabine decitabine tumorogenesis differentiation would would 
1.67@class tumour tumour daughtercells likely allthough dnmti gene gene become hypermethylated magnancies call inhibit inhibit unknown dna dna dna belong enzyme enzyme hypomethylated methyltransferase methyltransferase inhibitor mechanism mechanism block hypermethylation decitabine decitabine work many action drug haematological supressor supressor 
2.0@cancer article available dnmt way agent analog analog economist hypermethylated call island island cpg cytosine strand methylate establish allow demethylating remain reduce tumor tumor tumor longer assign nucleoside read demethylation cell cell cell cell cell methyl one suppressor replication answer add incorporate course suppessor anti bind lecture group presence dna dna dna dna dna divide decrease inhibitor probable gene gene rapidly effect effect methyltransferase division replicate methylation methylation decitabine decitabine decitabine decitabine decitabine daughter daughter daughter activity attach draw 
1.33@dacogen cancer methyltransferases predict cell use view agent already eisai classify leukemia md treat inhibit lead epigenetic development video precursor demethylating demethylating group impact wherethe week dnmtis difficult thus japanese removal tumour occurrence transfer myelo property acute acute overexpression methyl know prevent prevent prevent prevent particular company dna dna dna dna understand mark histone syndrome syndrome sell myelodysplastic myelodysplastic aml inhibitor onset thereby myelogenous methylation methylation decitabine decitabine decitabine decitabine decitabine method work mean methyltransferase 
2.0@cancer instead renewal class class effective accumulate note agent myelodysplastic methyltransferases dnmti leukemia call inhibit worth epigenetic methylate methylate silence silence silence demethylating reduce tumor tumor directly nucleoside methylation methylation methylation cell knudsons machinery suppressor suppressor dependent dependent also irreversibly via replication replication analogue purpose pertain especially prevent prevent prevent prevent prevent treatment dna dna dna dna dna dna dna divide acute bind syndrome dnmts dnmts drug drug drug continue remove belong replicate replicate myelogenous hypothesis decitabine decitabine decitabine work incorporate hit progression 
1.67@nucleoside dependent effec disrupt dnmt progress use analogue hence stop md acute treatment leukemia replication drug action final dna dna dna irreversibly malignant cell bind example inhibitor dnmts still cgi cgi cgi aml effect unclear mechanism rapidly blood hypermethylation hypermethylation replicate shore shore decitabine myelocytic incorporate demethylation hypo may 
1.67@heavy cancer cannot outcome use order analog since dnmti md decrease island island island nucleotide irreversibly strand time happen tumor tumor normal hypermethylation hypermethylation hypermethylation release nucleoside nucleoside like cell cell cell lower patient replication anti level dna dna dna dna dna dna get reverse bind bind inhibitor cpg cpg cpg poor methyltransferase methyltransferase methyltransferase effect place copy quickly quickly replicate methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter imp incorporate come approve prognostic associate associate 
2.0@could could instead class dnmt dnmt tumour tumour tumour manner cytidine cytidine nucleic deoxycytidin myelodysplastic substance generation hypermethylated unlike aza correspond promoter promoter methylated methylated belong hypomethylation island island island effective helpful hypermethylation genome express hypo lead expression suppressor suppressor dependent therefore drug cause genesproducts mutate show dna dna dna base cell cell syndrome inhibitor cpg cpg cpg gene gene methyltransferase disease accociated death division silence decitabine decitabine decitabine decitabine decitabine wide incorporate active modify heavily 
2.0@dna could function cpg remove effect tumor agent decitabine demethylating methylation reactivate gene demethylation island antitumoral supressor 
2.0@dacogen cancer cancer cancer cannot restore dnmt methyl include mark mark myelodysplastic fda normally md incorporation copy island cytosine irreversibly strand strand help antimetabolite inhibitor silence myeloid mechanism hypermethylation may directly nucleoside methylation cell cell cell cell tumour tumour suppressor leukaemia methylcytosines specifically cytidine also residue epigenetic presumably hallmark replication analogue msd however highly reverse present exact component parent approve treatment dna dna dna dna dna dna divide divide acute cytotoxic syndrome act target cpg poor aml effect unclear methyltransferase methyltransferase growth control bind kill prognosticator decitabine daughter gene sensitive machinery rapidly rapidly progression 
1.67@cancer regulation tumour tumour tumour tumour hypomethylation hypomethylation incorporation inhibit lead cytosine lose allow favour reduce undergo normal hypermethylation tumourous demethylator triphosphate cell cell cell cell cell incorporate incorporate suppressor depend regain replication certain suppression occur promoter dna dna dna dna get apoptsosis function cpg suffer hence hence remove methyltransferase preferentially believe silence modification methylation methylation decitabine typically typically differentiation chemical 
2.0@unregulated cancer cancer cancer cancer inhibitor inhibitor restore t t state faster hypomethylating make analog myelogenous silence growth leukemia direct suppress lead epigenetic epigenetic epigenetic intensely methylated think thereby hypomethylated impact tumor tumor tumor tumor tumor normal generally usually myelodysplastic metabolism promote suppressor cytidine also greater patient get alteration drug cause md toxic acute anti show prevent syndrome dna dna dna dna dna divide cell cell cell cell cell integrate function dependency aml effect effect effect believe belong since methylation decitabine decitabine decitabine decitabine gene gene gene incorporate sensitive methyltransferase class 
2.0@maybe cancer cancer neoplastic restore term regulation highest use use appear appear agent long md md md find inhibitor reactivate hypermethylated useful worry treat inhibit solid patient irreversibly tumour tumour tumour particularly precursor enzyme demethylating old happen demethlylation affect blood clear myelodysplastic younger nucleoside demethylation cell cell cell cell way leukaemia woman suppressor cause high epigenetic epigenetic epigenetic analogue mistake toxic low accumulation age type occur especially dna dna dna dna divide dose dose acute bind syndrome dnmts still gene rapidly effect induce methyltransferase systemic division due myelogenous decitabine decitabine decitabine decitabine disorder work incorporate kill pregnant 
0.33@dna could methylating restore gene slow tumor increase methylate methylation ul ul growth oncogene prevent would promote 
2.0@dacogen become suppressor suppressor produce tumor tumor tumor methyl methyl agent agent example eisai anti hypermethylated treat group group company dna help syndrome name function cpg island effect remove remove increase demethylating demethylating myelodysplastic allow gene gene gene activity active japanese would would decitabine 
2.0@effect dnmt dnmt dnmt include include cytidine situation analog since hypomethylation leukemia deficient island lead decrease help provide observe myeloid tumor tumor myelodisplastic hypermethylation turn cell suppressor dependent replication answer describe become bind antitumor chain dna dna dna dna acute wich syndrome cpg gene inhibitor must methylation decitabine decitabine decitabine drive incorporate action action 
1.0@higher higher growth analogmodified suppressor may hypomethylation hypomethylation synthesis marrow inhibit inhibit response response addition clinical nonreversible show pyrimidine hypermethylation thereby proliferation tumor tumor mechanism mechanism block normal link hematologic hypo cell cell cell expression expression acytosine lower lower promote position pharmacologic dose dose dose escape suppression methylate bhas immune demethylation treatment dna dna dna dna dna however ring inhibitory covalent support gene methyltransferase allow allow induce stimulation bone reverse signal decitabine decitabine decitabine decitabine decitabine establishment possible incorporate ink ink ink ink associate differentiation protein bgene leukemic 
1.33@inhibitor restore within reactivation reactivation hypomethylate retinoblastoma decitabine decitabine apoptosis normal cdh reactivate growth gene gene gene occur transferase lead suppress genesincluding dna dna dna hypomethylating cell cell cell gstp function halt epigenetically methyltransferase pi tumor tumor suppressant cadherin rb silence methylation agentacting affect cancerous cancerous gluatione would would inhibitation 
1.67@althoughdecitabine cancer lower dosage restore therefore dnmt upon upon much ofdecitabine agent agent hypomethylates effect anti hemimethylated inhibit dna dna dna dna dna divide strand leave dependent function demethylating demethylating right methyltransferase rate tumor pattern block normal division division decitabine decitabine daughter themethylation incorporate affect passive cell cell cell cell replication replication 
2.0@cancer methyltransferases term dnmt use use fda long myelodysplastic myelodysplastic myelodysplastic probably cannot rate treat inhibit unknown irreversibly strand pass consider well inhibitor inhibitor severely take effective affect neoplastic hypermethylation may surround nucleoside high high cell cell cell cell tumour tumour tumour leukaemia compare dependent also patient patient patient however drug drug drug analogue toxic toxic low fact anti cpgi myeloid extremely dna dna dna dna dna divide dose dose acute bind syndrome dnmts still methyltransferase effect effect effect effect place little tolerate division due methylation decitabine decitabine decitabine decitabine daughter approve side 
2.0@cancer daughter depend order replication analogue agent become copy particular dna dna dna dna dna irreversibly strand cell cell cell bind bind therefore act act demethylating severely rapidly inhibitor upon longer affect division replicate methylation release nucleoside nucleoside incorporate come action methyltransferase methyltransferase decitabine decitabine decitabine decitabine 
0.67@dna dna proper methylation decitabine allow demethylating gene drug expression remove abberant 
0.0@
1.33@dacogen myeloid transfer dysfunctional seem blood agent know decitabine decitabine decitabine hypomethylating myelodysplastic condition also meet leukemia hypometylating inhibit chain effect treatment dna dna dna dna strand strand acute ase syndrome develop drug drug unlike proliferation reduce tumor normal act rna nearby incorporate incorporate like side cell cell cell aml azacitidine 
2.0@cancer effective tumour freshly agent dinucleotides block make hemimethylated island suppress luckily lead epigenetic strand enzyme especially inhibit inhibit dnmt due grow hypermethylation anticancer actively cell cell cell methyl one therefore methylates drug carry activity best group cpg cpg cpg dna dna dna dna reverse act still gene gene methyltransferase copy demethylating mother silence methylation methylation decitabine decitabine motif work hypomethylated 
0.0@effect drug drug likely exchange acetyl since favor antitumor inhibit acetylation acetylation dna whereby histone help expression expression prevent inhibitor tumor mechanism deacetylase belong decitabine gene gene action methyl 
1.33@cancer replication carry cytidine revert analog cytotoxicity growth covalently hypermethylated incorporation decrease decrease dna dna dna dna action action bind capacity demethylase perform gene gene methyltransferase methyltransferase inhibitor tumor increase decitabine decitabine activity cell protein supressor 
2.0@fuctional decline cancer cancer overmethylation overmethylation cell cell cell cell use use include agent agent stop process myelodysplastic growth growth unmethylated make treat treat reactive epigenetic sure disease demethylating demethylating uncontrolled normal normal normal regulate tumour tumour expression expression suppressor suppressor transcription drug cause cause myeloma target without particular dna dna dna dna dna intervention surround syndrome site switch gene gene gene gene gene chemical effect control silence methylation methylation decitabine decitabine possible sensitive 
2.0@mitotically cancer article restore dnmt administration tumour tumour agent mark administrate since economist growth md change inhibit epigenetic pass common refer demethylating island mean normal feature hypermethylation hypermethylation express express demethylation cell cell decitabine decitabine one suppressor suppressor patient drug drug cause cause suppression result demethylated promoter myelodisplatic dna dna dna dna divide offspring syndrome inherit cpg suffer allow remove cellular silence methylation locate deregulation gene gene gene gene activity activity 
2.0@cancer cancer inhibitor change able uncontrolled state agent stop silence growth might island lead epigenetic discuss hypermethylation hypermethylation hypermethylation demethylating reactivation tumor tumor tumor question contribute fact genome case demethylation cell cell cell cell cell cell control decitabine decitabine decitabine suppressor suppressor also erase solve pas eventually problem anti hypomethylated dna dna dna histone despite cpg gene gene methyltransferase effect place first division division thus allow daughter mean return instance protein would 
2.0@cannot class enzymatic tumor tumor much dependent remodelling find clearly decrease epigenetic strand methylic well silence reduce amplify deal release high methylation methylation cell cell experimentally use suppressor faster lower insert irreversibly replication toxic incorporate effect effect effect group particular dna dna dna dna dna get dose dose bind bind inhibitor inhibitor inhibitor inhibitor gene methyltransferase methyltransferase methyltransferase rate remove must chromatin belong replicate regulator decitabine decitabine daughter lay action antitumoral 
2.0@methyltransferases inhibition bone dnmt tumour agent alteration myelodysplastic myelodysplastic myelodysplastic remain proliferate hypomethylation leukemia direct treat marrow incorporation variety demethylating comparatively mechanism mutation neoplastic phosphorylation although factor doi cell cell cell may risk patient study em subsequent lay result underlie anti treatment dna dna dna dna dna non syndrome syndrome syndrome cpg methyltransferase effect unclear report death dinucleotides unresponsive methylation methylation decitabine decitabine decitabine decitabine wide pathogenesis approve progression associate 
2.0@mean cancer methyltransferases methyltransferases uncontrolled process myelodysplastic dnmti leukemia hypermethylated inhibit inhibit lead irreversibly strand methylate help polymerase inhibitor inhibitor allow proliferation reduce tumor tumor normal neoplastic high myeloid cell cell cell control suppressor suppressor dependent nucleoside nucleoside therefore use regain replication replication analogue structure toxic proper result low anti methylated treatment dna dna dna dna dna dna dna dna dna dna dose dose acute bind syndrome le function function drug gene gene methyltransferase methyltransferase effect similar daughther division silence methylation decitabine decitabine decitabine decitabine incorporate incorporate action hence 
2.0@abnormal indicate via cause cause cause agent hypomethylating two low cytotoxicity hypomethylation hypomethylation direct inhibition incorporation marrow inhibit inhibit treatment dna dna dna dna dna dna dna dna antineoplastic dose syndrome myelodysplastic bone methyltransferase methyltransferase methyltransferase think induce mechanism death decitabine decitabine decitabine hematopoietic activity hypomethylates hypomethylates cell cell global 
2.0@article inhibition restore overmethylation regulation uncontrolled agent agent stop tend hypomethylating since reactivate hypomethylation back inhibit neoplastic neoplastic malignant lose refer demethylating group proliferation proliferation normal essential methylation cell cell cell methyl dna dna dna dna dna dna consequently cause add wrongly think reduction reduction get act function gene gene gene methyltransferase methyltransferase inactivate induce silence regulator decitabine decitabine differentiation 
2.0@cancer methyltransferases class use use agent agent stop hypomethylating myelodysplastic myelodysplastic myelogenous hypomethylates change treat minute grow might granddaughter epigenetic epigenetic epigenetic epigenetic strand pass erase erase precursor belong demethylating inhibit life cell cell cell tumour leukaemia specifically therefore assumption therapy half without anti though dna dna dna dna acute syndrome syndrome inhibitor drug effect character division actively decitabine decitabine decitabine daughter incorporate return kill 
1.67@cancer inhibitor inhibition dnmt much cause dependent irreversibly hypomethylation anti inhibit inhibit dna dna dna dna divide action bind bind dnmts rapidly effect effect effect tumor methyltransferase methyltransferase methyltransferase normal division longer release mitosis incorporate maintain cell cell drug decitabine decitabine decitabine decitabine decitabine 
2.0@unregulated cancer cancer toxicity restore restore methyl analog dnmti growth growth regulate allow hypomethylation tumor tumor block normal demethylation cell cell cell cell blood blockage belong suppressor suppressor suppressor cytidine also promote antimetabolite cause cause result prescribe become solid damage transeferase dna dna dna dna function gene gene gene azanucleoside inhibitor control increase division division thus methylation decitabine decitabine decitabine activity rather 
1.67@cancer cancer critical higher class suppressor methyl concentration concentration agent agent shore certainly member hypomethylation overall back island suppress area see without enzyme demethylating tumor tumor intergenic repair instability cell increase decitabine specifically transcription fight general drug accomplish mean describe deterioration demethylate group genomic dna dna dna dna decetabine expression cpg effect remove preferentially repeat thus methylation allow allow internally region region article nuclear would would would present 
1.33@dna dna cancer cancer eisei suppressor tumor methyl decatibine decatibine decatibine agent aberrantly contributor since reactivate sit type effectively group develop company several siginificant help silence silence demethylating island reduce remove mean progression hypermethylation gene gene cpg japanese tumorigenesis 
2.0@methyltransferases inhibition disrupt dnmt tumor tumor tumor tumor tumor tumor tumor methyl dnmts dnmts dnmts likely specific growth might inhibit inhibit inhibit inhibit suppress inhibitor enzyme heritability normal hypermethylation hypermethylation case cell cell decitablne suppressor suppressor suppressor mitotic drug mutate location anti group dna dna dna dna dna dna maintenance function gene gene gene resume effect die attach division thus methylation methylation decitabine decitabine drive action methyltransferase would 
1.67@suppressor cancer cancer cancer dicetabine replication dependent agent agent agent result hypomethylation anti incorporation subsequent inhibit inhibit benefit dna dna dna dna dna divide silence silence demethylating demethylating gene methyltransferase effect effect tumor tumor preferentially affect hypermethylation due actively decitabine decitabine work like like many cell cell 
1.67@dependent cause therefore action tumor use analogue fda acute leukemia replication treat transferase inhibit cpg progression dna dna dna irreversibly kill bind syndrome inhibitor dnmts still island myeloid unclear mechanism myelodysplasia hypermethylation thereby decitabine decitabine nucleoside incorporate approve cell demethylation methyl belong 
1.33@fuction cancer cancer effect effect effect class class western dnmt huge use state agent myelodysplastic analog analog find dnmti growth treat island cpg often irreversibly inhibitor inhibitor demethylating way tumor pattern contribute directly nucleoside factor possible uncontrolled tra dna dna dna dna dna incorporeted enzime epigenetic epigenetic relate alteration drug drug cause novo compose n contact anti methyl prevent prevent transmition promotion cell cell cell bind syndrome act dnmts progress aml important important fe responsable division division rase methylation methylation methylation decitabine decitabine em incorporate action methyltransferase mantain de 
2.0@cytidine lower combinated effective tumor tumor replication cause agent loss replace substance aza analog integrate dna dna dose methylate bind chemotherapy classic demethylating helpful local deoxycytidine protein hypermethylation treatment methylation decitabine decitabine decitabine many lead methyl 
1.33@cancer cancer methyltransferases higher use agent specific specific myelodysplastic cannot growth treat copy lead irreversibly strand tumour elading proliferation affect rase high cell cell cell methyl tra also dmnt even know toxic level prevent dna dna dna dna however non acute bind bind syndrome fe inhibitor methyltransferase rate try demethylating replicate replicate myelogenous methylation decitabine decitabine decitabine daughter work work eventually leukaemia 
2.0@dna dna dna dna dna cancer change last epigenetic manner tumour state include agent therapy target sequestration silence hypomethylation hypomethylation drug transferase prevent lead lung maintenance pass bind expression dnmts dnmts demethylating irreversible effect division mother nguyen methylation methylation methylation allow daughter gene gene cell cell cell methyl suppressor decitabine 
1.0@one concequences also daughter lower dnmt dnmt dnmt yet state agent process irreversibly analog strand anti drug show dna divide dose know bind act inhibitor inhibitor still affect affect effective pattern normal normal demethylating fastly decitabine decitabine decitabine nucleoside copy methylation cell cell cell cell cell tumour tumour tumour replication replication 
2.0@suppressor methyltransferases activate remove may agent mark analog hypomethylation lose inhibit nucleotide lead dna dna dna dna bind covalent demethylating gene tumor silence signal incorporate replication 
1.67@functionally cancer cancer inhibitor dnmt dnmt dnmt activate methyl dnmti hypomethylation inhibit inhibit lead allow facilitate reduce reduce tumor normal hypermethylation nucleoside otherwise like etc suppressor lower analogue mitiosis low problem address level irreversably family basically dna dna dna dna dna dna dna divide dose cell cell cell cell bind bind bind site act rapidly enzyme enzyme enzyme transferse silence thus thus methylation methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter accompany arrive 
1.0@srink methylating person successfully deploy use first agent really myelodysplastic myelogenous leukemia solid epigentic treat chemotherapy dna epigenetic even acute syndrome time time tumor tumor precursores good againt reaction next drug drug 
2.0@cancer cancer classify dnmt dnmt produce use require agent myelodysplastic meet dnmti treat ion inhibit previously expression status status development methylated methylated methylated inhibitor hyper demethylating tumor tumor tumor tumor clinically neoplastic contribute contribute turn nucleoside otherwise maintain demethylation cell cell methyl abbrently tra suppressor suppressor therefore therefore irreversibly replication replication analogue function function toxic ly result result low low dosage anti anti help dna dna dna dna dna dna bind syndrome fe dnmts gene gene gene gene gene gene side effect effect effect upon dependant along silence silence word rase methylation decitabine decitabine decitabine incorporate incorporate 
2.0@suppressor cancer cancer inhibitor inhibitor dnmt epigenetically drug drug drug agent know switch anti anti member reactivate growth make might call methylcytosine family potency dna dna dna dna substantial show chemotherapy function demethylating gene methyltransferase methyltransferase methyltransferase reduce reduce tumor protein antineoplastic mc thus decitabine decitabine decitabine decitabine silence sensitive cell cell global level 
1.67@dna cancer cancer effect suppressor tumour analogue cytidine could replace since cytosine anti methylated promoter inhibit compare deciabine expression gene reduce tumor normal quickly replicate methylation methylation expect incorporate incorporate cell cell cell would genome 
1.33@suppressor cancer mrna therefore therefore therefore begin produce produce dectabine use might compact myelodysplastic myelogenous fade become become treat among illness dna dna dna away syndrome le drug gene gene gene proliferation remove remove suppress suppress increase division methylgroups methylgroups decitabine decitabine serious production express express demethylation cell cell protein protein leukaemia 
2.0@cancer cancer methyltransferases category dnmt dnmt dnmt dnmt synthesize may rich rib newly newly analog classify malignancy de hypomethylation preserve effectively partially cpg cpg often cytosine strand call therefore variety link thereby tumor pattern normal hypermethylation parental demethylation cell cell cell line promoter region suppressor cytidine also antimetabolite methylates replication cause eoside body abundant level prevent oxy dna dna dna dna dna dna dna dna dna covalently bind chemotherapy dinucleotides affect methyltransferase inhibitor increase belong replicate replicate work methylation methylation decitabine decitabine decitabine daughter gene incorporate account various interfere methylating tissue 
1.67@heavy cancer methyltransferases methyltransferases inhibition use loss without really myelodysplastic dnmti drug drug drug drug affect island present molecule work severe well demethylating severely way reduce tumor round normal hypermethylation may may dilute nucleoside cell cell cell methyl methyl one dna dna dna dna dna dna dna faster cause patient therefore replication replication analogue product activity free number anti level group reason divide mark bind syndrome syndrome inhibitor cpg irreversible side effect effect longer methylation decitabine decitabine region incorporate approve methyltransferase methyltransferase associate 
1.33@dacogen article use chemically agent eisai analog myelogenous hypomethylates reactivate hypomethylation japanese treat mention inhibit inhibit strand manner precursor zac alaog tumor tumor id contribute myelodysplastic although induction induction cell expression suppressor cytidine also nucleoside relate seem decitabine decitabine decitabine apoptosis apoptosis moreover favor antitumor damage company dna dna dna dna dna acute syndrome sell function gene gene methyltransferase methyltransferase effect similar silence thus methylation rna incorporate incorporate azacitidine 
2.0@dacogen cancer methyltransferases mitotically produce use agent stop mark myelodysplastic myelogenous hypomethylates change change type treat grow might epigenetic epigenetic epigenetic epigenetic precursor demethylating inhibit take demethylation japanese tumour leukaemia one erase drug therapy idea anti normally could company dna dna dna acute syndrome sell eisai effect thus decitabine decitabine article return 
2.0@cancer dnmt dnmt dnmt use specific myelodysplastic myelogenous hypomethylation generation overall treat avoid inhibit inhibit hypermethylando regulate development help precursor island proliferation tumor tumor tumor mechanism express cell may may may deplete suppressor suppressor dependent therefore drug proteasomal promoter prevent syndrome dna dna acute degradation act expression cpg gene gene gene methyltransferase inhibitor induce copy increase well decitabine active active independent 
2.0@cancer cancer cancer inhibitor never available dnmt dnmt dnmt dnmt encounter much irreversably mark newly overall grow previously epigenetic strand strand silence control tumor tumor tumor hypermethylation release nucleoside cell cell cell cell cell cell cell try deplete one suppressor lower hypomethylated pretend analogue oridnarily even healthy bring promoter prevent though island dna dna dna dna get base base bind end gene methyltransferase effect copy copy copy cpg replicate replicate replicate replicate methylation methylation methylation decitabine decitabine work incorporate original protein 
1.67@cancer methyltransferases apart neoplasm produce uncontrolled include agent hypomethylating hypomethylating inhibit inhibit cannot hypomethylation resolve exert hinder respective lead cytosine position strand body well well silence observe biochemically hypermethylation carbon methylation attachment global correlate suppresor suppresor suppresor therefore drug drug ch product mean tumourigenicity express anti element halt tumour tumour tumour tumour group cpg repetitive dna dna dna methyl bind covalent dnmts dnmts dnmts dinucleotides gene gene gene gene effect cellular division regional decitabine decitabine work lay onto onto azacitidine 
1.67@mitotically speculative rate faster dnmt dnmt dnmt dnmt expect may require agent agent inhibit since hypomethylates md heritable decrease absence absence irreversibly strand lose well generally provide organ tumor tumor tumor mechanism normal hypermethylation expectedly thus absent case cell cell cell cell cell cell much much decitabine decitabine suppressor dependent dependent also also live divide divide exponential need need share result cancerous cancerous maintain replication normally solid dna dna dna dna applicable bind still gene methyltransferase disease die demethylating longer currently methylation methylation methylation methylation methylation methylation methylation double daughter eventually approve quicker quicker 
1.33@heavy wishart may term effective pazdur methyl fda fda specific long tzur d md md md becase incorprates epigenetic strand yes issue pmid tumor tumor richard affect affect affect database aug although readily cell cell cell cell cell ac mechanism irrevsibly knox therefore understand apoptosis relatively guo replication hypomethylated shrivastava treatment bind cheng act act myelodysplastic web cellular division severity well methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine undergo form cyctine dacogen effect higher dnmt dnmt produce gautam nucleic newly newly analog transferase island chemotherapeutics inhibit doss completly approval approval jan knowledgebase tolerate machinery acid identify rat presumably drug drug drug drug drug cause specfic hassanali target target low drugbank prevent severly dna dna dna dna divide divide re syndrome cpg inhibitor systemic replicate thus approve action differentiation associate 
0.0@methylating overmethylation spread cause cause include mutation healthy describe also also effect effect effect become know inhibit suppress per histone act enzyme ezh ezh ezh ezh gene gene nearby reduce reduce tumor tumor overactive silence silence decitabine decitabine decitabine decitabine work article cell cell overactivity drug apparent 
1.0@cancer effect dnmt dnmt dnmt activate epigenetically tumour prove example silence newly rest reactivate diminish importantly inhibit adduct addition lead effective epigenetic know en enzyme enhance reduce reduce response model suppress nucleoside otherwise cell cell cell mlh line promoter expression suppressor proteosomal consequently drug drug subsequent result result cytosine depletion depletion show covalent dna dna dna dna dna dna divide non increasingly cytotoxic degradation inhibitor gene gene gene methyltransferase mo induce induce sequestration cellular division replicate mediate methylation methylation methylation methylation methylation decitabine decitabine decitabine che em activity form modifier 
1.33@cancer cancer cancer cytidin hipomethylation hipomethylation may may state mark observation chance hypermethylation make incorporation inhibit disrupt lncrna even promoter consequence island oncosuppressor due give genome genome high maintain maintain demethylation demethylation cell cell cell global decitabine decitabine decitabine decitabine substitute dependent also also drug development know subsequent exclusively mean result impossible person better reagent treatment treatment dna dna dna dna dna pathway dose reverse chemotherapy expression cpg gene gene effect remove set modification new methylation methylation rna wide incorporate acquire various would would azacitidine 
1.33@dacogen cytidine restore suppressor state agent analog transcribe hypermethylated block aza dna dna strand silence demethylating gene methyltransferase order tumor deoxycytidine normal wikipedia actively decitabine decitabine attach enable 
2.0@cute reason cancer inhibitor effective progress use cause dependent dependent syndrome syndrome myelodysplastic myelodysplastic body leukemia lecture island approve lead dna dna dna divide synthesis video hypermethylation cpg severely rapidly myeloid tumor methyltransferase affect division replicate decitabine decitabine decitabine thats maybe cell cell cell demethylation demethylation much 
1.67@cancer class dnmt progress use analogue dependent irreversibly myelodysplastic dnmti replication replication bind bind occur show lead dna dna epigenetic strand transferase daughter syndrome dnmts hence inhibitor inhibitor affect dnmtis belong longer copy methylation release nucleoside incorporate come demethylation cell methyl decitabine 
1.67@cancer cancer cancer methyltransferases class class available dnmt dnmt dnmt dnmt dnmt dnmt dnmt use myelodysplastic since since dnmti normal inhibit lead irreversibly survive inhibitor inhibitor belong affect neoplastic divide release release role demethylation cell cell cell cell cell far methyl decitabine decitabine decitabine decitabine decitabine decitabine dependent transfer therefore epigenetic replication replication mean low dosage anti occur show group deal properly treatment dna dna dna dna get bind bind syndrome function drug drug rapidly effect great allow allow incorporate come administer hence hence hence 
2.0@dna dna suppressor cancer body inibitor demethylates demethylates demethylating gene gene gene methyltransferase agent stop denovo throughout dnmti tumour decitabine decitabine decitabine 
1.33@kind effect become class explain suppressor suppressor start use cause agent try make demethylated silence gene gene anti quite drug drug show grow suppress dna dna dna dna get name attack demethylating demethylating island reduce hypermathylated mean mean normal hypermethylation may thus methylation expect possible cpg cell tumour tumour tumour tumour tumour decitabine decitabine 
1.67@dependent inhibitor therefore dnmt progress use analogue fda could peak toxic process myelodysplastic low dnmti replication quite treat normal demethylation demethylation lead dna dna dna irreversibly dose rapidly bind syndrome dnmts aml effect tumor affect replicate decitabine decitabine incorporate approve cell cell may nuceloside 
1.67@dna dna decitabines leukaemia syndrome demethylating gene use happen remove agent acute unsilence myelodyspalstic myelogenous methylation decitabine growth treat cell control regulate 
1.0@inhibitor abnormal class use use title agent agent hypomethylating two cytotoxicity hypomethylation direct inhibition incorporation marrow inhibit molecule cytosine epigenetic demethylating impact mechanism high cell cell tumour decitabine decitabine decitabine decitabine decitabine cause identify nucleoside analogue hematopoietic describe describe low anti dna dna dna dna dna dna dna dna dna dose dose methyltransferase methyltransferase methyltransferase effect result death belong methylation ul ul ul ul ul ul bone mean hypomethylates chemical 
2.0@cancer cancer represed use state medicine myelodysplastic transfer part make make voulnerable response response restrain threatment despite belong threated tumor good z late decitabline trial methyl standard demethylylating patiens patiens patiens drug hypometylated epigentetic hardly cell hadsurprisingly show reason dna dna dna stag histone syndrome none inhibitor inhibitor chemoteraphy deacetylase lung developement decitabine form alter azacitidine 
2.0@inhibitor cgis term effective methyl fda likely long myelodysplastic probably since dnmti growth md md md treat call inhibit might lead irreversibly strand body consequence tumor tumor affect neoplastic hypermethylation nucleoside cell cell cell cell cell cell use tra dependent patient epigenetic replication replication analogue healthy healthy nonspecific target lack entail anti greatly prevent dna dna however bind syndrome fe function short drug drug methyltransferase effect upon copy undergo rase methylation decitabine decitabine daughter much mean mean approve otherhand frequently 
1.0@cancer cancer cancer cancer cancer cancer article growth last baylin slow invade agent agent epicentre find economist epigenomic susceptible make hypermethylated tumour tumour unlike significant epigenetic reversible methylated methylated methylated demethylating demethylating dr normal readily speculate cell cell cell cell cell standard way lung state state state patient drug mutation mutation reverse unmethylated unmethylated normally normally show dna dna dna dna dna deactylase histone chemotherapy likewise section section section inhibitor reversal decitabine advance mean form combine alter 
2.0@dna dna cancer methyltransferases faster therefore dnmt dnmt need analogue dependent dnmti part group recognize action methylated inhibitor irreversible effective normal linkage division replicate replicate decitabine decitabine nucleoside substrate incorporate active cell cell cell drug 
2.0@specifically inhibitor trigger therefore suppressor activity tumour tumour agent hypomethylating md myelogenous hypomethylation anti type treatment dna dna dna expression acute syndrome precursor contribute demethylating gene methyltransferase effect epigenetically hipermethylation silence myelodysplastic decitabine decitabine decitabine attribute class indicate leukaemia 
2.0@mitotically cancer cancer cancer cancer activity restore restore dnmt regulation induce induce use faithful mark analog strip reactivate hypomethylation hypermethylated diminish island evasion class epigenetic epigenetic epigenetic involve enzyme enzyme enzyme observe tumor tumor suppress suppress hypermethylation late proliferative nucleoside heritable signal cell cell cell may may heterochromatic suppressor faster transcription therapeutic cause cause epimarks ability loss incorporate replicative demethylated therapy therapy become halt promoter prevent duplication dna dna dna dna dna dose disable bind chemotherapy le function cpg gene gene methyltransferase methyltransferase methyltransferase inhibitor inhibitor upon growth death angiogenesis replicate replicate decitamine methylation methylation decitabine decitabine decitabine immortality rectify silence reversal 
1.67@vivo critical category reactivation formation induce use use agent process myelodysplastic member cytotoxicity hypomethylation md call adduct lead believe work covalent inhibitor silence demethylating proliferation anticancer tumor tumor interfere normal normal neoplastic may may demethylation demethylation demethylation cell way one suppressor suppressor also also antimetabolite drug syndrome trigger know treatment dna dna dna dna chemotherapy function function consecutive gene gene gene methyltransferase effect epigenetically cellular control restore restore belong vitro new methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine attribute class widely differentiation twofold 
1.33@allow cancer effect effect growth dnmt dnmt activate uncontrolled activity activity stop myelodysplastic transcription hypomethylation hypermethylated tumour tumour tumour island job lead effective irreversibly anti responsible enzyme enzyme enzyme ezh inhibit inhibit reduce hypermethylation hypermethylation surround release nucleoside unable methyl methyl decitabine decitabine decitabine decitabine suppressor suppressor transfer therefore replication replication replication analogue cause cell cell cell relax become protein protein group dna dna dna dna dna maintenance histone histone bind syndrome inhibitor cpg gene gene along chromatin antineoplastic silence methylation methylation inappropriate inappropriate daughter incorporate come overactivity attach 
2.0@decline effect effect suppressor suppressor fight tumour tumour tumour tumour near inhibitor cause lay result result find hypermethylation hypermethylation anti anti hemimethylated group demethylation lead lead dna dna dna dna dna irreversibly strand transferase bind act dnmts thereby inhibit activation division silence methylation decitabine decitabine gene gene incorporate counteract cell methyl methyl would dnmti 
2.0@cancer restore restore within produce tumor blood agent specific hypomethylates growth nteracts direct inhibit transport class strand body cross belong demethylating demethylating brain mechanism normal hematologic nucleoside aberrant demethylation cell cell cell cell control suppressor also antimetabolite cause target target enter number dna dna dna dna dna dna divide fluid cytotoxic function gene rapidly rapidly effect death distribute interfere thus methylation methylation decitabine decitabine decitabine malignancy methyltransferase 
1.67@mean mean cancer cancer methyltransferases dnmt dnmt mammalian much agent hypermethylated inhibit status strand able nucleoside demethylation demethylation cell cell cell methyl recover run therefore consequently replication analogue incorporate come dna dna dna dna dna bind fe inhibitor inhibitor inhibitor rapidly effect induce dependant copy division replicate rase methylation methylation decitabine decitabine decitabine daughter region activity upon sensitive action original 
1.67@one suppressor suppressor dependent methyltransferases drug fda already growth overall tumour tumour promoter promoter inhibit inhibit inhibit suppress dna dna dna help gene gene methyltransferase inhibitor tumor tumor affect approve hypermethylation epigenetics methylation methylation decitabine decitabine express primarily action enable would would 
1.67@catalyze cancer inhibitor inhibitor abnormal restore able able use use inhibit inhibit inhibit inhibit md reactivate hypomethylation make make treat marrow marrow marrow grow addition addition class epigenetic body enzyme enzyme thereby proceed reduce mechanism normal cell cell cell cell cell cell cell cell tumour tumour tumour suppressor decitabine decitabine decitabine decitabine decitabine reduction red transfer call patient drug healthy healthy white normally methyl better group dna dna dna dna dna dna blood blood blood reverse allow function gene gene gene methyltransferase methyltransferase platelet growth growth growth control set belong silence methylation methylation methylation expect create bone bone bone differentiate enough enough 
0.67@dna dna cancer cause methylated dnmt demethylating gene gene tumour tumour effect pression agent hypermethylation hypermethylation replicate allow case anti express promoter prevent prevent decitabine decitabine 
0.67@dna epigenetic transcription transcription involve inhibitor brd gene gene drug effect tumor block expression belong class decitabine factor anti myc protein demethylates 
2.0@one suppressor cancer cancer transfer restore residue relate relate tumor say cause destroy inhibitory cytosine latest discovery basically promoter group treatment dna epigenetic malignant sequence wich also act act tissue drug downstream inhibitor remove mechanism similar activate decitabine transcription gene researcher cell presumably methyl methyl azacitidine 
1.33@different cancer cancer cancer regard higher dnmt dnmt synthesize unmethylated agent agent process process process analog part predominantly hypermethylated drug drug drug drug normal normal inhibit rate strand methylate laboratory demethylating demethylating take take take affect genome nucleoside otherwise treatment replication replication dna dna dna dna understand insert bond get need highly result result low effect become develop poisonous kind kind divide divide dose cell cell cell cell bind act function positive irreversible methyltransferase along place place place administer thus methylation decitabine daughter come initiate 
2.0@suppressor suppressor cancer cancer methyltransferases methyltransferases faster faster selectiveness dnmt dnmt heritability drug agent likely probability analog also transcribe hypomethylation type decrease parent tumor tumor dna dna divide mark methylated act strand lose demethylating inhibit inhibit inhibitor induce benign must increase due fact methylation methylation methylation ensure nucleoside gene gene daughter many cell cell cell cell decitabine decitabine 
2.0@compound compound cancer cancer methyltransferases incorrectly use agent attatched dectibine number potential anti oncogene treat group back dna dna effect bind example hypermethylation positive inhibit reduce gene gene gene result control demethylating turn silence methylation work hypermethylated form methyl expression 
2.0@misplace suppressor suppressor cancer cause use certain agent mark mark cancerous hypomethylation leukemia type treat often dna dna dna lose act allow demethylating drug methyltransferase inhibitor tumor tumor division silence methylation methylation decitabine decitabine gene gene express cell cell pre 
2.0@net dacogen cancer methyltransferases abnormal dnmt dnmt dnmt dnmt dnmt inhibitor inhibitor use concentration agent agent document mechanism process sufficient de hypomethylation eisai higher treat appear alone act surprise methylated involve responsible demethylating partially interestingly tumor pattern pattern hypermethylation establish myelodysplastic cooperation like japanese cellular one indicate seem drug drug combination novo apoptosis specific effect effect radiotherapy occur especially treatment treatment dna dna dna dna dna maintenance maintenance modulation cytotoxic syndrome sell dnmts gene gene function must evidence angiogenesis mediate mediate methylation decitabine company promise differentiation exist cytostasis 
2.0@different different cancer methyltransferases abnormal specificity produce use appear agent long mark myelodysplastic myelogenous malignancy reactivate hypomethylation treat marrow marrow suppress irreversibly help term precursor demethylating adna inherent myeloid mechanism normal normal lack hypermethylation true nucleoside role many cell cell cell tumour tumour tumour leukaemia suppressor also cause become drive therefore therefore action action replication analogue could suppression acute gene gene depletion bind methyl dna dna dna blood kill dependent syndrome dnmts dependency effect effect remove dependant explain bone bone thus methylation methylation decitabine decitabine decitabine work work incorporate context tumorigenesis inhibitingdna haematological 
2.0@deleterious could could along specificity dnmt dnmt likely progress tumour tumour tumour exposure include neucleoside myelodysplastic lower almost reactivate hypomethylation oncogene treat transferase island response previously effective irreversibly show available hypometylation demethylating impact aza therapeutic cell cell cell global suppressor expression expression transient dna dna dna dependent also therefore sustain mostly replication replication analogue non know agent result relatively low reactivation anti methyl toxic cause multiple reduction divide divide dose dose bind syndrome use inhibitor cpg gene gene gene aml effect effect effect induce get get deoxycytidine memory antineoplastic silence silence longer methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine hence em incorporate incorporate come rapidly hit dnmti dnmti 
1.67@suppressor suppressor suppressor restore therefore tumor tumor tumor methyl methyl agent perhaps group group dna dna dna dna involve involve expression demethylating island remove upstream cpg silence silence vicinity decitabine decitabine gene gene gene gene mean methylation methylation removal would 
2.0@mean could cannot restore dnmt dnmt dnmt uncontrolled inhibitor inhibitor agent mark growth growth might transferase inhibit lead irreversibly strand strand decrease decrease responsible belong demethylating control affect containg factor cell cell cell cell removal methyl expression suppressor therefore epigenetic drug normal tumour tumour parent dna dna dna dna dna dna dna dna divide bind bind bind example dnmts irreversible reexpression copy division silence methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter daughter gene gene incorporate action alter class 
1.33@cancer inhibitor specificity efficacy methyl methyl fda dnmti leukemia transferase transferase suppress molecule lead irreversibly strand enzyme severely myeloid tumor tumor pattern normal neoplastic unexpectedly although cell cell cell cell trial drug drug drug nucleoside transfer insert patient patient consequently replication analogue function target target low anti show prevent good treatment treatment dna dna dna divide acute bind act act dnmts aml aml effect effect death concern replicate methylation decitabine decitabine daughter original approve side frequently 
2.0@one dacogen biomarker use agent agent hypomethylating eisai myelogenous hypomethylates anti treat inhibit prohibit company dna dna dna acute syndrome sell myelodysplastic demethylating hence methyltransferase effect precursor abnormality methylation decitabine decitabine decitabine decitabine japanese tumour tumour would leukaemia 
1.67@unregulated restore use agent myelodysplastic myelogenous hypomethylates growth growth growth treat call call inhibit exert regulate precursor demethylating reduce block normal hypermethylation turn repair leuk decitabineis cell cell cell tumour tumour blockage suppressor suppressor suppressor rise promote drug activity result gene gene gene gene anti ae dna dna dna dna dna dna acute syndrome function mi methyltransferase effect control division division division interfere thus methylation methylation methylation decitabine decitabine work class 
0.67@cancer cgis dnmt dnmt methyl could extra make irreversibly level exogenous myeloid pattern normal neoplastic show fact nucleoside cell cell cell cell replication promoter tra therapeutic drug analogue add see know dna dna dna divide non bind syndrome act methyltransferase inhibitor fe moretargetable division rase methylation methylation decitabine cgi dysplastic return rapidly 
2.0@one cancer cancer cancer growth growth essentially dnmt use cause fda switch suppression block block hypomethylation normally treat lead occur division division dna dna dna tumour methylated involve dnmts especially observe methyltransferase inhibitor turn uncontrolled syndrome approve belong may thus myelodysplastic decitabine gene gene class case drug cell demethylation control 
2.0@dna dna dna suppressor methylate bind demethylates dnmt gene methyltransferase inhibitor tumor tumor silence longer dnmti anti decitabine decitabine 
1.0@dacogen cancer cancer methyltransferases class use fda transfer eisai myelogenous hypomethylation hypermethylated treat call irreversibly precursor severely affect affect dnmtis myelodysplastic nucleoside japanese methyl leukaemia dependent dependent also drug drug analogue cell cell result replication replication group company dna dna dna dna dna acute bind syndrome sell dnmts dnmts methyltransferase inhibitor catalyze consequent belong replicate since decitabine em incorporate approve 
2.0@cancer cannot dnmt dnmt produce tumour unmethylated break break inactivation analog analog instead part make island interference strand methylate methylated enzyme demethylating fall fall replaicing replicate normal hypermethylation nucleoside nucleoside nucleoside cell cell may promoter suppressor owe lower stick stick subsequent bind level level level dna dna dna dna dna dna get get get cytidine cpg gene gene methyltransferase inhibitor upon keep division dependent find methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter sucessive another come active take take 
2.0@unregulated cancer proliferate restore restore within dnmt produce activity use fda agent agent process myelodysplastic cellular substance leukemia direct call relatively regulate regulate epigenetic inhibitor allow inhibit myeloid tumor metabolism normal insensitive demethylation cell cell cell cell cell cell cell cell control blockage expression suppressor suppressor suppressor also also block promote antimetabolite drug cause target result reference number become chemotherapy chemotherapy dna dna divide non acute cytotoxic syndrome function gene gene gene gene rapidly effect interact growth growth increase division division treatment thus methylation methylation decitabine decitabine decitabine work incorporate approve death methyltransferase 
1.67@cancer inhibitor able use add medicine analog worry avoid suppress sequence doctor silence take anymore tumor replicate life give nucleoside role cell cell methyl quality patient get get get replication expectancy problem old group good dna dna dna however bind incarcerate function perform gene gene methyltransferase methyltransferase effect place belong longer longer methylation decitabine decitabine incorporate incorporate side exist 
2.0@mitotically critical restore reactivation regulation induce prolifration agent hypomethylating myelodysplastic methylating cytotoxicity silence hypomethylation exert inhibit adduct attribute epigenetic treat enzyme inhibitor unlike change tumor conversion normal neoplastic formation may may directly nucleoside heritable triphosphate cell cell use suppressor cytidine also via drug analogue precursor result present gene gene gene responsible covalent dna dna dna dna dna dna dna divide acute syndrome function believe chemical effect advantage methyltransferase methyltransferase methyltransferase cellular control antineoplastic belong myelogenous decitabine decitabine decitabine decitabine em em incorporate incorporate form differentiation rapidly follow 
2.0@standard cannot tumor class asanucleoside get cell cell cell way itis agent actually generation erase change susceptible make inhibit action next dna dna epigenetic pass bind bind chemotherapy act belong demethylating last along upon division actively decitabine decitabine decitabine incorporate come dnamethyltransferase irreversiblyand replication alter 
1.67@suppressor suppressor cancer promotors patient tumour tumour certain agent stop myelodysplastic present potential type treat act act develop dna syndrome precursor allow demethylating demethylating gene expression tumor epigenome decitabine decitabine thereby alter 
2.0@mitotically cancer cancer methylating introduce suppressor activate use drug agent pas reproduce de change change change susceptible make make heritable island treat treatment dna epigenetic chemotherapy allow demethylates gene might effective epigenome decitabine daughter cpg cell cell tumour tumour chemotherapeutic 
1.33@cancer cancer characteristic abnormal restore produce produce use aid agent process myelodysplastic hypomethylates growth bone bone marrow marrow inhibit imply even help help inhibitor demethylating tumor uncontrolled normal demethylation cell cell cell cell control suppressor also anemia antimetabolite induction drug drug drug cause apoptosis treatment dna dna dna dna blood kill cytotoxic syndrome function hop hop methyltransferase methyltransferase effect die belong decitabine decitabine gene class 
2.0@suppressor cancer transfer restore dmti methyl analogue dependent specific marker demethylate tsg island island nucleotide action action regulate dna epigenetic cell function drug gene inhibitor tumor division ul ul ul ul ul ul cpg cpg various replication decitabine decitabine decitabine 
1.33@mitotically could also therefore suppressor scientist way agent decitabine decitabine anti discover silence change change useful effective decrease erase lead dna dna dna epigenetic epigenetic epigenetic epigenetic particularly inherit inherit demethylating gene effect tumor tumor hypermethylation since methylation repair daughter cell drug drug directly 
2.0@cancer methyltransferases growth growth administration uncontrolled state agent aberrantly aberrantly hypomethylation tumour tumour previously lead irreversibly methylated methylated involve silence demethylating group normal normal give give apoptotic maintain regulate methyl expression rise rise drug work could cycle apoptosis loss cancerous cancerous stop anti anti prevent dnmts dnmts dna dna dna dna dna dna pathway cell cell cell cell bind act function perform gene effect remove restore belong thus thus methylation methylation decitabine decitabine decitabine decitabine region class differentiation 
2.0@begin cancer larger inhibition inhibition inhibition effective effective say analog decitadine growth transferase inhibit dna dna dna decrease decrease silence especially island dnmt dnmt tumor tumor myelodisplastic hypermethylation spite nucleoside small demethylation demethylation cell cell methyl methyl level suppressor dependent high replication ability toxic limit limit promoter group reason reason however dose dose bind bind syndrome syndrome linear drug gene gene methyltransferase effect effect increase increase cpg thus thus methylation methylation decitabine incorporate associate recruit 
1.67@suppressorgenes dna result lockage methylation theb activity oft crease ani 
2.0@elod plastic methyltransferases lymphoma dnmt progress use fda specific long effect effect since hypomethylation inhibit suppress lead lead irreversibly term myeloid tumor tumor tumor mechanism normal clear methyltransferses many cell cell cell trial may suppressor also therefore include drug drug target target actual do solid treatment dna dna dna non acute bind syndrome whole still still multiply side along due methylation decitabine y approve various 
2.0@dacogen cancer inhibitor activity demethylates sometimes restore use agent hypomethylating myelodysplastic treat call inhibit inhibit regulate regulate regulate irreversibly belong demethylating way mechanism block normal expression produce may lead tumour decitabine decitabine suppressor suppressor also antimetabolite antimetabolite divide replication either cell cell cell kill bring anti bind bind occur antineoplastic damage action action syndrome dna dna dna dna dna dna dna dna get synthesis cytotoxic cytotoxic chemotherapy act function drug drug gene gene gene hence hence effect methyltransferase methyltransferase cellular protein increase division interfere thus methylation methylation ul ul incorporate come death indirectly proliferation 
2.0@cancer cancer dnmt dnmt activate use agent precise myelodysplastic analog since frequently replicate treat effectively island island represent thoroughly irreversibly development decrease belong thereby tumor tumor mechanism block normal neoplastic hypermethylation nucleoside demethylation demethylation cell cell cell way suppressor compare dependent dependent although replication likely inhiniting result low anti demonstrate dna dna dna dna understand dose bind syndrome expression cpg cpg gene methyltransferase effect upon believe division interfere methylation decitabine decitabine decitabine decitabine decitabine decitabine incorporate incorporate action action action 
2.0@dna dna dna cancer cancer cancer byreducing class class status methyl shore island describe reactivate change transferase prevent towards suppressorgenes epigenetic call tendingtowards global expression cpg inhibit inhibitor inhibitor inhibitor tumor pattern question normal normal increase increase belong methylation methylation methylation methylation methylation methylation decitabine decitabine possible return cell cell may may level dnmti 
2.0@suppressor cancer effect identify class tumor tumour cause anti describe describe demethylate back island cpg dna dna dna dna dna epigenetic inhibitor inhibitor demethylating gene impact remove methylations methylations belong turn methylation methylation ul ul ul ul ul ul decitabine decitabine decitabine 
1.33@cancer cancer cancer growth lower synthesize use slow system agent myelodysplastic also change leukemia generation treat decrease dna dna dna amount amount amount epigenetic effectively help help precursor proliferation reduce reduce tumor tumor tumor tumor tumor thus penetrate methylation methylation cell cell cell cell cell cell rapid suppressor suppressor methylating erase drug drug combination deacetylases occur eradicate treatment kind get acute syndrome act act act inherit inherit gene gene continue inhibitor control solid solid silence silence myelogenous actively decitabine decitabine daughter 
2.0@cancer cancer cancer cancer deacetylation restore restore dnmt dnmt progress may slow include stop charge article silence growth inhibit addition epigenetic show help inhibitor inhibitor inhibitor inhibitor enzyme enzyme ezh impact tumor mechanism normal normal hdac high like like like like cell cell deplete supressor therefore trait drug drug drug drug drug drug classic combination kill fashion specific amount better ready treatment non histone histone tumorostatic function outcome gene gene gene effect effect competitive human antineoplasic antineoplasic epigenetics methylation methylation methylation decitabine drive idea towards pacients 
0.67@cancer cancer inhibitor real dnmt dnmt synthesize slow build myelodysplastic also also hypomethylates growth growth md affect inhibit inhibit nucleotide strand strand strand methylate especially tumor mechanism block permanently methylation cell cell cell drug one one aza discover indicate however seem replication caner neither highly analogue know treatment dna dna dna dna dna dna divide surround bind syndrome function methyltransferase effect deoxycytidine replicate new normal decitabine decitabine decitabine decitabine decitabine incorporate 
2.0@time suppressor restore restore medication epigenetic agent agent process hypomethylates hypomethylation gene gene become hypomethlating call inhibit class dna dna dna divide function control methyltransferase change tumor word growth normal normal belong interfere thus methylation decitabine decitabine mitosis demethylation cell cell character 
0.67@standard methyltransferases class last use speculation agent agent agent hypomethylating myelodysplastic hypomethylates futhermore say susceptible make treat chemotherapy dna dna dna syndrome demethylating way inactivate aters belogs decitabine decitabine decitabine cell tumour 
2.0@suppressor dnmt dnmt tumor way phase decitabine decitabine apoptosis probably hypomethylates dnmti do hinder dna dna dna help division demethylating gene inhibitor induce react replicate group work cell drug belong 
1.0@dacogen cancer inhibition methil dnmt methilation methilation methilated eisai new dnmti make make make know island difficult difficult difficult inhibithor dna dna dna dna divide transferase hyper cpg cpg contain heavely thus methylation decitabine propagation cell drug 
2.0@cancer critical class dnmt may cycle since malignancy reactivate md incorporation melodysplastic inhibit cytosine irreversibly consider involve inhibitor silence demethylating impact hypermethylation high treatment tumour tumour tumour suppressor suppressor dependent position excessive general drug drug drug drug drug analogue function toxic result low anti arrest syndrome dna dna dna dna dna dna however dose dose cell cell bind mediate dnmts positive gene gene gene methyltransferase effect global reversal belong due thus methylation methylation decitabine decitabine incorporate action haematological 
2.0@abnormally dnmt replication analogue healthy result dnmti become become hypermethylated occur hypomethylated dna dna dna dna irreversibly bind bind end island methyltransferase inhibitor describe normal cpg decitabine nucleoside incorporate demethylation tissue 
2.0@cancer cancer inhibitor inhibitor class class outcome dna dna dna island agent make since dnmti dnmti dnmti dnmti dnmti direct might inhibit inhibit suppress lead epigenetic help well enzyme demethylating tolerate enhance tumor tumor mechanism affect hypermethylation clear effectiveness although cpg improvement cell cell cell cell rapid one suppressor user also patient irreversibly seem replication certain completely show show show show prevent reason several kill bind chemotherapy drug poor methyltransferase methyltransferase rate copy afterwards division division due methylation methylation methylation methylation methylation decitabine decitabine decitabine gene incorporate come active 
1.33@cancer effect class tumour tumour affect irreversibly strand body belong severely replicate block normal give release nucleoside cell cell cell cell much machinery dependent divide divide drug drug analogue target low anti show good dna dna dna dna get dose kill bind bind epigenetic inhibitor methyltransferase methyltransferase methyltransferase along upon copy division longer thus methylation decitabine decitabine decitabine daughter incorporate come action rapidly replication 
2.0@suppressor lead lead lead employ demthylates dnmt formation methyl cause inhibitor inhibitor mark probably methylate action growth growth treat decrease transferase amount previously class dna dna dna dna epigenetic work call use hypermethylation hypermethylation thereby inhibit enzyme normal death belong silence silence methylation methylation decitabine gene gene drug drug drug cell tumour tumour would would expression 
1.0@dna dna dna cancer advance manner tumour slow combination agent growth inhibit lead lung histone function demethylating methyltransferase inhibitor similar deacetylase belong decitabine azacitidine 
0.67@begin cancer cancer suppressor seem use work agent stop myelodysplastic myelodysplastic growth leukemia leukemia breakthrough back grow treat treat science dna dna away step syndrome le well demethylating demethylating drug take importantly tumor big normal new methylation methylation decitabine decitabine protect reinstate first form rapidly 
1.0@anit inhibitor class dnmt tumour tumour tumour tumour add mark find efect effectively island island suppress irreversibly strand methylated establish enzyme mechanism affect lack hypermethylation hypermethylation thus thus render express cell cell cell drug actively suppressor suppressor dependent nucleoside therefore therefore relate daugther replication analogue appropriate anti useless dna dna divide bind demthylating dnmts dnmts dnmts cpg cpg gene gene effect remove belong longer longer since methylation methylation decitabine daughter daughter daughter mitosis active 
2.0@cancer cancer restore able stimulate much cytindine agent region durable response apply part regulatory incorporation decrease adduct lead cytosine epigenetic severe demethylating contingence proliferation tumor tumor pattern pattern transformation nucleotide mode directly epigenomic like prognosis cell cell cell cell may compliance poorer couldinhibit hypomethylation certain run patient seem drug drug drug cause stability base healthy prove suppression fast anti consist limit could continuity dna dna dna dna dna divide critically action brake covalent important gene methyltransferase methyltransferase effect effect analog resemble belong modification thus methylation methylation methylation decitabine decitabine daughter time another influence form survival delay expression improve 
2.0@could methyltransferases methyltransferases class lymphoma methyl methyl agent hypomethylating dense make suppress lead epigenetic pack human ezh ezh prevent impact tumor tumor uncontrolled hypermethylation may possibility case many degree tumour belong suppressor identify reastablish cause mutation cell describe describe provide anti bind protein adequate dna dna histone histone group group expression use inhibitor inhibitor inhibitor gene gene methyltransferase effect induce overactive chromatin division due silence methylation methylation decitabine decitabine decitabine decitabine mainly attach 
2.0@observable cancer cancer cancer cancer stronger faster approvedfor term term use use fda agent agent long long syndrom myelodysplastic since since dnmti change tumour decrease prolonglife class epigenetic epigenetic generaly detectible help demethylating demethylating happen tumor pattern normal normal u whenhypermethylation cell cell cell trial yet older one suppressor dependent introduce patient irreversibly replication improve mutation target obvious reversible idea problem amount speak cellsvs though dna dna understand reverse bind dnamethylation inhibitor inhibitor drug drug gene methyltransferase effect effect hope hope belong replicate decitabine method dmnt incorporate cancerous machinerycan side side epi 
1.33@suppressor cancer cancer also growth cause agent stop cannot hypomethylation gene gene anti grow suppress properly properly dna work prevent prevent demethylating adna methyltransferase tumor tumor tumor tumor die turn turn metabolite decitabine multiply reproduce cell cell cell control 
1.67@suppressor suppressor suppressor cancer cancer undo evolve role new free dnmti hypomethylation hypomethylation treat inhibit dna aim gene methyltransferase methyltransferase inhibitor tumor tumor hypermethylation produce thus decitabine decitabine activity play 
1.67@cancer proliferate inhibition class dnmt dnmt dnmt tumour tumour dependent mark mark cannot malignancy reactivate normally island island island cpg cpg cpg cpg molecule epigenetic epigenetic epigenetic strand methylated would would responsible responsible attack inhibitor affect hypermethylation hypermethylation enzyme indiscriminately cell cell cell cell cell cell repress belong suppressor suppressor faster therefore mitotic methylates hemi decitabine decitabine incorporate case methylation methylation methylation methylation methylation occur occur dna dna maintenance bind lay target dinucleotides time methyltransferase rate must division division division silence silence regulator haematological mainly gene gene disproportionately maintain enzymatic small 
2.0@cancer cancer cancer methyltransferases inhibition effective effective dependent probably azacytidine hypermethylation leukemia principle inhibit island act molecule molecule particularly division methyltransferaseinhibitor myeloid myeloid round affect give nucleoside higher higher cell cell cell cell drug drug drug cytidine analogue bond therefore replication replication certain structure three toxic low dosage dosage become know dna dna dna dna divide acute syndrome le cpg upon interact similar quickly modification methylation methylation decitabine decitabine decitabine incorporate dysplastic sensitive follow 
0.33@un suppresor promote decitabine drug agent hole wilm spectrum cytosine cytosine silence silence balance oncogene tumour tumour effectively group previously push dna dna dna methylated methylated expression demethylating gene side remove remove normal normal hypermethylation display methylation repair repair mean like towards methyl precisely machinery 
2.0@suppressor suppressor tumor tumor methyl methyl agent decitabine hyper growth growth become normally island island suppress dna methylated function demethylating group group inactivate remove remove cpg cpg allow allow gene gene cell cell would unrestrained 
1.33@cancer cannot dnmt close spread agent stop repressive also useful locus analogous lead strand methylate particularly well silence demethylating demethylating tolerate nearby impact tumor tumor normal hypermethylation molecule methylation methylation methylation cell cell cell cell cell drug drug overproliferation overproliferation reason methylating therefore nuceoside general replication either ch lay result bring specific bind bind occur promoter prevent dna dna dna dna divide mark histone group thatprevent end gene gene chemical upon activatingmark control irreversibleand belong new actively decitabine decitabine decitabine incorporate heavily 
1.33@cancer inhibitor higher class essentially dnmt progress use use specific elderly myelodysplastic analog transferase inhibit benefit irreversibly call term well enzyme effective tumor mechanism normal dntm may hematologic nucleoside nucleoside cell cell cell cell methyl machinery dependent greater patient epigenetic presumably replication replication replication dose dose healthy toxic low exact solid long dna dna divide non bind act le drug drug drug aml effect effect effect effect unclear unclear tolerate interfere thus decitabine decitabine disorder work incorporate past action 
2.0@cancer promote fight seem goal problematic agent specific target result dosage hypomethylation drug drug drug copy prevent good class dna dna dna get daughter hypermethylation demethylating locus methyltransferase pattern particular division clear methylation genome although region incorporate case cell cell cell control decitabine 
0.67@cancer inhibitor affetcted able agent dnmti dnmti normally transferase prevent dna dna dna irreversibly bind bind rat demethylating demethylating repricate dnmt replicate decitabine high incorporate incorporate cell cell would 
1.67@elod suppressor suppressor suppressor cancer abnormal activate use agent myelogenous leukemia inhibition treat know island island act act dna acute dymethylating syndrome precursor allow cpg cpg gene gene plastic tumor tumor tumor hypermethylation hypermethylation produce find genome dymethylate y case cell cell would would decitabine decitabine 
1.33@cancer reduce higher class specificity dnmt tumour tumour tumour include agent myelodysplastic methylating treat effectively inhibit act act act irreversibly decrease involve demethylating impact normal release nucleoside case possible may transferase dependent analogue epigenetic appear replication carry actually incorporate also yet effect anti methyl know prevent dna dna dna dna dna dna divide cell cell cell cell cell cell bind syndrome use dnmts dnmts drug drug drug rate kill replicate replicate thus methylation methylation methylation decitabine much activity action generate 
2.0@cancer cancer methyltransferases restore restore tumour tumour tumour tumour tumour tumour tumour agent silence silence silence major de hypermethylated hypermethylated restrict inhibit inhibit inhibit inhibit previously often development well enzyme proliferation mechanism normal normal cell cell cell catalyze blockage suppressor suppressor suppressor suppressor methylating consequently consequently drug certain cycle result result anti know prevent dna dna dna dna dna dna bind function gene gene gene gene gene gene gene expression expression induce belong longer thus methylation methylation methylation activity progression class 
1.33@cancer inhibitor dnmt dnmt use genom agent agent azacytinide hypomethylating myelogenous reactivate hypomethylation potential treat inhibit methylcytosine lead cytosine development precursor silence silence demethylating reduce require therfore crucial nucleoside role tumour tumour suppressor leukaemia enzymatic also activation imprint total analogue strand nearly apoptosis incorporate result anti type myelodyplastic ra dna dna dna dna dna deoxyribose reverse syndrome act expression gene gene gene gene methyltransferase methyltransferase methyltransferase effect induce cellular increase belong methylation decitabine decitabine decitabine wide activity differentiation protein play 
2.0@transfer identify activate drug include agent agent agent hypomethylating hypomethylating hypomethylating anti result meet apply effect demethylate inhibit suppress suppress unfortunately dna dna dna epigenetic ase act appropriately inhibitor inhibitor time methyltransferase function tumor tumor tumor chromatin silence silence usually methylation decitabine decitabine gene gene gene gene 
2.0@suppressor suppressor impact dnmt dnmt dnmt dnmt class epigenetic anti prevent dna dna dna dna dna dna divide strand strand kill bind bind inhibitor inhibitor gene gene methyltransferase effect tumor tumor tumor tumor daugher copy copy belong replicate methylation methylation methylation methylation longer daughter daughter mean mean active cell cell cell decitabine decitabine decitabine decitabine decitabine 
1.33@cancer inhibitor inhibitor class hipomethylation use use slow agent myelodysplastic make call inhibit lead epigenetic help enzyme demethylating way impact tumor like cell tumour tra one one drug cause fe mutation apoptosis lot anti anti normally methyl dna dna dna dna histone wich chemotherapy act effect induce overactive reasearches deacetylase belong rase methylation decitabine decitabine decitabine differentiation overegulation 
2.0@suppressor inhibitor mitotic tumour tumour tumour work therfore stop hypomethylating since silence silence effect anti inhibit dna dna reverse reverse help ahve expression group continue reduce gene methyltransferase belong epigenetics eventualy decitabine decitabine region methylation methylation methylation drug recover 
1.0@cancer cancer restore effective activate use agent hypomethylating myelodysplastic hypomethylation hypermethylated copy island suppress strand strand corrupt enzyme dnmt intergenic affect ordinary instability otherwise cell cell cell cell tumour silent divide recombination cause hemi target become methylated genomic dna dna dna modulate dose moment syndrome act expression cpg gene gene gene rapidly inhibitor methyltransferase methyltransferase illegitimate repeat repeat division silence methylation methylation decitabine decitabine decitabine daughter region recognise mark small 
2.0@along along along promote dnmt dnmt dnmt replication specific since dnmti dnmti growth make bind bind decrease inhibit dna dna dna dna prevent prevent act act act inhibitor irreversible methyltransferase perpetuate tumor division division longer longer methylation methylation methylation decitabine region incorporate come cell cell cell 
1.67@cancer cancer methyltransferases use use use manner specific specific sit since change make might decrease nucleotide lead transcriptionally epigenetic transferase involve treat treat enzyme group take tumor tumor turn fastly genome render render homologue cell may care one one suppressor dependent transfer drug drug dectabine universnality cancerous type methyl methyl level prevent dna dna dna divide bind expression inhibitor inhibitor gene gene effect cellular thing methylation methylation methylation decitabine context active active active alter 
2.0@cancer cancer methyltransferases dnmt control use agent myelodysplastic dnmti dnmti part overall back normal methlytransfer unable strand level allow demethylating fall take reduce affect affect hypermethylation genome nucleoside aberrant maintain cell cell cell cell cell cell cell cell cell tumour tumour suppressor also therefore replication analogue cycle ultimately anti try know treatment dna dna dna dna dna bind bind syndrome dnmts drug gene rapidly along copy silence replicate replicate replicate methylation methylation methylation decitabine decitabine daughter incorporate inhibiters 
1.33@cancer cancer critical progress use fda agent mechanism myelodysplastic myelodysplastic hypomethylation leukemia treat treat explain island irreversibly strand think demethylating myeloid pattern affect neoplastic hypermethylation nucleoside factor good cell cell cell cell demethylation demethylation tumour drug drug however replication analogue normal result result low trigger anti fully prevent particular dna dna dna dna dna dna dna understand dose acute bind syndrome syndrome inhibitor cpg rapidly effect copy death replicate go methylation decitabine decitabine daughter incorporate undergo approve action complete methyltransferase methyltransferase progression 
2.0@cancer cancer cancer cancer classify abnormal abnormal class reactivation may may slow include agent entirely mark replace growth normally change decrease decrease island act act lead lead phenotype even epigentic enzyme enzyme demethylating tumor nucleotide hypermethylation rase repair successful like many cell cell cell methyl suppressor directly atom decytabine decytabine run drug cause cause actually mutation result cytosine elimination without hypermetylation type region promoter prevent prevent example dna dna dna dna dna kill fe le important cpg inihbitor inhibitor analog silence thus methylation gene gene gene gene gene gene activity modify number 
1.33@cancer cancer abnormal restore lymphoma uncontrolled protein protein system agent whose hypomethylating myelodysplastic myelogenous growth transferase inhibit job demethylates call help precursor enzyme enzyme enzyme ezh ezh group group proliferation proliferation tumor tumor many cell cell way leukaemia suppressor suppressor transfer drug cause cause ch ch overmethylates mutation acute stop become methyl methyl immune prevent family treatment dna dna dna histone histone syndrome gene gene overactive catalyze silence decitabine decitabine decitabine activity attach 
2.0@dinucleatides cancer cancer cancer cancer rate dnmt activate use use cell cell cell growth growth amount prevent suppress suppress potentially dna cpgs particularly inhibitor hypermethylation hypermethylation cpg inhibit methyltransferase reduce reduce affect division methylation methylation decitabine decitabine gene gene gene lead significant tumour 
0.67@mitotically could could characteristic use agent mark mark mark anti since growth tumorgenesis suppress suppress suppress epigenetic epigenetic epigenetic epigenetic pass demethylating island take reduce tumor tumor tumor tumor hypermethylation express cell cell cell inheritable one therefore activation actively actively drug cause cause moreover demethylate dna dna dna cancerous cpg removal effect effect remove remove silence main methylation decitabine daughter gene gene gene mean account active would would 
1.33@cancer classify class antimetabolite produce produce use syndrome agent anti anti md treatment dna body help chemotherapy inhibitor myelodysplastic gene take effect tumor tumor tumor hdac belong methylation decitabine decitabine decitabine decitabine demethylation drug deteriorate 
1.67@suppressor suppressor cancer cancer proliferate assume erase overmethylation overmethylation tumor tumor tumor tumor possibly agent agent agent could die effect result since change susceptible make treat decrease decrease prevent might might treatment dna dna dna divide even histone histone continue epigenetic least demethylating demethylating demethylating gene gene proliferation able able able remove jq similar silence silence decitabine decitabine decitabine daughter gsk apogenisis cell cell cell cell cell reprogram 
2.0@suppressor cytidine reduce dnmt dnmt tumour tumour tumour tumour hypomethylating irreversibly analog anti inhibit cpg dna dna dna divide bind drug island rapidly effect methyltransferase affect afterwards hypermethylation hypermethylation decitabine decitabine decitabine gene incorporate cell replication 
2.0@risk cancer cancer cancer characteristic abnormal although wide fight use share agent healthy decitabine fashion reactivate permanent associate tumour decrease island demethylaton promoter dna epigenetic see maintain silence drug gene gene proliferation effective mechanism affect cpg due methylation methylation genome arise mitosis free cell cell cell way would would would supressor 
2.0@loss instead restore irrevocably dnmt dnmt dnmt enzymatic use manner process since dnmti methyl methyl methyl mutagenic drug drug call erase disrupt cytosine cytosine cytosine epigenetic methylate regulator belong island reduce reduce hypermethylation hypermethylation may directly silence n never maintain passive cell passively cystosine suppressor also always release therefore class fda replication cause throughout describe synthesis occur group group dna dna dna dna dna dna carcinogenesis carcinogenesis base base base base reverse bind bind bind bind expression cpg gene gene methyltransferase inhibitor neucleotide division thus methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine incorporate approve tra methylating methylating de de de 
2.0@cancer cancer article epicenter class use process myelogenous economist reactivate reactivate leukemia treat marrow epigenetic call inhibitor silence deform tumor tumor tumor tumor tumor affect l cell blood one suppressor suppressor transfer therefore consequently drug drug drug ability ly limit describe realize anti anti dna dna ase le incidentally gene gene effect epigenetically little great methylation decitabine decitabine bone meet form would would 
2.0@cancer cancer cancer cancer reduce reduce growth dnmt dnmt dnmt dnmt dnmt activate tumor tumor tumor tumor use mitotic myelodysplastic myelogenous de hypomethylation leukemia make treat epigenetic responsible hypermethylation hypermethylation tissue outcome heritability key relate genome dntm like cell cell cell may may may suppressor suppressor risk also however candidate improve regulation certain evolve progeny healthy novo responsive good divide divide acute syndrome drug rapidly inhibitor inhibitor inhibitor inhibitor impact impact currently methylation methylation methylation decitabine decitabine region region form worse would would would associate 
2.0@cancer cancer cancer effect demethylates dnmt methyl agent tend inhibit inhibit inhibit since dnmti make heritable transferase island mitoticly methylated demethylating severely tumor tumor methylate normal metylated cell cell cell cell cell cell passively supressor dna dna dna dna dna dna dependent methylt function hemi promotor product highly demethylated transcribe ransferases devition divide kill bind dnmts gene gene rapidly supressing silence longer methylation decitabine decitabine decitabine region region activity 
0.0@cancer metastasis necessary drug certain could specific specific extent contributor result major therby problem group tail reverse lysine histone histone demethylases demethylases site belong remove remove methylations hypermethylation decitabine methyl 
1.0@methyltransferases methyltransferases abnormal restore may cause decitabine decitabine target class hypomethylation gene gene make know inhibit lead dna dna dna epigenetic tumorigenesis division responsible function prevent inhibitor inhibitor contact growth normal belong genome work incorporate cell cell directly 
2.0@abnormally methyltransferases restore restore regulation remove drug stability agent capability reparing also cytosine growth part hypermethylated antitumour group genomic previously imply dna dna dna expression expression enzyme demethylating inhibit hence effect tumor decitabine silence silence would region gene cell methyl reestablish supressors 
1.33@hand hand characteristic dnmt dnmt dnmt tumor tumor tumor tumor tumor methyl agent mark two analog de susceptible avoid inhibit inhibit inhibit cytosine epigenetic transferase epigenome proliferation serve normal hypermethylation aberrant program passive cell cell cell cell use decitabine decitabine one suppressor also also promote erase mainly necessary structure drug drug drug drug drive stability novo constantly present maintain anti occur prevent genomic dna dna dna dna dna dna maintenance function effect way demethylation new new methylation methylation methylation methylation allow establishment establishment em form alter 
1.33@drug agent myelodysplastic methyl treat decrease back weaken dna dna epigenetic syndrome use hyper demethylating gene gene disease put normal increase silence ing methylation decitabine decitabine tumour expression expression 
1.67@suppressor suppressor effect class tumor tumor tumor methyl methyl cause location find cancerous cancerous reactivate growth anti promoter group group cpg regulate dna dna dna dna epigenetic allow allow demethylating island inhibitor remove remove belong silence methylation decitabine decitabine gene gene gene express cell cell cell way 
2.0@cancer cancer cancer along available dnmt methyl aid hence tend analog note treat island island island suppress lead irreversibly development methylated methylated hypermethylation hypermethylation reduce tumor tumor normal generally myelodyspalstic nucleoside degree replication suppressor transfer divide divide situation drug cause cause mean mean problem effect normally occur promoter group develop dna dna dna dna get get cell cell cell bind bind syndrome act inhibitor cpg cpg cpg gene rapidly inactivate remove must upstream methylation methylation decitabine decitabine em incorporate come methyltransferase methyltransferase unable 
2.0@cancer cancer cancer cancer cancer effect lead reactivation use tend silence irreversibly find dnmti hypermethylated transferase island island often epigenetic development get involve inhibitor contribute contribute severely normal hypermethylation hypermethylation genome genome nucleoside regulator demethylation cell cell cell cell cell tumour tumour tumour region suppressor suppressor dependent carry divide replication replication analogue lay body gene gene anti methyl promoter prevent dna dna dna maintenance maintenance bind bind generally dnmts dnmts dnmts drug drug affect rapidly function upon cpg cpg since since since methylation methylation decitabine decitabine decitabine daughter much incorporate action enzymatic 
1.67@abnormal disrupt tumour tumour state agent switch inbition also also growth inhibit lead cytosine strand display enzyme demethylating inclusion irreversibily cell replication suppressor tie therefore drug analogue function target anti dnmts dna dna dna dna dna base reaction act expression perform gene recognise effect induce silence new methylation methylation decitabine decitabine associate 
1.67@dacogen impact cell uncontrolled agent stop process eisai myelogenous design make treat molecule epigenetic epigenetic epigenetic epigenetic even tumour regulator precursor enzyme demethylating proliferation happen underactivity readily ensure fault japanese way reversible enzymatic use use alteration drug affeting target target sequence sequence anti specify prevent prevent company dna dna acute syndrome sell myelodysplastic gene gene effect systemic vsince due methylation decitabine wariness rectify alter small 
2.0@myelodisplasic myelodisplasic myelodisplasic restore nucleoside use use use agent agent agent myelogenous susceptible tumour tumour affect imply irreversibly body methylated well demethylating demethylating demethylating group normal hypermethylation although case possible methyl leukaemia suppressor suppressor insert patient seem analogue precede cell promoter citosines dna dna dna acute bind syndrome syndrome syndrome name expression dependency methyltransferase inhibitor remove tolerate silence decitabine decitabine gene gene 
1.33@dacogen cancer growth growth last dna dna dna dna uncontrolled slow agent agent agent whose hypomethylating make analog myelogenous change susceptible decitabene treat normal occur imply cytosine epigenetic precursor complex demethylating demethylating demethylating way reduce job mechanism affect early dac like japanese tumour tumour tumour leukaemia suppressor cause use syndrome cell cell cell myelodysplastic stop distinct company standard non acute chemotherapy sell eisai gene inhibitor induce silence methylation decitabine decitabine nearby alter without 
1.0@cancer methyltransferases class get use dependent myelodysplastic myelogenous treat inhibit nucleotide irreversibly strand body precursor belong inhibitor inhibitor severely replicate affect release nucleoside cell cell cell leukaemia andis faster epigenetic analogue thismethyltransferase dnamethyltransferase dna dna dna divide acute bind bind syndrome dmnti aditionally along copy division longer methylation decitabine daughter incorporate come methyltransferase 
1.33@dna decrease therefore le dnmt dnmt inhibitor seem drug effect effect tumor tumor toxic low methylation decitabine decitabine high anti anti dosage dosage better inhibit 
1.67@dna dna cancer slow advance imprint use cause manner agent acute proper myelogenous hypomethylates similar growth inhibitor treat could occur presense lung histone lose syndrome precursor function demethylating hypomethylation tumor people deacetylase hypermethylation myelodysplastic decitabine decitabine decitabine decitabine possible azacitidine combine leukaemia 
1.67@mitotically cancer cancer cancer proliferate inhibition class use state include agent mark article economist adaptation treat inhibit heritable pass survive silence demethylating tumor normal cell cell cell cell cell may may may may immortal suppressor erase decitabine decitabine appear deposit deposit describe cancerous become type methyl develop dna dna reverse function gene methyltransferase reversal belong methylation methylation inappropriate inappropriate daughter work lay return 
2.0@cancer cancer inhibitor within effective methyl slow mutation long stag myelodysplastic since since meet dnmti dnmti dnmti growth leukemia leukemia leukemia md silence irreversibly pass term well enzyme group myeloid tumor people affect hypermethylation genome serious side primarily cell cell cell cell blood older older suppressor transfer transfer patient patient drug cause mutate typically reverse type prevent prevent prevent syndrome syndrome dna dna dna acute ase variety le additional aml effect effect similar tolerate bind concern currently methylation decitabine decitabine daughter daughter wide incorporate approve cpgs part methyltransferase exist exist 
2.0@heavy cancer effective nucleoside operandi dnmt use analogue agent agent mark myelodysplastic modus clonal present treat prevent particular family treatment dna dna irreversibly bind syndrome inhibitor dnmts demethylating demethylating island effect tumor tumor affect cpg belong replicate actively decitabine manteinance em incorporate methylation methylation cell drug 
0.33@different different gene dnmt dnmt way appear agent process malignancy susceptible genetic suppress like irreversibly pass allow demethylating reduce tumor tumor tumor tumor tumor tumor tumor mechanism mutation hypermethylation hypermethylation hypermethylation although role express cell use suppressor suppressor suppressor drive dna dna dna dna dependent dependent also greater nucleoside therefore epigenetic epigenetic replication analogue ie extent context therapy case depletion em know reduction intervention action bind dnmts drug dependency chemical methylation methylation decitabine decitabine daughter possible incorporate tumorigenesis eg haematological 
2.0@undesirable alt cancer inhibitor inhibition restore within mitotically progress fda myelodysplastic analog dnmti leukemia characterize heritable inhibit cytosine position pyrimidine island myeloid tumor tumor intracellularly normal hypermethylation convert img triphosphate cell cell suppressor faster therefore drug region promotor incorporate result src treatment dna dna dna dna dna replicate replicate ring acute syndrome cpg gene gene gene aml aml rate silence modification methylation methylation decitabine decitabine decitabine auppressor activity approve methyltransferase methyltransferase 
1.67@maybe cancer cancer cancer effect dnmt dnmt additionnaly much agent hypomethylating myelodysplastic azacytidine similar normal tumorgenesis nucleotide effective get disease severely way outcome tumor tumor affect hypermethylation hypermethylation release nucleoside role cell cell may decitabine decitabine decitabine decitabine decitabine suppressor transfer divide seem replication replication analogue context meet anti type dna dna dna syndrom ase bind act inhibitor cpg poor rapidly along upon dependant dependant dependant dependant stage stage still longer thus methylation ul ul drive incorporate come action 
1.33@decline cancer cancer methyltransferases class dnmt progress use include hyperactive growth quite treat irreversibly involve enzyme enzyme order tumor tumor tumor tumor dnmtis hypermethylation nucleoside nucleoside many cell cell cell cell myodysplastic control expression suppressor suppressor therefore require analogue analogue dose typically decitabine target result result result low become become type demethylation properly extremely dna dna dna dna dna dna dna divide divide domain allow syndrome function drug drug gene gene rapidly inhibitor methyltransferase bind silence methylation methylation alter incorporate incorporate aml efficiently 
2.0@suppressor could methyltransferases package may cause cause overexpressed agent dense chromatine descendant consequently growth bind solid better inhibit inhibit demethylation previously dna dna dna dna dna irreversibly histone methylated example silence demethylating gene methyltransferase inhibitor control ezh replicate methylation decitabine factor incorporate express many cell cell cell tumour tumour 
2.0@cancer cancer proliferate demethylates dnmt dnmt use specific tend disease since dnmti leukemia island unknown irreversibly strand methylated inhibitor quickly inhibit myeloid tumor mechanism mechanism affect fact myelodysplastic nucleoside demethylation demethylation cell cell cell cell far may expression suppressor dependent lower high analogue non cause toxic result course exact antitumor dna dna dna dna dna dna get dose dose acute bind bind syndrome function cpg gene gene methyltransferase methyltransferase effect effect relatively copy increase division methylation decitabine decitabine decitabine decitabine decitabine daughter daughter mitosis incorporate promise pattern beneficial 
1.33@mitotically cancer cancer class desirably way state agent stop deletorious tumorsupressor change change erease make genetic exert decrease island treat epigenetic epigenetic epigenetic body belong demethylating tumor tumor big tame hypermethylated behaviour cell cell cell cell drug drug expression standard also hopefully via need could could could mutation methlyation result kill therby malicious case vulnerable clone furthermore dna dna reverse reverse chemotherapy inherit cpg gene rather function advantage thereby thus methylation decitabine decitabine work theory oppose would would would would delete 
1.67@cancer cancer methyltransferases class term order tumor use long myelodysplastic dnmti unsure rate treat suppress epigenetic belong optimize amplify mechanism normal dnmtis dnmtis give nucleoside high many cell cell cell may dna dna dna dna dependent cause patient therefore drug drug analogue today knowns low like anti irreversably demethylation abnormally divide dose bind syndrome inhibitor inhibitor still methyltransferase effect effect effect division division decitabine decitabine decitabine incorporate action neoplastic 
1.0@dnmt dnmt cell use agent irreversibly mimic dnmti inhibit nucleotide dna dna divide kill bind suppose still methyltransferase mechanism lack demethylating due genome incorporate clear would decitabine 
2.0@unregulated cancer methyltransferases methyltransferases inhibition restore progress tumour tumour agent aberrantly process myelodysplastic growth importantly aza work inhibitor belong demethylating normal demethylated nucleoside demethylation cell cell blockage decitabine decitabine decitabine suppressor suppressor hypomethylation analogue promote consequence drug cause cause apoptosis activity result experiment become become arrest know treatment treatment dna dna dna dna dna dna syndrome dnmts gene gene gene aml function deoxycytidine suggest increase division silence methylation allow em incorporate follow 
1.67@dmnts cancer cancer effect class dnmt tumour analogue inhibitor inhibitor decitabine decitabine present like level suppress lead dna dna dna instance bind act fe silence drug drug drug drug gene reactivation induce belong rase methylation inappropriate nucleoside region icrs demethylation cell cell methyl tra 
2.0@cancer cancer inhibitor may process hypermethylated island nucleotide irreversibly strand well division tumor replicate affect release nucleoside cell cell replication region suppressor dependent patient need analogue antitumor prevent dna dna dna dna divide bind bind drug gene methyltransferase methyltransferase methyltransferase along upon cellular copy cpg longer methylation methylation decitabine daughter work incorporate come rapidly 
2.0@assist cancer inhibitor class fight tumor tumor methyl decitabine mark part prevent dna dna epigenetic repressor methylated hyper demethylating gene effect remove silence go genome mean case demethylation thereby belong 
2.0@cancer inactivate inactivate anticancer dnmt dnmt dnmt dnmt dnmt regulation regulation concentration concentration cycle cycle phase process process since reactivate growth growth vulnerable permanently inhibitor inhibitor inhibitor hypermethylation enhance reactivation tumor tumor tumor apoptotic normal efficacy rely repair high passive passive cell cell cell cell cell cell cell ref control expression suppressor dependent bond replication work therapy toxic pathway reproduce loss low best basic dna dna dna demethylation bind re important gene gene gene gene rapidly effect upon cellular rapid methylation decitabine decitabine daughter create incorporate covalently methyltransferase alter 
1.67@think available dnmt dnmt use use agent already two block growth treat treat island suppress previously clinical epigenetic epigenetic belong disease tumoral inhibit myeloid mechanism uncontrolled complex although human cell trial tumour leukaemia market compare therefore therefore irreversibly drug drug drug demethylated group cpg dna dna acute bind act expression still gene gene aml allow practice demethylating decitabine decitabine decitabine activity action methyltransferase azacitidine 
2.0@nucleooside cancer cancer dnmt produce progress way fda agent agent chromosomal chromosomal cure analog find efect functional change change leukemia genetic suppress epigenetic epigenetic epigenetic epigenetic scientiscs help tumotigenesis farmaceutics enhance impact tumor due hypermethylation novel count genome aberations demethylation demethylation cell try dnamethylation one one dmti appear drug drug drug instability instability therapy mutation support lot without depletion company among group group develop develop syndrome dna dna dna dna dna dna histone bind chemotherapy myelodysplastic aml inhibitor medicament concretely desease acetylation belong modification modification new methylation methylation decitabine decitabine decitabine mainly incorporate connection approve chromosome background 
2.0@gene gene gene gene gene unregulated cancer cancer cancer restore suppressor suppressor suppressor suppressor tumor tumor tumor use use cause agent agent hypomethylating hypomethylating become reverse hypomethylates growth growth leukemia md treat treat lead deoxycytide dna dna dna dna epigenetic blood form expression silence drug drug inhibit inhibit syndome allow methytransferse block normal increase division division methylation methylation methylation methylation blockage myetodyspatic regulate regulate demethylation cell cell cell cell cell control promote decitabine 
1.0@restore activate need cause agent healthy healthy type treat level level dna expression function function demethylating gene gene gene gene reduce reduce tumor normal normal necessary necessary silence silence silence methylation methylation methylation methylation genome cell cell drug decitabine 
1.0@several methyltransferases class dnmt produce may cycle myelodysplastic silent cytotoxicity moderate hypomethylation md incorporation affect inhibit inhibit aza significant epigenetic inhibitor belong observe grace tumor tumor tumor block inactive hypermethylation phosphorylation high role hypomethylant cell cell cell global suppressor also also become patient action hypomthylant replication cause therapy result low low reactivation bond anti anti prevent active covalent dna dna dna dna dna dose dose dose dose synthesis syndrome act dnmts dnmts drug drug drug gene gene methyltransferase effect deoxycytidine demethylation death human methylation decitabine decitabine decitabine mainly incorporate acquire form differentiation 
2.0@cancer cancer proliferate restore methyl agent agent specific hypomethylation treat treat island addition enzyme demethylating inhibit proliferation tumor pattern normal repair insensitive cell cell cell cell cell cell may unmethylation cytidine transfer therefore replication analogue cause cycle cycle apoptosis highly normally promoter group good dna dna dna dna dna dna dna non example function cpg gene methyltransferase control increase methylation methylation decitabine decitabine decitabine incorporate alter 
2.0@unregulated cancer unrestricted class begin tumor tumor tumor tumor use include cytidine silence become currently dnmti growth growth growth growth effectively inhibit resultant regulate strand strand decitabines responsible enzyme hypomethylation proceed take dnmt dnmt dnmt job block primary lack bond role methylation methylation methylation cell cell cell cell cell blood suppressor suppressor suppressor belong mode dependent replication analogue marrow unblock result result methylate anti occur prevent dna dna dna dna dna covalently expression inhibitor gene gene gene gene methyltransferase effect effect place increase division division division division thus thus disallow decitabine decitabine decitabine decitabine bone eventually inclusion approve action alter play 
1.0@cancer abnormal inter methyl methyl methyl agent genic myeloplastic analog myelogenous dnmti island island island leukemia sit decrease decrease inhibit advance strand transferase transferase transferase methylated methylated methylated methylated methylated methylated normally normally normally hyper hyper hyper hyper locus tumor tumor round hypo hypo hypo ensure express many cell cell cell majority suppressor suppressor cytidine preparation intra could gpis become become become element promoter prevent prevent repetitive dna dna dna dna dna dna block acute syndrome cpg cpg cpg gene gene inhibitor division division replicate silence methylation methylation methylation decitabine daughter region region would would would 
1.67@cancer cancer class use agent demythlating demythlating two since since balance oncogene regulate epigenetic epigenetic well enzyme proliferation proliferation dysregulation mechanism uncontrolled thus thus cell cell cell tumour tumour tumour tumour expression expression one suppressor suppressor suppressor tilt general drug drug drug drug suit therapy appropriate target result ultimately respectively anti type methyl group dna dna dna often suppression perform gene gene gene gene gene function remove control control death belong main methylation decitabine decitabine decitabine upregulated 
1.0@cancer cancer effect class determine produce disease use agent agent hypomethylating sample sample aza reactivate hypomethylation hypomethylation sit treat call inhibit methylcytosine suggest cytosine epigenetic decrease decrease medication variety intrinsic bone pattern pattern primary anticancer content via dac dac demethylation cell cell cell cellular expression expression chemical analogue pyrimidine position imprint total cause cause cause marrow cd cd md property result dinucleotide across reaction type promoter damage damage treatment dna dna ring synthesis syndrome myelodysplastic cpg gene gene gene rather rate induce deoxycytidine evidence death human methylation methylation decitabine decitabine decitabine decitabine decitabine modify protein 
2.0@dna dna dna suppressor reduce reduce growth growth formation gene methyltransferase cause tumor stop hypermethylation methylation methylation decitabine deactivate encourage promoter inhibit drug 
1.33@appearance cause class dnmt tumour analogue shore process island demethylates dna dna dna irreversibly reverse bind inhibitor important cpg methyltransferase effect hypermethylation decitabine nucleoside incorporate demethylation belong 
2.0@cancer cancer cancer cancer cancer methyltransferases growth growth growth growth dnmt activate tumor tumor tumor tumor tumor uncontrolled stimulate agent detrimental article economist hypomethylation inhibit demethyating class effective help help discuss allow allow drive drive overmethylation helpful suppress hypermethylation turn reduce reduce much instability role cell cell standard may suppressor suppressor suppressor genome dna dna dna dna dna dna dependent activation replication wide former result arrest promoter cpg reduction dose chemotherapy smaller inhibitor drug gene effect chromatin increase belong silence methylation methylation methylation methylation decitabine em context perhaps would would 
1.33@progenitor cancer cannot essentially may slow agent agent pattern hypomethylating analog methyltransferases overall avoid island island degree cytosine pass methylated methylated methylated demethylating observe reduce mechanism hypermethylation otherwise express cell also therefore drug mitosis target target target know know particular basically dna dna dna dna get cpg cpg gene gene impact methylation methylation methylation decitabine decitabine decitabine pathology work work incorporate tumorigenesis 
0.67@methylating demethylates therefore expression cpg gene drug tumor agent stop decitabine growth change island de 
1.67@suppressor could happen tumor tumor growth induce surroundgenes include change effect anti aza imply dna epigenetic epigenetic histone allow gene gene inhibitor deoxycitidine silence silence methylation decitabine decitabine decitabine work case demethylation cell control control expression 
1.33@one cancer near enzime overcoat tumour region agent mutation relate ofdna decrease normally wich methyl methyl methyl avoid avoid group group group group supress often work histone histone methylated methylated involve overgrowth belong ezh gene gene gene block demethylating silence decitabine decitabine level mean active regulate attach attach would example 
1.33@cancer cancer cancer methyltransferases effective use use use use appear agent tend myelodysplastic remain myelogenous dnmti dnmti drug precursor severely word affect neoplastic classify nucleoside case demethylation cell much leukaemia one dna dna dna dependent lower become high consequently seem replication analogue cause toxic anti anti show treatment kind however dose dose chemotherapy least inhibitor inhibitor still rapidly effect unclear syndrome replicate since methylation decitabine decitabine incorporate approve action 
2.0@cancer cancer cancer cancer cancer characteristic restart within specific process eisai since mitotic growth growth growth make dmnt island island suppress suppress regulate regulate epigenetic responsible responsible epigenome demethylating inhibit reduce tumor tumor normal normal early dilute signal factor inability inability methylation methylation methylation methylation demethylation increasingly control unrestrained one transfer promote fight drug cause demethylated oppose become develop dna dna dna divide mark mark cell cell cell cell cell cell cell demonstrate important cpg cpg gene rapidly allow remove increase division silence actively decitabine decitabine daughter production action protein protein protein protein exist tissue 
1.67@allegedly cancer cancer cancer methyltransferases term dnmt dnmt progress every manner agent long myelodysplastic remain frequently might call island molecule unknown irreversibly strand efficient inhibitor hypermethylation demethylating nearby pattern test suppose contribute go nucleoside passive cell cell cell cell far one dependent also high depend however presumably replication analogue could toxic although low present type demethylation dna dna dna dna dna divide dose dose bind syndrome act function cpg affect aml effect copy division undergo thus methylation decitabine daughter rather incorporate strongly prove rapidly 
1.67@cancer inhibitor dnmt use agent hypomethylating myelodysplastic hypomethylates hypomethylation treat affect inhibit inhibit epigenetic epigenetic sequence consider thereby way normal nucleoside demethylation cell cell cell tumour enzymatic analogue drug cause apoptosis target result anti presence dna dna dna dna dna divide syndrome rapidly effect cellular replicate thus regulator decitabine decitabine decitabine decitabine incorporate differentiation methyltransferase methyltransferase methyltransferase replication 
1.33@net dacogen cancer cancer brca therefore suppressor suppressor remove methyl agent appropriate island mean find maybe anti anti decrease decrease group counteract tumor tumor tumor tumor dna dna dna egger mgmt promoter promoter allow demethylating gene gene gene effect effect effect hassler rb increase increase hypermethylation methylation methylation decitabine decitabine decitabine cpg many many mlh expression expression 
1.67@suppressor class tumour cause agent medicine experiment reactivate hypomethylation show inhibit dna dna dna hypomethylating stressman lyko silence demethylating gene methyltransferase epigenetically belong vitro decitabine 
0.33@mitotically cancer category tumour tumour agent agent cocktail hypomethylating two since change md treat treat response prevention open epigenetic epigenetic better allow demethylating fall tumor tumor tumor standard crucial possibility case antagonistic cell inheritable use expression expression suppressor suppressor suppressor patient patient actively drug approach chemotherapeutic express pronged solid show prevent dna dna syndrome myelodysplastic gene gene gene gene effect effect growth silence unless decitabine decitabine daughter methylation 
2.0@cancer cancer cannot standard dnmt dnmt dnmt dnmt dnmt cpd synthesize use use loss newly analog azacytidine silence growth myleiod treat island prevention igf strand methylate methylate belong tumor hdac hypermethylation turn thus nucleoside progress cell cell methyl suppressor tra dna dna dna dna dna dna dependent also action imprint replication result result chemotherapeutic become best prevent prevent prevent prevent ireversibly treatment reduction get myelodplastis acute bind bind syndrome fe inhibitor inhibitor gene gene along upon control division replicate rase methylation methylation decitabine decitabine decitabine method possible progression ultimately 
2.0@growththat cancer cancer methyltransferases hipomethylation suppressor use agent agent stop onthe since island correspond epigeneticdrug wide demethylating demethylating adna uncontrolled hypermethylation hypermethylation hypermethylation genome many cell cell tumour region desregulations maternal epigenetic cause revert revert revert specific inhibitsdna promoter promoter decitabineis treatment treatment dna dna example expression cpg gene effect induce increase new methylation decitabine time generate generate 
2.0@dna dna dna suppressor suppressor cancer bind dnmt dnmt dnmt demethylating gene gene methyltransferase allow remove system increase silence replicate methylation decitabine decitabine incorporate express cell inhibit tumour tumour 
2.0@cancer cancer along mitotical dnmt dnmt dnmt use agent specific myelodysplastic analog since hypomethylates restrict affect inhibit nucleotide epigenetic strand demethylating island dramatically order heritability longer normal neoplastic hypermethylation release nucleoside fairly cell cell cell cell probablly drug drug deplete commonly depend get get get get presumably replication limit low anti methylation methylation show good dna dna dna dna dna dna divide dose bind bind syndrome inhibitor cpg rapidly effect upon copy division replicate thus thereto decitabine decitabine daughter incorporate come action action methyltransferase methyltransferase hit progression 
2.0@block cancer inhibitor change change suppressor induce use use part agent hypomethylating myelodysplastic analog analog myelogenous reactivate hypomethylation leukemia unmethylating treat transferase transferase epigenetic epigenetic epigenetic tumour tumour laboratory human stick separate test nucleoside progress regulator cell cell methyl methyl enzymatic faster become become daughter get alteration cause cause could apoptosis low anti know see dna dna dna dna dna dna divide dose acute syndrome act act affect continue effect epigenetically place copy division replicate replicate silence methylation decitabine decitabine cant gene incorporate attach 
1.67@cancer cancer inhibitor higher class mode tumour appear activity specific mark myelodysplastic dnmti dnmti might inhibit whereas irreversibly show enzyme effective tumor neoplastic hypermethylation hypermethylation thus blood nucleoside demethylation incorporate unknow suppressor suppressor regain replication analogue dose dose actually toxic lay result low yet anti type subsequent prevent dna dna dna dna dna non bind syndrome drug drug gene methyltransferase methyltransferase effect remove relatively emerge belong new methylation decitabine decitabine decitabine eventually silence action 
1.33@myc regulation progress tumour tumour tumour tumour tumour system prove hypomethylating hypomethylating hypomethylates apply part hypermethylated hypermethylated exert call call inhibit suppress suppress clinical epigenetic disease block factor methylation try one transcription patient therefore activation include drug cause agent agent activity result encode suppressive group unusually dna dna dna gene effect jq regulator decitabine decitabine decitabine decitabine region region eventually brd protein associate 
2.0@effect effect effect abnormal class two find cytotoxicity reactivate hypomethylation direct direct direct inhibition exert marrow inhibit cytosine strand strand silence bone tumor nucleoside cell cell decitabine decitabine decitabine decitabine decitabine suppressor also via analogue cause pathway hematopoietic low bind dna dna dna dna dna dna dna dna dose cytotoxic gene methyltransferase methyltransferase methyltransferase methyltransferase inhibitor epigenetically death belong methylation rna arise em em em em incorporate incorporate covalently heavily 
2.0@cancer cancer proliferate class tumour mostly agent aberrantly analog dmnt dmnt growth incorporation call irreversibly strand sequence inhibitor inhibitor silence demethylating tumor tumor longer dmt affect thing release nucleoside insensitive like good cell cell cell cell cell cell demethylation demethylation replication daughter therefore therefore epigenetic suppresors cause cause rapidily apoptosis normal relatively body anti arrest antineoplastic presence dna dna dna dna divide non bind act function gene gene methyltransferase effect induce copy death belong replicate thus methylation decitabine decitabine decitabine decitabine decitabine decitabine cant work incorporate 
2.0@cancer inhibitor use use slow island island find growth inhibit often often strand methylated particularly silence silence silence thereby grow reduce reduce felt normal normal consequently genome genome case cell cell cell cell tumour tumour tumour expression suppressor lower promote remethylation drug uninhibited result across help promoter prevent prevent particular dna dna dna divide le important cpg cpg gene gene gene gene gene rapidly effect copy division since methylation methylation methylation decitabine decitabine decitabine wide strongly action methyltransferase methyltransferase associate associate 
2.0@et kantarjian inhibitor randomize patient patient outcome study tumour tumour improve phase myelodysplastic myelodysplastic result malik silence leukemia leukemia anti iii decrease inhibit particular treatment treatment dna dna acute acute syndrome belong demethylates island methyltransferase effect elderly cpg hypermethylation thus al decitabine decitabine decitabine gene class myeloid myeloid cashen use suppressor 
2.0@hypomethlyation dnmt tumour tumour tumour tumour tumour add mark mark frequently growth sit permanently passively unable survive able affect bind genome genome express cell cell cell cell cell methyl suppressor suppressor transfer drug certain cause cause cause target become lose halt hypomethylated dna dna dna dna divide divide ase cpg gene continue inhibitor copy death silence methylation methylation methylation decitabine daughter disproportionately enzymatic 
1.33@lung dacogen cancer cancer cancer instead lymphoma dnmt dnmt methyl cellsso loss loss cutaneous myelogenous citosine apply transferase island act epigenetic methylated belong take normale tumor thepassively hypermethylation vidaza nucleoside like cell cell relationship tumour supressor compare lower rapid study drug drug reactivation anti joint level dna dna dna histone bind bind theaza thetumour inhibitor inhibitor cpg cpg gene gene hence effect deacetylase impact reductuin methylation methylation methylation decitabine decitabine decitabine irreversible activity leukaemia demostrate azacitidine azacitidine azacitidine 
1.33@cancer cancer methyltransferases methyltransferases class whichshow dnmt preventingfurther yet itis mostly long lifespan disease find noticable sothe quite incorporation island act act act sinhibitory ideal inhibitor hypermethylation effective tumor seemingly life preventsaction style may myelodysplastic nucleoside case cell cell way great suppressor speculation discover patient patient successfully divide seem seem drug analogue cause however incorporate without inproving effect replication thedna counter irreversably mode dna dna dna blockquote blockquote dose syndrome use thus cpg gene side feature advantage dependant elderly increase belong due go decitabine decitabine decitabine another action action action action small 
1.33@class cancercells use slow agent agent myelodysplastic myelogenous growth transferase inhibit occur daughter development precursor belong demethylating demethylating group dnmt mechanism oevrexpressed suppress hypermethylation release successful like cell tumour tumour leukaemia dependent transfer promote therefore get seem replication work strand trap mean mean introduce gene gene methyl methyl prevent particular treatment dna dna divide acute bind syndrome act drug drug drug drug calleddna rapidly effect cellular division divisionand decitabine decitabine effctive irreversible incorporate protein 
2.0@translocation cancer produce island island island island likely andgenerally hypomethylates thoseconditions abnormally avoid alone lead epigenetic level particularly hyper demethylating inhibit inhibit inhibit tumor tumor tumor tumor tumor normal normal mutation amplification genome high cell control control machinery suppressor suppressor suppressor suppressor genesrequired therefore relate failure drug agent importanton thedisruption anti fully show dna dna dna dna histone point expression expression expression cpg cpg cpg cpg gene gene gene gene methyltransferase effect effect remove cellular ofthe modification silence silence silence methylation methylation methylation methylation methylation decitabine decitabine region enable would associate associate 
1.67@cancer abnormal growth able decitabine decitabine decitabine seem blood blood blood analogue red stop toxic white make hypomethylates hypomethylation gene anti specialization byincorporating grow promote dna dna dna dna hypomethylating strand body cytidine act act platelet inhibit methyltransferase methyltransferase effect induce md better normal metabolite ul ul work work call cell cell cell cell protein switch switch 
1.0@cancer cancer cancer cancer inhibitor dnmt dnmts affinity analog dnmti rate decrease sequence demethylating proliferation able mechanism mechanism reason normal normal high high demethylation cell cell cell cell cell cell drug drug drug market compare dependent seem replication therapy low consist amount good dna dna get get get dose act important side effect preferentially stucked decitabine decitabine possible incorporate incorporate action action discriminate 
1.67@one cancer also enzime enzime category category therefore therefore able inhibitor others use fda add stop island therapy effect anti tumour inhibit inhibit develop kind authorize action action act division drug drug drug drug group group continue wil responsable cpg belong belong decitabine dmnt dmnt dmnt transferation like cell methyl methyl recently 
2.0@suppressor methyltransferases thus activate methyl analogue shore hypomethylating dnmti inhibit island dna dna dna dna dna strand hyper cpg cpg prevent proliferation inhibitor tumor tumor methyltransferase methyltransferase silence turn ing decitabine decitabine decitabine nucleoside incorporate cell control 
2.0@dna suppressor inhibitor dnmt nucleoside expression cpg gene reduce tumor cause decitabine decitabine analogue thus methylation allow hypomethylation island example 
1.0@cancer inhibitor produce andhistone include agent agent product hypomethylates number change susceptible make dna dna dna epigenetic pass chemotherapy demethylating demethylating reduce combination deacetylase division decitabine cell cell cell 
0.0@myc cancer cancer cancer inhibition class use use agent process myelodysplastic myelogenous leukemia treat treat call epigenetic common responsible belong percent block precursor factor factor particpates power dna transcription transcription therapeutic drug cause encode inhibitng fifteen acute syndrome expression gene gene inhibitor epigenetically jq human regulator decitabine decitabine activity malfunction brd brd protein methylating azacitidine 
2.0@cancer effect effect growth growth tend selective hypomethylation transferase inhibit adjust irreversibly particularly hypermethylation carefully tumor tumor normal epigenome genome genome high high express extent decitabine decitabine decitabine decitabine one suppressor patient therefore general cause toxic limit limit limit cancerous gene gene gene anti promoter prevent prevent unfortunately dna dna dna bind function affect inhibitor must silence due methylation methylation methylation methylation allow region dosage enough beneficial 
1.67@cancer growth formation tumour tumour cause cause agent metilation hypomethylation hypomethylation avoid island cpg apply dna act allow demethylating gene remove hypermethylation decitabine case supressor drug tissue 
0.67@cancer cancer cancer inhibitor although therefore action progress use drug drug drug myelodysplastic relatively low without replication replication best treat transferase fact syndrome dna dna dna dna dna irreversibly dose dose know bind specificity still affect affect bothnormal effect unclear mechanism normal aml due thus decitabine decitabine decitabine decitabine decitabine high work incorporate incorporate side active cell cell cell cell cell methyl probably 
1.0@suppressor impact expression inhibitor decebatine gene gene effect tumor tumor tumor supressor cause belong surround reduce anti hypermethyation dnmti 
1.33@dna epigenetic histone decrease decrease tumour tumour affect use inhibitor agent along deacetylase process hypermethylation demethylated decitabine decitabine solid level drug drug drug 
1.33@dacogen cancer cancer cancer growth advantage use use slow agent myelodysplastic change change change part part treat treat avoid histon allow demethylating tumor pattern pattern pattern supressors appearance cell cell tumour prevetion deacytilase one one dna dna dna dna dna successfully relate certain certain ie methyl group together kind syndrome least important sell inhibitor remove remove hand main methylation methylation methylation decitabine tha azzacitidine 
2.0@cancer inhibitor inhibitor class dnmt dnmt remove tumour tumour tumour stand mark mark since silence silence lead irreversibly get get get methylated enzyme proliferation mechanism affect affect hypermethylation degrade nucleoside methylation methylation demethylation cell cell control suppressor suppressor decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine specifically dependent cause epigenetic epigenetic epigenetic epigenetic seem drug analogue hemi lay lay exact anti know dna dna dna dna dna dna divide reverse reverse bind bind act target target gene gene rapidly effect induce induce belong replicate thus regulator ul ul daughter incorporate incorporate replication action action methyltransferase enzymatic 
1.67@mitotically cancer cancer cancer within may agent suppression see decitabane without change potential treat treat decrease tumour dna pass epigenome demethylating gene gene expression expression advantage block kill hypermethylation word methylation methylation possible cell cell removal removal use alter 
1.33@cancer cancer action regulation tumour drug agent agent stop subsequent process hypermethylation growth overall tomourogenesis transferase group lead dna dna dna speed call call decrease decrease decrease hyper demethylating inhibit hence hence belong ing methylation methylation decitabine decitabine decitabine gene suppressive form survival methyl 
2.0@cancer critical restore proportion use trap become analog dnmti hypomethylation hemimethylated inhibit significant cytosine strand strand inhibitor proliferation round affect neoplastic neoplastic may phosphorylation carbon much second good cell cell cell cell control decitabine decitabine substitute dependent lower substitution drug cause dose uptake result synthesis effect anti occur presence presence dna dna dna dna dna dna dna divide non hypo powerful least dnmts gene rapidly function induce place place cellular cellular demethylation nitrogen division replicate replicate methylation methylation methylation double case incorporate action differentiation full 
2.0@suppressor progress agent reactivate antitumor inhibit dna dna dna strand prevent syndrome demethylating gene aml effect tumor myelodisplastic silence new methylation decitabine decitabine decitabine epigenetically cell methyltransferase 
1.33@et reduce restore suppressor suppressor suppressor use mutation myelodysplastic reactivate sit exert inhibit inhibit incorporation subclass epigenetic sequence pyrimidine pyrimidine glycosyl source island island island proliferation impact tumor tumor santos aza neoplastic hypermethylation hypermethylation show fact nucleoside nucleoside cpg cpg cpg demethylation cell cell control control compound sensitivity cytidine cause patient therefore cdkn replication analogue analogue analogue conjugate md md apoptosis carbohydrate underlie promoter promoter promoter tumour dna antineoplastic reverse lyko syndrome expression drug gene gene gene gene chemical effect epigenetically methyltransferase methyltransferase deoxycytidine increase silence silence due thus al decitabine decitabine decitabine decitabine stresemann incorporate ink bank class 
2.0@multiple inhibitor growth dnmt dnmt regulation tumour tumour tumour cause inactivation result result result extra cancerous hypomethylation hypomethylation strong replication inhibit suppress generate dna dna dna bind bind function thereby gene gene methyltransferase impact undergo normal hypermethylation replicate allow operate express active cell cell cell repress decitabine 
1.67@cancer cancer cancer cancer class dnmt tumor methyl methyl mark mark since hypomethylation call inhibit onwards irreversibly strand body involve island effective hemimethylated nucleoside case maintainence cell cell cell cell cell cell drug tra dependent analogue therefore favorable replication replication certain incorporate type know transferase demethylation laydown dna dna dna dna dna dna divide kill bind syndrome act dnmts cpg rapidly inhibitor fe belong rase methylation methylation methylation decitabine decitabine decitabine lay myodisplastic 
2.0@et et higher growth growth methyl agent specific hypomethylation nevertheless transferase locus suppress cytosine epigenetic epigenetic promoter antimetabolite responsible thereby inhibit tumor tumor tumor mechanism mechanism mechanism nucleotide neoplastic neoplastic hypermethylation bond aberrant mund cell level expression suppressor promote therefore nonreversible relate drug analogue subsequent suppression result moreover anti anti methylation immune dna dna dna dna dose dose action covalent act dnmts dnmts believe effect dual dependant leone reversal silence al al decitabine gene gene gene incorporate form differentiation stimulation 
2.0@pronounce body cancer cancer inhibitor inhibitor restore slow stop mark since dnmti growth part change epigentic locus suppress benefit class area area decrease particularly allow island impact tumor tumor normal hypermethylation hypermethylation hypermethylation like like cell cell cell drug suppressor call spread inherit therapy around specific demethylate dna dna function function cpg gene methyltransferase effect replicate decitabine daughter return would would would would frequently 
2.0@cancer methylating restore dnmt synthesize may induce phase cycle apoptosis newly result critical hypomethylation hypomethylation replication inhibit dna dna dna dna divide rapidly act responsible enzyme inhibitor gene proliferation function upon methyltransferase cellular cellular normal phosphorylation directly incorporate active cell cell differentiation differentiation control decitabine decitabine 
0.67@cancer cancer cancer cancer article class term able epigenetically methyl inhibitor agent specific already myelogenous since breakthrough hypermethylated treat locus area area know discuss belong demethylating hypomethlyation precursor hypermethylation may may may genome genome genome although icrs counteract treatment use leukaemia one multiple multiple patient therefore epigenetic epigenetic relate decibatine drug drug drug drug region could proper anti element amount level group tumour repetitive dna epicentre epicentre reverse syndrome least function effect effect effect remove control contain provide epigenetics hypermethlyated would methylation limit normally circulation adverse 
1.33@cancer cancer cancer inhibitor inhibitor inhibitor specificity dnmt use leukemia fda mark myelodysplastic analog since hypomethylation susceptible genetic treat affect molecule lead irreversibly lesser see allow enter myeloid tumor tumor normal rase readily nucleoside small demethylation cell cell cell cell cell cell methyl tra suppressor set therefore replication cause strand decitabine target target result low regression treatment dna dna dna dna however dose acute bind syndrome fe expression gene methyltransferase effect upon stage stage increase replicate replicate thus thus methylation sequence daughter much activity widely approve death side require 
1.67@cancer inhibitor nucleoside effective replication replication analogue dependent process since dnaduring class irreversibly strand bind particularly dnmt dnmt mechanism copy belong methylation decitabine decitabine daughter incorporate action 
1.0@suppressor cancer cancer ctr patient tumor tumor use agent augment mechanism hypomethylating myelodysplastic hypomethylation hypomethylation treat decrease solid dna syndrome expression observe observe reduce induce sudden hypermethylation methylation methylation genome wide cell global independent decitabine decitabine 
1.33@myelodisplasic therefore dnmt progress use analogue fda depend chemotherapeutic action dna epigenetic epigenetic u bind syndrome act act dnmts still irreversible aml unclear mechanism regulator decitabine decitabine nucleoside alteration incorporate approve form replication machinery 
2.0@mitotically cancer silent class epigenetic hypermethylaton hypermethylaton cause agent pattern mark mark activity result transfer meet hypomethylation gene gene become heritable permit prevent dna dna dna dna dna dna transcriptionally area ase inhibit resume tumor tumor undergo normal antineoplastic belong convert dacitabine methylation methylation methylation directly aberrant aberrant incorporate triphosphate demethylation array drug drug suppressor suppressor decitabine decitabine 
1.67@one cancer cancer analogue nucleoside dnmt need state state die incorpporated heritable treatment dna dna irreversibly duplicate bind dnmts rapidly inhibitor turn keep hypermethylation replicate methylation decitabine decitabine daughter cell cell cell cell methyltransferase 
0.67@cancer methyltransferases abnormal way agent myelodysplastic growth make dosis normal normal nucleotide irreversibly strand tumour well demethylating specifity affect affect neoplastic release much case cell cell cell cell minor one large get fight need cause actually toxic lack effect effect anti dna dna dna dna dna however kill bind bind syndrome use drug time rapidly along upon copy replicate methylation methylation decitabine decitabine daughter incorporate come replication replication small 
1.67@cancer inhibitor faster term outcome produce produce progress use likely long correct inactivation entirely since dnmti dnmti growth drug drug drug drug effectively island epigenetic body think severely effective tumor normal neoplastic hypermethylation nucleoside affect affect affect demethylation cell cell cell cell may dependent cause cause patient however replication analogue know know low anti halt show dna dna dna dna divide dose syndrome syndrome syndrome myelodysplastic myelodysplastic myelodysplastic cpg poor aml effect effect dependant range death division replicate decitabine decitabine irreversible incorporate approve action methyltransferase methyltransferase 
2.0@cancer myeloid higher dnmt activate irreversively fda agent agent myelodysplastic break hypomethylates leukemia md molecular previously unknown epigenetic strand strand level level consider involve despite effective tumor tumor tumor tumor mechanism administration fact hypomethylate express demethylation cell food machinery one one suppressor suppressor consequently drug drug drug drug therapy describe low exact like solid promoter hypomethylated degradation dna dna dna dna dna dna dna dna however acute syndrome act still gene gene aml inhibitor inhibitor induce induce death silence authority methylation decitabine decitabine decitabine decitabine incorporate approve action methyltransferase methyltransferase 
1.33@myc myc cancer reduce class lymphoma dnmt regulation tumor tumor use slow could process two transcription since growth treat dhank inhibit nucleotide lead epigenetic strand involve human dr dr nearby happen demethlayates percent block block aza directly bond factor gsk express express cell cell cell cell cell way release team team discover discover cannot cannot replication cause myeloma encode discovery bradner common dna dna dna get bind act inhibitor inhibitor multiply methyltransferase effect jq deoxycytidine rapid belong replicate thus decitabine decitabine daughter daughter gene activity come brd incorperated 
1.67@cancer cancer cancer adenosine achieve restore phosphorylated others others others purpose applicated hmsh significantly bahar member cdh reactivate growth make make inhibit inhibit inhibit aza gastric team proliferation reduce tumor tumor tumor tumor affect affect kidney investigation express express treatment occurrence suppressor hypomethylation beta therefore drug analogue mouse md natural gadd become bladder bladder show prevent alleman dna dna dna dna cell cell cell cell contribution colorectal expression gene gene transplantation deoxycytidine deoxycytidine report report report vitro thus methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine possible kawakami recently 
1.67@methyltransferases higher class class use hematological likely specific inhibit inhibit analog malignancy dnmti rate hypermethylated treat island island suppress imply epigenetic decitabines inhibitor inhibitor group impact tumor tumor question normal dnmtis epigenome severely nucleoside cell cell cell cell cell try preleukemia indicate successfully irreversibly seem add target methyl know prevent prognosis dna dna bind syndrome name myelodysplastic cpg cpg poor methyltransferase effect effect belong replicate replicate thus thus methylation methylation methylation decitabine decitabine decitabine daughter daughter much incorporate 
2.0@cancer cancer cancer rate higher class dnmt progress use hematological fda exhibit specific silence anti since malignancy dnmti call island suppress epigenetic pass responsible enzyme inhibitor inhibitor observe tumor tumor tumor pattern normal hypermethylation hypermethylation hypermethylation myelodysplastic nucleoside nucleoside implicate like many cell cell cell cell demethylation tumour suppressor suppressor specifically dependent cause patient irreversibly replication replication replication analogue analogue result effect depletion type know compare example dna dna dna dna dna dna locus bind syndrome dnmts dnmts cpg aml aml function upon explain belong due thus methylation methylation decitabine decitabine decitabine decitabine decitabine daughter drive incorporate first approve tumorigenesis methyltransferase 
1.67@cancer cancer cancer instead class dnmt dnmt dnmt dnmt activate induce use fda mutation process phenomenon proliferate design methyation potential abnormally genetic transferase inhibit degradation cytosine reversible hyper hyper hyper especially unlike silence silence tumor worldwide formation bond exploit like cell cell cell methyl one suppressor lower nucleoside therefore divide relate methylates replication replication analogue dose trap therapeutic effect treatment dna dna dna dna dna dna get mark reverse reverse bind covalent act inhibitor drug drug azacytosine azacytosine azacytosine rapidly enzyme remove division thus methylation methylation methylation methylation methylation decitabine decitabine decitabine decitabine gene gene gene gene incorporate approve form dnmti 
2.0@cancer methyltransferases class use agent hypomethylating eisai design methyl methyl hypermethylated hypermethylated inhibit inhibit epigenetic allow demethylating fall take tumor inactive case japanese tumour tumour tumour deplete care transfer drug drug drug drug ability anti supress group company dna dna dna dna dna cell fe inhibitor gene gene gene hence hence effect supressor supressor supressor rase methylation decitabine activity activity active tra 
0.67@analoguethat dependent abnormalhypermethylation abnormal daughter dnmt dnmt use cancer cancer cancer cancer cancer dominate however mean thattheir hypomethylated nucleotide abnormally divide divide beneficialin cell cell cell cell cell decrease le division inhibitor adna rapidly effective hypermethylation hypermethylation due dilute sensitive mainly region bindsirreversibly case case decitabineis action methyltransferase inthe decitabine 
1.67@inhibitor restore cytocine state state make make also hypomethylation leukemia md md incorporation normal normal normal inhibit analogous define epigenetic epigenetic regulator silence become proliferation change tumor tumor tumor furthur swithced hypermethylation hypermethylation turn abbarently vital promotor role express cell cell cell cell cell cell cell control fate transcription suppresor cause toxic ultimate cancerous maintain anti type occur show etc dna dna dna dna frequency switch gene gene gene gene gene gene gene effect effect contain contain belong methylation methylation methylation decitabine decitabine decitabine region region class associate differentiation play 
1.33@cancer also activation use certain overexpressed stop myelodysplastic result result marker oncogene oncogene treat know inhibit inhibit aza dna dna dna syndrome act disease hypomethylated methyltransferase methyltransferase deoxycytidine hypermethylation hypermethylation epigenetics decitabine decitabine gene many 
1.67@different tendency cancer cancer dnmt dnmt dnmt dnmt may may attempt stop myelodysplastic myelodysplastic find frequently part make treat transferase inhibit nucleotide errantly strand methylate methylated methylated overmethylate chromosome happen due develop hypermethylation go ensure nucleoside capture methylation methylation cell cell cell use leukaemia suppressor let relate cause mutate mean free express become help methyl tumour though syndrome syndrome dna dna acute bind point gene similarity inhibitor division replicate replicate myelogenous material decitabine decitabine decitabine incorporate sufficiently 
1.0@dna dna dna dna cancer effect inhibition advance advance balance irreversibly remove use slow agent mark dnmti dnmti growth already anti bind test inhibit paste division division lung area copy methylated inhibitor hyper demethylating methyltransferase dnmts dnmts tumor tumor people permanently belong dependent mthylation methyltransferses decitabine decitabine work methylation methylation methylation cell cell attach azacitidine 
1.67@cancer cancer methyltransferases effective progress tumour bigger include mutation mutation specific md md md probably malignancy dnmti oncongenic generation quite drug inhibit nucleotide next irreversibly strand methyltransferase quicker quicker leukemia impact impact longer u neoplastic give release nucleoside scientist myeloid demethylation cell cell cell cell cell cell blood analogue erase epigenetic fda hematopoeitic cause whereby pas switch pertain low dosage anti know maximum treatment dna dna dna divide divide acute bind bind syndrome myelodysplastic consecutive gene aml effect methylations copy increase division replicate epigenetics methylation methylation decitabine decitabine decitabine decitabine decitabine daughter much approve kill acetylation 
1.67@dna epigenetic cancer inhibitor bind dnmt dnmt dnmt favourable state one unfavourable maintain alter decitabine decitabine decitabine 
2.0@suppressor cancer effect restore way add result frequently growth maintain promoter island previously expression dna dna dna dna divide strand particularly inhibitor function cpg gene methyltransferase methyltransferase methyltransferase reduce reduce tumor tumor pattern block normal division replicate silence methylation methylation methylation methylation decitabine decitabine daughter like sensitive cell cell cell cell drug drug tissue 
1.67@cancer inhibitor inhibitor inhibitor higher class class effective tumor methyl methyl fda agent hypomethylating myelodysplastic analog transfer dnmti sit increase transferase island epigenetic call especially inhibit inhibit intothe nucleoside promoter supressor supressor supressor one also also irreversibly concentration concentration drug therapy low ase show treatment dna dna dna dna bind syndrome act expression cpg gene gene gene hence effect effect upstream belong methylation methylation methylation decitabine region incorporate approve side 
2.0@reexpression genomewide restore cell methyl agent shore hypomethylating analog invasion possibly epression abnormal transferase island adduct class sustain promoter promoter pyrimidine silence silence demethylating demethylating demethylating demethylating proliferation proliferation reduce reduce tumor hypermethylation subclass control recover metastasis antimetabolite excessive drug drug drug drug production pathway suppression gene gene gene gene gene antitumor know dna dna dna reverse decrease decrease covalent function function regulatory irreversible effect cellular cpg cpg methylation decitabine decitabine decitabine accompany hormone form differentiation associate 
1.33@mean mean inhibitor tumour every incorporate dnmti hypomethylation transferase absence administer irreversibly enzyme mechanism dilution high passive cell methyl occurrence dna dna dna dna analogue nucleoside drug drug drug cause toxic lay result low yet anti occur show demethylation study however dose dose bind bind dnmts dnmts irreversible effect effect division due methylation methylation decitabine decitabine unravel action replication 
1.67@reason inhibitor think class reactivation produce epigenetically way unmethylated link hypomethylation leukemia treat lecture hypothemylation antitumor act important dna dna dna blood syndrome syndrome precursor enzyme enzyme enzyme deform gene methyltransferase effect tumor accord belong anticancer silence decitabine decitabine decitabine narrow bone mean cell myelodysplatic supressor 
2.0@suppressor cancer turn epigenetic start tumour tumour tumour tumour tumour mutate decitabine decitabine suppression result stop growth enable regulatory methyl normal normal group suppress suppress regulate dna dna dna divide divide divide pass help methyltransferase methyltransferase develop function inhibit resume inhibitor remove mechanism control division division longer methylation allow gene gene gene gene gene gene normally cell cell cell cell cell cell cell attach expression 
2.0@suppressor methyltransferases hypomethylation dnmt dnmt cannot analogue cause hypomethylating hypomethylating low phase growth effect effect decitibine inhibit inhibit suppress dna dna dna dna irreversibly irreversibly dose methylate bind bind inhibitor allow gene methyltransferase transcription tumor demethylation division since decitabine decitabine decitabine decitabine nucleoside active cell cell cell 
2.0@suppressor suppressor suppressor cancer slow tumor tumor tumor therefore progress island island promotors agent agent hypomethylates might inhibit inhibit cpg cpg treatment dna dna dna dna dna histone histone silence demethylating observe methyltransferase close protein hypermethylation hypermethylation methylation decitabine decitabine gene gene gene cell attach 
0.67@class fix expression inhibitor allow gene gene reduce reduce tumor tumor tumor deacetylase correct belong histone histone decitabine decitabine supression overmethylation overmethylation overmethylation prevent supressor supressor 
0.0@cancer think pregnancy clear n youd animal thalidomide thalidomide thalidomide de de de de de others generation harm statin next epigenetic epigenetic severe child association demonstration antibiotic people life give give intergenerational popular million million like offspring use pharmaceutical tra woman woman also demonstrably deleterious drug drug drug cause nothing today today complication yet prescribe bring lesson show show prevent experience later study identify miscarriage fluoroquinolone ssri effect effect effect effect effect reproductive frighten generational epigenetics epigenetics adverse adverse possible learn learn root expose tract would 
1.33@dna block methyltransferases decrease decrease expression inhibitor enzyme demethylating gene effect agent activation novo hypermethylation methylation de connect antitumor appropriate isdna decitabine 
2.0@suppressor suppressor inhibitor inhibitor inhibition activation methyl methyl cause irreversibly fashion reactivate aberration anti transferase transferase prevent dna dna dna dna dna epigenetic action action bind act enzyme drug gene gene gene gene dnmt tumor tumor tumor tumor dependant block affect affect silence due methylation methylation methylation decitabine decitabine daughter cell replication replication dnmti 
1.67@cancer inhibitor higher dnmt dnmt induce tumour agent agent nucleic hypomethylating two cytotoxicity dnmti hypomethylation part direct inhibition incorporation transferase molecule irreversibly even marrow efficient think demethylating stick close mechanism mechanism block release high cell cell methyl decitabine decitabine haemotological particulary efficiency patient whole via replication cause strand structural base activity activity result low could family dna dna dna dna dna dna syndrom dose dose dose bind bind integrate myelodysplastic still drug drug methyltransferase methyltransferase conformation unclear explain antineoplastic belong due methylation methylation rna bone copy malignancy active death 
0.0@aspect different cancer cancer think abnormal lymphoma tumor tumour process process process excite find find growth leave make treat might someday someone open epigenetic epigenetic show show lab reduce picture picture normal normal style fact align birdseed cell cell cell cell cell cell one also also drug information text gsk gsk natural focus anti lecture treatment study saw example name inhibitor inhibitor hop continue effect division division division new sort nearby another selection protein protein background 
1.67@mitotically cancer helpful way susceptible agent epicentre mark mark sit economist possibly make island counter demethylating reduce tumor tumor tumor round turn unexpectedly cell cell cell cell suppressor suppressor drug april subsequent cancerous show furthermore good dna dna divide reaction chemotherapy chemotherapy act cpg gene gene remove methylation methylation decitabine daughter mean th active alter 
1.67@different cancer methyltransferases negatively use mostly mutation idh myelodysplastic analog currently hypomethylation leukemia leukemia md md md md md inhibit inhibit inhibit dna dna dna dna dna patient demethylases disease thereby myeloid affect hypermethylation hypermethylation hypermethylation cover predictor prognosis prognosis promote decitabine decitabine decitabine promotion cytidine indicate therefore drug likely tet result reverse reverse lecture blow treatment treatment several lysine acute syndrome dnmts dnmts dnmts side effect effect induce methylation methylation ul ul worse full progression 
2.0@suppressor suppressor suppressor suppressor suppressor suppressor suppressor silent class able fight tumor tumor tumor tumor tumor tumor use slow ability decitabine decitabine decitabine methylate bring de growth growth growth unmethylated hypermethylated back inhibit inhibit stop dna dna dna dna away decitabines consequently expression inhibitor inevitably take impact remove hypermethylation hypermethylation due thus sort allow allow allow methylation methylation hypomethylates methyltransferase methyltransferase would would belong 
2.0@dna dna epigenetic oftumor inhibitor help help patient patient demethylating fight gene reduce agent promotor belong methylation decitabine growth region class demythylation suppressor lead 
2.0@suppressor suppressor effect effect greater class therefore dnmt tumour tumour tumour tumour tumour agent specific decitabine decitabine decitabine island lay result stop growth growth anti anti inhibition level inhibit cpg dna dna dna dna dna epigenetic expression inhibitor dnmts demethylating gene gene methyltransferase reduce reduce reduce reduce increase belong thus signal proliferative methylation methylation methylation mean enzyme may may associate 
2.0@cancer cancer cancer methyltransferases class lower dependend tumour mostly agent process myelodysplastic since dnmti susceptible susceptible genetic unresolved island lead open epigenetic epigenetic belong demethylating unlike effective mechanism affect dnmtis dnmtis hypermethylation high case demethylation cell cell however may dependent also nucleoside therefore therefore divide drug drug drug drug analogue cause mutation highly anti type toxic treatment dna dna intervention dose dose bind syndrome act inhibitor cpg irreversible chemical effect methyltransferase division decitabine decitabine rapidly 
2.0@suppressor cancer effect fully use system myelodysplastic result growth methyl immune lead suppress suppress unable dna transferase methylated syndrome treat inhibitor gene gene reduce reduce uncontrolled silence silence methylation methylation allow express cell cell cell tumour tumour tumour decitabine 
1.33@able able able supression methyl methyl cause compact agent place methlyation group group tumor tumor tumor dna dna area histone allow demethylating gene gene gene gene take remove remove supressor thereby silence decitabine work activity express express form methlation region 
2.0@dacogen drug leukaemia activate use drive agent agent acute hypomethylating myelodysplastic myelogenous dnmti deplation treat decrease inhibit suppress dna dna dna dna transferase syndrome sell demethylating gene tumor tumor tumor precursor hypermethylation clear thus methylation methylation methylation decitabine decitabine level mean tumorigenesis methyl sed supressor supressor 
1.67@net suppressor uncontrolably class epigenetic methyl cause agent scilencing mean mean since gene gene lation regulatory inhibit inhibit inhibit inhibit call prevent job properly dna dna dna dna dna dna divide expression le hyper demethylating group methyltransferase methyltransferase methyltransferase effect tumor tumor tumor tumor keep keep belong due methylation decitabine decitabine decitabine work lay express cell cell drug supressor 
2.0@heavy cancer cancer cannot cgis category enzymatic tumor methyl methyl process myelodysplastic analog dnmti drug transferase inhibit suppress molecule irreversibly inhibitor inhibitor disease fall effective sydrome normal egger usually go release nucleoside methylation methylation methylation methylation cell cell rapid recall machinery module module specifically specifically dependent transfer therefore epigenetic epigenetic epigenetic replication replication promotors non target bind prevent prevent prevent treatment dna dna dna divide mark mark group function cpg cpg gene aml dnmts dnmts existent awry division thus regulator decitabine decitabine decitabine work lay lay methyltransferase hit small 
1.33@dacogen cancer cancer cancer inhibitor change change lymphoma suppressor cell cell cell cell uncontrolled slow include agent stop stop though two myelogenous growth growth treat call erase erase might granddaughter epigenetic epigenetic epigenetic epigenetic pass therefore precursor silence demethylating grow people job whose myelodysplastic like japanese use kill leukaemia leukaemia lung cause advance successfully deploy methylates drug attmepts combination acute therapy approach result histone histone without solid tumour tumour tumour prevent reason company dna surround syndrome sell eisai gene gene rather effect notable deacetylase division thus actively decitabine decitabine daughter time first return form overactivity azacitidine 
1.67@cancer effect effect restore outcome hand hand myelodysplastic dnmti dnmti growth nucleotide class inhibitor contribute tumor tumor normal neoplastic hypermethylation release nucleoside cell cell cell cell control one suppressor hypomethylation hypomethylation hypomethylation analogue therefore divide replication cause result result anti bind bind dna dna dna dna get kill cytotoxic syndrome function cpg gene rapidly along upon copy death belong longer methylation decitabine decitabine daughter poor incorporate come methyltransferase methyltransferase methyltransferase prognostic associate 
2.0@suppressor cancer impact whichtumour tumour agent normalexpression dectibine hypomethylates hypermethylation surpressor surpressor anti type treat decrease inhibit cpg cpg dna dna dna dna dna dna reactived important demethylating island island methyltransferase effect theabnormal methylation methylation decitabine decitabine gene gene demethylation 
2.0@decline cancer cancer also restore lymphoma dnmt cancerthe use lower agent agent cause cell result histone ofchemotherapeutic silence change change gene gene division dose pass erase function demethylating adna allow tumor dramatic belong onduring thetumor actively decitabine decitabine somecases class original demethylation allowstherefore reverse suppressor suppressor 
2.0@cancer cancer inhibitor dnmt tumour appear agent agent myelodysplastic possibly md md md treat island island phenotype deploy strand demethylating hypermethylation nucleoside demethylation cystosine dependent patient cimp irreversibly replication replication analogue attempt appropriate result low loss anti prognosis dna dna dna dna dose bind syndrome dnmts dnmts cpg cpg poor methylator effect copy methylation methylation decitabine decitabine daughter possible incorporate methyltransferase associate 
1.0@dacogen cancer inhibitor inhibitor inhibition category term efficacy may fda agent agent stand long precise myelodysplastic md md md alone unknown unknown clinical irreversibly know metabolite well enzyme demethylating dnmt dnmt block block normal neoplastic give divide approval treatment trial tolerate belong belong market effective epigenetic combination chemotherapeutic anti anti show show syndrome dna dna process cell cell cell bind chemotherapy function rapidly effect effect remarkable division methylation decitabine decitabine decitabine decitabine decitabine decitabine method class action 
1.0@mean dependent transfer daughter daughter daughter dnmt dnmt dnmt much status decitabine decitabine irreversibly analog cannot normal nucleotide action etc dna dna dna divide strand get bind bind severely rapidly inhibitor tumor tumor additionally affect increase division replicate replicate since methylation methylation longer nucleoside incorporate cell cell cell cell copy release 
2.0@functionally cancer cancer cancer cancer abnormal restore restore restore reactivation use part agent agent hypomethylating anti growth note md decrease aza lead lead lead lead clinical status methylated methylated involve demethylating demethylating deoxycytosine tumor tumor tumor tumor tumor tumor normal normal hypermethylation metabolite myelodysplastic like many cell cell cell control expression suppressor suppressor suppressor suppressor suppressor suppressor also also patient certain structure decitabine decitabine decitabine activity activity cytosine anddecitabine derivative look better demethylation treatment abnormally process non syndrome function outcome gene gene gene gene gene gene important death division due rna work class sensitive 
2.0@cancer myeloid class within within dnmt dnmt mark myelodysplastic analog incorporate hypomethylation leukemia overall treat treat affect island island island molecule achieve cytosine epigenetic epigenetic strand strand strand strand promoter promoter methylated reduce reduce tumor tumor normal hypermethylation hypermethylation confine gene gene gene maintain replication one one suppressor suppressor patient erase erase irreversibly regain drug drug another inheritance actively success type level prevent dna dna dna dna acute bind syndrome circumstance dnmts dinucleotides change methyltransferase inhibitor global cpg cpg cpg cpg replicate thus unless decitabine decitabine decitabine decitabine daughter daughter methylation methylation methylation methylation activity associate associate 
1.33@mitotically cancer cancer cancer cancer inhibitor inhibitor dnmt dnmt dnmt dnmt methyl likely frequency process find meet hypermethylation ya heritable affect island suppress lead lead disruption pass methylated consequence cgi cgi cgi cgi tumor tumor tumor normal normal lack bind high like cell cell cell cell cell cell cell one suppressor suppressor suppressor dependent transfer activation general replication occurance describe hypomethyaltion type promoter dna dna divide mark mark ase act function cpg irreversible rapidly hyper methylation methylation methylation methylation inactiavation division division division ti new often decitabine decitabine decitabine decitabine gene gene gene mean various 
1.0@dna dna dna decitabina overmethylation demethylating methyltransferase enzyme tumor place revert agent hypomethylates take cell cell inhibit drug 
2.0@cancer restore methyl name agent cell cell cell change anti company group act act division dna epigenetic pass tell sell function demethylates take tumor normal epigenome decitabine like demethylation japanese drug drug drug 
2.0@cancer cancer cancer myeloid class dnmt dnmt dnmt dnmt progress use fda agent canno elucidate myelodysplastic analog hypomethylation leukemia affect island island epigenetic strand strand strand promoter silence silence demethylating adna reduce tumor tumor mechanism round normal release nucleoside longercopy cell cell cell may suppressor suppressor dna dna dna dna dna dependent irreversibly replication replication replication replication cause yet result actionis occur know presence several get acute bind bind syndrome act cpg cpg gene gene gene methyltransferase inhibitor inhibitor copy belong methylation methylation methylation methylation decitabine decitabine decitabine decitabine daughter daughter region incorporate approve action 
2.0@maybe cancer inhibitor inhibitor cgis class dnmt dnmt dnmt use agent agent phase consequentialloss hypomethylating malignancy frequently marker md epigentitic halt regulate irreversibly strand strand onto belong demethylating effective mechanism hypermethylation thus genome nucleoside demethylation cell cell cell tumour tumour suppressor suppressor dependent greater intergenic sincethey replication replication analogue analogue sincehypomethylation result across hypomethylationat replicatemore become element occur know prevent prevent repetitive dna dna dna dna dna dna precise mark bind decetabine expression drug gene gene gene effect unclear copy division division new methylation methylation methylation decitabine decitabine daughter region incorporate action would reactivate 
1.67@cytosine cancer cancer analogue inhibition drug drug cause low hypomethylation anti inhibit dna dna dna dna dose use inhitior gene gene chemical expression increase belong methylation decitabine nucleoside demethylation methyltransferase 
2.0@cancer cancer cancer cancer adhere roadblock dnmt hypomethylate use use fda disorder disorder stop stop myelodysplastic analog currently de part hypermethylated copy island class daughter belong able tumor tumor normal dir metabolic nucleoside instrumental treatment blood firmly live extend drug cause novo target configure opoptosis become damage lineage syndrome dna dna divide dose cell cell cell cell cell cell cell bind chemotherapy act expression cpg gene methyltransferase methyltransferase inhibitor inhibitor die creation approve quickly replicate new methylation decitabine decitabine decitabine decitabine ltr work return continue small 
1.67@cancer class progress use could myelodysplastic analog currently md treat transferase transferase inhibit nucleotide epigenetic epigenetic usage mt longer release nucleoside unless cell tumour drug drug drug replicative low dosage anti anti methyl methyl prevent dna dna dna dna dna dna dna get bind bind bind syndrome act act act isan hence aml inhibitor inhibitor inhibitor upon belong replicate thus thus methylation decitabine decitabine decitabine incorporate come methyltransferase methyltransferase replication 
1.67@unregulated cancer think class formation aka island island island add mark commonly sit call inhibit previously often epigenetic epigenetic effectively methylated responsible demethylating observe tumor tumor tumor block hypermethylation hypermethylation dilute genome factor maintain thereby replication decitabine decitabine decitabine suppressor suppressor transcription transcription transcription activation drug deactivate agent agent result result free without child region promoter promoter prevent dna dna dna dna dna hypomethylating cell cell cell bind act act act expression cpg cpg cpg cpg cpg gene gene gene gene gene methyltransferase inhibitor remove remove protein division find actively reenable methylation methylation methylation methylation enable methylating associate 
0.0@cancer inhibitor restore restore within within reactivation produce produce epigenetically way fda agent process md treatment growth direct call inhibit category chemical hypothemylation dnmt tumor tumor word normal normal anticancer myelodysplastic demethylation metabolism control supressor suppressor hypomethylation decitabinebelongs antimetabolite divide cause cause cause cell cell cell cell cell cell result synthesis number target damage damage syndrome dna dna dna hypomethylating substance substance reaction cytotoxic chemotherapy function gene gene rapidly effect effect induce interact cellular cellular death death silence interfere thus thus methylation decitabine decitabine decitabine work incorporate similar approve protein 
1.33@different vos inactivate dnmt dnmt use two analog cytotoxicity de hypomethylation hypomethylation hypomethylation ann overveld inhibit previously lead cytosine epigenetic epigenetic strand inhibitor enzyme van observe derive provoke mechanism bibliography myelodysplastic myelodysplastic nucleoside second cell cell cell first hematol drug drug drug drug cause development mutate gene bind dec treatment dna dna dna dna historical suppl syndrome syndrome act dnmts review methyltransferase effect deoxycytidine death decitabine decitabine decitabine possible incorporate differentiation reactivate 
2.0@methyltransferases class dnmt dnmt may potential require irreversible myelodysplastic malignancy islandsin incorporation decrease inhibit next cytosine covalent methylated hyper effective tumor tumor mechanism mechanism round hypermethylation association nucleoside reexpression drug drug drug drug drug cell cell pre belong one suppressor dependent cause patient replication replication analogue extent low cancerous anti occur treatment dna dna dna dna dna dna dna dose particullarly bind bind syndrome inhibitor cpg gene hence effect unclear intermediate elderly still replicate silence methylation methylation decitabine decitabine decitabine disorder possible incorporate form haematological leukemic 
0.33@cancer cancer lymphoma produce tumour cause include agent whose decitabine demethylating surround stop growth methyl group job dna histone enzyme ezh gene gene proliferation reduce tumor uncontrolled protein hypermethylation silence allow activity activity cell cell attach supressor 
2.0@cancer abnormal class reactivation use lock rich stem myelogenous hypermethylation incorporation call island treat treat treat irreversibly belong precursor give demethylating demethylating demethylating might might tumor tumor tumor tumor contribute myelodysplastic myelodysplastic nucleoside cell cell blood blood leukaemia suppressor suppressor methylating rise indicate cg replication analogue analogue agent agent white condition methyl promoter prevent dna dna dna dna dna get get bind bind syndrome syndrome dnmts dnmts cpg gene gene hence thereby thereby decitabine region incorporate granulocyte drive 
1.33@dna dna acute syndrome precursor demethylating use agent agent hypomethylating myelodysplastic myelogenous decitabine decitabine work treat inhibit methyltransferase leukaemia 
2.0@cancer cancer inhibitor class dnmt dnmt dnmt dnmt viable could functional make epigenetic well enzyme reduce tumor normal normal normal essential contribute capture cell cell cell cell cell cell cell drug genomic machinery also mouse require analogue stability decitabine decitabine target knockout though unwanted dna dna dna dna divide divide non non bind act dnmts rapidly effect obviously die must must increase division methylation methylation nuceloside incorporate incorporate incorporate survival methyltransferase dnmti 
2.0@hypermethylations dacogen cancer cannot low mitotically use every trasnferases agent really eisai myelogenous dnmti useful treat transferase inhibit heritable typical establish allow demethylating island tumor tumor tumor precursor capable hypermethylation like japanese may leukaemia suppressor suppressor therefore consequence drug cause cell cell cell acute inhibitor methyl methyl methyl group company dna dna dna dna divide dose reverse syndrome act myelodysplastic cpg sell demethylated effect remove time silence new methylation decitabine decitabine decitabine decitabine gene side mark 
1.67@cancer inhibitor thet dnmt replication replication manner dependent anywhere else frequently amount normal anologues dna dna divide copy bind bind act act dnmts irreversible methyltransferase reduce status affect longer since methylation methylation decitabine nucleoside incorporate come cell cell cell drug irrevesibly 
1.67@cancer cancer cancer article article epicenter class activate activate use use agent process switch economist growth growth treat affect inhibit suppress lead epigenetic dna dna dna generally demethylating demethylating island tumor tumor normal hypermethylation antibiotic may aberrant express cell cell myelodysplatic recover one suppressor suppressor uncontrollable drug drug drug retain actually publish describe describe cancerous methyl group treatment treatment several syndrome act act important cpg gene gene gene methyltransferase nature remove character belong decitabine decitabine hence 
1.67@cancer cancer cancer reduce change change tumour tumour slow slow agent hypomethylating myelodysplastic also hypomethylates frequently growth leukemia heritable inhibit clinical status precursor hypermethylation island activation tumor link case cell cell cell cell use use supressor one suppressor cause researcher epigenetic epigenetic recurrence drug drug drug certain moreover realize occur promoter treatment treatment dna dna already reverse syndrome epigeneticists cpg gene gene methyltransferase myelodysplasias silence thus decitabine daughter would 
1.33@dna dna dna get kill bind release inhibitor dnmt methyltransferase analogue stop decitabine longer cancerous hemi nucleoside incorporate methylated cell attract spread without 
2.0@cancer cancer cancer inhibitor abnormal class suppressor methyl methyl methyl appear agent therapeutic process insult dnmti say overall transferase transferase transferase inhibit benefit regulate effective irreversibly see methylated cumulative demethylating island island reduce tumor tumor mechanism block normal abnormality hypermethylation hypermethylation silence silence methylation decrease cell cell may may belong multiple therefore epigenetic mitotic drug drug drug certain novo target pass number underlie anti type type occur know knudson particular treatment dna mark reverse reverse bind act suppression cpg cpg gene effect effect division division due thus hypothesis decitabine tumorigenic profound de 
2.0@cancer class synthesize tumour tumour tumour agent aberrantly repressive inactivation myelogenous reactivate hypomethylation treat decrease grow epigenetic call call methylated precursor demethylating inhibit round dilute regulator cell cell removal use supressor suppressor therefore therefore divide failure replication cause result methylate stop gene gene become help presence dna dna dna dna dna dna dna hypomethylating mark mark acute syndrome newly drug myelodysplastic methyltransferase methyltransferase methyltransferase upon semiconservative silence longer methylation methylation methylation decitabine decitabine work active leukaemia protein 
2.0@normalize could apoptosis tumour agent cycle hypomethylating express express best previously dna dna divide allow demethylating gene inhibitor remove normal silence methylation decitabine dmnt mean case return return cell cell use supressor 
2.0@suppressor cancer transfer excessive methyl agent hypomethylating growth overall decrease decrease group dna dna dna level mediate inhibit methyltransferase tumor block contribute turn methylation decitabine decitabine gene action survival onto 
2.0@maximum glioma effective shall shall use slow likely specific specific long hypomethylating probably since since hypomethylates reactivate island act unknown irreversibly even therefore therefore silence tumoral tumoral tumoral tumoral inhibit impact tumor tumor tumor hypermethylation hypermethylation high frantic neuroblastoma cell cell cell cell drug drug drug reach one one greater patient year replication speed healthy healthy healthy local anti old show dna dna non non bind le colorectal dnmts cpg time side effect effect elderly preferably quicker replicate replicate replicate decitabine gene action adverse 
2.0@cancer cancer toxicity restore suppressor progress may may state fda island md md md since dnmti dnmti leukemia characterize effectively inhibit fully previously lead effective irreversibly inhibitor disease especially severely myeloid tumor mechanism normal hypermethylation hypermethylation myelodysplastic nucleoside demethylation cell cell cell specifically dependent also replication analogue low occur significance dna dna dna dose acute bind syndrome le dnmts cpg cpg affect aml function function methyltransferase replicate regulator decitabine decitabine decitabine decitabine decitabine gene incorporate action action action indication rapidly enzymatic 
0.0@chemical isused produce cause cause agent myelodysplastic result acute hypomethylates reaction treat inhibit inhibit damage damage dna dna dna dna dna dna strand synthesis syndrome precursor demethylating methyltransferase effect cellular death anticancer myelogenous decitabine decitabine decitabine decitabine incorporate cell protein leukaemia 
2.0@elod plastic cancer effect effect effect demethylates term dnmt dnmt use agent agent specific xml xml analog extremely hypomethylates response inconvenient hypermethylated affect inhibit nucleotide lead irreversibly strand sequence step en en en en well respond demethylating demethylating interest pattern secondary normal normal normal release cell cell cell cell tumour promoter anyway dependent patient therefore replication replication subsequent y u u u u idea chemotherapeutic introduce try long good treatment treatment dna dna dna dna dna lot bind syndrome inhibitor drug drug right methyltransferase enzyme lang lang lang lang aza deoxycytidine deacitabine deacitabine division longer methylation genome daughter copy 
0.67@one cancer overmethylation activate drug agent agent could promotor decitabile decitabile occur among dna around expression expression demethylating demethylating right reduce tumor tumor silence methylation methylation methylation gene gene gene gene gene another many supressor supressor 
2.0@cancer similarly restore reactivation produce say likely specific tend since reactivate growth leukemia direct oncogene demythlator inhibit treat amount possess traditional group reduce reduce tumor tumor tumor tumor tumor tumor normal assist may retain passive cell cell way suppressor suppressor cannot sense excessive excessive seem drug drug deactivate deactivate actually condition anti anti normally halt level level prevent demethylation treatment dna dna dna however methyl act function average specifically effect effect remove methyltransferase pre hypomethylator methylation methylation methylation methylation methylation decitabine decitabine daughter necessarily active form rather would would leukemic 
2.0@undesirable dnmt administration methyl add stop process myelodysplastic find tumorigenic hypermethylated avoid island recognize irreversibly strand hemimethylated help enzyme derive myeloid nucleoside cell cell drug drug drug food leukaemia stack outcome replication analogue cycle kill group myelodyplastic treatment dna dna acute syndrome syndrome cpg poor aml division new methylation decitabine decitabine incorporate approve prognostic 
1.33@cancer methyltransferases inhibition hypomethylation activate tumour cycle phase process analog uk action cellular growth growth adduct molecule cytosine involve early myeloid turn turn normal source convert late directly triphosphate cell cell cell cell cell cell cell use leukaemia cause cause suicide patient therefore activation regular certain structure structure ring appropriate apoptosis suppression condition ribose age joint prevent either emulate dna dna dna citidine acute act function prodrug suffer methyltransferase inhibitor stage stage death silence senescence decitabine decitabine decitabine gene gene incorporate return form would would 
2.0@cancer cancer inhibitor restore dnmt produce tumour tumour cycle methylating dnmti growth hypermethylated treat dmnt island nucleotide irreversibly strand methylated methylated demethylating inhibit reduce longer normal hypermethylation nucleoside factor passive cell cell cell checkpoint control region namely certain assume imprint replication analogue cause cause anti normally amount amount prevent demethylation dna dna dna dna dna dna dna divide segment bind still right methyltransferase effect remove deoxycytidine cpg replicate methylation decitabine decitabine gene incorporate enable 
2.0@suppressor suppressor cancer cancer noncancerous depend depend irreversibly use analogue agent myelodysplastic since reactivate direct prevent demethylation dna dna dna divide reverse bind syndrome dnmts demethylating rather effective tumor hypermethylation hypermethylation affect division thus dilute decitabine nucleoside incorporate methylation methylation approve cell cell cell rapidly replication 
1.67@suppressor suppressor formation remove cause cause agent silence demethylate occur prevent dna dna hypermethylation demethylating gene gene allow tumor tumor tumor tumor little thereby usually main methylation methylation methylation decitabine decitabine region region mean tumorigenesis expression expression 
2.0@suppressor cancer cancer inhibitor dnmt dnmt class therefore sensible remove drug drug drug deactivate dir healthy healthy tend island roughly reactivate unmethylated oncogene oncogene inhibition decrease inhibit often compare divide help daughter division cpg gene gene methyltransferase activation tumor hope belong methylation methylation decitabine decitabine ltr population maintain cell cell cell cell cell cell tumour 
0.67@cancer cancer instead therefore stronger analogue agent toxic correct azacytidine frequently hypomethylation bind bind prevent nucleotide dna dna irreversibly synthesis cytotoxic inhibitor dnmts dnmts effect due normal normal belong modification fact decitabine decitabine decitabine nucleoside devide incorporate influence cell cell cell cell 
2.0@mitotically cancer cancer cancer cancer impact impact impact last dnmt dnmt dnmt dnmt use agent since growth growth suppresor treat island island heritable irreversibly pass allow demethylating grow severe effective tumor tumor tumor tumor tumor normal normal hypermethylation hypermethylation reduce reduce reduce reduce demethylation cell cell cell cell suppressor expression dna dna dna dna also greater drug ability mean indefinitely type could prevent reduction divide bind act function cpg cpg gene gene rapidly inhibitor inhibitor thereby thereby thus methylation methylation methylation decitabine daughter create incorporate continue would would would 
2.0@cancer cannot also dnmt dnmt dnmt dnmt dnmt regulation much classify methyltransferases chance dnmti growth susceptible island lead irreversibly strand methylated silence silence interestingly reduce reduce replicate hypermethylation consequently release nucleoside maintain demethylation cell cell tumour tumour tumour suppressor suppressor dna dna dna dna dependent analogue therefore activation due replication replication carry activity anti prevent particular reduction get mitigate bind bind inhibitor drug gene gene gene effect effect effect upon copy cpg word since methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter region region incorporate 
1.67@cancer inhibitor able methyl agent analog hypomethylates dnmti exact bind affect inhibit action action unknown dna dna dna dna dna dna dna irreversibly get dependent tra fe demethylating severely methyltransferase effective effective tumor mechanism block normal believe hypermethylation replicate replicate rase decitabine nucleoside gene incorporate malignancy cell cell cell replication haematological supressor 
2.0@inhibitor higher higher class list tumour tumour agent phase hypomethylates inhibit lead belong demethylating dnmt replicate nucleoside demethylation cell cell cell cell cell firstly way decitabine decitabine decitabine suppressor cause cause replication analogue non non cycle highly low specific specific specific anti arrest dna dna dna dna dna repress dose dose dose bind expression gene gene gene chemical effect induce methyltransferase control death death death division due due methylation allow eg incorporate incorporate secondly 
1.67@cancer inhibitor inhibition hypomethylation dnmt dnmt dnmt may stop chromosomal since growth inhibit whereas methylate reduce tumor tumor tumor tumor tumor tumor tumor tumor hypermethylation genome instability suppressor globally dna dna dna dependent always general cause cause result phase phase anti anti anti occur genomic reduction example act gene effect effect effect effect location belong longer ifthe methylation methylation methylation decitabine decitabine decitabine decitabine wide context class 
1.67@one loss could essentially scientist use use unmethylated unmethylated include agent duo hypomethylating analog analog hypomethylates type direct inhibit inhibit inhibit inhibit locus globin globin cytosine flood strand see methylated methylated enzyme enzyme grow impact nucleoside express many cell cell cell cell distinguish compare cytidine beta beta residue mouse know hypothesize methylate normally occur show show treatment dna dna dna dna dna dna dna dna action integrate expression expression perform gene gene methyltransferase methyltransferase effect cellular examine experiment methylation methylation methylation methylation decitabine severely azacytidine azacytidine azacytidine azacytidine restriction chemical 
2.0@strain strain cancer inhibitor class class dnmt dnmt huge use use include two two dnmti dnmti make make treat epigenetic pass methylated methylated methylated silence silence mechanism affect usually myelodysplastic vidaza progress role role express cell cell cell cell tumour tumour one one suppressor divide fda drug drug drug drug case anti sure dna dna however however bind syndrome le le important irreversible aml effect belong mother mother go methylation methylation decitabine decitabine decitabine decitabine daughter daughter gene gene gene come approve 
2.0@mitotically cancer cancer methyltransferases growth growth target reactivation use use slow include agent agent stop hypomethylating hypomethylating myelodysplastic conjuction methylating hypomethylation treat normal grow heritable whereas effective epigenetic epigenetic body methylated tumour tumour inhibit property change change promoter mean mean damage tomour suppressor suppressor onto side side minimal regulate methyl kill kill dna dna also indiscriminately action fight fewer carry cause add cell cell cell cell loss histone without deacetylases become become show group compare chemotherapy chemotherapy lung divide dont syndrome bowel specifically effect effect effect hair line silence decitabine decitabine decitabine decitabine hypomethylated cpgs cpgs cpgs rapidly would 
2.0@cancer along restore tumour tumour agent shore analog growth hypermethylated inhibit promoter involve demethylating island reduce normal hypermethylation usually genome cell control level suppressor cytidine therapeutic hallmark divison condition demethylated anti show hypomethylated dna dna dna understand act name function cpg cpg gene gene effect effect methylation decitabine decitabine generate would 
2.0@allegedly methyltransferases inhibition depend dnmt dnmt seem tumour tumour certain agent inactivation analogue haem exert inhibit dna dna development help act function demethylating activelyenhance ological cpg methylation decitabine decitabine nucleoside gene gene action supressor 
2.0@dacogen cancer cancer myeloid term reactivation get use appear agent shore long hypomethylating analog hypomethylation hypomethylation leukemia poorly treat island island island molecule irreversibly strand methylate inhibit inhibit impact tumor mechanism nucleoside cell cell cell cell cell drug drug market suppressor greater divide divide general replication cause healthy fda know dna dna dna dna dna dna dna however acute bind bind act le cpg cpg cpg gene aml aml effect methyltransferase methyltransferase dnmt dnmt thus methylation methylation methylation decitabine decitabine decitabine decitabine daughter incorporate approve action rapidly 
1.67@myc regulation progress tumour tumour tumour tumour tumour system prove hypomethylating hypomethylating hypomethylates apply part hypermethylated hypermethylated exert call call inhibit suppress suppress clinical epigenetic disease block factor methylation try one transcription patient therefore activation include drug cause agent agent activity result encode suppressive group unusually dna dna dna gene effect jq regulator decitabine decitabine decitabine decitabine region region eventually brd protein associate 
1.0@dna suppressor histone restore restore demthylating function gene tumour inhibitor agent deacetylase belong thus normal decitabine growth work demethylation cell control 
1.0@suppressor cancer commonly call apc tumour tumour fhit cytidine agent hypomethylating analog de hypermethylated rassf genesare inhibit auto dna methylate correlate irreversible aml destruction let repair gene gene gene ink methyltransferase decitabine decitabine 
2.0@suppressor suppressor cancer cancer cancer instabilty greater depend stronger tumour tumour tumour tumour cause agent tend become silence demethylate type decitabinewill dna dna dna dna divide work cell cell cell cell cell help help well respond demethylating demethylating partly remove stage normal division fact methylation methylation methylation genome worsen active instance may may decitabine decitabine 
1.33@cancer cancer methyltransferases methyltransferases class methyl agent perfect mark two two cannot cannot frequently call inhibit epigenetic strand strand strand copy copy copy demethylating prevent prevent tumor grow affect cell cell cell cell cell cell drug helix helix helix decitabine decitabine one one dna dna dna dna dna dna dna also also block attach spread create create structure parent somatic split divide divide group expression gene rapidly methyltransferase chromatin new methylation methylation double double double daughter daughter daughter daughter em reproduction active full alter 
2.0@suppressor suppressor suppressor effect slow stop novo ofdna inhibitingdna inhibitingdna de growth rescue anti especially inhibit cpg promoter dna dna expression expression even tumorigenesis kind give demethylating island methyltransferase methyltransferase reduce reduce tumor tumor tumor tumor tumor tumor hypermethylation undergo fact methylation methylation decitabine region region otherwise cell level progression 
1.67@enzymatic cancer cancer inhibitor higher therefore dnmt use work place cell cell cell cell cell cell selective original worry copy prevent prevent somatic dna epigenetic epigenetic adult target drug mother rate pattern normal replicate new methylation methylation decitabine decitabine daughter daughter aberrant regulator sensitive period replication would would would would machinery 
2.0@cancer cannot class dnmt dnmt dnmt dnmt dna dna upon since malignancy hypomethylation nucleotide irreversibly irreversibly strand body effective tumor tumor affect hypermethylation release nucleoside cell cell cell cell deplete suppressor suppressor dependent dependent therapeutic solely replication replication analogue ability result result largely prevent reduction divide divide bind bind bind inhibitor gene rapidly effect induce copy belong replicate thus thus methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter daughter daughter daughter incorporate come action haematological 
1.33@compound cancer cancer cancer cancer inhibitor think hypomethylation use state likely specific process depletion growth growth change decrease partially act act class epigenetic epigenetic tumour belong inhibit inhibit metabolite metabolite metabolite case cell cell cell cell cell cell may earlier also therefore seem drug drug drug cause tumorous therapy toxic approach result stop attractive anti anti anti anti anti halt know presence dna dna dna dna dna however reverse chemotherapy least methyltransferase methyltransferase effect effect division division undergo new methylation methylation decitabine decitabine decitabine activity 
0.67@cancer cancer article standard last regulation tumour tumour tumour slow first agent agent stop epicentre felt growth growth make battle affect erase response class epigenetic epigenetic epigenetic epigenetic pass consider therefore belong demethylating unlike might change change change accord later good epigenetics routine cell cell cell cell cell trial way lung also patient successfully seem drug drug caner combination therapy kill without without solid show show show sensitive treatment treatment dna stag grand histone gene chemo chemo inhibitor time deacetylase division go actively decitabine daughter daughter em promise return form 
2.0@cancer inhibitor higher change change dnmt use dnmts mostly agent hypomethylating inactivation phenomenon phenomenon hypomethylation hypermethylated oncogene inhibit inhibit area strand promoter belong demethylating island take reduce tumor tumor pattern hypermethylation hypermethylation nucleoside level suppressor suppressor expression expression expression dna dna dna dna duplication aid aid promote get include analogue activity among several myeloplastic bind syndrome act function gene gene gene gene methyltransferase enzyme place gpc thing work decitabine decitabine create incorporate tumorigenesis 
1.33@cancer cancer methyltransferases genomewide neoplasm methionine use hematological sam lower change regulatory decrease sustain applicability promoter promoter variety enzyme inhibitor inhibitor biological serve key hypermethylation may reexpression attractive mtase methyl methyl transfer broad wide therapy toxic pathway approach low azacitidine antitumor know group family dna dna dna dna dna dna dna dna dna like dose dose adenosyl le function management gene gene methyltransferase methyltransferase effect cellular catalyze reversal silence methylation methylation methylation decitabine decitabine accompany efficacious donor associate 
1.67@dacoden cancer cancer cancer restore use slow agent myelodysplastic myelogenous reactivate growth treat epigentic unlike lead epigenetic reversible lose belong demethylating inhibit inhibit proliferation change tumor tumor tumor normal hypermethylation cell cell cell cell leukaemia compound suppressor state daugther drug drug drug drug mutation target suppresed uncontrollably revert group company dna divide japanese syndrome suitable sell succesfuly induce division methylation decitabine gene gene chemical 
2.0@market inhibitor disrupt produce use use agent pattern already already two myelogenous de hypomethylation hypomethylation leukemia decatabine hypermethylated hypermethylated tumour marrow lyse unknown cytosine methylated methylated precursor contribute demethylating inducedbythe tumor mechanism whichisa link thus repair silence thereby blood belong one one methylating suppresor tear activation drug target target condition acute anti among dna dna dna dna theb cell cell syndrome intreatment epigeneticallysuppressed methyltransferase effect myelodysplatic deform respectively methylation decitabine gene gene gene class exist 
2.0@cancer metastasis restore restore therefore dnmt dnmt mistake tend correct analog cdh dnmti hypermethylated make methylated level level locus particular particular dna dna dna dna strand cytidine act act site expression inhibit inhibit methyltransferase pattern bind inhibtors dilute release daughter gene mean mean methylation methylation methylation decitabine decitabine decitabine decitabine decitabine 
1.33@dacogen cancer patient suppressor suppressor aka uncontrolled agent product encode hypomethylation anti call inhibit inhibit reason lead lead lead dna dna dna dna methylated le silence demethylating gene gene gene proliferation effect effect effect tumor tumor tumor tumor methyltransferase hypermethylation may may thus methylation decitabine decitabine work cell cell protein would 
1.33@cancer classify myeodiplastic use fda susceptible make often irreversibly help observe take research tumor tumor tumor normal hypermethylation assume dnamethyltransferase may suppressor also seem drug drug drug drug syndrome target replication replication whenever treatment treatment dna dna dna cell cell cell bind chemotherapy inhibitor still gene rapidly effect effect place explain replicate decitabine decitabine incorporate strongly approve methyltransferase associate 
2.0@unregulated restore restore synthesize cycle cycle phase phase dnaand newly member hypomethylation inhibit inhibit regulate responsible enzyme demethylating tumor block normal thus mammalian cell cell cell cell cell cell cell control blockage decitabine suppressor suppressor suppressor methylating promote therefore drug activity result result whichincorporates become know peripherally dna dna dna dna dna dna act function gene gene gene methyltransferase methyltransferase inhibitor growth growth increase division division new methylation allow class specific progression 
1.0@cancer reduce cancel reset lymphoma uncontrolled agent mark mark animal silence silence growth overactively tumour tumour tumour normal inhibit epigentic culture enzyme demethylating lab lab impact test cure gsk cell cell cell cell cell cell inheritable may demythylating suppressor correct methylating identify promote future relate daugther drug drug drug mitoticaly purpose target hallmark without methylated among dna dna get non lot demonstrate syndrome myelodysplastic gene gene effect remove subsequntly set ezh ezh modification thus thus methylation methylation methylation decitabine decitabine nearby proliferation 
1.0@dacogen dacogen red think abnormal restore suppressor tumor use either manner agent decitabine decitabine white dethylation growth gene anti better aza treatment dna hypomethylating myelodysplsatic allow syndrome act platelet affect function function upon mechanism deoxycytidine normal interfere metabolite methylation accordingly production cell cell cell blood blood azacitidine 
0.67@unregulated cancer promote depend suppressor suppressor drug drug exposure agent agent pattern pattern process activity result chemotherapeutic growth become change show demethylation demethylation regulate regulate dna dna dna know expression expression belong gene gene gene gene effect tumor mechanism block increase division division turn new methylation methylation allow class sensitive cell cell cell cell blockage decitabine 
1.67@dna dna irreversibly malignant rate bind depend divinding inhibitor affect methyltransferase methyltransferase effect upon rapid nucleotide decitabine incorporate thedna cell cell drug drug replication replication 
2.0@effect effect higher class progress island fda find dnmti hypomethylation hypermethylated make quite treatmyeloblastic lead irreversibly body consider inhibit initial tumor mechanism though generally nucleoside side demethylation trial decitabine decitabine fortunately however candidate drug analogue toxic result low exact anti inmyeloblastic know good treatment dna dna dna dna get dose dose bind syndrome syndrome syndrome le inhibitor cpg aml myeloblastic molecular belong methylation ul ul incorporate approve methyltransferase 
1.67@mitotically cancer article away tumor use slow agent pas myelodysplastic actually effect effect overmethylation treat group group demethylation dna dna epigenetic methyl methyl syndrome function drug gene gene gene take provoke remove accord affect silence decitabine proliferation mean supresssor active cell antitumoral would would would without 
2.0@dna dna contain decrease cpg supression methyltransferase agent hypomethylating methylation decitabine decitabine hypermethylated inhibit degree island tumour would beneficial 
1.0@cancer cancer cancer think disrupt disrupt methyl methyl myelodysplastic find dnmti presence direct genetic call subsequently imply cytosine cytosine epigenetic class involve disease inmethylation prevent prevent damage generally genome nucleoside nucleoside name demethylation dnamethyltransferase compound transfer deleterious replication analogue foreign result error cancerous group particular treatment dna dna dna cell cell syndrome initially inhibitor upon effecoffer belong methylation decitabine decitabine decitabine daughter site incorporate malfunction approve action progression 
2.0@cancer methyltransferases inhibition growth use agent specific myelodysplastic hypomethylation treat inhibit lead lead cytosine development hyper demethylating island proliferation tumor tumor mechanism supressors cell genome previosly pathological activation cause apoptosis prevent prevent dna dna correspond syndrome expression cpg gene hence increase normalisation methylation methylation decitabine decitabine regulate supressor revival would 
2.0@reduce reduce contact therefore drug hypomethylation decrease decrease inhibit chain class dna dna dna dna epigenetic act inhibitor inhibitor proliferation impact tumor uncontrolled may methylation methylation methylation methylation decitabine decitabine high incorporate cell cell methyltransferase 
2.0@cancer baylin slow agent demthylation ul ul stephen growth tumour inhibit inhibit lead promoter enzyme enzyme demethylating tumor tumor people silence hopkins methyl belong suppressor suppressor run researcher combination baltimore result show dna dna dna dna medicine school histone fe advance gene gene methyltransferase inhibitor epigenetically john deacetylase lung rase decitabine decitabine decitabinereactivates recently azacitidine 
1.67@different different cancer receptive way way slow agent process switch switch growth make treat decrease might advance epigenetic epigenetic kind allow demethylating later affect metylation suseptible treatment treatment tumour tumour tumour pharmaceutical dna dna also patient patient namee use regular cause cell become become solid show show company lung harder histone chemotherapy sell drug drug drug gene inhibitor deacetylase due methylation decitabine decitabine work mean active alter azacitidine 
2.0@cancer inhibition dnmt dnmt dnmt dnmt use agent stop since apply normally transferase often status round hypermethylation may may release express many cell cell cell cell cell cell demethylation tumour expression methylating general replication mitosis result free number methyle particular dna dna reverse act dnmts dnmts dnmts gene gene inhibitor inhibitor supressor copy increase silence methylation methylation methylation decitabine decitabine decitabine work work work tumorigenesis associate associate 
2.0@suppressor suppressor suppressor lower therefore dnmt dnmt progress use use work fda myelodysplastic reactivate anti hypermethylated hypermethylated epimutation prevent treat dna dose reverse bind syndrome inhibitor drug gene gene gene aml effect tumor tumor tumor tumor demethylation increase silence methylation methylation decitabine create approve may small 
1.67@cancer methylating methylating disorder effective relate use agent myelodysplastic analog de leukemia type drug among inhibit inhibit common treatment dna maintenance hypo erroneous erroneous syndrome act expression thereby gene gene methyltransferase suppressant suppressant tumor tumor feature presumably silence methylation methylation allow cytidine cell blood decitabine decitabine 
1.67@blewitt cancer cancer inhibitor class enzymatic marnie use fda agent thank concept dnmti treat whereas epigenetic epigenetic development tumour evaluation video demethylating dr reduce epigenome epigenome outline nucleoside wish demethylation integration dna dna therefore irreversibly via drug drug drug drug analogue target anti type lecture several stag bind act additional cpg effect effect upon upon range emerge belong new regulator decitabine dmnt theory approve 
2.0@methyltransferases methyltransferases use agent mark mark myelodysplastic myelodysplastic remain cannot unmethylated treat inhibit inhibit recognize strand strand strand strand strand lose depend responsible silence demethylating hypomethylated tumor tumor tumor normal hypermethylation rase maintain cell cell cell methyl methyl methyl tra suppressor suppressor patient therefore seem add anti methylated group group dna dna dna dna dna dna syndrome syndrome fe gene gene effect template template division division division replicate new new new methylation methylation methylation methylation decitabine decitabine decitabine lay lay active action 
2.0@suppressor suppressor cancer cancer inhibitor growth growth erase spread certain include finally hypomethylation hypermethylated become unmethylating heritable promoter promoter lead lead lead dna dna dna epigenetic pass enhance silence hence methyltransferase effect tumor tumor dmt division modification methylation methylation decitabine decitabine daughter gene gene gene cell cell cell cell cell control 
1.33@dna nearby cancer effect effective thereby tumour reduce reduce agent normal demethylating treatment hypermethylation hypermthylation make case cell cell proliferation decitabine decitabine decitabine apparent 
1.33@genomewide use include include agent stem myelogenous hypomethylates tumorigenic change renew regulatory treat decrease inhibit response addition expression epigenetic precursor demethylating tumor tumor inhibition like cell leukaemia drug key pathway inhibitory trigger anti anti promoter subpopulation dna dna dna dna acute syndrome act myelodysplastic gene methyltransferase effect memory methylation decitabine decitabine accompany activity self 
1.67@dna suppressor suppressor suppressor cancer promotors expression cpg inhibit inhibit continue effect tumor tumor tumor tumor agent decitabine silence demethylating thus methylation allow anti island protein associate 
2.0@cancer class term dnmt dnmt unclear use use appear specific specific long myelodysplastic dnmti dnmti unsure drug transferase island previously irreversibly well consequence effective affect hypermethylation may high demethylation cell cell cell methyl nuceloside lower patient get replication analogue dose dose toxic target occur dna dna dna divide non bind syndrome still inhibitor upon range tolerate believe cpg replicate normal decitabine much incorporate hit 
2.0@heavy cancer also dacogen decitabine decitabine decitabine decitabine uncontrolled cause fda dependent whose agent silence myelodysplastic myelodysplastic myelodysplastic lower stop growth anti effective decrease island island job treatment dna dna reverse syndrome syndrome syndrome demthylating well cpg cpg poor effect tumor tumor know hypermethylation hypermethylation suppressor methylation methylation outcome gene approve cell prognostic ul ul 
1.67@cancer cancer cancer cannot class determine dnmt dnmt progress may fda myelodysplastic since dnmti dnmti dnmti hypomethylation rate useful inhibit nucleotide epigenetic strand inhibitor inhibitor silence island myeloid mechanism normal normal order release cell cell tumour tumour tumour leukaemia suppressor dependent dependent greater greater therefore therefore irreversibly irreversibly replication replication cause yet low progression amp amp dna dna dna dna however dose acute bind bind bind syndrome dnmts cpg gene aml effect upon methyltransferase methyltransferase enzymatic copy belong replicate methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter arrive incorporate approve action enable onto tissue 
2.0@cancer article dnmt dnmt much use use agent specific find malignancy de hypomethylation call inhibit traditionally involve inhibitor inhibitor demethylating mechanism affect neoplastic hypermethylation high specifc primarily tumour suppressor greater depend seem non novo result actual toxic anti level dna dna dna dna maintenance dose dose smaller dnmts dnmts dnmts dnmts still gene methyltransferase effect unclear alco methylation methylation decitabine em action haematological 
1.0@cancer myeloid reactivation produce epigenetically use reversion mutation myelodysplastic analog since de de treat recognize epigenetic inhibitor dnmt dnmt dnmt hypermethylation dilute nucleoside cell cycle tumour tumour leukaemia suppressor dependent methylating irreversibly relate decibatine decibatine replication replication agent apoptosis upregulation result result result cytosine anti revert syndrome dna dna dna dna dna acute bind degradation function gene gene gene gene gene methyltransferase effect induce silence silence due subsequent methylation methylation decitabine decitabine incorporate action associate 
2.0@reduction cancer methyltransferases restore suppressor suppressor suppressor suppressor imprint imprint tumour tumour tumour tumour tumour region agent could epicentre result result result th april effect anti hypermethylated promoter island dna dna dna dna expression use inhibitor demethylating control reduce activation normal cpg silence methylation methylation methylation icrs gene gene economist enable decitabine decitabine 
1.33@market dacogen suppressor suppressor regulation induce drug analogue fda agent already eisai result cytosine silence gene gene treat approve treatment dna dna epigenetic degradation le le sell disease demethylating myelodysplastic methyltransferase tumor tumor tumor methylations block syndrome hypermethylation morrow methylation decitabine decitabine disorder bone lay preleukemic active lead dntm dntm helpful 
2.0@suppressor growth methilation agent island hypomethylates silence hypomethylation gene gene change change promoter inhibit cpg together promote dna dna dna dna epigenetic additional demethylating prevent methyltransferase tumor tumor source thus methylation hypermethilated high region decitabine decitabine 
2.0@dna dna suppressor treat syndrome act myelodysplastic demethylating gene replication effect tumor probably cause hypermethylation usually demetylation ul ul inhibitor methyl transferase use 
2.0@one one dna dna cancer extend haematopoietic agent acute myelodysplastic myelogenous element anti type tumour among inhibit treatment hallmark specially syndrome precursor demethylating demethylating different effect intergenic hypermethylation methylation decitabine decitabine decitabine region region account approve repetitive take leukaemia 
1.67@cancer effect dnmt induce induce apoptosis two forcell low cytotoxicity hypomethylation hypomethylation anti hypermethylated reactivegene suppress dnamethyltransferase dna dna dna dna dna medicine dose dose synthesis inhibitor important gene proliferation reduce tumor whichis increase thus mechanismsunderlying decitabine decitabine decitabine high incorporate lead differentiation methyltransferase deplete expression 
1.33@cancer cancer classify class within produce use find malignancy succesfully substance decrease island component inhibit inhibit tumor normal metabolite hematologic cell cell cell cell cell supressor one dna dna also enzime consequently drug drug drug drug cause toxic type chemoterapy myelodyplastic antimetabolic treatment several dnamt syndrome act cpg gene methyltransferase interact similar death methylation methylation decitabine decitabine observe 
1.67@restore use transfer myelodysplastic transcription hypomethylates deoxycytidine hypomethylation hypomethylation incorporation inhibit inhibit inhibit aza onkaryotype sequence proliferation tumor normal may may nucleoside demethylation demethylation methyl decitabine decitabine decitabine decitabine suppressor cytidine cause cause replication analogue analogue normalization apoptosis result treatment dna dna dna dna dna dna dna dna ase syndrome function drug gene gene methyltransferase methyltransferase inhibitor cellular cellular control silence methylation rna rna incorporate influence differentiation differentiation chemical dnmti 
1.67@dna dna dna dna transferase bind restore inhibitor function methyl effect tumor normal belong result cancerous decitabine decitabine hypomethylation hypomethylation anti cell cell way opf class 
2.0@suppressor suppressor cytidine analogue therefore dnmt dnmt tumor tumor tumor replication cause result result hypomethylation gene gene gene anti promoter promoter inhibit inhibit methyltransferase methyled treatment dna dna dna dna dna maintenance responsible expression time chemical effect remove mechanism division division division methylation methylation methylation decitabine decitabine decitabine decitabine exploit incorporate demethylation demethylation cell cell cell repress 
2.0@cancer happen dnmt dnmt dnmt tumour tumour tumour fda whose process additionally negative hypermethylated hinder irreversibly development methylate enzyme especially impact due hypermethylation hypermethylation genome nucleoside many cell suppressor crucial specifically methylating promote drug analogue embed promoter prevent oftumour dna dna dna dna dna dna dna bind gene gene continue inhibitor silence longer thus methylation methylation methylation methylation decitabine decitabine decitabine daughter create mean come approve 
2.0@unregulated cancer restore able regulation relieve agent agent hypomethylating significantly since hypermethylated might converge island decrease methylated belong demethylating inhibit tumor tumor tumor tumor tumor fact genome genome many cell cell cell promoter promoter supressor suppressor suppressor suppressor drug drug drug drug cause cycle number become antitumor especially prevent dna base expression expression cpg gene gene gene gene methyltransferase effect division methylation methylation decitabine region come action 
2.0@strain cancer ul ul nd synthesize methyl dnmts agent aberrantly significantly replace myelogenous functional growth leukemia treat hemimethylated island island suppress decitabine decitabine decitabine decitabine expression cytosine increase strand methylated methyle precursor demethylating take able tumor tumor round convert carbon phosphorylated phosphorylated triphosphate demethylation cell cell use double atom atom reductase myelodysplastic drug cause subsequent apoptosis result acute shore anti arrest group presence dna dna dna dna dna dna synthesis synthesis syndrome newly cpg cpg gene effect remove replay nitrogen silence longer rna rna ribonucleotide incorporate incorporate form full 
2.0@cancer cancer cancer ethy class dnmt dnmt agent silence call inhibit inhibit suppress provide phenotype decrease decrease enzyme demethylating tumor tumor tumor turn affect usually na express suppressor suppressor suppressor also methylates drug drug cause result effect occur know treatment dna dna dna dna dna allow le expression expression gene gene gene gene gene inhibitor belong due main methylation methylation methylation methylation decitabine decitabine decitabine decitabine ransferase beneficial associate 
1.67@suppressor cancer class tumour remain growth counteract dna dna epigenetic allow demethylating gene inhibitor tumor belong silence methylation decitabine decitabine otherwise active thereby control would 
2.0@cancer change dnmt dnmt dnmt tumour tumour tumour tumour include could newly growth growth potential decrease island island dna dna dna dna dna patient epigenetic strand methylate allow disrupt mechanism permanently hypermethylation express many cell cell demethylation demethylation may one suppressor also researcher fda drug drug deactivate improve cause cause present encourage anti normally though outlook study divide maintain cpg cpg gene effect global longer methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine drive approve form would 
1.67@cancer dnmt rtl agent situation myelodysplastic inhibit inhibit irreversibly methylate disease especially island tumor tumor tumor normal hypermethylation hypermethylation hypermethylation style nucleoside right align hemymethaylated demethylation drug suppressor suppressor cause cause thats replication analogue dir text bring anti syndrome dna dna dna dna dna reverse bind example expression cpg gene effect enter silence methylation decitabine demathylase 
2.0@cancer cancer cancer inhibitor think demethylates dnmt excess use agent process remain growth treat mehtylation inhibit restore cytosine epigenetic decrease help enzyme unaffected optimal normal give turn crucial methylation methylation cell cell cell cell cell cell cell tumour one suppressor dependent also antimetabolite replication replication cause add product gene gene gene gene type methyl toxic group dna dna dna dna divide dose surround example example function drug drug drug affect affect effect control death actively decitabine decitabine work incorporate return 
2.0@cancer cancer inhibitor inhibition suppressor heritability process exhibit specific long repressive inhibit since impair tumorigenic growth hypermethylation consolidation decrease island restrict addition epigenetic see enzyme locus proliferation tumor due give icrs demethylation cell cell decitabine decitabine decitabine dna dna dna dna dna dna dna dna dependent mitotic require cause whose gain counter counter several maintenance mark histone histone expression function function cpg gene methyltransferase methyltransferase effect methylations range increase silence modification thus methylation methylation methylation methylation anti region activity activity lres 
1.0@dna inhibitor syndrome methyl effect cause antineoplastic myelodysplastic decitabine region hypermethylated transferase demethylates 
1.67@article article class lymphoma suppressor suppressor tumour tumour state manner agent hypermethylationto inhibit allowingthe development inhibitor refer ezh ezh nearby key normal hypermethylation hypermethylation hypermethylation turn isa decitabinereduce thereby allowsthe belong earlier hallmark subside drug drug cause cause describe describe reduceshistone number dna however histone histone histone thetumour expression gene gene resume enzyme similar demethylating silence methylation decitabine decitabine decitabine decitabine production return action action 
1.67@cannot cannot inhibition restore dnmt dnmt dnmt dnmt tumour tumour tumour tumour tumour anti hypomethylation normal inhibit class irreversibly methylated methylated inhibitor inhibitor silence severely able affect incoorporated cell cell control suppressor suppressor dependent therefore therefore epigenetic replication cause function result demethylated demethylated become become prevent dna dna dna dna however bind dnmts gene gene rapidly effect growth growth belong replicate methylation decitabine decitabine decitabine decitabine lay active expose methyltransferase 
1.67@inhibitor inhibitor class dnmt tumour enzyme enzyme meet dnmti growth overall refuse island act lead irreversibly work work methylate belong stick impact tumor intergenic hypermethylation hypermethylation go nucleoside nucleoside factor anymore like demethylation cell cell drug decitabine decitabine let transfer via via via require analogue ultimate cancerous enymes anti element element prevent repetitive dna dna dna dna dna dna dna divide ase bind bind bind overexpression cpg gene methyltransferase methyltransferase effect effect division thus methylation allow irreversible incorporate incorporate incorporate instance would would 
2.0@dacogen methyltransferases abnormal transform dnmt dnmt radiation use agent hypomethylating disease invincibility myelogenous growth treat aza expression expression epigenetic well attack control proliferation myeloid block normal myelodysplastic maintain meaninng treatment tumour tumour leukaemia suppressor unwanted formula mutate decitabine target unchecked better begin amp potentially dna dna dna dna mark blood cell cell cell cell chemotherapy sell dnmts gene gene gene resume inhibitor remove remove remove remove deoxycytidine syndrome silence methylation methylation methylation methylation methylation methylation allow chemical 
1.33@cancer height agent stop repressive functional decrease decrease inhibit decitabine decitabine decitabine epigenetic lose enzyme demethylating dnmt dnmt dnmt tumor tumor normal hypermethylation style genome regulator cell cell cell cell line heterochromatic euchromatic suppressor suppressor also relate replication replication replication replication replication dir could subsequent target dnmti dnmti dnmti express become dna dna non histone bind maintain maintain maintain drug gene gene gene gene gene methyltransferase inhibitor induce chromatin increase silence silence silence interfere methylation methylation methylation methylation methylation methylation methylation methylation follow ltr dmnt enzymatic associate associate 
1.33@cancer along think dnmt dnmt formation progress cycle cycle mark analog cannot dnmti part generation hypermethylated hypermethylated hypermethylated normal island next epigenetic strand pass allow thereby prevent prevent prevent tumor tumor tumor tumor affect nucleoside express cell cell cell control suppressor suppressor suppressor transfer necessary replication target halt parent treatment dna dna bind expression cpg gene gene gene gene gene methyltransferase inhibitor silence silence silence interfere methylation methylation decitabine decitabine decitabine decitabine incorporate come would 
1.33@suppressor tumor tumor replication cause cause stay agent preservation without demethylate methylated prevent dna dna dna dna dna dna dna cell help help demethylating gene methyltransferase methyltransferase remove essential hypermethylation longer methylation methylation decitabine decitabine production reproduce surpress tumorigenesis 
2.0@cancer cancer eliminate class state agent tend desregulation appearence malignancy treat decrease epigenetic malignant avoid avoid methylated allow demethylating tumor tumor transformation hypermethylation thus express cell cell cell cell suppressor suppressor cause cause cycle cycle mean promoter promoter promoter hypomethylated properly dna dna however expression gene gene gene gene hence inhibitor induce belong capable methylation methylation decitabine decitabine decitabine immortality would progression 
2.0@suppressor cytidine tumour tumour tumour chemically agent hypomethylating analog anti promoter island cpg dna dna dna dna act demethylating demethylating gene methyltransferase effect similar hypermethylation interfere inhibithing methylation decitabine region region incorporate cell azacitidine 
2.0@cancer code within activate methyl methyl state agent island suppress suppress open admimistration pack level disease demethylating tumor tumor tumor affect repair may transcription transcription transcription decitibine decitibine cause cause cause could could could likely loosley decitibines anti promoter group group dna dna dna effect bind example cpg gene gene gene gene gene enzyme remove remove chromatin chromatin increase increase increase silence thus methylation decitabine action would 
2.0@unregulated cancer restore restore misshapen produce produce use agent process myelodysplastic major growth treat marrow regulate regulate believe allow demethylating twofold tumor mechanism block normal anticancer thus count member demethylation demethylation cell cell cell cell cell cell cell way blockage decitabine decitabine decitabine one suppressor suppressor suppressor promote drug work healthy white activity result low low become know group platelet dna dna dna dna expression blood blood blood syndrome function gene gene gene gene side effect effect condition bone control increase division division interfere new methylation methylation methylation ul ul possible class growt enough 
1.33@cancer inhibitor inhibition dnmt dnmt dnmt dnmt use use agent agent replicate hypomethylating myelodysplastic analog since hypomethylates leukemia severilly treat nucleotide strand demethylating myeloid longer release nucleoside cell cell tumour tumour cytidine daughter replication analogue kill anti affacted dna dna dna dna dna get acute bind bind syndrome drug irreversible aml effect upon copy division dependent methylation decitabine decitabine method much incorporate form methyltransferase methyltransferase 
2.0@cancer cancer cancer cancer reduce class dnmt dnmt dnmt formation tumor preserve agent mark apply part call grow lead epigenetic strand methylate demythlation common responsible demethylating inhibit inhibit chromosome able methylatiing mechanism passive cell cell cell cell cell removal expression one failure drug methlyation methlyation methlyation result result involve dna dna dna dna dna function methyltransferase inhibitor inhibitor death methylation decitabine decitabine daughter daughter form indirectly would would 
1.67@methyltransferases restore dnmt n use agent newly hypomethylates de inhibit decitabine recognize epigenetic development methylate nameddnmt demethylating adna pattern myelodisplastic early express methyl methyl tra dna dna dna dna transcription residue presumably alteration embryo novo reverse cytosine cytosine promoter promoter group treatment something inhibitory act fe source allow remove set classic rase methylation sequence mainly gene downstream 
0.67@cancer dependend replication replication replication fda analog azacytidine dnmti dnmti inhibit nucleotide nucleotide division dna dna get bind bind function gene methyltransferase methyltransferase inhibitor inhibitor upon must belong decitabine decitabine nucleoside incorporate similar approve cell cell 
1.67@elod suppressor drug y activate use certain agent agent specific target overmethylated since growth growth demethylate methyl methyl tumour tumour group group regulate dna dna dna dna histone histone histone histone syndrome syndrome myelodysplastic demethylating demethylating inhibit plastic inhibitor remove methyltransferase belong silence silence decitabine decitabine decitabine gene gene gene gene role like cell regulation protein would expression expression expression expression 
2.0@suppressor suppressor cancer transfer transfer inhibition malignance depend use use hematological meet meet dnmti thy thy lead dna dna decrease decrease ase ase hypermethylation gene gene inhibitor tumor tumor belong methylation methylation decitabine decitabine decitabine reactive drug 
1.67@dacogen cancer carry higher slowly need analogue inhibitor inhibitor stop commonly already target rest effect effect tumour tumour copy island dnmts dnmts dnmts dnmts dna dna dna divide work bind site refer cpg methyltransferase methyltransferase rate normal methylation decitabine decitabine decitabine daughter create create cell cell cell cell cell cell cell cell nucelosides would 
1.33@suppressor cancer cancer analogue medication reactivation produce use cause citidine could apoptosis deoxynucleoside low hypomethylation hypomethylation treat inhibit dna dna dna consideration dose gene take methylases fact decitabine cell tumour follow 
0.0@stable dnmt dnmt dnmt formation tumor kinase kinase include deoxycytidine inactivation analog analog currently reactivate hypomethylation sit overall transferase inhibit strand decrease enzyme enzyme demethylating island monophosphate due inhibition inhibition complex complex phosphorylation phosphorylated aberrant triphosphate cell methyl market suppressor cytidine cytidine polymerase activation induction drug trap apoptosis natural bring dna dna dna dna dna dna dna dna dna dna non covalent dnmts cpg cpg gene gene inhibitor sufficient result result cellular contain enter senescence silence methylation methylation methylation methylation methylation decitabine decitabine decitabine difference region incorporate incorporate form form form 
2.0@suppressor cancer methylating patient therefore activate tumour tumour agent stem result growth effect anti overall amount better inhibit prevention dna dna dna stabilise gene methyltransferase reduce control methylation methylation allow hematopoietic cell cell may decitabine 
1.67@loss till tumour tumour state likely shore situation mark mark malignancy incorporatied hypermethylated decrease decrease inhibit lead lead irreversibly work inhibitor island island island tumor mechanism hypermethylation nucleoside reexpression cell may drive suppressor suppressor dependent also therefore however replication analogue reverse anti dnmts dnmts dna dna dna repressive repressive histone histone bind heterochromatin function cpg cpg cpg cpg gene gene methyltransferase effect unclear characterise ac ac increase silence methylation methylation decitabine decitabine decitabine decitabine region context active action would associate 
1.67@suppressor suppressor reduce decline may cause agent ability reactivation hypermethylation hypermethylation growth growth become regulate division demethylating time effect tumor block link methylation decitabine decitabine gene gene gene gene cancerous cell cell cell control expression 
2.0@inhibitor inhibition able activate tumour tumour tumour tumour tumour tumour tumour tumour cycle phase malignancy silence hypomethylation hypermethylated back inhibit irreversibly help generally dnmt dnmt dnmt dnmt dnmt due hypermethylation dilute repair nucleoside maintain maintain cell cell cell control belong suppressor suppressor suppressor suppressor divide replication replication replication analogue subsequent result anti properly dna dna dna dna dna dna dna dna maintenance maintenance progressively reverse bind expression expression expression function gene gene gene gene gene rapidly rapidly effect status status status increase division replicate replicate thus methylation methylation methylation methylation methylation decitabine decitabine decitabine dependency incorporate incorporate methyltransferase haematological 
2.0@mitotically inhibitor restore able tumor tumor tumor tumor may trait stop hypomethylating remain remain since choke island island unmethylated sit sit treat inhibit heritable heritable well silence grow proliferation put affect lack aberrant aberrant cell cell cell cell cell cell cell cell replication suppressor suppressor suppressor also also therefore spread progeny apoptosis demethylated free parent treatment treatment dna dna dna dna product product brake end gene gene gene gene methyltransferase methyltransferase methyltransferase effect induce cellular cpg cpg replicate thus thus methylation methylation methylation decitabine decitabine daughter daughter methyly activity remove would would 
1.67@suppressor cancer classify overmethylation excess tumor methyl cause cause agent could mutation effect anti tumour group protect dna dna epigenetic enzyme demethylating gene gene inhibitor remove silence silence thus methylation methylation reduce control decitabine decitabine 
1.0@cancer rate promote te drug slow agent shore loss frequently growth growth growth restrict level island island cpg dna dna see example overexpression expression demethylating gene gene reduce tumor result hypermethylation thus methylation decitabine cell cell 
1.67@mean cancer cancer inhibitor abnormal restore tumour process replace growth hypermethylated inhibit lead irreversibly promoter global well silence island island island island reduce tumor tumor tumor pattern normal hypermethylation hypermethylation hypermethylation may fact genome nucleoside nucleoside cell cell way expression one suppressor hypomethylation carcinogenesis prevalence replication analogue prevalent suppression fast anti type type show treatment dna dna dna get get bind bind epigenetic act dnmts cpg cpg cpg cpg gene gene effect vary great methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine another acquire would 
1.33@article demethylates use drug agent easier marker anti treat group suppress treatment dna dna epigenetic histone allow demethylating gene gene gene versus effect tumor tumor accord attach epigenome silence methylation decitabine decitabine possible express influence methyl expression 
2.0@cancer cancer reduce class dnmt dnmt dnmt formation tumour unmethylated agent skeptism acctions since since irrevesibly potential oncogene unmethylating inhibit inhibit suppress addition unable clinical strand sequence help demethylating group impact tumor tumor tumor nucleoside successful cpg like primarily trial methyl methyl supressor one suppressor conventional analogue hemi toxic hereby hereby target result result methylate therapy overexpression methylated methylated act act prevent though chemotherapy dna dna dna dna dna expression bind fe le inhibitor inhibitor dinucleotides gene gene effect systemic demethylation belong replicate rase decitabine decitabine decitabine region prove tra would would 
1.67@plastic perpetuation inhibitor od encounter use agent mark mark gal hypomethylation direct marrow act unable cytosine irreversibly strand strand strand methylate enzyme bone block produce effectively genome genome genome genome nucleoside case treatment treatment methyl ensure residue presumably replication replication analogue development throughout incorporate incorporate cancerous become prevent synthesise dna dna dna dna dna dna dna dna cell cell cell cell bind syndrome site newly methyltransferase methyltransferase methyltransferase true copy copy y replicate new methylation methylation decitabine decitabine decitabine decitabine daughter daughter daughter lay original form 
1.67@dna dna kill demethylates name hypermethylation cpg tumour agent stop mechanism already demethylating describe decitabine suggest doubt 
0.67@cancer inhibitor inhibitor deacetlyas lower others tumour tumour tumour mark reactivet acetyl transfer de hypomethylation activion island addition chages histon histon histon histon histon hypometylation inhibit preventind hypermethylation turn funxion funxion e one suppressor suppressor suppressor suppressor also imprint drug cause cause cause cause icr result result among prevent prevent prevent growt growt growt dna dna deacetlylas ase incloding cilencing cpg gene gene gene gene gene methyltransferase effect remove return return word silenc methylation methylation decitabine decitabine deaceetlylas active active acetylation acetylation 
1.67@specifically cancer methylating dnmt dnmt dnmt use drug inhibitor agent ie irreversibly myelodysplastic hypomethylation treat inhibit inhibit amount epigenetic dna dna dna dna dna divide divide disable cell cell cell cell bind syndrome act act administer demethylating gene gene target reduce methyltransferase methyltransferase dir dir dir affect affect division optimum methylation decitabine decitabine decitabine decitabine ltr ltr ltr demethylation thereby replication machinery 
2.0@one cancer cancer transfer transfer transfer abnormal epigenetic mitotic methyl methyl methyl carry agent decitabine hypomethylating newly newly newly strand associate prevent dna dna dna dna dna divide mark cell cell cell cell cell act enzyme inhibit inhibit heritability pattern pattern copy copy methylation methylation methylation crucial form form form parental 
2.0@cancer cancer cancer inhibitor term dnmt use agent specific long myelodysplastic analog incorporation island molecule unknown irreversibly depend demethylating effective effective tumor mechanism neoplastic hypermethylation hypermethylation hematologic nucleoside cell drug suppressor dependent also high therefore replication dose dose toxic low anti know prevent treatment dna dna dna non bind syndrome le cpg gene methyltransferase effect effect probably unaffected decitabine decitabine decitabine action action 
2.0@cancer cancer cancer along may silence become analog since dnmti sit dna dna dna dna dna dna lead lead lead lead irreversibly methylate contribute severely reduce tumor tumor tumor mechanism affect neoplastic hypermethylation hypermethylation nucleoside nucleoside actively demethylation cell cell cell try decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine suppressor suppressor divide divide replication anti anti promoter reduction however bind inhibitor cpg gene gene gene methyltransferase methyltransferase effect effect effect unclear still thus methylation allow work incorporate incorporate come action rapidly 
1.33@mitotically cancer inhibitor inhibitor inhibitor class dnmt dnmt dnmt dnmt dnmt dnmt dnmt use attempt myelodysplastic sit treat irreversibly strand body well reduce tumor tumor mechanism block hypermethylation establish inbititors like many cell cell cell cell cell cell passively specifically transfer epigenetic hallmark replication target maintain demethylate prevent dna dna dna dna dna dna dna divide divide bind syndrome inherit drug drug rapidly dnmts upon methyltransferase new methylation methylation methylation methylation methylation decitabine decitabine daughter incorporate active protein 
1.0@dna cancer histone demethylating demethylating prevent use agent protein silence decitabine gene treat group tumour supressor 
1.33@cancer cancer glioma term dnmt dnmt dnmt administration way every include exhibit exhibit long hypomethylating capable hypomethylation md inhibit inhibit inhibit phenotype phenotype irreversibly cimp cimp cimp inhibitor island island effective effective pattern normal life nucleoside case neuroblastoma cell myodysplastic replication compare methylating quality although therefore therefore use fda drug analogue could agent encourage bind extent minimal common dna dna carcinoma syndrome colorectal function function cpg cpg gene methyltransferase effect effect effect due find methylation methylation decitabine decitabine decitabine decitabine incorporate commonly approve side 
1.33@cancer cancer methyltransferases inhibition uncontrolled include agent stop myelodysplastic growth leukemia tumour tumour call inhibit job methylate enzyme enzyme enzyme demethylating proliferation reduce normal myeloid cell cell cell cell methyl suppressor transfer drug cause acute mutation surround whose become group family treatment dna dna dna dna histone syndrome gene gene methyltransferase effect overactive catalyze silence thus decitabine decitabine work nearby apparent 
1.33@decline overmethylation produce methyl agent process myelodysplastic myelogenous growth susceptible treat call inhibit epigenetic reversible precursor enzyme enzyme ezh ezh proliferation reduce uncontrolled like cell cell use leukaemia cause histone histone amount tumour group treatment dna dna intervention acute syndrome chemical overactive attach demethylating methylation decitabine activity protein dramatically 
2.0@suppressor cancer effect correspond tsgs tsgs dnmt tumour tumour certain inhibitor function activity loss dnmti hypermethylated anti import island cpg lead lead dna dna dna expression enhance methylated bind le enzyme drug group methyltransferase methyltransferase reduce increase belong thus allow underexpressed gene gene class case counteract cell methyl would decitabine decitabine decitabine 
1.67@important decline decline cancer pathogenesis inhibition dnmt dnmt dnmt regulation tumour tumour tumour include aberrantly myelodysplastic analog since malignancy reactivate leukemia block island nucleotide play cytosine epigenetic strand promoter silence severely detect mechanism key affect hypermethylation hematologic release nucleoside seem role cell cell way expression suppressor suppressor dependent also irreversibly general replication decitabine decitabine decitabine decitabine level progression treatment dna dna dna dna dna dna dna acute bind bind syndrome inhibitor cpg gene gene gene gene methyltransferase effect upon copy division division due myelogenous methylation methylation methylation methylation methylation longer daughter incorporate incorporate action associate 
2.0@dna cancer cancer cancer transfer upwith class specifically scientist drug cause om target amole bring aberration edge methylation change among ethyl figure define cut epigenetic level den kind tode gene as exclusive find al method come cell ula 
2.0@cancer cancer cancer cancer cancer cannot restore dnmt hassler use dnmts dnmts dnmts mutation suppression disease analog since de change change md md treat treat effectively island disruption regulate irreversibly strand copy inhibitor contribute severely tumor tumor pattern pattern affect abnormality hypermethylation turn myelodysplastic nucleoside recurrent like like cell cell cell cell cell cell cell may machinery drug regular epigenetic epigenetic epigenetic replication replication cause mutate novo selectively target target anti methylation methylation methylation methylation potentially dna dna dna dna divide reverse bind syndrome act function cpg rapidly effect upon probably suggest division replicate normal normal decitabine decitabine decitabine decitabine decitabine decitabine daughter incorporate methyltransferase methyltransferase 
2.0@mitotically methyltransferases class dnmt dnmt tumour tumour tumour tumour include build myelodysplastic currently reactivate treat inhibit passively lead irreversibly strand strand strand strand help help parent nucleoside cell cell trial may supressor one get variant demethylated trigger type solid prevent dna dna dna divide action bind bind syndrome drug drug drug gene rapidly along unclear copy copy copy methylation methylation methylation decitabine daughter daughter work reproduce come approve leukaemia design 
1.67@cancer cancer also class lower dnmt inpregnated tumour analogue dependent cause cause decitabine irreversibly strand susceptible make drug drug drug island cpg action dna dna dna dna epigenetic dose get bind syndrome inhibitor inhibitor myelodysplastic anti effect upon tranferases hypermethylation methylation allow nucleoside daughter case demethylation cell cell mehtyl replication replication belong 
2.0@cancer cannot dnmt disease use fda two hope leukemia decrease nucleotide degree cytosine strand well give group research tumor tumor normal effective may release although myeloid demethylation cell cell cell methyl american one also tolerate therapeutic replication replication carry cause side relatively kill healthy best occur prevent dna dna dose acute bind inhibitor right aml effect stage copy solid replicate methylation decitabine decitabine decitabine daughter work approve methyltransferase 
1.67@elod plastic cancer cancer cancer class lymphoma use slower agent deacethylases really phenomenon member functional leukemia make treat grow significant epigenetic epigenetic development demethylases demethylases precursor proliferation reduce affect leucemia high myeloide like like good cell cell cellular decitabine one dna dna dna also study drug drug drug drug iso add result low dosage present do occur show show show show day treatment reduction base every chemotherapy important gene gene demethylated syndroms silence azacitidie methylation sensitive promise deciptabine combine azacitidine 
0.67@dacogen cancer cancer cancer inhibitor cgis change cell cell cell cell cell use slow appear agent esc acethylation stem myelogenous growth enrich hypermethylated treat decrease decrease suppress epigenetic perm methylated ethylation demethylating heterocromatin people normal normal hypermethylation hypermethylation vidaza gene gene gene demethylation azacitidine azacitidine tumour tumour tumour tumour leukaemia suppressor dependent also suppresor advance successfully deploy drug region combination acute mutation precursor target histone histone acethylated depletion solid among dna dna dna form collaboration syndrome sell sell myelodysplastic time rate deacetylase increase lung modification methylation methylation methylation methylation decitabine wide context first tumorigenesis embrionic drive pcr 
2.0@suppressor transfer transfer class tumour tumour deme effect anti methyl thy group dna ase silence thereby prevent inhibitor block belong methylation methylation decitabine gene gene case express express onto 
1.67@suppressor effective class however methyl methyl analogue malignancy exact bind know inhibit dna dna dna dna irreversibly transferase group inhibitor hypermethylation drug drug drug gene effect tumor mechanism belong hematologic decitabine decitabine nucleoside incorporate methylation action may 
1.33@suppressor cancer cancer inhibitor nucleoside specificity tumour tumour stop stop unknownthis anti methyl transferase class dna divide divide action act pressor drug drug gene gene rapidly effect normal normal hypermethylation decitabine theyaffect cell cell cell cell may hit dnmti 
1.67@plastic elod cell abnormal use rea tot yn decitabine growth y drome 
1.33@mitotically cancer therefore dnmt uncontrolled transferease agent mark since growth anti heritable inhibit dna dna reverse bind function demethylating effect tumor pattern hypermethylation methylation decitabine work work lay stall methyl methyl azacitidine 
0.33@dna dna cancer analogue manner dependent agent reducedna ace reduction irreversibly bind capacity dnmts demethylating enhance normal division replicate methylation methylation incorporate cell cell nuceloside 
2.0@suppressor could impact think general general tumour agent specific specific decitabine hypomethylating growth anti promoter promoter inhibit dna dna dna example inhibitor drug drug drug drug gene gene gene gene methyltransferase effect tumor tumor generate hypermethylation turn induce genome methylation methylation methylation demethylation tissue relationship control exist associate 
2.0@suppressor suppressor suppressor cancer cancer fight via improve agent ability reverse become normally promoter suppress tumor tumor tumor body thus gene gene gene effect remove demethylation hypermethylation hypermethylaton methylation decitabine active 
0.67@myc myc decline cancer cancer cancer overmethylation regulation wrong tumour part system activity animal find comercial myelogenous treat treat treat call call inhibit amount epigenetic epigenetic jam culture common precursor institute nearby dr dramatically reduce block normal bradner dhanak go factor gsk second boston cell cell cell colleague leukaemia one surprisingly also farber understand posible drug cause acute crucially dana capable approach describe histone th encode isused show group laboratory dna however proliferation syndrome name name myelodysplastic gene effect treatment new regulator decitabine decitabine decitabine transcription work another brd apparent protein yield 
1.33@suppressor may may slow agent aberrantly result growth decrease inhibit dna dna dna divide rapidly function demethylating gene methyltransferase allow tumor tumor normal methylation decitabine decitabine decitabine cell repress expression 
1.0@specifically cancer faster daughter dnmt tumour analogue dependent decitabine decitabine mark target synthesis cytotoxicity dnmti hypomethylation replication replication replication bind drug prevent lead lead dna maintenance kill cytidine use dnmts dnmts provide continue inhibitor mechanism normal replicate methylation genome nucleoside incorporate cell cell cell may tissue 
1.33@inhibitor abnormal dnmt dnmt dnmt tumour agent dependant remain since unmethylated inhibit inhibit provide strand consequence demethylating replicate replicate normal clear aberrant cell cell cell cell much one transfer therefore therefore imprint need lgf old dna dna dna dna dna dna bind eliminate irreversible methyltransferase effect unmenthylated division probably new new methylation methylation decitabine daughter region pattern cpgs rapidly 
2.0@suppressor inhibition dnmt administration cycle decitabine diminish avoid lead dna dna act allow gene gene methyltransferase inhibitor tumor death hypermethylation silence methylation repair work cell control machinery 
1.67@suppressor could demethylates therefore reactivation regulation tumor tumour tumour agent stop cycle result reactivate growth anti inhibit dna dna dna divide demethylating gene methyltransferase effect epigenetically silence potency decitabine cell cell drug 
1.33@suppressor methylating class therefore epigenetically drug agent reactivate effect anti know dna function gene methyltransferase inhibitor tumor tumor belong vitro silence decitabine asdna 
1.33@cancer cancer cancer characteristic restore approximately agent myelodysplastic find de hypomethylation hypermethylated treat explain island island island island act act lead lead tumour tumour methylated responsible enzyme demethylating inhibit clear normal precursor usually rase behaviour cell cell cell methyl methyl promoter promoter promoter leukaemia transfer become use could property free underlie express anti anti show group dna dna dna dna acute syndrome fe expression cpg cpg cpg cpg cpg gene gene effect effect hand suggest keep catalyze due myelogenous methylation methylation methylation decitabine decitabine decitabine decitabine tra methylating 
2.0@dna dna suppressor inhibitor tumor syndrome treat silence gene use effect epigenetically methyltransferase contribute reactivate hypomethylation antitumor show myelodysplatic decitabine decitabine 
2.0@dna cancer discover dnmt activate way possible inhibitor agent myelodysplastic leukimia low meet hypermethylation regulatory act inhibit cpg cpg analogous normalize epigenetic cytosine syndrome precursor hyper demethylating gene specifically enzyme tumor droug droug belong ti silence methylation methylation reduce nucleoside hilum dosage active cell cell decitabine decitabine decitabine 
2.0@suppressor cancer cancer analogue suicide poptosis drug unwanted include cytidine apoptosis course make inhibit inhibit grow several dna dna dna commit bind site enzyme enzyme prevent prevent methyltransferase methyltransferase tumor belong silence silence methylation decitabine decitabine gene gene gene mean active cell cell cell protein 
1.33@proliferate inhibition restore induce may agent phase hypomethylating myelodysplastic leukamia meet hypomethylation hypomethylation regulatory affect inhibit lead lead enzyme proliferation myeloid normal neoplastic convert metabolic nucleoside substrate insensitive triphosphate treatment treatment way decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine cytidine also bond replication cause u adversely cycle cycle analogue acute specific anti bind protein methyltransferase methyltransferase syndrome dna dna dna dna dna dna dna dna divide non cell cell cell cell cell cell cell cell ase covalent act act function gene rapidly epigenetically relatively cellular control death silence europe rna rna transfer incorporate incorporate approve form differentiation chemical present 
2.0@suppressor cancer methyltransferases faster consequently tumour tumour tumour analogue analogue dependent aberrantly become become demethylated demethylated growth replication replication bind act prevent suppress dna dna dna dna irreversibly methylated particularly use silence inhibit inhibitor active affect hypermethylation replicate thus methylation methylation decitabine decitabine decitabine nucleoside nucleoside gene gene incorporate express counteract cell cell cell much 
1.67@inhibitor inhibition dnmt tumour agent hypomethylating myelodysplastic selective hypomethylation md md treat treat aza irreversibly usage severe demethylating tumor life potent demethylation demethylation use suppressor cytidine quality patient patient general replication analogue improve low anti show dna dna dose bind syndrome dnmts dnmts gene side effect effect induce dependant deoxycytidine longer hypermetylated decitabine decitabine decitabine decitabine decitabine decitabine incorporate survival 
2.0@cancer also restore excessive synthesize may novo hypomethylating result de gene anti overall might decrease prevent promoter promoter potentially dna dna dna dna dna strand various expression responsible enzyme inhibitor inhibit methyltransferase effect effect tumor tumor tumor silence due due thus methylation methylation methylation methylation decitabine decitabine region lead treatment level supressor supressor 
1.33@cancer methyltransferases large seem may agent actually hypomethylating hypomethylating counterintuitive problem part occur hinder suppress suppress suppress often dna dna naturally function function thereby gene gene gene allow allow tumor tumor tumor though decitabine decitabine work 
0.33@ean cancer gue dnmt tumour tumour concentration agent specific process myelodysplastic myelogenous overall transferase inhibit am lead epigenetic precursor wikipedia derive reduce block test blood hypermethylation high alo often methyl decitabine suppressor irreversibly replication combination non therapy toxic cell low inhibitor bind solid level good treatment dna dna dna divide dose histone acute syndrome target drug affect effect deacetylase demethylating methylation tid mainly drive incorporate approve action 
2.0@clinical cancer patient suppressor supression use analogue cytidine myelodysplastic result present cellsinhibits know methyltransferase treatment dna dna syndrome gene chemical inhibitor tumor tumor pro practice apoptotic methylation decitabine decitabine induction drug 
1.33@suppressor cancer activity activity restore get get trough use drug cycle myelodysplastic growth gene lose treat promoter inhibit inhibit inhibit dna dna dna dna dna maintenance methylated syndrome le function cpg island methyltransferase methyltransferase expression tumor symptom control division division consequently methylation decitabine possible hypomethylated demethylation cell cell cell cell enable 
2.0@et cancer methyltransferases dnmt dnmt use serine yan shore myelodysplastic analog reactivate growth leukemia hypermethylated island island island island act act irreversibly silence demethylating inhibit reduce reduce reduce tumor tumor hypermethylation hematologic genome nucleoside methylation methylation methylation cell may suppressor suppressor dependent also residue via replication incorporate vol treatment dna dna dna dna dna profile blood acute bind syndrome site inhibitor cpg cpg cpg cpg gene gene methyltransferase myeloid epigenetically globally especially thus thus al decitabine decitabine decitabine disorder wide activity active 
1.33@cancer inhibitor restore restore within dnmt produce produce use agent process member de de growth growth direct treat myelodisplastic class death regulate tumor normal anticancer thus cell cell cell cell way suppressor suppressor also antimetabolite drug cause target number prevent metabolism dna divide substance hypo cytotoxic cytotoxic syndrome function gene gene rapidly effect effect effect interact cellular control believe division interfere since methylation methylation methylation methylation decitabine decitabine work incorporate methylating 
1.33@rk afte class dnmt agent myelodysplastic tumo rpo diminish island rome well belong demethylating r rug rug rase rase release inhibito reve cell cell hype dependent longe rsibly thei synd methylt methylt analogue wo occu nuceloside ration rmethylation dna dna dna dna dna divide bind act dnmts anti befo effect effect cpg new methylation methylation decitabine decitabine decitabine inco ransfe ransfe 
1.0@suppressor class tumour tumour agent depletion island suppress bydepleting dna epigenetic act hypermethylation demethylating inhibitor calleddna cpg methylation decitabine drive tumorigenesis drug drug belong 
1.33@abnormal term dnmt dnmt methyl agent long mark charge myelogenous useful hypermethylated restrict myelodisplastic inhibit inhibit treat body young precursor disease disease demethylating decibitane decibitane affect hypermethylation celular cell cell leukaemia transfer enzime patient drug cause course specially prevent consequencies dna dna dna dna dna dna syndrom wich function side effect effect division replicate replicate methylation methylation decitabine strong action 
1.67@cancer cancer cancer dnmt dnmt dnmt dnmt activate use stop newly newly since growth precursor myelogenous treat affect inhibit suppress suppress suppress suppress molecule responsible enzyme thereby island island proliferation reduce reduce tumor tumor tumor tumor tumor tumor pattern normal normal hypermethylation new counteract cell cell cell cell cell cell cell cell repress leukaemia via drug drug drug drug cause cause apoptosis potentially dna dna dna divide divide divide acute bind syndrome myelodysplastic cpg cpg gene gene gene rapidly inhibitor die copy defect replicate thus thus thus methylation methylation methylation decitabine decitabine decitabine daughter work methyltransferase 
2.0@methyltransferases inhibition hollenbach dnmt dnmt tumour unmethylated process myelodysplastic transfer meet reactivate hypomethylation hypomethylation leukemia direct oncogene partially fully show methylated variety contribute island proliferation myeloid tumor tumor mechanism mechanism affect hypermethylation nucleoside treatment expression one suppressor dependent dependent cause become high plo replication analogue acute decitabine decitabine decitabine suppression result result low depletion ase antitumour immune damage syndrome dna dna dna dna dna dose dose cell cell cell bind mediate inhibitor cpg irreversible effect haematologic christman since sensitive disorder gene gene gene incorporate malignancy approve differentiation stimulation associate 
2.0@cancer cancer cancer cancer inhibitor inhibitor change causal tumor tumor tumor tumor may may may thereby agent agent silence silence silence myelodysplastic malignancy functional growth md epigenetic development reversible inappropriately common hyper hyper hyper hyper demethylating demethylating categorize normal methylated human relationship expression suppressor suppressor cure drug cause cause cause apoptosis cell relatively number ribose anti arrest group group dna dna dna dna dna deoxy reverse powerful syndrome function function gene gene gene gene gene target effect induce induce reversal belong due thus methylation methylation methylation methylation methylation decitabine decitabine decitabine hematopoietic incorporate progression eg tumorigenic 
1.33@suppressor methyl methyl cause cause strand island myelodysplastic low low de try transferase transferase prevent syndrome dna dna dna dna dna irreversibly dose dose kill bind involve cpg gene inhibitor tumor tumor copy hypermethylation replicate may methylation methylation methylation decitabine decitabine decitabine decitabine daughter incorporate cell replication 
2.0@hemotologic malignance lead ctr suppresor use platinum platinum require mylodysplastic ahypomethylated activity reverse cytotoxicity chemotherapeutic growth gene gene anti inhibition methyl epigenatic resistant syndrome dna aberrant aberrant transporter methylated methylated redused expression ly ly inhibit tranferase tumor tumor tumor tumor especially may may silence decitabine decitabine adent factor regulate cell cell propose copper reactivate 
2.0@cancer myelodisplasic higher dnmt use inhibitor agent specific hypomethylating growth growth leukemia hypermethylated restrict affect affect island cpg degree involve involve precursor silence demethylating myeloid tumor normal normal effectiveness contrary nucleoside high demethylation demethylation treatment treatment much reach cytidine greater greater promote replication replication analogue analogue overexpressed could toxic cell cell cell anti bind bind wouldnt wouldnt wouldnt point dna dna however dose dose dose acute dependent syndrome name dnmts drug drug irreversible aml effect effect effect suggest belong well decitabine decitabine gene gene incorporate faster organism 
2.0@cancer restore restore within within produce way process similar growth direct incorporation call decitabinealso category believe twofold tumor anticancer normal normal may may instability demethylation demethylation cell cell cell cell cell cell control one suppressor antimetabolite antimetabolite divide drug cause cause function structural target number bind methyl know damage metabolism dna dna dna dna dna get substance substance synthesis cytotoxic chemotherapy demethylase gene rapidly effect effect induce interact cellular death death belong belong interfere thus methylation decitabine work incorporate incorporate obstruct class 
1.33@cancer cancer cancer article inhibition tumour demethylating demethylating hypomethylates hypomethylation hypomethylation affect dna dna dna dna dna dna dna previously class class epigenetic epigenetic epigenetic provide proliferation impact tumor tumor tumor normal normal normal cell cell cell may suppressor suppressor suppressor dependent also analogue answer apoptosis reference anti normally process cytotoxic act function function gene gene gene gene methyltransferase interact cellular cellular antineoplastic belong belong methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine economist enable follow effect effect effect effect restore within use include agent agent epicentre growth direct direct hypermethylated treat island incorporation lead lead division inhibit question question epigenome phosphorylation nucleoside control identify antimetabolite drug cause cause restoration appropriate target result promoter metabolism several divide point expression cpg rapidly inhibitor inhibitor describe describe describe explain death silence senescence thus thus thus incorporate differentiation 
1.33@cancer methyltransferases methyltransferases dnmt manifest unclear yet inhibitor agent myelodysplastic emergence leukemia treat copy irreversibly strand tumour tumour tumour establish demethylating severely reduce mechanism affect neoplastic precursor possibility methylation demethylation cell cell way nucleoside dependent lower although therefore get replication analogue mean kill anti anti show show prevent dna dna dna dna dna divide dose acute bind syndrome use eliminate effect effect molecular myelogenuous division actively decitabine decitabine decitabine decitabine daughter incorporate upon action action action 
2.0@cancer inhibitor inhibitor reactivation epigenetically use use order agent myelodysplastic myelogenous dnmti dnmti hypomethylation treat affect irreversibly precursor silence demethylating observe dnmt dnmt normal link nucleoside nucleoside methylation demethylation cell cell tumour tumour leukaemia dependent cause high get consequence replication analogue toxic mean low anti know dna dna dna dna dna divide dose dose acute bind bind syndrome important drug drug drug gene rapidly effect upon copy division replicate induce decitabine decitabine decitabine severely incorporate come supressor methyltransferase 
2.0@suppressor suppressor cancer cancer effect restore sometimes use use agent specific result result result result result silence change change hypermethylated anti overall drug drug decrease decrease lead treatment dna dna dna promoter le expression expression expression expression demethylating island reduce tumor tumor tumor cpg thus methylation methylation decitabine decitabine gene gene gene gene gene cell may tissue 
1.33@suppressor suppressor cancer therefore use agent myelodysplastic result myelogenous hypomethylation leukemia demethylate treat show island cpg dna acute syndrome precursor allow demethylating gene gene gene expression tumor tumor widespread hypermethylation silence methylation decitabine decitabine decitabine region region region action promoter promoter promoter 
1.67@et cancer cancer randomize series uncontrolled concentration agent stop hypomethylating myelodysplastic tumour tumour inhibit lead lead epigenetic even outcome optimal normal hypermethylation may may may mitotically much instability methylation methylation cell cell use kind faster faster transfer iii patient drug improve result phase genomic study process mark reverse syndrome gene increase silence replicate al decitabine decitabine decitabine disorder incorporate 
2.0@suppressor cancer effect promote therefore dnmts inhibitor inhibitor target analog growth growth anti type restrict show island exert nucleus dna dna dna dna irreversibly strand level level bind daughter overexpression hypermethylation cpg gene gene gene methyltransferase methyltransferase methyltransferase reduce reduce tumor tumor division silence methylation methylation contribute nucleoside incorporate like cell hence would decitabine decitabine decitabine 
1.33@suppressor cancer decitabinealso restore antimetabolite divide regain use cause agent toxic myelodysplastic growth leukemia tumour show prevent action lead dna dna dna intervention methylate help help syndrome act think positive operation rapidly effect effect tumor methyltransferase block death demethylating treatment methylation methylation decitabine decitabine decitabine gene hypo cell cell cell control pharmaceutical 
2.0@inhibitor class dnmt use appear alteration silence significantly malignancy dnmti dnmti dnmti hypomethylation hypomethylation direct exert affect inhibit inhibit incorporation achieve epigenetic well disease myelodysplatic island proliferation reduce tumor tumor mode normal neoplastic hypermethylation apoptotic phosphorylation hematologic genome induction define synthesis yet promote suppressor suppressor dependent patient action concentration replication cause restoration toxic apoptosis highly reverse without exact gene gene gene completely know cpg syndrome dna dna dna dna dna divide cell cell death function drug drug haematologic side effect epigenetically methyltransferase cellular control antineoplastic antineoplastic belong vitro thus decitabine decitabine em influence associate differentiation rapidly reactivate 
2.0@mitotically dependent change decitabine tumor tumor alteration mutation actually initiation process replace reversible hypomethylates without hypomethylation genetic genetic heritable could could inhibit suppress lead lead dna dna dna dna epigenetic kill responsible enzyme enzyme drug drug gene methyltransferase expression elimiate methylations division modification methylation pharmaceutical manipulation contrary cell asdna would progression 
2.0@elod plastic proliferate dnmt dnmt use um fda genic impair dnmti generation treat island irreversibly strand preclude methylaion substantially tumor tumor tumor optimum genome aberrant like cell cell suppressor dependent basis abate replication analogue dose subsequent subsequent property cancerous ultimately maintain specially later dna dna dna dna base bind syndrome dnmts cpg gene inhibitor oft y methylation methylation decitabine decitabine decitabine decitabine wide incorporate approve 
1.33@momparler activate kinase state concentration agent phase hypomethylationby process inactivation analog reactivate hypomethylation incorporation call inhibit methylcytosine lead enzyme tumor aza formation bond aberrant decitabineis cell itpromotes discover drug azacytosine photophosphorylation result low specific obsereved company decitabineor treatment dna dna dna dna dna dna ring japanese covalent eisai prodrug gene methyltransferase place deoxycytidine deoxycytidine deoxycytidine antineoplastic end due silence methylation decitabine decitabine decitabine decitabine sensitive action leukemic 
1.67@cancer restore use drug drug agent mean growth might know island suppress class dna act demthylating demethylating gene chromosome reduce disrupt pattern normal belong methylation methylation decitabine cpg cell tumour tumour example 
2.0@suppressor suppressor cancer inhibitor class activate tumor tumor methyl extent mark since silence associate island dna dna dna epigenetic reverse demethylase cpg gene reduce remove hypermethylation hypermethylation thus thus methylation decitabine decitabine decitabine lay enzyme cell machinery use belong 
1.33@cancer outcome use slow agent agent stop betterresponses also also de apply apply possibly make back treat treat open area even level level methylated methylated demethylating demethylating tumor people normal normal thus withdecitabine otherwise cell option may decitabine leave methylating patient could result low bring help look show good orother treatment dna dna dna dna kill death death strip methylation methylation methylation expect possible conventional 
2.0@cancer cancer cancer methyltransferases growth stimulation use agent suppression tend myelodysplastic analog analog hypomethylation hypomethylation hypomethylation sit overall treat island island molecule molecule cytosine cytosine cytosine epigenetic strand strand decitabines tumor tumor mechanism mechanism block block normal hypermethylation genome replace cell cell cell cell cell pre promoter promoter expression substitute suppressor general need decitabine decitabine proper hallmark ultimately occur immune hypomethylated hypomethylated dna dna dna divide divide action bind bind syndrome act important cpg cpg gene dnmts dnmts result copy new new newly stereochemically differentiation natural associate 
2.0@suppressor suppressor suppressor dependent dependent faster therefore irreversibly induce use agent myelodysplastic myelogenous hypomethylates hypermethylation hypermethylation replication treat affect inhibit dna dna dna dna dna dna divide acute bind syndrome precursor dnmts cpg island methyltransferase tumor tumor tumor tumor tumor mean normal demethylating especially decitabine decitabine decitabine gene gene incorporate malignancy demethylation demethylation cell cell cell much haematological leukaemia 
1.33@cancer inhibitor dnmt dnmt behave upon appear agent process analog since malignancy avoid belong irreversivily tumor tumor mechanism affect hypermethylation nucleoside implicate like like cell cell drug enzym supressor enzymatic therefore replication replication incorporate exact anti specially group neverthless dna dna get bind act act still gene effect unclear demethylating regulator decitabine multiply activity come action haematological 
1.0@loss drug drug agent stop myelodysplastic growth anti oncogene treat could inhibit inhibit inhibit potentially dna epigenetic tumour syndrome expression expression expression demethylating gene gene effect methylation decitabine decitabine decitabine factor use would 
1.67@heavy cancer inhibitor dnmt dnmt may may fda week myelodysplastic md md drug drug affect island nucleotide irreversibly strand severely tumor mechanism normal hypermethylation divide release nucleoside factor demethylation cell cell cell chemotherapeutics control machinery reason dependent also daughter epigenetic epigenetic replication analogue target anti approve treatment dna dna dna get get bind bind syndrome expression cpg poor rapidly effect upon methyltransferase copy division replicate meyhylation decitabine decitabine decitabine cant gene incorporate active action action aml prognostic 
0.33@myc myc myc myc myc class medication regulation state system agent agent two block growth leukemia inhibit suppress suppress significant involve refer demethylating demethylating myeloid tumor question myelodysplastic factor belong one transcription appear appear appear appear drug ability slow shut cancerous number know approve treatment dna dna dna acute syndrome expression gene gene gene gene gene important human regulator decitabine activity activity heterogenetic brd indirectly 
1.33@several cancer methyltransferases promote therefore tumor drug decitabine decitabine growth potential back inhibit dna dna dna hipomethylation hipomethylation hypermethylation gene effect induce induce supressor division rely silence methylation pathologically turn mean demethylation cell alter machinery 
2.0@growth suppressor reduce tsgs therefore activation tumour tumour tumour agent hypomethylating limit result hypomethylation hypomethylation anti class dna allow gene effect widespread normal belong decitabine may 
2.0@dna dna suppressor suppressor suppressor suppressor loss inhibitor le belong gene gene gene tumour tumour tumour tumour dnmt cancer cause cause cause increase hypermethylation hypermethylation decitabine decitabine accompany demethylation demethylation expression expression 
2.0@cancer cancer class class tumor tumor tumor methyl methyl fda work work alteration already malignancy dnmti growth treat transferase transferase island suppress molecule epigenetic epigenetic strand call call help inhibit inhibit reduce reduce put permanently hypermethylation hypermethylation hypermethylation continually failure express many treatment way pharmaceutical machinery one one suppressor suppressor also via replication cause cause target target present normally promoter prevent develop company dna dna dna dna divide divide cell cell cell cell bind dnmts dnmts drug drug drug gene gene inhibitor inhibitor remove copy cpg thus methylation methylation decitabine decitabine decitabine decitabine daughter em approve enable small 
2.0@cancer inhibitor class effective relieve partly already member dnmti inhibit cytosine epigenetic putative island reduce tumor tumor hypermethylation hypermethylation proliferative nucleoside constitutively cell cell cell cell methyl suppressor residue irreversibly analogue progeny target anti amount promoter group dna dna dna bind act cpg methyltransferase effect effect remove silence replicate thus methylation decitabine decitabine region incorporate 
2.0@suppressor cancer inhibitor dnmt activate use specific revert island underlie affect prevent treatment dna divide divide cell cell le belong cpg gene gene methyltransferase enzyme block normal hypermethylation methylation decitabine decitabine although harmful tumour tissue 
1.33@dacogen cancer inhibitor available order disease use agent eisai myelogenous hypomethylates leukemia japanese tumour tumour call call island island island back epigenetic epigenetic promoter methylated precursor hyper demethylating demethylating inhibit methyltransferaseacts ion hypo manufacture treatment blood pharmaceutical market mode mode patient drug cause anti methyl methyl show group myelodyplastic myelodyplastic myelodyplastic company dna dna dna acute syndrome syndrome act cpg cpg cpg gene effect remove remove remove methylations similar word decitabine decitabine decitabine come return action action 
1.0@cancer term dnmt dnmt dnmt seven use viable agent long process myelodysplastic analog myelogenous economist leukemia incorporation genetic treat fastest act june unknown unknown epigenetic reversible slowly precursor enzyme demethylating inhibit effective tumor tumor mechanism normal mutation may week nucleoside case demethylation demethylation demethylation cell cell cell cell control level expression unlike compare also therefore therapeutic epimutations epicentre therapy toxic approach relatively low th april occur lecture methyltransferase video dna dna dna dna dna divide divide dose acute bind syndrome besides target drug drug gene specifically effect die catalyze division thus methylation decitabine decitabine action rapidly 
2.0@important cancer methyltransferases dnmt dnmt activate tumor tumor tumor hematological agent rd analog since economist dnmti dnmti dnmti inhibit precisely lead irreversibly nonspecific inhibitor inhibitor think demethylating demethylating observe optimal affect expression hypermethylation consideration high st demethylation cell cell cell decitabine decitabine suppressor suppressor dependent anucleoside depend get seem replication toxic incorporate describe low dosage anti type level article dna dna dna dna dna divide dose bind point thus gene gene rapidly effect effect effect must replicate constantly methylation learn work mean malignancy malignancy hence study yield 
1.33@cancer cannot higher dnmt dnmt dnmt use transfer proliferate meet leave tumour affect inhibit work severe methylated methylated way replicate normal lack nucleoside instability demethylation cell cell cell cell methyl region lower need analogue strand reproduce anti bind bind bind level group genomic dna dna dna dna dna dna dna ase capacity inhibitor inhibitor drug drug drug rapidly effect effect death longer since since methylation decitabine decitabine decitabine decitabine drive incorporate irreversibility replication 
2.0@suppressor cancer cancer inhibitor inhibition therefore activate replication cause agent aberrantly trap cr cr depletion analog growth derivative grow aza aza decitabine decitabine decitabine lead dna dna dna dna dna dna dna get dexoy demethylating inhibit methyltransferase reduce tumor tumor silence methylation methylation methylation inside nucleoside gene incorporate cell cell cell rapidly onto azacitidine 
2.0@cancer inhibitor class dnmt dnmt dnmt methyl methyl agent analog azacytidine must transferase transferase inhibit cytosine cytosine irreversibly call component belong island island order tumor tumor affect release express many cell cell cell cell decitabine decitabine decitabine decitabine decitabine substitute suppressor replication target anti type prevent prevent normal normal dna dna dna dna dna divide divide bind hypomethylizing cpg cpg cpg gene rapidly effect dependant similar division longer methylation methylation allow work incorporate action 
1.33@cancer transfer insert daughter get use cause cause non relatively currently since hypomethylation bind bind bind strand nucleotide nucleotide unable dna dna dna dna divide divide dose dose cytotoxic act inhibitor want rapidly effect methyltransferase methyltransferase death division low major decitabine decitabine decitabine high insensitive methylation demethylation cell cell cell cell replication replication replication 
1.67@reglate unregulated classify restore restore within produce process major growth direct regulate death allow tumor mechanism block normal thus demethylation demethylation demethylation decitabline decitabline control blockage expression expression suppressor suppressor suppressor drug drug cause target result number ia antineoplastic antimetabolic metabolism dna dna divide cell cell cell cell cell cell cytotoxic chemotherapy function gene gene gene gene gene rapidly effect interact cellular increase division division go methylation work incorporate 
2.0@mean cancer cancer inhibitor available available dnmt dnmt dnmt dnmt methyl methyl slow easily easily inhibiter dnmti make make make analogous epigenetic strand strand enzyme enzyme enzyme enzyme especially impact tumor replicate replicate normal nucleoside case cell cell cell cell cell cell cell cell rapid belong one therefore consequently replication replication replication subsequent incorporate anti group group dna dna dna dna dna dna dna dna however bind bind suffer rapidly effect division division longer go methylation decitabine decitabine decitabine decitabine decitabine daughter daughter daughter irreversible lay lay come methyltransferase 
1.0@et et cancer class tumor use fda agent rib process myelodysplastic de hypomethylation treat transferase inhibit inhibit latter dual well demethylating proliferation stimulate mechanism mechanism affect high cell cell cell cell methyl eoside also enzime patient drug drug syndrome suppression low present immune oxy nucleus dna dna dna dose dose mediate expression gene effect explain believe belong interfere al al decitabine decitabine method mean approve action differentiation hollenbach hollenbach would 
1.67@inhibitor inhibitor dnmt synthesize tumour tumour fda exhibit newly charge dnmti rate treat decrease irreversibly strand strand hypermethylation pattern block itelf nucleoside enzyme cell drug high epigenetic use replication analogue incorporate result anti dna dna dna dna dna mind syndrome act myelodysplastic methyltransferase effect explain belong replicate methylation methylation decitabine decitabine decitabine em em em lay approve 
2.0@dna dna dna supresor cpg cause mediate act hypermethylation demethylating gene methyltransferase effect agent island anti silence decitabine hypermethilaton inhibit tumour tumour 
1.33@cancer cancer methyltransferases summary use agent size treat effectively inhibit lead lead irreversibly pass help time especially reduce reduce tumor high capture demethylation demethylation cell cell cell global faster also drug certain toxic dosage dosage demethylate normally show prevent division dna dna dna dna dna dna dna dna dna dna divide bind act demethylase right rapidly rate induce try death demethylating methylation methylation decitabine decitabine decitabine decitabine decitabine work incorporate action methyltransferase 
2.0@cancer cancer abnormal negative able able tumour tumour tumour tumour tumour mutation island reactivate hypomethylation part sit nevertheless might grow decresed molecule lead increase development responsible enzyme demethylating demethylating demethylating inhibit inhibit proliferation proliferation due affect abnormality epigenome epigenome directly high demethylation cell cell cell global promote genome genome suppressor suppressor dependent imparing therefore consequently decitabine decitabine drug drug strand promotor target type group dna dna dna dna whole cpg cpg gene gene gene gene methyltransferase methyltransferase effect effect cellular death division entire new methylation methylation methylation cop wide silence silence form indirectly associate 
2.0@dacogen methyltransferases class dnmt dnmt inhibting supression methyl inhibitor agent agent hypomethylating myelodysplastic capable growth md treat affect adduct lead strand get component pyrimidine responsible responsible hyper demethylating eisai stimulate normal formation enzyme enzyme primarily primarily cell cell control kill cytidine transfer tumor antimetabolite divide certain inhibtion precursor activity result low without depletion methylation act group myelomic company dna dna dna dna modulate dose japanese bind covalent sell function gene gene rapidly attack name syndrome belong analogue thereby thereby decitabine leukima incorporate action commercial 
0.67@dacogen cancer also erase dnmt tumour work work work work throughout long suppression myelodyplastic oncogene treat treat suppress dna dna epigenetic stretch syndrome sell eisai drug gene methyltransferase inhibitor enable meiosis unless decitabine decitabine mitosis actively term demethylation repress 
1.33@cancer inhibitor restore restore tumour agent process analog growth affect irreversibly strand body belong demethylating nucleotid normal release nucleoside demethylation cell cell cell control decitabine suppressor dependent divide replication mean severily dna dna dna dna dna dna get bind bind function gene methyltransferase methyltransferase methyltransferase methyltransferase along upon copy division replicate thus methylation longer daughter much incorporate come action rapidly 
1.67@dna dna dna cytosine cancer methyltransferaseinhibitor class demethylating hypermethylation cpg island methyltransferase inhibitor belong dnmti early stadium inhibit character decitabine decitabine 
1.67@patient activation tumour agent agent apoptosis myelogenous show inhibit cpg dna dna hypomethylating acute act hypermethylation demethylating methyltransferase reduce contribute methylation decitabine decitabine region like cell leukaemia 
1.67@cancer cancer methyltransferases fda syndrom cure cure analog hypermethylated might normal island irreversibly affect fact myelodysplastic myelodysplastic nucleoside case demethylation cell cell enzymatic dependent patient epigenetic drug drug drug cause cause target result demethylated type obtain good dna dna dna divide thank bind syndrome dnmts dnmts cpg rapidly division regulator decitabine incorporate approve associate 
2.0@cancer reduce reduce class class dnmt dnmt use dnmti replicate tumour call island irreversibly strand methylate able tumor mechanism hypermethylation demethylation cell may may suppressor dna dna dna dna dna understand patient patient divide general drug drug drug cause cause incorporate result result problem anti type reduction however bind epigenetic epigenetic inhibitor inhibitor inhibitor cpg gene methyltransferase effect increase increase belong longer methylation decitabine decitabine decitabine daughter activity action complete would 
2.0@suppressor cancer cancer cause cause therefore dnmt dnmt tumor may analogue nucloside decitabine highly exact effect antitumor decrease prevent prevent occur dna dna divide inhibitor drug drug island impact unclear mechanism though hypermethylation silence methylation genome wide cpg cell cell replication release 
1.67@suppressor suppressor suppressor class tumor tumor tumor drug cause decitabine decitabine product hypomethylation gene gene gene promoter island island suppress prevention dna dna dna dna epigenetic call expression hypermethylation cpg cpg inhibit methyltransferase inhibitor inhibitor induce increase belong thus methylation methylation allow work demethylation tumorigenesis associate 
1.33@cancer cancer cancer inhibitor restore outcome activate induce tumour state stop stop remain liquid potential oncogene back transferase effective epigenetic even common give dnm happen mechanism feature feature start special penetrate genome methylation demethylation cell cell therefore therefore irreversibly cause stability allthough another plasma whether problem type better damage nucleus nucleus dna get dont bind bind act function indirectly dnmts dnmts unclear regulator decitabine decitabine possible incorporate specific action complete previous previous 
1.0@suppressor cancer inhibitor dnmt dnmt produce methylates use hypomethylating myelodysplastic dnmti growth replication inhibit avoid avoid prevent syndrome dna dna dna malignant bind dnamethylation enzyme drug drug irreversible way allow tumor methyltransferase hypermethylation methylation decitabine decitabine gene gene cell attach expression 
0.67@dnmt methyl analogue thus agent decitabine decitabine decitabine island hypomethylation inhibit nucleotide lead dna dna dna dna irreversibly bind fe stabilise demethylating prevent cpg hypermethylation rase genome incorporate tra 
1.67@cancer use agent anti myelogenous meet treat decrease decrease island regulate work mroe precursor demethylating as tumor tumor tumor tumor normal level many cell promoter leukaemia suppressor suppressor cytidine transfer analogue cycle product ypermethylation become better return dna dna dna acute bind syndrome myelodysplastic cpg gene gene gene effect thereby since methylation methylation decitabine region activity active supressor would would 
0.33@transient cancer cancer nanomolar genomewide epithelial neoplasm produce baylin hematological include rapid without thank stem cytotoxicity cytotoxicity change regulatory inhibition participant decrease inhibit response next sustain applicability broad culture time dr tumor key damage unexpectedly routine high reexpression second cell cell experimentally tumour promoter immediate study lower successfully epigenetic epigenetic drug drug drug cause exposure toxic pathway low chemotherapeutic deploy like antitumor antitumor show show good employ subpopulation dna dna dna dna dose dose dose dose reaction primary le inhibitor management gene effect induce cellular relevant solid go methylation methylation methylation decitabine decitabine decitabine accompany first efficacious memory leukemic 
1.67@machinary cancer rate higher class effective seem tumour cause stop without side quantity specific effect inhibit inhibit epigentic grow molecule dna dna epigenetic surround help inhibitor additional prevent dmnti happen normal normal belong methylation methylation decitabine decitabine small small reproduce enzyme demethylation cell cell cell cell part attach adverse enough 
1.67@cannot excessively methyl methyl agent decitabine decitabine decitabine cancerous dnmti apply become bind bind transferase transferase inhibit analogous class dna dna dna dna dna get methylated act drug drug drug irreversible hence inhibitor tumor affect belong replicate thus methylation molecule nucleoside severely incorporate case cell cell cell cell replication follow demythylating 
2.0@cancer unrestricted growth able administration use use agent agent agent intergenic become become silence hypomethylation useful transferase island suppress regulate consider naturally allow allow demethylating enhance tumor tumor tumor curtail significant although lead methyl suppressor decitabine decitabine standard also hallmark drug region anti occur prevent particularly dna chemotherapy act inhibitor cpg gene gene gene effect effect remove cellular solid division thus methylation methylation would gen protective protective reproduction active active combine unsuppressed 
2.0@reduce abnormal reactivation induce agent agent characterize hypomethylating dysregulated myelogenous hypomethylates leukemia leukemia useful treat inhibit might particularly precursor link myeloid tumor pattern hypermethylation turn role case cell myelodysplatic supressor antitumour hypothemylation chemotherapy chemotherapy dna dna dna dna dna acute acute syndrome expression gene gene methyltransferase effect epigenetically sensitize silence methylation methylation decitabine decitabine resistance aml play 
2.0@fail momparler momparler methyltransferases dnmt may include phase mechanism mark inhibiter reactivate reactivate hypomethylation susceptible susceptible indirect quite transferase island fully regulate clinical irreversibly promoter promoter methylated involve involve however reduce tumor tumor accord epigenetics repair general cell cell cell cell blood deplete angiogenesis suppressor suppressor also consequently appear cause novo apoptosis highly cytosine cancerous without inactivate transmission solid subsequent either dna dna dna dna dna karahoca karahoca non bind chemotherapy methylase suppression cpg gene gene gene gene rather effect copy supply thus thus methylation methylation decitabine decitabine decitabine daughter em incorporate differentiation de 
1.67@dacogen dictabine class produce tumor use cause inhibitor induce suppression myelogenous hypomethylation hypomethylation treat marrow reverse dna dna dna acute syndrome sell myelodysplastic deform methyltransferase effect epigenetically precursor belong silence decitabine decitabine bone cell blood leukaemia 
2.0@strain cancer cgis restore dnmt dnmt dnmt dnmt inhibting use agent process reactivate growth preserve hypermethylated hemimethylated hemimethylated inhibit inhibit lead silence demethylating pattern pattern pattern repair repair ordinarily cell cell cell cell cell cell cell cell cell tumour suppressor specifically hypomethylation regain aberrant aberrant mean become promoter parent parent dna dna dna dna dna dna dna dna dna dna dna divide bind function gene gene methyltransferase methyltransferase methyltransferase methyltransferase copy copy division thus thus methylation methylation methylation methylation methylation methylation decitabine decitabine daughter daughter daughter lay original original recognise onto 
2.0@tumpr along abnormal class suppressor suppressor exposure inactivation replace find hypomethylation replacement usual chromatin island dna dna lead believe clincal depleetion decondensation pyrimidine inhibitor hypometylation dnmt tumor key nucleotide sister carbon treatment decitabine decitabine decitabine decitabine compound atom methylating foundation dnmts cause cause md entrapment bring know multiple covalent reduction expression ring reverse allow syndrome myelodysplastic cpg gene azanucleosides enzyme deoxycytidine ecpression nitrogen belong silence methylation methylation analong production activity protein follow azacitidine 
1.67@cancer cannot inhibition effective manifest tumour tumour tumour tumour agent methyltransferases hypomethylation incorporation avoid island cytosine cytosine cytosine wherever promoter methylated inhibitor demethylating fall way block hypermethylation thus genome high cell cell cell methyl decitabine decitabine decitabine decitabine decitabine suppressor suppressor promote spread analogue add occur occur level level prevent prevent prevent dna dna dna dna dna dna dna dna dna dna bind bunch dnmts cpg gene gene hence hence hence effect place keep division find methylation methylation methylation methylation methylation group action methyltransferase 
2.0@suppressor suppressor loss effect hypomethylation epigenetic apoptosis remove tumour tumour tumour cause agent agent mark mark result cannot hypermethylation trigger anti promoter inhibit inhibit cpg example dna dna dna dna dna hypomethylating allow expression enzyme demethylating island methyltransferase methyltransferase reduce tumor word division replicate thus methylation methylation repair gene gene mean cell decitabine decitabine decitabine 
2.0@net cancer cancer cancer methyltransferases methyltransferases methyltransferases available dnmt dnmt produce say cannot dnmti growth growth growth pathological back transferase suppress addition effective get silence silence hypomethylated reduce normal normal bind bind molecule high case cell cell cell cell cell uncontrolled expression suppressor also transfer run therefore divide cause amount result methylate type methyl methyl methyl level group dna dna dna dna dna dna dna dna dna however cytotoxic fe inhibitor gene gene rapidly effect join division rase methylation methylation decitabine decitabine decitabine decitabine possible generate enzymatic small 
2.0@et et cancer cancer methyltransferases lead lead lead relieve loss whose myelodysplastic dnmti dnmti growth leukemia md hypermethylated transferase island island cpg cpg regulate malignant show particularly inhibitor aggressive tumor curik curik nucleoside methylation many cell cell cell cell ref global suppressor dependent transcription replication analogue structure apoptosis apoptosis incorporate arrest methyl promoter prevent demethylation repression dna dna dna divide action bind bind syndrome capacity dnmts dnmts drug drug gene gene gene effect place chromatin belong al al decitabine another influence azacitidine azacitidine differentiation differentiation recently 
1.0@suppressor inhibitor inhibitor class specificity general tumour tumour actually actually appropriate course dnmti methyl avoid dna epigenetic level help keep act issue drug gene reduce lack epigenetics methylation methylation decitabine mean may 
2.0@different et cancer cancer myeloid class class dnmt dnmt progress island potential hat could already find dnmti dnmti fda leukemia tumour decrease inhibit myelodisplastic characteristically epigenetic among well enzyme inhibitor inhibitor navada research tumor mechanism test hdac hypermethylation hypermethylation general methylation cashen tolerate hdmt one suppressor patient relate relate seem drug drug drug whether apoptosis target malik underlie anti know treatment dna publish acute syndrome expression cpg gene gene effect elderly hmt belong undergo silence al decitabine decitabine decitabine approve approve 
2.0@dnmt dnmt activate use neutralize fda agent two myelogenous leukemia md hemimethylated inhibit inhibit methylcytosine lead strand strand strand strand transferase methylated precursor enzyme enzyme demethylating island effective tumor tumor separate hypermethylation anticancer fact automatically primarily cell cell methyl suppressor suppressor successfully consequently replication replication mielodysplastic antitumour promoter promoter prevent cpg dna dna dna dna maintenance base acute syndrome syndrome act dnmts drug gene aml effect upon stage increase division due main methylation methylation methylation decitabine decitabine decitabine decitabine daughter daughter oppose approve form form 
1.67@cancer inhibitor activate uncontrolled uncontrolled slow agent agent stop stop myelodysplastic growth growth growth growth treat suppress suppress suppress tumour tumour tumour enzyme demethylating control reduce job overly cell cell cell methyl suppressor cause advance attach methylates tunour combination result result surround become group ezh dna histone histone histone use gene gene gene allow deacetylase lung silence silence methylation methylation decitabine work form protein azacitidine 
1.67@mean cancer inhibitor inhibitor hypomethylation dnmt dnmt dnmt dnmt progress use agent specific myelodysplastic analog myelogenous similar growth treat affect inhibit aza class clinical irreversibly strand body currently therefore severely efficacy mechanism test metabolic nucleoside cell cell trial rapid rapid leukaemia malignance dependent large high rat action replication cause structure non toxic activity result low cytosine number anti dna dna dna dna get dose dose acute bind syndrome act function exert methyltransferase effect unclear remain deoxycytidine loss belong detail decitabine decitabine decitabine decitabine incorporate incorporate towards 
2.0@inhibitor dnmt dnmt dnmt use near specific myelodysplastic find hypermethylated inhibit decrease decrease island irreversibly promoter firstly superior tumor tumor tumor normal neoplastic neoplastic mode nucleoside acivity cell cell cell replication replication suppressor dependent cause large drug analogue dose dose toxic mean anti anti show get non bind syndrome act cpg gene side effect methylation decitabine decitabine aganist activity action 
1.33@dependent effect maintenance analogue agent mean intensively family dna dna dna dna dna divide bind inhibitor division demethylating irreversible methyltransferase methyltransferase reduce tumor preferentially affect belong usually methylation decitabine decitabine decitabine decitabine nucleoside witch incorporate cell cell cell 
2.0@kind cancer cause inhibition demethylates effective regulation via drug certain agent already myelodysplastic low hypermethylation high promoter promoter syndrome dna dna dose dose cytotoxic involve belong especially gene gene proliferation tumor tumor methyltransferase must report demethylating destabilize decitabine decitabine oncology work cell cell differentiation helpful suppressor 
2.0@cancer cancer cancer inhibitor dnmt demethylationas methyl order agent process analog since since dnmti hypermethylated transferase inhibit irreversibly irreversibly strand know naturally allow demethylating island able tumor normal thus work strongest nucleoside caveat express cell cell cell cell try one suppressor dependent also dosage get replication cause could purpose target cancerous gene completely alsoadversely prevent atlow dna dna dna dna dna dna dna divide divide bind bind bind cpg affect rapidly effect upon copy division new methylation decitabine possible incorporate strongly methyltransferase hit 
2.0@abnormal induce use agent agent two currently cytotoxicity hypomethylation direct inhibition inhibition treat marrow inhibit incorporation strand strand allow demethylating demethylating mechanism myelodysplastic polyribosomes high cell ecitabine transfer via drug cause incorporate incorporate result low dna dna dna dna dna dna dna dose dose acceptor syndrome function function methyltransferase methyltransferase effect defective similar antineoplastic bone disassembly methylation rna rna rna hematopoietic production another protein azacitidine 
2.0@suppressor cancer methyltransferases class epigenetic suppose use drug agent stop demethylate myelodysplastic growth anti treat normal inhibit inhibit division dna dna dna divide methylated syndrome inhibitor dnmts demethylating gene gene gene rapidly effect remove affect belong silence methylation methylation decitabine decitabine decitabine decitabine activity express cell cell cell cell tumour tumour tumour 
2.0@methylating consequently activate use slow agent synergistically dnmti growth growth possibly make cooperative drug inhibit suppress treatment dna chemotherapy demethylating gene modifier susceptible decitabine successful tumour tumour tumour de 
1.67@pronounce alt cancer cancer disrupt use agent process since growth growth completely treat inhibit suppress suppress tumour tumour inappropriately therefore demethylating heritability affect hypermethylation methylated img cell cell cell cell much one one faster lower patient rat mitotic certain healthy result see course type src parent experience treatment treatment dna dna dna divide mark inherit gene methyltransferase effect silence thus thus methylation methylation decitabine decitabine decitabine decitabine daughter activity beneficial 
1.33@cancer classify class include agent hmti acetyl hypomethylates dnmti dnmti dnmti broad inhibit epigenetic body inhibitor inhibitor inhibitor inhibitor inhibitor demethylating severely affect release cytidine like demethylation cell cell drug dependent transfer always hat replication replication cause mean hdaci bind methyltransferase methyltransferase methyltransferase dnamethyltransferase dna dna dna dna dna divide histone histone histone histone ase demethylase strandthereby rapidly along upon analog copy hdmi longer methylation decitabine decitabine decitabine daughter deacetylase incorporate come azacytidine 
2.0@suppressor suppressor cancer also antimetabolite hypomethylate cause meanwhile agent interfer genesmay demethylate inhibit dna dna dna divide chemotherapy function demethylating gene methyltransferase effect tumor tumor normal death belong thus methylation ul ul berestored cell decitabine 
1.33@cancer undo cause agent likely oncogene become hypermethylated hypomethylated cpg cpg dna dna dna expression demethylating demethylating island island reduce remove generally methylation decitabine mean many cell would 
2.0@suppressor suppressor could inhibitor therefore dnmt tumour tumour tumour agent mark myelodysplastic since cancerous anti decrease suppress dna dna dna epigenetic syndrome allow demethylating gene gene take effect turn division replicate methylation episode express cell cell cell would would decitabine decitabine 
2.0@could methyltransferases incorportated term enzymatic dna dna dna dna dna continue specific long analog toxicity malignancy dnmti growth island suppress effective irreversibly well inhibitor trhe reduce tumor mechanism mechanism block block block normal hypermethylation least nucleoside cell fine drug suppressor methylating replication window dose toxic result tune amount promoter reduction non bind act act capacity function still gene gene methyltransferase effect unclear remain cpg thus methylation decitabine decitabine possible activity active action action enable 
0.67@dependent cause identify class class therefore dnmt dnmt decitabine decitabine decitabine decitabine decitabine seem use use analogue toxic anti describe describe lower lower effect replication tumour good dna dna dna irreversibly dose dose dose dose bind epigenetic amp amp amp amp dnmts inhibitor inhibitor inhibitor impact affect antineoplastic belong belong methylation methylation ul ul high incorporate recently much nuceloside an an an 
1.67@cancer methyltransferases methyltransferases class use inhibitor becouse myelodysplastic analog acknowledge malignancy myelogenous treat lead epigenetic precursor demethylating tumor tumor hypermethylation nucleoside demethylation t leukaemia suppressor suppressor dependent todnmti decitabine decitabine drug agent lay men promoter good markup dna dna dna dna acute bind syndrome dnmts irreversible effect belong epigenetics methylation ul ul gene incorporate form haematological 
1.67@one dependent effect effect irreversibly tumour tumour tumour analogue agent methlyation hypomethylation anti drug inhibit dna dna dna dna divide bind act enzyme demethylating demethylating rapidly impact methyltransferase normal normal belong decitabine decitabine nucleoside incorporate cell cell cell replication 
2.0@cancer cancer inhibitor stable dnmt induce much hematological align mark inhibit lower malignancy leave might island irreversibly belong especially severely as tumor affect neoplastic hypermethylation decitabicin decitabicin release although role maintain demethylation cell cell bind dna dna dna dna dna dependent dependent transfer transfer dnmts dnmts dnmts dnmts depend epigenetic replication incorporate anti type good disease several divide dose ase syndrome myelodysplastic cpg rapidly effect upon stage division longer thus methylation methylation decitabine decitabine decitabine lay meet meet action action 
2.0@inhibitor inhibitor inhibitor restore restore remember dnmt dnmt dnmt hypomethylate use dnmts order mutation specific myelodysplastic remain hypomethylation leave leave leave inhibit unlike cpg class epigenetic reversible island able able mechanism hypermethylation hypermethylation style style style may although align align align unknown tumour tumour tumour suppressor suppressor always irreversibly alteration drug text text text incorporate become know know dna dna dna dna however reverse bind syndrome important positive methyltransferase effect still thus methylation decitabine decitabine decitabine decitabine decitabine drive activity action beneficial 
1.67@mitotically cancer cancer methyltransferases higher class dnmt formation progress use uneffective agent frequently leukemia md heritable often epigenetic see inhibitor inhibitor belong demethylating happen happen block normal thats myeloid demethylation demethylation cell cell cell cell cell cell tumour tumour machinery dependent lower therefore via drug cause cause toxic target anti occur prevent prevent dna dna dna dna dna dna dna divide divide dose dose acute bind bind act dnmts aml effect methyltransferase division division tumourogenesis methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine decitabine approve rapidly dnmti 
2.0@methyltransferases growth synthesize agent aberrantly newly analog aza hypomethylation call inhibit response previously regulate physiological methylated methylated methylated consequence demethylating tumor tumor participate contribute nucleoside maintain cell cell suppressor cytidine also therefore irreversibly cause cycle apoptosis demethylated express express anti type dna dna dna dna dna bind dnmts dnmts gene gene effect status deoxycytidine silence longer thus decitabine incoporating 
0.0@compound cancer nature depakote regulation way agent process growth treat epilepsy lead epigenetic epigenetic component inhibitor enzyme twofold tumor anticancer genome demethylation regulate use blockage blockage blockage decitabine decitabine decitabine one suppressor suppressor suppressor promote antimetabolite depression unregulation extent cell cell condition anti anti dna dna dna histone deacetyleasen chemotherapy important drug drug gene gene gene effect effect result result range increase division interfere interfere thus methylation methylation methylation allow work activity activity differentiation 
2.0@cancer cancer cancer encounter use agent stop pattern pattern pattern newly de best treat affect irreversibly strand strand strand establish replicate replicate replicate normal readily nucleoside maintain primarily cell cell cell cell cell methyl methyl tra methylating divide replication replication analogue add type type group synthesise dna dna dna maintenance bind syndrome fe myelodysplastic methyltransferase inhibitor inhibitor inhibitor inhibitor interfere rase methylation methylation methylation decitabine decitabine work incorporate follow frequently 
2.0@dna dna reverse silence demethylating gene gene methyltransferase aid agent suppress suppression result cancerous decitabine hypomethylation useful hypermethylated inhibit tumour tumour 
1.0@cancer critical hava methyl methyl fda agent agent process myelodysplastic intervenirse hypomethylation md genetic transferase transferase adduct lead lead epigenetic epigenetic development consider disease conceptualization proliferation tumor act aproved cell cell cell control control machinery suppressor also therefore chemically drug drug restoration cycle result thia among dna dna dna dna dna divide non cytotoxic syndrome treatmen function gene gene effect effect effect induce demethylating interfere methylation methylation decitabine decitabine decitabine form differentiation 
2.0@suppressor inhibitor think class term dnmt use analogue agent decitabine decitabine hypomethylating hypomethylating myelodysplastic describe citosine dnmti anti hypermethylated inhibit genesthat epigenetic expression dna dna dna irreversibly bind syndrome dnmts provide chemical able tumor methyltransferase methyltransferase downregulated increase proliferative therapeutic activity action drug deplete present 
2.0@inhibitor inhibitor restore restore dnmt dnmt dnmt dnmt dnmt methyalation methyl agent hypomethylating hypomethylates old call absence granddaughter epigenetic strand strand strand hyper inhibit inhibit inhibit proliferation tumor tumor tumor tumor rase absent suppressive decitabline replication template belong suppressor methylates require subsequent activity result result maintain anti completely dna dna dna dna dna dna dna cell cell cell demonstrate fe gene gene methyltransferase effect keep division division due due new new methylation methylation methylation decitabine decitabine decitabine class tra 
2.0@one dacogen cancer cancer cause cause restore lang lang lang lang tumour antimetabolitic agent xml xml hypomethylating medicine anti decrease decrease inhibit suppress dna divide u u u u en en en en name function gene rapidly effect effect tumor methyltransferase hand hand death new methylation methylation decitabine decitabine demethylation cell commercial way 
1.67@dna dna dna namely cancer cause demethylating methyltransferase effect cytidine agent hypermethylation insult thus thus hypomethylates decitabine anti oncogene counter inhibit tumour analog 
0.67@cancer cancer article magazine tumour sub sub agent agent cite elucidate epicentre observation remain classify economist inhibit recognize responsible enzyme proceed susceptibility mechanism although cell methyl standard transfer however study precise ch april th anti promoter group treatment dna dna hypomethylating chemotherapy act gene methyltransferase effect effect suggest increase decitabine decitabine decitabine decitabine work methylating 
2.0@suppressor suppressor could reduce release release able use drug drug agent decitabine decitabine myelodysplastic myelogenous demethylate treat example dna dna area acute methylated syndrome responsible demethylating demethylating demethylating way effect effect tumor tumor tumor tumor mean block precursor belong genesis gen activity activity replication leukaemia 
2.0@different suppressor cancer although dnmt dnmt tumour tumour already describe course island type type type might lecture inhibit particular treatment treatment dna dna dna development development decrease decrease example hypermethylation hypermethylation cpg favour methyltransferase effective effective mechanism question source main decitabine decitabine arise gene gene activity perhaps various way promoter 
1.0@decline also overmethylation use use cause include agent agent agent crucially cell cell cell myelogenous whenhistones stop growth effect treat tumour tumour job surround dna dna dna histone methylated syndrome precursor myelodysplastic demethylating demethylating demethylating gene gene dramatically reduce uncontrolled normal amount whose silence decitabine nearby acute apparent proliferation suppressor leukaemia 
2.0@cancer characteristic lead class able methyl senescent become treat effectively locus regulate call methylated wild inhibitor allow prevent dnmt pattern pattern normal normal fact ensure affect cell cell cell cell cell cell tumour tumour tumour suppressor suppressor un transfer closer therefore therefore drug drug drug drug region mean cod cancerous cancerous like anti methylation methylation methylation group develop dna dna divide form function unlikely gene gene continue effect belong due silence disallow decitabine decitabine tumourigenesis eventually action protein would would associate 
2.0@dna dna suppressor cancer myelodysplasitc syndrome allow allow demethylating gene use tumor agent remain fight turn methylation decitabine treat cell inhibit active 
1.67@cell cell cell use cause agent phase cycle myelodysplastic result myelogenous hypomethylation leukemia make treat inhibit company dna dna acute syndrome demethylating methyltransferase death decitabine decitabine japanese 
1.33@cancer use use aberrant include agent agent specific suppression result result make hypermethylated might decrease decrease occur dna dna dna dna however promoter involve hypermethylation hypermethylation demethylating gene gene tumor tumor global belong generalization accurately methylation methylation methylation decitabine decitabine accompany may region region 
1.67@cancer slowly dnmt synthesize methyl exposure fda newly dnmti generation transferase subsequently cytosine irreversibly strand level level lose reduce tumor pattern dilute cell cell cell cell cell replication therefore drug drug analogue healthy result severe dna dna divide divide base bind act function rapidly inhibitor upon copy quickly methylation methylation methylation decitabine incorporate approve modify follow 
1.33@inhibitor effective decitabine decitabine n methyl methyl methyl cause agent subsequent hypomethylating hypomethylation anti know inhibit lead dna dna dna dna epigenetic ase act silence silence removal removal effect effect mechanism mechanism belong prior thus thus methylation group group group gene gene far tumour tra 
1.0@dna area area cancer cancer cancer reverse help syndrome myelodysplastic demethylating drug cause stop stop belong since methylation methylation methylation decitabine decitabine make demethylation grow wrong wrong 
1.67@dna dna irreversibly bind syndrome dnmt methyltransferase inhibitor agent hypomethylating myelodysplastic hypomethylates decitabine use treatment 
1.67@cancer cancer inhibitor inhibitor restore efficacy activate use slow agent tend hypomethylating myelodysplastic easily since growth growth md md hypermethylated treat enhancer enhancer inhibit achieve call well silence silence demethylating dr tumor tumor tumor hypermethylation island island cell cell baylin find suppressor suppressor patient patient undo drug marrow fluid cancerous anti solid promoter promoter promoter reverse dna dna dna however blood histone environment syndrome function cpg cpg gene gene gene gene methyltransferase methyltransferase effect similar deacetylase upstream bone thus decitabine decitabine decitabine decitabine hence recently combine would azacitidine 
1.33@cancer inhibitor inhibitor cgis available dnmt progress use analogue fda dependent decitabine irreversibly frequently repetitive approve incorporation affect amount epigenetic treatment dna dna dna dna divide bind bind syndrome hypermethylate drug severely aml reduce methyltransferase methyltransferase normal myelodysplastic molecule nucleoside region incorporate small cell cell cell replication machinery 
2.0@effect restore methyl member hypomethylation catalyse inhibit addition regulate epigenetic involve demethylating group reduce dir dir convert may directly ordinarily triphosphate cell cell cell tumour also function result prevent dna dna dna dna dna dna dna integrate inhibitor gene methyltransferase methyltransferase methyltransferase think induce growth growth first death division thus decitabine decitabine decitabine decitabine ltr ltr class action combine follow 
2.0@cytosine could could analogue disrupt drug state agent stop result reside reactivate hypomethylation anti hypermethylated methyl transferase inhibit dna dna dna dna dna reverse gene gene effect growth demetylating fact methylation methylation decitabine region region incorporate tumour tumour tumour promoter promoter supressor 
1.33@market suppressor tumour agent myelodysplastic myelodysplastic dnmti gene drug inhibit treat dna irreversibly bind syndrome syndrome enzyme demethylating prevent unclear mechanism hypermethylation may decitabine decitabine work action use 
1.67@different loss inactivate cgis irreverseably yet state serine agent along die mark mark myelodysplastic probably azacytidine hypomethylation possibly replicate replicate effectively lead infer methylated therefore take dnmt dnmt dnmt tumor tumor tumor mechanism addional may fact genome genome nucleoside instability hypermethylated case higher cell cell cell cell cell demethylation much suppressor also greater residue analogue structure accumulation replicative effect effect promoter genomic dependently dna dna dna divide covalently bind syndrome site end gene chemical rate prevention suppresed usually passively similiar belong modification methylation decitabine decitabine decitabine decitabine work active maintain rapidly 
0.67@interaction interaction critical real change change suppressor produce tumour exhibit process switch biochemical growth inhibition avoid occur epigenetic development see inhibitor allow research tumor tumor question turn induction caspase methylation methylation anwering cell cell drug drug drug expression one dna dependent greater activation via dlbcl region apoptosis impac result effect effect effect anti acetylate level adequate reason base histone histone mediate act synergistic gene gene gene chemical chemical field prevous deacetylase increase seem epigenetics hdacis hdacis decitabine decitabine decitabine decitabine decitabine decitabine time promise study 
2.0@epigenitically inhibitor abnormal growth produce may superssor agent agent hypomethylating hypomethylating necessary hypomethylation hypomethylation hypomethylation bone bone affect inhibit inhibit nucleotide restore epigenetic work work decitabne help silence silence thereby island island proliferation as tumor tumor tumor tumor mechanism normal normal complex nucleoside cell cell cell cell cell blood promote expression suppressor transfer dimethyl abberant appear analogue analogue marrow marrow result anti promoter modefied dna dna dna dna dna dna base kill bind function cpg cpg gene gene gene gene methyltransferase effect induce desilencing cellular control control belong thus methylation decitabine decitabine decitabine region class hypomethylates differentiation associate 
0.33@growth series think abnormal sequentially conclusion upon assess appear agent specific hypomethylating hypomethylating hypomethylating epigenome analog change change change change leukemia md treat affect aza imply cytosine decrease median complex blast myeloid detect mechanism primary early metabolite dac dac dac directly vivo distinct cell cell global indicate scarcely also patient patient patient patient seem mrna link toxic myeloblast infusion anti occur day dna dna dna dna dna dna already non acute act expression gene gene aml aml effect effect effect induce deoxycytidine control line methylation methylation methylation methylation decitabine work first transcriptome analysis study 
2.0@cancer cancer stronger inhibition dnmt upon upon way dnmts include add mark rest treat transferase island solid strand strand strand body methylated inhibitor allow especially tumor tumor tumor block hypermethylation thus andirreversibly todnmt demethylation cell cell cell cell cell cell control supressor dependent accordance nucleoside activation replication replication analogue function result th methyl group cpg cpg dna dna dna dna dna divide non loose loose bind initially important drug supresors rapidly effect induce template silence new new methylation methylation decitabine decitabine gene gene incorporate original mehtyl 
1.67@cytosine cancer transfer inhibition class residue work cytidine cytidine agent culminate analog meet hypomethylation incorporation know inhibit inhibit cpg cpg imply imply dna dna dna dna dna dna reverse ase belong demethylating island island hence hence place antineoplastic hypermethylation hypermethylation longer methylation decitabine decitabine possible incorporate incorporate come 
1.0@mitotically mitotically cancer class tumour tumour tumour near fully agent transfer correct also silence silence heritable heritable inhibit suppress amount epigenetic speed reversible methylated hyper demethylating island island reduce hypo hypo block block hypermethylation hypermethylation like repressor methyl methyl enzym one epimutations methylating activation use drug drug promotors cause result result formerly methylation methylation occur counter group group description dna dna cell le cpg cpg gene methyltransferase methyltransferase remove belong epigenetics actively decitabine decitabine decitabine ofgenes 
1.33@suppressor cancer along dnmt dnmt cellswhich methyl order dependent agent hypomethylating dnmti hypomethylation come bind bind transferase nucleotide tumor dna dna irreversibly strand upon inhibitor gene effect itreactivates copy division replicate silence methylation release daughter incorporate epigenetically action replication decitabine decitabine 
1.33@cancer myeloid class lower dnmt formation progress use state fda mark myelodysplastic remain currently leukemia might transferase transferase island lead epigenetic incorprated inhibitor thereby severely happen close mechanism affect hypermethylation nucleoside cell methyl methyl expression expression dependent cause replication analogue decitabine also anti supress show tumour tumour dna dna dna dna divide dose acute bind syndrome le dnmts cpg gene gene aml effect effect remove remove silent silent chromatin longer thus thus methylation ul ul approve action side 
2.0@suppressor dnmt activate n methyl agent result cod anti inhibit dna dna expression enzyme demethylating gene gene effect tumor tumor silence rase decitabine decitabine work activity tra 
0.0@dna divide cancer cancer cause decitabine mathylation correct spread cell mistake stop stop 
2.0@heavy myeloid dnmt administration progress use myelodysplastic myelodysplastic dnmti drug drug island nucleotide irreversibly strand demethylating undesired neoplastic hypermethylation release nucleoside cell tumour food leukaemia analogue seem seem replication cause low anti know cpg dna dna dna dna dna dose acute bind bind syndrome syndrome syndrome inhibitor outcome poor aml effect upon methyltransferase methyltransferase methyltransferase copy great produce methylation methylation decitabine decitabine daughter region incorporate come approve kill resume prognostic 
2.0@cancer cancer cancer cancer rate higher term progress way specific long process analog find leukemia direct treat affect unknown irreversibly sure disease tumoral myeloid tumor mechanism normal normal complex myeodysplastic nucleoside cell cell cell cell cell cell cell say carry divide replication cause low anti occur show great damage treatment dna dna dna demthylation dose acute bind syndrome inhibitor hence methyltransfere effect effect division decitabine decitabine create kill methyltransferase recently 
2.0@mitotically cancer methyltransferases methyltransferases class dnmt dnmt disease methyl order pattern mark mark myelodysplastic since dnmti hypomethylation possibly newly heritable transferase carefully irreversibly know responsible belong inhibitor island effective due neoplastic epigenome fact high maintain maintain demethylation cell cell cell cell cell drug drug drug drug drug drug inhibit inhibit example dependent monitor greater replication cause lay result low cancerous anti level synthesise dna dna dna dna dna dna dna dna bind establish dnmts cpg rapidly effect effect syndrome division replicate replicate new methylation methylation methylation methylation methylation methylation decitabine decitabine work incorporate dosage dosage alter operate 
0.33@cancer cancer proliferate inhibition growth dnmt dnmt dnmt dnmt use mutation process epigenomic treat normal inhibit deleterious severely proliferation reduce affect family nucleoside nucleoside instability cell cell tumour tumour tumour suppressor dependent analogue advance therefore replication replication cause target cancerous anti prevent prevent genomic analoge dna dna dna dna get bind inhibitor drug drug drug gene methyltransferase methyltransferase effect effect upon belong methylation methylation decitabine decitabine irreversible incorporate action hence tissue 
2.0@like plan mechainisims gene etunor dnmt check may limit th rectify make hypermethylated drug inhibit inhibit suppress sepigentic lead dna dna dna keep euchrmotin demthylating act wahtever especially island island reduce molecular mechanism death cpg cpg fact methylation methylation decitabine work activity cancerous tumor express etc tissue 
1.33@vivo proliferate inhibition restore formation may may concentration major cytotoxicity pharmacokinetic hypomethylation hypomethylation hypomethylation hypomethylation direct incorporation normal inhibit exert achieve believe proliferation parameter adduct neoplastic phosphorylation insensitive cell cell cell control critical study also divide cause cause apoptosis suppression relatively show dna dna dna dna dna dna dna however non synthesis covalent function gene rapidly effect induce induce induce cellular cellular antineoplastic vitro vitro methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine attribute incorporate differentiation differentiation methyltransferase methyltransferase 
2.0@standard cancer cancer cancer inhibitor patient therefore epigenetic tumour tumour tumour tumour slow improve agent agent epicentre result economist silence growth anti hypermethylated hypermethylated know suppress class dna dna area development allow allow chemotherapy source demethylating demethylating gene gene gene gene effect remove expression belong epigenetics methylation contribute express may may decitabine decitabine 
2.0@begin cancer cannot dna dna dna dna dna decibabine cytidine meet hypermethylated exert island suppress lead lead position methylated enter inhibit take tumor tumor tumor tumor tumor tumor grow normal express cell cell cell cell cell removal decitabine decitabine decitabine decitabine suppressor suppressor faster transfer replication analogue toxic occupy result anti show reduction get ase cpg gene gene gene gene chemical effect effect silence thus thus thus methylation methylation rna incorporate incorporate 
2.0@cancer cancer inhibitor class dnmt use use seventy agent specific myelodysplastic myelodysplastic myelogenous inhibtors treat affect irreversibly body leukaemia well well respond demethylating severely precursor release nucleoside demethylation cell tolerate belong dependent cause patient get drug drug drug analogue low anti treatment dna dna dna dna divide dose acute bind syndrome syndrome dnmts rapidly effect elderly division longer decitabine decitabine incorporate action methyltransferase 
1.67@nature class thus inhibitor tumour tumour cluster appoptosis agent agent whose correct myelogenous since de hypomethylation hypomethylation hypomethylation genetic change call inhibit inhibit suppress expression transferase transferase transferase operation amino silence demethylating ion tumor tumor tumor normal main pentofuranosyl name cell cell cell cell methyl methyl methyl leukaemia one specifically therefore need region region decitabine decitabine suppression suppression result pass gene gene anti solid know dna dna deoxy responsible responsible use function triazin erythro effect effect effect effect fe belong epigenetics methylation sequence sequence daughter em mean action action action chemical chemical small small 
2.0@suppressor residue dnmt dnmt replication replication trap mark cytosine cancerous extinguish lose inhibit dna dna irreversibly bind bind integrate allow gene rapidly inhibitor tumor place normal hypermethylation replicate find methylation decitabine cell cell methyltransferase expression 
1.33@cancer proliferate abnormal disrupt lead dnmt dnmt regulation use use agent agent agent hypomethylating myelodysplastic myelogenous question leukemia md md hypermethylated treat island am am class see help repression allow allow myeloid promoter key normal normal count level otherwise higher cell cell cell cell cell cell repress reach one ratio pathological therefore certain healthy result cod renewal show prevent prevent prevent demethylation demethylation treatment dna dna dna blood blood blood blood acute bind syndrome expression expression cpg gene gene gene gene methyltransferase inhibitor control methylation methylation decitabine decitabine decitabine establishment production lay would 
0.0@one dnamti cancer cancer rate greater dnmt may work neighbor make type type dna treatment effective suitable time especially irreversible effect rely division division replicate decitabine bond create incorporate cell cell cell drug drug unknown 
0.67@prelukaemia abnormality drug cause unmethylates text text text text text originally myelodysplastic myelodysplastic myelodysplastic myelogenous myelogenous myelogenous leave leave leave leave leave occur know prevent prevent develop dna epigenetic acute acute acute help syndrome syndrome style style style style style keep interfere interfere thus methylation methylation decitabine decitabine decitabine align align align align align indirectly syncrome leukaemia leukaemia leukaemia 
1.67@different series cancer cancer methyltransferases dnmt dnmt adhesion activity activity methyl add decitabin two phenomenon almost hypermethylation hypermethylation hypomethylation md inhibit lead lead dmnts level enzyme island tumor severity deoxynucleoside regulation fight silence case cell cell cell cycle blood promoter myelodysplasic enzymatic cytidine relate study analogue could likely apoptosis apoptosis property show show group particular dna dna dna expression syndrome correlate cpg differentiation disease induce charge cellular increase increase human motility thus methylation decitabine gene gene gene context form survival selectively 
0.67@cytosine methyltransferases class msonormal manner agent acute subsequent hypomethylating myelodysplastic myelodysplastic synthesis cytotoxicity bind treat prevent incorporation syndrome syndrome dna dna dna dna dna get reaction help covalent precursor enzyme function block leukaemia myelogenous methylation decitabine decitabine decitabine incorporate lead drug azacitidine azacitidine 
2.0@cancer reduce reduce reduce tumour tumour silence reactivate growth decrease act act strand methylated allow initial inactive render cell cell control extent tra one suppressor metastasis spread permanently subsequent methyl level level level prevent dna dna dna dna dna bind dilution fe function gene gene methyltransferase inhibitor upon passively repeat division division rase methylation methylation methylation methylation methylation decitabine decitabine decitabine drive supressor 
1.33@kind cancer abnormal abnormal therefore may may may agent demethylate demethylate since anti hypermethylated island island dna lot methylated hypermethylation demethylating gene effect tumor cpg cpg decitabine decitabine cell help 
2.0@mitotically cancer inhibition class dnmt formation fda process process analog since hypomethylates inhibit disrupt irreversibly strand strand methylated allow tumor tumor affect link nucleoside express cell cell inheritable drug drug drug one suppressor suppressor epigenetic epigenetic replication cause know dna dna dna dna mark mark four bind expression gene gene methyltransferase copy copy belong methylation methylation methylation methylation decitabine decitabine decitabine decitabine daughter daughter daughter incorporate come approve lump 
1.67@suppressor cancer cancer class may slow agent hypomethylating switch growth particular dna dna dna dna toswitching act demethylating gene methyltransferase methyltransferase tumor longer protein belong due decitabine active cell cell proliferation 
2.0@dacogen cancer cancer cancer inhibition restore within effective blood slow agent tend mark leukemia find growth growth part hypermethylated hypermethylated locus locus methylcytosine methylcytosine runaway cytosine epigenetic epigenetic strand demethylating tumor tumor tumor normal normal early early genome although express cell cell cell cell methyl expression therapeutic drug drug exclusively suppression suppression describe trade mass anti normally know group though treatment dna dna dna dna base act name target mislead gene aml aml effect remove remove result death since methylation methylation decitabine decitabine decitabine pharmacologic class broadly protein protein protein associate 
2.0@inhibition disrupt available able tumor methyl methyl agent hypomethylating remain remain since efficiency transferase transferase represent lead cytosine irreversibly strand strand pass enzyme enzyme enzyme enzyme demethylating take close mechanism disrupteddue deplete compound atom lower beta present position replication replication structure detachment detachment proper result entrapment number nitrogen bind bind bind group later dna dna dna dna dna mark base environment chemical place set due methylation methylation methylation decitabine daughter incorporate progression elimination 
2.0@cancer inhibitor dnmt regulation tumour tumour tumour state agent shore analog dnmti oncogene avoid island irreversibly strand severely normal hypermethylation hypermethylation style style nucleoside align align affect demethylation cell cell drug drug extent expression justify justify suppressor faster epigenetic replication replication text text icrs anti show prevent prevent dna dna dna dna bind act function cpg cpg gene methyltransferase effect replicate thus methylation decitabine decitabine decitabine daughter incorporate various enzymatic 
2.0@cancer cancer cancer cancer cancer activity disrupt dnmt dnmt dnmt dnmt cell cell cell may agent silence silence silence silence silence goal hence de hypomethylation tumour inhibit inhibit inhibit suppress nearby dnmtdna responsible enzyme enzyme demethylating prevent proliferation proliferation tumor tumor tumor uncontrolled source human catalyze decitabine decitabine suppressor suppressor suppressor rapid therefore attach hypomethylated via ie target result ability problem therapy normally methyl could group intend dna dna dna dna histone gene gene gene gene methyltransferase effect overactive stage repress set division undergo thus methylation methylation allow em em incorporate prone protein 
2.0@cancer inhibitor inhibitor higher dnmt dnmt tumour agent chance dnmti hypermethylated inhibit inhibit molecule often strand strand strand methylated enzyme island effective neoplastic nucleoside demethylation cell methyl lower lower lower drug carry cause toxic analogue anti anti tranferase dna dna dna dna dna dna dose dose dose bind bind function cpg hence effect effect upon copy unable belong replicate replicate methylation decitabine decitabine decitabine decitabine daughter daughter daughter incorporate come replication replication small 
2.0@one suppressor suppressor cancer transfer depend synthesize tumour tumour tumour agent silence silence newly proliferate hypomethylates reactivate gene gene promoter inhibit several dna dna dna dna strand inhibitor demethylating time methyltransferase reduce reduce pattern hypermethylation thus thus thus methylation methylation methylation decitabine decitabine daughter daughter mitosis cell cell cell need exist 
1.33@elod plastic cancer effect higher class progress use use use fda toacute tend since dnmti leukemia treat strand belong myeloid tumor mean mean affect neoplastic demethylation cell cell much dependent lower drug drug drug cause y low moreover anti dna dna dna dna get dose dose kill allow inhibitor aml rate upon syndromethat copy division division replicate find methylation decitabine daughter incorporate approve methyltransferase 
0.67@suppressor suppressor methyltransferases think tumour tumour state effect anti promoter dna dna dna tumoural expression inhibitor gene methyltransferase allow interact block hypermethylation reduce reduce mean come action decitabine decitabine decitabine 
2.0@cancer cancer inactivate standard excess upon use slow stop become analog dnmti dnmti growth growth generation effectively response molecule irreversibly strand allow tumor tumor tumor outright hypermethylation nucleoside case demethylation cell cell cell cell cell cell cell drug drug drug suppressor suppressor lower depend activation replication unwanted anti conjunction prevent several dna dna dna dna divide divide kill bind chemotherapy inhibitor rapidly effect effect effect remove methyltransferase methyltransferase division division replicate methylation methylation methylation decitabine daughter incorporate combine 
1.0@dacogen cancer produce use agent myelodysplastic genetic exert inhibit inhibit aza lead treat precursor demethylating island tumor block suppress hypermethylation hypermethylation hypermethylation hypermethylation hypermethylation regulate control control suppressor also imprint icr loss highly result dna dna dna dna dna dna cell cell syndrome sell expression cpg gene gene methyltransferase methyltransferase deoxycytidine division longer go decitabine decitabine decitabine activity active alter 
1.67@suppressor also lower lower use fda progeny agent limit result currently reactivate growth leukemia treat level level inhibit lead dna dna dna acute syndrome myelodysplastic cpg island methyltransferase myeloid tumor demethylating methylation methylation decitabine gene approve cell 
1.67@hypermethylations cancer cancer cancer classify dnmt dnmt dnmt progress use fda agent myelodysplastic since dnmti leukemia treat copy island cpg unknown epigenetic strand around involve stronger might might effective mechanism demethylasing normal nucleotide accute release nucleoside like demethylation cell cell cell cell way dna dna dna dependent analogue therefore irreversibly relate replication cause metaltranferase myeloid bind bind usa treatment malignance divide often syndrome inhibitor still aml effect upon world division longer methylation decitabine decitabine decitabine decitabine decitabine decitabine daughter much incorporate come approve action action haematological 
2.0@mitotically cancer cancer methyltransferases class term dnmt upon tumour tumour tumour tumour exhibit long probably size growth overall treat decrease heritable lead effective irreversibly level lose particularly despite belong inhibitor reduce reduce lack hypermethylation divide genome cell cell cell cell cell yet specificity suppressor methylating epigenetic excessive replication drug healthy extent target typically perform anti bind amount show prevent treatment dna dna dna dna dna intervention often function unknown gene aml effect effect efficacy quickly replicate replicate since since methylation methylation methylation decitabine decitabine slowly work incorporate come fact hit 
2.0@blewitt cancer effect effect class target dnmt synthesize sugar slow agent nucleic hypomethylating newly inapoptosis malignancy growth possibly md island island nucleotide cytosine irreversibly strand lecture inhibitor inhibitor allow dr tumor tumor tumor tumor coursera neoplastic hypermethylation heavy nucleoside nucleoside marnie enzyme demethylation cell cell cell catalyze decitabine decitabine decitabine decitabine acid dependent lower become high residue get replication analogue analogue toxic suppression suppression result like anti show group good disease dna dna dna dna divide dose dose reverse bind bind act dnmts cpg cpg gene gene rapidly reexpression reexpression upon copy contain division epigenetics methylation methylation methylation ul ul daughter incorporate methyltransferase haematological 
2.0@cancer methyltransferases class dnmt dnmt tumour system loss stop stop silence characteristic reactivate treat island might epigenetic know methylated disease mechanism hypermethylation dilute contribute maintain passive cell way belong suppressor novo moreover present malfunction revert good example dna dna dna dna generally cpg gene inhibitor division thus methylation methylation methylation methylation decitabine decitabine decitabine mitosis lay lay oppose various de 
1.33@cancer cancer employ change change lymphoma regulation use slow agent stop example myelodysplastic myelogenous growth treat erase erase might next epigenetic epigenetic epigenetic pass therefore precursor demethylating grow happen people though unexpectedly routine participant factor granddaughter tumour tumour kill leukaemia leukaemia lung transcription advance successfully deploy drug drug combination acute therapy form cell cell cell histone without unlike show good involve dna reaction syndrome inhibitor gene rather effect deacetylase solid division actively decitabine daughter time first return azacitidine chemotherapeutic 
1.67@cancer investigate class dnmt aka use hematological fda specific significantly since malignancy malignancy dnmti dnmti approve exert transferase transferase island cpg irreversibly promoter involve disease thereby observe comparatively tumor standard hypermethylation nucleoside nucleoside seem demethyl demethyl demethylation cell cell inhibit inhibit compound suppressor lower lower fewer analogue improve dose therapy prior activity activity mimic dosage demonstrate especially though treatment treatment treatment dna dna dna dna divide regiment histone bind chemotherapy inhibitor inhibitor outcome gene side effect conventionally deacetylase belong decitabine decitabine region incorporate hdaci subsequently 
2.0@cancer inhibitor higher growth growth target dnmt methyl include agent agent suppression hypomethylating myelodysplastic hypomethylation hypomethylation leave md md md treat call inhibit inhibit inhibit class cytosine epigenetic show show well hypermethylation demethylating demethylating proliferation neoplasm tumor tumor tumor mechanism mechanism block normal essential link style align thereby use use expression expression suppressor suppressor also promote nonreversible analogue text apoptosis cell cell cell result immune transferase covalent dna dna dna dna dna dna dna dna dna dose synthesis syndrome dnmts gene gene gene methyltransferase inactivate induce control belong methylation decitabine decitabine decitabine decitabine decitabine hematopoietic incorporate differentiation differentiation stimulation 
1.33@cancer critical mode regulation uncontrolled agent agent hypomethylating significantly growth growth exert inhibit often epigenetic allow reduce reduce tumor correctly normal normal normal enzyme enzyme cell cell control control expression suppressor suppressor suppressor therefore result chemotherapeutic express amount prevent division division division dna dna dna dna dna dna dna process promotion consequence act function gene gene gene gene methyltransferase methyltransferase inhibitor describe cellular word impact interfere methylation methylation methylation methylation methylation decitabine decitabine decitabine activity action 
1.0@cancer inhibitor od dnmt agent analog replicate replicate affect nucleotide epigenetic strand belong demethylating severely impact longer normal divide release itinhibits cell cell cell drug drug dna dna dna dna dna dna faster nucleoside irreversibly replication mean group reason get bind bind bind methyltransferase methyltransferase methyltransferase methyltransferase along along upon must copy division dependent methylation decitabine daughter incorporate come come action 
2.0@cancer inhibitor abnormal abnormal overmethylation activate huge use dependent silence myelodysplastic dnmti growth growth tumour decrease act act lead responsible enzyme proliferation tumor tumor tumor tumor tumor uncontrolled hypermethylation hypermethylation turn check case demethylation regulate methyl tra suppressor suppressor suppressor faster activation cause cause cause cell cell result become occur treatment dna histone syndrome fe anti anti gene gene gene effect effect effect upon place keep division replicate rase methylation decitabine decitabine decitabine decitabine decitabine decitabine action action 
2.0@one suppressor suppressor loss effect abnormal class dnmt presumably replication favorable progeny myelodysplastic result result major anti occur show island response dna dna epigenetic call syndrome inhibitor inhibitor drug gene reduce reduce tumor tumor tumor demethylation dnmtis belong silence methylation methylation methylation methylation decitabine production cpg cpg passive cell cell cell cell abnormality protein promoter promoter 
2.0@suppressor suppressor cancer also become therefore dnmt dnmt tumor tumor tumor much cause faster agent process highly bring permanent effect effect anti normally occur dna dna dna strand duplicate duplicate bind bind available available inhibitor target demethylating gene impact remove copy silence longer methylation methylation release daughter come active cell cell drug would decitabine decitabine decitabine 
2.0@cancer cancer cancer cancer cancer inhibitor inhibitor abnormal dnmt tumour agent agent hypomethylating hypomethylating myelodysplastic economist aza aza aza analogous cytosine epigenetic epigenetic help silence feb reduce reduce tumor inactive supressors nucleoside translator portuguese mode become google consequently cause strategy therapy activity anti translate treatment dna dna dna dna dna dna bind decitanibe act act gene methyltransferase methyltransferase effect oncol oncol deoxycytidine deoxycytidine deoxycytidine oct novel methylation methylation decitabine decitabine decitabine incorporate azacytidine clin action 
2.0@shoud tumour tumour cause agent desabling meet part anti grow act dna dna dependence bind re fe function demethylating prevent prevent effect tumor supressor e replicate silence decitabine decitabine gene mean cell replication tra 
1.33@et cancer cancer randomize class outcome hypomethylate hail agent phase myelodysplastic myelodysplastic cytotoxicity call inhibit lead jp epigenetic demethylating cell study iii patient c issa issa drug improve property result reference prevent amp treatment dna dna dna dna dna synthesis synthesis rosenfeld rosenfeld syndrome syndrome methyltransferase inhibitor similar belong kantarjian kantarjian al decitabine decitabine eventually come azacitidine 
1.67@aspect cancer cancer inhibitor specificity dnmt activate use agent long medicine element useful overall might might decrease irreversibly help term demethylating transposition lack may instability consider case demethylation harmful tumour supressor recombination cause promote need certain type level genomic repetitive dna dna however bind expression dnmts gene gene effect illegitimate silence due methylation decitabine decitabine decitabine indirectly would would organism 
1.67@one cancer cancer cancer cancer inhibitor class dnmt dnmt use dnmts fda mutation epigenome easily since leave genetic treat decrease inhibit inhibit molecule lead sign epigenetic epigenetic transferase regulator enzyme enzyme unaffected research tumor normal hypermethylation epigenetics myelodysplastic repair methylates express cell cell cell tsg yet nuceloside expression find suppressor analogue tsgs irreversibly alteration drug drug cause therapy parallel result focus methyl protect dna dna dna dna get bind syndrome recent target target gene gene hence disease silence thus thus thus methylation decitabine decitabine decitabine decitabine work practical approve action small 
1.0@one periphery also become coresponding histone way add stop place limit around bring recognise surpressor wrap replication methyl could lead action treatment dna dna dna dna strand strand move methylated methylated operation le le enzyme group chromosome methyltransferase division silence methylation methylation supressors gene express active cell cell tumour tumour tumour inhibit decitabine decitabine 
2.0@cancer cancer treate sometimes cell use use dysplasia agent agent agent mark semi growth susceptible make treat inhibit indicate epigenetic show show well human demethylating demethylating demethylating myeloid tumor tumor tumor tumor tumor key permanently improvement genome operate role treatment suppressor suppressor transcription patient relate via combination subsequent suppression result chemotherapeutic slower solid solid better prevent prevent syndrome dna originally histone chemotherapy myelodysplastic gene inhibitor remove deacetylase lung methylation decitabine advance perhaps perhaps azacitidine azacitidine alter play 
2.0@suppressor suppressor class drug agent suppression strip part call grow grow demethylates dna dna however methylated demethylating prevent tumor tumor tumor tumor tumor belong turn turn demethylated methylation decitabine decitabine decitabine gene gene gene gene associate 
2.0@different interaction cancer use exhibit specific hypomethylating two analog transfer bind hypomethylation direct hypermethylated treat lead phenotype believe strand strand tumour inhinits precursor prevent give main myelodysplastic myelodysplastic express express demethylation cell cell way leukaemia dysfunctional cytidine also suppresor antimetabolite drug certain cause agent enebling ase methyl methyl group metabolism dna dna blood acute cytotoxic syndrome syndrome act function perform gene gene effect induce cellular death myelogenous hovewer decitabine decitabine decitabine work incorporate incorporate 
1.0@synthesise could could could azatcitidine reactivation encounter hypomethylate tumour tumour agent agent furter hypomethylating hypomethylating two analog since de susceptible make might incorporation lead lead reactivate tumor normal bond instability chemicaly way supressor cytidine either greater transposable cancer promotors tide whereas apoptosis incorporate incorporate fast gene anti element rib prevent genomic oxy potentially dna dna dna dna divide cell cell cell deciabine covalent newly ribonucleotide chemical effect similar undergo methylation decitabine decitabine decitabine possible another methyltransferase azacitidine 
1.33@dacogen cancer cancer inhibitor use fda leukaemia acute decitabine decitabine eisai myelogenous come anti treat copy suppress company dna dna dna dna dna irreversibly strand japanese bind syndrome sell myelodysplastic drug drug methyltransferase methyltransferase methyltransferase along mean normal precursor longer methylation release daughter incorporate case approve cell cell cell cell far tumour replication replication replication play 
1.67@suppressor cancer cancer restore able uncontrolled cause agent demethylate result myelogenous course growth growth make tsg tsg tsg treat promoter promoter description dna dna dna tumour methylated methylated syndrome le functionality demethylating nornal proliferation hypomethylation normal lack silence thus thus material decitabine decitabine decitabine decitabine gene gene activity cell cell cell use use 
1.67@cancer proliferate proliferate class dna dna dna dna dna dna dna dna methyl slow rapid mark make replace stall hypomethylation line sit overall restrict inhibit treat unable cytosine cytosine epigenetic epigenetic epigenetic development pass particularly inhibitor belong island proliferation disrupt block normal hypermethylation may myelodysplastic demethylators aberrant program cell cell cell cell cell cell cell tumour tumour tumour tumour tra promotion transfer insert methylates need analogue cause suppression ultimately effect cpg reduction like synthesis fe use function perform rapidly enzyme methyltransferase methyltransferase pre death quickly rase methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter daughter mitosis differentiation selectively selectively efficiently efficiently 
2.0@elod elod elod dacogen cancer cancer methyltransferases cell use use inhibitor leukemia treat decrease island unknown differential precursor give give demethylating inhibit plastic plastic plastic hypermethylation although primarily treatment market reason dependent replication cause subsequent property decitabineis potentially dna dna divide dose harmful bind syndrome syndrome syndrome dnmts cpg gene rapidly effect effect methyltransferase suggest methylation decitabine y y y form aml overpromotion small 
1.33@dna irreversibly inhibitor bind dnmt dnmt gene effect serve thus methylation methylation decitabine anti inhibit inhibit suppressor tumor tumor 
2.0@expresed dependent dependent transfer use analogue inhibitor agent md hypomethylating incorporate myelogenous hypomethylation leukemia replication ease treat could dna dna dna acute syndrome act myelodysplastic drug gene aml consequence tumor belong methylation decitabine nucleoside drive role context methyl supressor 
1.67@suppressor effect effect inhibition dnmt use azacytosine acute myelodysplastic result myelogenous cytosine reactivate anti treat show lead suppress syndrome dna dna dna expression expression ring dmethylation covalent precursor inhibitor gene gene methyltransferase reactiveate tumor tumor silent methylation decitabine decitabine bond region incorporate malignancy specific form promoter leukaemia 
2.0@cancer cannot class dnmt dnmt produce n tumour tumour tumour state concentration way way silence preserve oncogene diminish inhibit suppress molecule irreversibly malignant promoter methylated belong island charasteristic hypermethylation release nucleoside maintain cell cell methyl tra suppressor dependent therefore replication analogue inhibitiors anti anti bind among particular dna dna dna ase cpg gene gene gene effect division thus thus methylation decitabine decitabine incorporate active active 
1.33@dysfunctional certain abnormal use cause agent cell cell cell condition myelogenous hypomethylates treat marrow inhibit dna dna dna acute syndrome precursor myelodysplastic demethylating methyltransferase death bone decitabine hematopoietic form blood azacitidine 
1.67@tumorsuppressor tumorsuppressor cytidine dnmt use em agent reexpressed decitabine hypomethylating myelodysplastic analog hypomethylates hypermethylation anti better island division dna dna havebeen promoter help syndrome function cpg gene gene current effect tumor block demethylating usually silence allow aberrant cell cell control region 
2.0@ox suppressor cytidine methyltransferases reactivation tumor may cause cause analog selective de hypomethylation promoter inhibit dna dose gene gene eoside induce death senescence low decitabine program cell cell cell differentiation follow 
1.0@cancer decitabine use analogue dependent agent hypomethylating myelodysplastic fast inhibit inhibit dna dna dna irreversibly divisons cell cell bind syndrome syndrome severely methyltransferase methyltransferase methyltransferase beacause mechanism affect division replicate longer action nuceloside release 
2.0@methyltransferases reactivation cytidine cytidine hypomethylating analog cannot frequently island island methylate methylated instead inhibit take tumor tumor tumor hypermethylation hypermethylation replace cell cell cell drug suppressor suppressor dependent therefore divide divide replication target result result cancerous methylted normally especially prevent dna dna dna however bind cpg cpg gene methyltransferase effect place try division replicate since methylation decitabine decitabine decitabine incorporate would 
2.0@mean cancer proliferate restore term dnmt dnmt dnmt lock stop long affect methylate well issue demethylating normal like dont compound noncancerous divide presumably replication perhaps however eventually idea effect know dna dna dna dna dna dna dna dna get get cell cell cell cell cell bind function gene rapidly inhibitor inhibitor inhibitor inhibitor inhibitor go methylation decitabine decitabine cant work incorporate come methyltransferase methyltransferase methyltransferase 
1.33@suppressor transcription standard standard unmethylation drug analogue therapeutic silence cytosine islandsso change withdrawal call inhibit active lead dna development termination prevent act give hipometilante gene gene methyltransferase inhibitor tumor tumor normal cpg belong new combat decitabine decitabine decitabine nucleoside factor incorporate methylation methylation return class 
1.67@cancer category within within dnmt produce way process hypomethylates similar substance substance direct call inhibit restore restore death strand tumor normal normal anticancer demethylation demethylation cell cell cell cell cell control suppressor therefore cause target number metabolism dna dna dna dna divide cytotoxic chemotherapy function gene rapidly effect effect interact cellular believe belong interfere thus methylation decitabine work incorporate incorporate 
1.33@mean cancer think abnormal restore restore start methyl agent agent hypomethylating hypomethylating myelodysplastic goal demthylating aberrrant surpressor md treat inhibit regulate help metabolite belong tumor tumor tumor rid block normal normal produce produce rase demethylation cell cell cell cell use blockage tra one suppressor suppressor drug activity anti anti type type dna dna medicine blood kill syndrome fe function gene gene gene gene effect growth increase increase division main methylation decitabine class form 
1.0@critical abnormal restore causal transcriptional may agent hypomethylating myelodysplastic myelogenous malignancy malignancy hypomethylation md md tsg tsg treat inhibit expression strand reversible precursor island island epigenomic change tumor tumor tumor normal hypermethylation hypermethylation hypermethylation hematologic directly phosphorylated uptaken role role many many cell cell cell cell use pharmaceutical leukaemia suppressor suppressor transfer tsgs cdkn drug cause apoptosis hematopoietic acute promoter dna dna dna dna dna kill ase syndrome inactivation inactivation cpg cpg gene gene gene aml aml important important important upon produce decitabine decitabine decitabine region incorporate meet associate proliferation play play 
0.0@regulation cancer epigenetics involve type end gene lot specific 
1.67@dna dna dna ecitabine strand hypomethylation demethylating methyltransferase induce agentsclass belong decitabine trigger incorporate thedna inhibit 
2.0@cancer inhibitor promote dnmt hypomethylate drug state state state revert inhibit result useful hypermethylated back island class dna dna dna see cpg gene methyltransferase supressing tumor activation normal normal methylation decitabine hypomethylated hypomethylated 
1.67@suppressor cancer cannot therefore dnmt dnmt tumour analogue irreversiblyto add toxic become result low dnmti maintain replication occur group demethylation consequentlydies dna dna dna dna dna divide divide dose arrive bind drug drug drug methyltransferase inhibitor division actively decitabine decitabine nucleoside work incorporate methylation active cell cell cell cell methyl 
2.0@cancer effect suppresor unambiguously may may cause manner dependent island island island island analog since since since hypomethylation gene gene gene gene anti inhibition occur reverse mainenance suppress suppress lead lead dna dna dna dna dna dna lesser see common silence cpg cpg cpg cpg inhibit methyltransferase methyltransferase nature tumor tumor tumor usually nucleotide feature hypermethylation hypermethylation due methylation methylation methylation decitabine decitabine region activity many many various replication promoter 
2.0@mean cancer research disrupt dnmt dnmt activate methyl aid could could become dnmti growth tumour tumour tumour transferase class epigenetic methylated inhibitor inhibitor silence reactivation heritability dilution reduce reduce nucleoside cell may decitabine decitabine decitabine suppressor also metastasis therefore cytodine mitotic spread analogue able hemi slow incorporate incorporate result fashion anti lead dna dna dna dna dna dna dna apoptosis bind function irreversible effect effect induce suggest belong methylation methylation methylation methylation would would gene gene gene lay replication 
1.33@suppressor cancer cancer inhibitor decreses class therefore overmethylation overmethylation overmethylation overmethylation tumour tumour tumour tumour cause include agent stop surround whose thatattach anti anti methyl call prevent job dna dna dna dna epigenetic histone histone histone histone histone group know know enzyme enzyme demethylating inhibit inhibit inhibit resposible effect growth protein belong silence silence methylation methylation decitabine decitabine decitabine decitabine decitabine gene gene gene gene decrease cell cell overactivity uncontrolled supressor 
2.0@cancer cancer transfer use methlation agent decitabine decitabine decitabine island demethylated dnmti effect anti drug group suppress suppresser suppresser lead dna dna methylated expression hyper demethylating observe interferase reduce tumor tumor tumor tumor gradually generally interfere thus thus methylation methylation allow silence silence gene gene gene cpg cell cell methyl belong 
2.0@different plastic could could rate restore restore multiple tumor may phase process process network myelogenous growth leukemia genetic mention inhibit differents regulate responsible inhibitor serve accord question normal abnormality thus investigation methylation methylation demethylation demethylation cell cell control suppressor expression one one dna dna dna also also iii antimetabolite subtances study drug drug drug drug syndrome ability chronic activity propose success know treatment several publish acute ii function function gene specifically inherit y similar explain belong belong interfere find combat decitabine decitabine decitabine mainly work article article first elod various potently methyltransferase 
1.67@cancer classify restore suppressor tumour tumour slow fda fda haci stop precise significantly acetyl also bind dnmti growth might might decrease island treat unknown irreversibly strand dnmt mechanism hypermethylation hypermethylation nucleoside disable incorporate dna dna dna analogue therefore area imprint drug drug certain another result satisfy transfer type hence promoter standard histone ase chemotherapy act expression still gene methyltransferase methyltransferase methyltransferase inhibitor inhibitor inhibitor inhibitor control increase cpg decitabine decitabine hematopoietic region activity chance approve approve combine 
2.0@could inhibition oncogenic maturation every mark mark mark make probably since hypomethylation susceptible useful inhibit inhibit disrupt epigenetic epigenetic epigenetic even pass lose tumor dilution thus lead lead dna dna dna dna cause subsequent apoptosis inheritance particular standard decitabin cell cell cell cell cell cell chemotherapy least gene methyltransferase methyltransferase methyltransferase daugter cellular death division division oncogenesis methylation methylation methylation daughter return instance differentiation disable eradicate 
1.67@suppressor suppressor cancer cancer effect therefore necessary drug agent agent agent correct since marker unmethylated unmethylated treat call dna dna dna dna example hallmark epigenetic error within act function demethylating gene gene proliferation reduce reduce tumor tumor similar normal normal death hypermethylation due especially methylation methylation allow cell cell resume decitabine 
1.67@cancer cancer cancer pair dnmt produce decibitabine decibitabine decibitabine specific specific methyltransferase methyltransferase probably methylating dnmti dnmti marker island aza cytosine cytosine epigenetic strand pass methylated methylated responsible inhibitor perfect reduce mechanism neoplastic genome instability demethylation cell cell cell cell cell cell minus abnormally also irreversibly cannot hemi match target target target demethylated toxic anti element limit show prevent genomic repetitive dna dna dna dna dna dna divide divide non bind localize function cpg cpg side side effect effect effect analog analog deoxycytidine due daughter region region incorporate incorporate rapidly would would 
1.67@suppressor cancer inhibitor restore area produce use syndrome agent cause myelodysplastic result member transcribe growth alsointeract call treatment dna divide cytotoxic epigenetic demethylating demethylating gene rapidly effect responsable death decitabine class cell cell control 
1.67@cancer proliferate methyl inhibitor cycle stop event increase decrease decrease epigenetic epigenetic uncontrollably coud allow germinal tumor tumor tumor restablish normal opportunity give give rase although otherwise cell cell cell cell repress level tra cause window prolong therapy type show treatment dna dna repressor expression expression expression fe thus thus thus gene gene gene oportunitiy rate rate mutate silence modification new methylation methylation methylation decitabine decitabine could activity supressor 
0.33@cancer cancer inhibitor inhibitor change change lymphoma lymphoma regulation firm use slow stop cutaneous medicine stephen growth make might call erase erase illness lead epigenetic epigenetic epigenetic pass therefore treat grow granddaughter people though jersey factor hopkins cell cell cell cell baylin leukaemia celgene transcription researcher successfully deploy merck drug combination school therapy baltimore kill without example unlike show tumour tumour involve lung base histone histone form gene rather effect john rare deacetylase deacetylase solid division new actively advance daughter time another first return azacitidine recently 
2.0@unregulated class effective effective may agent myelodysplastic find key make call suppress suppress expression methylated disease demethylating tumor tumor tumor tumor mechanism block inactive generally express cell decitabine decitabine one one also become therefore relate drug drug subsequent overgrowth number anti occur show normal dna chemotherapy limit gene gene gene effect effect effect belong silence methylation methylation allow activity 
1.0@dna dna neoplastic cause belong demethylating effect tumor stop increase increase contribute contribute methylation decitabine decitabine anti develop 
2.0@cancer cannot restore restore dnmt dnmt tumour tumour likely whose myelodysplastic probably hypermethylated island disruption disrupt irreversibly inhibitor inhibit order pattern pattern hypermethylation hypermethylation release nucleoside cgi cgi cgi locate suppressor analogue analogue replication cause cause stability therapy decitabine decitabine decitabine incorporate anti promoter genomic dna dna dna dna expression bind bind syndrome function cpg gene effec methylation methylation methylation ul ul mainly region eventually eventually associate associate 
2.0@allow inhibition murine may may may system clinically network member economist evaluate synergy interaction regulate regulate epigenetic epigenetic epigenetic strand epigenome demethylating impact tumor tumor tumor pattern block affect although cell cell cell cell cell cell cell cell cell cell cell cell cell cell cell cell cell way blockage cytidine also promote manner dlbcl dlbcl dlbcl apoptosis apoptosis condition condition suggest suggest differentially anti confirm confirm tolerability panobinostat panobinostat study xenografting acute cytotoxic reveal function function gene gene gene gene gene gene gene gene gene gene gene gene cellular increase increase validation vitro new decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine decitabine work malignancy antitumoral follow restore restore activate use use use include process process major deoxycytidine growth growth growth xenograft acc call believe sequence belong belong derive derive activation blood wt caspase line recover recover rna dysfunctional chemotherapy identify identify bisulfite via drug drug drug drug certain know target describe describe describe diffuse acetylate analyze metabolism dna dna dna dna dna dna dna dna dna dna single histone histone carcinoma mediate property property myelodysplastic effect effect effect effect effect effect effect effect explain germinal experiment adrenocortical adrenocortical incorporate incorporate incorporate play unregulated cancer cancer cancer cancer article category effective tumour chemically exhibit exhibit hypomethylating hypomethylates substance substance leukemia microarrays normal normal achievable aza represent explore promoter within within disease myeloid adjuvant mechanism test model model overlap express possible suppressor suppressor suppressor basis large patient patient patient answer reference number number vhl among several treatment treatment epicentre dependent name synergistic synergistic expression expression expression expression molecular interact time syndrome division division interfere methylation methylation methylation methylation methylation methylation tceb antitumor rare dacogen inhibitor inhibitor inhibitor class class class lymphoma produce produce agent agent diras analog center twofold direct inhibit treat treat advance silence silence silence anticancer primary unique thus analyse role role like like demethylation demethylation control one antimetabolite antimetabolite origin induction cause combination combination combination combination therapy therapy activity activity activity result result trade become level chain divide dose point uniquely rapidly investigate induce similar similar deacetylase death aml hdacis hdacis hdacis chromosome alter azacitidine azacitidine 
1.0@dna cancer promoter decrease demethylates expression demethylating gene tumor tumor agent stop phenomenon methylation decitabine growth region hypermethylated level common reestablish supressor 
1.67@cancer commonly greater class dnmt use inhibitng dependent irreversibly hypomethylates growth leukemia characterize know dna dna dna divide acute bind bind syndrome inhibitor division drug drug rapidly effect tumor methyltransferase belong myelodysplastic decitabine decitabine incorporate myeloid cell rapid replication 
1.67@suppressor cancer silent especiallyif havea state agent result formerly methylated inhibit lead dna consider le expression positive gene gene gene impact tumor demethylating turn methylation decitabine work express would 
1.67@methylating dnmt dnmt dnmt dnmt stop analog dnmti growth become occur occur occur inhibit inhibit dna dna dna dna irreversibly methylate bind bind inhibitor time methyltransferase able able tumor division decitabine decitabine decitabine nucleoside work incorporate demethylation demethylation demethylation cell 
1.67@cancer methyltransferases inhibition decitabine way analogue agent toxic cell cell cell cell higher incorporation incorporation protein prevent molecule lead lead dna dna dna dna dna synthesis synthesis bind covalent belong demethylating group chemical rate normal division vidaza nucleoside production incorporate leukemic drug rna rna 
0.67@dysfunctional myeloid abnormal class use agent agent stop hypomethylating myelodysplastic condition leukemia generation treat marrow inhibit particular represent dna dna acute syndrome syndrome disease demethylating methyltransferase effect bone decitabine decitabine cell cell blood 
2.0@along restore effective methyl removal fda fda decitabin myelodysplastic analog also malignancy dnmti dnmti dnmti call island lead lead sequence well well lymphoid tumor tumor normal vidaza nucleoside cellularly use promoter suppressor suppressor transfer greater rat drug drug work work stability four therapy ultimately inhibitor translate traditional better group chemotherapy dna dna however dose dose inhibitory syndrome smaller expression cpg decitaine side effect remove belong selective methylation decitabine decitabine gene another hdaci approve approve small survival le class 
1.0@suppressor lower reactivation induction may analogue result result cytosine hypomethylation promoter inhibit dna dose gene gene methyltransferase tumor death senescence decitabine nucleoside program cell cell cell differentiation selectively follow 
1.33@cancer cancer lead effective use agent myelodysplastic myelogenous hypomethylates leukemia quite treat treat island island suppress unknown unknown area area methylated demethylating disinhibiting dnmt dnmt dnmt tumor mechanism affect hypermethylation genome much hypermethylated thereby yet inhibit inhibit also drug drug target prevent dna dna dna acute syndrome act cpg cpg gene methyltransferase effect still decitabine decitabine decitabine decitabine work universally longterm 
1.33@cancer reduce reduce incressing action tend hypermethylation hypermethylated downregulates island island dna dna dna epigenetic level level expression expression demethylase cpg cpg inhibit proliferation inhibitor tumor tumorsupressor tumorsupressor tumorsupressor contribute thus thus methylation methylation decitabine decitabine gene various methyltransferase belong 
1.33@market rate inhibition much agent agent agent myelodysplastic myelogenous growth supporsed normal normal island island cytosine epigenetic precursor demethylating tumor tumor tumor tumor block affect hypermethylation possibility light sort demethylation cell cell cell cell may leukaemia one suppressor suppressor faster also use drug analogue depress express express medical medical treatment dna dna dna however acute syndrome sell cpg cpg gene gene methyltransferase effect methylation decitabine decitabine make possible side 
2.0@could inhibition able tightly tightly include acetyl detail enable subtle deacetylase open open open pack discount tumor tumor mechanism hdac hdac complex methylation accessible express supressor transcriptionally greater therefore study structure structure highly result result result course without wrap anti simplest naive group decitabineimpacts dna dna dna histone histone histone histone histone gene gene gene rather effect effect remove chromatin chromatin thus hypothesis decitabine region account acetylation acetylation 
1.0@cancer cancer inhibitor inhibitor essentially dnmt tumour tumour agent analog since since nucleotide irreversibly strand body demethylating severely replicate replicate affect neoplastic release nucleoside cell cell cell cell way dependent beauty divide replication lie anti anti dna dna dna dna dna dna get kill bind bind methyltransferase methyltransferase methyltransferase methyltransferase effect upon copy division longer methylation decitabine decitabine daughter incorporate come form repidly rapidly azacitidine 
1.0@alt cancer inhibitor inhibitor inhibitor lymphoma dnmt may slow appear agent myelodysplastic myelodysplastic leukemia leukemia leukemia myelogenous economist growth high high lation treat epigenetic deploy strand src concomitantly precursor hyper therapeutic tumor tumor people anticancer anticancer nucleoside induction img drug drug drug drug drug option classical suppressor expression risk dependent disposition advance successfully irreversibly combination replication analogue therefore acute target result transporter secondary promise solid show tumour treatment dna dna dna prevalence histone bind syndrome syndrome syndrome use use dnmts te irreversible rather effect deacetylase lung regulator decitabine decitabine decitabine decitabine gene incorporate incorporate azacytidine influence administer meylodysplastic methyltransferase enzymatic azacitidine 
1.33@dacitibine dacitibine dacitibine od class dnmt much agent analog irreversiblyit affect divisiondependent necceseary strand strand body demethylating enhance copythe nucleotide moreseverely release nucleoside cell cell cell intodna decitabine also divide relate drug replication replication willl chain dnamethyltransferase dna dna dna dna dna get bind bind bind inhibitor rapidly along upon belong longer methylation rna daughter incorporate incorporate incorporate come action methyltransferase methyltransferase azacitidine 
1.67@maybe cancer cancer instead higher higher able way concentration build lower meet meet dnmti rate decrease island nucleotide often location methylate inhibitor grade unspecific inhibit tumor tumor tumor normal normal neoplastic hypermethylation anymore enzyme cell cell cell cell suppressor transfer transfer therefore imprint replication prefer icr toxic loss enter anti bind analogon reason dna dna dna dna dna dna dna dna dna divide dose nucleosid ase ase act act desoxycytidin cpg irreversible effect effect effect effect interact must division replicate silence methylation decitabine decitabine decitabine decitabine decitabine decitabine decitabine mainly gene incorporate kill would couple 
2.0@cancer cancer cancer article specificity dnmt methyl appear agent agent agent chromosomal hypomethylating hypomethylates potential might effectively inhibit suppress refer demethylating demethylating limitation enhance reduce permanently lack hypermethylation hypermethylation conversely instability methylation methylation cell tumour suppressor genome dna dna dna dna dna need depletion group reduction divide reverse bind risk important methyltransferase effect remove actively decitabine drive drive incorporate tumorigenesis tumorigenesis inherent progression 
1.67@market cancer cancer hypomethylation specificity mild tumour unmethylated agent process easily change theoretically genetic treat epigentic epigentic inhibit clinical epigenetic epigenetic development tra issue demethylating reduce affect generally rase possibility alteration case trial methyl supressor one one surprisingly already also also area imprint drug drug dangerous reverse hypermetylation discovery prevent genomic dna dna however instance fe gene effect induce new methylation decitabine decitabine influence open adverse 
1.67@cancer cancer toxicity cgis effective oncological haematopoietic near myelodysplastic kinase malignancy md tsg consistent aza represent represent ideal even disease demethylating cgi mechanism aberrant cell cell tumour suppressor also patient candidate instability structural show several diagnostic hallmark synthesis degradation function gene recognise upon deoxycytidine deoxycytidine believe methylation methylation methylation decitabine decitabine dnmt include agent administrate marker restrict inhibit often cytosine human undergo phosphorylation dac via obstruction one analogue tsgs application induction ability ganetsky low therapy promoter though relative dna dna dna dna dose syndrome poor chemical myeloblastic induce induce death silence due thus region incorporate differentiation prognostic leukemic 
2.0@mean cancer methyltransferases downstreamare especiallyat able check use use agent rich hypomethylating myelodysplastic analog hypomethylates de hypomethylation leukemia sit sit inhibit orat keep strand kind demethylating island myeloid tumor tumor tumor usually itinhibits cell cell cell blood suppressor decitabine decitabine decitabine dysfunctional cytidine also orsuppressed high rat drug drug drug drug drug novo activity condition anti promoter presence treatment treatment dna dna dna dna dna dna dna dna acute syndrome cpg cpg gene methyltransferase effect upstream silence thus methylation methylation locate incorporate 
2.0@could inhibitor standard standard dnmt dnmt way mutation mutation myelodysplastic analog malignancy easier make genetic back inhibit treat class effective epigenetic show responsible enzyme island island reduce reduce tumor tumor mechanism people hypermethylation hypermethylation usually nucleoside original cell use level older suppressor suppressor patient irreversibly replication replication combination bring gene gene promoter prevent chemotherapy chemotherapy dna dna dna dose bind syndrome expression drug hop side side effect effect dependant little cpg cpg methylation decitabine decitabine uncontrolable incorporate perhaps action methyltransferase haematological notorious 
2.0@pronounce dacogen cancer inhibitor inhibitor inhibition lymphoma dnmt methyl slow fda specific process disease leukemia myelogenous dnmti dnmti dnmti growth penetrate exert transferase treat irreversibly azacitidineand sequence comparison precursor hypermethylation organ organ effective tumor tumor tumor hdac difficult difficult nucleoside cell cell cell replication suppressor leukaemia dna dna dependent therefore need analogue result result result solid solid act treatment treatment lung divide divide acute bind syndrome sell myelodysplastic drug gene rapidly effect effect effect find methylation decitabine decitabine decitabine promise approve combine 
1.67@dimer cancer cancer inhibition dnmt dnmt dnmt manipulation use use order mutation stop probably since susceptible useful genetic dilution island aza molecule molecule often epigenetic reversible particularly enzyme interest proliferation efficacy due normal hypermethylation mode fact contrary nucleoside cell cell cell cell tumour tumour decitabine decitabine decitabine specifically analogue depend fight alteration replication replication cause incorporate methylate considerable dna dna bind syndrome act act act epigenetics cpg cpg progressive target inhibitor dependant deoxycytidine replicate thus thus methylation longer activity action myleodysplastic small 
0.67@cancer inhibitor inhibitor dnmt progress use fda myelodysplastic analog dnmti leukemia treat nucleotide clinical irreversibly strand replicate release nucleoside myeloide like cell cell trial replication one dependent drug first mean dna dna dna dna dna get acute bind bind bind syndrome methyltransferase methyltransferase methyltransferase methyltransferase along along upon copy set division longer methylation decitabine daughter incorporate come come approve action aml 
1.33@plastic elod dnmt appear mutation process dnmti genetic treat epigenetic epigenetic decitabinestopping reversible effective tumor mechanism mechanism anduses neoplastic usually nucleoside cell cell dependent dependent also isreplication replication analogue difference approach type treatment dna dna itirreversibly bind syndrome isincorporated methyltransferase inhibitor copy replicate go methylation decitabine decitabine thusit work y andit frequently 
1.67@strain cannot suppresor depend dnmt way whose whose whose nucleotid process target analog bring hypomethylation type useful inhibition occur inhibit dna dna dna dna development bind repression gene methyltransferase tumor tumor mechanism methylation decitabine substrate moreover action insert drug 
2.0@suppressor cancer cancer inhibitor inhibition drug drug activity specific hypomethylating myelodysplastic analog major number growth therapy methylation methylation promoter mediate treatment dna dna process syndrome silence silence gene gene methyltransferase effect tumor tumor big hypermethylation since regulator decitabine decitabine nucleoside work role like play 
2.0@cancer cancer along hypomethylation term dnmt dnmt unclear may may activity stop long find dnmti growth overall nucleotide irreversibly strand allow inhibitorslike give release nucleoside methylation cell cell cell global immediate dependent analogue high ideal replication cause cause cause toxic target without extent genomic dna dna dna dna divide divide dose dose kill bind bind inhibitor still gene rapidly effect upon copy division longer since lower decitabine decitabine decitabine daughter incorporate come methyltransferase hit 
2.0@cancer last dnmt dnmt still slow specific mark inhibit clinical help enzyme ofimportance tumor tumor tumor question hypermethylation fact many cell cell cell demethylation demethylation demethylation dna dna dna dna dependent also patient pression passive passive result result type compare replica non bind le le act positive gene effect effect effect unclear unclear range explain division new methylation decitabine decitabine decitabine survival full 
2.0@normally cancer cancer methyltransferases think think class lower cause progress uncontrolled include stop myelodysplastic myelogenous de growth leukemia treat call precisely suppress irreversibly reversible certain allow inhibitor inhibitor tumor tumor mechanism affect neoplastic clear nucleoside area many cell use use use machinery one suppressor analogue become become epigenetic epigenetic alteration drug carry throughout target fast acute anti anti methylation methylation methylation thusly though dna dna dna dna dna dose surround bind syndrome switch gene gene gene methyltransferase effect remove silence replicate replicate isnt decitabine decitabine decitabine decitabine work incorporate active action 
1.33@cancer methyltransferases dnmt use analog malignancy hypomethylation vulnerable useful island surprise consider attack proliferation mechanism test hypermethylation speculate cell trial tumour tumour tumour suppressor dependent also nucleoside drug cause generic low dosage dosage anti anti type toxic prevent later dna dna dna bind generally reveal inhibitor still effect effect unclear rapid cpg thus decitabine decitabine decitabine decitabine decitabine work first action haematological 
2.0@inhibitor restore restore suppressor island agent hypomethylating analog hypomethylates hypomethylation inhibit passively class class irreversibly strand allow control tumor due normal release nucleoside regulator demethylation cell drug specifically get replication target dna dna dna dna dna dna process bind bind epigenetic function cpg gene methyltransferase methyltransferase methyltransferase methyltransferase along upon growth copy belong longer thus methylation decitabine decitabine decitabine daughter incorporate come enzymatic 
1.67@cancer cancer methyltransferases dnmt induce cytidine mark myelodysplastic analog analog since hypomethylation hypomethylation md inhibit molecule often epigenetic epigenetic see inhibitor island therapeutic tumor tumor tumor hypermethylation hypermethylation thus nucleoside methylation demethylation demethylation demethylation cell cell cell cell removal rapid example suppressor dependent therefore therefore irreversibly replication replication replication target result anti promoter lead lead treatment dna dna dna dna dna dna dna dna non bind syndrome inactivate cpg gene methyltransferase effect effect upon due currently regulator decitabine decitabine decitabine daughter incorporate approve selectively enzymatic small 
2.0@cancer stable class class dnmt use fda agent tend mark myelodysplastic myelogenous dnmti growth propagate useful treat absence incorporation irreversibly responsible enzyme inhibit mechanism precursor hypermethylation rely nucleoside methylation methylation methylation methylation propagation cell however leukaemia also epigenetic replication analogue toxic mean low maintain novo potentially dna dna dna dna dna dna dna dna hypomethylating dose acute bind syndrome dnmts dnmts dnmts still methyltransferase inhibitor inhibitor unclear belong longer thus unless decitabine decitabine decitabine decitabine decitabine decitabine daughter lay approve action would de 
2.0@mean cancer inhibitor class dnmt dnmt tumour make frequently generation generation effectively inhibit unable development mehtylation responsible belong pattern pattern affect cell cell cell cell cell cell cell multiple lower lower lower efficiency depend need daughtercells patter normal fast amount develop later later dna divide divide methyltransferase le le continue effect methylations copy division new new methylation methylation methylation methylation methylation decitabine decitabine daughter lay lay hence 
2.0@elod plastic cancer cancer cancer inhibitor paralogue dnmt dnmt put use use inhibit exceed reactivate treat effectively island prohibit unable cytosine irreversibly strand help norm belong control reduce tumor hypermethylation may nucleoside enzyme cell cell cell cell way decitabine decitabine occurrence suppressor depend consequence replication replication drug lay result moreover become frequency methyl methyl group group cpg cpg dna dna dna dna dna dna base u bind syndrome dinucleotides gene gene methyltransferase methyltransferase effect y character division division word thus methylation methylation locate daughter incorporate enable dnmti 
2.0@find suppressor often lower change risk use cause cause agent prescribe hypomethylating low dosage hypermethylation hypomethylation hypermethylated hypermethylated tumour tumour tumour inhibit cpg cpg treatment dna dna dna epigenetic decitabines consider syndrome function function drug drug island island methyltransferase reduce myelodysplatic lack bind main methylation decitabine decitabine time role whereas spread spread 
2.0@one suppressor suppressor cancer emergence available activation tumour tumour tumour agent agent currently anti normally exert explain inhibit restrict lead dna dna dna epigenetic involve hyper demethylating demethylating island effect mechanism mechanism affect cpg methylation decitabine decitabine decitabine gene gene cell drug drug 
1.67@cancer inhibitor antileukemic class class dnmt dnmt dnmt activate synthesize agent long myelodysplastic since deoxycytidine hypomethylation hypomethylation sit inhibition aza cytosine know variety take activation tumor tumor tumor inactivation complex phosphorylation approval potent treatment treatment first first formation suppressor suppressor unique discover polymerase arabinoside drug lts md apoptosis result result restoration senescene promoter though covalent dna dna dna dna dna re cell syndrome capacity function cpg gene gene gene inactivate induce cellular silence methylation methylation methylation decitabine decitabine decitabine decitabine time incorporate approve differentiation 
1.33@inhibitor class dnmt may include analog susceptible overall tumour inhibit inhibit potentiator irreversibly strand methylate display tumor give unexpectedly routine vidaza nucleoside cell cell try standard patient via drug prior kill chemotherapeutic show good dna dna dna however reaction bind chemotherapy act act methyltransferase effect makingthe belong methylation decitabine decitabine decitabine decitabine daughter study azacitidine 
2.0@suppressor suppressor methyltransferases inhibit inhibit reactivate growth amount island often dna dna dna dna methylated cpg gene gene gene methyltransferase inhibitor tumor tumor tumor tumor block silence methylation methylation reduce activity cell decitabine 
2.0@cancer classify class dnmt dnmt use agent agent specific silence myelodysplastic currently reactivate leukemia demythalizes call locus aza addition lead antineoplastic belong thereby thereby inhibit myeloid tumor tumor resistant essential effectiveness dac hypomethalyzing bond passive treatment treatment treatment treatment trial drug drug expression suppressor also also promote antimetabolite action replication replication therapy trap cell low uptake type solid demethylation demethylation intend covalent dna dna dna dna dose acute cytotoxic syndrome chemotherapy chemotherapy gene methyltransferase proces transporter increase division replicate thus decitabine decitabine decitabine incorporate previously form chemo membrane 
2.0@suppressor suppressor let inhibitor restore incorrectly tumor tumor replication methlylated decitabine decitabine epicentre irreversibly mimic growth gene gene gene bind lecture prevent job dna dna dna dna epigenetic mark copy methylated methyltransferase methyltransferase function control target enzyme chemoreceptor longer normal nucleotide replicate replicate methylation allow daughter aritcledrugs incorporate cell heavily machinery 
2.0@cancer cancer cannot reactivation progress use fda induce inactivation hypomethylation leukemia tumour tumour affect nucleotide nucleotide regulate irreversibly see inhibitor inhibitor silence severely myeloid mechanism normal hypermethylation release cell cell cell cell cell need expression suppressor suppressor dependent get relate replication analogue result anti dna dna dna dna divide acute bind syndrome myelodysplastic gene gene gene rapidly effect epigenetically division replicate methylation decitabine decitabine decitabine incorporate upon approve methyltransferase methyltransferase methyltransferase would 
1.67@eliminate state agent stag hypomethylation mention inhibit dna dna dna dna dna methylated division demethylating locus tumor question hypermethylation hypermethylation hypermethylation hypermethylation hypermethylation dilute passive cell ac recover suppressor promote metyl imprint replication cause cause answer suppression normally promoter group demethylation kind example cpg regiones methyltransferase inhibitor belong new methylation methylation decitabine gene incorporate tumorigenesis would 
1.67@suppressor suppressor suppressor cancer inhibitor restore therefore action use agent agent decitabine decitabine cell cell myelodysplastic myelogenous growth growth treat normal achieve dna dna dna dna acute division syndrome precursor function demethylating gene gene gene hypomethylation tumor block control increase give fact methylation methylation blockage activity demethylation regulate way promote leukaemia 
2.0@cancer inhibitor inhibitor class dnmt dnmt attempt receive quantity nucleotide irreversibly methylate allow stick impact tumor tumor tumor tumor dnmtis hypermethylation hypermethylation usually cell belong suppressor suppressor lower commence epigenetic drug drug function mean fast demethylated without anti know confuse dna divide dinucleotide dnmts dnmts cpg time methyltransferase effect division decitabine gene gene eventually 
2.0@cancer cancer cancer cannot higher class within dnmt dnmt dnmt progress use fda agent hypomethylating myelodysplastic dnmti growth treat transferase inhibit inhibit inhibit notoriously cytosine irreversibly tumour tumour inhibitor demethylating effective normal neoplastic hypermethylation hypermethylation nucleoside express cell cell cell methyl methyl leukaemia suppressor suppressor dependent transfer replication replication analogue anti bind show group myeloid dna dna dna dna dna dna dna divide dose acute frequency syndrome function drug drug drug gene gene aml effect division methylation decitabine decitabine decitabine decitabine incorporate approve small require 
1.67@cancer cancer cancer class dnmt dnmt uncontrolled could since dnmti growth growth unmethylated tumour tumour tumour tumour effectively effectively incorporation cytosine epigenetic strand strand promoter quickly take efficacy hypermethylation express cell cell replication replication suppressor suppressor suppressor suppressor one hallmark hallmark dependent irreversibly regain drug drug analogue subsequent another cancerous become environment environment know dna dna dna divide non bind incorporate incorporate gene gene gene methyltransferase inhibitor inhibitor remove remove cellular cellular control contain belong silence decitabine decitabine decitabine decitabine activity 
2.0@cancer growth chemotherapy transposon activate progress use use slow agent mark inhibit also azacytidine azacytidine hypomethylation treat effectively alone aza whole epigenetic methylated global enzyme demethylating control enhance outcome tumor tumor nano dilute express demethylation cell cell cell passively suppressor decitabine decitabine decitabine decitabine sensitivity dependent cause unspecificity therefore drug drug drug drug analogue combination combination therapy cycle tet target myelodysplastic technology do contrast unlike could either treatment dna dna dna dna dna like histone cytidine syndrome act act dnmts gene gene hence inhibitor globally deoxycytidine deacetylase division due methylation rna mechanistically active 
1.33@reduce promote instability agent significantly synthesis hypomethylation genomic lead dna dna dna regression methyltransferase inhibitor tumor block death belong thus thus methylation drive cell protein 
1.67@extreme cancer methyltransferases higher dnmt formation progress way slow slow permanent inactivation analog lethal reactivate abnormal dosis dosis inhibit covalent pyrimidine disease proliferation tumor mechanism myelodisplastic turn recommend demethylation cell cell cell use care suppressor promote drug cause could could could could low bond promoter group particular degradation dna dna divide syndrome act involve inhibitor place repress death administer longer methylation decitabine decitabine gene action take take progression 
1.33@dacogen cancer responce use include agent hypomethylating methy myelogenous hypomethylates leukemia anti japanese treat transferase inhibit company dna dna dna epigenetic strand expose syndrome sell stem drug eisai induce memory precursor myelodysplastic decitabine decitabine decitabine like subpopulation cell cell tumour tumour incorparated 
0.67@foming blewitt cancer cancer restore administration use hematological fda agent lecture hypomethylating myelodysplastic analog azacytidine reactivate note propagate inhibit epigenetic error enzyme leukemia susceptibility myeloid tumor tumor tumor hypermethylation hypermethylation nucleoside aberrant like like journal control suppressor suppressor cytidine also bond coursera front drug cycle apoptosis cell reverse reverse reference gene gene gene know syndrome dna carcinogenesis deoxy deoxy acute lyko covalent act demethylase irreversible methyltransferase oncol int silence silence treatment decitabine decitabine stresemann em em em em malignancy approve momparler 
0.67@cancer translation order use use compact agent silence newly capable must characterize treat elderly grow consider particularly well hypermethylation demethylating inhibit people permanently generally genome render factor demethylation cell cell cell cell cell cell methyl rna risk transcription transcription daughter erase work work work embryo healthy decitabine decitabine decitabine decitabine decitabine decitabine decitabine hematopoietic primordial free problem demethylate normally protein group develop develop dna dna dna dna dna dna dna dna divide divide blood bind bind syndrome syndrome myelodysplastic myelodysplastic rapidly methyltransferase methyltransferase widespread germ unavailable since methylation heterchromatin disorder create eventually enable 
2.0@suppressor suppressor cancer cancer cancer therefore dnmt dnmt dnmt produce tumour tumour tumour cause fuction decitabinebinds hypermethylated suppress unable dna dna irreversibly methylate bind dnmts gene gene inhibitor hypermethylation methylation decitabine decitabine daughter daughter daughter daughter maintain maintain demethylation cell cell cell cell cell cell cell 
2.0@compound series cancer methyltransferases state supresor activate use use certain order agent therapy mean result silence unmethylated replication type dna dna dna reaction bind enzyme demethylating gene consequently tumor block hypermethylation thus methylation decitabine decitabine work activity catalyze 
1.67@et cancer cancer inhibitor class nulceoside methyl methyl manner agent irreversible silence hypomethylation incorporation transferase transferase previously lead lead irreversibly methylated particularly well belong demethylating hypermethylation anticancer al cell cell drug drug expression dna dna dna dna dna dna faster therefore need analogue therapy target sequestration express prevent abnormally divide divide bind maintain dnmts dnmts gene gene effect result lung nguyen methylation decitabine decitabine work active 
2.0@suppressor effect class dnmt activate tumour tumour agent myelodysplastic anti island cpg dna dna dna dna syndrome demethylating gene enhance inhibitor belong methylation methylation decitabine decitabine decitabine demethylation removal removal 
1.67@dna dna cancer cancer silent restore activation administration hypermethylaion cause cause cause agent decitabine decitabine inactivation hypomethylation hypomethylation gene gene oncogene promoter inhibit cpg cpg either often hallmark act function function demethylating demethylating island island methyltransferase expression tumor normal belong directly work class cell cell enhance suppressor associate 
2.0@market dacogen cancer cancer state suppresor region suppressor suppressor suppressor produce via tumour tumour tumour tumour title agent agent typically hypomethylating eisai cancerous cancerous benefical growth gene gene gene gene hypermethylated hypermethylated drug grow cpg cpg cpg cpg often dna dna dna dna tumuors island island island function demethylating inhibit inhibit inhibit methyltransferase methyltransferase allow allow hypermethylation locate work hypomethylated hypomethylates return cell use would decitabine decitabine decitabine 
1.67@cancer cancer class use include agent whose myelodysplastic myelogenous silence growth leukemia make treat inhibit job stop precursor enzyme enzyme demethylating impact tumor tumor uncontrolled methylates cell methyl suppressor system cause cause acute mutation surround number anti immune group dna dna histone histone syndrome gene gene effect overactive attach belong thus methylation decitabine decitabine decitabine activity overactivity protein 
2.0@cancer instead dnmt dnmt dnmt regulation tumour chemically agent inactivation inactivation remain hypomethylation hypomethylation hemimethylated inhibit cytosine irreversibly cgi cgi guanine block hypermethylation dinucleotides implicate cell suppressor cytidine cytidine replication restoration context result result abundant occur dna dna dna dna dinucleotide bind act expression cpg gene gene methyltransferase analog division methylation methylation decitabine decitabine decitabine region incorporate attach associate 
2.0@cancer cancer higher growth last tumour tumour agent stop two hypomethylation susceptible make treat inhibit might whereas epigenetic epigenetic epigenetic epigenetic pass erase erase demethylating change change granddaughter way decitabine decitabine decitabine market dna dna dna dna cause therefore drug drug drug speculation therapy cell cell cell cell low dosage without anti level standard dose dont chemotherapy methyltransferase effect effect division due main actively rna daughter work work work return kill alter azacitidine azacitidine 
0.0@cancer decitabine growth spread cell interfere 
1.33@dna suppressor suppressor cancer expression cpg gene use reduce tumor tumor agent could demethylating decitabine decitabine hypermethylated treat island lead 
2.0@cancer cancer rate term dnmt unclear methyl likely long analog since since since azacytidine dnmti hypermethylated transferase unknown irreversibly decrease inhibitor especially tumor tumor mechanism normal neoplastic generally high anymore express demethylation cell cell cell drug suppressor suppressor dependent replication replication replication cause novo simply fast methylate anti treatment dna dna dna bind bind dnmts dnmts still gene gene gene effect effect upon methylation decitabine incorporate incorporate action complete de 
1.33@cancer cancer effect effect effect higher higher growth dnmt dnmt use use use use dnmts specific specific unknwon analog lower succesfully hypomethylation nucleotide nucleotide nowadays inhibit suppress myelodisplastic lead lead lead sensible hypermethylation unspecific island reduce tumor normal neoplastic link proliferative demethylation cell cell cell much much decitabine decitabine dependent generalise insert therefore accept replication healthy toxic suppression completely know genomic genomic treatment dna dna dose dose syndrome act function function function function cpg time highly rate rate cellular global unsuccesfully deregulate due silence silence expect gene gene gene regulate modify methyltransferase 
0.67@dna dna dna suppressor suppressor demethylating cpg cpg inhibit tumor agent decitabine decitabine inactivation activate methylation methylation hypermethylation gene gene demethylate often island island associate 
1.33@also proliferate restore formation may may agent hypomethylating incorporate relatively critical cytotoxicity hypomethylation inhibit adduct dna dna dna dna divide non rapidly covalent function gene proliferation induce methyltransferase methyltransferase cellular normal neoplastic decitabine decitabine decitabine decitabine decitabine attribute insensitive hypomethylates cell cell cell differentiation control 
2.0@different clinical cancer indicate use use cause mutation anemia agent hypomethylating target leukemia histone across wrap md type drug inhibit inhibit inhibit particular treatment dna dna dna generate around syndrome function ezh methyltransferase disease tumor chromatin myelodyspastic methylation genome widely widely blood decitabine decitabine 
2.0@unregulated cancer cancer cancer inhibitor inhibitor restore within dnmt produce tumour tumour since meet meet growth growth normally direct inhibit effectively decitabinealso category call belong belong demethylating severely reduce affect demonstrate cell cell cell cell cell cell cell cell cell cell much decitabine decitabine decitabine decitabine suppressor dependent transfer transfer antimetabolite drug drug cause interfer target number anti ase ase know metabolism dna dna dna dna divide divide cytotoxic bind function gene rapidly rapidly effect effect interact cellular control death division division replicate replicate thus methylation allow work work incorporate class 
0.0@belong histone ul ul decitabine azacitidine combination deacetylase 
2.0@cancer happen restore formation failure uncontrolled tend island proper presence growth reproduction characterize diminish affect lead lead suppress suppress potentially dna dna dna inhibitor cpg inhibit methyltransferase methyltransferase reduce tumor tumor tumor tumor chromatin hypermethylation hypermethylation silence methylation decitabine decitabine gene gene gene gene gene express cell cell occur nearby expression 
0.67@cytidine transfer transfer transfer restore formation methyl state hypomethylating incorporate incorporate analog also also meet meet gene replication normal group adduct may lead dna dna dna dna apoptosis strand strand form ase ase covalent act allow inhibit proliferation expression cellular cellular control due new decitabine factor role cell differentiation differentiation enable 
2.0@suppressor cancer proliferate daughter daughter dnmt activate progress use analogue myelodysplastic myelogenous unmethylated dnmti leukemia anti treat prevent dna dna irreversibly acute bind syndrome inhibitor dmnti gene aml effect tumor tumor division methylation release nucleoside mitosis incorporate cell cell cell cell methyltransferase decitabine decitabine 
1.0@growth growth growth cancer class minimise regulation methyl methyl agent process member change hypermethylated hypermethylated traditional genetic tumour tumour tumour decrease inhibit disruption lead clinical area promoter allow allow allow demethylating island research normal attain clear crucial nucleoside like next trial may level example example suppressor certain ependymoma cimp hopefully use analogue basis show group group act chemotherapy dna dna dna future shut epigenetic epigenetic recent expression expression expression cpg worse remove remove hope increase increase due methylation decitabine gene sensitive propose 
1.0@deliver abate methyl methyl carry agent transfer ly limit improper meet hypomehtlyating anti bind inhibit inhibit group group basically cytosine ase function grow effect tumor tumor tumor question hypermethylation due thus methylation methylation methylation methylation decitabine decitabine arise aberrant enzyme enzyme regulate 
1.67@cancer cancer cancer article disrupt slowly dnmt healthy healthy use stop mark replace also economist dnmti dnmti change susceptible make call grow addition class irreversibly well enzyme pattern pattern affect dnmtis genome speculate like like cell cell cell cell cell cell may may may transfer greater therefore epigenetic require therapy mean actually demethylate demethylate methylation methylation treatment dna dna dna dna dna divide divide kill bind chemotherapy inhibitor drug drug hence rapidly effect effect remove belong mother actively decitabine decitabine daughter work incorporate methyltransferase without 
1.67@cancer inhibitor inhibitor inhibitor lower neoplasm progress use inherit specific really myelodysplastic myelogenous since dnmti dnmti dnmti dnmti leukemia treat nucleotide tumor tumor irreversibly strand body dnmt bad mechanism good neoplastic release nucleoside demethylation cell cell cell much decitabine analogue high replication cause cause dose toxic kill dosage dosage anti anti anti presence dna dna dna dna dna dna dna divide therefor acute bind bind syndrome important still side effect effect effect effect effect unclear methyltransferase methyltransferase belong replicate new methylation longer come action rapidly 
1.33@cancer cancer methyltransferases use use agent phase hypomethylating myelodysplastic analog myelogenous growth treat repristinate inhibit molecule lead irreversibly precursor enzyme enzyme reduce tumor fact genome nucleoside purpose like cell cell tumour leukaemia suppressor suppressor commonly therefore therefore replication cycle apoptosis incorporate acute normally methyl group protect example dna dna dna surround bind syndrome gene effect control silence methylation decitabine decitabine lay action overactivity 
2.0@dna dna suppressor become allow demethylating gene tumour tumour effect agent methyltransferaseand decitabine unmethylated anti active inhibit use 
2.0@acid suppressor suppressor cancer dnmt tumor tumor methyl methyl cause likely nucleic target gene could inhibit often dna see bind appropriately group group methyltransferase demethylase demethylase remove remove silence thus methylation allow work active protein decitabine decitabine decitabine 
1.33@cancer predict dnmt methyl state agent specific process process goal lower dnmti potential inhibit silence epigenetic development around methylated enzyme island island island neoplasm tumor affect early turn irretrievably although aberrant cell cell cell cell cell way suppressor specifically methylating insert promote depend future replication replication analogue ability target target mimic become become best dysfunctional group dna dna originally dose unavailable bind nucleoside cpg cpg cpg methyltransferase inhibitor division replicate demethylated methylation methylation methylation decitabine decitabine decitabine decitabine decitabine daughter daughter work activity delivery delivery delivery return action de 
0.67@cancer characteristic class remove regular regular cause analog since cancerous anti try thedna copy dna dna divide divide strand rapidly bind inhibitor time methyltransferase methyltransferase effect tumor affect belong longer thus methylation decitabine daughter incorporate demethylation cell cell cell cell cell much nuceloside 
1.33@dacogen cancer effect wait use use use slow agent already leukemia myelogenous frequently growth layer make heritable tandem suppress suppress previously lead epigenetic epigenetic see inhibitor think demethylating myeldysplastic hard difficult penetrate susceptible treatment trial way decitabine decitabine lung tumor tumor tumor tumor advance successfully untreated drug drug drug drug combination combination therapy acute wing type traditional show syndrome dna histone allow chemotherapy sell function still gene gene resume mitiotically remove presume deacetylase human methylation permanent em first label 
2.0@slightly cancer cancer demethylates dnmt activate agent stop rib hypomethylates de growth inhibit call island island aza previously previously strand methylated methylated demethylating subsequently effective tumor tumor ribonucleoside read em cell eoside decitabine decitabine decitabine suppressor suppressor transfer antimetabolite recommence drug drug cause apoptosis oppose unchecked demethylate help help oxy dna dna dna dna dna dna reverse ase cpg cpg gene gene hence similar silence methylation rna rna region incorporate incorporate meet would azacitidine 
2.0@dna dna dna cancer restore canclear function cpg gene methyltransferase suppressant remove normal silence demethylating byinhibitingdna thus methylation methylation decitabine cell cell island drug tumor 
1.67@cancer inhibitor cgis class dnmt dnmt dnmt activity use use use could could could stop unmethylated treat call chemotherapeutics greatest epigenetic strand strand methylated methylated well well belong happen tumor mechanism block normal hypermethylation thus parental substrate enzyme cell cell cell cell cell cell tolerate one one also suppresor patient irreversibly replication hemi incorporate low myelodisplastic methyl group dna dna dna dna dna dna divide divide dose bind syndrome drug drug affect affect rapidly effect methyltransferase division division undergo new methylation decitabine decitabine decitabine decitabine decitabine daughter gene lay action combine 
2.0@cancer cancer cancer cancer characteristic demethylates dnmt dnmt dnmt use concentration since malignancy might normal island cpg affencted irreversibly inhibitor inhibitor inhibitor hypermethylation severely optimal mechanism affect neoplastic epigenome maximal nucleoside enzyme drug drug drug cell cell cell tumour suppressor decitabine decitabine decitabine decitabine tolerable dependent dependent replication analogue toxic low low like anti nonspecific treatment treatment dna dna dna divide divide dose dose bind dnmts still gene rapidly effect effect effect unclear methyltransferase belong replicate ul ul work incorporate action rather haematological 
2.0@cancer cancer cancer cancer methyltransferases methyltransferases growth growth dnmt excess use problematic agent agent hypomethylating also necessary evaluate hypomethylation hypomethylation leave transposition insert inhibit carefully suppress decitabine decitabine lead lead epigenetic sequence involve involve attack grow reduce reduce reduce reduce tumor tumor intergenic panacea particular hypermethylation hypermethylation silence silence global inappropriate one suppressor methylating reexpress therefore area relate fewer drug tumorous mutation result unchecked know know though dna dna dna dna dna mark mark mark allow allow expression gene gene gene resume enzyme globally repeat belong unrepressed methylation methylation methylation methylation methylation methylation methylation deletion work class untargetted form 
2.0@cancer myelodisplasic restore restore dysregulation use agent agent hypomethylating growth multiplication andcell inhibit lead lead epigenetic allow demethylating tumor block normal anticancer demethylation demethylation cell cell control control blockage belong suppressor suppressor suppressor promote therefore regulategrowth occur treatment dna dna dna dna process syndrome act function gene gene gene effect increase division division interfere methylation methylation decitabine decitabine decitabine activity class 
2.0@cancer cancer class class term reactivation activate use agent specific long long hypomethylating entirely silent hypomethylation hypomethylation oncogene genetic change demethylation demethylation inhibit act previously lead lead clinical epigenetic epigenetic reversible discuss consequence consequence efficacy tumor mechanism question particular feature give clear alteration primarily unknown trial may may may may may promoter hematopoetic carcinogenesis carcinogenesis induction drug drug whether mutation result loss trigger know genomic treatment dna dna however action demonstrate example seconday function gene gene gene methyltransferase effect epigenetically widespread global silence due thus thus decitabine decitabine region period hypmethylation imbalance present 
0.67@cytosine cytosine cytosine cancer transfer dnmt dnmt dnmt methionine ade dependent dependent trap activity activity cytotoxicity independent covalently anti normally exert suggest group group group group prohibit addition addition dna dna dna dna position ring ring ring action covalent covalent inhibitor demethylating thereby prevent dnmts induce damage complex may nosy methylation methylation release bond bond incorporate form form form methyl methyl methyl decitabine decitabine decitabine decitabine 
2.0@suppressor cancer happen lead class western tumor tumor drug drug could since anti might inhibit potentially dna dna dna dna area therefore expression demethylating demethylating group nearby effect remove remove methylation methylation decitabine atached gene gene gene mean regulate methyl 
2.0@cancer article growth growth last cell cell cell cell cell tumour tumour slow agent epicentre economist hypomethylation change inhibit granddaughter epigenetic epigenetic pass allow demethylating dr proliferation tumor tumor tumor mechanism block link speculate thereby way suppressor suppressor also promote erase nonreversible drug combination suppression baylin synthesis immune dna dna dna dna histone covalent expression expression gene gene methyltransferase inhibitor induce deacetylase division decitabine decitabine decitabine daughter incorporate differentiation stimulation alter 
1.33@already cannot oncogenic likely tumor tumor tumor agent agent stop appropriate mark dosage encode introduce unmethylated become hypermethylated hypermethylated obtain island island suppress suppress addition dna dna epigenetic cpg cpg gene gene remove remove methylation decitabine daughter lay express demethylation cell cell 
1.33@cancer inhibitor inhibitor inhibition hypomethylation hypomethylation overmethylation tumour tumour stop hypomethylating hypomethylates growth direct incorporation decrease inhibit exert previously class epigenetic allow demethylating proliferation reduce reduce hdna phosphorylation demethylation cell cell uncontrolled suppressor therefore cause cause trigger anti amount dna dna dna dna dna dna dna histone histone expression believe methyltransferase methyltransferase effect effect cellular antineoplastic belong due silence methylation decitabine decitabine decitabine decitabine decitabine gene 
2.0@cancer cancer dnmt dnmt dnmt dnmt dnmt progress use use maximum tend analog lower md treat irreversibly enzyme thereby group group effective effective tumor normal nucleoside demethylation cell cell cell replication decitabine decitabine suppressor dependent transfer transfer patient drug drug drug drug target methyl methyl prevent dna dna dna divide dose bind expression gene gene rapidly inhibitor inhibitor must especially replicate actively allow incorporate aml 
0.0@methyltransferases methyltransferases inhibition sugar state tend critical azacytidine azacytidine predominantly hypermethylated hypermethylated inhibit aza achieve cytosine step efficient enzyme thereby tumor tumor directly nucleoside maintain lead drug decitabine suppressor analogue use use actively need cause idea become component whereas dna dna dna dna dna cell cell suitable function gene methyltransferase inhibitor deoxycytidine catalyze division modification silence methylation rna rna incorporate incorporate widely influence chemical 
2.0@cancer able tumour tumour agent stand island suppress irreversibly strand methylated demethylating inhibit take take due nucleotide release cell cell decitabine decitabine suppressor get get regain drug drug analogue thedaughter describe agentis promotor dna dna dna dna divide bind bind function cpg gene gene methyltransferase methyltransferase effect effect place copy quickly replicate work methylation methylation longer longer daughter cellsthey incorporate whenreplication 
1.33@dacogen classify use chemically agent agent myelodysplastic analog myelogenous hypomethylates characterize treat transferase inhibit expression epigenetic strand strand precursor think demethylating tumor tumor mechanism hypermethylation convert methyltransferaseafter nucleoside tumour leukaemia suppressor suppressor cytidine irreversibly relate drug analogue decitabine decitabine decitabine decitabine decitabine demethylated inhibitor inhibitor anti dnm know chain dna dna dna dna dna acute bind syndrome dnmts still gene gene gene gene effect unclear silence rna incorporate incorporate malignancy action haematological 
2.0@suppressor suppressor rate become class therefore dnmt cannot cannot via tumour tumour tumour tumour process otherwise since silence growth growth effect anti bind occur effectively division dna dna dna dna dna irreversibly know methylated epigenetic inhibitor inhibitor give gene gene methyltransferase methyltransferase reduce reduce upon mean belong demethylated methylation methylation decitabine decitabine incorporate enzyme active cell replication would 
2.0@could could could rate higher higher class dnmt dnmt dnmt dnmt regulation methyl methyl methyl slow add major neoplasic dnmti inhibition call inhibit addition addition achieve dmnts epigenetic decitiabine repression belong tumor tumor mechanism block nucleoside like like cell cell cycle use decitabine decitabine suppressor suppressor dependent analogue irreversibly replication cause improve toxic avoid compose low anti bind promoter group group group involve dna dna dna however dose dose dose decrease expression expression expression inhibitor drug drug gene gene gene gene gene gene effect effect increase division methylation allow incorporate would 
1.67@suppressor suppressor suppressor suppressor cancer reduce patient therefore activation relate tumour tumour tumour tumour tumour agent could inactivation anti oncogene island island cpg cpg lead dna dna dna hypermethylation hypermethylation demethylating gene gene effect remove abnormality belong thus methylation methylation decitabine decitabine activate 
1.67@one suppressor suppressor cancer methyltransferases activate tumour tumour tumour growth do decrease decrease inhibit promoter dna dna dna see prevent inhibitor gene gene normal methylation methylation methylation decitabine decitabine work active may level level 
2.0@cancer instead dnmt dnmt dnmt dnmt dnmt synthesize synthesize methyl inherit trap process process two analog since de unmethylated elsewhere molecule recognize epigenetic epigenetic strand strand strand strand survive establish enzyme inhibitor island undergo undergo block somatic nucleoside maintain many cell cell cell cell way decitabine decitabine decitabine decitabine one cytosine cytosine cytosine therefore consequently cannot methylates replication replication novo without parent parent damage dna dna dna dna dna mark mark mark mark bind bind act newly newly cpg irreversible important control end replicate replicate methylation methylation double mitosis mitosis incorporate selectivity form present present 
2.0@suppressor suppressor critical therefore therefore tumour tumour tumour tumour cause island anti result cytosine hypomethylation effect sit inhibit dna dna dna dna dna dna irreversibly bind le allow cpg grow methyltransferase methyltransferase methyltransferase inhibitor hypermethylation silence methylation decitabine decitabine gene gene incorporate express drug 
2.0@could could reduce dnmt dnmt inhibitor methyl fda agent two dnmti leukemia sit sit instability act tumorgenesis cpg cpg expression clinical epigenetic precursor enzyme demethylating island impact tumor tumor tumor tumor tumor block normal hypermethylation hypermethylation turn frase factor case demethylation ra may genome one reduction like effective effective azactidine drug drive drive drive drive decitabine decitabine cell do supress promoter group together potentially dna dna dna dna however potentialy acute allow syndrome use myelodysplastic outcome gene gene hence supressing supressing neoplasia belong methylation methylation would would wide activity approve approve adverse 
2.0@enzymatically inhibitor inhibitor growth lymphoma dnmt dnmt dnmt dnmt responsible likely myelodysplastic hypomethylation cancer inhibit inhibit often irreversibly strand promoter promoter display discuss allow island island tumor tumor tumor inactive dir usually new render cell cell pre expression suppressor suppressor disorder therefore therefore analogue therapy result show prevent prevent particular dna dna dna dna dna bind syndrome nucleoside switch switch cpg cpg gene gene gene methyltransferase effect division main methylation methylation methylation methylation decitabine decitabine decitabine ltr incorporate promise 
1.67@blewitt cancer article higher malignancy marnie use use fda specific epicentre myelodysplastic myelogenous neoplasic dosis dosis azacitine date video inhibitor inhibitor source dr reduce helpful mechanism dnmtis hypermethylation may demethylator unclear primarily tumour tumour leukaemia suppressor dependent also therefore percursor replication april toxic acute anti solid lecture chemotherapy dna dna dna histone bind syndrome dnmts still gene methyltransferase effect haematol deacetylase decitabine decitabine decitabine usefulfor incorporate economist approve form combine small 
2.0@cancer cancer cancer stronger inhibition restore dnmt dnmt dnmt dnmt use agent myelodysplastic analog frequently might inhibit treat unable irreversibly strand enzyme demethylating island reduce tumor tumor tumor normal normal nucleotide nucleotide nucleotide suppress cell cell cell cell cell much much suppressor suppressor dependent therefore excessive replication replication demethylated promoter promoter parent capability dna dna dna dna dna get bind bind syndrome inhibitor cpg gene gene effect upon copy copy copy especially replicate silence methylation methylation methylation methylation methylation decitabine decitabine decitabine decitabine daughter daughter possible incorporate come action action 
1.67@cancer cancer cancer epigenie marnie tumour tumour include agent agent epicentre anti code economist silence genetic back chromatin chromatin tumor coursera pack video enzyme demethylating densely biochimie reduce hassler normal egger turn thus express cell cell methyl decitabine decitabine decitabine suppressor suppressor methylating epigenomics cancerous read become euchromatin lecture dna repress histone histone histone heterochromatin gene gene gene gene effect remove control ezh epigenetics epigenetics methylation methylation allow unravel active protein protein protein 
0.0@mean growth order others use use every agent specific myelodysplastic myelogenous stage substance useful treat decrease decrease decrease grow whereas even boths precursor allow demethylating island island enhance reduce reduce tumor clear hypermethylation may may fact supressors role mixture tumour tumour tumour tumour tumour tumour level level level leukaemia study therefore therefore general drug tumorgenecity dangerous dependentand see depletion promoter particular dna dna dna dna dna acute syndrome expression cpg cpg gene gene hypometylation must repeat since methylation methylation methylation methylation methylation decitabine decitabine decitabine context supressor would 
2.0@cancer cancer effect growth tumour particulary agent whose epicentre ability hypomethylation hypomethylation anti level inhibit job stop dna dna dna demethylating island reduce tumor cpg methylation decitabine cause gene activity cell du uncontrolled supressor 
1.67@several methyltransferases bind function drug slow agent cause result transcription decitabine decitabine hypomethylation hypomethylation factor lose tumorogenesis block partially production 
1.0@methyltransferases decitabime andcdkn may may may agent impair growth type useful oncogene might enhancer island island restore latter help ezh tumor tumor tumor normal hypermethylation hypermethylation turn repair demethylation demethylation demethylation cell cell suppressor suppressor zeste indeed inflict ability tothe result trigger balance promoter rb dna dna dna histone environment expression cpg cpg gene gene crutial silence homolog methylation decitabine arise insult 
2.0@et cancer randomize hypomethylation outcome use kantarjian aberrantly pattern myelodysplastic myelodysplastic myelogenous reactivate apply inhibit dna dna dna dna know help establish demethylating island correctly normal normal hypermethylation hypermethylation express cell tumour tumour leukaemia suppressor suppressor iii patient therefore consequently improve drug cause evolve cycle result phase methylation methylation region promoter treatment abnormally acute syndrome syndrome cpg gene gene methyltransferase inhibitor silence silence due due well al decitabine decitabine decitabine decitabine disorder em em em em em specific study 
1.67@different cancer cancer cancer devision dnmt dnmt dnmt use state thatdecitabine hypomethylating since since since hypomethylation treat decrease inhibit irreversibly effectively deleterious hypermethylation island island reduce affect affect generally clear cell cell cell may therefore divide drug healthy target target moreover type myelodyplastic myelodyplastic dna dna however bind syndrome syndrome site still rapidly effect dependant preferentially global cpg cpg methylation methylation decitabine decitabine decitabine somehow active 
2.0@mitotically cancer cancer proliferate restore dnmt synthesize methyl cycle newly transfer meet frequently heritable inhibit inhibit recognize irreversibly strand strand tumour methylated inhibitor summary normal hypermethylation dilute cell cell cell cell much nuceloside analogue therefore replication rreversibly hemi incorporate anti bind bind presence dna dna dna dna dna dna dna dna ase dnmts dnmts dnmts dnmts effect since methylation methylation methylation decitabine decitabine decitabine decitabine lay 
1.67@suppressor suppressor cancer inhibitor class uncontrolled cause agent stop growth anti job dna dna dna dna epigenetic silence demethylating demethylating demethylating gene gene gene effect tumor tumor tumor affect belong methylation decitabine decitabine decitabine cell 
1.33@reduction reduction dependent methyltransferases although dnmt tumor may analogue manner agent align align silence irreversibly center center cancerous reactivate growth round prevent prevent cpg cpg dna dna dna dna divide action bind daughter division still island island reduce unclear mechanism hypermethlation copy demethylating suppressor methylation methylation methylation decitabine nucleoside gene incorporate cell cell cell replication would would 
2.0@introduction instead irrevocably dnmt dnmt dnmt tumour fda agent specific myelodysplastic analog analog growth hypermethylated overall drug drug island suppress molecule epigenome demethylating proceed take reduce reduce optimal normal neoplastic contribute content release nucleoside like cell cell cell cell cell pre suppressor dependent indicate replication replication replication toxic uninhibited context synthesis anti prevent treatment dna dna dna dna dna dna dose action bind bind syndrome act cpg gene methyltransferase effect effect silence thus methylation methylation methylation decitabine decitabine incorporate approve tumorigenesis 
2.0@suppressor inhibitor way demethylated without express become antitumor island lead lead dna dna dna divide methylated demethylating inhibit methyltransferase effect effect tumor cpg new actively decitabine methylation cell cell 
2.0@cancer inhibitor inhibition dnmt dnmt progress use agent process myelodysplastic leukemia island irreversibly strand myeloid tumor tumor hypermethylation high demethylation demethylation demethylation replication suppressor cause nucleoside drug analogue appropriate appropriate result result low dosage anti amount dna dna dna dna dna dna dna dose acute bind syndrome act cpg gene aml effect copy methylation decitabine decitabine daughter incorporate methyltransferase methyltransferase 
1.67@plastic dacogen lat also abnormal productionof thy drug cause agent agent eisai condition condition fix economist gene md md pome ye know inhibit dna dna dna dna blood cell hematologicalmedical syndrome sell human demethylating ah methyltransferase methyltransferase expression y wikipedia wikipedia due methylation inappropriate ineffective article hypomethylates lod inhibitingdna myelodysplasia decitabine decitabine decitabine 
2.0@suppressor suppressor decrease prevent inhibitor dnmt cpg gene gene tumour tumour tumour cause decitabine hypermethylation silence methylation allow observe cell island expression 
2.0@dacogen commercialize methyltransferases inhibition depend dnmt progress may agent island newly result result bring silence hypomethylation hypomethylation gene gene eisai multiplication copy inhibit dna dna dna strand reverse erase suppression demethylating progressive proliferation proliferation tumor tumor control cpg thus thus methylation methylation genome mitosis synthetized cell global would decitabine 
1.67@itsdna azac azac manner agent myelodysplastic myelogenous malignancy deoxycytidine aza aza aza aza cytosine epigenetic precursor enzyme block areanalogues dc dc passive one irreversibly fda drugdecitabine jones result inhibitory ofhematologic dna dna citidine acute bind syndrome function function gene methyltransferase methyltransferase methyltransferase pa similar reversal silence fortreatment methylation michalowsky progressive incorporate la approve de 
1.67@suppressor suppressor daughter therefore activate uncontrolled analogue include agent mean mean cancerous growth unmethylated decrease decrease prevent prevent dna dna dna dna dna irreversibly bind bind act enzyme demethylating inhibit section methyltransferase formation methylation methylation directly nucleoside gene gene incorporate come cell cell tumour tumour tumour decitabine decitabine 
2.0@inhibitor inhibitor class thus activate tumour state ie decitabine decitabine stop stop growth replication back transferase transferase regulate dna dna dna dna irreversibly bind function gene gene gene slot lack belong go methylation methylation casuse activity original original cell methyl methyl supressor 
2.0@cancer cancer inhibitor abnormal restore available dnmt dnmt produce xml xml myelodysplastic hypomethylation element abnormally harm might island lead irreversibly latter methylate methylated methylated en en en en hypermethylation demethylating demethylating tumor tumor tumor tumor intergenic contribute whether fact genome nucleoside instability repetitive region typically suppressor suppressor analogue become patient patient depend drug cause hemi whole u u u u present anti type type occur show genomic potentially dna dna dna dna dna divide cell cell bind syndrome le le expression cpg gene methyltransferase effect lang lang lang lang stage silence silence thus decitabine decitabine decitabine decitabine decitabine mitosis incorporate continue progressively help help 
2.0@cancer inhibitor class available dnmt tumour tumour state state myelogenous hypomethylation transferase transferase suppress regulate irreversibly methylated particularly precursor demethylating order order correctly block hypermethylation nucleoside actively dnmi methyl methyl expression analogue cease drug drug certain certain pas pas cell cell cell result histone anti normally treatment dna dna dna dna dna acute bind bind function gene gene effect remove due methylation methylation methylation decitabine decitabine decitabine daughter work incorporate come leukaemia would 
2.0@decline enzyme demethylates dnmt dnmt dnmt replication cause cause decitabine decitabine decitabine decitabine mark mark mark analog without substance gene gene gene make effective counter parent island island dna dna dna dna dna divide strand strand pass bind function cpg cpg inhibit able tumor tumor tumor tumor similar copy copy set hypermethylation longer longer silence methylation methylation methylation methylation allow nucleoside nucleoside level daughter daughter express cell cell disable suppressor suppressor release 
2.0@inhibitor inhibitor class dnmt dnmt dnmt regulation regulation tumour tumour tumour process disease methylating growth growth expect inhibit dna dna dna dna rapidly work see responsible enzyme proliferation reduce affect neoplastic rase myelodysplastic ensure nucleoside responsibe cell cell cell methyl supressor one specifically certain drug analogue improve cause result methylate region promoter prevent treatment reduction divide mark mark action bind expression fe thus gene gene resume go remove time control new methylation methylation methylation decitabine decitabine decitabine decitabine daughter mitosis reproduce approve tra take would would would would 
1.67@methyltransferases term dnmt dnmt use use compact agent long cytoside cannot hypomethylation might affect island treat irreversibly inhibitor think facilitate take reduce put mechanism normal myelodysplastic release demethylation cell cell cell cell cell tumour tumour tumour tumour expression suppressor suppressor divide divide divide replication analogue whether suppression result result result result cancerous promoter dna dna dna dna get availability bind syndrome le le dense cpg gene gene gene methyltransferase methyltransferase effect unclear chromatin word since methylation methylation decitabine decitabine work mean action 
2.0@tumour tumour tumour tumour tumour state agent stop hypomethilating already myelodysplastic meet sit sit treat grow grow see hyper island reduce reduce normal normal hypermethylation supressors hilum use inhibit supressor itis drug promotors specific lie anti normally thedna thednaby hypomethylated syndrome expression expression cpg gene gene gene methyltransferase effect silence ti methylation methylation decitabine decitabine mean methastasis enable 
1.67@cancer cancer activation need mostly agent agent agent agent epigenitic switch modifier transcribe hypermethylated protein demethylation demethylation achieve dna dna dna dna reverse reverse act act act silence demethylating demethylating demethylating gene gene gene effect pattern normal normal epigeniticmeans belong methylation decitabine decitabine decitabine region region unmethylate cell cell cell control alter 
1.33@dna dna suppressor cancer group allow demethylating gene methyl effect remove remove agent tend cpg methylation hypermethylated anti express decitabineis island tumour tumour would would 
1.33@dependent inhibitor class dnmt dnmt synthesize tumour analogue subsequent activity free de replication novo absence absence dna dna dna irreversibly action bind daughter dnmts anti group effect effect upon mechanism belong due thus methylation decitabine nucleoside em lay give cell downstream methyl deplete 
2.0@cancer methyltransferases dnmt dnmt dnmt dnmt progress use fda trap mark two analog cannot dnmti hypomethylation leukemia back inhibit inhibit inhibit lead epigenetic strand strand strand strand body methylated methylated inhibitor enzyme thereby thereby myeloid tumor tumor mechanism dilluted hypermethylation turn genome genome nucleoside passive passive may suppressor suppressor decitabine decitabine decitabine decitabine decitabine dna dna dna dna dna dna dna insert daughter daughter daughter understand replication certain dir reactivate entire natural normally fully know particular split process acute syndrome myelodysplastic gene gene gene aml effect demethylation demethylation silence vitro new new methylation methylation double ltr lay approve methyltransferase associate 
1.67@dacogen cancer cancer cancer methyltransferases abnormal abnormal mitotically use untouched include agent agent agent japenese mark two article article economist leave breakthrough treat mention market heritable epigenetic epigenetic intracellular consider inhibitor inhibitor demethylating absence dnmt dnmt mechanism normal normal strictly fact present directly nucleoside appearance name cell host one commercialize analogue erase therapeutic replication cause chemotherapeutic exact bind clone presence treatment dna dna dna dna epicentre action dependent syndrome act myelodysplastic still irreversible methyltransferase effect unclear cellular enter new signal decitabine decitabine decitabine influence hypomethylator azacitidine 
1.33@dacogen inhibitor inhibitor available dnmt produce yet dnmts fda japanesse two detail meet meet change leukemia myelogenous market act act act effective epigenetic anyhow precursor firstly demethylating inhibit as mechanism rase bond name drug tra one dependent transfer nucleoside agent agent manner replication analogue prove reverse fully group company dna dna dna dna understand acute syndrome fe eisai irreversible aml myeloblastic currently decitabine decitabine create incorporate approve 
1.67@dna inhibitor le dnmt dnmt cpg island tumour tumour effect hypermethylation analogue silence methylation decitabine nucleoside gene anti inhibit decrease prevent supressor 
1.67@cancer cancer inhibitor abnormal growth growth dnmt use slow could stop mark susceptability destruction also change generation decrease inhibit epigenetic pass en methyltransferaseinhibitor tumor tumor grow hypermethylation island island cell cell cell may suppressor dna dna dna transfer deleterious methyltransferasethereby drug cause result cancerous shore erasure conjunction potentially standard histone chemotherapy cpg cpg rapidly rate irreversiblybinding deacetylase increase decitabine decitabine daughter incorporate without 
2.0@abnormal growth dnmt dnmt administration synthesize methyl sequester analog analog azacytidine hypomethylation newly transferase island lead cytosine cytosine irreversibly marrow bone unlike proliferation tumor tumor normal hypermethylation may may like replace regulate stem blood expression expression suppressor methylating promote drug suppression result unchecked dna dna dna cell cell cell bind syndrome myelodysplastic cpg gene gene gene continue inhibitor remove location silence silence thus decitabine decitabine action 
1.67@elod plastic cancer methyltransferases devision pharmacologically reactivation use use cytidine specific analog desoxycytidine hypomethylation hypomethylation md genetic unlike solid expression correlate epigenetic reversible inhibitor inhibitor link decitabineacts island dnmt dnmt tumor tumor block hypermethylation potent case cell cell cell tumour suppressor suppressor decitabine decitabine decitabine growth lesion dependent also butit alteration need pluripotency y loss low anti alza promoter treatment treatment dna dna dna get allow syndrome function cpg gene gene gene effect induce induce silent methylation dnainneoplastic work work incorporate action differentiation replication 
1.67@cancer dnmt dnmt dnmt every agent mark epigenome analog since growth overall decrease inhibit lead strand operation enzyme order tumor affect hypermethylation rely nucleoside cell cell rapid cytidine hypomethylating mitotic replication adversely inheritance halt irreversably dna dna get duplicate bind bind division division undergo methylation methylation decitabine decitabine daughter incorporate enable tissue 
1.33@dna dna mean cancer cancer cancer also help silence silence fight supression state tumor agent agent demethylating demethylating demethylated methylation decitabine decitabine methylated gene gene express express cell inhibit would would would 
1.33@cancer inhibitor patient order mitotic tumour toxic become analog prescribe dosage high anti bind parent nucleotide class dna dna dna dna dna dna dna dna irreversibly strand strand strand help enzyme inhibit methyltransferase methyltransferase methyltransferase methyltransferase effect heritability copy copy belong thus methylation methylation methylation release daughter daughter facilitate past replication decitabine decitabine decitabine decitabine 
0.0@standard cancer cancer every disrupt erase formation tumor tumor may slow agent agent phase cycle break chemotherapeutic change susceptible make transmission call prevent class dna epigenetic epigenetic malignant kill inhibitor demethylating rather nature upon growth belong rely would daughter cell cell cell cell alter decitabine 
2.0@suppressor cancer patient progress drug state manner agent ability myelodysplastic leukemia md hypermethylated inhibit treatment dna dna lose syndrome usefull enzyme demethylating gene methyltransferase inactivate tumor normal antineoplastic thus methylation decitabine decitabine region activity express 
1.67@cancer cancer cancer cancer cancer proliferate overmethylation use include mutation correct since growth make treat decrease lead even help help enzyme furthermore dnmt tumor tumor tumor uncontrolled normal lot cell cell cell cell cell may may suppressor suppressor dependent lower therefore drug drug cause cause histone dosage replication prevent dna dna dna divide surround affect methyltransferase inhibitor overactive keep silence methylation methylation decitabine gene gene gene active rapidly 
1.0@mitotically cancer methyltransferases last effective yet allis deoxynucleoside since succesfully overall tumour inhibit aza indicate cytosine know therefore hypermethylation myeloid mechanism round affect pre clear epigenetics although triphosphate demethylation cell cell cell methyl decitabine decitabine decitabine decitabine suppressor patient erase divide drug three metabolize appropriate condition experiment progressive become occur subsequent group prognosis treatment treatment dna dna dna dna dna however dose synthesis syndrome use inhibitor cpg poor demethylated effect interact deoxycytidine elderly replicate low methylation methylation preliminary mainly gene incorporate incorporate dysplastic return indicator follow leukemic 
1.33@effect class spread agent accomplish hypomethylating hypomethylation anti affect inhibit dna epigenetic call inhibitor multiply methyltransferase reduce tumor tumor normal belong thus decitabine decitabine decitabine cell cell nearby 
2.0@methyltransferases abnormal restore reactivation use activity tend inactivation myelogenous de growth growth hypermethylated treat lead lead neoplastic survive precursor reduce normal feature turn myelodysplastic high cell cell cell cell cell tumour tumour leukaemia suppressor suppressor cytidine lower drug analogue cause cause cause suppression result reverse become become bind level group treatment dna dna dna dna dose dose acute cytotoxic syndrome increase irreversible methyltransferase tolerate death division division thus methylation methylation decitabine decitabine decitabine decitabine disorder gene incorporate covalently haematologic 
2.0@begin cancer able way anit methylating de de growth oncogene regulatory incorporation call inhibit inhibit regulate sequence methylated enzyme thereby affect nucleoside substrate express cell cell cell cell tumour decitabine decitabine decitabine un un cytidine transcription regain replication cause cause adversely analogue controlledand present allow become become protein presence dna dna dna dna dna dna dna divide bind act gene gene chemical effect methyltransferase methyltransferase control methylation rna rna rna rna incorporate form rapidly 
2.0@cancer cancer proliferate change dnmt dnmt use use state example epression way alternatively hypomethylation susceptible make treat inhibit lead irreversibly establish thereby unlike proliferation reactivation tumor tumor block normal dnmtis epigenome myelodysplastic genome cell cell cell cell may decitabine decitabine decitabine suppressor suppressor patient require apoptosis activity result syndrome dna dna dna dna expression expression promotion reverse bind chemotherapy dnmts drug drug gene gene methyltransferase inhibitor inhibitor inhibitor induce chromatin silence silence interfere methylation would incorporate action enzymatic reactivate 
2.0@cannot class tumour tumour tumour myelodysplastic myelogenous leukemia hypermethylated treat inhibit occur whereas amount strand strand help precursor silence hypomethylater reduce turn epigenome overact express license cell methyl tra suppressor suppressor decitabine decitabine decitabine decitabine categorise surround anti euchromatin prevent prevent prevent dna dna dna dna dna histone histone syndrome fe gene gene gene tumourigenisis effect generate demethylating rase methylation methylation methylation rna rna wide associate methyltransferase azacitidine 
1.33@cancer also greater low dnmt use use cause agent myelodysplastic myelogenous chemotherapeutic anti increase increase treat show show prevent effectiveness act dna dna divide divide dose action bind syndrome precursor inhibitor demethylating rapidly effect effect effect methyltransferase normal normal neoplastic dnmtis due thus actively decitabine decitabine therapeutic hdacis demethylation cell cell drug tissue 
1.67@cancer reexpression genomewide epithelial produce use exposure include hypomethylating stem myelogenous hypomethylates change regulatory treat decrease inhibit response inhibition sustain strand promoter culture demethylating tumor key primary like cell cell leukaemia transient drug decitabine decitabine pathway low antitumor antitumor show subpopulation dna dna dna dna dose acute cytotoxic syndrome myelodysplastic gene methyltransferase effect cellular memory antineoplastic finally finally methylation double accompany aml leukemic 
1.67@suppressor inhibitor dnmt dnmt dnmt dnmt methyl add irreversibly analog since treat decrease group incorporation dna dna get bind bind site stick methyltransferase effective tumor tumor hypermethylation methylation decitabine decitabine decitabine decitabine nucleoside gene come hence 
2.0@dnmtis dnmtis dnmtis myeloid higher class progress use fda agent myelodysplastic transfer malignancy leukemia useful hypermethylated call inhibit irreversibly nonspecific level inhibitor inhibitor enzyme demethylating reduce mechanism neoplastic hypermethylation nucleoside nucleoside area demethylation tumour suppressor lower patient therefore epigenetic replication analogue function toxic mean therapeutic anti methyl show group treatment dna dna dna dna however dose dose acute bind syndrome act dnmts dnmts drug gene aml aml effect range belong longer silence methylation decitabine narrow work incorporate approve methyltransferase haematological 
2.0@cancer effect dnmt dnmt use state fda myelodysplastic myelogenous malignancy leukemia approve incorporation treat irreversibly precursor allow demethylating neoplastic hypermethylation nucleoside cell cell tumour tumour suppressor suppressor dependent lower high analogue toxic result unmethylated anti show good dna dna divide dose dose acute bind syndrome act function function gene gene rapidly inhibitor preferentially division decitabine decitabine decitabine return action resume haematological 
1.67@one cancer cancer reduce indeed therefore imprint tumour loss therapy target dnmti dnmti problem anti mention suppress common dna dna dna epigenetic dose reversible decrease decrease decrease depend inhibitor gene methyltransferase effect neoplastic hypermethylation modification silence methylation methylation methylation decitabine decitabine drug drug level level level 
2.0@suppressor cancer cancer faster dnmt dnmt activate tumour dependent analog dnmti dnmti cgis hypermethylated effectively inhibit action dna dna dna dna irreversibly kill bind act affect methyltransferase methyltransferase inhibitor upon result normal division replicate replicate actively decitabine decitabine decitabine decitabine nucleoside gene mean perhaps demethylation cell cell cell cell replication 
0.33@gene gene gene suppressor cancer transcription class activate tumor tumor tumor tumor tumor develoopment process deactivation suprssor effect anti oncogene call prevent imply epigenetic histone inhibitor inactivate knudson supressing multi block believe belong supresson methylation allow thatworks theory hit decitabine decitabine 
2.0@suppressor dependent depend dnmt dnmt hypomethylated use agent myelodysplastic low malignancy hypermethylation anti know inhibit analogous dna dna dna irreversibly dose bind syndrome dnmts demethylating gene gene inhibitor unclear mechanism still suspect methylation decitabine decitabine although work incorporate replication tumour tumour haematological belong 
1.67@size height apostosis add since reactivate growth unmethylated unmethylated unmethylated decatabine overall inhibit passively irreversibly strand strand methylated methylated pair tumor nucleotide nucleotide mutation style operate font program many cell cell cell cell control expression suppressor methylating dnmt dnmt cg abundance replication replication cause hemi novo degenerate gain px px prevent dna dna dna dna dna dna dna dna bind death inhibitor gene gene methyltransferase effect induce must line increase silence replicate methylation methylation methylation decitabine decitabine daughter em em incorporate active action attract de 
2.0@dna suppressor cancer cannot aremethylatedso pressor cpg gene gene cpgislandsso tumor tumor demethyline decitabine metylates express cell island decitabinede exprest 
2.0@cancer cancer inhibitor inhibitor dnmt dnmt dnmt dnmt dnmt progress use agent myelodysplastic myelogenous hypomethylates growth drug inhibit inhibit irreversibly strand consider silence especially island longer longer affect con release nucleoside nucleoside like cell cell cell tumour tumour tumour leukaemia suppressor dependent therefore get replication replication analogue analogue methlyation anti prevent severly treatment dna dna dna dna dna dna divide acute bind bind syndrome demethylating cpg gene rapidly effect copy division replicate since methylation decitabine decitabine decitabine decitabine decitabine daughter much incorporate come action methyltransferase 
1.67@one dna dna dna dna dna dna inhibitor activity suppressor myelodysplastic methylates use analogue likely decitabine decitabine suppression result low gene replication type treatment reduction dose syndrome fe event drug drug treatable methyltransferase reduce tumor tumor affect reversal hypermethylation hypermethylation rase methylation allow nucleoside general incorporate enzyme tra methyl associate 
1.33@happen uncontrolled agent decitabine decitabine silence methylating number decrease decrease prevent dna unnormally level usefull enzyme demethylating demethylating gene gene provoke tumor tumor tumor supressor supressor division cover methylation genome activity case cell cell overactivity belong 
1.0@sndromes reactivation drug cause agent suppression result myelogenous hypomethylation hypermethylated treat suppress lead dna dna epigenetic acute precursor myelodysplastic demethylating gene gene tumor decitabine tumorigenesis use leukaemia 
1.33@cancer myeloid dnmt activate progress tumour tumour tumour fda hence depletion selective hypomethylation hypermethylated make overall treat previously irreversibly methylated kind kind inhibitor inhibitor epigenome epigenome epigenome demethylating demethylating proliferation reactivation affect generally myelodysplastic genome nucleoside cell cell cell cell control leukaemia leukaemia leukaemia suppressor suppressor suppressor also become become replication analogue demethylated demethylate greatly among hypomethylated hypomethylated later dna dna acute bind syndrome dnmts dnmts drug gene gene gene methyltransferase effect upon globally globally belong replicate replicate thus actively decitabine decitabine decitabine decitabine incorporate approve heavily would 
1.67@abnormally cancer tumour certain agent agent overmethylated anti genetic island dna get reverse methylated demethylating demethylating demethylating group effect remove cpg decitabine arise work methyl region region region 
2.0@suppressor inhibitor growth therefore therefore activation activate remove uncontrolled state tumorous decitabine decitabine island become hypomethylation anti prevent protect achieve dna dna dna dna cpg inhibit methyltransferase effect tumor tumor mean hypermethylation methylation genome gene hypomethylated behaviour lead enable associate 
0.0@myc myc decline cancer overmethylation regulation tumour system animal wrong substance part treat call call inhibit common epigenetic culture laboratory proliferation reduce block normal go factor factor gsk cell cell cell one surprisingly also cause crucially activity encode amount know particular involve dna histone name expression gene gene effect jq protein human find find regulator transcription transcription nearby another brd dramatically apparent 
2.0@allow inhibitor inhibitor decitabine use agent ideally myelodysplastic reactivate leukemia become treat amount euchromatin suppresser dna dna dna dna area area area reverse methylated methylated syndrome le function demethylating gene methyltransferase reduce tumor tumor normal especially act act act silence methylation methylation previously mean return cell drug reach genome 
2.0@one enzymatic cancer cancer inhibitor consequently actsby use itis anti result reactivate methyl oncogene treat decrease group underexpression expression expression dna dna dna epigenetic development involve overexpression enzyme gene gene gene methyltransferase methyltransferase effect tumor tumor tumor supressor supressor block either abberant methylation decitabine lay regulator form drug drug onto associate 
2.0@mitotically cancer standard standard effective produce use slow agent stop myelodysplastic capable growth susceptible susceptible make make treat treat suggest grow heritable addition advance epigenetic epigenetic epigenetic pass therefore demethylating inhibit change tumor tumor tumor tumor tumor tumor either azacidine directly treatment lung azatidine patient patient erase drug drug drug cause combination ability subsequent cell cell cell cell cell kill without therapy solid group together syndrome dna dna histone chemotherapy chemotherapy function methyltransferase inhibitor deacetylase belong due actively decitabine daughter possible beneficial 
0.67@cancer effect effect term supression use dnmts could stop long proccess myelodysplastic charge dnmti growth treat inhibit incorporation involve allow group way mechanism uncontrolled health like cell cell cell tumour tumour expression expression kind transfer metyl drug drug cause supresses whole problem know prevent dna dna dacogene bind syndrome suppression suppression still irreversible methyltransferase inhibitor unclear division methylation decitabine decitabine gene gene gene gene action 
0.67@suppressor suppressor cancer inhibitor inhibitor target target dnmt dnmt tumour tumour analogue hemateological neucleoside irreversibly since malignancy dnmti bind methyl transferase inhibit inhibit epigenic molecule expression dna dna dna divide action dependent dependent regulator enzyme drug gene gene rapidly allow affect hypermethylation readily decitabine decitabine incorporate methylation counteract cell replication enzymatic small 
1.0@dna passage acute acute syndrome syndrome syndrome precursor myelodysplastic myelodysplastic demethylating use agent suppress hypermethylation myelogenous decitabine decitabine leukemia leukemia counteract counter treat involve 
2.0@cancer cancer cancer dimished abnormal class available dnmt methyl methyl slow process dnmti diminish transferase transferase island island molecule effective epigenetic epigenetic strand help belong severely impact impact tumor tumor replicate normal hypermethylation theraputic blood suppressor suppressor dna dna dna dna drug drug development development target know prevent particular treatment several get cell cell cell bind bind example site cpg cpg gene gene rapidly inhibitor inhibitor copy division longer silence methylation methylation methylation decitabine decitabine daughter irreversible incorporate 
1.67@different methyltransferases class specificity dnmt dnmt tumour tumour possibly part normal suppress nonspecificly lead strand particularly belong becausedecitabine happen big affect give genome cell cell cell cell replication patient however however drug illnes toxic occur nonspecific good dna dna dna divide dose dose bind demethylates inhibitor side effect effect effect interact demetylates methylation methylation decitabine daughter incorporate small small tissue 
2.0@reinstiute suppressor oust restore therefore use cause agent myelodysplastic result growth direct tumour tumour treatment dna dna cytotoxic syndrome act function demethylating control effect remove antimetabolite normal death methylation methylation decitabine decitabine gene incorporate cell cell way 
1.67@allow cancer methyltransferases methyltransferases methyltransferases methyltransferases methyltransferases oncogenic induce agent process disassembly incorporation inhibit significant class trna show methylated know inhibitor belong tumor tumor word ribosomal hypermethylation gene gene gene gene express many drug deplete region region suppressor suppressor replication cause answer throughout decitabine decitabine decitabine decitabine decitabine decitabine highly result present like anti ob promoter prevent prevent prevent demethylation demethylation capability dna dna dna dna dna dna base inhibitorsstate bind bind bind expression act act function art methyltransferase effect defective cellular repeat unavailable additionally silence silence silence methylation methylation methylation rna production incorporate covalently differentiation protein azacitidine 
2.0@cancer cancer dnmt use cause agent correct find dnmti hypomethylation promoter island cpg often often dna dna dna dna help help expression dinucleotides gene gene methyltransferase inhibitor inhibitor remove remove demethylating new methylation methylation decitabine silence create create destroy return cell cell 
1.67@blewitt blewitt cancer inhibitor inhibitor inhibitor dnmt dnmt dnmt dnmt dnmt dnmt dnmt every mark mark analog growth affect island island chemotherapeutics regulate epigenetic strand strand strand get methylated allow severely tumor tumor html html dilution source ensure nucleoside passive cell cell cell cell cell replication machinery suppressor dependent near irreversibly methylates drug carry hemi target result demethylated moreover anti normally promoter demethylation dna dna dna dna dna dna divide bind bind bind expression cpg cpg gene gene rapidly effect upon retrieve retrieve copy division division replicate methylation methylation methylation methylation decitabine decitabine daughter daughter incorporate incorporate action methyltransferase onto 
1.67@reduction cancer cancer cancer inhibition suppressor suppressor suppressor use cause dnmti dnmti growth treat inhibit methyltransferase lead dna dna dna allow allow observe proliferation inhibitor exceessive increase silence may may thus thus methylation methylation methylation decitabine gene gene gene cell cell cell tumour tumour tumour expression 
1.67@could reduce class lymphoma lymphoma lymphoma overmethylation use use susceptible include agent agent myelodysplastic find silence leukemia make make treat treat call illness surround amount epigenetic precursor refer demethylating demethylating dramatically initial tumor tumor durgs response unexpectedly routine speculate cell cell cell first belong suppressor discover researcher successfully methylates drug drug drug acute mutation result reaction chemotherapeutic solid show good good syndrome dna dna histone histone histone demonstrate chemotherapy inhibitor gene gene go overactive rare cutaneous ezh myelogenous decitabine decitabine overactivity alter 
2.0@meintenance suppressor cancer methyltransferases inhibition dnmt tumor ring novo cannot cannot th de successive demethylation demethylation lead lead dna dna dna position deoxy methylated methylated methylated pyrimidine methylase inactivate inhibitor inhibit reactivation frequently cellular nitrogen decitabine em incorporate passive azacitidine azacitidine 
2.0@inhibitor inhibitor inhibitor class dnmt dnmt dnmt activate tumour tumour tumour tumour tumour exhibit become since growth sit hypermethylated island irreversibly impact replicate replicate normal hypermethylation release nucleoside counteract cell cell cell supressor suppressor suppressor faster epigenetic drug analogue cancerous demethylate occur dna dna bind expression anti gene gene effect effect effect remove must cpg longer methylation decitabine decitabine work incorporate would would would would 
2.0@cancer cancer cancer methyltransferases willexperience dnmt dnmt tumour require activity specific dnmti dnmti growth growth subsequently suppress epigenetic strand theclass belong demethylating island order key feature hypermethylation nucleoside methylation treatment treatment rapid daughter action relate replication replication analogue analogue canreverse present type promoter prevent methylationand dnamethyltransferase dna dna dna dna dna dna cell cell cell cell ifhypermethylation bind bind bind le cpg irreversible irreversible methyltransferase inhibitor inhibitor inhibitor inhibitor upon copy division division silence thereby decitabine decitabine decitabine decitabine decitabine dnmtsare gene gene incorporate incorporate restriction protein 
2.0@categorization blewitt enzymatically think cgis class dnmt synthesize use fda shore accord newly analog analog lower dnmti dnmti treat call job irreversibly transferase allow dr take effective effective tumor tumor pattern though nucleoside cell may may mechanism suppressor transfer patient patient drug drug drug know highly low bind bind fully show prognosis see dna dna dna dose kill decrease syndrome myelodysplastic gene aml inhibitor increase belong thus methylation methylation methylation methylation decitabine decitabine decitabine incorporate approve continue 
1.67@cancer cannot dnmt demethylationoccurs unmethylated islandsinthe add myelodysplastic since leave tumour transferase transferase locus cpg cpg lead irreversibly strand methylated particularly hypermethylation control effective actand normal analogueand isa nucleoside methylation methylation cell cell cell cell methyl methyl methyl dnmtthen suppressor dependent sothe therefore specificdna hypomethylated drug daughterdna targetscancer hemi newlycreated low methylateddna promoter group dna dna dna dna dna dna dna dna divide dose dinucleotide bind syndrome act act inhibitor sobecomes recognise enzyme repress division division replicate replicate bereleased andimprint decitabine future region incorporate rapidly tissue 
2.0@cancer cancer inhibitor decitabone reactivation tumour tumour tumour mutation stop stop process myelodysplastic analog growth growth call inhibit dna dna dna irreversibly reversible reversible kind responsible hypometylation island dnmt dnmt dnmt dnmt inactive nucleotide like cell cell cell may may care suppressor dependent epigenetic epigenetic epimutations replication therapy suppression suppression result hypomethylations methylation methylation methylation methylation methylation show standard divide divide reverse bind syndrome le drug drug drug affect rapidly enzyme induce cpg due normal decitabine tag gene gene mean mean supressor methyltransferase exist tissue 
2.0@cancer inactivate restore dnmt dnmt regulation mutation specific analog hypomethylation lation incorporation previously phenotype strand reversible involve hyper tumoral proliferation reduce tumor pattern produce style style repair nucleoside toward align align demethylation cell cell cell cycle contrary suppressor justify justify mismatch decitabine decitabine decitabine cause could text text apoptosis result low reactivation without anti particular mediate dna dna dna dna dna dna dna dna dose degradation expression gene gene gene methylator effect effect induce increase silence longer methylation methylation methylation complex daughter daughter reproduce differentiation methyltransferase 
1.33@plastic cancer cancer cancer apply apply remember dnmt dnmt others way agent dnmti change affect affect epigenetic strand doctor silence tumor tumor block normal high demethylation treatment drug drug suppressor dependent lower however replication toxic cell cell cell low realize nonspecific good good company dna dna dna get dose dose dose japanese bind act gene rapidly effect upon protein division division word decitabine decitabine decitabine decitabine daughter neo incorporate come attach follow 
0.0@important series cancer cancer cancer cancer cancer cancer cancer article renewal may may insight model baylin baylin exposure introduction metastatic investigator annual meet aberrancy growth xenograft treat effectively inhibit disrupt epigenetic epigenetic write know complex property research research tumor journal day give govern new vital role nm cell cell cell cell cell colleague colleague american cause patient present present association actually offer therapy pathway approach result result experiment aacr terminate demonstrate show damage treatment dna dose kill communication use function target effect advantage emerge shrink low breast breast decitabine decitabine activity self rather azacitidine azacitidine azacitidine 
2.0@suppressor dependent inhibitor therefore dnmt fda tumour tumour include aberrantly demethylate analog cytosine malignancy growth replication transferase inhibit treatment dna dna dna dna irreversibly bind expression act consequence gene gene reduce increase silence methylation genesis nucleoside regain incorporate approve methyl haematological decitabine decitabine decitabine 
1.33@myc cancer cancer cancer cancer demethylates produce produce produce methyl near system agent whose regulatory oncogene oncogene avoid avoid avoid island island lead area know ezh hypermethylation hypermethylation factor case demethylation cell promoter supressor one let transcription promote drug drug drug knowledge course like anti anti recognition obtain group dna dna dna dna u expression expression expression expression hypomethilation cpg cpg gene gene gene gene effect effect effect remove azacitadine decitabine decitabine wide another active part demethylateing 
1.33@cancer produce produce use use improve anormal myelodysplastic finally hypermethylation change like demethylate occur group treat dna dna dna epigenetic epigenetic acute syndrome precursor belong demethylsting division myelogenous decitabine decitabine case cell cell drug drug drug drug hereted leukaemia 
2.0@suppressor suppressor inhibitingdna inhibition restore precusor dnmt tumor tumor use agent acute revert hypomethylating myelodysplastic myelogenous hypermethylation treat inhibit demthylates dna dna dna methylate syndrome function demethylating gene methyltransferase methyltransferase inhibitor induce belong silence decitabine decitabine decitabine class hypo hence would leukaemia 
1.67@market suppressor suppressor cancer tumor tumor order progress tumorous agent specific aforementioned mark myelodysplastic currently silence growth leukemia treat counter locus dna dna see hallmark expression common action syndrome correlate demethylating gene gene proliferation rate remove hypermethylation usually myelogenous combat allow high eventually methylation cell decitabine decitabine 
1.67@dna dna dna mean cancer expression relate gene methyltransferase inhibitor tumor tumor death hypermethylation destruction event methylation decitabine decitabine silence work lead cell cell prevent supressor supressor 
0.67@dna dna epicentre research class inhibit methyltransferase slow tumor agent hypomethylating result article hypomethylates decitabine growth show show cances 
2.0@critical inhibition restore formation may may concentration major cytotoxicity hypomethylation hypomethylation direct incorporation epigentic inhibit exert achieve inhibitor inhibitor proliferation adduct neoplastic phosphorylation methylation cell cell control also cause cause apoptosis suppression know dna dna dna dna dna dna dna dna divide synthesis covalent function gene rapidly effect induce cellular cellular antineoplastic belong vitro normal decitabine decitabine decitabine decitabine decitabine decitabine attribute incorporate differentiation differentiation methyltransferase methyltransferase methyltransferase class 
1.67@dependent inhibitor inhibitor class therefore dnmt replication analogue fda tolerant low dnmti anti bind epigenetic dna dna irreversibly dose help syndrome dnmts effect tumor belong ul ul nucleoside incorporate approve decitabine decitabine decitabine 
0.0@cancer effect lymphoma formation uncontrolled uncontrolled cycle overactive mark hypermethylate part island suppress open epigenetic help help help inhibitor belong ezh ezh prevent prevent tumor tumor tumor tumor repressive thereby thereby methyl decitabine decitabine suppressor suppressor prc structure structure three add cell cell cell anti normally condense promoter group tri potentially lysine histone histone expression expression expression cpg gene gene gene gene gene methyltransferase function hmti chromatin chromatin division division silence silence methylation allow allow allow region active 
2.0@mitotically loss instead higher ofdecitabine dnmt activate activate tumour tumour tumour tumour tumour cytidine mark mark de rate usual heritable hemimethylated dilution disruption lead cytosine irreversibly strand cause allow inhibitor hypomethylated due due affect generally nucleoside cell cell cell cell cell cell cycle suppressor suppressor tumorigenesis dna dna dna dna dna dna faster faster methylating therefore action decitabine replication replication replication analogue healthy novo pathway arrest occur occur prevent prevent prevent several apoptosis dose synthesis synthesis bind bind covalent dnmts dnmts irreversible methyltransferase effect contain silence replicate methylation longer incorporate death death 
1.0@suppressor suppressor methyltransferases inhibition class myelodysplastic hypermethylation alleviate hypermethylated normal island cpg lead dna dna epigenetic allow demethylating inhibit expression tumor tumor syndroms ihibitors belong decitabine decitabine gene gene treatment 
2.0@unregulated cancer restore restore agent process member hypomethylates growth growth inhibit aza regulate regulate allow demethylating tumor mechanism block normal thus major demethylation demethylation cell cell cell cell control blockage suppressor suppressor suppressor promote drug result become know dna dna dna dna dna dna expression gene gene gene gene methyltransferase function deoxycytidine increase division division interfere new methylation methylation methylation decitabine decitabine work activity class 
1.67@cancer cancer cancer cancer inhibitor dnmt dnmt use use aid mostly specific mark myelodysplastic myelodysplastic myelodysplastic treat decrease decrease irreversibly well well think able normal normal link demethylation cell cell cell cell cell incorporate patient therefore general drug drug cause theory become occur better extremely dna dna dna dna divide lot chemotherapy function cpg methyltransferase effect syndrome syndrome syndrome replicate methylation methylation methylation methylation decitabine decitabine decitabine decitabine decitabine work work work work lay come replication 
2.0@cancer methyltransferases restore dnmt dnmt methyl state agent agent agent fluorouracil code code efects change hypermethylated nucleotide regulate cytosine epigenetic reversible repression responsible responsible enzyme enzyme demethylating tumor tumor pattern pattern pattern normal thus carbon like cell cell cell de pre suppressor msi sensitivity ccr transfer establishment action drug drug drug improve hypermthylated novo low chemotherapeutic ia maintain occur group presence treatment dna dna dna maintenance dose histone demonstrate expression pontencially mlh inactivate line increase capable methylation methylation methylation methylation reestablish resistance gene gene gene gene activity modify reverse alter reactivate reactivate 
1.67@time silencingby cancer also may agent novo process since dnmti know prevent suppress dna dna dna maintenance bind expression inhibitor dnmts demethylating gene gene hypermethylationof reduce reduce tumor tumor revert increase division thus methylation methylation methylation decitabine decitabine press em cell methyltransferase de 
1.0@suppressor suppressor size restore restore remove tumour tumour tumour promotors agent mark find without hypermethylated normal normal island dna apoptosis decrease function demethylating gene gene induce affect cpg methylation decitabine decitabine much cell cell may 
2.0@inhibitor inhibitor class dnmt dnmt tumour tumour tumour tumour tumour tumour slow correct newly dnmti dnmti growth locus irreversibly strand inhibit inhibit due normal hypermethylation hypermethylation strongest although problematic dont may immediate immediate suppressor dependent also become depend divide divide divide replication replication wont introduce strong anti hypomethylated experience action dna dna dna dna mark cell cell cell cell cell cell bind epigenetic drug gene rapidly rapidly effect effect effect effect upon upon cellular cellular copy belong replicate thus thus methylation methylation decitabine decitabine decitabine decitabine decitabine daughter arrive similar expose methyltransferase onto 
2.0@different cancer cancer inactivate activity category within dnmt dnmt dnmt hand progress use agent agent process two metil find cellular growth leukemia direct decrease inhibit inhibit aza restore restore epigenetic transferase well enzyme inhibitor island tumor tumor block normal nucleotide produce turn myeloyd nucleoside demethylation demethylation demethylation cell cell cell cell abnormality control myelodysplasic suppressor suppressor bond antimetabolite antimetabolite divide fight drug drug cause cdr number level metabolism dna dna syndrom acute cytotoxic covalent function cpg gene gene target effect interact hypermetilation death belong thus methylation decitabine incorporate form 
2.0@cancer inhibitor cgis class tumour tumour tumour tumour agent agent hypomethylating myelodysplastic economist treat inhibit aza lead epigenetic strand hypometylation demethylating impact hypermethylation incorporate decitabine decitabine decitabine decitabine decitabine decitabine decitabine suppressor identify epicentre certain april limit describe describe anti anti type occur particular dna dna dna dna dna dna process reverse syndrome use gene methyltransferase effect effect deoxycytidine belong methylation methylation ul ul ul ul ul ul activity 
1.67@suppressor suppsressors class dnmt dnmt tumour tumour tumour cause build meythlated present part inhibit dna dna methylate act expression demethylating gene inhibitor belong decitabine decitabine decitabine incorporate demethylation cell cell 
1.67@dacogen cancer effect company activation use analogue stability agent eisai signal myelogenous hypomethylates occur inhibit treat relative weaken dna dna dna dna acute cytidine syndrome sell myelodysplastic demethylating gene gene chemical reduce mechanism precursor silence silence thus methylation decitabine decitabine methyltransferase confer demethylation japanese removal may may leukaemia 
2.0@substitute suppressor suppressor suppressor permanent cannot cannot restore therefore dnmt dnmt dnmt tumor tumor tumor methyl methyl methyl deactivate agent without hypomethylating transfer cytosine dnmti effect replication transferase group group suppress lead dna dna dna dna dna dna dna irreversibly base bind bind strand functionality inhibitor inhibit continue enzyme remove protect thus methylation methylation methylation methylation decitabine decitabine gene gene gene incorporate catalyze deplete de 
1.67@could inhibitor epigenetic tumour appropriate target low bring methyltranferse anti particular enzymic dna dna dna dna irreversibly dose cell bind dnmts gene effect good neoplastic capable methylation methylation decitabine decitabine decitabine aberrant incorporate regulator form drug kill 
1.67@cancer methyltransferases methyl dependent add dnmti affect prevent dna dna dna decrease bind dnmts drug group methyltransferase inhibitor tumor preferentially permanently dnmtis contribute replicate methylation methylation decitabine decitabine like cell cell replication 
2.0@mean mean cancer inhibitor inhibitor inhibition dnmt use concentration agent agent aberrantly reactivate growth unlike nucleotide lead irreversibly strand body methylated consequence demethylating demethylating severely tumor tumor tumor longer affect bind bind bind may release conventional cell cell cell cell much suppressor dependent dependent lower tolerate get manner replication activity best maximum dna dna dna dna dna divide dose cytotoxic important drug gene rapidly along upon copy division replicate replicate methylation decitabine daughter incorporate come action propose methyltransferase methyltransferase methyltransferase methyltransferase 
2.0@cancer available dnmt dnmt dnmt dnmt dnmt tumor tumor uncontrolled mark mark mark mark methlylation dnmti growth part hypermethylated inhibit inhibit lead strand strand strand responsible silence silence prevent prevent heritability mechanism release nucleoside often suppressor analogue mitotic cause suppression inheritance normally parent island dna dna dna dna cell cell cell cell cell cell bind bind le cpg gene gene methyltransferase inhibitor copy copy division division replicate new methylation methylation decitabine decitabine decitabine decitabine daughter work incorporate action action 
1.33@inthis inhibition serine agent complex anti meet decrease island expression epigenetic allow demethylating inhibit as tumor tumor hypermethylation aberrant enzyme cell supressor transfer residue manner drug drug result cancerous become type promoter hypomethylated covalent dna dna dna group syndrome site myelodysplastic cpg irreversible effect belong silence decitabine decitabine gene inadecuatelly active form 
1.67@suppressor cancer methylating lymphoma uncontrolled carry overexpressed agent stop inactivation silence growth restrict inhibit dna dna responsible responsible enzyme demethylating adna proliferation inhibitor theenzyme ezh ezh ezh thus methylation decitabine decitabine gene activity cell cell tumour tumour 
2.0@cancer inhibition restore restore may agent specific hypomethylating hypomethylates growth potential broad inhibit involve take tumor mechanism normal clear aberrant aberrant potent demethylation demethylation cell process process control suppressor large carcinogenesis preclinical therapy target number exact show definition dna dna dna dna dna dna however mediate function still gene gene methyltransferase methyltransferase methyltransferase inhibitor inhibitor molecular place range suggest antineoplastic silence interfere thus methylation methylation methylation methylation decitabine decitabine decitabine work activity activity tumorigenesis 
1.67@unregulated cancer cancer cancer cancer characteristic growth destabilize may state likely article economist hypomethylation genetic oncogene oncogene mention island island island suppress suppress greatest guess disease demethylating demethylating hazard tumor tumor intergenic intergenic hypermethylation hypermethylation genome genome genome possibility instability hypermethylated express many cell control control control supressor risk also also patient activation could agent agent demethylate prevent demethylation acceptable future cpg cpg cpg gene gene gene gene current current allow remove silence decitabine decitabine decitabine region region region activity eg would 
2.0@decline cancer cancer cancer cancer methyltransferases synthesize synthesize may manner faster newly newly cannot decrease decrease previously irreversibly strand strand decitabines methylated inhibitor reduce tumor tumor tumor big normal normal hypermethylation turn genome nucleoside elicit cell cell cell cell cell cell cell much release one suppressor suppressor dependent lower therefore replication replication replication analogue proper free without anti amount amount level level level dna dna dna dna divide bind bind dnmts dnmts dnmts dnmts dnmts dnmts gene gene function sufficient template division since methylation methylation methylation decitabine decitabine decitabine daughter daughter characteristic incorporate incorporate dosage influence would 
2.0@mitotically cancer methyltransferases methyltransferases available un activate need agent hypomethylating transcription hypomethylates without growth gene gene become become heritable grow though lead dna dna dna dna divide methylated involve organism inhibit inhibit tumor tumor tumor demethylation life division may may thus methylation methylation methylation repair alsopossible time maintain maintain active cell cell use suppressor suppressor decitabine decitabine decitabine 
0.67@mitotically could change slow agent stop since growth heritable decrease potentially dna epigenetic even frequency demethylating effect tumor hypermethylation decitabine mean would 
2.0@methyltransferases class dnmt methyl methyl slow add dnmti growth decrease island nucleotide unable irreversibly strand enzyme pattern may although tumorigenicity cell cell cell cell replication render descendant cause incorporate result mimic become halt group group dna dna dna dna dna dna dna kill bind cpg continue inhibitor remove copy new methylation methylation decitabine decitabine decitabine lay methyltransferase onto 
1.0@one suppressor suppressor suppressor suppressor cancer cancer also succeptible tumor tumor tumor tumor tumor tumor tumor may agent mark limit reduction growth leave growht mehtylation lead lead dna treatment hallmark divide silence demethylating time proliferation proliferation proliferation remove uncontrolled hypermethylation thus methylation decitabine gene gene gene gene many cell cell cell cell cell control control 
1.67@suppressor suppressor cancer reduce way region region agent demethylate fast demethylated number anti type know grow dna dna dna help name silence demethylating gene gene effect tumor tumor tumor suggest human methylation possible express cell cell drug dicitabine dicitabine 
2.0@inhibitor patient therefore therefore dnmt dnmt dnmt mitotic mitotic bad regular chemically add tend myelodysplastic result unmethylated might might affect affect island good molecule disrupt disrupt dna dna divide divide divide strand cell cell cell cell cell bind syndrome responsible division especially observe methyltransferase litation litation tumor disruption generally therfore methylation methylation methylation decitabine decitabine decitabine decitabine daughter cpg cpgs survival 
2.0@cancer cancer cancer reduce abnormal restore activate others use use inhibitor inhibitor agent stop mark cure probably probably since reactivate leukemia useful treat transferase island class class class irreversibly see currently well allow demethylating research produce normal normal hypermethylation hypermethylation may thus genome nucleoside like cell cell methyl methyl remove suppressor dependent indicate epigenetic drug analogue know know healthy replication replication solid tumour tumour prevent prevent treatment dna dna dna dna dmts blood bind act act recent function function cpg gene gene rapidly myelodysplasias upon methyltransferase preferentially protein belong replicate myelogenous decitabine decitabine incorporate silence action attach dnmti 
2.0@cancer cancer negate abnormal abnormal rapidly unstable tumour tumour tumour mutation silence silence seek llike dnmti dnmti hypomethylation make inhibition transferase island irreversibly work broad wide inhibitor enzyme unlike rarely normal normal hypermethylation hypermethylation usually drive genome genome nucleoside nucleoside like basic cell cell cell cell cell cell cell cell methyl genrally one suppressor suppressor cause methylating study hypermethylationat poison therapy therapy side target target mimic cancerous cancerous best traditional show daughtercell dna dna dna dna divide divide non bind function function cpg gene gene gene gene chemo effect methyltransferase force copy division oncogenesis methylation decitabine decitabine daughter create incorporate eg haematological frequent 
2.0@cancer cancer inhibitor dnmt use use slow could could mark anti anti dnmti change unmethylated decrease inhibit suppresser epigenetic enzyme effective undergo demethylation cell cell cell cell cell cell cell cell tumour tumour tumour transcription therefore activation drug drug drug dectabine dectabine dectabine nucelosomes target result result reverse become nucleosomes level prevent dna dna dna dna tumerogenesis bind bind example gene methyltransferase methyltransferase effect effect copy copy contain silence replicate methylation methylation methylation daughter daughter possible enable would would would frequently 
1.67@phenotype cancer promote decibatine certain tumorous agent shore result growth anti anti promoter island suppress suppress tumor dna dna dna maintenance methylated sell function demethylating gene gene gene expression remove normal cpg methylation methylation methylation case cell exist 
1.33@suppressor suppressor cancer lower promote agent hypomethylating suppression reference growth inhibit dna dna dose allow gene gene expression tumor tumor tumor ben silence due methylation methylation decitabine decitabine aberrant 
1.67@suppressor cancer cancer fight drug hypomethylating target growth growth island dna dna dna epigenetic typical act demethylating inhibit inhibit methyltransferase effect remove cpg may thus methylation methylation decitabine activate tumour 
2.0@cancer class dnmt dnmt dnmt dnmt dnmt dnmt radiation blood include agent agent stop stop myelodysplastic also also malignancy malignancy frequently growth transferase act effective epigenetic combinatorial allow demethylating demethylating demethylating activation tumor tumor tumor tumor normal normal hypermethylation access utilize affect cell cell cell cell cell trial drug suppressor dependent transcription irreversibly fda replication cause improve likely suppression chemotherapeutic type solid know treatment treatment dna dna dna dna dna future bind syndrome methylase dnmts prove gene gene aml inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor inhibitor upon death replicate decitabine decitabine decitabine incorporate approve 
1.67@class dnmt use specific process analog dnmti transferase transferase lead lead strand strand methylated hyper stick tumor tumor normal link high anymore cell cell cell cell cell methyl methyl belong nucleoside depend get replication replication cause stay demethylated demethylated cancerous become dna dna dna dna dna divide dose bind bind le affect inhibitor remove irriversibly copy death quickly decitabine decitabine decitabine daughter daughter region incorporate incorporate 
2.0@mitotically cancer cancer transcription restore dnmt replication certain stop free dnmti anti anti type treat decrease decrease island island develop dna dna dna dna promoter inhibitor enzyme enzyme cpg cpg gene gene gene methyltransferase effect tumor tumor tumor tumor increase increase administer word silence methylation methylation methylation methylation methylation allow notability heritable action indirectly protein suppressor suppressor decitabine decitabine decitabine decitabine 
1.67@cancer cannot use use require specific myelodysplastic analog myelogenous treat irreversibly strand body tumour precursor belong inhibitor inhibitor inhibitor severely severe affect neoplastic health release nucleoside case demethylation cell cell cell cell cell cell rapid leukaemia dependent lower patient replication replication replication cause toxic side without maintain anti obtain good dna dna dna dna dna dna dna dna get dose acute bind bind syndrome inherit drug aml effect effect effect upon range copy division methylation methylation decitabine decitabine decitabine decitabine daughter much incorporate methyltransferase methyltransferase methyltransferase methyltransferase methyltransferase recently 
1.33@supresor methyltransferases growth antimetabolite tumor tumor use use proper analog low therby hypomethylation hypomethylation depletion type know promote dna dna dna dna dna dna dna nonreversible dose suppression drug drug gene methyltransferase methyltransferase expression induce cytosine link usually find methylation decitabine decitabine cant incorporate passive cell differentiation replication 
1.67@enzymatic dependent methyltransferases therefore may analogue inhibitor process regard neoplasic effect effect anti abnormally drug decrease decrease previously important dna dna dna dna level level bind consequence act dnmts dnmts tumoral irreversible side enzyme tumor normal increase replicate methylation methylation decitabine nucleoside incorporate regulator cell cell replication 
1.0@different immediate cancer cancer cancer change available may may cluster mutation halation halation halation process switch switch meet meet meet growth make genetic back locus suppress often epigenetic around particularly hyper hyper hyper island island island island impact tumor tumor tumor demethalating response generally association thus repair within case neighbourhood cell cell cell tumour promoter compound suppressor suppressor suppressor patient also fortunately indeed epimutations drug carry improve typically suppression suppression result reversible frequent shore occur show particular common dna dna chemotherapy target cpg cpg cpg gene gene gene gene gene ameliorate believe silence new methylation decitabine daughter work limit adverse associate associate 
0.67@cancer cancer inhibitor unclear tumour agent tend myelogenous de treat call island island imply transferase precursor belong demethylating mechanism myelodisplastic may may nucleoside drug drug cell use level leukaemia dependent relate replication analogue decitabine decitabine underlie methyl promoter promoter group dna dna dna dna reverse bind syndrome act dnmts cpg cpg gene effect molecular demetylating still silence methylation methylation hypermethilated incorporate action 
2.0@cancer impact class dnmt dnmt tumour tumour purpose island island transfer impair dnmti dnmti make treat epigentic inhibit lead effective irreversibly methylate inappropriately inhibitor inhibitor unavailable reducethe reactivation normal hypermethylation cel nucleoside nucleoside methylation methylation many cell cell control supressor dependent certain regain replication analogue able restoration body belong methyl could group dna dna dna dna dna divide bind function function cpg cpg gene gene methyltransferase allow place division thus actively decitabine decitabine decitabine incorporate silence onto associate 
2.0@cancer critical growth dnmt formation may agent accurate almost silence silence hypomethylation make make hypermethylated inhibit suppress suppress suppress unable cytosine irreversibly well enzyme demethylating island reactivation tumor tumor tumor tumor tumor mechanism mammal usually hematologic demethylation cell cell methyl methyl cystosine suppressor suppressor suppressor refer therapeutic decitabine decitabine induction drug add exclusively result result cancerous ultimately replication occur promoter group dna dna dna dna dna dna product product form bind inhibitor dinucleotides gene gene gene gene gene methyltransferase methyltransferase effect describe contain cpg cpg due thus thus methylation longer article malignancy action 
2.0@classify restore restore able tumour tumour tumour agent make growth growth specialization hypermethylated incorporation inhibit lead direct body demethylating cpi better normal phosphorylation nucleoside decitabineis cell cell cell cell cell cell blood blood blood expression expression suppressor suppressor red also also promote antimetabolite analogue white promoter promoter promoter particular dna dna dna dna apoptosis platelet gene gene gene gene gene organism induce deoxycytidine control silence demetylation demetylation decitabine injure 
1.33@begin cancer cancer cancer methyltransferases dnmt excess excess uncontrolled mutation process phenomenon article article one silence growth methyl treat inhibit suppress suppress lead cytosine epigenetic pack island naturally allow ezh group tumor tumor tumor tumor accord affect feature purportedly genome genome express cell cite market transcription inactivity general drug cause cause cause healthy describe cancerous tightly normally occur especially inaccessible together treatment dna dna already act cpg gene gene gene gene suppressant remove chromatin configuration demethylating thus thus thus methylation methylation methylation methylation decitabine decitabine case come attach would 
